0001618921-22-000004.txt : 20220106 0001618921-22-000004.hdr.sgml : 20220106 20220106164633 ACCESSION NUMBER: 0001618921-22-000004 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20211130 FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Walgreens Boots Alliance, Inc. CENTRAL INDEX KEY: 0001618921 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 471758322 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36759 FILM NUMBER: 22515345 BUSINESS ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: (847) 315-2500 MAIL ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 10-Q 1 wba-20211130.htm 10-Q wba-20211130
0001618921--08-312022Q1falsehttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent00016189212021-09-012021-11-300001618921us-gaap:CommonStockMember2021-09-012021-11-300001618921wba:A3600NotesPayableDue2025Member2021-09-012021-11-300001618921wba:A3450NotesPayableDue2026Member2021-09-012021-11-3000016189212021-12-31xbrli:shares00016189212021-11-30iso4217:USD00016189212021-08-31iso4217:USDxbrli:shares0001618921us-gaap:CommonStockMember2021-08-310001618921us-gaap:TreasuryStockMember2021-08-310001618921us-gaap:AdditionalPaidInCapitalMember2021-08-310001618921us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-08-310001618921us-gaap:RetainedEarningsMember2021-08-310001618921us-gaap:NoncontrollingInterestMember2021-08-310001618921us-gaap:RetainedEarningsMember2021-09-012021-11-300001618921us-gaap:NoncontrollingInterestMember2021-09-012021-11-300001618921us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-012021-11-300001618921us-gaap:CommonStockMember2021-09-012021-11-300001618921us-gaap:TreasuryStockMember2021-09-012021-11-300001618921us-gaap:AdditionalPaidInCapitalMember2021-09-012021-11-300001618921us-gaap:CommonStockMember2021-11-300001618921us-gaap:TreasuryStockMember2021-11-300001618921us-gaap:AdditionalPaidInCapitalMember2021-11-300001618921us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-11-300001618921us-gaap:RetainedEarningsMember2021-11-300001618921us-gaap:NoncontrollingInterestMember2021-11-300001618921us-gaap:CommonStockMember2020-08-310001618921us-gaap:TreasuryStockMember2020-08-310001618921us-gaap:AdditionalPaidInCapitalMember2020-08-310001618921us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-08-310001618921us-gaap:RetainedEarningsMember2020-08-310001618921us-gaap:NoncontrollingInterestMember2020-08-3100016189212020-08-310001618921us-gaap:RetainedEarningsMember2020-09-012020-11-300001618921us-gaap:NoncontrollingInterestMember2020-09-012020-11-3000016189212020-09-012020-11-300001618921us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-012020-11-300001618921us-gaap:CommonStockMember2020-09-012020-11-300001618921us-gaap:TreasuryStockMember2020-09-012020-11-300001618921us-gaap:AdditionalPaidInCapitalMember2020-09-012020-11-300001618921srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-08-310001618921us-gaap:NoncontrollingInterestMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-08-310001618921srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-08-310001618921us-gaap:CommonStockMember2020-11-300001618921us-gaap:TreasuryStockMember2020-11-300001618921us-gaap:AdditionalPaidInCapitalMember2020-11-300001618921us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-11-300001618921us-gaap:RetainedEarningsMember2020-11-300001618921us-gaap:NoncontrollingInterestMember2020-11-3000016189212020-11-30wba:segment0001618921wba:AllianceHealthcareMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2021-06-010001618921wba:AllianceHealthcareMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2021-06-012021-06-010001618921wba:AllianceHealthcareMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2020-09-012020-11-300001618921wba:AllianceHealthcareMemberus-gaap:SegmentContinuingOperationsMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2020-09-012020-11-300001618921wba:VillageMDMember2021-11-23xbrli:pure0001618921wba:VillageMDMember2021-11-240001618921wba:VillageMDMember2021-11-242021-11-240001618921wba:ShieldsHealthSolutionsParentLLCMember2021-10-280001618921wba:ShieldsHealthSolutionsParentLLCMember2021-10-290001618921wba:ShieldsHealthSolutionsParentLLCMember2021-10-292021-10-290001618921wba:ShieldsHealthSolutionsParentLLCMember2021-09-012021-11-300001618921us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-09-012021-11-300001618921us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMembersrt:MinimumMember2018-12-202018-12-200001618921wba:TransformationalCostManagementProgramMembersrt:MinimumMember2021-10-122021-10-120001618921country:GBwba:TransformationalCostManagementProgramMember2021-10-122021-10-12wba:store0001618921wba:TransformationalCostManagementProgramMembercountry:US2021-10-122021-10-120001618921country:GBwba:TransformationalCostManagementProgramMember2021-07-012021-07-310001618921wba:TransformationalCostManagementProgramMembercountry:US2021-07-012021-07-310001618921wba:TransformationalCostManagementProgramMembersrt:MinimumMember2021-11-300001618921wba:TransformationalCostManagementProgramMembersrt:MaximumMember2021-11-300001618921wba:TransformationalCostManagementProgramMembersrt:MinimumMemberwba:ExitAndDisposalCostsMember2021-11-300001618921wba:TransformationalCostManagementProgramMembersrt:MaximumMemberwba:ExitAndDisposalCostsMember2021-11-300001618921srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberwba:TransformationalCostManagementProgramMemberus-gaap:RetainedEarningsMember2019-09-010001618921wba:TransformationalCostManagementProgramMember2021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:LeaseObligationsandOtherRealEstateCostsMember2021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:AssetImpairmentRestructuringChargesMember2021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMember2021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMemberwba:LeaseObligationsandOtherRealEstateCostsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:LeaseObligationsandOtherRealEstateCostsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:LeaseObligationsandOtherRealEstateCostsMemberwba:CorporateAndReconcilingItemsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:LeaseObligationsandOtherRealEstateCostsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMemberwba:AssetImpairmentRestructuringChargesMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:AssetImpairmentRestructuringChargesMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:AssetImpairmentRestructuringChargesMemberwba:CorporateAndReconcilingItemsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:AssetImpairmentRestructuringChargesMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMemberwba:UnitedStatesReportableSegmentMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMemberwba:InternationalReportableSegmentMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMemberwba:CorporateAndReconcilingItemsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:InformationTechnologyTransformationAndOtherExitCostsMemberwba:CorporateAndReconcilingItemsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberwba:CorporateAndReconcilingItemsMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMember2021-09-012021-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMemberwba:LeaseObligationsandOtherRealEstateCostsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:LeaseObligationsandOtherRealEstateCostsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:LeaseObligationsandOtherRealEstateCostsMemberwba:CorporateAndReconcilingItemsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:LeaseObligationsandOtherRealEstateCostsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMemberwba:AssetImpairmentRestructuringChargesMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:AssetImpairmentRestructuringChargesMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:AssetImpairmentRestructuringChargesMemberwba:CorporateAndReconcilingItemsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:AssetImpairmentRestructuringChargesMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMemberwba:UnitedStatesReportableSegmentMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMemberwba:InternationalReportableSegmentMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMemberwba:CorporateAndReconcilingItemsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:InformationTechnologyTransformationAndOtherExitCostsMemberwba:CorporateAndReconcilingItemsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:CorporateAndReconcilingItemsMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMember2020-09-012020-11-300001618921wba:TransformationalCostManagementProgramMemberwba:LeaseObligationsandOtherRealEstateCostsMember2021-08-310001618921wba:TransformationalCostManagementProgramMemberwba:AssetImpairmentRestructuringChargesMember2021-08-310001618921wba:TransformationalCostManagementProgramMemberwba:EmployeeSeveranceAndBusinessTransitionCostsMember2021-08-310001618921wba:TransformationalCostManagementProgramMemberwba:InformationTechnologyTransformationAndOtherExitCostsMember2021-08-310001618921wba:TransformationalCostManagementProgramMember2021-08-310001618921srt:MinimumMember2021-11-300001618921srt:MaximumMember2021-11-300001618921wba:AmerisourceBergenCorporationMember2021-11-300001618921wba:AmerisourceBergenCorporationMember2021-08-310001618921wba:OtherEquityMethodInvestmentsMember2021-11-300001618921srt:MinimumMemberwba:OtherEquityMethodInvestmentsMember2021-11-300001618921srt:MaximumMemberwba:OtherEquityMethodInvestmentsMember2021-11-300001618921wba:OtherEquityMethodInvestmentsMember2021-08-310001618921srt:MinimumMemberwba:OtherEquityMethodInvestmentsMember2021-08-310001618921srt:MaximumMemberwba:OtherEquityMethodInvestmentsMember2021-08-310001618921wba:AmerisourceBergenAndOtherEquityMethodInvestmentsMember2021-11-300001618921wba:AmerisourceBergenAndOtherEquityMethodInvestmentsMember2021-08-310001618921wba:AmerisourceBergenCorporationMember2021-09-012021-11-300001618921wba:AmerisourceBergenCorporationMember2020-09-012020-11-300001618921wba:AmerisourceBergenCorporationMemberwba:OpiodLitigationMember2020-07-012020-09-300001618921wba:AmerisourceBergenCorporationMemberus-gaap:FairValueInputsLevel1Member2021-11-300001618921wba:AmerisourceBergenCorporationMemberus-gaap:FairValueInputsLevel1Member2021-08-310001618921wba:OtherEquityMethodInvestmentsMember2021-09-012021-11-300001618921wba:OtherEquityMethodInvestmentsMember2020-09-012020-11-300001618921wba:VillageMDMember2021-09-012021-11-300001618921us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-09-012021-11-300001618921us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-09-012020-11-300001618921srt:MinimumMember2021-06-010001618921srt:MaximumMember2021-06-010001618921wba:OtherInternationalReportingUnitMember2021-06-010001618921wba:BootsReportingUnitMember2021-11-300001618921wba:OtherInternationalReportingUnitMember2021-11-300001618921srt:MinimumMemberwba:BootsReportingUnitMember2021-11-300001618921srt:MaximumMemberwba:BootsReportingUnitMember2021-11-300001618921wba:BootsReportingUnitMember2021-08-310001618921us-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2021-08-310001618921us-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2021-08-310001618921us-gaap:OperatingSegmentsMemberwba:WalgreensHealthMember2021-08-310001618921us-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2021-09-012021-11-300001618921us-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2021-09-012021-11-300001618921us-gaap:OperatingSegmentsMemberwba:WalgreensHealthMember2021-09-012021-11-300001618921us-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2021-11-300001618921us-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2021-11-300001618921us-gaap:OperatingSegmentsMemberwba:WalgreensHealthMember2021-11-300001618921wba:CustomerRelationshipsAndLoyaltyCardHoldersMember2021-11-300001618921wba:CustomerRelationshipsAndLoyaltyCardHoldersMember2021-08-310001618921wba:PrimaryCareProviderNetworkMember2021-11-300001618921wba:PrimaryCareProviderNetworkMember2021-08-310001618921us-gaap:TrademarksAndTradeNamesMember2021-11-300001618921us-gaap:TrademarksAndTradeNamesMember2021-08-310001618921wba:PurchasingAndPayerContractsMember2021-11-300001618921wba:PurchasingAndPayerContractsMember2021-08-310001618921us-gaap:DevelopedTechnologyRightsMember2021-11-300001618921us-gaap:DevelopedTechnologyRightsMember2021-08-310001618921us-gaap:OtherIntangibleAssetsMember2021-11-300001618921us-gaap:OtherIntangibleAssetsMember2021-08-310001618921us-gaap:TrademarksAndTradeNamesMember2021-11-300001618921us-gaap:TrademarksAndTradeNamesMember2021-08-310001618921wba:PharmacyLicensesMember2021-11-300001618921wba:PharmacyLicensesMember2021-08-310001618921us-gaap:CommercialPaperMember2021-11-300001618921us-gaap:CommercialPaperMember2021-08-310001618921us-gaap:RevolvingCreditFacilityMember2021-11-300001618921us-gaap:RevolvingCreditFacilityMember2021-08-310001618921wba:A3300NotesPayableDue2021Member2021-11-300001618921wba:A3300NotesPayableDue2021Member2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:DebtIssuanceNoteTwoMember2021-11-300001618921wba:A3100NotesPayableDue2022Memberus-gaap:UnsecuredDebtMember2021-11-300001618921wba:A3100NotesPayableDue2022Member2021-11-300001618921wba:A3100NotesPayableDue2022Member2021-08-310001618921wba:OtherShortTermDebtMember2021-11-300001618921wba:OtherShortTermDebtMember2021-08-310001618921us-gaap:RevolvingCreditFacilityMember2021-11-300001618921us-gaap:RevolvingCreditFacilityMember2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:DebtIssuanceNoteEightMember2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A09500NotesPayableDue2023Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A09500NotesPayableDue2023Member2021-08-310001618921wba:DebtIssuanceNoteSevenMemberus-gaap:UnsecuredDebtMember2021-11-300001618921wba:A3200NotesPayableDue2030Memberus-gaap:UnsecuredDebtMember2021-11-300001618921wba:A3200NotesPayableDue2030Memberus-gaap:UnsecuredDebtMember2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:A4100NotesPayableDue2050Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A4100NotesPayableDue2050Member2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:DebtIssuanceNoteFourMember2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A3450NotesPayableDue2026Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A3450NotesPayableDue2026Member2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:A4650NotesPayableDue2046Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A4650NotesPayableDue2046Member2021-08-310001618921wba:DebtIssuanceNoteOneMemberus-gaap:UnsecuredDebtMember2021-11-300001618921wba:A3800NotesPayableDue2024Memberus-gaap:UnsecuredDebtMember2021-11-300001618921wba:A3800NotesPayableDue2024Memberus-gaap:UnsecuredDebtMember2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:A4500NotesPayableDue2034Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A4500NotesPayableDue2034Member2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:A4800NotesPayableDue2044Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A4800NotesPayableDue2044Member2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:DebtIssuanceNoteFiveMember2021-11-30iso4217:GBP0001618921us-gaap:UnsecuredDebtMemberwba:A3600NotesPayableDue2025Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A3600NotesPayableDue2025Member2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:DebtIssuanceNoteSixMember2021-11-30iso4217:EUR0001618921us-gaap:UnsecuredDebtMemberwba:A2125NotesPayableDue2026Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A2125NotesPayableDue2026Member2021-08-310001618921wba:A3100NotesPayableDue2022Memberus-gaap:UnsecuredDebtMember2021-08-310001618921us-gaap:UnsecuredDebtMemberwba:A4400NotesPayableDue2042Member2021-11-300001618921us-gaap:UnsecuredDebtMemberwba:A4400NotesPayableDue2042Member2021-08-310001618921us-gaap:UnsecuredDebtMember2021-11-300001618921us-gaap:UnsecuredDebtMember2021-08-310001618921wba:A3300NotesPayableDue2021Member2021-09-180001618921us-gaap:UnsecuredDebtMemberwba:A09500NotesPayableDue2023Member2021-11-170001618921us-gaap:UnsecuredDebtMemberwba:A09500NotesPayableDue2023Member2021-11-172021-11-170001618921us-gaap:LoansPayableMemberwba:DelayedDrawTermLoanCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-150001618921us-gaap:LoansPayableMemberwba:DelayedDrawTermLoanCreditFacility364DayFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-152021-11-150001618921us-gaap:LoansPayableMemberwba:DelayedDrawTermLoanCreditFacility364DayFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-150001618921us-gaap:LoansPayableMemberwba:DelayedDrawTermLoanCreditFacilityTwoYearFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-152021-11-150001618921wba:DelayedDrawTermLoanCreditFacilityTwoYearFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-150001618921wba:DelayedDrawTermLoanCreditFacilityThreeYearFacilityMemberus-gaap:LoansPayableMemberus-gaap:RevolvingCreditFacilityMember2021-11-152021-11-150001618921wba:DelayedDrawTermLoanCreditFacilityThreeYearFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-150001618921us-gaap:LoansPayableMemberwba:DelayedDrawTermLoanCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-11-300001618921us-gaap:RevolvingCreditFacilityMemberwba:A2020RevolvingCreditAgreement364DayFacilityMember2020-12-230001618921us-gaap:RevolvingCreditFacilityMemberwba:A2020RevolvingCreditAgreement364DayFacilityMember2020-12-232020-12-230001618921us-gaap:RevolvingCreditFacilityMemberwba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember2020-12-230001618921us-gaap:RevolvingCreditFacilityMemberwba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember2020-12-232020-12-230001618921us-gaap:BridgeLoanMemberwba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember2020-12-230001618921us-gaap:RevolvingCreditFacilityMemberwba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember2021-11-300001618921wba:August2018RevolvingCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2018-08-290001618921wba:August2018RevolvingCreditAgreementMemberus-gaap:LetterOfCreditMember2018-08-290001618921wba:August2018RevolvingCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-11-300001618921us-gaap:CommercialPaperMember2021-09-012021-11-300001618921us-gaap:CommercialPaperMember2020-09-012020-11-300001618921us-gaap:CommercialPaperMembersrt:ReportableLegalEntitiesMembersrt:GuarantorSubsidiariesMember2020-09-012020-11-300001618921us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-11-300001618921us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-11-300001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-11-300001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-11-300001618921us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-11-300001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2021-11-300001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMember2021-11-300001618921us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-11-300001618921us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-11-300001618921us-gaap:TotalReturnSwapMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-11-300001618921us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-08-310001618921us-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-08-310001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-08-310001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-08-310001618921us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-08-310001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2021-08-310001618921us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMember2021-08-310001618921us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-08-310001618921us-gaap:OtherCurrentAssetsMemberus-gaap:TotalReturnSwapMemberus-gaap:NondesignatedMember2021-08-310001618921us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-08-310001618921us-gaap:TotalReturnSwapMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-08-310001618921us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-09-012021-11-300001618921us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2020-09-012020-11-300001618921us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:TotalReturnSwapMemberus-gaap:NondesignatedMember2021-09-012021-11-300001618921us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:TotalReturnSwapMemberus-gaap:NondesignatedMember2020-09-012020-11-300001618921us-gaap:ForeignExchangeForwardMemberwba:OtherIncomeExpensesMemberus-gaap:NondesignatedMember2021-09-012021-11-300001618921us-gaap:ForeignExchangeForwardMemberwba:OtherIncomeExpensesMemberus-gaap:NondesignatedMember2020-09-012020-11-300001618921us-gaap:FairValueMeasurementsRecurringMember2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-11-300001618921us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel1Member2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMember2021-11-300001618921us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CrossCurrencyInterestRateContractMember2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CrossCurrencyInterestRateContractMember2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CrossCurrencyInterestRateContractMember2021-11-300001618921us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CrossCurrencyInterestRateContractMember2021-11-300001618921us-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMember2021-11-300001618921us-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-11-300001618921us-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-11-300001618921us-gaap:FairValueInputsLevel3Memberus-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMember2021-11-300001618921us-gaap:FairValueMeasurementsRecurringMember2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-08-310001618921us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMemberus-gaap:FairValueInputsLevel1Member2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMember2021-08-310001618921us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CrossCurrencyInterestRateContractMember2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CrossCurrencyInterestRateContractMember2021-08-310001618921us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CrossCurrencyInterestRateContractMember2021-08-310001618921us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CrossCurrencyInterestRateContractMember2021-08-310001618921us-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMember2021-08-310001618921us-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-08-310001618921us-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-08-310001618921us-gaap:FairValueInputsLevel3Memberus-gaap:TotalReturnSwapMemberus-gaap:FairValueMeasurementsRecurringMember2021-08-310001618921us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-11-300001618921us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-11-300001618921us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-09-012021-11-300001618921us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-09-012020-11-300001618921us-gaap:OtherExpenseMember2021-09-012021-11-300001618921us-gaap:OtherExpenseMember2020-09-012020-11-300001618921us-gaap:OtherIncomeMember2021-09-012021-11-300001618921us-gaap:OtherIncomeMember2020-09-012020-11-300001618921country:US2021-09-012021-11-300001618921country:US2020-09-012020-11-300001618921us-gaap:ForeignPlanMember2021-09-012021-11-300001618921us-gaap:ForeignPlanMember2020-09-012020-11-300001618921us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-08-310001618921us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-08-310001618921wba:AOCINetInvestmentHedgesParentMember2021-08-310001618921us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-08-310001618921wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember2021-08-310001618921us-gaap:AccumulatedTranslationAdjustmentMember2021-08-310001618921us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-012021-11-300001618921us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-012021-11-300001618921wba:AOCINetInvestmentHedgesParentMember2021-09-012021-11-300001618921us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-012021-11-300001618921wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember2021-09-012021-11-300001618921us-gaap:AccumulatedTranslationAdjustmentMember2021-09-012021-11-300001618921us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-11-300001618921us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-11-300001618921wba:AOCINetInvestmentHedgesParentMember2021-11-300001618921us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-11-300001618921wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember2021-11-300001618921us-gaap:AccumulatedTranslationAdjustmentMember2021-11-300001618921us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-08-310001618921us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-08-310001618921wba:AOCINetInvestmentHedgesParentMember2020-08-310001618921us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-08-310001618921wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember2020-08-310001618921us-gaap:AccumulatedTranslationAdjustmentMember2020-08-310001618921us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-012020-11-300001618921us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-012020-11-300001618921wba:AOCINetInvestmentHedgesParentMember2020-09-012020-11-300001618921us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-012020-11-300001618921wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember2020-09-012020-11-300001618921us-gaap:AccumulatedTranslationAdjustmentMember2020-09-012020-11-300001618921us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-11-300001618921us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-11-300001618921wba:AOCINetInvestmentHedgesParentMember2020-11-300001618921us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-11-300001618921wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember2020-11-300001618921us-gaap:AccumulatedTranslationAdjustmentMember2020-11-300001618921us-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2020-09-012020-11-300001618921us-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2020-09-012020-11-300001618921us-gaap:OperatingSegmentsMemberwba:WalgreensHealthMember2020-09-012020-11-300001618921wba:CorporateAndReconcilingItemsMember2021-09-012021-11-300001618921wba:CorporateAndReconcilingItemsMember2020-09-012020-11-300001618921us-gaap:OperatingSegmentsMemberwba:PharmacyMemberwba:UnitedStatesReportableSegmentMember2021-09-012021-11-300001618921us-gaap:OperatingSegmentsMemberwba:PharmacyMemberwba:UnitedStatesReportableSegmentMember2020-09-012020-11-300001618921us-gaap:RetailMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2021-09-012021-11-300001618921us-gaap:RetailMemberus-gaap:OperatingSegmentsMemberwba:UnitedStatesReportableSegmentMember2020-09-012020-11-300001618921us-gaap:OperatingSegmentsMemberwba:PharmacyMemberwba:InternationalReportableSegmentMember2021-09-012021-11-300001618921us-gaap:OperatingSegmentsMemberwba:PharmacyMemberwba:InternationalReportableSegmentMember2020-09-012020-11-300001618921us-gaap:RetailMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2021-09-012021-11-300001618921us-gaap:RetailMemberus-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMember2020-09-012020-11-300001618921us-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:PharmaceuticalWholesaleMember2021-09-012021-11-300001618921us-gaap:OperatingSegmentsMemberwba:InternationalReportableSegmentMemberwba:PharmaceuticalWholesaleMember2020-09-012020-11-300001618921us-gaap:TradeAccountsReceivableMember2021-11-300001618921us-gaap:TradeAccountsReceivableMember2021-08-310001618921us-gaap:SegmentContinuingOperationsMember2021-11-300001618921us-gaap:SegmentContinuingOperationsMember2021-08-310001618921wba:VillageMDMember2021-09-012021-11-30





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended November 30, 2021
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period From _______to _______
Commission File Number
001-36759
WALGREENS BOOTS ALLIANCE, INC.
(Exact name of registrant as specified in its charter)
Delaware47-1758322
(State or Other Jurisdiction of Incorporation or Organization)
(I.R.S. Employer Identification No.)
108 Wilmot Road, Deerfield, Illinois
60015
(Address of principal executive offices)(Zip Code)
(847) 315-3700
(Registrant’s telephone number, including area code)
__________________________________________
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueWBAThe NASDAQ Stock Market LLC
3.600% Walgreens Boots Alliance, Inc. notes due 2025WBA25The NASDAQ Stock Market LLC
2.125% Walgreens Boots Alliance, Inc. notes due 2026WBA26The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.         Yes  þ      No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                              Yes þ     No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer þ
Accelerated filer 
Non-accelerated filer 
Smaller reporting company 
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes       No þ
The number of shares outstanding of the registrant’s Common Stock, $0.01 par value, as of December 31, 2021 was 863,272,027.



WALGREENS BOOTS ALLIANCE, INC.

FORM 10-Q FOR THE THREE MONTHS ENDED NOVEMBER 30, 2021

TABLE OF CONTENTS

PART I.  FINANCIAL INFORMATION
 Item 1.
  a)
  b)
  c)
  d)
  e)
  f)
 Item 2.
a)
b)
c)
d)
e)
f)
g)
h)
i)
j)
k)
 Item 3.
 Item 4.



















WBA Q1 2022 Form 10-Q
2

PART I. FINANCIAL INFORMATION
Item 1. Consolidated Condensed Financial Statements (Unaudited)

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)
(in millions, except shares and per share amounts)
 November 30, 2021August 31, 2021
Assets  
Current assets:  
Cash and cash equivalents$4,135 $1,193 
Accounts receivable, net5,960 5,663 
Inventories9,475 8,159 
Other current assets745 800 
Total current assets20,314 15,814 
Non-current assets: 
Property, plant and equipment, net12,295 12,247 
Operating lease right-of-use assets21,826 21,893 
Goodwill21,520 12,421 
Intangible assets, net12,770 9,936 
Equity method investments (see Note 6)6,367 6,987 
Other non-current assets1,413 1,987 
Total non-current assets76,192 65,471 
Total assets$96,507 $81,285 
Liabilities, redeemable noncontrolling interest and equity  
Current liabilities:  
Short-term debt$2,647 $1,305 
Trade accounts payable (see Note 17)12,452 11,136 
Operating lease obligations2,266 2,259 
Accrued expenses and other liabilities6,973 7,260 
Income taxes110 94 
Total current liabilities24,447 22,054 
Non-current liabilities:  
Long-term debt11,199 7,675 
Operating lease obligations22,103 22,153 
Deferred income taxes1,970 1,850 
Other non-current liabilities3,422 3,413 
Total non-current liabilities38,694 35,091 
Commitments and contingencies (see Note 11)
Total liabilities63,141 57,145 
Redeemable noncontrolling interest2,787 319 
Equity:
Preferred stock $.01 par value; authorized 32 million shares, none issued
  
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at November 30, 2021 and August 31, 2021
12 12 
Paid-in capital10,966 10,988 
Retained earnings38,286 35,121 
Accumulated other comprehensive loss(2,301)(2,109)
Treasury stock, at cost; 308,671,242 shares at November 30, 2021 and 307,139,982 shares at August 31, 2021
(20,700)(20,593)
Total Walgreens Boots Alliance, Inc. shareholders’ equity26,263 23,419 
Noncontrolling interests4,316 402 
Total equity30,579 23,822 
Total liabilities, redeemable noncontrolling interest and equity$96,507 $81,285 
The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.

WBA Q1 2022 Form 10-Q
3


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EQUITY
(UNAUDITED)
(in millions, except shares)



Three months ended November 30, 2021
Equity attributable to Walgreens Boots Alliance, Inc.
Common stock sharesCommon stock amountTreasury stock amountPaid-in capitalAccumulated other comprehensive income (loss)Retained earningsNoncontrolling interestsTotal equity
August 31, 2021865,373,636 $12 $(20,593)$10,988 $(2,109)$35,121 $402 $23,822 
Net earnings— — — — — 3,580 (27)3,552 
Other comprehensive income (loss), net of tax— — — — (193)— (3)(196)
Dividends declared and distributions— — — — — (415)— (415)
Treasury stock purchases(3,179,750)— (154)— — — — (154)
Employee stock purchase and option plans1,648,490 — 47 (59)— — — (11)
Stock-based compensation— — — 35 — — — 35 
Business combination— — — — — — 3,944 3,944 
Noncontrolling interests contribution and other— — — 2 — — — 2 
November 30, 2021863,842,376 $12 $(20,700)$10,966 $(2,301)$38,286 $4,316 $30,579 

Three months ended November 30, 2020
 Equity attributable to Walgreens Boots Alliance, Inc.  
 Common stock sharesCommon stock amountTreasury stock amountPaid-in capitalAccumulated other comprehensive income (loss)Retained earningsNoncontrolling interestsTotal equity
August 31, 2020865,603,519 $12 $(20,575)$10,761 $(3,771)$34,210 $498 $21,136 
Net earnings (loss)— — — — — (308)9 (299)
Other comprehensive income (loss), net of tax— — — — 88 — 2 90 
Dividends declared and distributions— — — — — (405)— (405)
Treasury stock purchases(3,000,000)— (110)— — — — (110)
Employee stock purchase and option plans1,298,298 — 43 (39)— — — 4 
Stock-based compensation— — — 36 — — — 36 
Adoption of new accounting standards— — — — — (3)(3)(5)
Business combination— — — 117 — — — 117 
Noncontrolling interests contribution and other— — — 1 — — — 1 
November 30, 2020863,901,817 $12 $(20,642)$10,876 $(3,682)$33,495 $506 $20,563 

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.


WBA Q1 2022 Form 10-Q
4


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
(UNAUDITED)
(in millions, except per share amounts)



 Three months ended November 30,
 20212020
Sales$33,901 $31,438 
Cost of sales26,326 24,808 
Gross profit7,574 6,630 
Selling, general and administrative expenses6,391 5,792 
Equity earnings (loss) in AmerisourceBergen100 (1,373)
Operating income (loss)1,283 (535)
Other income2,617 63 
Earnings (loss) before interest and tax3,900 (472)
Interest expense, net86 136 
Earnings (loss) before tax3,814 (607)
Income tax provision (benefit)275 (207)
Post tax (loss) earnings from other equity method investments(7)15 
Net earnings (loss) from continuing operations3,531 (385)
Net earnings from discontinued operations 87 
Net earnings (loss)3,531 (299)
Net (loss) earnings attributable to noncontrolling interests - continuing operations(48)5 
Net earnings attributable to noncontrolling interests - discontinued operations 4 
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.$3,580 $(308)
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.:
Continuing operations$3,580 $(391)
Discontinued operations 83 
Total$3,580 $(308)
Basic net earnings (loss) per common share:  
Continuing operations$4.13 $(0.45)
Discontinued operations 0.10 
Total$4.13 $(0.36)
Diluted net earnings (loss) per common share:
Continuing operations$4.13 $(0.45)
Discontinued operations 0.10 
Total$4.13 $(0.36)
Weighted average common shares outstanding:  
Basic865.8 865.3 
Diluted867.6 865.3 

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.


WBA Q1 2022 Form 10-Q
5


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
(in millions)



 Three months ended November 30,
 20212020
Comprehensive income:  
Net earnings (loss)$3,531 $(299)
Other comprehensive (loss) income, net of tax:  
Pension/postretirement obligations(5)11 
Unrealized gain on cash flow hedges1 4 
Net investment hedges 44 (7)
Movement on available for debt sale securities(96) 
Share of other comprehensive (loss) income of equity method investments(46)5 
Currency translation adjustments(94)80 
Total other comprehensive (loss) income(196)94 
Total comprehensive income (loss)3,336 (206)
Comprehensive (loss) income attributable to noncontrolling interests(51)14 
Comprehensive income (loss) attributable to Walgreens Boots Alliance, Inc.$3,387 $(220)

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.


WBA Q1 2022 Form 10-Q
6

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in millions)
 Three months ended November 30,
 20212020
Cash flows from operating activities:
  
Net earnings (loss)$3,531 $(299)
Adjustments to reconcile net earnings to net cash provided by operating activities:  
Depreciation and amortization500 475 
Deferred income taxes164 (348)
Stock compensation expense35 36 
Equity (earnings) loss from equity method investments(93)1,350 
Gain on previously held investment interests(2,576) 
Other95 (71)
Changes in operating assets and liabilities:  
Accounts receivable, net(127)(259)
Inventories(1,352)(1,225)
Other current assets(58)36 
Trade accounts payable1,335 1,398 
Accrued expenses and other liabilities(399)(105)
Income taxes79 132 
Other non-current assets and liabilities(36)74 
Net cash provided by operating activities1,099 1,195 
Cash flows from investing activities:
  
Additions to property, plant and equipment(454)(431)
Proceeds from sale-leaseback transactions202 231 
Business, investment and asset acquisitions, net of cash acquired(1,800)(77)
Other95 19 
Net cash (used for) investing activities(1,958)(259)
Cash flows from financing activities:
  
Net change in short-term debt with maturities of 3 months or less937 (347)
Proceeds from debt7,940 3,310 
Payments of debt(4,444)(2,807)
Stock purchases(154)(110)
Proceeds related to employee stock plans19 4 
Cash dividends paid(413)(405)
Other(7)4 
Net cash provided by (used for) financing activities3,877 (352)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(20)10 
Changes in cash, cash equivalents and restricted cash:
  
Net increase in cash, cash equivalents and restricted cash2,998 594 
Cash, cash equivalents and restricted cash at beginning of period1,270 746 
Cash, cash equivalents and restricted cash at end of period$4,268 $1,339 

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.

WBA Q1 2022 Form 10-Q
7

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

Note 1. Accounting policies

Basis of presentation
The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated.

The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2021, as amended by Form 10-K/A for the fiscal year ended August 31, 2021 filed on November 24, 2021.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of the COVID-19 pandemic (“COVID-19”). The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous factors discussed throughout this Quarterly Report on Form 10-Q including, but not limited to, the severity and duration of COVID-19, the extent to which it will impact our customers, team members, suppliers, vendors, business partners and distribution channels. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of November 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ.

In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years.

On June 1, 2021, the Company completed the sale of the majority of the Company's Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (“Disposal Group”) to AmerisourceBergen Corporation (“AmerisourceBergen”). The Disposal Group met the criteria to be reported as discontinued operations. Therefore, the operating results of the Disposal Group are reported as discontinued operations for all prior periods.

Effective as of the first quarter of fiscal year 2022, the Company is aligned into three reportable segments: United States, International and Walgreens Health. Unless otherwise specified, disclosures in these Consolidated Condensed Financial Statements reflect continuing operations only. Certain prior period data, related to discontinued operations has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. See Note 2 Discontinued operations and Note 15 Segment reporting for further information.

Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented.



WBA Q1 2022 Form 10-Q
8

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2. Discontinued operations

On June 1, 2021, the Company completed the sale of Alliance Healthcare, for total consideration of $6.9 billion, which included cash consideration of $6.7 billion, subject to net working capital and net cash adjustments and 2 million shares of AmerisourceBergen common stock.

As of November 30, 2021, Other current assets include a $98 million receivable for purchase price consideration due from AmerisourceBergen that is subject to change upon the finalization of net working capital adjustments.

The operating results of the Disposal Group are reported as discontinued operations as the disposition reflected a strategic shift that has, or will have, a major effect on the Company’s operations and financial results.

Results of discontinued operations were as follows (in millions):
 Three months ended November 30, 2020
Sales$5,327 
Cost of sales4,818 
Gross profit509 
Selling, general and administrative expense415 
Operating income from discontinued operations94 
Other expense(2)
Interest expense, net(4)
Earnings before income tax – discontinued operations88 
Income tax provision8
Post tax earnings from other equity method investments7
Net earnings from discontinued operations$87 

Sales from the Disposal Group to the Company's continuing operations are not eliminated and aggregate to (in millions):
 Three months ended November 30, 2020
Sales$458 

Cash flows from operating and investing activities for discontinued operations are (in millions):
 Three months ended November 30, 2020
Cash used in operating activities - discontinued operations$(45)
Cash used for investing activities - discontinued operations(19)

See Note 17 Related parties, to the Consolidated Condensed Financial Statements for more information on the Company's transactions and continuing involvement with AmerisourceBergen.


WBA Q1 2022 Form 10-Q
9

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 3. Acquisitions

VillageMD
On November 24, 2021, the Company completed the acquisition of Village Practice Management Company, LLC (“VillageMD”). Pursuant to the terms and subject to the conditions set forth in the Unit Purchase Agreement, the Company purchased additional outstanding equity interests of VillageMD, increasing the Company’s total beneficial ownership in VillageMD’s outstanding equity interests from approximately 30% to approximately 63%, on a fully diluted basis, for a purchase price of $5.2 billion. The total purchase price comprises cash consideration of $4.0 billion and a promissory note of $1.2 billion. The cash consideration consisted of $2.9 billion to be paid to existing shareholders, after giving affect to the $1.9 billion tender offer described below, as well as $1.1 billion paid in exchange for new preferred units issued by VillageMD. Subject to notice being served, the Company has an option to prepay the promissory note at any time and VillageMD may require the Company to redeem the promissory note after February 1, 2022. The promissory note is eliminated in consolidation within the Consolidated Condensed Balance Sheets.

On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.

The Company accounted for this acquisition as a business combination resulting in consolidation of VillageMD within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. As of November 30, 2021, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired. As such, the preliminary purchase price allocation will be subject to further refinement and may change. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified.

As a result of this acquisition, the Company recognized a pre-tax gain in Other income in the Consolidated Condensed Statements of Earnings, of $1,597 million related to the fair valuation of the Company’s previously held minority equity interest. The Company also recorded a pre-tax gain of $577 million in Other income in the Consolidated Condensed Statements of Earnings related to the conversion to equity of the Company’s previously held investment in convertible debt securities of VillageMD, reclassified from within accumulated other comprehensive income.

The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):

Purchase Price Allocation:
Total purchase price$5,200 
Less: purchase price for issuance of new preferred units at fair value 1
(2,300)
Net consideration$2,900 
Fair value of share-based compensation awards attributable to pre-combination services 2
683 
Fair value of previously held equity and debt3,211 
Fair value of non-controlling interest3,257 
Total$10,051 
Identifiable assets acquired and liabilities assumed:
Tangible assets 1
$637 
Intangible assets1,982 
Liabilities(241)
Total identifiable net assets$2,378 
Goodwill$7,673 

WBA Q1 2022 Form 10-Q
10

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

1.Comprises cash consideration of $1.1 billion and a promissory note of $1.2 billion. This consideration was provided in exchange for the issuance of new preferred units by VillageMD. VillageMD’s tangible assets acquired exclude this $1.1 billion of cash and $1.2 billion promissory note receivable.
2.Primarily related to vested share-based compensation awards.

The goodwill represents anticipated future growth and expansion opportunities into new markets. Pro forma sales and net earnings of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported.

Shields acquisition
On October 29, 2021, the Company completed the acquisition of Shields Health Solutions Parent, LLC (“Shields”). Pursuant to the terms and subject to the conditions set forth in the Securities Purchase Agreement, the Company purchased additional outstanding equity interests of Shields, increasing the Company’s total beneficial ownership in Shields’ outstanding equity interests from 25% to approximately 70%, on a fully diluted basis, for cash consideration of $969 million, subject to certain purchase price adjustments.

The Company accounted for this acquisition as a business combination resulting in consolidation of Shields within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. Under the terms of the transaction agreements, the Company has an option to acquire the remaining equity interests of Shields in the future. Shields’ other equity holders will also have an option to require the Company to purchase the remaining equity interests. Considering the contractual terms related to the noncontrolling interest, it is classified as redeemable noncontrolling interest in the Consolidated Condensed Balance Sheets.

As of November 30, 2021, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired. As such, the preliminary purchase price allocation will be subject to further refinement and may result in changes. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified.

As a result of this acquisition, the Company remeasured its previously held minority equity interest in Shields at fair value resulting in a pre-tax gain of $402 million recognized in Other income in the Consolidated Condensed Statements of Earnings.

The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):

Purchase Price Allocation:
Cash consideration$969 
Fair value of share-based compensation awards attributable to pre-combination services13 
Fair value of previously held equity interests502 
Fair value of non-controlling interests589 
Total$2,074 
Identifiable assets acquired and liabilities assumed:
Tangible assets$84 
Intangible assets1,060 
Liabilities(528)
Total identifiable net assets$616 
Goodwill$1,457 

The goodwill represents anticipated future growth and expansion opportunities into new healthcare offerings. Pro forma sales and net earnings of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported.

WBA Q1 2022 Form 10-Q
11

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

See Note 15 Segment reporting and Note 16 Sales for further information.

Other acquisitions
The Company acquired certain prescription files and related pharmacy inventory primarily in the U.S. for the aggregate purchase price of $74 million and $38 million during the three months ended November 30, 2021 and 2020, respectively.

Note 4. Exit and disposal activities

Transformational Cost Management Program
On December 20, 2018, the Company announced a transformational cost management program that was expected to deliver in excess of $2.0 billion of annual cost savings by fiscal 2022 (the “Transformational Cost Management Program”). The Company achieved this goal at the end of fiscal 2021.

On October 12, 2021, the Company’s Board of Directors approved an expansion and extension of the Transformational Cost Management Program through the end of fiscal 2024. As a result, the Company increased its annual cost savings target to $3.3 billion by the end of fiscal 2024.

The Transformational Cost Management Program, which is multi-faceted and includes divisional optimization initiatives, global smart spending, global smart organization and the transformation of the Company’s information technology (IT) capabilities, is designed to help the Company achieve increased cost efficiencies. To date, the Company has taken actions across all aspects of the Transformational Cost Management Program which focus on the United States and International reportable segments along with the Company’s global functions. Divisional optimization within the Company’s segments includes activities such as optimization of stores. As a result of the expanded program, the Company plans to reduce its presence by up to 150 Boots stores in the UK and up to 150 stores in the United States over the next three years which are incremental to the previously planned reductions of approximately 200 Boots stores in the UK and approximately 250 stores in the United States.

The Company currently estimates that the Transformational Cost Management Program will result in cumulative pre-tax charges to its GAAP financial results of approximately $3.6 billion to $3.9 billion, of which $3.3 billion to $3.6 billion are expected to be recorded as exit and disposal activities. In addition to these impacts, as a result of the actions related to store closures taken under the Transformational Cost Management Program, the Company recorded $508 million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard (Topic 842) that became effective on September 1, 2019.

Since the inception of the Transformational Cost Management Program to November 30, 2021, the Company has recognized cumulative pre-tax charges to its financial results in accordance with GAAP of $1.5 billion, which were primarily recorded within selling, general and administrative expenses. These charges included $442 million related to lease obligations and other real estate costs, $292 million in asset impairments, $550 million in employee severance and business transition costs and $172 million of information technology transformation and other exit costs.

Costs related to exit and disposal activities under the Transformational Cost Management Program for the three months ended November 30, 2021 and 2020, respectively, were as follows (in millions):
Three months ended November 30, 2021United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$87 $2 $ $89 
Asset impairments15 25  40 
Employee severance and business transition costs20 10 7 37 
Information technology transformation and other exit costs1 7 1 9 
Total pre-tax exit and disposal charges$123 $44 $9 $175 


WBA Q1 2022 Form 10-Q
12

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Three months ended November 30, 2020United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$22 $ $ $22 
Asset impairments4 (2) 1 
Employee severance and business transition costs12 28 12 52 
Information technology transformation and other exit costs10 (5) 5 
Total pre-tax exit and disposal charges$48 $21 $12 $81 

The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):
Lease obligations and other real estate costsAsset ImpairmentsEmployee severance and business transition costsInformation technology transformation and other exit costsTotal
Balance at August 31, 2021$17 $ $77 $20 $114 
Costs89 40 37 9 175 
Payments(15) (51)(7)(74)
Other(72)(40)(3) (115)
Currency  (1) (1)
Balance at November 30, 2021$19 $ $59 $23 $101 

Note 5. Leases

The Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. For the majority of leases in the U.S., the initial lease term is typically 15 to 25 years, followed by additional terms containing renewal options typically at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.

Supplemental balance sheet information related to leases were as follows (in millions):

Balance Sheet supplemental information:November 30, 2021August 31, 2021
Operating Leases:
Operating lease right-of-use assets$21,826 $21,893 
Operating lease obligations - current2,266 2,259 
Operating lease obligations - non-current 22,103 22,153 
Total operating lease obligations$24,369 $24,412 
Finance Leases:
Right-of-use assets included in:
Property, plant and equipment, net$713 $725 
Lease obligations included in:
Accrued expenses and other liabilities37 37 
Other non-current liabilities963 974 
Total finance lease obligations$1,000 $1,010 

WBA Q1 2022 Form 10-Q
13

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Supplemental income statement information related to leases were as follows (in millions):
Three months ended November 30,
Statement of Earnings supplemental information:20212020
Operating lease cost
Fixed$805 $805 
Variable 1
205 158 
Finance lease cost
Amortization$11 $11 
Interest13 13 
Sublease income25 20 
Impairment of right-of-use assets68 10 
Gain on sale and leaseback 2
87 93 

1Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume.
2Recorded within selling, general and administrative expenses.

Other supplemental information related to leases were as follows (in millions):
Three months ended November 30,
Other Supplemental Information:20212020
Cash paid for amounts included in the measurement of lease obligations:
Operating cash flows from operating leases$846 $857 
Operating cash flows from finance leases12 12 
Financing cash flows from finance leases11 10 
Total$869 $879 
Right-of-use assets obtained in exchange for new lease obligations:
Operating leases$544 $787 
Finance leases5  
Total$549 $787 

Average lease term and discount rate were as follows:
Weighted average terms and discount rates:November 30, 2021August 31, 2021
Weighted average remaining lease term in years:
Operating leases10.210.3
Finance leases20.120.2
Weighted average discount rate:
Operating leases4.75 %4.77 %
Finance leases5.18 %5.18 %


WBA Q1 2022 Form 10-Q
14

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):
Future lease payments:
Fiscal yearFinance leaseOperating lease
2022 (Remaining period)$67 $2,608 
202388 3,376 
202488 3,260 
202587 3,145 
202687 3,032 
202786 2,924 
Later1,054 12,801 
Total undiscounted minimum lease payments$1,556 $31,146 
Less: Present value discount(556)(6,777)
Lease liability$1,000 $24,369 

Note 6. Equity method investments

Equity method investments were as follows (in millions, except percentages):
 November 30, 2021August 31, 2021
 Carrying valueOwnership percentageCarrying valueOwnership percentage
AmerisourceBergen$4,393 28%$4,407 28%
Others1,974 
8% - 50%
2,580 
8% - 50%
Total$6,367  $6,987  

AmerisourceBergen investment
As of November 30, 2021 and August 31, 2021, the Company owned 58,854,867 AmerisourceBergen common shares representing approximately 28.3% of its outstanding common stock based on the most recent share count publicly reported by AmerisourceBergen in its most recent Annual Report on Form 10-K.

The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings (loss) attributable to the Company’s investment being classified within the operating income of its United States segment. Due to the timing and availability of financial information of AmerisourceBergen, the Company accounts for this equity method investment on a financial reporting lag of two months. Equity earnings (loss) from AmerisourceBergen are reported as a separate line in the Consolidated Condensed Statements of Earnings.

During the three months ended November 30, 2021 and 2020, the Company recognized equity income of $100 million and equity losses of $1.4 billion, in AmerisourceBergen, respectively. The equity losses for the period ended November 30, 2020 were primarily due to AmerisourceBergen's recognition of loss of $5.6 billion, net of tax, related to its ongoing opioid litigation in its financial statements for the three months ended September 30, 2020.

The Level 1 fair market value of the Company’s equity investment in AmerisourceBergen common stock at November 30, 2021 and August 31, 2021 was $6.8 billion and $7.2 billion, respectively. As of November 30, 2021 the carrying value of the Company’s investment in AmerisourceBergen exceeded its proportionate share of the net assets of AmerisourceBergen by $4.3 billion. This premium of $4.3 billion was recognized as part of the carrying value in the Company’s equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets.

Other investments
The Company’s other equity method investments include its U.S. investments in HC Group Holdings I, LLC (“HC Group Holdings”) which owns equity interest in Option Care Health, and BrightSpring Health Services, and the Company’s China investments in Sinopharm Medicine Holding Guoda Drugstores Co., Ltd, Guangzhou Pharmaceuticals Corporation and Nanjing

WBA Q1 2022 Form 10-Q
15

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Pharmaceutical Company Limited. The Company reported $7 million of post-tax equity losses and $15 million of post-tax equity earnings from other equity method investments for the three months ended November 30, 2021 and 2020, respectively.

During the three months ended November 30, 2021, the Company acquired majority equity interests in VillageMD and Shields. The Company accounted for these acquisitions as business combinations resulting in the remeasurement of its previously held minority equity interests and convertible debt securities at fair value resulting in pre-tax gains of $2,174 million and $402 million for VillageMD and Shields, respectively, recognized in Other income in the Consolidated Condensed Statements of Earnings. As a result of these transactions, the Company now consolidates VillageMD and Shields within the Walgreens Health segment in its financial statements.

Summarized financial information

Summarized financial information for the Company’s equity method investments in aggregate is as follows:

Statements of earnings (loss) (in millions)
 Three months ended November 30,
20212020
Sales$67,588 $56,088 
Gross Profit3,420 2,410 
Net earnings (loss)308 (4,806)
Share of earnings (loss) from equity method investments93 (1,357)

The summarized financial information for equity method investments has been included on an aggregated basis for all investments as reported at the end of each reporting period.

Note 7. Goodwill and other intangible assets

Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit or intangible asset below its carrying value.

Based on the analysis completed during fiscal 2021, as of the June 1, 2021 valuation date, the fair values of the Company’s reporting units exceeded their carrying amounts ranging from approximately 18% to approximately 195%. Boots reporting unit's fair value was in excess of its carrying value by approximately 18%, compared to a nominal amount as of June 1, 2020. Other international reporting unit's fair value was in excess of its carrying value by approximately 29%. As of November 30, 2021 the carrying values of goodwill were $1.0 billion and $372 million for Boots reporting unit and Other international reporting unit, respectively. The fair values of indefinite-lived intangibles within the Boots reporting unit exceeded their carrying value amounts ranging from approximately 5% to approximately 27%. As of November 30, 2021 and August 31, 2021 the carrying value of the indefinite-lived intangibles within the Boots reporting unit was $7.2 billion and $7.3 billion, respectively.

The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions with respect to the business and financial performance of the Company’s reporting units, as well as how such performance may be impacted by COVID-19.

Although the Company believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions, including the impact of COVID-19, could have a significant impact on either the fair value of the reporting units and indefinite-lived intangibles, the amount of any goodwill and indefinite-lived intangible impairment charges, or both. These estimates can be affected by a number of factors including, but not limited to, the impact of COVID-19, its severity, duration and its impact on global economies, general economic conditions as well as our profitability. The Company will continue to monitor these potential impacts, including the impact of COVID-19 and economic, industry and market trends and the impact these may have on the Boots and Other international reporting units.


WBA Q1 2022 Form 10-Q
16


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions):

Goodwill roll forward:United StatesInternationalWalgreens HealthWalgreens Boots Alliance, Inc.
August 31, 2021$10,947 $1,474 $ $12,421 
Acquisitions  9,130 9,130 
Currency translation adjustments (32) (32)
November 30, 2021$10,947 $1,443 $9,130 $21,520 

The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):

Intangible assetsNovember 30, 2021August 31, 2021
Gross amortizable intangible assets  
Customer relationships and loyalty card holders 1
$4,430 $3,522 
Primary care provider network1,660  
Trade names and trademarks708 361 
Purchasing and payer contracts317 317 
Developed technology290  
Others 75 221 
Total gross amortizable intangible assets$7,479 $4,421 
Accumulated amortization  
Customer relationships and loyalty card holders 1
$1,395 $1,335 
Trade names and trademarks228 226 
Purchasing and payer contracts284 227 
Developed technology17  
Others 29 37 
Total accumulated amortization1,953 1,826 
Total amortizable intangible assets, net$5,526 $2,595 
Indefinite-lived intangible assets  
Trade names and trademarks$5,208 $5,276 
Pharmacy licenses2,036 2,066 
Total indefinite-lived intangible assets$7,244 $7,342 
Total intangible assets, net$12,770 $9,936 

1Includes purchased prescription files.

Amortization expense for intangible assets was $165 million and $95 million for the three months ended November 30, 2021, and 2020, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2021 is as follows (in millions):
 2022 (Remaining period)20232024202520262027
Estimated annual amortization expense$462 $560 $541 $514 $490 $443 

WBA Q1 2022 Form 10-Q
17


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 8. Debt

Debt carrying values are presented net of unamortized discount and debt issuance costs, where applicable, and foreign currency denominated debt is translated using the spot rates as of the balance sheet date. Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):

 November 30, 2021August 31, 2021
Short-term debt   
Commercial paper$875 $ 
Credit facilities799  
$8 billion note issuance 1
3.300% unsecured notes due 2021 2
 1,250 
$4 billion note issuance 4
3.100% unsecured notes due 2022
731  
Other 3
242 56 
Total short-term debt$2,647 $1,305 
Long-term debt   
Credit facilities $2,990 $ 
$850 million note issuance 1
0.9500% unsecured notes due 2023
848  
$1.5 billion note issuance 1
3.200% unsecured notes due 2030
497 497 
4.100% unsecured notes due 2050
792 792 
$6 billion note issuance 1
  
3.450% unsecured notes due 2026
1,442 1,442 
4.650% unsecured notes due 2046
318 318 
$8 billion note issuance 1
3.800% unsecured notes due 2024
1,154 1,154 
4.500% unsecured notes due 2034
301 301 
4.800% unsecured notes due 2044
868 868 
£700 million note issuance 1
3.600% unsecured Pound sterling notes due 2025
403 408 
750 million note issuance 1
2.125% unsecured Euro notes due 2026
846 873 
$4 billion note issuance 4
3.100% unsecured notes due 2022
 731 
4.400% unsecured notes due 2042
263 263 
Other 3
477 29 
Total long-term debt, less current portion$11,199 $7,675 

1Notes are unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding.
2On September 18, 2021, the Company redeemed in full the $1.25 billion aggregate principal amount outstanding of its 3.300% unsecured notes due 2021 issued by the Company on November 18, 2014.
3Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. Other long term debt includes $447 million of debt acquired as part of Shields acquisition.

WBA Q1 2022 Form 10-Q
18


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
4Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.

$850 million Note Issuance
On November 17, 2021, the Company issued, in an underwritten public offering, $850 million of 0.95% Notes due 2023. The Notes contain a call option which allow for the Notes to be repaid, in full or in part, prior to May 17, 2022 (the “Par Call Date”) at 100% of the principal amount of the Notes to be redeemed or the sum of the present values of the remaining scheduled payments thereof to the Par Call Date discounted at the applicable treasury rate, plus 10 basis points and (ii) on or after the Par Call Date, at 100% of the principal amount of the Notes to be redeemed, in each case plus accrued and unpaid interest.

Credit facilities

November 15, 2021, Delayed Draw Term Loan
On November 15, 2021, the Company entered into a $5.0 billion senior unsecured multi-tranche delayed draw term loan credit facility, (the “November 2021 DDTL”) consisting of (i) a 364-day senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the“364-day loan”), (ii) a two-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the “two-year loan”) and (iii) a three-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $1.0 billion (the “three-year loan”). An aggregate amount of $3.0 billion or more of the November 2021 DDTL is for the purpose of funding the consideration due in respect of the purchase of an increased equity stake in VillageMD, and paying fees and expenses related to the foregoing, and the remainder can be used for general corporate purposes. The November 2021 DDTL is available for drawing in one or more tranches until May 15, 2022. The maturity date on the 364-day loan, the two-year loan and the three-year loan is, in each case, the earlier of the date that is 364 days, two years and three years from the date of the first drawing under each facility and February 14, 2023, February 15, 2024 and February 15, 2025 respectively. As of November 30, 2021 there were $3.0 billion in borrowings outstanding under the November 2021 DDTL.

December 23, 2020, Revolving Credit Agreement
On December 23, 2020, the Company entered into a $1.25 billion senior unsecured 364-day revolving credit agreement and a $2.25 billion senior unsecured 18-month revolving credit facility, with a swing line subfacility commitment amount of $350 million, with designated borrowers from time to time party thereto and lenders from time to time party thereto (the “2020
Revolving Credit Agreement”). The 364-day facility’s termination date is the earlier of (i) 364 days from December 23, 2020, the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the 364-day facility pursuant to the 2020 Revolving Credit Agreement. The 18-month facility’s termination date is the earlier of (i) 18 months from the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the 18-Month Facility pursuant to the 2020 Revolving Credit Agreement. As of November 30, 2021 there were $800 million in borrowings outstanding under the 2020 Revolving Credit Agreement.

August 2018 Revolving Credit Agreement
On August 29, 2018, the Company entered into a revolving credit agreement (the “August 2018 Revolving Credit Agreement”) with the lenders and letter of credit issuers from time-to-time party thereto. The August 2018 Revolving Credit Agreement is an unsecured revolving credit facility with aggregate commitment in the amount of $3.5 billion, with a letter of credit subfacility commitment amount of $500 million. The facility termination date is the earlier of (a) August 29, 2023, subject to extension thereof pursuant to the August 2018 Revolving Credit Agreement, and (b) the date of termination in whole of the aggregate amount of the revolving commitments pursuant to the August 2018 Revolving Credit Agreement. As of November 30, 2021, there were no borrowings outstanding under the August 2018 Revolving Credit Agreement.

Debt covenants
Each of the Company’s credit facilities described above contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, subject to increase in certain circumstances set forth in the applicable credit agreement. The credit facilities also contain various other customary covenants.


WBA Q1 2022 Form 10-Q
19


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Commercial paper
The Company periodically borrows under its commercial paper program and may borrow under it in future periods. The Company had average daily U.S. commercial paper outstanding of $712 million and $1.6 billion at a weighted average interest rate of 0.25% and 0.63% for the three months ended November 30, 2021 and 2020, respectively.

A subsidiary of the Company had average daily commercial paper outstanding, which was issued under the Joint HM Treasury and Bank of England's COVID Corporate Financing Facility commercial paper program, of £300 million, or approximately $401 million at a weighted average interest rate of 0.43% for the three months ended November 30, 2020. The subsidiary of the Company repaid the commercial paper issued under the Joint HM Treasury and Bank of England's COVID Corporate Financing Facility commercial paper program on May 14, 2021.

Interest
Interest paid by the Company was $153 million and $234 million for the three months ended November 30, 2021 and 2020, respectively.

Note 9. Financial instruments

The Company uses derivative instruments to hedge its exposure to market risks, including interest rate and currency risks, arising from operating and financing risks.

The Company has non-U.S. dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.
The notional amounts and fair value of derivative instruments outstanding were as follows (in millions):

November 30, 2021Notional Fair
Value
Location in Consolidated Condensed Balance Sheets
Derivatives designated as hedges:
Foreign currency forwards$5 $ Other non-current assets
Cross currency interest rate swaps1534Other non-current assets
Foreign currency forwards17 Other non-current liabilities
Cross currency interest rate swaps633 8 Other non-current liabilities
Foreign currency forwards61017Other current assets
Foreign currency forwards85 1 Other current liabilities
Cross currency interest rate swaps1575Other current liabilities
Derivatives not designated as hedges:
Foreign currency forwards$3,900 $64 Other current assets
Foreign currency forwards2,968 2 Other current liabilities
Total return swap271 11 Other current liabilities

WBA Q1 2022 Form 10-Q
20


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
August 31, 2021NotionalFair
Value
Location in Consolidated Condensed Balance Sheets
Derivatives designated as hedges:
Cross currency interest rate swaps$155 $1 Other non-current assets
Foreign currency forwards6  Other non-current assets
Foreign currency forwards23 1 Other non-current liabilities
Cross currency interest rate swaps801 23 Other non-current liabilities
Foreign currency forwards575 7 Other current assets
Foreign currency forwards31 1 Other current liabilities
Cross currency interest rate swaps109 9 Other current liabilities
Derivatives not designated as hedges:
Foreign currency forwards$3,636 $38 Other current assets
Total return swap224 2 Other current assets
Foreign currency forwards808 3 Other current liabilities
Total return swap37  Other current liabilities

Net investment hedges
The Company uses cross currency interest rate swaps and foreign currency forward contracts to hedge net investments in subsidiaries with non-U.S. dollar functional currencies. For qualifying net investment hedges, changes in the fair value of the derivatives are recorded in the currency translation adjustment within accumulated other comprehensive income (loss).
Cash flow hedges
The Company uses interest rate swaps to hedge the variability in forecasted cash flows of certain floating-rate debt. For qualifying cash flow hedges, changes in the fair value of the derivatives are recorded in accumulated other comprehensive income (loss) and released to the Consolidated Statements of Earnings when the hedged cash flows affect earnings.
Derivatives not designated as hedges
The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of foreign currency risks. The Company also utilizes total return swaps to economically hedge variability in compensation charges related to certain deferred compensation obligations. The income (expenses) due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):
  Three months ended November 30,
 Location in Consolidated Condensed Statements of Earnings20212020
Foreign currency forwardsSelling, general and administrative expenses$55 $(29)
Total return swapSelling, general and administrative expenses(2)13 
Foreign currency forwardsOther income (expense)(1)(9)

Derivatives credit risk
Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.

Derivatives offsetting
The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.



WBA Q1 2022 Form 10-Q
21


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 10. Fair value measurements

The Company measures certain assets and liabilities in accordance with Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2 - Observable inputs other than quoted prices in active markets.
Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
 November 30, 2021Level 1Level 2Level 3
Assets:
    
Money market funds 1
$319 $319 $ $ 
Investments in equity securities 2
1 1   
Investments in debt securities 3
20   20 
Foreign currency forwards 5
81  81  
Cross currency interest rate swaps 6
4  4  
Liabilities:
    
Foreign currency forwards 5
$4 $ $4 $ 
Cross currency interest rate swaps 6
12  12  
Total return swap11  11  
 August 31, 2021Level 1Level 2Level 3
Assets:
    
Money market funds 1
$634 $634 $ $ 
Investments in equity securities 2
2 2   
Investments in debt securities 4
663   663 
Foreign currency forwards 5
46  46  
Cross currency interest rate swaps 6
1  1  
Total return swaps2  2  
Liabilities:
Foreign currency forwards 5
$5 $ $5 $ 
Cross currency interest rate swaps 6
32  32  

1Money market funds are valued at the closing price reported by the fund sponsor.
2Fair values of quoted investments are based on current bid prices as of November 30, 2021 and August 31, 2021.
3Level 3 debt securities are valued using standard valuation techniques based on income and market approach.
4Level 3 debt securities include investments in convertible debt securities of VillageMD which are valued on a quarterly basis using the Probability Weighted Expect Return Method with gains or losses recorded in Other Comprehensive Income. Inputs include the enterprise value, expected holding term of the investment, volatility and risk-free interest rates.
5The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 9 Financial instruments, for additional information.
6The fair value of interest rate swaps and cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 9 Financial instruments, for additional information.

There were no transfers between Levels for the three months ended November 30, 2021.

WBA Q1 2022 Form 10-Q
22


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the Consolidated Financial Statements. As of November 30, 2021 the carrying amounts and estimated fair values of long-term notes outstanding including the current portion were $8.5 billion and $9.2 billion, respectively. The fair values of the notes outstanding are Level 1 fair value measures and determined based on quoted market prices and translated at the November 30, 2021 rate, as applicable. The fair values and carrying values of these issuances do not include notes that have been redeemed or repaid as of November 30, 2021. See Note 8 Debt, for further information.

The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

Note 11. Commitments and contingencies

The Company is involved in legal proceedings, including litigation, arbitration and other claims, and investigations, inspections, subpoenas, audits, claims, inquiries and similar actions by pharmacy, healthcare, tax and other governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized.

Like other companies in the retail pharmacy and pharmaceutical wholesale industries, the Company is subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which it operates. There continues to be a heightened level of review and/or audit by regulatory authorities of, and increased litigation regarding, the Company’s and the rest of the health care and related industry’s business, compliance and reporting practices. As a result, the Company regularly is the subject of government actions of the types described above. The Company also may be named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.

The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. With respect to litigation and other legal proceedings where the Company has determined that a material loss is reasonably possible, except as otherwise noted, the Company is unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.

On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co. and Walgreen Co., as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. (Cutler v. Wasson et al., No. 1:14-cv-10408 (N.D. Ill.)) The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On May 18, 2015, the case was stayed in light of a securities class action that was filed on April 10, 2015, described below. On November 3, 2016, the Court entered a stipulation and order extending the stay until the resolution of the securities class action.


WBA Q1 2022 Form 10-Q
23


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. (Washtenaw County Employees’ Retirement System v. Walgreen Co. et al., No. 1:15-cv-3187 (N.D. Ill.)) The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. A motion to dismiss a consolidated class action complaint filed on August 17, 2015 was granted in part and denied in part on September 30, 2016. The court granted plaintiff’s motion for class certification on March 29, 2018 and plaintiff filed a first amended complaint on December 19, 2018. A motion to dismiss the first amended complaint was granted in part and denied in part on September 23, 2019. Fact discovery and expert discovery have concluded. On November 2, 2021, the Court denied plaintiffs’ motion for summary judgment and granted in part and denied in part defendants’ cross motion.

On December 11, 2017, purported Rite Aid shareholders filed an amended complaint in a putative class action lawsuit in the U.S. District Court for the Middle District of Pennsylvania (the “M.D. Pa. action”) arising out of transactions contemplated by the merger agreement between the Company and Rite Aid. The amended complaint alleged that the Company and certain of its officers made false or misleading statements regarding the transactions. The Court denied the Company’s motion to dismiss the amended complaint on April 15, 2019. The Company filed an answer and affirmative defenses, and the Court granted plaintiffs' motion for class certification. Fact discovery has concluded and expert discovery is ongoing. In October and December 2020, two separate purported Rite Aid Shareholders filed lawsuits in the same court as the M.D. Pa. action opting out of the class in the M.D. Pa. action making nearly identical allegations as those in the M.D. Pa. action (the “Direct Actions”). On December 24, 2020, the parties to the Direct Actions filed a joint stipulation to stay the Direct Actions until the earlier of (a) 30 days after the entry of an order resolving any pre-trial dispositive motions in the M.D. Pa. action, or (b) 30 days after the entry of an order of final approval of any settlement of the M.D. Pa. action. The court so ordered the joint stipulation on December 28, 2020.

In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against an array of defendants by various plaintiffs such as counties, cities, hospitals, Indian tribes, and others, alleging claims generally concerning the impacts of widespread opioid abuse. The consolidated multidistrict litigation, captioned In re National Prescription Opiate Litigation (MDL No. 2804, Case No. 17-md-2804), is pending in the U.S. District Court for the Northern District of Ohio ("N.D. Ohio"). The Company is involved in the following multidistrict litigation (MDL) bellwether cases: (1) two consolidated cases in N.D. Ohio (Cnty. of Summit, Ohio, et al v. Purdue Pharma L.P., et al., Case No. 18-op-45090; Cnty. of Cuyahoga, Ohio, et al. v. Purdue Pharma L.P., Case No. 18-op-45004), previously scheduled for trial in November 2020 but postponed indefinitely; (2) one remanded to the U. S. District Court for the Eastern District of Oklahoma (The Cherokee Nation v. McKesson Corp., et al., Case No. 18-CV-00056-RAW-SPS), scheduled for trial in September 2022; and (3) one remanded to the U.S. District Court for the Northern District of California (City and Cnty. of San Francisco, et al. v. Purdue Pharma L.P., et al., Case No. 3:18-cv-07591-CRB), originally scheduled for trial in October 2021, but rescheduled for April 2022. The Company was also involved in two additional consolidated cases in N.D. Ohio (Cnty. of Lake, Ohio v. Purdue Pharma L.P., et al., Case No. 18-op-45032; Cnty. of Trumbull, Ohio v. Purdue Pharma L.P., et al., Case No. 18-op-45079), initially scheduled for trial in May 2021 but continued until October 2021. The jury in that case returned a verdict in favor of the plaintiffs as to liability, and the court will schedule a second trial regarding remedies to take place at some point in 2022. The court has yet to determine how much each defendant will pay in damages. The Company is unable to predict the outcome relative to remedies or apportionment and believes it has very strong grounds for appeal. In April 2021, the MDL court selected five additional bellwether cases involving the Company, all currently pending in N.D. Ohio: (1) Cobb Cnty. v. Purdue Pharma L.P., et al., Case No. 18-op-45817; (2) Durham Cnty. v. AmerisourceBergen Drug Corp., et al., Case No. 19-op-45346; (3) Montgomery Cnty. Bd. of Cnty. Commrs., et al. v. Cardinal Health, Inc., et al., Case No. 18-op-46326; (4) Board of Cnty. Commrs. of the Cnty. of Santa Fe v. Purdue Pharma L.P., et al., Case No. 18-op-45776; and (5) Cnty. of Tarrant v. Purdue Pharma L.P., et al., Case No. 18-op-45274.

The Company also has been named as a defendant in numerous lawsuits brought in state courts relating to opioid matters. Trial dates have been set in cases pending in state courts in New Mexico (State of New Mexico, ex rel. Hector Balderas, Attorney General v. Purdue Pharma L.P., et al., Case No. D-101-cv-2017-02541, First Judicial District Court, Santa Fe County, New Mexico - September 2022); West Virginia (State of West Virginia, ex rel. Patrick Morrisey, Attorney General v. Walgreens Boots Alliance, Inc., et al., Civil Action No.20-C-82 PNM, Circuit Court of Kanawha County, West Virginia, - September 2022; Missouri (Jefferson County, Missouri v. Dannie E. Williams, M.D., et al., Cause No. 20JE-CC00029, Twenty-Third Judicial Circuit, Jefferson County, Missouri - April 2023); Florida (State of Florida, Office of the Attorney General, Department of Legal Affairs v. Purdue Pharma L.P., et al., Case No. 2018-CA-001438, Sixth Judicial Circuit in and for Pasco County, Florida - April 2022); Nevada (State of Nevada v. McKesson Corporation, et al., Case No. A-19-796755-B, Eighth Judicial District Court, Clark County, Nevada - April 2023); Michigan (State of Michigan, ex rel. Dana Nessel, Attorney General v. Cardinal Health, Inc., et al., Case No. 19-016896-NZ, Circuit Court for Wayne County, Michigan - October 2022);

WBA Q1 2022 Form 10-Q
24


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
and Alabama (The DCH Health Care Authority, et al. v. Purdue Pharma LP, et al., Cause No. CV-2019-000007.00, Circuit Court of Conecuh County, Alabama - July 2022).

The relief sought by various plaintiffs in these matters includes compensatory, abatement and punitive damages, as well as injunctive relief. Additionally, the Company has received from the Department of Justice and the Attorney Generals of numerous states subpoenas, civil investigative demands, and/or other requests concerning opioid matters. The Company has also had communications with the Department of Justice with respect to purported violations of the federal Controlled Substances Act and the federal False Claims Act in dispensing prescriptions at certain Walgreens locations.

As discussed above, legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs and penalties incurred in these matters can be substantial.

Note 12. Income taxes

The effective tax rate for the three months ended November 30, 2021 was an expense of 7.2%, primarily due to lower tax expense on gains from consolidation of the Company’s investment in VillageMD and Shields, as a portion of these gains is not subject to tax. See Note 3 Acquisitions for further information.

The effective tax rate for the three months ended November 30, 2020 was a benefit of 34.0%, on a pretax loss for the three months ended November 30, 2020, primarily due to the discrete tax effect of equity losses in AmerisourceBergen. See Note 6 Equity method investments for further information.

Income taxes paid for the three months ended November 30, 2021 were $34 million, compared to $16 million for the three months ended November 30, 2020.

Note 13. Retirement benefits

The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan.

Defined benefit pension plans (non-U.S. plans)
The Company has various defined benefit pension plans outside the U.S. The principal defined benefit pension plan is the Boots Pension Plan (the “Boots Plan”), which covers certain employees in the UK. The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis.

Components of net periodic pension costs (income) for the defined benefit pension plans (in millions):
 Three months ended November 30,
 Location in Consolidated Condensed Statements of Earnings20212020
Service costsSelling, general and administrative expenses$1 $1 
Interest costsOther expense39 33 
Expected returns on plan assets/otherOther income(74)(80)
Total net periodic pension costs (income)$(33)$(45)

The Company made cash contributions to its defined benefit pension plans of $1 million for the three months ended November 30, 2021, which primarily related to committed payments. The Company plans to contribute an additional $40 million to its defined benefit pension plans in fiscal 2022.

Defined contribution plans
The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution is in the form of a guaranteed match which is made pursuant to the applicable plan document approved by the Walgreen Co. Board of Directors. Plan activity is reviewed

WBA Q1 2022 Form 10-Q
25


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
periodically by certain Committees of the Walgreens Boots Alliance Board of Directors. The profit-sharing provision was an expense of $69 million and $57 million for the three months ended November 30, 2021 and 2020, respectively.

The Company also has certain contract based defined contribution arrangements. The principal arrangement is based in UK to which both the Company and participating employees contribute. The Company recognized an expense of $25 million and $26 million for the three months ended November 30, 2021 and 2020, respectively.

Note 14. Accumulated other comprehensive income (loss)

The following is a summary of net changes in accumulated other comprehensive income (“AOCI”) by component and net of tax for the three months ended November 30, 2021 and 2020 (in millions):

Pension/ post-retirement obligationsUnrealized gain (loss) on cash flow hedgesNet investment hedgesUnrealized gain (loss) on available for sale securitiesShare of OCI of equity method investmentsCumulative translation adjustmentsTotal
Balance at August 31, 2021$(359)$(10)$(35)$96 $(29)$(1,772)$(2,109)
Other comprehensive income (loss) before reclassification adjustments(1)1 53 450 (60)(88)356 
Amounts reclassified from AOCI(5)1  (577) (4)(585)
Tax benefit (provision)1  (9)31 14  37 
Net change in other comprehensive income (loss)(5)1 44 (96)(46)(91)(193)
Balance at November 30, 2021$(364)$(9)$9 $ $(74)$(1,863)$(2,301)

Pension/ post-retirement obligationsUnrealized gain (loss) on cash flow hedgesNet investment hedgesUnrealized gain (loss) on available for sale securitiesShare of AOCI of equity method investmentsCumulative translation adjustmentsTotal
Balance at August 31, 2020$(748)$(31)$(34)$ $(10)$(2,948)$(3,771)
Other comprehensive income (loss) before reclassification adjustments17 4 (14) 7 72 85 
Amounts reclassified from AOCI(2)1    3 2 
Tax benefit (provision)(4)(1)8  (1) 1 
Net change in other comprehensive income (loss)11 4 (7) 5 75 88 
Balance at November 30, 2020$(736)$(27)$(41)$ $(5)$(2,873)$(3,682)


WBA Q1 2022 Form 10-Q
26


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 15. Segment reporting

In conjunction with the launch of its new consumer-centric healthcare strategy, in fiscal 2022, the Company announced the creation of a new operating segment, Walgreens Health. As a result, beginning in fiscal year 2022, the Company is now aligned into three reportable segments: United States, International and Walgreens Health. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.

United States
The Company’s United States segment includes the Walgreens business which includes the operations of retail drugstores, health and wellness services, and specialty and home delivery pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise.

International
The Company’s International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, the Benavides brand in Mexico and the Ahumada brand in Chile. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products.

Walgreens Health
The Company’s Walgreens Health segment currently consists of Walgreens Health, an organically developed consumer-centric omni-channel business that contracts with payors and providers to deliver clinical healthcare services to their members through both digital and physical channels; a majority equity ownership position in VillageMD, a leading, national provider of value-based primary care services; a majority equity ownership position in Shields, a specialty pharmacy integrator and accelerator for hospitals.

Selling, general and administrative costs for Walgreens Health for the three months ended November 30, 2020 have been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation.

The results of operations for reportable segments include procurement benefits. Corporate-related overhead costs are not allocated to reportable segments and are reported in the “Corporate and Other”.


WBA Q1 2022 Form 10-Q
27


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
The following table reflects results of operations of the Company’s reportable segments (in millions):

Three months ended November 30,
20212020
Sales:
United States$28,032 $27,163 
International5,818 4,285 
Walgreens Health51  
Corporate and Other 1
 (10)
Walgreens Boots Alliance, Inc.$33,901 $31,438 
Adjusted Operating income:
United States$1,690 $1,155 
International164 87 
Walgreens Health(13)(3)
Corporate and Other 1
(63)(42)
Walgreens Boots Alliance, Inc.$1,777 $1,196 

1Includes certain eliminations.

The following table reconciles adjusted operating income to operating income (in millions):

Three months ended November 30,
20212020
Adjusted operating income$1,777 $1,196 
Transformational cost management(203)(100)
Acquisition-related amortization(165)(95)
Acquisition-related costs(71)(21)
Adjustments to equity earnings (loss) in AmerisourceBergen(43)(1,481)
LIFO provision(14)(33)
Operating income (loss)$1,283 $(535)



WBA Q1 2022 Form 10-Q
28


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 16. Sales

The following table summarizes the Company’s sales by segment and by major source (in millions):
Three months ended November 30,
20212020
United States
Pharmacy$21,105 $20,869 
Retail6,927 6,294 
Total28,032 27,163 
International
Pharmacy1,017 895 
Retail1,796 1,522 
Wholesale3,005 1,868 
Total5,818 4,285 
Walgreens Health51  
Corporate and Other 1
 (10)
Walgreens Boots Alliance, Inc.$33,901 $31,438 
1Includes certain eliminations.

See Note 19 Supplemental information for further information on receivables from contracts with customers.

Note 17. Related parties

The Company has a long-term pharmaceutical distribution agreement with AmerisourceBergen pursuant to which the Company sources branded and generic pharmaceutical products from AmerisourceBergen principally for its U.S. operations. Additionally, AmerisourceBergen receives sourcing services for generic pharmaceutical products.
Related party transactions with AmerisourceBergen (in millions):
 Three months ended November 30,
 20212020
Purchases, net$15,791 $15,441 

 November 30, 2021August 31, 2021
Trade accounts payable, net$6,909 $6,589 

See Note 2 Discontinued operations for further information.

Note 18. New accounting pronouncements

Adoption of new accounting pronouncements

Receivables - nonrefundable fees and others
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other. This ASU clarifies the accounting for the amortization period for certain purchased callable debt securities held at a premium by giving consideration to securities which have multiple call dates. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

WBA Q1 2022 Form 10-Q
29


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

Investments — equity securities; Investments — equity method and joint ventures; Derivatives and hedging
In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Income taxes - simplifying the accounting for income taxes
In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Effects of reference rate reform on financial reporting
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable, or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to the above the ASU to clarify certain optional expedients in Topic 848. The Company adopted the new standard effective September 1, 2021, and the adoption did not have a material impact on the Company’s results of operations, cash flows or financial position.

New accounting pronouncements not yet adopted

Acquired contract assets and contract liabilities in a business combination
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance.

Disclosures by business entities about government assistance
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021 (fiscal 2023). The Company is evaluating the effect of adopting this new accounting guidance.

Note 19. Supplemental information

Accounts receivable
Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, including amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies). Trade receivables were $4.6 billion and $4.5 billion at November 30, 2021 and August 31, 2021, respectively. Other accounts receivable balances, which consist primarily of receivables from vendors and manufacturers, including receivables from AmerisourceBergen (see Note 17 Related parties), were $1.3 billion and $1.1 billion at November 30, 2021 and August 31, 2021, respectively.

WBA Q1 2022 Form 10-Q
30


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

Depreciation and amortization
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):
Three months ended November 30,
20212020
Depreciation expense$335 $342 
Intangible asset and other amortization165 95 
Total depreciation and amortization expense$500 $437 

Accumulated depreciation and amortization on property, plant and equipment was $13.3 billion at November 30, 2021 and $13.1 billion at August 31, 2021.

Restricted cash
The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):
November 30, 2021August 31, 2021
Cash and cash equivalents - continuing operations$4,135 $1,193 
Restricted cash - continuing operations (included in other current assets)133 77 
Cash, cash equivalents and restricted cash$4,268 $1,270 

Redeemable noncontrolling interest
The redeemable noncontrolling interest balance as of November 30, 2021 was $2,787 million increasing primarily due to acquisitions during the three months ended November 30, 2021. See Note 3 Acquisitions for further information.

The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):
Redeemable noncontrolling interest roll forward:Walgreens Boots Alliance, Inc.
August 31, 2021$319 
Acquisitions 1
2,489 
Net (loss)(21)
Redemption value adjustment7 
Currency translation adjustments and other(8)
November 30, 2021$2,787 

1 Includes $1.9 billion of redeemable non-controlling interest representing the maximum purchase price to redeem non-controlling units in VillageMD for cash. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.






WBA Q1 2022 Form 10-Q
31


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Earnings per share
The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 16.1 million weighted outstanding options to purchase common shares that were anti-dilutive and excluded from the first quarter earnings per share calculation as of November 30, 2021 compared to 18.5 million as of November 30, 2020.

Due to the anti-dilutive effect resulting from the reported net loss for the three months ended November 30, 2020, the incremental impact of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding.

Cash dividends declared per common share
Cash dividends per common share declared were as follows:

Quarter ended20212020
November$0.4775 $0.4675 


WBA Q1 2022 Form 10-Q
32


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
Item 2. Management’s discussion and analysis of financial condition and results of operations
The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes included elsewhere herein and the Consolidated Condensed Financial Statements, accompanying notes and management’s discussion and analysis of financial condition and results of operations and other disclosures contained in the Walgreens Boots Alliance, Inc. Annual Report on Form 10-K for the fiscal year ended August 31, 2021, as amended by Form 10-K/A for the fiscal year ended August 31, 2021 filed on November 24, 2021 (the “2021 10-K”). This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are not limited to, those discussed below under “Cautionary note regarding forward-looking statements”, and in Item 1A, Risk factors, in our 2021 10-K. References herein to the “Company”, “we”, “us”, or “our” refer to Walgreens Boots Alliance, Inc. and its subsidiaries, and in each case do not include unconsolidated partially-owned entities, except as otherwise indicated or the context otherwise requires.

Certain amounts in the management's discussion and analysis of financial condition and results of operations may not add due to rounding. All percentages have been calculated using unrounded amounts for each of the periods presented.

INTRODUCTION AND SEGMENTS

Walgreens Boots Alliance, Inc. and its subsidiaries (“Walgreens Boots Alliance” or the “Company”) is a global leader in retail pharmacy and is positioning to become a leading provider of healthcare services. Its operations are conducted through three reportable segments:
United States,
International, and
Walgreens Health

See Note 15 Segment reporting and Note 16 Sales, to the Consolidated Condensed Financial Statements for further information.

FACTORS, TRENDS AND UNCERTAINTIES AFFECTING OUR RESULTS AND COMPARABILITY
The Company has been, and we expect it to continue to be, affected by a number of factors that may cause actual results to differ from our historical results or current expectations. These factors include: the impact of the COVID-19 pandemic (“COVID-19”) on our operations and financial results; the financial performance of our equity method investees, including AmerisourceBergen Corporation (“AmerisourceBergen”); the influence of certain holidays; seasonality; foreign currency rates; changes in vendor, payer and customer relationships and terms and associated reimbursement pressure; strategic transactions and acquisitions, dispositions, joint ventures and other strategic collaborations; changes in laws, including U.S. tax law changes; changes in trade, tariffs, including trade relations between the U.S. and China, and international relations, including the UK's withdrawal from the European Union and its impact on our operations and prospects and those of our customers and counterparties; the timing and magnitude of cost reduction initiatives, including under our Transformational Cost Management Program (as defined below); the timing and severity of the cough, cold and flu season; fluctuations in variable costs; the impacts of looting, natural disasters, war, terrorism and other catastrophic events; and changes in general economic conditions in the markets in which the Company operates.

Specialty pharmacy represents a significant and growing proportion of prescription drug spending in the U.S., a significant
portion of which is dispensed outside of traditional retail pharmacies. To better serve the evolving specialty pharmacy market, in March 2017, we and Prime Therapeutics LLC, a pharmacy benefit management (“PBM”) company, closed a transaction to form a combined central specialty pharmacy and mail services company, AllianceRx Walgreens Prime, using an innovative model that seeks to align pharmacy, PBM, and health plans to coordinate patient care, improve health outcomes and deliver cost of care opportunities. Certain clients of our joint venture are not obligated to contract through our joint venture, and have in the past, and may in the future, enter into specialty pharmacy and other agreements without involving our joint venture. During fiscal 2021, and the first three months of fiscal 2022, certain clients chose not to renew their contracts through our joint venture which impacts gross sales. However, considering the relatively low margin nature of this business, the Company does not anticipate this will have a material impact on operating income.

These and other factors can affect the Company’s operations and net earnings for any period and may cause such results not to be comparable to the same period in previous years. The results presented in this report are not necessarily indicative of future operating results.


WBA Q1 2022 Form 10-Q
33


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
COVID-19
COVID-19 has severely impacted, and may continue to impact, the economies of the U.S., the UK and other countries around
the world. COVID-19 has created significant public health concerns as well as significant volatility, uncertainty and economic
disruption in every region in which we operate, which has adversely affected, and may again adversely affect, our industries and our business operations. Further, financial and credit markets experienced, and may again experience, volatility. Policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, temporary closure or reduced hours of operation of certain store locations in the U.S., the UK and other countries, reduced customer traffic and sales in our retail pharmacies and the adoption and continuation of work-from-home policies.

In response to COVID-19 and emerging variants, various domestic and foreign, federal, state and local governmental legislation, regulations, orders, policies and initiatives have been implemented that are designed to reduce the transmission of COVID-19, as well as to help address economic and market volatility and instability resulting from COVID-19. The Company has assessed and will continue to assess the impact of these governmental actions on the Company. The Company has participated in certain of these programs, including for example availing itself to certain tax deferrals which were introduced by the CARES Act in the U.S., and certain tax deferral and benefit and employee wage support in the UK, and if available, may continue to do so in the future.

The Company continues to play a critical role in fighting the COVID-19 pandemic. The Company has worked with the Centers for Disease Control and Prevention (“CDC”), U.S. Department of Health and Human Services (“HHS”) and the U.S. government to help administer COVID-19 vaccinations to the general public, high priority groups, including long-term care facility residents and staff. The United States segment also expanded vaccination models to ensure convenient access, including same-day and walk-in appointments, mobile clinics, employer partnerships and extended hours. As of November 30, 2021, the Company has administered more than 50 million COVID-19 vaccinations, including 8 million boosters, and more than 20 million COVID-19 tests in the U.S. During the three months ended November 30, 2021, the Company has administered more than 15.6 million COVID-19 vaccinations, including 8 million boosters, and more than 6.5 million COVID-19 tests in the U.S.

During the three months ended November 30, 2021, performance was driven by execution in COVID-19 vaccine and testing delivery, US retail sales growth, and continued recovery in International. In the US segment, comparable prescriptions filled increased in the quarter primarily driven by COVID-19 vaccinations. Comparable retail sales increased in the quarter, reflecting broad based growth across all categories including health and wellness, which was aided by at-home COVID-19 tests. Gross profit increased compared with the year-ago quarter driven by improved pharmacy margin, aided by COVID-19 vaccinations. The International segment experienced an increase in retail sales in the UK market following the lifting of COVID-19 restrictions, however footfall on the high street remained below pre-COVID-19 levels. The Company also incurred an increase in selling, general and administrative expenses (“SG&A”) when compared to prior year from investments to support COVID-19 vaccinations and testing in the US and COVID-19 related government support in the UK which occurred in the prior year-ago quarter.

The situation surrounding COVID-19 remains fluid, and could result in additional mandates and directives, including revisions
thereto, from foreign, federal, state, county and city authorities throughout the continuation of the COVID-19 pandemic and for
sometime thereafter. The impact on the U.S. and global economies, including supply chains and the labor force, and consumer, customer and health care utilization pattern depends upon the evolving factors and future developments related to COVID-19. As a result, the financial and/or operational impact on the Company, operating results, cash flows and/or financial condition is uncertain, but the impact, singularly or collectively, could be material and adverse.

The Company’s current expectations described above are forward-looking statements and our actual results may differ. Factors that might cause a difference include, but are not limited to, those discussed below under “Cautionary note regarding forward-looking statements” and in Item 1A, Risk factors, in our 2021 10-K.


WBA Q1 2022 Form 10-Q
34


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
STRATEGIC UPDATE
In October 2021, the Company announced the launch of its new healthcare strategy. The Company plans to become a leading provider of local clinical care services by leveraging its consumer-centric technology and pharmacy network to deliver value-based care. The Company also plans to continue to transform its core pharmacy and retail business. The Company’s goal is to provide better consumer experiences, improve health outcomes and lower costs.

WALGREENS HEALTH
At the center of the Company’s healthcare strategy is Walgreens Health, a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omni-channel experience across the care journey. Walgreens Health delivers improved health outcomes and lower costs for payors and providers by delivering care through owned and partnered assets. To advance its strategy, the Company completed majority equity investments in Village Practice Management Company, LLC (“VillageMD”) and Shields Health Solutions Parent, LLC (“Shields”) and announced investment in CareCentrix, Inc. (“CareCentrix”).

The Company has created a new operating segment, Walgreens Health, and is now aligned into three reportable segments: United States, International and Walgreens Health. Fiscal 2021 data related to the Walgreens Health segment, has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation.

See Note 15 Segment reporting to the Consolidated Condensed Financial Statements for further information.

RECENT TRANSACTIONS

VillageMD acquisition
On November 24, 2021, the Company completed the acquisition of VillageMD. Pursuant to the terms and subject to the conditions set forth in the Unit Purchase Agreement, the Company purchased additional outstanding equity interests of VillageMD, increasing the Company’s total beneficial ownership in VillageMD’s outstanding equity interests from approximately 30% to approximately 63%, on a fully diluted basis, for a purchase price of $5.2 billion. The total purchase price comprises cash consideration of $4.0 billion and a promissory note of $1.2 billion. The cash consideration consisted of $2.9 billion to be paid to existing shareholders, after giving affect to the $1.9 billion tender offer described below, as well as $1.1 billion paid in exchange for new preferred units issued by VillageMD. Subject to notice being served, the Company has an option to prepay the promissory note at any time and VillageMD may require the Company to redeem the promissory note after February 1, 2022. The promissory note is eliminated in consolidation within the Consolidated Condensed Balance Sheets.

On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.

The Company accounted for this acquisition as a business combination resulting in consolidation of VillageMD within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. As of November 30, 2021, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired. As such, the preliminary purchase price allocation will be subject to further refinement and may change. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified.

See Note 3 Acquisitions, and Note 6 Equity method investments to the Consolidated Condensed Financial Statements for further information.

Shields acquisition
On October 29, 2021, the Company completed the acquisition of Shields. Pursuant to the terms and subject to the conditions set forth in the Securities Purchase Agreement, the Company purchased additional outstanding equity interests of Shields, increasing the Company’s total beneficial ownership in Shields’ outstanding equity interests from 25% to approximately 70%, on a fully diluted basis, for cash consideration of $969 million, subject to certain purchase price adjustments.


WBA Q1 2022 Form 10-Q
35


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
The Company accounted for this acquisition as a business combination resulting in consolidation of Shields within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. Under the terms of the transaction agreements, the Company has an option to acquire the remaining equity interests of Shields in the future. Shields’ other equity holders will also have an option to require the Company to purchase the remaining equity interests. Considering the contractual terms related to the noncontrolling interest, it is classified as redeemable noncontrolling interest in the Consolidated Condensed Balance Sheets.

See Note 3 Acquisitions, and Note 6 Equity method investments to the Consolidated Condensed Financial Statements for further information.

CareCentrix acquisition
On September 4, 2021, the Company executed a Membership Interest Purchase Agreement to acquire a majority equity interest
in CareCentrix, a leading player in the post-acute and home care management sectors, which after the application of a net debt adjustment, is expected to be approximately $330 million.

The investment will result in the Company owning approximately 55% controlling equity interest in CareCentrix. Under the terms of the Agreement, the Company has an option to acquire the remaining equity interests of CareCentrix in the future. CareCentrix’ other equity holders will also have an option to require the Company to purchase the remaining equity interests.

The transaction is subject to the receipt of required regulatory clearances and approvals and other customary closing conditions. Upon closing, the Company will account for this acquisition as a business combination and consolidate CareCentrix in its financial statements.

Pharmaceutical Wholesale business in Germany
On November 30, 2021, the Company signed an agreement with McKesson Corporation to acquire the remaining 30% equity interest in the pharmaceutical wholesale business in Germany not currently owned by the Company. The transaction is subject to standard regulatory clearance by the relevant local authorities.

AllianceRx Walgreens Prime
On December 31, 2021, the Company completed a transaction with Prime Therapeutics LLC to acquire the remaining 45% minority equity interest in AllianceRx Walgreens Prime. AllianceRx Walgreens Prime is a specialty and home delivery pharmacy business in the United States.

TRANSFORMATIONAL COST MANAGEMENT PROGRAM
On December 20, 2018, the Company announced a transformational cost management program that was expected to deliver in excess of $2 billion of annual cost savings by fiscal 2022 (the “Transformational Cost Management Program”). The Company achieved this goal at the end of fiscal 2021.

On October 12, 2021, the Company’s Board of Directors approved an expansion and extension of the Transformational Cost Management Program through the end of fiscal 2024. As a result, the Company increased its annual cost savings target to $3.3 billion by the end of fiscal 2024.

The Transformational Cost Management Program, which is multi-faceted and includes divisional optimization initiatives, global smart spending, global smart organization and the transformation of the Company’s information technology (IT) capabilities, is designed to help the Company achieve increased cost efficiencies. To date, the Company has taken actions across all aspects of the Transformational Cost Management Program which focus on the United States and International reportable segments along with the Company’s global functions. Divisional optimization within the Company’s segments includes activities such as optimization of stores. As a result of the expanded program, the Company plans to reduce its presence by up to 150 Boots stores in the UK and up to 150 stores in the United States over the next three years which are incremental to the previously planned reductions of approximately 200 Boots stores in the UK and approximately 250 stores in the United States.

The Company currently estimates that the Transformational Cost Management Program will result in cumulative pre-tax charges to its GAAP financial results of approximately $3.6 billion to $3.9 billion, of which $3.3 billion to $3.6 billion are expected to be recorded as exit and disposal activities. The Company estimates that approximately 85% of the cumulative pre-

WBA Q1 2022 Form 10-Q
36


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
tax charges relating to the Transformational Cost Management Program represent current or future cash expenditures, primarily related to employee severance and business transition costs, IT transformation and lease and other real estate payments.

The Company currently estimates that it will recognize aggregate pre-tax charges to its GAAP financial results related to the Transformational Cost Management Program as follows:
Transformational Cost Management Program ActivitiesRange of Charges
Lease obligations and other real estate costs 1
$1,250 to 1,350 million
Asset impairments 2
$525 to 575 million
Employee severance and business transition costs$1,150 to 1,200 million
Information technology transformation and other exit costs$400 to 450 million
Total cumulative pre-tax exit and disposal costs$3.3 to 3.6 billion
Other IT transformation costs$275 to 325 million
Total estimated pre-tax costs$3.6 to 3.9 billion

1 Includes impairments relating to operating lease right-of-use and finance lease assets.
2 Primarily related to store closures and other asset impairments.

Since the inception of the Transformational Cost Management Program to November 30, 2021, the Company has recognized aggregate cumulative pre-tax charges to its financial results in accordance with GAAP of $1.7 billion, of which $1.5 billion are recorded as exit and disposal activities. See Note 4 Exit and disposal activities, to the Consolidated Condensed Financial Statements for additional information. These charges included $442 million related to lease obligations and other real estate costs, $292 million in asset impairments, $550 million in employee severance and business transition costs, $172 million of information technology transformation and other exit costs and $227 million other IT costs.

In addition to the impacts discussed above, as a result of the actions related to store closures taken under the Transformational Cost Management Program, the Company recorded $508 million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard (Topic 842) on September 1, 2019.

Costs from continuing operations under the Transformational Cost Management Program, which were primarily recorded in selling, general and administrative expenses for the three months ended November 30, 2021 and 2020, were as follows (in millions):
Three months ended November 30, 2021United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$87 $$— $89 
Asset impairments15 25 — 40 
Employee severance and business transition costs20 10 37 
Information technology transformation and other exit costs
Total pre-tax exit and disposal costs$123 $44 $9 $175 
Other IT transformation costs18 10 — 27 
Total pre-tax costs$141 $53 $9 $203 




WBA Q1 2022 Form 10-Q
37


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
Three months ended November 30, 2020United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$22 $— $— $22 
Asset impairments(2)— 
Employee severance and business transition costs12 28 12 52 
Information technology transformation and other exit costs10 (5)— 
Total pre-tax exit and disposal costs$48 $21 $12 $81 
Other IT transformation costs13 — 19 
Total pre-tax costs$61 $27 $12 $100 

The amounts and timing of all estimates are subject to change until finalized. The actual amounts and timing may vary materially based on various factors. See “Cautionary note regarding forward-looking statements” below.

INVESTMENT IN AMERISOURCEBERGEN
As of November 30, 2021 and August 31, 2021, the Company owned 58,854,867 of AmerisourceBergen common shares, representing approximately 28.3% of its outstanding common stock based on the share count publicly reported by AmerisourceBergen in its most recent Annual Report on Form 10-K. The Company has a shareholders agreement with AmerisourceBergen, which was most recently amended and restated in connection with the Alliance Healthcare Sale (the “A&R Shareholders Agreement”). Pursuant to the A&R Shareholders Agreement, the Company has designated one member of AmerisourceBergen’s board of directors. The Company is also permitted to acquire up to an additional 8,398,752 AmerisourceBergen shares in the open market, and thereafter to designate another member of AmerisourceBergen’s board of directors. The amount of permitted open market purchases is subject to increase or decrease in certain circumstances.

The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings (loss) attributable to the investment classified within the operating income (loss) of the Company's United States segment. During the three months ended November 30, 2021 and 2020, the Company recognized equity income of $100 million and equity losses of $1.4 billion, in AmerisourceBergen, respectively. The equity losses for the period ended November 30, 2020 were primarily due to AmerisourceBergen's recognition of loss of $5.6 billion, net of tax, related to its ongoing opioid litigation in its financial statements for the three months ended September 30, 2020.

The financial performance of AmerisourceBergen will impact the Company’s results of operations. Additionally, a substantial and sustained decline in the price of AmerisourceBergen’s common stock could trigger an impairment evaluation of our investment. These considerations may materially and adversely affect the Company’s financial condition and results of operations.

For more information, see Note 2 Discontinued operations and Note 6 Equity method investments, to the Consolidated Condensed Financial Statements.


WBA Q1 2022 Form 10-Q
38


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
EXECUTIVE SUMMARY
The following table presents certain key financial statistics.
 (in millions, except per share amounts)
 Three months ended November 30,
 20212020
Sales$33,901 $31,438 
Gross profit7,574 6,630 
Selling, general and administrative expenses6,391 5,792 
Equity earnings (loss) in AmerisourceBergen100 (1,373)
Operating income (loss)1,283 (535)
Adjusted operating income (Non-GAAP measure)1
1,777 1,196 
Earnings (loss) before interest and income tax provision3,900 (472)
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. - continuing operations (GAAP)3,580 (391)
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. - continuing operations (Non-GAAP measure)1
1,455 947 
Diluted net earnings (loss) per common share - continuing operations (GAAP)4.13 (0.45)
Adjusted diluted net earnings per common share - continuing operations (Non-GAAP measure)1
1.68 1.09 

 Percentage increases (decreases)
 Three months ended November 30,
 20212020
Sales7.85.1
Gross profit14.2(2.2)
Selling, general and administrative expenses10.4(1.3)
Operating income (loss)NM(158.1)
Adjusted operating income (Non-GAAP measure) 1
48.5(11.0)
Earnings (loss) before interest and income tax provisionNM(149.3)
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. - continuing operations (GAAP)NM(150.8)
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. - continuing operations (Non-GAAP measure)1
53.5(15.4)
Diluted net earnings (loss) per common share - continuing operations (GAAP)NM(152.3)
Adjusted diluted net earnings per common share - continuing operations (Non-GAAP measure)1
53.2(12.8)
 Percent to sales
 Three months ended November 30,
 20212020
Gross margin22.321.1
Selling, general and administrative expenses18.918.4

1See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.

NM - Not meaningful. Percentage increases above 200% or when one period includes income and other period includes loss are considered not meaningful.

WBA Q1 2022 Form 10-Q
39


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS

WALGREENS BOOTS ALLIANCE RESULTS OF OPERATIONS

Net earnings from continuing operations
Net earnings attributable to the Company for the three months ended November 30, 2021 was $3.6 billion compared to a net loss of $391 million for the prior year period. Diluted net earnings per share was $4.13 compared to diluted net loss per share of $0.45 for the prior year period. The increases in net earnings and diluted net earnings per share reflect a $2.5 billion after-tax gain due to the remeasurement of the Company's previously held minority equity and debt investments in VillageMD and Shields to fair value during the three months ended November 30, 2021, and a $1.2 billion charge, net of tax, from the company's equity earnings in AmerisourceBergen in the year-ago quarter.

Other income for the three months ended November 30, 2021 was $2.6 billion compared to $63 million for the prior year quarter. The increase in other income is mainly due to the remeasurement of the Company's previously held equity and debt investments in VillageMD and Shields to fair value during the three months ended November 30, 2021.

Net interest expense was $86 million and $136 million for the three months ended November 30, 2021 and 2020, respectively. The decrease in interest expense was primarily the result of debt extinguishments completed during fiscal 2021 and lower interest rates on remaining debt.

The Company's effective tax rate for the three months ended November 30, 2021 was an expense of 7.2 percent, primarily due to lower tax expense on gains from consolidation of the Company’s investment in VillageMD and Shields, as a portion of these gains is not subject to tax. See Note 3 Acquisitions, to the Consolidated Condensed Financial Statements for further information. The effective tax rate for the three months ended November 30, 2020 was a benefit of 34.0 percent, on a pretax loss for the three months ended November 30, 2020, primarily due to the discrete tax effect of equity losses in AmerisourceBergen. See Note 6 Equity method investments, to the Consolidated Condensed Financial Statements for further information.

Adjusted net earnings from continuing operations (Non-GAAP measure)
Adjusted net earnings attributable to the Company for the three months ended November 30, 2021 increased 53.5 percent to $1.5 billion compared with the prior year quarter. Adjusted diluted net earnings per share for the three months ended November 30, 2021 increased 53.2 percent to $1.68 compared with the year-ago quarter. Adjusted diluted net earnings and adjusted diluted net earnings per share were not significantly impacted by currency translation.

Excluding the impact of currency translation, the increases in adjusted net earnings for the three months ended November 30, 2021 primarily reflect strong adjusted gross profit growth across both pharmacy and retail in the United States and a continued rebound in International segment sales and profitability. See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.

RESULTS OF OPERATIONS BY SEGMENT

United States
The Company's United States segment includes the Walgreens business which includes the operations of retail drugstores, health and wellness services, and mail and central specialty pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise.


WBA Q1 2022 Form 10-Q
40


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
FINANCIAL PERFORMANCE(in millions, except location amounts)
 Three months ended November 30,
 20212020
Sales$28,032 $27,163 
Gross profit6,347 5,639 
Selling, general and administrative expenses5,091 4,770 
Equity earnings (loss) in AmerisourceBergen100 (1,373)
Operating income (loss)1,356 (504)
Adjusted operating income (Non-GAAP measure)1
1,690 1,155 
Number of prescriptions 2
218.0 204.6 
30-day equivalent prescriptions 2,3
313.8 297.3 
Number of locations at period end8,942 9,001 

 Percentage increases (decreases)
 Three months ended November 30,
 20212020
Sales3.23.9
Gross profit12.6(1.3)
Selling, general and administrative expenses6.7(0.8)
Operating income (loss)NM(154.9)
Adjusted operating income (Non-GAAP measure) 1
46.3(11.4)
Comparable sales 4
7.93.7
Pharmacy sales1.15.9
Comparable pharmacy sales 4
6.85.0
Retail sales10.1(2.2)
Comparable retail sales 4
10.60.4
Comparable number of prescription 2,4
7.1(2.5)
Comparable 30-day equivalent prescriptions 2,3,4
6.22.7

 Percent to sales
 Three months ended November 30,
 20212020
Gross margin22.620.8
Selling, general and administrative expenses18.217.6

1See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.
2Includes vaccinations, including COVID-19.
3Includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
4Comparable sales are defined as sales from stores that have been open for at least twelve consecutive months without closure for seven or more consecutive days, including due to looting or store damage, and without a major remodel or being subject to a natural disaster, in the past twelve months as well as e-commerce sales. E-commerce sales include

WBA Q1 2022 Form 10-Q
41


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
digitally initiated sales online or through mobile applications. Relocated stores are not included as comparable sales for the first twelve months after the relocation. Acquired stores are not included as comparable sales for the first twelve months after acquisition or conversion, when applicable, whichever is later. Comparable sales, comparable pharmacy sales, comparable retail sales, comparable number of prescriptions and comparable number of 30-day equivalent prescriptions refer to total sales, pharmacy sales, retail sales, number of prescriptions and number of 30-day equivalent prescriptions, respectively. Comparable retail sales for previous periods have been restated to include e-commerce sales. The method of calculating comparable sales varies across the retail industry and our method of calculating comparable sales may not be the same as other retailers’ methods.

NM - Not meaningful. Percentage increases above 200% or when one period includes income and other period includes loss are considered not meaningful.

Sales for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Sales for the three months ended November 30, 2021 increased by 3.2 percent to $28.0 billion. Comparable sales increased by 7.9 percent for the three months ended November 30, 2021.

Pharmacy sales increased by 1.1 percent for the three months ended November 30, 2021 and represented 75.3 percent of the segment’s sales. Excluding AllianceRx Walgreens Prime, pharmacy sales increased by 5.8 percent. The increase is due to higher brand inflation and favorable COVID-19 vaccinations and testing, partially offset by reimbursement pressure. For the three months ended November 30, 2020, pharmacy sales increased 5.9 percent and represented 76.8 percent of the segment’s sales. Comparable pharmacy sales increased 6.8 percent for the three months ended November 30, 2021 compared to an increase of 5.0 percent in the year-ago quarter. Within comparable sales, prescriptions filled during the three months ended November 30, 2021 increased by 6.2 percent from a year earlier, including a positive impact of approximately 5.3 percent from COVID-19 vaccinations. The effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 0.3 percent for the three months ended November 30, 2021 compared to a reduction of 0.4 percent for the year-ago quarter. The effect of generics on segment sales was a reduction of 0.2 percent for the three months ended November 30, 2021 compared to a reduction of 0.3 percent for the year-ago quarter. Third party sales, where reimbursement is received from managed care organizations, governmental agencies, employers or private insurers, were 97.2 percent of prescription sales for the three months ended November 30, 2021 compared to 97.5 percent in the year-ago quarter. The total number of prescriptions (including vaccinations) filled for the three months ended November 30, 2021 was 218.0 million compared to 204.6 million in the year-ago quarter. Prescriptions (including vaccinations) adjusted to 30-day equivalents were 313.8 million in the three months ended November 30, 2021 compared to 297.3 million in the year-ago quarter.

Retail sales increased by 10.1 percent for the three months ended November 30, 2021 and were 24.7 percent of the segment’s sales. In comparison, in the year-ago quarter, retail sales decreased by 2.2 percent and comprised 23.1 percent of the segment’s sales. Comparable retail sales increased 10.6 percent in the three months ended November 30, 2021 and 0.4 percent in the year-ago quarter. The increase in comparable retail sales in the current quarter was primarily driven by health & wellness, including favorable impact of at-home COVID-19 tests and cough cold flu, as well as beauty and personal care categories, partially offset by the continued de-emphasis of tobacco.

Operating income for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Operating income for the three months ended November 30, 2021 was $1.4 billion, including $100 million from the Company's share of equity earnings in AmerisourceBergen. This compared with a loss of $504 million in the prior year quarter, including $1.4 billion from Company's equity loss in AmerisourceBergen. Excluding the impact of AmerisourceBergen, the increase was due to gross profit growth across both pharmacy and retail.

Gross margin was 22.6 percent for the three months ended November 30, 2021 compared to 20.8 percent in the year-ago quarter. Gross margin was positively impacted in the current quarter by pharmacy margins, primarily due to COVID-19 vaccinations and testing. The increase in pharmacy margins was partially offset by reimbursement pressure. Retail margin was negatively impacted by shrink and increased import freight costs for the three months ended November 30, 2021.

Selling, general and administrative expenses as a percentage of sales were 18.2 percent for the three months ended November 30, 2021 and 17.6 percent for the three months ended November 30, 2020. Costs related to COVID-19 vaccinations and testing were partially offset by savings related to the Company's Transformational Cost Management Program.


WBA Q1 2022 Form 10-Q
42


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
Adjusted operating income (Non-GAAP measure) for the three months ended November 30, 2021 and 2020
Adjusted operating income for the three months ended November 30, 2021 increased by 46.3 percent to $1.7 billion. The increase was primarily due to adjusted gross profit growth across both pharmacy and retail.

See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.

International
The Company's International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, the Benavides brand in Mexico and the Ahumada brand in Chile. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products.

The International segment operates in currencies other than the U.S. dollar, including the British pound sterling, Euro, Chilean peso and Mexican peso and therefore the segment’s results are impacted by movements in foreign currency exchange rates. See Item 3, “Quantitative and qualitative disclosure about market risk, foreign currency exchange rate risk”, for further information on currency risk.

The Company presents certain information related to operating results in “constant currency,” which is a non-GAAP financial measure. Comparable sales in constant currency, comparable pharmacy sales in constant currency and comparable retail sales in constant currency exclude the effects of fluctuations in foreign currency exchange rates. See “--Non-GAAP Measures.”

FINANCIAL PERFORMANCE(in millions, except location amounts)
 Three months ended November 30,
 20212020
Sales$5,818 $4,285 
Gross profit1,207 990 
Selling, general and administrative expenses1,153 952 
Operating income54 39 
Adjusted operating income (Non-GAAP measure)1
164 87 
Number of locations at period end4,020 4,116 
 Percentage increases (decreases)
 Three months ended November 30,
 20212020
Sales35.813.4
Gross profit21.9(6.9)
Selling, general and administrative expenses21.1(6.0)
Operating income39.8(25.1)
Adjusted operating income (Non-GAAP measure) 1
89.0(1.0)
Comparable sales in constant currency 2
12.0(3.1)
Pharmacy sales13.6(0.3)
Comparable pharmacy sales in constant currency 2
9.23.7
Retail sales18.0(10.3)
Comparable retail sales in constant currency 2
13.73.8

WBA Q1 2022 Form 10-Q
43


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
 Percent to sales
 Three months ended November 30,
 20212020
Gross margin20.723.1
Selling, general and administrative expenses19.822.2

1See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.
2Comparable sales in constant currency are defined as sales from stores that have been open for at least twelve consecutive months without closure for seven or more consecutive days, including due to looting or store damage, and without a major remodel or being subject to a natural disaster, in the past twelve months as well as e-commerce sales. Comparable sales in constant currency exclude wholesale sales in Germany. E-commerce sales include digitally initiated sales online or through mobile applications. Relocated stores are not included as comparable stores for the first twelve months after the relocation. Acquired stores are not included as comparable sales for the first twelve months after acquisition or conversion, when applicable, whichever is later. Comparable sales in constant currency, comparable pharmacy sales in constant currency and comparable retail sales in constant currency refer to total sales, pharmacy sales and retail sales, respectively. Comparable retail sales in constant currency for previous periods have been restated to include e-commerce sales. The method of calculating comparable sales in constant currency varies across the retail industry and our method of calculating comparable sales in constant currency may not be the same as other retailers’ methods.

NM - Not meaningful. Percentage increases above 200% or when one period includes income and other period includes loss are considered not meaningful.

Sales for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Sales for the three months ended November 30, 2021 increased 35.8 percent to $5.8 billion, which includes incremental sales associated with the Company's pharmaceutical wholesale combined business in Germany. The favorable impact of currency translation on sales was 1.6 percentage points. Comparable sales in constant currency increased 12.0 percent, mainly due to higher sales in Boots UK. Sales in the comparable year ago-quarter include the adverse impact of strict COVID-19 restrictions on store footfall, as the UK entered a second national lockdown in November 2020.

Pharmacy sales increase 13.6 percent in the three months ended November 30, 2021 and represented 17.5 percent of the segment’s sales. The favorable impact of currency translation on pharmacy sales was 4.6 percentage points. Comparable pharmacy sales in constant currency increased 9.2 percent, primarily in the UK, reflecting stronger demand for pharmacy services.

Retail sales increased 18.0 percent for the three months ended November 30, 2021 and represented 30.9 percent of the segment’s sales. The favorable impact of currency translation on retail sales was 4.4 percentage points. Comparable retail sales in constant currency increased 13.7 percent reflecting higher retail sales in the UK, including a recovery in store footfall compared to a year ago-quarter, as COVID-19 restrictions were lifted. Footfall on the UK high street remains below pre-COVID-19 levels.

Operating income for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Operating income for the three months ended November 30, 2021 increased 39.8 percent to $54 million. Operating income was negatively impacted by 3.8 percentage points ($1 million) as a result of currency translation. Excluding the impact of currency translation, the increase in operating income was primarily in the UK, reflecting recovery in UK footfall, following the lifting of COVID-19 restrictions. This was partially offset by higher costs associated with the Company's wholesale business in Germany.

Gross profit increased 21.9 percent for the three months ended November 30, 2021. Gross profit was favorably impacted by 3.7 percentage points ($37 million) as a result of currency translation. The remaining increase was primarily due to higher retail sales and stronger demand for pharmacy services in the UK, together with the incremental gross profit associated with the Company's pharmaceutical wholesale business in Germany. This was partially offset by higher NHS reimbursement levels in the year ago quarter.


WBA Q1 2022 Form 10-Q
44


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
Selling, general and administrative expenses increased 21.1 percent for the three months ended November 30, 2021. Expenses were adversely impacted by 4.0 percentage points ($38 million) as a result of currency translation. Excluding the impact of currency translation, the increase reflects increased investments in acquisition related activity compared to the year-ago quarter, incremental expenses associated with the Company's wholesale business in Germany and the non-recurring COVID-19 related government support in the year ago quarter.

As a percentage of sales, selling, general and administrative expenses were 19.8 percent in the three months ended November 30, 2021 compared to 22.2 percent in the year-ago quarter.

Adjusted operating income (Non-GAAP measure) for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Adjusted operating income for the three months ended November 30, 2021 increased 89.0 percent to $164 million. Adjusted operating income in the quarter was not significantly impacted by currency translation. Excluding the impact of currency translation, the increase in adjusted operating income was primarily in the UK, reflecting higher retail sales and stronger demand for pharmacy services.

See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.

Walgreens Health
The Company’s Walgreens Health segment currently consists of Walgreens Health, an organically developed consumer-centric omni-channel business that contracts with payors and providers to deliver clinical healthcare services to their members through both digital and physical channels; a majority equity ownership position in VillageMD, a leading, national provider of value-based primary care services; a majority equity ownership position in Shields, a specialty pharmacy integrator and accelerator for hospitals.

FINANCIAL PERFORMANCE(in millions, except location amounts)
 Three months ended November 30,
 20212020
Sales$51 $— 
Gross profit20 — 
Selling, general and administrative expenses65 
Operating (loss)(45)(3)
Adjusted operating (loss) (Non-GAAP measure)1
(13)(3)
Number of payor/provider partnerships at period end— 
Number of locations with Walgreens Health Corners at period end45 — 
Number of VillageMD co-located clinics at period end72 — 


WBA Q1 2022 Form 10-Q
45


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
1See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.

Sales for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Sales for the three months ended November 30, 2021 were $51 million. This includes VillageMD sales of $26 million reflecting ownership since the acquisition date of November 24, 2021 and Shields sales of $25 million reflecting ownership since the acquisition date of October 29, 2021.

Operating income for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Operating loss for the three months ended November 30, 2021 was $45 million, compared to a loss of $3 million in the year-ago quarter.

Selling, general and administrative expenses were $65 million for the three months ended November 30, 2021 compared to $3 million for the three months ended November 30, 2020. Selling, general and administrative expenses reflect the two acquisitions and accelerating of investments in Walgreens Health for the three months ended November 30, 2021.

Adjusted operating income (Non-GAAP measure) for the three months ended November 30, 2021 compared to three months ended November 30, 2020
Adjusted operating loss was $13 million for the three months ended November 30, 2021, reflecting the two acquisitions and accelerating of investments in Walgreens Health compared to a loss of $3 million in the year-ago quarter. See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.


NON-GAAP MEASURES
The following information provides reconciliations of the supplemental non-GAAP financial measures, as defined under the SEC rules, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures herein, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. See notes to the “Net Earnings (loss) From Continuing Operations (GAAP)” to “Adjusted diluted net earnings per common share (Non-GAAP measure)” reconciliation table for definitions of non-GAAP financial measures and related adjustments presented below.

These supplemental non-GAAP financial measures are presented because management has evaluated the Company's financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the Company from period to period and trends in the Company's historical operating results. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein.

The Company does not provide a reconciliation for non-GAAP estimates on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing or amount of various items that have not yet occurred, are out of the Company’s control or cannot be reasonably predicted, and that would impact the most directly comparable forward-looking GAAP financial measure. These items may include but are not limited to merger integration expenses, restructuring charges, acquisition-related costs, asset impairments and other significant items that currently cannot be predicted without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures may vary materially from the corresponding GAAP financial measures.

The Company also presents certain information related to current period operating results in “constant currency”, which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the U.S. reporting in currencies other than the U.S. dollar and such presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.

WBA Q1 2022 Form 10-Q
46


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS


Operating income to Adjusted operating income by segments


(in millions)
Three months ended November 30, 2021
United StatesInternationalWalgreens HealthCorporate and OtherWalgreens Boots Alliance, Inc.
Operating income (loss) (GAAP)1,356 54 (45)(82)1,283 
Transformational cost management141 54 — 203 
Acquisition-related amortization140 17 — 165 
Acquisition-related costs(3)39 24 11 71 
Adjustments to equity earnings in AmerisourceBergen43 — — — 43 
LIFO provision14 — — — 14 
Adjusted operating income (loss) (Non-GAAP measure)$1,690 $164 (13)$(63)$1,777 

(in millions)
Three months ended November 30, 2020
United StatesInternationalWalgreens HealthCorporate and OtherWalgreens Boots Alliance, Inc.
Operating income (loss) (GAAP)$(504)$39 $(3)$(66)$(535)
Transformational cost management60 27 — 12 100 
Acquisition-related amortization76 19 — — 95 
Acquisition-related costs— 12 21 
Adjustments to equity earnings (loss) in AmerisourceBergen1,481 — — — 1,481 
LIFO provision33 — — — 33 
Adjusted operating income (loss) (Non-GAAP measure)$1,155 $87 $(3)$(42)$1,196 

















WBA Q1 2022 Form 10-Q
47


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS

Net Earnings to Adjusted net earnings & Earnings per share to Adjusted Earnings per share
(in millions)
 Three months ended November 30,
 20212020
Net earnings (loss) from continuing operations (GAAP)$3,580 $(391)
Adjustments to operating income (loss):
Transformational cost management 1
203 100 
Acquisition-related amortization 2
165 95 
Acquisition-related costs 3
71 21 
Adjustments to equity earnings (loss) in AmerisourceBergen 4
43 1,481 
LIFO provision 5
14 33 
Total adjustments to operating income (loss)495 1,731 
Adjustments to other income:
Net investment hedging loss 6
Gain on previously held investments 7
(2,576)— 
Total adjustments to other income(2,574)
Adjustments to income tax provision (benefit):
Equity method non-cash tax 8
18 (346)
Tax impact of adjustments 8
(26)(61)
Total adjustments to income tax provision (benefit)(8)(407)
Adjustments to post tax (loss) earnings in other equity method investments:
Adjustments to equity earnings in other equity method investments 9
15 13 
Total adjustments to post tax (loss) earnings from other equity method investments15 13 

WBA Q1 2022 Form 10-Q
48


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
Adjustments to net (loss) earnings attributable to noncontrolling interests:
Transformational cost management 1
(1)— 
Acquisition-related amortization 2
(32)(4)
Acquisition-related costs 3
(17)— 
LIFO provision 5
— (3)
Total adjustments to net (loss) earnings attributable to noncontrolling interests(50)(8)
Adjusted net earnings attributable to Continuing Operations (Non-GAAP measure)$1,455 $948 
Net earnings attributable to Walgreens Boots Alliance, Inc. - discontinued operations (GAAP)— 83 
Transformational cost management 1
— 
Acquisition-related amortization 2
— 21 
Acquisition-related costs 3
— 
Tax impact of adjustments 8
— (5)
Total adjustments to net earnings (loss) attributable to Walgreens Boots Alliance, Inc. - discontinued operations$— $22 
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. - discontinued operations (Non-GAAP measure)$ $105 
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)$1,455 $1,052 
Diluted net earnings per common share - continuing operations (GAAP) 10
$4.13 $(0.45)
Adjustments to operating income0.57 2.00 
Adjustments to other income(2.97)0.01 
Adjustments to income tax provision (benefit)(0.01)(0.47)
Adjustments to post tax (loss) earnings from other equity method investments 9
0.02 0.01 
Adjustments to net (loss) earnings attributable to noncontrolling interests(0.06)(0.01)
Adjusted diluted net earnings per common share - continuing operations (Non-GAAP measure)$1.68 $1.09 
Diluted net earnings per common share - discontinued operations (GAAP)$ $0.10 
Total adjustments to net earnings attributable to Walgreens Boots Alliance, Inc. – discontinued operations
— 0.03 
Adjusted diluted net earnings per common share - discontinued operations (Non-GAAP measure)$ $0.12 
Adjusted diluted net earnings per common share (Non-GAAP measure)$1.68 $1.22 
Weighted average common shares outstanding, diluted (in millions) 11
867.6 865.3 

WBA Q1 2022 Form 10-Q
49


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
1Transformational Cost Management Program charges are costs associated with a formal restructuring plan. These charges are primarily recorded within selling, general and administrative expenses. These costs do not reflect current operating performance and are impacted by the timing of restructuring activity.
2Acquisition-related amortization includes amortization of acquisition-related intangible assets and inventory valuation adjustments. Amortization of acquisition-related intangible assets includes amortization of intangibles assets such as customer relationships, trade names, trademarks and contract intangibles. Intangible asset amortization excluded from the related non-GAAP measure represents the entire amount recorded within the Company’s GAAP financial statements. The revenue generated by the associated intangible assets has not been excluded from the related non-GAAP measures. Amortization expense, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired, or the estimated useful life of an intangible asset is revised. These charges are primarily recorded within selling, general and administrative expenses. Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of the inventory reflects cost of acquired inventory and a portion of the expected profit margin. The acquisition-related inventory valuation adjustments excludes the expected profit margin component from cost of sales recorded under the business combination accounting principles.
3Acquisition-related costs are transaction and integration costs associated with certain merger, acquisition and divestitures related activities. These costs include all charges incurred on certain mergers, acquisition and divestitures related activities, for example, including costs related to integration efforts for successful merger, acquisition and divestitures activities. Examples of such costs include deal costs, severance and stock compensation. These charges are primarily recorded within selling, general and administrative expenses. These costs are significantly impacted by the timing and complexity of the underlying merger, acquisition and divestitures related activities and do not reflect the Company’s current operating performance.
4Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBergen consistent with the Company’s non-GAAP measures. The Company recognized equity losses in AmerisourceBergen of $1,373 million during the three months ended November 30, 2020. These equity losses are primarily due to AmerisourceBergen's recognition of $5.6 billion, net of tax, charges related to its ongoing opioid litigation in its financial statements for the three months period ended September 30, 2020.
5The Company’s United States segment inventory is accounted for using the last-in-first-out (“LIFO”) method. This adjustment represents the impact on cost of sales as if the United States segment inventory is accounted for using first-in first-out (“FIFO”) method. The LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences. Therefore, the Company cannot control the amounts recognized or timing of these items.
6Gain or loss on certain derivative instruments used as economic hedges of the Company’s net investments in foreign subsidiaries. These charges are recorded within other income (loss). We do not believe this volatility related to mark-to-market adjustment on the underlying derivative instruments reflects the Company’s operational performance.
7Includes significant gains on business combinations due to the remeasurement of previously held minority equity interests and debt securities to fair value. During the three months ended November 30, 2021, the Company recorded such pretax gains of $2,174 million and $402 million for VillageMD and Shields respectively.
8Adjustments to income tax provision (benefit) include adjustments to the GAAP basis tax provision (benefit) commensurate with non-GAAP adjustments and certain discrete tax items including U.S. tax law changes and equity method non-cash tax. These charges are recorded within income tax provision (benefit).
9Adjustments to post tax (loss) earnings from other equity method investments consist of the proportionate share of certain equity method investees’ non-cash items or unusual or infrequent items consistent with the Company’s non-GAAP adjustments. These charges are recorded within post tax (loss) earnings from other equity method investments. Although the Company may have shareholder rights and board representation commensurate with its ownership interests in these equity method investees, adjustments relating to equity method investments are not intended to imply that the Company has direct control over their operations and resulting revenue and expenses. Moreover, these non-GAAP financial measures have limitations in that they do not reflect all revenue and expenses of these equity method investees.
10Due to the anti-dilutive effect resulting from the reported net loss, the impact of potentially dilutive securities on the per share amounts has been omitted from the quarterly calculation of weighted-average common shares outstanding for diluted EPS for the three months ended November 30, 2020.
11Includes impact of potentially dilutive securities in the quarterly calculation of weighted-average common shares, diluted for adjusted diluted net earnings per common share calculation purposes for the three months ended November 30, 2020.

The Company considers certain metrics presented in this report, such as comparable sales, comparable pharmacy sales, comparable retail sales, comparable number of prescriptions, and comparable 30-day equivalent prescriptions, to be key performance indicators because the Company’s management has evaluated its results of operations using these metrics and believes that these key performance indicators presented provide additional perspective and insights when analyzing the core operating performance of the Company from period to period and trends in its historical operating results. These key performance indicators should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein. These measures, which are described in more detail in this report, may not be comparable to similarly-titled performance indicators used by other companies.

WBA Q1 2022 Form 10-Q
50


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS

LIQUIDITY AND CAPITAL RESOURCES
The Company's long-term capital policy is to: maintain a strong balance sheet and financial flexibility; reinvest in its core strategies; invest in strategic opportunities that reinforce its core strategies and meet return requirements; and return surplus cash flow to stockholders in the form of dividends and share repurchases over the long term. In June 2018, the Company’s Board of Directors reviewed and refined the Company’s dividend policy to set forth the Company’s current intention to increase its dividend each year.

The Company’s cash requirements are subject to change as business conditions warrant and opportunities arise. The timing and
size of any new business ventures or acquisitions that the Company may complete may also impact its cash requirements.
Additionally, the Company's cash requirements, and its ability to generate cash flow, have been and may continue to be
adversely affected by COVID-19 and the resulting market volatility and instability. For further information regarding the impact of COVID-19 on the Company, including on its liquidity and capital resources, please see Item 1A, Risk factors in the 2021 10-K.

The Company expects to fund its working capital needs, capital expenditures, pending acquisitions, continuing obligations for recently completed acquisitions, dividend payments and debt service obligations from liquidity sources including cash flow from operations, availability under existing credit facilities, commercial paper programs, working capital financing arrangements and current cash and investment balances. The Company believes that these sources, and the ability to obtain other financing will provide adequate cash funds for the Company's foreseeable working capital needs, capital expenditures, pending acquisitions, dividend payments and debt service obligations for at least the next 12 months. See Part II. Item 3, Qualitative and quantitative disclosures about market risk, below for a discussion of certain financing and market risks.

Cash, cash equivalents and restricted cash were $4.3 billion (including $286 million in non-U.S. jurisdictions) as of November 30, 2021 compared to $1.3 billion (including $204 million in non-U.S. jurisdictions) as of August 31, 2021. Short-term investment objectives are primarily to minimize risk and maintain liquidity. To attain these objectives, investment limits are placed on the amount, type and issuer of securities. Investments are principally in U.S. Treasury money market funds.

On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement. The Company has also previously announced its intention to make further cash investments for the acquisition of CareCentrix. Additionally, certain acquisitions include put options which may be exercised in the future. The Company currently expect that the incremental investment resulting from the exercise of the put options in the future could be between approximately $1.3 billion and $1.6 billion.

As of November 30, 2021, the Company had an aggregate borrowing capacity of $9 billion, including funds already drawn. At November 30, 2021, the Company had no guarantees outstanding and no amounts issued under letters of credit. See Note 8 Debt, to the Consolidated Condensed Financial Statements for further information on the Company’s debt instruments and its recent financing actions.

Cash flows from operating activities
Cash provided by operations and the incurrence of debt are the principal sources of funds for expansion, investments, acquisitions, remodeling programs, dividends to stockholders and stock repurchases. Net cash provided by operating activities for the three months ended November 30, 2021 was $1.1 billion, compared to $1.2 billion for the prior year period. The decrease in cash provided by operating activities reflects higher cash outflows from inventories and lower cash inflows from accrued expenses and other liabilities, partially offset by an increase in operating performance. Changes in inventories and accrued expenses and other liabilities are mainly driven by timing.

Cash flows from investing activities
Net cash used for investing activities was $2.0 billion for the three months ended November 30, 2021 compared to $0.3 billion for the prior-year period. Net cash used for investing activities for the three months ended November 30, 2021 includes business acquisitions, net of cash acquired of VillageMD and Shields for $0.8 billion and $0.9 billion, respectively. Net cash used for the business acquisition of VillageMD includes net consideration of $2.9 billion of which $1.9 billion was held as cash by VillageMD on November 30, 2021, and subsequently used for the tender offer which completed on December 28, 2021. See Note 3 Acquisitions, to the Consolidated Condensed Financial Statement for further information.

WBA Q1 2022 Form 10-Q
51


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS

Capital Expenditure
Capital expenditure includes information technology projects and other growth initiatives. Additions to property, plant and
equipment were as follows (in millions):

 Three months ended November 30,
 20212020
United States$355 $343 
International84 59 
Walgreens Health15 10 
Discontinued operations— 20 
Total$454 $431 
Cash flows from financing activities
Net cash used for financing activities for the three months ended November 30, 2021 was $3.9 billion compared to $352 million in the prior-year period. In the three months ended November 30, 2021 there were $8.9 billion in proceeds from debt, primarily from revolving credit facilities and the issuance of notes, compared to $3.0 billion in proceeds from debt in three months ended November 30, 2020. In the three months ended November 30, 2021 there were $4.4 billion in payments of debt made primarily for revolving credit facilities and commercial paper debt compared to $2.8 billion in three months ended November 30, 2020. See Note 8 Debt, to the Consolidated Condensed Financial Statement for further information. The Company repurchased shares totaling $154 million in the three months ended November 30, 2021 to support the needs of its employee stock plans compared to $110 million in the prior year period which also included stock repurchase program described below. Cash dividends paid were $413 million during the three months ended November 30, 2021 compared to $405 million for the prior year period.

See Item 3, Qualitative and quantitative disclosures about market risk, below for a discussion of certain financing and market risks.

Stock repurchase program
In June 2018, the Company's Board of Director's approved a stock repurchase program (the “June 2018 stock repurchase program”), which authorized the repurchase of up to $10.0 billion of the Company's common stock of which the Company had repurchased $8.0 billion as of November 30, 2021. The June 2018 stock repurchase program has no specified expiration date. In July 2020, the Company suspended repurchases under this program. The Company may continue to repurchase stock to offset anticipated dilution from equity incentive plans.
The Company determines the timing and amount of repurchases, including repurchases to offset anticipated dilution from equity incentive plans, based on its assessment of various factors, including prevailing market conditions, alternate uses of capital, liquidity and the economic environment. The Company has repurchased, and may from time to time in the future repurchase, shares on the open market through Rule 10b5-1 plans, which enable the Company to repurchase shares at times when we otherwise might be precluded from doing so under federal securities laws.

Debt covenants
Each of the Company’s credit facilities described in Note 8 Debt, to the Consolidated Condensed Financial Statements, contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, subject to increase in certain circumstances set forth in the applicable credit agreement. The credit facilities also contain various other customary covenants. As of November 30, 2021, the Company was in compliance with all such applicable covenants.

Credit ratings
As of January 5, 2022, the credit ratings of Walgreens Boots Alliance were:
Rating agencyLong-term debt ratingCommercial paper ratingOutlook
Moody’sBaa2P-2Negative
Standard & Poor’sBBBA-2Stable


WBA Q1 2022 Form 10-Q
52


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
In assessing the Company’s credit strength, each rating agency considers various factors including the Company’s business model, capital structure, financial policies and financial performance. There can be no assurance that any particular rating will be assigned or maintained. The Company’s credit ratings impact its borrowing costs, access to capital markets and operating lease costs. The rating agency ratings are not recommendations to buy, sell or hold the Company’s debt securities or commercial paper. Each rating may be subject to revision or withdrawal at any time by the assigning rating agency and should be evaluated independently of any other rating.

CRITICAL ACCOUNTING ESTIMATES
The Consolidated Condensed Financial Statements are prepared in accordance with GAAP and include amounts based on management’s prudent judgments and estimates. Actual results may differ from these estimates. Management believes that any reasonable deviation from those judgments and estimates would not have a material impact on our consolidated financial position or results of operations. To the extent that the estimates used differ from actual results, however, adjustments to the Consolidated Statements of Earnings and corresponding Consolidated Balance Sheets accounts would be necessary. These adjustments would be made in future periods. For a discussion of our significant accounting policies, please see the Company's 2021 10-K. Some of the more significant estimates include business combinations, leases, goodwill and indefinite-lived intangible asset impairment, cost of sales and inventory, equity method investments, pension and postretirement benefits and income taxes.

NEW ACCOUNTING PRONOUNCEMENTS
A discussion of new accounting pronouncements is described in Note 18 New accounting pronouncements, to the Consolidated Condensed Financial Statements of this Quarterly Report on Form 10-Q and is incorporated herein by reference.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report and other documents that we file or furnish with the SEC contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, any statements regarding the Company's future operations, financial or operating results, capital allocation, anticipated debt levels and ratios, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. Words such as “expect,” “likely,” “outlook,” “forecast,” “preliminary,” “pilot,” “project,” “intend,” “plan,” “goal,” “target,” “aim,” “continue,” “believe,” “seek,” “anticipate,” “upcoming,” “may,” “possible,” and variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated. These risks, assumptions and uncertainties include those described in Item 1A, Risk factors, above, which are incorporated herein by reference, and in other documents that we file or furnish with the SEC. If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. All forward-looking statements we make or that are made on our behalf are qualified by these cautionary statements. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made.

We do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this report, whether as a result of new information, future events, changes in assumptions or otherwise.

WBA Q1 2022 Form 10-Q
53


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Item 3. Quantitative and qualitative disclosure about market risk
Interest rate risk
The Company is exposed to interest rate volatility with regard to existing variable-rate debt instruments and future incurrences of fixed or variable-rate debt, which exposure primarily relates to movements in various interest rates, such as U.S treasury rates and commercial paper rates. From time to time, the Company uses interest rate swaps and forward-starting interest rate swaps to hedge its exposure to the impact of interest rate changes on existing debt and future debt issuances respectively, to reduce the volatility of financing costs and, based on current and projected market conditions, achieve a desired proportion of fixed-rate versus floating-rate debt. Generally, under these swaps, the Company agrees with a counterparty to exchange the difference between fixed-rate and floating-rate interest amounts based on an agreed upon notional principal amount.

On March 5, 2021, the UK Financial Conduct Authority (the “FCA”), which regulates the London Interbank Offered Rate, or
LIBOR, issued an announcement on the future cessation or loss of representativeness of LIBOR benchmark settings currently published by ICE Benchmark Administration. That announcement confirmed that LIBOR will either cease to be provided by
any administrator or will no longer be representative after December 31, 2021, for all non-USD LIBOR reference rates, and for
1W and 2M USD LIBOR and after June 30, 2023, for other USD LIBOR reference rates.

Certain of our credit facilities provide that, under certain circumstances set forth in such credit facilities, we and the
administrative agent may amend the applicable credit facility to replace LIBOR with an alternate benchmark rate, giving due
consideration to any evolving or then existing convention for similar syndicated credit facilities in the U.S. market for
alternative benchmarks. Such an alternative benchmark rate could include the secured overnight financing rate, also known as
SOFR, published by the Federal Reserve Bank of New York.

Information regarding the Company's transactions are set forth in Note 9 Financial instruments, to the Consolidated Condensed Financial Statements. These financial instruments are sensitive to changes in interest rates. As of November 30, 2021, the Company had $3.0 billion of long-term debt obligations at floating interest rates. The amounts exclude the impact of any associated derivative contracts.

Foreign currency exchange rate risk
The Company is exposed to fluctuations in foreign currency exchange rates, primarily with respect to the British pound sterling and certain other foreign currencies, which may affect its net investment in foreign subsidiaries and may cause fluctuations in cash flows related to foreign denominated transactions. The Company is also exposed to the translation of foreign currency earnings to the U.S. dollar. The Company enters into foreign currency forward contracts to hedge against the effect of exchange rate fluctuations on non-functional currency cash flows. These transactions are almost exclusively less than 12 months in maturity. In addition, the Company enters into foreign currency forward contracts that are not designated in hedging relationships to offset, in part, the impacts of certain intercompany activities (primarily associated with intercompany financing transactions).

The Company’s foreign currency derivative instruments are sensitive to changes in exchange rates. A hypothetical 1% change in foreign currency exchange rates versus the U.S. dollar would change the fair value of the foreign currency derivatives held as of November 30, 2021 by approximately $55 million. The foreign currency derivatives are intended to partially hedge anticipated transactions, foreign currency trade payables and receivables and net investments in foreign subsidiaries.

Equity price risk
Changes in AmerisourceBergen common stock price may have a significant impact on the fair value of the equity investment in AmerisourceBergen described in Note 6 Equity method investments, to the Consolidated Condensed Financial Statements. See “--Investment in AmerisourceBergen” above.


WBA Q1 2022 Form 10-Q
54


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
ITEM 4. CONTROLS AND PROCEDURES
Item 4. Controls and procedures

Evaluation of disclosure controls and procedures
Management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of the Company’s management, including its Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”).

As of the end of the period covered by this report, the Company had completed the acquisition of a majority equity interest in VillageMD and Shields. The Company accounted for these acquisitions as business combinations resulting in consolidation within the Walgreens Health Segment. The scope of management's assessment of the effectiveness of the Company's disclosure controls and procedures did not include the internal controls over financial reporting of the acquired businesses. This exclusion is in accordance with the SEC staff's general guidance that an assessment of a recently acquired business may be omitted from the scope of management's assessment for one year following the acquisition. The recognition of goodwill and intangible assets, however, is covered by our internal controls over mergers and acquisitions, which were included in management's assessment of the effectiveness of the Company's internal control over financial reporting as of November 30, 2021.

Based upon the controls evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC, and that such information is accumulated and communicated to management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in internal control over financial reporting
In the ordinary course of business, the Company reviews its internal control over financial reporting and makes changes to its systems and processes that are intended to enhance such controls and increase efficiency while maintaining an effective internal control environment. Changes may include such activities as updating existing systems, automating manual processes, standardizing controls and modifying monitoring controls.

As we transform our business processes, we continue to make strategic changes in how we perform certain key business functions. These changes include the continued leveraging of extended workforces via third-party outsource arrangements as well as our continued implementation of new information systems. These initiatives are not being implemented in response to any identified internal control deficiency or weakness. As these changes occur, we will evaluate quarterly whether such changes materially affect, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

In connection with the evaluation pursuant to Exchange Act Rule 13a-15(d) of the Company’s internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) by the Company’s management, including its CEO and CFO, no changes during the quarter ended November 30, 2021 were identified that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Inherent limitations on effectiveness of controls
Our management, including the CEO and CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.


WBA Q1 2022 Form 10-Q
55


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
PART II. OTHER INFORMATION

Item 1. Legal proceedings
The information in response to this item is incorporated herein by reference to Note 11 Commitments and contingencies, to the Consolidated Condensed Financial Statements of this Quarterly Report.

As previously disclosed, the Company has been under investigation by certain counties within the State of California for
alleged noncompliance with state hazardous waste regulations. The Company has worked with state and local officials in an
effort to resolve this matter. The Company executed a settlement agreement in October 2020 which includes a monetary
payment and injunctive provisions, including funding of supplemental environmental projects. The total settlement value is $3.5
million. On December 17, 2020, the settlement was approved by a California state court in Alameda County (People of the
State of California v. Walgreen Co., Case No. RG20081172), and its injunctive provisions will be in effect for three years.

Item 1A. Risk factors
In addition to the other information set forth in this report, you should carefully consider the factors discussed in item 1A. “Risk factors” in the 2021 10-K, which could materially affect our business, financial condition, or future results.

Item 2. Unregistered sales of equity securities and use of proceeds
The following table provides information about purchases by the Company during the quarter ended November 30, 2021 of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act. Subject to applicable law, share purchases may be made from time to time in open market transactions, privately negotiated transactions including accelerated share repurchase agreements, or pursuant to instruments and plans complying with Rule 10b5-1, among other types
of transactions and arrangements.
 Issuer purchases of equity securities
PeriodTotal number of shares purchased by monthAverage price paid per share
Total number of shares purchased by month as part of publicly announced repurchase programs1
Approximate dollar value of shares that may yet be purchased under the plans or program 1
09/01/21 - 09/31/21— $— — $2,003,419,960 
10/01/21 - 10/31/21— — — 2,003,419,960 
11/01/21 - 11/30/213,179,750 48.39 — 2,003,419,960 
3,179,750 $48.39 — $2,003,419,960 
1In June 2018, Walgreens Boots Alliance authorized a stock repurchase program, which authorized the repurchase of up to $10.0 billion of Walgreens Boots Alliance common stock. This program has no specified expiration date. In July 2020, the Company announced that it had suspended activities under this program.

Item 5. Other information
None.


WBA Q1 2022 Form 10-Q
56


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
PART II. OTHER INFORMATION
Item 6. Exhibits

Exhibit No.DescriptionSEC Document Reference
Securities Purchase Agreement, by and among Walgreen Co., the several equity holders of Shields Health Solutions Parent, LLC listed on Schedules A and B thereto, the stockholders of WCAS Shields Holdings, Inc. listed on Schedule C thereto, Shields Health Solutions Parent, LLC, WCAS Shields Holdings, Inc. and WCAS XIII Associates, LLC, solely in its capacity as Sellers’ Representative thereunder.**

Incorporated by reference to Exhibit 2.1 to Walgreen’s Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on September 21, 2021.
Class D Preferred Unit Purchase Agreement, dated as of October 14, 2021, by and among WBA Acquisition 4, LLC, WBA Financial, LLC, Walgreens Boots Alliance, Inc., Village Practice Management Company, LLC and certain members of Village Practice Management Company, LLC **
Incorporated by reference to Exhibit 2.1 to Walgreen’s Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on October 14, 2021.
Amended and Restated Certificate of Incorporation of Walgreens Boots Alliance, Inc.Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014.
Amended and Restated Bylaws of Walgreens Boots Alliance, Inc.Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 10, 2016.
First Supplemental Indenture, dated as of October 13, 2021, by and between Walgreens Boots Alliance, Inc. and Wells Fargo Bank, National Association, as trustee.Incorporated by reference to Exhibit 4.13 to Walgreens Boots Alliance, Inc.'s Annual Report on Form 10-K for the year ended August 31, 2021 (File No. 1-36759) filed with the SEC on October 14, 2021.
Form of 0.950% Notes due 2023.
Incorporated by reference to Exhibit 4.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on November 17, 2021.
Second Amended and Restated Limited Liability Company Agreement of Shields Health Solutions Parent, LLC.**
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on October 29, 2021.
Seventh Amended and Restated Limited Liability Company Agreement of Village Practice Management Company, LLC.**
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on November 26, 2021.
Appointment and Waiver Agreement, dated as of November 24, 2021, by and among Walgreens Boots Alliance, Inc., WBA Acquisition 5, LLC and Village Practice Management Company, LLC.
Incorporated by reference to Exhibit 10.2 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on November 26, 2021.
Form of Performance Share Award agreement (effective October 2021).Filed herewith.

WBA Q1 2022 Form 10-Q
57


WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
PART II. OTHER INFORMATION
Form of Stock Option Award agreement (effective October 2021).Filed herewith.
Form of Restricted Stock Unit Award agreement (effective October 2021).Filed herewith.
Form of Restricted Stock Unit Award agreement for Executive Chairman (November 2021).Filed herewith.
Delayed Draw Term Loan Credit Agreement, dated as of November 15, 2021, by and among Walgreens Boots Alliance, Inc., the Designated Borrowers from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent.
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance Inc.’s Current Report on Form 8-K (File No. 1-36759) filed on November 16, 2021.
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Filed herewith.
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith.
Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.Furnished herewith.
Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.Furnished herewith.
101.INSInline XBRL Instance Document (The following financial information from this Quarterly Report on Form 10-Q for the quarter ended November 30, 2021 formatted in Inline XBRL (Extensive Business Reporting Language) includes: (i) the Consolidated Condensed Balance Sheets; (ii) the Consolidated Condensed Statements of Equity; (iii) the Consolidated Condensed Statements of Earnings; (iv) the Consolidated Condensed Statements of Comprehensive Income; (v) the Consolidated Condensed Statements of Cash Flows; and (vi) Notes Financial Statements).Filed herewith.
101.SCHInline XBRL Taxonomy Extension Schema DocumentFiled herewith.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentFiled herewith.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentFiled herewith.
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentFiled herewith.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith.
104Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101)Filed herewith.
___________________________

* Management contract or compensatory plan or arrangement.

** Certain schedules and exhibits to this agreement have been omitted pursuant to Items 601(a)(5) of Regulation S-K, and Walgreens Boots Alliance, Inc. agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

WBA Q1 2022 Form 10-Q
58


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 Walgreens Boots Alliance, Inc.
 (Registrant)
  
Dated: January 6, 2022/s/ James Kehoe
 James Kehoe
 Executive Vice President and Global Chief Financial Officer
 Principal Financial Officer
Dated: January 6, 2022/s/ Manmohan Mahajan
Manmohan Mahajan
Senior Vice President, Global Controller and Chief Accounting Officer
Principal Accounting Officer


WBA Q1 2022 Form 10-Q
59
EX-10.4 2 a11302021exhibit104.htm EX-10.4 Document

EXHIBIT 10.4



WALGREENS BOOTS ALLIANCE, INC.

2021 OMNIBUS INCENTIVE PLAN

PERFORMANCE SHARE AWARD AGREEMENT









These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by Walgreens Boots Alliance, Inc., not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments. These materials were prepared by Walgreens Boots Alliance, Inc., which is solely responsible for their contents and for compliance with legal and regulatory requirements. Fidelity is not connected with any offering or acting as an underwriter in connection with any offering of your company's securities or financial instruments. Fidelity does not review, approve or endorse the contents of these materials and is not responsible for their content.






WALGREENS BOOTS ALLIANCE, INC.
2021 OMNIBUS INCENTIVE PLAN
PERFORMANCE SHARE AWARD AGREEMENT

Participant Name:
Participant ID:
Grant Date:         (the "Grant Date")
Performance Period: Fiscal Years – 2022 - 2024 (the "Performance Period")
Shares Granted:
Acceptance Date:
Electronic Signature:
This document (referred to below as this "Agreement") spells out the terms and conditions of the Performance Share Award (the "Award") granted to you by Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), pursuant to the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (the "Plan") on and as of the Grant Date designated above. Except as otherwise defined herein, capitalized terms used in this Agreement have the respective meanings set forth in the Plan. For purposes of this Agreement, "Employer" means the entity (the Company or the Affiliate) that employs you on the applicable date. The Plan as it may be amended from time to time, is incorporated into this Agreement by this reference.
You and the Company agree as follows:
1.Grant of Performance Shares. Pursuant to the approval and direction of the Compensation and Leadership Performance Committee of the Company's Board of Directors (the "Committee"), the Company hereby grants you the target number of Performance Shares specified above (the "Performance Shares"), subject to the terms and conditions of the Plan and this Agreement. This "target" number of shares is computed by dividing the target award dollar amount for your position by the average closing stock price of the Company's common stock, par value US$.01 per share ("Stock") for the last 30 trading days of the fiscal year preceding the Grant Date.
2.Performance Measure. The number of Performance Shares earned at the end of the three-year Performance Period will vary depending on the degree to which the following performance goals for the Performance Period, as established by the Committee, are met: 70% allocated to adjusted earnings per share growth for each fiscal year of the Performance Period; and 30% allocated to constant currency revenue growth for each fiscal year of the Performance Period.
3.Determination of Performance Shares Earned. For each component fiscal year calculation described in Section 2 above, at the target level, 100% performance will be achieved; at the threshold level, 50% performance will be achieved; below the threshold level, 0% performance will be achieved; and at the maximum level or above, 150% performance will be achieved. Performance between minimum and target, and between target and maximum, will achieve performance levels on a pro-rated basis between 50% and 100%, and 100% and 150%, respectively. As established and approved by the Committee, the resulting total achieved performance level for each fiscal year of the Performance Period will be averaged to arrive at the final earned performance percentage for the Performance Period.
1



The amount earned will be calculated according to the following:
Percent of
Performance=TargetXTarget
Shares AwardedPerformance SharesPerformance Shares Earned
4.Disability or Death. If during the Performance Period you have a Termination of Service by reason of Disability or death, then the number of Performance Shares earned (based on performance as of the end of the Performance Period) shall become vested at the end of the Performance Period. Any Performance Shares becoming vested by reason of your Termination of Service by reason of Disability or death shall be paid at the same time Performance Shares are paid to other Participants.
5.Retirement. If during the Performance Period you have a Termination of Service by reason of Retirement, as reasonably determined and approved by the Committee or its delegates, then, subject to such approval, the number of Performance Shares earned (based on performance as of the end of the Performance Period) will be prorated to reflect the portion of the Performance Period during which you remained employed by the Company. Such prorated portion shall equal the full number of earned Performance Shares, multiplied by a fraction equal to the number of full months of the Performance Period completed as of your Termination of Service, divided by 36. Any Performance Shares becoming vested by reason of your Retirement shall be paid at the same time Performance Shares are paid to other Participants.
6.Termination of Service Following a Change in Control. If during the Performance Period there is a Change in Control of the Company and within the one-year period thereafter you have a Termination of Service initiated by your Employer other than for Cause (as defined in Section 7), then your earned Award shall equal your target number of Performance Shares, prorated to reflect the portion of the Performance Period during which you remained employed by the Company. Such prorated portion shall equal your target number of Performance Shares, multiplied by a fraction equal to the number of full months of the Performance Period completed as of your Termination of Service, divided by the number of months in the Performance Period. This prorated award will be settled in cash (subject to required tax withholdings) in accordance with Section 9.01(b) of the Plan within 45 days after your Termination of Service. For purposes of this Section 6, a Termination of Service initiated by your Employer shall include a Termination of Employment for Good Reason under - and pursuant to the terms and conditions of – the Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan, but only to the extent applicable to you as an eligible participant in such Plan.
7.Other Termination of Service. If during the Performance Period you have a voluntary or involuntary Termination of Service for any reason other than as set forth in Section 4, 5 or 6 above, as determined by the Committee, then all of your Performance Shares shall be forfeited. For purposes of this Agreement, "Cause" means any one or more of the following, as determined by the Committee in its sole discretion:
(a)    your commission of a felony or any crime of moral turpitude;
(b)    your dishonesty or material violation of standards of integrity in the course of fulfilling your duties to the Company or any Affiliate;
(c)    your material violation of a material written policy of the Company or any Affiliate violation of which is grounds for immediate termination;
(d)    your willful and deliberate failure to perform your duties to the Company or any Affiliate in any material respect, after reasonable notice of such failure and an opportunity to correct it; or
2



(e)    your failure to comply in any material respect with the United States ("U.S.") Foreign Corrupt Practices Act, the U.S. Securities Act of 1933, the Exchange Act, the U.S. Sarbanes-Oxley Act of 2002, the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the U.S. Truth in Negotiations Act, or any rules or regulations thereunder.
8.Settlement of Earned Performance Shares. At the end of the Performance Period actual performance for the entire Performance Period shall be reviewed, and the amount of the earned Award shall be determined based on this performance and communicated to you. Subject to the requirements of Section 12 below, the Company shall transfer to you one (1) share of Stock for each Performance Share earned at that time, net of any applicable tax withholding requirements in accordance with Section 9 below. The Performance Shares payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, the Performance Shares will be settled in shares of Stock no later than the 15th day of the third month following the end of the fiscal year of the Company (or if later, the calendar year) in which the Performance Shares are earned.
Notwithstanding the foregoing, if you are resident or employed outside of the U.S., the Company, in its sole discretion, may provide for the settlement of the Performance Shares in the form of:
(a)     a cash payment (in an amount equal to the Fair Market Value of the shares of Stock that corresponds with the number of earned Performance Shares) to the extent that settlement in shares of Stock (i) is prohibited under local law, (ii) would require you, the Company or an Affiliate to obtain the approval of any governmental or regulatory body in your country of residence (or country of employment, if different), (iii) would result in adverse tax consequences for you, the Company or an Affiliate or (iv) is administratively burdensome; or
(b)     shares of Stock, but require you to sell such shares of Stock immediately or within a specified period following your Termination of Service (in which case, you hereby agree that the Company shall have the authority to issue sale instructions in relation to such shares of Stock on your behalf).
9.Responsibility for Taxes; Tax Withholding.
(a)    You acknowledge that, regardless of any action taken by the Company or your Employer, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you ("Tax-Related Items"), is and remains your responsibility and may exceed the amount actually withheld by the Company or your Employer, if any. You further acknowledge that the Company and/or your Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including, but not limited to, the grant, vesting or settlement of the Award, the subsequent sale of shares of Stock acquired pursuant to such settlement and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, as applicable, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(b)    Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or your Employer to satisfy all Tax-Related Items. In this regard, except as provided below, the Company, your Employer or its agent shall satisfy the obligations with regard to all Tax-Related Items by withholding from the shares of Stock to be delivered upon settlement of the Award that number of shares of Stock having a Fair Market Value equal to the amount required by law to be withheld. For purposes of the foregoing tax withholding, no fractional shares of Stock will be withheld. Notwithstanding the foregoing, if you are a Section 16 officer of the Company under the Exchange Act at the time of any applicable tax withholding event, you may make a cash payment to the Company, your
3



Employer or its agent to cover the Tax-Related Items that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan. If you are not a Section 16 officer of the Company at the time of any applicable tax withholding event, the Company and/or your Employer may (in its sole discretion) allow you to make a cash payment to the Company, your Employer or its agent to cover such Tax-Related Items.
The Company may withhold or account for Tax-Related Items by considering applicable statutory withholding rates (as determined by the Company in good faith and in its sole discretion) or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding from the shares of Stock to be delivered upon settlement of the Award, for tax purposes, you will be deemed to have been issued the full number of shares of Stock subject to the earned Award, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items.

The Company may refuse to issue or deliver the shares of Stock (or cash payment) or the proceeds from the sale of shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items.

10.Nontransferability. During the Performance Period and thereafter until shares of Stock are transferred to you in settlement thereof, you may not sell, transfer, pledge, assign or otherwise alienate or hypothecate the Performance Shares, whether voluntarily or involuntarily or by operation of law, other than by beneficiary designation effective upon your death, or by will or by the laws of intestacy.
11.Rights as Stockholder. You shall have no rights as a stockholder of the Company with respect to the Performance Shares until such time as a certificate of stock for the shares of Stock issued in settlement of the Performance Shares has been issued to you or such shares of Stock have been recorded in your name in book entry form. Except as provided in Section 17 below, no adjustment shall be made for dividends or distributions or other rights with respect to such shares of Stock for which the record date is prior to the date on which you become the holder of record thereof. Anything herein to the contrary notwithstanding, if a law or any regulation of the U.S. Securities and Exchange Commission or of any other regulatory body having jurisdiction shall require the Company or you to take any action before shares of Stock can be delivered to you hereunder, then the date of delivery of such shares may be delayed accordingly.
12.Securities Laws. If a Registration Statement under the U.S. Securities Act of 1933, as amended, is not in effect with respect to the shares of Stock to be delivered pursuant to this Agreement, you hereby represent that you are acquiring the shares of Stock for investment and with no present intention of selling or transferring them and that you will not sell or otherwise transfer the shares of Stock except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Stock may then be listed.
13.Not a Public Offering. If you are resident outside the U.S., the grant of the Performance Shares is not intended to be a public offering of securities in your country of residence (or country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Performance Shares is not subject to the supervision of the local securities authorities.
14.Insider Trading/Market Abuse Laws. By participating in the Plan, you agree to comply with the Company's policy on insider trading, to the extent that it is applicable to you. You further acknowledge that, depending on your or your broker's country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to shares of Stock, or rights linked to the value of shares of Stock during such times you are considered to have "inside information" regarding the Company as defined by the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party
4



(other than on a "need to know" basis) and (ii) "tipping" third parties or causing them otherwise to buy or sell securities. You understand that third parties include fellow employees and/or service providers. Any restrictions under these laws and regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions and, therefore, you should consult your personal advisor on this matter.
15.Repatriation; Compliance with Law. If you are resident or employed outside the U.S., you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan in accordance with applicable foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and its Affiliates, as may be required to allow the Company and its Affiliates to comply with local laws, rules and/or regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal obligations under local laws, rules and/or regulations in your country of residence (and country of employment, if different).
16.No Advice Regarding Grant. No employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock underlying the Performance Shares. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.
17.Change in Stock. In the event of any change in the shares of Stock, by reason of any stock dividend, recapitalization, reorganization, split-up, merger, consolidation, exchange of shares, or of any similar change affecting the shares of Stock, the number of the Performance Shares subject to this Award Agreement shall be equitably adjusted by the Committee.
18.Nature of the Award. In accepting the Award, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and limited in duration, and it may be modified, amended, suspended or terminated by the Company, in its sole discretion, at any time;
(b)    the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Performance Shares, or benefits in lieu of Performance Shares, even if Performance Shares have been granted in the past;
(c)    all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company, including, but not limited to, the form and timing of the Award, the number of shares of Stock subject to the Award, and the earning provisions applicable to the Award;
(d)    the Award and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company or any Affiliate and shall not interfere with the ability of the Company, your Employer or an Affiliate, as applicable, to terminate your employment or service relationship;
(e)    you are voluntarily participating in the Plan;
(f)    the Award and the shares of Stock subject to the Award are not intended to replace any pension rights or compensation;
(g)    the Award, the shares of Stock subject to the Award and the income and value of the same, is an extraordinary item of compensation outside the scope of your employment (and employment contract, if any) and is not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses,
5



long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, your Employer or any Affiliate;
(h)    the future value of the shares of Stock underlying the Award is unknown, indeterminable and cannot be predicted with certainty;
(i)    unless otherwise determined by the Committee in its sole discretion, a Termination of Service shall be effective from the date on which active employment or service ends and shall not be extended by any statutory or common law notice of termination period;
(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from a Termination of Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and in consideration of the grant of the Award to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, your Employer or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer and all Affiliates from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim;
(k)    unless otherwise provided herein, in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of Stock of the Company; and
(l)    neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Award or of any amounts due to you pursuant to the settlement of the Award or the subsequent sale of any shares of Stock acquired upon settlement of the Award.
19.Committee Authority; Recoupment. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, including the enforcement of any recoupment policy, all of which shall be binding upon you and any claimant. Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.
20.Personal Data. Pursuant to applicable personal data protection laws, the Company hereby notifies you of the following in relation to your personal data and the collection, processing and transfer of such data in relation to the Company's grant of the Performance Shares and your participation in the Plan. The collection, processing and transfer of personal data is necessary for the Company's administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of personal data may affect your participation in the Plan. As such, you voluntarily acknowledge and consent (where required under applicable law) to the collection, use, processing and transfer of personal data as described herein:
(a)    The Company and your Employer hold certain personal information about you, specifically: your name, home address, email address and telephone number, date of birth, social security, passport or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all entitlements to shares of Stock awarded, canceled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan ("Data"). Data may be provided by you or collected, where lawful, from the Company, its Affiliates and/or third parties, and the Company and your Employer will process Data for
6



the exclusive purpose of implementing, administering and managing your participation in the Plan. Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations in your country of residence (or country of employment, if different). Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought. Data will be accessible within the organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and for your participation in the Plan.
(b)    The Company and your Employer will transfer Data internally as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and/or your Employer may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Plan. You hereby authorize (where required under applicable law) the recipients to receive, possess, use, retain and transfer Data, in electronic or other form, as may be required for the administration of the Plan and/or the subsequent holding of the shares of Stock on your behalf, to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.
(c)    You may, at any time, exercise your rights provided under applicable personal data protection laws, which may include the right to (i) obtain confirmation as to the existence of Data, (ii) verify the content, origin and accuracy of Data, (iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of Data, (iv) oppose, for legal reasons, the collection, processing or transfer of Data which is not necessary or required for the implementation, administration and/or operation of the Plan and your participation in the Plan, and (v) withdraw your consent to the collection, processing or transfer of Data as provided hereunder (in which case, your Performance Shares will become null and void). You may seek to exercise these rights by contacting your Human Resources manager or the Company's Human Resources Department, who may direct the matter to the applicable Company privacy official.
21.Addendum to Agreement. Notwithstanding any provision of this Agreement to the contrary, the Performance Shares shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as set forth in the addendum to this Agreement, attached hereto as Exhibit A (the "Addendum"). Further, if you transfer your residence and/or employment to another country reflected in the Addendum, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Performance Shares and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). The Addendum shall constitute part of this Agreement.
22.Additional Requirements. The Company reserves the right to impose other requirements on the Performance Shares, any shares of Stock acquired pursuant to the Performance Shares and your participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Performance Shares and the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.
23.Amendment or Modification, Waiver. Except as set forth in the Plan, no provision of this Agreement may be amended or waived unless the amendment or waiver is agreed to in writing, signed by you and by a duly authorized officer of the Company. No waiver of any condition or provision of this Agreement shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.
24.Electronic Delivery. The Company may, in its sole discretion, deliver by electronic means any documents related to the Award or your future participation in the Plan.
7



You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.
25.Governing Law and Jurisdiction. This Agreement is governed by the substantive and procedural laws of the state of Illinois, U.S.A. You and the Company shall submit to the exclusive jurisdiction of, and venue in, the courts in Illinois, U.S.A., in any dispute relating to this Agreement without regard to any choice of law rules thereof which might apply the laws of any other jurisdiction.
26.English Language. If you are resident in a country where English is not an official language, you acknowledge and agree that it is your express intent that this Agreement, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English. You further acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English so as to allow you to understand the terms and conditions of the Agreement, the Plan or any other documents related to the Award. If you have received this Agreement, the Plan or any other documents related to the Award translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
27.Conformity with Applicable Law. If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
28.Successors. This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder.
****
This Agreement contains highly sensitive and confidential information. Please handle it accordingly.
Please read the attached Exhibit A. Once you have read and understood this Agreement and Exhibit A, please click the acceptance box to certify and confirm your agreement to be bound by the terms and conditions of this Agreement and Exhibit A and to acknowledge your receipt of the Prospectus, the Plan and this Agreement and your acceptance of the terms and conditions of the Award granted hereunder.






8



EXHIBIT A
ADDENDUM TO THE
WALGREENS BOOTS ALLIANCE, INC. 2021 OMNIBUS INCENTIVE PLAN
PERFORMANCE SHARE AWARD AGREEMENT
In addition to the terms of the Plan and the Agreement, the Award is subject to the following additional terms and conditions to the extent you reside and/or are employed in one of the countries addressed herein. Pursuant to Section 21 of the Agreement, if you transfer your residence and/or employment to another country reflected in this Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Performance Shares and the Plan (or the Company may establish alternative terms as may be necessary or advisable to accommodate your transfer). All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.
EUROPEAN UNION ("EU") / EUROPEAN ECONOMIC AREA ("EEA") / SWITZERLAND / THE UNITED KINGDOM

Personal Data. The following provision replaces Section 20 of the Agreement in its entirety:
The Company, with its registered address at 108 Wilmot Road, Deerfield, Illinois 60015, U.S.A. is the controller responsible for the processing of your personal data by the Company and the third parties noted below.

(a)Data Collection and Usage. Pursuant to applicable data protection laws, you are hereby notified that the Company collects, processes and uses certain personal information about you for the legitimate purpose of implementing, administering and managing the Plan and generally administering awards; specifically: your name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares or directorships held in the Company, and details of all Performance Shares, any entitlement to shares of Stock awarded, canceled, exercised, vested, or outstanding in your favor, which the Company receives from you or the Employer ("Personal Data"). In granting the Performance Shares under the Plan, the Company will collect, process, use, disclose and transfer (collectively, "Processing") Personal Data for purposes of implementing, administering and managing the Plan. The Company's legal basis for the Processing of Personal Data is the Company's legitimate business interests of managing the Plan, administering employee awards and complying with its contractual and statutory obligations, as well as the necessity of the Processing for the Company to perform its contractual obligations under the Agreement and the Plan. Your refusal to provide Personal Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan. As such, by accepting the Performance Shares, you voluntarily acknowledge the Processing of your Personal Data as described herein.

(b)Stock Plan Administration Service Provider. The Company may transfer Personal Data to Fidelity Stock Plan Services, LLC ("Fidelity"), an independent service provider based, in relevant part, in the United States, which may assist the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Personal Data with another company that serves in a similar manner. The Company's service provider will open an account for you to receive and trade shares of Stock pursuant to the Performance Shares. The Processing of Personal Data will take place through both electronic and non-electronic means. Personal Data will only be accessible by those individuals requiring access to it for purposes of implementing, administering and operating the Plan. When receiving your Personal Data, if applicable, Fidelity provides appropriate safeguards in accordance with the EU Standard Contractual Clauses or other appropriate cross-border transfer solutions. By participating in the Plan, you understand that the service provider will Process your Personal Data for the purposes of implementing, administering and managing your participation in the Plan.

9



(c)International Data Transfers. The Company is based in the United States, which means it will be necessary for Personal Data to be transferred to, and Processed in the United States. When transferring your Personal Data to the United States, the Company provides appropriate safeguards in accordance with the EU Standard Contractual Clauses, and other appropriate cross-border transfer solutions. You may request a copy of the appropriate safeguards with Fidelity or the Company by contacting your Human Resources manager or the Company's Human Resources Department.

(d)Data Retention. The Company will use Personal Data only as long as is necessary to implement, administer and manage your participation in the Plan or as required to comply with legal or regulatory obligations, including tax and securities laws. When the Company no longer needs Personal Data related to the Plan, the Company will remove it from its systems. If the Company keeps Personal Data longer, it would be to satisfy legal or regulatory obligations and the Company's legal basis would be for compliance with relevant laws or regulations.

(e)Data Subject Rights. To the extent provided by law, you have the right to (i) subject to certain exceptions, request access or copies of Personal Data the Company Processes, (ii) request rectification of incorrect Personal Data, (iii) request deletion of Personal Data, (iv) place restrictions on Processing of Personal Data, (v) lodge complaints with competent authorities in your country, and/or (vi) request a list with the names and addresses of any potential recipients of Personal Data. To receive clarification regarding your rights or to exercise your rights, you may contact your Human Resources manager or the Company's Human Resources Department. You also have the right to object, on grounds related to a particular situation, to the Processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting your Human Resources manager or the Company's Human Resources Department in writing. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to administer the Performance Shares, or grant other awards or administer or maintain such awards. For more information on the consequences of the refusal to provide Personal Data, you may contact your Human Resources manager or the Company's Human Resources Department in writing. You may also have the right to lodge a complaint with the relevant data protection supervisory authority.

CHILE

    Private Placement. The following provision shall replace Section 13 of the Agreement:

The grant of the Performance Shares hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.
a)The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean Commission for the Financial Market;
b)The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;
c)The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean Commission for the Financial Market; and
d)The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
a)La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la Comisión para el Mercado Financiero en Chile;
b)La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la Comisión para el Mercado Financiero en Chile, por lo que tales valores no están sujetos a la fiscalización de ésta;
c)Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y
10



d)Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente.
GERMANY

No country-specific provisions.

HONG KONG

1.Form of Payment. Notwithstanding any provision in the Agreement or Plan to the contrary, the Performance Shares shall be settled only in Shares (and not in cash).

2.IMPORTANT NOTICE. WARNING: The contents of the Agreement, this Addendum, the Plan, the Plan prospectus, the Plan administrative rules and all other materials pertaining to the Performance Shares and/or the Plan have not been reviewed by any regulatory authority in Hong Kong. You are hereby advised to exercise caution in relation to the offer thereunder. If you have any doubts about any of the contents of the aforesaid materials, you should obtain independent professional advice. Neither the grant of the Performance Shares nor the issuance of the shares of Stock upon vesting of the Performance Shares constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Affiliates. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Performance Shares (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Affiliates and may not be distributed to any other person.

3.Wages. The Performance Shares and shares of Stock subject to the Performance Shares do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

IRELAND

No country-specific provisions.

ITALY

    Plan Document Acknowledgment. In accepting the Performance Shares, you acknowledge that a copy of the Plan was made available to you, and you have reviewed the Plan and the Agreement, including this Addendum, in their entirety and fully understand and accept all provisions of the Plan, the Agreement and the Addendum.

You further acknowledge that you have read and specifically approve the following provisions in the Agreement: Section 3: Determination of Performance Shares Earned (threshold levels for earning Performance Shares); Section 4: Disability or Death (terms of payment of Performance Shares upon a Termination of Service by reason of Disability or death); Section 5: Retirement (terms of payment of Performance Shares upon a Termination of Service by reason of retirement); Section 6: Termination of Service Following a Change in Control (terms of payment of Performance Shares in the event of a Termination of Service following a Change in Control); Section 7: Other Termination of Service (forfeiture of Performance Shares in other cases of Termination of Service); Section 9(a): Responsibility for Taxes; Tax Withholding (liability for all Tax-Related Items related to the Performance Shares and legally applicable to the participant); Section 10: Nontransferability (Performance Shares shall not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated); Section 17: Change in Stock (right of the Company to equitably adjust the number of Performance Shares subject to this Agreement in the event of any change in Stock); Section 18(j): Nature of the Award (waive any claim or entitlement to compensation or damages arising from forfeiture of the Performance Shares resulting from a Termination of Service); Section 18(l): Nature of the Award (the Company is not liable for any foreign exchange rate fluctuation impacting the value of the Performance Shares); Section 19: Committee Authority; Recoupment (right of the Committee to administer, construe, and make all determinations necessary or appropriate for the administration of the Performance Shares and this Agreement, including the enforcement of any
11



recoupment policy); Section 21: Addendum to Agreement (the Performance Shares are subject to the terms of the Addendum); Section 22: Additional Requirements (Company right to impose additional requirements on the Performance Shares in case such requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate operation and administration of the Performance Shares and the Plan); Section 24: Electronic Delivery (Company may deliver documents related to the Award or Plan electronically); Section 25: Governing Law and Jurisdiction (Agreement is governed by Illinois law without regard to any choice of law rules thereof; agreement to exclusive jurisdiction of Illinois courts); Section 26: English Language (documents will be drawn up in English; if a translation is provided, the English version controls); and the provision titled “Personal Data” under the heading "European Union (‘EU’) / European Economic Area (‘EEA’) / Switzerland / the United Kingdom", included in this Addendum.

MEXICO

1.Commercial Relationship. You expressly recognize that your participation in the Plan and the Company's grant of the Performance Shares does not constitute an employment relationship between you and the Company. You have been granted the Performance Shares as a consequence of the commercial relationship between the Company and the Affiliate in Mexico that employs you ("WBA Mexico"), and WBA Mexico is your sole employer. Based on the foregoing, you expressly recognize that (a) the Plan and the benefits you may derive from your participation in the Plan do not establish any rights between you and WBA Mexico, (b) the Plan and the benefits you may derive from your participation in the Plan are not part of the employment conditions and/or benefits provided by WBA Mexico, and (c) any modifications or amendments of the Plan by the Company, or a termination of the Plan by the Company, shall not constitute a change or impairment of the terms and conditions of your employment with WBA Mexico.

2.Extraordinary Item of Compensation. You expressly recognize and acknowledge that your participation in the Plan is a result of the discretionary and unilateral decision of the Company, as well as your free and voluntary decision to participate in the Plan in accordance with the terms and conditions of the Plan, the Agreement and this Addendum. As such, you acknowledge and agree that the Company, in its sole discretion, may amend and/or discontinue your participation in the Plan at any time and without any liability. The Award, the shares of Stock subject to the Award and the income and value of the same is an extraordinary item of compensation outside the scope of your employment contract, if any, and is not part of your regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of WBA Mexico.

3.Securities Law Notification. The Performance Shares and shares of Stock offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, this Agreement and any other document relating to the Performance Shares may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and WBA Mexico and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of WBA Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.

MONACO

    Use of English Language. You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

12



SWITZERLAND

    Securities Law Notification. Neither this document nor any other materials relating to the Performance Shares (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, or approved or supervised by, any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

THAILAND

No country-specific provisions.

UNITED KINGDOM

    1.    Indemnification for Tax-Related Items. Without limitation to Section 9 of the Agreement, you hereby agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, your Employer or by Her Majesty's Revenue & Customs ("HMRC") (or any other tax authority or any other relevant authority). You also hereby agree to indemnify and keep indemnified the Company and your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, if you are a director or executive officer (as within the meaning of Section 13(k) of the Exchange Act), the terms of the immediately foregoing provision will not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to you on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or your Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or your Employer may recover from you at any time thereafter by any of the means referred to in Section 10 of the Agreement.

    2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Performance Shares, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Performance Shares. Upon the grant of the Performance Shares, you shall be deemed irrevocably to have waived any such entitlement.

*** *** *** *** ***
    By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Performance Share Award Agreement to which this Addendum is attached as Exhibit A, and I agree to the terms and conditions expressed in this Addendum.
13
EX-10.5 3 a11302021exhibit105.htm EX-10.5 Document

EXHIBIT 10.5



WALGREENS BOOTS ALLIANCE, INC.

2021 OMNIBUS INCENTIVE PLAN

STOCK OPTION AWARD AGREEMENT










These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by Walgreens Boots Alliance, Inc., not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments. These materials were prepared by Walgreens Boots Alliance, Inc., which is solely responsible for their contents and for compliance with legal and regulatory requirements. Fidelity is not connected with any offering or acting as an underwriter in connection with any offering of your company's securities or financial instruments. Fidelity does not review, approve or endorse the contents of these materials and is not responsible for their content.

        


WALGREENS BOOTS ALLIANCE, INC.
2021 OMNIBUS INCENTIVE PLAN
STOCK OPTION AWARD AGREEMENT

Participant Name:
Participant ID:
Grant Date:     (the "Grant Date")
Grant Price:
Shares Granted:     (the "Shares Granted")
Vesting: One third of the Shares Granted vest on each of the first, second and third anniversaries of the Grant Date (the "Vesting Dates")
Expiration Date:     (the "Expiration Date")
Acceptance Date:
Electronic Signature:
This document (referred to below as this "Agreement") spells out the terms and conditions of the stock option (the "Option") granted to you by Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), pursuant to the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (the "Plan") on and as of the Grant Date designated above. Except as otherwise defined herein, capitalized terms used in this Agreement have the respective meanings set forth in the Plan. For purposes of this Agreement, "Employer" means the entity (the Company or the Affiliate) that employs you on the applicable date. The Plan, as in effect on the date of this Agreement and as it may be amended from time to time, is incorporated into this Agreement by this reference.
You and the Company agree as follows:
1.Grant of Option. Pursuant to the approval and direction of the Compensation and Leadership Performance Committee of the Company's Board of Directors (the "Committee"), the Company hereby grants you an Option to purchase all or any part of the number of Shares Granted set forth above of common stock of the Company, par value US$.01 ("Stock"), at the per-share exercise price, which is 100% of the Fair Market Value of a share of Stock on the Grant Date (the "Exercise Price"), subject to the terms and conditions of the Plan and this Agreement. The Option is intended to be a "non-qualified stock option" and shall not be treated as an incentive stock option within the meaning of Section 422 of the Code.
2.Vesting/Exercise/Expiration. You may not exercise the Option prior to the Vesting Date or Dates set forth above absent action by the Committee to waive or alter such restrictions or as may be permitted under the below paragraphs. Thereafter, except as hereinafter provided, you may exercise the Option, to the extent it is vested, at any time and from time to time until the close of business on the Expiration Date set forth above. The Option may be exercised to purchase any number of whole shares of Stock, except that no purchase shall be for less than ten (10) full shares of Stock, or the remaining unexercised shares, if less. The Option is deemed to be "outstanding" until it has been exercised in full or expired pursuant to the terms of this Agreement.
3.Disability. If, without having fully exercised the Option, you have a Termination of Service due to Disability, then any Shares Granted under the Option that are not yet vested at



that time shall thereupon become vested and (a) you may exercise the Option for the full number of Shares Granted (less any shares for which the Option was previously exercised), but (b) your right to exercise the Option shall terminate upon the earlier of the Expiration Date or a date which is one (1) year following the date of your Termination of Service.
4.Death. If, without having fully exercised the Option, you have a Termination of Service due to your death, then any Shares Granted under the Option that are not yet vested at that time shall thereupon become fully vested and (a) the Option may be exercised by the executor or administrator of your estate or by such person or persons who shall have acquired your rights hereunder by bequest or inheritance or by designation as your beneficiary for the full number of Shares Granted (less any shares for which the Option was previously exercised), but (b), such person's right to exercise the Option shall terminate upon the earlier of the Expiration Date or a date which is one (1) year after the date of your death.
5.Retirement. If without having fully exercised the Option you have a Termination of Service by reason of Retirement, as reasonably determined and approved by the Committee or its delegates, then, subject to such approval (a) any Shares Granted under the Option that are not vested at that time shall thereupon become vested, and (b) you may exercise the Option for the full number of Shares Granted (less any shares for which the Option was previously exercised) until the Expiration Date set forth above.
6.Termination of Service Following a Change in Control. If there is a Change in Control of the Company and within the one-year period thereafter you have a Termination of Service initiated by your Employer other than for Cause (as defined in Section 8), then any Shares Granted under the Option that are not yet vested at that time shall thereupon become vested, and you may exercise the Option for the full number of Shares Granted (less any shares for which the Option was previously exercised) until the Expiration Date set forth above. Shares Granted for which you cannot exercise the Option under this Section 6 shall be forfeited. The foregoing is also subject to the Committee's exercise of its discretion under Section 9.01 of the Plan. For purposes of this Section 6, a Termination of Service initiated by your Employer shall include a Termination of Employment for Good Reason under - and pursuant to the terms and conditions of – the Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan, but only to the extent applicable to you as an eligible participant in such plan.
7.Other Termination of Service. If without having fully exercised the Option you have a voluntary or involuntary Termination of Service for any reason other than as set forth in Section 3, 4, 5 or 6 above, as determined by the Committee, then (a) for any Shares Granted with respect to which such Termination of Service is prior to the applicable Vesting Date, the Option shall be forfeited, and (b) for any Shares Granted with respect to which such Termination of Service is on or after the applicable Vesting Date, then your right to exercise the Option shall terminate upon the earlier of the Expiration Date or a date which is ninety (90) days after the date of your Termination of Service. The foregoing is subject to the right of the Committee to extend the exercise period of the Option, including any extension granted by the Committee or its delegate as needed to allow your right to exercise to extend beyond a period during which you are restricted from exercising the Option due to a Company-designated trading blackout period, and is subject to earlier expiration as provided in Section 8 below.
8.Forfeiture of Outstanding Options Upon Termination for Cause or Upon Other Violations. Notwithstanding any provision of this Agreement to the contrary, the Option (whether vested or unvested) shall immediately terminate if you are terminated for Cause or if and when you violate any obligation that you may have to the Company during or post-employment, including but not limited to a violation of any applicable provision of the NNCA Agreement (defined in Section 22 below) or any other non-competition, non-solicitation, confidentiality, non-disparagement or other restrictive covenant. For purposes of this Agreement, "Cause" means any one or more of the following, as determined by the Committee in its sole discretion:



(a)your commission of a felony or any crime of moral turpitude;
(b)your dishonesty or material violation of standards of integrity in the course of fulfilling your duties to the Company or any Affiliate;
(c)your material violation of a material written policy of the Company or any Affiliate violation of which is grounds for immediate termination;
(d)your willful and deliberate failure to perform your duties to the Company or any Affiliate in any material respect, after reasonable notice of such failure and an opportunity to correct it; or
(e)your failure to comply in any material respect with the United States ("U.S.") Foreign Corrupt Practices Act, the U.S. Securities Act of 1933, the Exchange Act, the U.S. Sarbanes-Oxley Act of 2002, the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the U.S. Truth in Negotiations Act, or any rules or regulations thereunder.
9.Exercise Process. The Option may be exercised by giving notice to Fidelity Stock Plan Services, LLC ("Fidelity"), the third party administrator administering the Option exercise process or any other third party administrator the Company may engage in the future. The exercise notice (a) shall be signed by you or (in the event of your death) your legal representative, (b) shall specify the number of full shares of Stock then elected to be purchased, and (c) shall be accompanied by payment in full of the Exercise Price of the shares of Stock to be purchased. Payment may be made in cash or by check payable to the order of the Company, and such payment shall include any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan that are required to be withheld ("Tax-Related Items"), as set forth in Section 10 below. Alternatively, the Committee may allow for one or more of the following methods of exercising the Option:
(a)    Payment for shares of Stock as to which the Option is being exercised and/or payment of any Tax-Related Items may be made by transfer to the Company of shares of Stock you already own, or any combination of such shares of Stock and cash, having a fair market value determined at the time of exercise of the Option equal to, but not exceeding, the Exercise Price and/or any Tax-Related Items, as the case may be.
(b)    A "same day sale" transaction pursuant to which a third party (engaged by you or the Company) loans funds to you to enable you to purchase the shares of Stock and pay any Tax-Related Items, and then sells a sufficient number of the exercised shares of Stock on your behalf to enable you to repay the loan and any fees. The remaining shares of Stock and/or cash are then delivered by the third party to you.
(c)    A "net exercise" transaction, pursuant to which the Company delivers to you the net number of whole shares of Stock remaining from the portion of the Option being exercised after deduction of a number of shares of Stock with a fair market value equal to the Exercise Price and the amount of any Tax-Related Items.
    As promptly as practicable after receipt of such notice of exercise and payment (including payment with respect to any Tax-Related Items), subject to Section 13 below, the Company shall cause to be issued and delivered to you (or in the event of your death to your legal representative, as the case may be), certificates for the shares of Stock so purchased. Alternatively, such shares of Stock may be issued and held in book entry form.
Notwithstanding any provision within this Agreement to the contrary, if you are resident or employed outside of the U.S., the Committee may require that you (or in the event of your death, your legal representative, as the case may be) exercise the Option in a method other than as specified above, may require you to exercise the Option only by means of a "same day sale" transaction (either a "sell-all" transaction or a "sell-to-cover" transaction) as it shall determine in its sole discretion, or may require you to sell any shares of Stock you acquire under the Plan immediately or within a specified period following your Termination of Service (in which



case, you hereby agree that the Company shall have the authority to issue sale instructions in relation to such shares of Stock on your behalf).
10.Responsibility for Taxes; Tax Withholding.
(a)    You acknowledge that, regardless of any action taken by the Company or your Employer, the ultimate liability for all Tax-Related Items related to your participation in the Plan and legally applicable to you is and remains your responsibility and may exceed the amount actually withheld by the Company or your Employer, if any. You further acknowledge that the Company and/or your Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of shares of Stock acquired pursuant to such exercise and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, as applicable, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(b)    Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or your Employer to satisfy all Tax-Related Items. In this regard, except as provided below, the Company, your Employer or its agent shall satisfy the obligations with regard to all Tax-Related Items by withholding from the shares of Stock to be delivered upon exercise of the Option that number of shares of Stock having a Fair Market Value equal to the amount required by law to be withheld. For purposes of the foregoing, no fractional shares of Stock will be withheld or issued pursuant to the grant of the Option and the issuance of shares of Stock hereunder. Notwithstanding the foregoing, if you are a Section 16 officer of the Company under the Exchange Act at the time of any applicable tax withholding event, you may make a cash payment to the Company, your Employer or its agent to cover the Tax-Related Items that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan. If you are not a Section 16 officer of the Company at the time of any applicable tax withholding event, the Company and/or your Employer may (in its sole discretion) allow you to make a cash payment to the Company, your Employer or its agent to cover such Tax-Related Items.
The Company may withhold or account for Tax-Related Items by considering applicable statutory withholding rates (as determined by the Company in good faith and in its sole discretion) or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding from the shares of Stock to be delivered upon exercise of the Option, for tax purposes, you will be deemed to have been issued the full number of shares of Stock subject to the exercised Option, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items.
The Company may refuse to issue or deliver the shares of Stock or the proceeds from the sale of shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items.
11.Limited Transferability. You may not sell, transfer, pledge, assign or otherwise alienate or hypothecate the Option, whether voluntarily or involuntarily or by operation of law, other than by beneficiary designation effective upon your death, by will or by the laws of intestacy. During your lifetime, the Option and all rights granted hereunder shall be exercisable only by you. Notwithstanding the foregoing, you may transfer the Option, in whole or in part, by gift to a Permitted Transferee in accordance with rules and subject to any conditions specified by the Committee under the Plan.



12.Rights as Stockholder. You shall have no rights as a stockholder of the Company with respect to the shares of Stock subject to the Option until such time as the Exercise Price has been paid and a certificate of stock for such shares has been issued to you or such shares of Stock have been recorded in your name in book entry form. Except as provided in Section 18 below, no adjustment shall be made for dividends or distributions or other rights with respect to such shares of Stock for which the record date is prior to the date on which you become the holder of record thereof. Anything herein to the contrary notwithstanding, if a law or any regulation of the U.S. Securities and Exchange Commission or of any other regulatory body having jurisdiction shall require the Company or you to take any action before shares of Stock can be delivered to you hereunder, then the date of delivery of such shares may be delayed accordingly.
13.Securities Laws. If a Registration Statement under the U.S. Securities Act of 1933, as amended, is not in effect with respect to the shares of Stock to be delivered pursuant to this Agreement, you hereby represent that you are acquiring the shares of Stock for investment and with no present intention of selling or transferring them and that you will not sell or otherwise transfer the shares of Stock except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Stock may then be listed.
14.Not a Public Offering. If you are resident outside the U.S., the grant of the Option is not intended to be a public offering of securities in your country of residence (or country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Option is not subject to the supervision of the local securities authorities.
15.Insider Trading/Market Abuse Laws. By participating in the Plan, you agree to comply with the Company's policy on insider trading, to the extent that it is applicable to you. You further acknowledge that, depending on your or your broker's country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to shares of Stock (e.g., the Option) or rights linked to the value of shares of Stock during such times you are considered to have "inside information" regarding the Company as defined by the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a "need to know" basis) and (ii) "tipping" third parties or causing them otherwise to buy or sell securities. You understand that third parties include fellow employees and/or service providers. Any restrictions under these laws and regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions and, therefore, you should consult your personal advisor on this matter.
16.Repatriation; Compliance with Law; Method of Exercise. If you are resident or employed outside the U.S., you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan in accordance with applicable foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and its Affiliates, as may be required to allow the Company and its Affiliates to comply with local laws, rules and/or regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal obligations under local laws, rules and/or regulations in your country of residence (and country of employment, if different).
17.No Advice Regarding Grant. No employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock underlying the Option. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan and you should carefully review all of the materials related to the Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.



18.Change in Stock. In the event of any change in the shares of Stock by reason of any stock dividend, recapitalization, reorganization, split-up, merger, consolidation, exchange of shares, or of any similar change affecting the shares of Stock, the number of shares of Stock subject to the Option and the Exercise Price shall be equitably adjusted by the Committee.
19.Nature of the Option. In accepting the Option, you acknowledge, understand and agree that:
(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and limited in duration, and it may be modified, amended, suspended or terminated by the Company, in its sole discretion, at any time;
(b)    the grant of the Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of stock options, or benefits in lieu of stock options, even if stock options have been granted in the past;
(c)    all decisions with respect to future grants of stock options or other grants, if any, will be at the sole discretion of the Company, including, but not limited to, the form and timing of any grant, the number of shares of Stock subject to the stock options, vesting provisions, and the exercise price applicable to the stock option;
(d)    the Option and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company or any Affiliate and shall not interfere with the ability of the Company, your Employer or an Affiliate, as applicable, to terminate your employment or service relationship;
(e)    you are voluntarily participating in the Plan;
(f)    the Option and the shares of Stock subject to the Option are not intended to replace any pension rights or compensation;
(g)    the Option, the shares of Stock subject to the Option and the income and value of the same, is an extraordinary item of compensation outside the scope of your employment (and employment contract, if any) and is not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, your Employer or any Affiliate;
(h)    the future value of the shares of Stock underlying the Option is unknown, indeterminable and cannot be predicted with certainty and if you exercise a vested Option, the value of the underlying shares of Stock may increase or decrease, even below the Exercise Price;
(i)    unless otherwise determined by the Committee in its sole discretion, a Termination of Service shall be effective from the date on which active employment or service ends and shall not be extended by any statutory or common law notice of termination period;
(j)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from a Termination of Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and in consideration of the grant of the Option to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, your Employer or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer and all Affiliates from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue



such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim;
(k)    unless otherwise provided herein, in the Plan or by the Company in its discretion, the Option and the benefits evidenced by this Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of Stock of the Company; and
(l)    neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Option or of any amounts due to you pursuant to the settlement of the Option or the subsequent sale of any shares of Stock acquired upon settlement of the Option.
20.Committee Authority; Recoupment. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, including the enforcement of any recoupment policy, all of which shall be binding upon you and any claimant. Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.
21.Personal Data. Pursuant to applicable personal data protection laws, the Company hereby notifies you of the following in relation to your personal data and the collection, processing and transfer of such data in relation to the Company's grant of the Option and your participation in the Plan. The collection, processing and transfer of personal data is necessary for the Company's administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of personal data may affect your participation in the Plan. As such, you voluntarily acknowledge and consent (where required under applicable law) to the collection, use, processing and transfer of personal data as described herein:
(a)    The Company and your Employer hold certain personal information about you, specifically: your name, home address, email address and telephone number, date of birth, social security, passport or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all entitlements to shares of Stock awarded, canceled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan ("Data"). Data may be provided by you or collected, where lawful, from the Company, its Affiliates and/or third parties, and the Company and your Employer will process Data for the exclusive purpose of implementing, administering and managing your participation in the Plan. Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations in your country of residence (or country of employment, if different). Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought. Data will be accessible within the organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and for your participation in the Plan.
(b)    The Company and your Employer will transfer Data internally as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and/or your Employer may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Plan. You hereby authorize (where required under applicable law) the recipients to receive, possess, use, retain and transfer Data, in electronic or other form, as may be required for the administration of the Plan and/or the subsequent holding of the shares of Stock on your behalf, to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.



(c)    You may, at any time, exercise your rights provided under applicable personal data protection laws, which may include the right to (i) obtain confirmation as to the existence of Data, (ii) verify the content, origin and accuracy of Data, (iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of Data, (iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and/or operation of the Plan and your participation in the Plan, and (v) withdraw your consent to the collection, processing or transfer of Data as provided hereunder (in which case, the Option will become null and void). You may seek to exercise these rights by contacting your Human Resources manager or the Company's Human Resources Department, who may direct the matter to the applicable Company privacy official.
22.Non-Competition, Non-Solicitation and Confidentiality. As a condition to the receipt of the Option, you must agree to the Non-Competition, Non-Solicitation and Confidentiality Agreement (the "NNCA Agreement") attached hereto as Exhibit A. By clicking the acceptance box for this Agreement, you also agree to the terms and conditions expressed in the NNCA Agreement. Failure to accept the terms of this Agreement and NNCA Agreement within 120 days of the Grant Date shall constitute your decision to decline to accept this Award.
23.Addendum to Agreement. Notwithstanding any provision of this Agreement to the contrary, the Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as set forth in the addendum to this Agreement, attached hereto as Exhibit B (the "Addendum"). Further, if you transfer your residence and/or employment to another country reflected in the Addendum, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Option and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). The Addendum shall constitute part of this Agreement.
24.Additional Requirements. The Company reserves the right to impose other requirements on the Option, any shares of Stock acquired pursuant to the Option and your participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Option and the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.
25.Amendment or Modification, Waiver. Except as set forth in the Plan, no provision of this Agreement may be amended or waived unless the amendment or waiver is agreed to in writing, signed by you and by a duly authorized officer of the Company. No waiver of any condition or provision of this Agreement shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.
26.Electronic Delivery. The Company may, in its sole discretion, deliver by electronic means any documents related to the Option or your future participation in the Plan. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.
27.Governing Law and Jurisdiction. This Agreement is governed by the substantive and procedural laws of the state of Illinois, U.S.A. You and the Company shall submit to the exclusive jurisdiction of, and venue in, the courts in Illinois, U.S.A., in any dispute relating to this Agreement without regard to any choice of law rules thereof which might apply the laws of any other jurisdiction.
28.English Language. If you are resident in a country where English is not an official language, you acknowledge and agree that it is your express intent that this Agreement, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Option, be drawn up in English. You further acknowledge that you are



sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement, the Plan or any other document related to the Option. If you have received this Agreement, the Plan or any other documents related to the Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
29.Conformity with Applicable Law. If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
30.Successors. This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder.
****
    This Agreement contains highly sensitive and confidential information. Please handle it accordingly.
Please read the attached Exhibits A and B. Once you have read and understood this Agreement and Exhibits A and B, please click the acceptance box to certify and confirm your agreement to be bound by the terms and conditions of this Agreement and Exhibits A and B, and to acknowledge your receipt of the Prospectus, the Plan and this Agreement and your acceptance of the terms and conditions of the Option granted hereunder.




EXHIBIT A
WALGREENS BOOTS ALLIANCE, INC. NON-COMPETITION, NON-SOLICITATION
AND CONFIDENTIALITY AGREEMENT
This Exhibit (the “Non-Compete Agreement”) forms a part of the Stock Option Award Agreement covering Options awarded to an employee (“Employee” or “I”) of Walgreens Boots Alliance, Inc. or an affiliate thereof, on behalf of itself, its affiliates, subsidiaries, and successors (collectively referred to as the “Company”).
WHEREAS, the Company develops and/or uses valuable business, technical, proprietary, customer and patient information it protects by limiting its disclosure and by keeping it secret or confidential;
WHEREAS, Employee acknowledges that during the course of employment, he or she has or will receive, contribute, or develop such Confidential Information and Trade Secrets (as defined below); and
WHEREAS, the Company desires to protect from third parties (e.g. competitors and customers) such Confidential Information and Trade Secrets and also desires to protect its legitimate business interests and goodwill in maintaining its employee and customer relationships.
NOW THEREFORE, in consideration of the Stock Option issued to Employee pursuant to the Agreement to which this is attached as Exhibit A and for other good and valuable consideration, including but not limited to employment or continued employment, the specialized knowledge, skill and training that the Company provides Employee, and the goodwill that Employee develops with customers on behalf of the Company, Employee agrees to be bound by the terms of this Non-Compete Agreement as follows:
1.Confidentiality.
(a)At all times during and after the termination of my employment with the Company, I will not, without the Company’s prior written permission, directly or indirectly for any purpose other than performance of my duties for the Company, utilize or disclose to anyone outside of the Company any Trade Secrets (defined in subparagraph 1(a)(i)) or other Confidential Information (defined in subparagraph 1(a)(ii)) or any information received by the Company in confidence from or about third parties, as long as such matters remain Trade Secrets or otherwise confidential.

(i)For purposes of this Non-Compete Agreement, “Trade Secrets” means a form of intellectual property that are protectable under applicable state and/or Federal law, including the Uniform Trade Secrets Act (as amended and adapted by the states) and the Federal Defend Trade Secrets Act of 2016 (the “DTSA”). They include all tangible and intangible (e.g., electronic) forms and types of information that is held and kept confidential by the Company and is not generally known outside of the Company, including but not limited to information about: the Company’s financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs or codes, and may in particular include such things as pricing information, business records, software programs, algorithms, inventions, patent applications, and designs and processes not known outside the Company.

(ii)For purposes of this Non-Compete Agreement, “Confidential Information” means Trade Secrets and, more broadly, any other tangible and intangible (e.g., electronic) forms and types of information that are held and kept confidential by the Company and are not generally known outside the Company, and which relates to the actual or anticipated business of the Company or the Company’s actual or prospective vendors or clients. Confidential Information



shall not be considered generally known to the public if is revealed improperly to the public by me or others without the Company’s express written consent and/or in violation of an obligation of confidentiality to the Company. Examples of Confidential Information include, but are not limited to: customer, referral source, supplier and contractor identification and contacts; special contract terms; pricing and margins; business, marketing and customer plans and strategies; financial data; company created (or licensed) techniques; technical know-how; research, development and production information; processes, prototypes, software, patent applications and plans, projections, proposals, discussion guides, and/or personal or performance information about employees.

(b)I understand that this obligation of non-disclosure shall last so long as the information remains confidential. I, however, understand that, if I live and work primarily in Wisconsin, Virginia, or any other state  requiring a temporal limit on non-disclosure clauses, Confidential Information shall be protected for two (2) years following termination of my employment (for any reason).  I also understand that Trade Secrets are protected by statute and are not subject to any time limits.  I also agree to contact the Company before using, disclosing, or distributing any Confidential Information or Trade Secrets if I have any questions about whether such information is protected information.
(c)The restrictions set forth in this paragraph are in addition to and not in lieu of any obligations I have by law with respect to the Company’s Confidential Information, including any obligations I may owe under the DTSA and any applicable state statutes. Nothing herein shall prohibit me from divulging evidence of criminal wrongdoing to law enforcement or prohibit me from disclosing Confidential Information or Trade Secrets if compelled by order of court or an agency of competent jurisdiction or as required by law; however, I shall promptly inform the Company of any such situations and shall take reasonable steps to prevent disclosure of Confidential Information or Trade Secrets until the Company has been informed of such required disclosure and has had a reasonable opportunity to seek a protective order. Pursuant to the DTSA, I understand that an individual may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a Trade Secret that: (A) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, I understand that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the Trade Secret to his or her attorney and use the Trade Secret information in the court proceeding, so long as any document containing the Trade Secret is filed under seal and the individual does not disclose the Trade Secret, except pursuant to court order. Nothing in this Non-Compete Agreement is intended to conflict with the DTSA or create liability for disclosures of Trade Secrets that are expressly allowed by DTSA.
2.Non-Competition. I agree that during my employment with the Company and for twelve (12) months after the termination of my employment (for any reason), I will not, directly or indirectly have Responsibilities with respect to any Competing Business Line. As set forth in paragraph 9(b) below, I understand that the restrictions in this paragraph apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary. These restrictions shall not apply to passive investments of less than five percent (5%) ownership interest in any entity. For purposes of this Non-Compete Agreement, “Responsibilities” means the same or similar material responsibilities I performed for the Company during the two (2) years prior to my last day of employment with the Company and within the same geographic scope, or portion thereof, where I performed those responsibilities for the Company. For purposes of this Non-Compete Agreement, “Competing Business Line” means any business that is in competition with any business engaged in by the Company and for which I had Responsibilities during the two (2) years prior to my last day of employment with the Company. Competing Business Line shall also include businesses or business lines that may not be directly competitive with the Company in most respects (such as pharmacy benefit managers), but only to the extent I am engaged by any such business in a role: (a) that involves my performing Responsibilities for Competing Products or Services; or (b) where I would be called upon to inevitably rely upon or disclose Confidential Information and



such reliance or disclosure would competitively harm the Company. For purposes of this Non-Compete Agreement, “Competing Products or Services” means products or services that are competitive with products or services offered by, developed by, designed by or distributed by the Company during the two (2) years prior to my last day of employment with the Company.
3.    Non-Solicitation. I agree that during my employment with the Company and for two (2) years after the termination of my employment from the Company (for any reason):
(a)    I will not directly or indirectly, solicit any Restricted Customer for purposes of providing Competing Products or Services, or offer, provide or sell Competing Products or Services to any Restricted Customer. For purposes of this Non-Compete Agreement, “Restricted Customer” means any person, company or entity that was a customer, vendor, supplier or referral source of the Company and with which I had direct contact for purposes of performing responsibilities for the Company or for which I had supervisory responsibilities on behalf of the Company, in either case at any time during the two (2) years prior to my last day of employment with the Company. To the extent permitted by applicable law, “Restricted Customer” also means any prospective customer(s), vendor(s), supplier(s) or referral source(s) with which I had business contact on behalf of the Company in the twelve (12) months prior to my last day of employment with the Company; and
(b)    I will not, nor will I assist any third party to, directly or indirectly (i) raid, solicit, or attempt to persuade any then-current employee of the Company with whom I currently work or with whom I had direct contact work during the two years prior to my last day of employment with the Company,  and who possesses or had access to Confidential Information of the Company, to leave the employ of the Company; (ii) interfere with the performance by any such employee of his/her duties for the Company; and/or (iii) communicate with any such employee for the purposes described in items (i) and (ii) in this subparagraph 3(b).
4.    Non-Inducement. I will not directly or indirectly assist or encourage any person or entity in carrying out or conducting any activity that would be prohibited by this Non-Compete Agreement if such activity were carried out or conducted by me.
5.    Non-Disparagement. During my employment with the Company and thereafter, I agree not to make negative comments or otherwise disparage the Company or any of its officers, directors, employees, shareholders, members, agents or products. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings); and the foregoing shall not apply to any claims for harassment or discrimination to the extent so restricted by applicable state law.
6.    Intellectual Property. The term “Intellectual Property” shall mean all trade secrets, ideas, inventions, designs, developments, devices, software, computer programs, methods and processes (whether or not patented or patentable, reduced to practice or included in the Confidential Information) and all patents and patent applications related thereto, all copyrights, copyrightable works and mask works (whether or not included in the Confidential Information) and all registrations and applications for registration related thereto, all Confidential Information, and all other proprietary rights contributed to, or conceived or created by, or reduced to practice by Employee or anyone acting on his/her behalf (whether alone or jointly with others) at any time from the beginning of Employee’s employment with the Company to the termination of that employment plus ninety (90) days, that (i) relate to the business or to the actual or anticipated research or development of the Company; (ii) result from any services that Employee or anyone acting on its behalf perform for the Company; or (iii) are created using the equipment, supplies or facilities of the Company or any Confidential Information.
a.Ownership. All Intellectual Property is, shall be and shall remain the exclusive property of the Company. Employee hereby assigns to the Company all right, title and interest, if any, in and to the Intellectual Property; provided, however, that, when applicable, the Company shall own the copyrights in all copyrightable works included in the Intellectual Property pursuant to the “work-made-for-hire” doctrine (rather than by



assignment), as such term is defined in the 1976 Copyright Act. All Intellectual Property shall be owned by the Company irrespective of any copyright notices or confidentiality legends to the contrary that may be placed on such works by Employee or by others. Employee shall ensure that all copyright notices and confidentiality legends on all work product authored by Employee or anyone acting on his/her behalf shall conform to the Company’s practices and shall specify the Company as the owner of the work. The Company hereby provides notice to Employee that the obligation to assign does not apply to an invention for which no equipment, supplies, facility, or Trade Secrets of the Company was used and which was developed entirely on the Employee’s own time, unless (i) the invention relates (1) to the business of the Company, or (2) to the Company’s actual or demonstrably anticipated research or development, or (ii) the invention results from any work performed by Employee for the Company.
b.Keep Records. Employee shall keep and maintain, or cause to be kept and maintained by anyone acting on his/her behalf, adequate and current written records of all Intellectual Property in the form of notes, sketches, drawings, computer files, reports or other documents relating thereto. Such records shall be and shall remain the exclusive property of the Company and shall be available to the Company at all times during my employment with the Company.
c.Assistance. Employee shall supply all assistance requested in securing for the Company’s benefit any patent, copyright, trademark, service mark, license, right or other evidence of ownership of any such Intellectual Property, and will provide full information regarding any such item and execute all appropriate documentation prepared by Company in applying or otherwise registering, in the Company’s name, all rights to any such item or the defense and protection of such Intellectual Property.
d.Prior Inventions. Employee has disclosed to the Company any continuing obligations to any third party with respect to Intellectual Property. Employee claims no rights to any inventions created prior to his/her employment for which a patent application has not previously been filed, unless he/she has described them in detail on a schedule attached to this Non-Compete Agreement.
e.Trade Secret Provisions. The provisions in paragraph 1 of this Non-Compete Agreement with regard to Trade Secrets and the DTSA shall apply as well in the context of the parties’ Intellectual Property rights and obligations.
7.    Return of Company Property. I agree that all documents and data accessible to me during my employment with the Company, including Confidential Information and Trade Secrets, regardless of format (electronic or hard copy), including but not limited to any Company computer, monitor, printer equipment, external drives, wireless access equipment, telecom equipment and systems (“Company Equipment”), are and remain the sole and exclusive property of the Company and/or its clients, and must be returned to the Company upon separation or upon demand by the Company. I further agree that I will provide passwords to access such Company Equipment and I will not print, retain, copy, destroy, modify or erase Company U.S. data on Company Equipment or otherwise wipe Company Equipment prior to returning the Company Equipment.
8.    Consideration and Acknowledgments. I acknowledge and agree that the covenants described in this Non-Compete Agreement are essential terms, and the underlying Stock Option Award would not be provided by the Company in the absence of these covenants. I further acknowledge that these covenants are supported by adequate consideration as set forth in this Non-Compete Agreement and are not in conflict with any public interest. I further acknowledge and agree that I fully understand these covenants, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Non-Compete Agreement, and have voluntarily agreed to comply with these covenants for their stated terms. I further acknowledge and agree that these covenants are reasonable and enforceable in all respects.
9.    Enforceability; General Provisions.



(a)I understand that my non-compete and/or non-solicitation obligations in this Non-Compete Agreement shall not apply to me if I am covered under applicable state or local statutory law prohibiting non-competes or non-solicits on the basis of my income and/or position level at the time of enforcement, including but not limited to those addressed in Exhibit A-1.
(b)I agree that the restrictions contained in this Non-Compete Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Non-Compete Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me. I further understand that the restrictions in this Non-Compete Agreement apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary.
(c)Because the Company is incorporated in the state of Delaware (i) this Non-Compete Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any conflict of law provisions, and (ii) I consent to personal jurisdiction and the exclusive jurisdiction of the state and federal courts of Delaware with respect to any claim, dispute or declaration arising out of this Non-Compete Agreement.
(d)In the event of a breach or a threatened breach of this Non-Compete Agreement, I acknowledge that the Company will face irreparable injury which may be difficult to calculate in dollar terms and that the Company shall be entitled, in addition to all remedies otherwise available in law or in equity, to temporary restraining orders and preliminary and final injunctions enjoining such breach or threatened breach in any court of competent jurisdiction without the necessity of posting a surety bond, as well as to obtain an equitable accounting of all profits or benefits arising out of any violation of this Non-Compete Agreement.
(e)I agree that if a court determines that any of the provisions in this Non-Compete Agreement is unenforceable or unreasonable in duration, territory, or scope, then that court shall modify those provisions so they are reasonable and enforceable, and enforce those provisions as modified.
(f)If any one or more provisions (including paragraphs, subparagraphs and terms) of this Non-Compete Agreement or its application is determined to be invalid, illegal, or unenforceable to any extent or for any reason by a court of competent jurisdiction, I agree that the remaining provisions (including paragraphs, subparagraphs and terms) of this Non-Compete Agreement will still be valid and the provision declared to be invalid or illegal or unenforceable will be considered to be severed and deleted from the rest of this Non-Compete Agreement. I further agree that if any court of competent jurisdiction finds any of the restrictions set forth in this Non-Compete Agreement to be overly broad and unenforceable, the restriction shall be interpreted to extend only over the maximum time period, geographic area, or range of activities or clients that such court deems enforceable
(g)Notwithstanding the foregoing provisions of this Non-Compete Agreement, the non-competition provisions of paragraph 2 above shall not restrict Employee from performing legal services as a licensed attorney for a Competing Business to the extent that the attorney licensure requirements in the applicable jurisdiction do not permit Employee to agree to the otherwise applicable restrictions of paragraph 2.
(h)Waiver of any of the provisions of this Non-Compete Agreement by the Company in any particular instance shall not be deemed to be a waiver of any provision in any other instance and/or of the Company’s other rights at law or under this Non-Compete Agreement.



(i)I agree that the Company may assign this Non-Compete Agreement to its successors and assigns and that any such successor or assign may stand in the Company’s stead for purposes of enforcing this Non-Compete Agreement.
(j)I agree to reimburse the Company for all attorneys’ fees, costs, and expenses that it reasonably incurs in connection with enforcing its rights and remedies under this Non-Compete Agreement, but only to the extent the Company is ultimately the prevailing party in the applicable legal proceedings.
(k)I understand and agree that, where allowed by applicable law, the time for my obligations set out in paragraphs 2 – 6 shall be extended for period of non-compliance up to an additional two (2) years following my last day of employment with the Company (for any reason).
(l)I fully understand my obligations in this Non-Compete Agreement, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Non-Compete Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.
(m)I agree that all non-competition, non-solicitation, non-disclosure and use, non-recruiting, and disclosure obligations in this Non-Compete Agreement shall survive any termination of this Non-Compete Agreement and extend to the proscribed periods following my last day of employment with the Company (for any reason) and no dispute regarding any other provisions of this Non-Compete Agreement or regarding my employment or the termination of my employment shall prevent the operation and enforcement of these obligations.
(n)I understand that nothing in this Non-Compete Agreement, including the non-disclosure and non-disparagement provisions, limit my ability to file a charge or complaint with the Equal Employment Opportunity Commission, Department of Labor, National Labor Relations Board, Occupational Safety and Health Administration, Securities and Exchange Commission or any other federal, state or local governmental agency or commission. I also understand that this Non-Compete Agreement does not limit my ability to communicate with any government agencies or otherwise participate in any investigation or proceeding that may be conducted by any government agency, including providing documents or other information, without notice to the Company.  Finally, I understand that nothing in this Non-Compete Agreement is intended to restrict my legally-protected right to discuss wages, hours or other working condition with co-workers, or in any way limit my rights under the National Labor Relations Act or any whistleblower act.
10.    Relationship of Parties. I acknowledge that my relationship with the Company is “terminable at will” by either party and that the Company or I can terminate the relationship with or without cause and without following any specific procedures. Nothing contained in this Non-Compete Agreement is intended to or shall be relied upon to alter the “terminable at will” relationship between the parties. I agree that my obligations in this Non-Compete Agreement shall survive the termination of my employment from the Company for any reason and shall be binding upon my successors, heirs, executors and representatives.
11.    Modifications and Other Agreements. I agree that the terms of this Non-Compete Agreement may not be modified except by a written agreement signed by both me and the Company. This Non-Compete Agreement shall not supersede any other restrictive covenants to which I may be subject under an employment contract, benefit program or otherwise, such that the Company may enforce the terms of any and all restrictive covenants to which I am subject. The obligations herein are in addition to and do not limit any obligations arising under applicable statutes and common law.
12.    State and Commonwealth Law Modifications. I agree that if I, on the last day of my employment with the Company (for any reason), primarily reside and work in California, Illinois, Louisiana, Massachusetts, Nebraska, Oklahoma, Puerto Rico, South Carolina, Virginia,



Washington or Wisconsin, I am subject to the modifications to this Non-Compete Agreement set forth in Exhibit A-1 applying to such state and to the extent such state law applies.
13.    Notification. I agree that in the event I am offered employment at any time in the future with any entity that may be considered a Competing Business Line, I shall immediately notify such Competing Business of the existence and terms of this Non-Compete Agreement. I also understand and agree that the Company may notify anyone attempting to or later employing me of the existence and provisions of this Non-Compete Agreement.
*** *** *** *** ***
    By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Stock Option Award Agreement to which this Non-Compete Agreement is attached as Exhibit A, and I agree to the terms and conditions expressed in this Non-Compete Agreement, including the modifications set forth in Exhibit A-1, as applicable.




EXHIBIT A-1
WALGREENS BOOTS ALLIANCE, INC. NON-COMPETITION, NON-SOLICITATION
AND CONFIDENTIALITY AGREEMENT
State and Commonwealth Law Modifications
This Exhibit A-1 to the Walgreens Boots Alliance, Inc. Non-Competition, Non-Solicitation and Confidentiality Agreement (the “Non-Compete Agreement”) includes jurisdiction-specific “Addenda,” which modify the Non-Compete Agreement as applied to individuals who primarily reside and work in one of the applicable jurisdictions, but only to the extent the laws of such jurisdiction are applicable to the Non-Compete Agreement. The Addenda of this Exhibit A-1 should be read in conjunction with the rest of the Non-Compete Agreement and enforced to the fullest extent permissible to protect the Company’s legitimate business interests.

CALIFORNIA ADDENDUM
No. 1:
The covenants in paragraph 2 “Non-Competition” apply during my employment with the Company, but do not apply post-employment, during such time(s) that I primarily reside and work in California.
No. 2:
The covenants in paragraph 3 “Non-Solicitation” apply during my employment with the Company, but do not apply post-employment, during such time(s) that I primarily reside and work in California.
No. 3:
Paragraph 5 “Non-Disparagement” is stricken and replaced with the following:
During my employment with the Company and thereafter, I agree not to make negative comments or otherwise disparage the Company or any of its officers, directors, employees, shareholders, members, agents or products, except as otherwise allowed by law, including California Government Code Section 12964.5.
No. 4:
Paragraph 6 “Intellectual Property” is supplemented with the following language:
The terms of this Non-Compete Agreement requiring disclosure and assignment of inventions to the Company do not apply to any invention that qualifies fully under California Labor Code Section 2870, which reads:
(a)    Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:
(1)  Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or



(2)  Result from any work performed by the employee for the employer.
(b)    To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.
While employed, I will advise the Company promptly in writing of any inventions that I believe meet the criteria in California Labor Code Section 2870 for a confidential ownership determination.
No. 5:
Paragraph 9 “Enforceability; General Provisions”, subparagraph (c) by this Addendum shall substitute “California” for “Delaware” with respect to the choice of law and forum, during such time(s) that I primarily reside and work in California.
ILLINOIS ADDENDUM
Addendum No. 1:

A new Section 9(a)(i) is added as follows:

Effective if I sign this Non-Compete Agreement after January 1, 2022, I understand that (A) the non-competition obligations under Section 2 do not apply to me if I do not earn the statutory minimum compensation set by Illinois statute (e.g., between January 1, 2021 and January 2, 2027, the statutory threshold is $75,000 per year or less); and (B) the non-solicitation obligations under Section 3 do not apply to me if I do not earn the statutory minimum compensation set by Illinois statute (e.g., between January 1, 2022 and January 2, 2027, the statutory threshold is $45,000 per year or less).

Addendum No. 2:

    A new Section 9(a)(ii) is added as follows:

I agree that before being required to sign this Non-Compete Agreement, the Company provided me with at least fourteen (14) calendar days to review it. The Company also hereby advises me to consult with an attorney before entering into this Non-Compete Agreement.

LOUISIANA ADDENDUM
No. 1:
The definition of “Responsibilities” in paragraph 2 is stricken and replaced with the following:
For purposes of this Non-Compete Agreement, “Responsibilities” means the same or similar material responsibilities I performed for the Company, including my representation of the Company or my business contact with Restricted Customers, during the two (2) years prior to my last day of employment with the Company and within the Restricted Area, or portion thereof, where I performed those responsibilities for the Company. “Restricted Area” means the Louisiana Parishes that the Company identifies in separate written amendment(s) in the form set forth in Schedule A to this Addendum, including at the time of entering into this Non-Compete Agreement. The Parishes include certain of the following: Acadia Parish, Allen Parish, Ascension Parish, Assumption Parish, Avoyelles Parish, Beauregard Parish, Bienville Parish, Bossier Parish, Caddo Parish, Calcasieu Parish, Caldwell Parish, Cameron Parish, Catahoula Parish, Claiborne



Parish, Concordia Parish, DeSoto Parish, East Baton Rouge Parish, East Carroll Parish, East Feliciana Parish, Evangeline Parish, Franklin Parish, Grant Parish, Iberia Parish, Iberville Parish, Jackson Parish, Jefferson Parish, Jefferson Davis Parish, Lafayette Parish, Lafourche Parish, LaSalle Parish, Lincoln Parish, Livingston Parish, Madison Parish, Morehouse Parish, Natchitoches Parish, Orleans Parish, Ouachita Parish, Plaquemines Parish, Pointe Coupee Parish,  Rapides Parish, Red River Parish, Richland Parish, Sabine Parish, St. Bernard Parish, St. Charles Parish, St. Helena Parish, St. James Parish, St. John the Baptist Parish, St. Landry Parish, St. Martin Parish, St. Mary Parish, St. Tammany Parish, Tangipahoa Parish, Tensas Parish, Terrebonne Parish, Union Parish, Vermilion Parish, Vernon Parish, Washington Parish, Webster Parish, West Baton Rouge Parish, West Carroll Parish, West Feliciana Parish, and Winn Parish, all so long as the business of the Company is transacted therein. I hereby stipulate that the Company does business in certain of the aforementioned parishes, counties, and municipalities as of the date of this Addendum. I also understand that the Company serves those counties of the adjacent states that border the State of Louisiana and that I will equally be bound in those geographic areas where I also perform responsibilities for the Company.
I acknowledge that the Company’s business and my Responsibilities for the Company are expanding. Accordingly, I agree that the Company may amend the Restricted Area by way of separate written amendment(s) in the form set forth in Schedule A to this Addendum specifying new or additional parishes and counties. Any such separate written amendment(s) shall have the same force and effect as if the amendment(s) were originally a part of, or such parishes and counties were originally listed in, this Addendum. The Company will provide me with any and all amendments that amend the Restricted Area. I agree that if the Company provides me with an amendment that amends the Restricted Area that it will represent as fact that the Company does business in all of the geographical areas identified in such an exhibit.

No. 2:
The first sentence of paragraph 3(a) is stricken and replaced with the following
I will not directly or indirectly, solicit any Restricted Customer within in the Restricted Area, as defined in paragraph 2, for purposes of providing Competing Products or Services, or offer, provide or sell Competing Products or Services to any Restricted Customer within the Restricted Area.
No. 3:    
The first sentence of paragraph 9(c) is stricken and replaced with the following:
The interpretation, validity, and enforcement of this Non-Compete Agreement will be governed by the laws of the State of Louisiana, without regard to any conflicts of law principles that require the application of the law of another jurisdiction.
*    *    *

SCHEDULE A TO LOUISIANA ADDENDUM – FORM OF AMENDMENT
AMENDMENT NO. 1 TO THE LOUISIANA ADDENDUM

The parties agree that this Amendment No. 1 to the Louisiana Addendum (“First Amendment”) shall modify the term “Restricted Area” contained in the Louisiana Addendum to the Walgreens Boots Alliance, Inc. Non-Competition, Non-Solicitation and Confidentiality Agreement (the “Non-Compete Agreement”). This First Amendment shall be read in conjunction with the rest of the Non-Compete Agreement and the Louisiana Addendum and enforced to the fullest extent permissible to protect the Company’s legitimate business interests.



    With respect to Louisiana Parishes, I agree that the Restricted Area shall include the following Parishes (IN BOLD OR CIRCLED) where the Company does business and I am performing Responsibilities for the Company: Acadia Parish, Allen Parish, Ascension Parish, Assumption Parish, Avoyelles Parish, Beauregard Parish, Bienville Parish, Bossier Parish, Caddo Parish, Calcasieu Parish, Caldwell Parish, Cameron Parish, Catahoula Parish, Claiborne Parish, Concordia Parish, DeSoto Parish, East Baton Rouge Parish, East Carroll Parish, East Feliciana Parish, Evangeline Parish, Franklin Parish, Grant Parish, Iberia Parish, Iberville Parish, Jackson Parish, Jefferson Parish, Jefferson Davis Parish, Lafayette Parish, Lafourche Parish, LaSalle Parish, Lincoln Parish, Livingston Parish, Madison Parish, Morehouse Parish, Natchitoches Parish, Orleans Parish, Ouachita Parish, Plaquemines Parish, Pointe Coupee Parish,  Rapides Parish, Red River Parish, Richland Parish, Sabine Parish, St. Bernard Parish, St. Charles Parish, St. Helena Parish, St. James Parish, St. John the Baptist Parish, St. Landry Parish, St. Martin Parish, St. Mary Parish, St. Tammany Parish, Tangipahoa Parish, Tensas Parish, Terrebonne Parish, Union Parish, Vermilion Parish, Vernon Parish, Washington Parish, Webster Parish, West Baton Rouge Parish, West Carroll Parish, West Feliciana Parish, and Winn Parish, all so long as the business of the Company is transacted therein. I hereby continue to stipulate that the Company does business in all of the above bolded or circled parishes, counties, and municipalities as of the date of this Addendum. I also understand that the Company serves those counties of the adjacent states that border the State of Louisiana and that I will equally be bound in those geographic areas where I also perform responsibilities for the Company.
By my signature below, I agree to the terms and conditions expressed in this Amendment No. 1 to the Louisiana Addendum.
EmployeeWalgreens Boots Alliance, Inc.

By:                        

Name:                        

Dated:                        

By:                        

Name:                        

Title:                        

Dated:                         
 

MASSACHUSETTS ADDENDUM
No. 1:
Paragraph 2 “Non-Competition” is stricken and replaced with the following:
2.    Non-Competition. In exchange for the Company providing me the consideration set forth in the Non-Compete Agreement, I agree that during my employment and for a period of one (1) year from the Termination Date – i.e., the date of my voluntary termination of employment, or of the involuntary termination of my employment with Cause (as defined below) – I will not, directly or indirectly, engage in “Competition” (as defined below) within the “Geographic Region” (as defined below).
(a)    “Cause” means misconduct, violation of any policy of the Company, including any rule of conduct or standard of ethics of the Company, breach of the Non-Compete Agreement (including this Addendum) or the breach of any confidentiality, non-disclosure, non-solicitation or assignment of inventions obligations to the Company, failure to meet the Company’s reasonable performance expectations, or other grounds directly and reasonably related to the legitimate business needs of the Company.
(b)    “Competing Business” means a business that is in competition with any business engaged in by the Company.
(c)    “Competition” means to provide the same or substantially similar services to a Competing Business as those that I provided to the Company during the last two (2) years of my employment with the Company. “Competition” does not include passive investments of less than five percent (5%) ownership interest in any entity.



(d)    “Geographic Region” means the geographic area in which I, during any time within the last two years of my employment with the Company, provided services or had a material presence or influence.
(e)    If the Company enforces the restrictions in this paragraph 2 for a period of time after the Termination Date (the “Restraint Period”), it will pay me, during the Restraint Period, an amount equal to fifty percent (50%) of my annual base salary. My annual base salary, for the purposes of this paragraph 2(e), will be calculated based on my average annual salary for my last two (2) years of employment, less any applicable deductions, and excluding any incentive compensation, bonuses, benefits, or other compensation, less any applicable deductions (the “Restraint Payment”). The Restraint Payment will be paid on a pro-rata basis during the Restraint Period in the same manner that I would have received wages from the Company had I been employed during the Restraint Period.
(f)    The Restraint Period shall be extended from one (1) year following the Termination Date to two (2) years following the Termination Date if I (i) breached Employee’s fiduciary duty(ies) to the Company, or (ii) unlawfully took, physically or electronically, property belonging to the Company. In the event that the Restraint Period is extended due to my breach of my fiduciary duty(ies) to the Company, or due to my having unlawfully taken, physically or electronically, property belonging to the Company, the Company shall not be required to provide payments to me during the extension of the Restraint Period.
(g)    I understand that if the Company elects to waive the non-competition provisions set forth herein, I will not receive any compensation or consideration described in paragraph 2(e). I further understand that at the time of my separation from employment, the Company shall elect whether to waive its enforcement of the non-competition provisions in the Non-Compete Agreement (including this Massachusetts Addendum). I will be notified by the Company of its election or waiver by letter, in the form set forth in the below Schedule A to this Massachusetts Addendum.
(h)    If I was already employed by the Company on the date of my signature on the Non-Compete Agreement, I acknowledge that the Non-Compete Agreement, including this Massachusetts Addendum, was delivered to me at least ten (10) business days before the date that this Addendum was executed by both of the parties (the “Effective Date”). If I was not already employed by the Company on the date of the my signature on the Non-Compete Agreement, I acknowledge that the Non-Compete Agreement, including this Massachusetts Addendum, was delivered to me (i) before a formal offer of employment was made by the Company, or (ii) ten (10) business days before the commencement of my employment with the Company, whichever was earlier.
(i)    I acknowledge that I have been advised of my right to consult with counsel of my own choosing prior to signing the Non-Compete Agreement and this Massachusetts Addendum. By signing the Non-Compete Agreement and this Addendum, I acknowledge that I had time to read and understand the terms of the Non-Compete Agreement and this Addendum, and to consult with my own legal counsel, not including counsel for the Company, regarding the Non-Compete Agreement and the Addendum prior to their execution. I agree that I have actually read and understand the Non-Compete Agreement and this Addendum and all of their terms, and that I am entering into and signing the Non-Compete Agreement and this Addendum knowingly and voluntarily, and that in doing so I am not relying upon any statements or representations by the Company or its agents.
(j)    I acknowledge that (i) the Non-Competition covenant contained in this paragraph 2 is no broader than necessary to protect the Company’s trade secrets, Confidential Information, and goodwill, and (ii) the business interests



identified in the Non-Compete Agreement cannot be adequately protected through restrictive covenants other than the Non-Competition covenant contained in this paragraph 2, including without limitation the non-solicitation and non-disclosure restrictions set forth in the Non-Compete Agreement.
No. 2:
Paragraph 9(b) “Enforceability; General Restrictions” is stricken and replaced with the following:
I agree that the restrictions contained in this Non-Compete Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Non-Compete Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place an undue restraint on me. I further understand that the restrictions in this Non-Compete Agreement – other than the non-competition restrictions set forth in paragraph 2 – apply no matter whether my employment is terminated by the Company or me and no matter whether that termination is voluntary or involuntary. I understand that the non-competition provisions in paragraph 2 apply following the voluntary termination of my employment or the involuntary termination of my employment for Cause, as defined in paragraph 2, unless the Company elects to waive the non-competition provisions of [paragraph 2 as set forth in subparagraph 2(g).
No. 3:
Paragraph 9c) “Enforceability; General Restrictions” is stricken and replaced with the following:
(c)(i)  Because the Company is incorporated in Delaware, except with respect to the non-competition provisions of paragraph 2, this Non-Compete Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any conflict of law provisions, and I consent to personal jurisdiction and the exclusive jurisdiction of the state and federal courts of Delware with respect to any claim, dispute, or declaration – other than a claim, dispute, or declaration arising out of paragraph 2 – that arises out of this Non-Compete Agreement.
(c)(ii)  The interpretation, validity, and enforcement of the non-competition provisions set forth in paragraph 2 of this Non-Compete Agreement and Massachusetts Addendum will be governed by the laws of the Commonwealth of Massachusetts, without regard to any conflicts of laws principles that would require the application of the law of another jurisdiction. The parties agree that any action relating to or arising out of the non-competition provisions shall be brought in (1) the United States District Court for the District of Massachusetts, Eastern Division, if that Court has subject matter jurisdiction over the dispute; or, if it does not, in (2) the Business Litigation Session of the Suffolk County Superior Court, or, if the Business Litigation Session does not accept the case for whatever reason whatsoever, the Suffolk County Superior Court. The parties agree and consent to the personal jurisdiction and venue of the federal or state courts of Massachusetts for resolution of any disputes or litigation arising under or in connection with the Non-Competition provisions set forth in paragraph 2 of this Non-Compete Agreement and Massachusetts Addendum, and waive any objections or defenses to personal jurisdiction or venue in any such proceeding before any such court.
No. 4:
Paragraph 9(m) “Enforceability; General Restrictions” is stricken and replaced with the following:



I agree that all non-solicitation, non-disclosure and use, non-recruiting, and disclosure obligations in this Non-Compete Agreement shall survive any termination of this Agreement and extend to the proscribed periods following my last day of employment with the Company (for any reason) and no dispute regarding any other provisions of this Non-Compete Agreement or regarding my employment or the termination of my employment shall prevent the operation and enforcement of these obligations. I further agree that all non-competition obligations in this Non-Compete Agreement shall survive the voluntary termination of my employment or the involuntary termination of my employment for Cause, as defined in paragraph 2, unless the Company elects to waive the non-competition provisions of paragraph 2 as set forth in subparagraph 2(g), and no dispute regarding any other provisions of this Non-Compete Agreement or regarding my employment or the termination of my employment shall prevent the operation and enforcement of these obligations.
*    *    *

SCHEDULE A TO MASSACHUSETTS ADDENDUM – FORM OF AGREEMENT
SCHEDULE A TO MASSACHUSETTS ADDENDUM

_____________ (the “Hiring Entity”), Walgreens Boots Alliance, Inc., and any subsidiaries, affiliates, or divisions, direct or indirect predecessors, successors, parents, business units or affiliated companies of Walgreens Boots Alliance, Inc. to which I, directly in succession after the Hiring Entity, transfer or accept employment (each a “Company Entity” and collectively with the Hiring Entity, the “Company”), pursuant to the Massachusetts Addendum to the Walgreens Boots Alliance, Inc. Non-Competition, Non-Solicitation, and Confidentiality Agreement between the Company and the undersigned Employee (the “Non-Compete Agreement”), in its sole discretion, elects to:
image_0.jpgEnforce the one year Restraint Period according to paragraph 2 the Addendum. As agreed to by the Parties, the Company agrees to pay me the amounts described in paragraph 2 of the Massachusetts Addendum.
image_0.jpgWaive enforcement of the Restraint Period. I shall not receive any compensation or consideration pursuant to paragraph 2 the Massachusetts Addendum.
Regardless of the election or waiver, I remain bound by all other terms of the Non-Compete Agreement, and also remain bound by the terms of any and all other agreements between the Company and me.
Accepted and agreed to:
EmployeeWalgreens Boots Alliance, Inc.

By:                        

Name:                        

Dated:                        

By:                        

Name:                        

Title:                        

Dated:                         
 





NEBRASKA ADDENDUM

No. 1:

The obligations under paragraph 2 “Non-Competition” do not apply to me during such time(s) that I primarily reside and work in Nebraska, but do apply, as stated, to other competitive activity.

No. 2:

    The obligations under paragraph 3 “Non-Solicitation” are strictly limited to those current and existing Restricted Customers or employees with whom I actually did business and had direct, personal contact while employed by the Company.
    All other covenants, agreements and promises contained in the Non-Compete Agreement remain in full force and effect and still apply to Nebraska employees doing business inside and outside of Nebraska.

OKLAHOMA ADDENDUM

No. 1:
The covenants in paragraph 2 “Non-Competition” do not apply to me during such time(s) that I primarily reside and work in Oklahoma.
No. 2:
Paragraph 3 “Non-Solicitation” is stricken and replaced with the following:
I covenant and agree that for a period of twelve (12) months after my employment with the Company ends (for any reason), I will not directly solicit the sale of goods, services or a combination of goods and services from the established customers of the Company.

PUERTO RICO ADDENDUM
No. 1:
Paragraphs 2 and 3 are stricken and replaced by the following covenants and definitions:
“Similar Business” means the same or substantially the same business activity or activities performed or engaged by me for, or on behalf, of the Business of the Company or one of its subsidiaries or affiliated companies.
“Engage” means participate in, consult with, be employed by, or assist with the organization, policy making, ownership, financing, management, operation or control of any Similar Business in any capacity (i.e., as an independent contractor, consultant, employee, shareholder, member-owner, or business partner).
“Goodwill” means any tendency of customers, distributors, representatives, employees, vendors, suppliers, or federal, state, local or foreign governmental entities to continue or renew any valuable business relationship with the Company or any Similar Business with which I may be associated, based in whole or in part on past successful relationships with the Company or the lawful efforts of the Company to foster such relationships, and in which I actively participated at any time during the most recent twelve (12) months of my employment.



“Competing Business” means any individual (including me), corporation, limited liability company, partnership, joint venture, association, or other entity, regardless of form, that is directly engaged in whole or in relevant part in any business or enterprise that is the same as, or substantially the same as, that part of the Company for which I provided services during the last two (2) years of my employment, or that is taking material steps to engage in such business.
“Customers” means those individuals, companies, or other entities for which the Company has provided or does provide products or services in connection with the business of the Company, or those individuals, companies, or other entities to which the Company has provided written proposals concerning the business of the Company in the two (2) year period preceding the termination of my employment.
“Restricted Territory” means those municipalities within the Commonwealth of Puerto Rico in which I performed the Competing Business.
Non-Competition.  I acknowledge and agree that the Company would be irreparably damaged if I – in any capacity (i.e., as an independent contractor, consultant, employee, shareholder, member, owner or business partner) – were to provide services to any person directly or indirectly competing with the Company or any of its affiliates or Engaged in a Competing Business and that such competition by me would result in a significant loss of Goodwill by the Company. Therefore, I agree that the following are reasonable restrictions and agree to be bound by such restrictions:
(a)    During my employment, and for a period of twelve (12) months immediately following the termination of such employment for any reason, I shall not, directly or indirectly – in any capacity (i.e., as an independent contractor, consultant, employee, shareholder, member, owner or business partner) – Engage in Competing Business services or activities within the Restricted Territory; provided, that nothing herein shall prohibit me from being a passive owner of not more than five percent (5%) of the outstanding stock of any class of a corporation which is publicly traded so long as I do not have any active participation in the business of such corporation.
(b)    I warrant and represent that the nature and extent of this non-competition clause has been fully explained to me by the Company and that my decision to accept the same is made voluntarily, knowingly, intelligently and free from any undue pressure or coercion. I further warrant and represent that I have agreed to this non-competition clause in consideration of the Stock Option I will be receiving under this Non-Compete Agreement.
Non-Solicitation of Customers I agree that for a period of twelve (12) months following the voluntary or involuntary termination of my employment for any reason, I will not, either on my own behalf or for any Competing Business, directly or indirectly solicit, divert, or appropriate (or attempt to solicit, divert, or appropriate) any Customer with which I had material business contact in the six (6) month period preceding the termination of my employment, for providing products or services that are the same as or substantially similar to those provided by the Company.
Non-Solicitation of Employees.  I recognize and admit that the Company has a legitimate business interest in retaining its employees, representatives, agents and/or consultants and of protecting its business from previous employees, representatives, agents and/or consultants, which makes necessary the establishment of a non-solicitation clause in this Non-Compete Agreement. I agree that for a period of twelve (12) months following the voluntary or



involuntary termination of my employment for any reason, I shall not, directly or indirectly, (a) induce or attempt to induce any employee, representative, agent or consultant of the Company or any of its affiliates or subsidiaries to leave the employ or services of the Company or any of its affiliates or subsidiaries, or in any way interfere with the relationship between the Company or any of its affiliates or subsidiaries and any employee, representative, agent or consultant thereof or (b) hire any person who was an employee, representative, agent or consultant of the Company or any of its affiliates or subsidiaries at any time during the twelve (12) month period immediately prior to the date on which such hiring would take place. No action by another person or entity shall be deemed to be a breach of this provision unless I directly or indirectly assisted, encouraged or otherwise counseled such person or entity to engage in such activity.
No. 2:
Subparagraph 9(c) “Enforceability; General Restrictions” is modified to add the following choice of law:
The laws of Puerto Rico will govern the interpretation, validity, and enforcement of the non-competition provisions set forth in paragraph 2 of this Non-Compete Agreement and Puerto Rico Addendum.
No. 3:
Subparagraph 9(e), subparagraph 9(f), and subparagraph 9(k)Enforceability; General Restrictions” are stricken.

SOUTH CAROLINA ADDENDUM
No. 1:
The definition of “Confidential Information” in paragraph 1 is further limited to that Confidential Information I learn about or am exposed to through my employment with the Company.
No. 2:
Paragraphs 2 and 3 of the Non-Compete Agreement are replaced by the following covenants and definitions:
“Competing Business” means any individual (including me), corporation, limited liability company, partnership, joint venture, association, or other entity, regardless of form, that is directly engaged in whole or in relevant part in any business or enterprise that is the same as, or substantially the same as, that part of the Company for which I provided services during the last two (2) years of my employment, or that is taking material steps to engage in such business.
“Customers” means those individuals, companies, or other entities for which the Company has provided or does provide products or services in connection with the business of the Company, or those individuals, companies, or other entities to which the Company has provided written proposals concerning the business of the Company in the two (2) year period preceding the termination of my employment.
“Restricted Territory” means:
1) the counties or areas where I worked for the Company or had material business contact with the Customers in the two (2) year period preceding the termination of my employment with the Company: and/or



2) the geographic territory in which I worked for the Company, represented the Company, or had material business contact with the Customers in the two (2) year period preceding the termination of my employment with the Company.
I agree that subsections 1) and 2) above are separate and severable covenants.
Non-Competition. I agree that for a period of one (1) year following the voluntary or involuntary termination of my employment for any reason, I will not, directly or indirectly, own, manage, operate, join, control, be employed by or with, or participate in any manner with a Competing Business anywhere in the Restricted Territory where doing so will require me to provide the same or substantially similar services to any such Competing Business as those that I provided to the Company during the last two (2) years of my employment.
Non-Solicitation of Customers. I agree that for a period of two (2) years following the voluntary or involuntary termination of my employment for any reason, I will not, either on my own behalf or for any Competing Business, directly or indirectly solicit, divert, or appropriate, or attempt to solicit, divert, or appropriate any Customer with which I had material business contact in the two (2) year period preceding the termination of my employment, for the purposes of providing products or services that are the same as or substantially similar to those provided by the Company.
VIRGINIA ADDENDUM
No. 1:
    The geographic scope in paragraph 2 “Non-Competition” is limited to twenty-five (25) miles from any location where I physically worked and performed Responsibilities for the Company.

No. 2:

Paragraph 2 “Non-Competition” and paragraph 3 “Non-Solicitation” shall not apply if, at the time of my termination of employment (for any reason), I am considered a “low-wage employee” pursuant to Virginia Code § 40.1-28.7:8(A), meaning that I earn less than the average weekly wage of the Commonwealth of Virginia as determined by subsection B of Virginia Code § 65.2-500.

No. 3:

Paragraph 3(b)(i) “Non-Solicitation” shall be amended to provide: “ (i) raid, solicit, or attempt to persuade any then-current employee of the Company with whom I currently work or with whom I had direct contact work during the two years prior to my last day of employment with the Company,  and who possesses or had access to Confidential Information of the Company, to leave the employ of the Company and become employed by a person or entity who provides Competing Products or Services.”

WASHINGTON ADDENDUM
No. 1:
Paragraph 2 is stricken and replaced with the following:



Non-Competition.
(a)The non-competition provisions of this paragraph 2 shall only apply when my annualized salaried exceeds the compensation requirements of the Restrictions on Noncompetition Covenants Bill 5478 as codified in RCW 49.
(b)I agree that during my employment with the Company and for one (1) year after the termination of my employment for any reason, I will not, directly or indirectly, engage in Competing Services with respect to any Competing Business Line. As set forth in paragraph 10(a) below, I understand that the restrictions in this paragraph apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary. The above restrictions shall not apply to passive investments of less than five percent (5%) ownership interest in any entity. For purposes of this Non-Compete Agreement, “Competing Business Line” means any business that is in competition with any business engaged in by the Company and for which I performed Competing services during the two (2) years prior to my last day of employment with the Company. For purposes of this Non-Compete Agreement, “Competing Services” means the same or similar responsibilities I performed for the Company during the two (2) years prior to my last day of employment with the Company and within the same geographic scope, or portion thereof, with respect to which I performed those responsibilities for the Company.
(c)I agree that, if and after my employment with the Company ends because of or in connection with a layoff or reduction-in-force, the non-competition provisions of paragraph 2(a) above will not be enforced by the Company unless and to the extent that it pays me an amount that is equal to or greater than my base salary rate that is in effect on the last day of my employment with the Company. Such payments will be made to me at regular payroll intervals for the duration of the one (1) year post-employment non-competition period or such shorter period during which the Company enforces these non-competition provisions. I agree that I must promptly inform the Company of the date on which I begin any other employment or engagement by, with or for the benefit of any other individual or entity, at which time I agree the Company may and will terminate all such payments to me. Although such payments by the Company will terminate when I commence employment or any other engagement by, with or for the benefit of another individual, entity or employer, I agree that the paragraph 2(a) non-competition restrictions will remain in effect until one (1) year after my Company employment ends. I also agree that if I fail to timely notify the Company of any other employment or engagement, and if the Company’s payments to me therefore continue after I have commenced any such employment or engagement, then any such payments to me will be deemed to be placed by me in constructive trust for the benefit of the Company, and I agree that I must and will promptly return all such payments to the Company.
No. 2:
Subparagraph 9(c) of the Non-Compete Agreement is stricken and replaced with the following:
This Non-Compete Agreement shall be governed by and construed in accordance with the laws of the State of Washington without giving effect to any conflict of law provisions. Any claim, dispute or declaration arising out of or in connection with this Non-Compete Agreement will be resolved exclusively in the state or federal courts in the State of Washington.
WISCONSIN ADDENDUM



No. 1:
Paragraph 1 “Confidentiality” is amended by adding the following at the end of Paragraph 1(b):
To the extent the above obligation of non-use and non-disclosure of Confidential Information applies after the termination of my employment and to Confidential Information that does not meet the definition of a trade secret under applicable law, it shall apply only for two years after the termination of my employment and only in geographic areas in which the unauthorized use or disclosure of such Confidential Information would be competitively damaging to the Company.
No. 2:
Paragraph 2 “Non-Competition” is amended by striking the definition of “Responsibilities” and replacing it with the following:
“Responsibilities” means the same or similar responsibilities I performed for the Company during the two (2) years prior to my last day of employment with the Company in which the Confidential Information I have would be competitively valuable and within the same geographic scope, or portion thereof, with respect to which I performed those responsibilities for the Company.
No. 3:
Paragraph 3 “Non-Solicitation” is amended by stricking the definition of “Restricted Customer” in paragraph 3(a) and replacing it with the following:
“Restricted Customer” means any person, company or entity that was a customer of the Company and with which I had direct contact for purposes of performing responsibilities for the Company or for which I had supervisory responsibilities on behalf of the Company, in either case at any time during the two (2) years prior to my last day of employment with the Company.
Paragraph 3(a) is further amended by striking the following sentence:
To the extent permitted by applicable law, Restricted Customer also means any prospective customer(s), vendor(s), supplier(s) or referral source(s) with which I had business contact on behalf of the Company in the twelve (12) months prior to my last day of employment with the Company;
Paragraph 3(b) is amended by replacing it with the following:
I will not, nor will I assist any third party to, directly or indirectly (i) raid, solicit, or attempt to persuade any then-current employee of the Company with whom I currently work or with whom I worked at any point during the two years prior to my last day of employment with the Company, and who possesses or had access to Confidential Information of the Company, to leave the employ of the Company and join a competitor; (ii) interfere with the performance by any such employee of his/her duties for the Company; or (iii) communicate with any such employee for the purposes described in items (i) and (ii) in this subparagraph 3(b). This restriction shall apply in all geographic areas in which the Company does business.
No. 4:
Paragraph 9 “Enforceability, General Provisions” is amended as follows: Paragraph 9(f) is amended by adding the following text to the end of the paragraph:



“The restrictive covenants in this Non-Compete Agreement are intended to be divisible and interpreted and applied independent of each other.”
Paragraph 9(k) is stricken and shall not be applied or referred to.




EXHIBIT B
ADDENDUM TO THE
WALGREENS BOOTS ALLIANCE, INC. 2021 OMNIBUS INCENTIVE PLAN
STOCK OPTION AWARD AGREEMENT
In addition to the terms of the Plan and the Agreement, the Option is subject to the following additional terms and conditions to the extent you reside and/or are employed in one of the countries addressed herein. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in this Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Option and the Plan (or the Company may establish alternative terms as may be necessary or advisable to accommodate your transfer). All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.
EUROPEAN UNION ("EU") / EUROPEAN ECONOMIC AREA ("EEA") / SWITZERLAND / THE UNITED KINGDOM

Personal Data. The following provision replaces Section 21 of the Agreement in its entirety:
The Company, with its registered address at 108 Wilmot Road, Deerfield, Illinois 60015, U.S.A. is the controller responsible for the processing of your personal data by the Company and the third parties noted below.

(a)Data Collection and Usage. Pursuant to applicable data protection laws, you are hereby notified that the Company collects, processes and uses certain personal information about you for the legitimate purpose of implementing, administering and managing the Plan and generally administering awards; specifically: your name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares or directorships held in the Company, and details of all stock options, any entitlement to shares of Stock awarded, canceled, exercised, vested, or outstanding in your favor, which the Company receives from you or the Employer ("Personal Data"). In granting the Option under the Plan, the Company will collect, process, use, disclose and transfer (collectively, "Processing") Personal Data for purposes of implementing, administering and managing the Plan. The Company's legal basis for the Processing of Personal Data is the Company's legitimate business interests of managing the Plan, administering employee awards and complying with its contractual and statutory obligations, as well as the necessity of the Processing for the Company to perform its contractual obligations under the Agreement and the Plan. Your refusal to provide Personal Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan. As such, by accepting the Option, you voluntarily acknowledge the Processing of your Personal Data as described herein.

(b)Stock Plan Administration Service Provider. The Company may transfer Personal Data to Fidelity Stock Plan Services, LLC ("Fidelity"), an independent service provider based, in relevant part, in the United States, which may assist the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Personal Data with another company that serves in a similar manner. The Company's service provider will open an account for you to receive and trade shares of Stock pursuant to the Option. The Processing of Personal Data will take place through both electronic and non-electronic means. Personal Data will only be accessible by those individuals requiring access to it for purposes of implementing, administering and operating the Plan. When receiving your Personal Data, if applicable, Fidelity provides appropriate safeguards in accordance with the EU Standard Contractual Clauses or other appropriate cross-border transfer solutions. By participating in the Plan, you understand that the service provider will Process your Personal Data for the purposes of implementing, administering and managing your participation in the Plan.




(c)International Data Transfers. The Company is based in the United States, which means it will be necessary for Personal Data to be transferred to, and Processed in the United States. When transferring your Personal Data to the United States, the Company provides appropriate safeguards in accordance with the EU Standard Contractual Clauses, and other appropriate cross-border transfer solutions. You may request a copy of the appropriate safeguards with Fidelity or the Company by contacting your Human Resources manager or the Company's Human Resources Department.

(d)Data Retention. The Company will use Personal Data only as long as is necessary to implement, administer and manage your participation in the Plan or as required to comply with legal or regulatory obligations, including tax and securities laws. When the Company no longer needs Personal Data related to the Plan, the Company will remove it from its systems. If the Company keeps Personal Data longer, it would be to satisfy legal or regulatory obligations and the Company's legal basis would be for compliance with relevant laws or regulations.

(e)Data Subject Rights. To the extent provided by law, you have the right to (i) subject to certain exceptions, request access or copies of Personal Data the Company Processes, (ii) request rectification of incorrect Personal Data, (iii) request deletion of Personal Data, (iv) place restrictions on Processing of Personal Data, (v) lodge complaints with competent authorities in your country, and/or (vi) request a list with the names and addresses of any potential recipients of Personal Data. To receive clarification regarding your rights or to exercise your rights, you may contact your Human Resources manager or the Company's Human Resources Department. You also have the right to object, on grounds related to a particular situation, to the Processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting your Human Resources manager or the Company's Human Resources Department in writing. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to administer the Option, or grant other awards or administer or maintain such awards. For more information on the consequences of the refusal to provide Personal Data, you may contact your Human Resources manager or the Company's Human Resources Department in writing. You may also have the right to lodge a complaint with the relevant data protection supervisory authority.

CHILE

    Private Placement. The following provision shall replace Section 14 of the Agreement:

The grant of the Option hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.
a)The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean Commission for the Financial Market;
b)The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;
c)The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean Commission for the Financial Market; and
d)The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
a)La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la Comisión para el Mercado Financiero en Chile;
b)La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la Comisión para el Mercado Financiero en Chile, por lo que tales valores no están sujetos a la fiscalización de ésta;
c)Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y



d)Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente.
GERMANY

No country-specific provisions.

HONG KONG

1.Sale of Shares of Stock. Shares of Stock purchased upon exercise of the Option are accepted as a personal investment. In the event that shares of Stock are issued in respect of the Option within six (6) months after the Grant Date, you agree that the shares of Stock may not be offered to the public or otherwise disposed of prior to the six-month anniversary of the Grant Date.

2.IMPORTANT NOTICE. WARNING: The contents of the Agreement the Addendum, the Plan, the Plan prospectus, the Plan administrative rules and all other materials pertaining to the Option and/or the Plan have not been reviewed by any regulatory authority in Hong Kong. You are hereby advised to exercise caution in relation to the offer thereunder. If you have any doubts about any of the contents of the aforesaid materials, you should obtain independent professional advice. Neither the grant of the Option nor the issuance of the shares of Stock upon exercise of the Option constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Affiliates. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Option (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Affiliates and may not be distributed to any other person.

3.Wages. The Option and shares of Stock subject to the Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

IRELAND

No country-specific provisions.

ITALY

    1.    Plan Document Acknowledgment. In accepting the Option, you acknowledge that a copy of the Plan was made available to you, and you have reviewed the Plan and the Agreement, including this Addendum, in their entirety and fully understand and accept all provisions of the Plan, the Agreement and the Addendum.

You further acknowledge that you have read and specifically approve the following provisions in the Agreement: Section 2: Vesting/Exercise/Expiration (expiration of the right to exercise the Option after the Expiration Date); Section 3: Disability (term for exercising the Option prior to the Vesting Dates in the case of a Termination of Service due to Disability); Section 4: Death (term for exercising the option prior to the Vesting Dates in the case of a Termination of Service due to death); Section 5: Retirement (term for exercising the Option prior to the Vesting Dates in the case of a Termination of Service by reason of Retirement); Section 6: Termination of Service Following a Change in Control (term for exercising the Option in the event of a Termination of Service following a Change in Control); Section 7: Other Termination of Service (term to exercise the vested Option and forfeiture of the unvested Option in other cases of Termination of Service); Section 8: Forfeiture of Outstanding Options Upon Termination for Cause or Following Termination of Service; Section 10(a): Responsibility for Taxes; Tax Withholding (liability for all Tax-Related Items related to the Option and legally applicable to the participant); Section 11: Limited Transferability (Option shall not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated); Section 18: Change in Stock (right of the Company to equitably adjust the Option and the Exercise Price in the event of any change in the Stock); Section 19(j): Nature of the Option (waive any claim or entitlement to compensation or damages arising from forfeiture of the Option resulting from a Termination of Service); Section



19(l): Nature of the Option (the Company is not liable for any foreign exchange rate fluctuation impacting the value of the Option); Section 22: Non-Competition, Non-Solicitation and Confidentiality (the receipt of the Option is conditioned upon agreement of the Non-Competition, Non-Solicitation and Confidentiality Agreement attached hereto as Exhibit A); Section 23: Addendum to Agreement (the Option is subject to the terms of the Addendum); Section 24: Additional Requirements (Company right to impose additional requirements on the Option in case such requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate operation and administration of the Option and the Plan); Section 26: Electronic Delivery (Company may deliver documents related to the Option or Plan electronically); Section 27: Governing Law and Jurisdiction (Agreement is governed by Illinois law without regard to any choice of law rules thereof; agreement to exclusive jurisdiction of Illinois courts); Section 28: English Language (documents will be drawn up in English; if a translation is provided, the English version controls); and the provision titled “Personal Data” under the heading "European Union (‘EU’) / European Economic Area (‘EEA’) / Switzerland / the United Kingdom", included in this Addendum.

MEXICO

1.Commercial Relationship. You expressly recognize that your participation in the Plan and the Company's grant of the Option does not constitute an employment relationship between you and the Company. You have been granted the Option as a consequence of the commercial relationship between the Company and the Affiliate in Mexico that employs you ("WBA Mexico"), and WBA Mexico is your sole employer. Based on the foregoing, you expressly recognize that (a) the Plan and the benefits you may derive from your participation in the Plan do not establish any rights between you and WBA Mexico, (b) the Plan and the benefits you may derive from your participation in the Plan are not part of the employment conditions and/or benefits provided by WBA Mexico, and (c) any modifications or amendments of the Plan by the Company, or a termination of the Plan by the Company, shall not constitute a change or impairment of the terms and conditions of your employment with WBA Mexico.

2.Extraordinary Item of Compensation. You expressly recognize and acknowledge that your participation in the Plan is a result of the discretionary and unilateral decision of the Company, as well as your free and voluntary decision to participate in the Plan in accordance with the terms and conditions of the Plan, the Agreement and this Addendum. As such, you acknowledge and agree that the Company, in its sole discretion, may amend and/or discontinue your participation in the Plan at any time and without any liability. The Option, the shares of Stock subject to the Option and the value of the same are an extraordinary item of compensation outside the scope of your employment contract, if any, and is not part of your regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of WBA Mexico.

3.Securities Law Notification. The Option and shares of Stock offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Plan, this Agreement and any other document relating to the Option may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and WBA Mexico and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of WBA Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.

MONACO

    Use of English Language. You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures



judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

SWITZERLAND

Securities Law Notification. Neither this document nor any other materials relating to the Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, or approved or supervised by, any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

THAILAND

No country-specific provisions.

UNITED KINGDOM

    1.    Indemnification for Tax-Related Items. Without limitation to Section 10 of the Agreement, you hereby agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, your Employer or by Her Majesty's Revenue & Customs ("HMRC") (or any other tax authority or any other relevant authority). You also hereby agree to indemnify and keep indemnified the Company and your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

    Notwithstanding the foregoing, if you are a director or executive officer (as within the meaning of Section 13(k) of the Exchange Act), the terms of the immediately foregoing provision will not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to you on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or your Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or your Employer may recover from you at any time thereafter by any of the means referred to in Section 10 of the Agreement.

    2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Option, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Option. Upon the grant of the Option, you shall be deemed irrevocably to have waived any such entitlement.

    3.    Post-Termination Restrictions. To the extent that you are employed by your Employer pursuant to an employment agreement governed by the laws of England, Wales, Scotland and/or Northern Ireland, Paragraphs 2 and 3 of the NNCA Agreement attached to the Agreement as Exhibit A shall not apply to you.


*** *** *** *** ***
    By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Stock Option Award Agreement to which this Addendum is attached as Exhibit B, and I agree to the terms and conditions expressed in this Addendum.


EX-10.6 4 a11302021exhibit106.htm EX-10.6 Document

EXHIBIT 10.6
WALGREENS BOOTS ALLIANCE, INC.
2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT









These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by Walgreens Boots Alliance, Inc., not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments. These materials were prepared by Walgreens Boots Alliance, Inc., which is solely responsible for their contents and for compliance with legal and regulatory requirements. Fidelity is not connected with any offering or acting as an underwriter in connection with any offering of securities or financial instruments of Walgreens Boots Alliance, Inc. Fidelity does not review, approve or endorse the contents of these materials and is not responsible for their content.





WALGREENS BOOTS ALLIANCE, INC.
2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
Participant Name:
Participant ID:
Grant Date:     (the "Grant Date")
Units Granted:
Vesting: One third of the Shares Granted vest on each of the first, second and third anniversaries of the Grant Date (the "Vesting Dates")
Acceptance Date:
Electronic Signature:
    This document (referred to below as this "Agreement") spells out the terms and conditions of the Restricted Stock Unit Award (the "Award") granted to you by Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), pursuant to the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (the "Plan") on and as of the Grant Date designated above. Except as otherwise defined herein, capitalized terms used in this Agreement have the respective meanings set forth in the Plan. For purposes of this Agreement, "Employer" means the entity (the Company or the Affiliate) that employs you on the applicable date. The Plan, as it may be amended from time to time, is incorporated into this Agreement by this reference.
You and the Company agree as follows:
1.Grant of Restricted Stock Units. Pursuant to the approval and direction of the Compensation and Leadership Performance Committee of the Company's Board of Directors (the "Committee"), the Company hereby grants you the number of Restricted Stock Units specified above (the "Restricted Stock Units"), subject to the terms and conditions of the Plan and this Agreement.
2.Restricted Stock Unit Account and Dividend Equivalents. The Company will maintain an account (the "Account") on its books in your name to reflect the number of Restricted Stock Units awarded to you as well as any additional Restricted Stock Units credited as a result of Dividend Equivalents. The Account will be administered as follows:
(a)The Account is for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company's general assets with respect to such Account.
(b)As of each record date with respect to which a cash dividend is to be paid with respect to shares of Company common stock par value US$.01 per share ("Stock"), the Company will credit your Account with an equivalent amount of Restricted Stock Units determined by dividing the value of the cash dividend that would have been paid on your Restricted Stock Units if they had been shares of Stock, divided by the value of Stock on such date.
(c)If dividends are paid in the form of shares of Stock rather than cash, then your Account will be credited with one additional Restricted Stock Unit for each share of Stock that would have been received as a dividend had your outstanding Restricted Stock Units been shares of Stock.
1


(d)Additional Restricted Stock Units credited via Dividend Equivalents shall vest or be forfeited at the same time as the Restricted Stock Units to which they relate.
3.Restricted Period. The period prior to the vesting date with respect each Restricted Stock Unit is referred to as the "Restricted Period." Subject to the provisions of the Plan and this Agreement, unless vested or forfeited earlier as described in Section 4, 5, 6 or 7 of this Agreement, as applicable, your Restricted Stock Units will become vested and be settled as described in Section 8 below, as of the vesting date or dates indicated in the introduction to this Agreement.
4.Disability or Death. If during the Restricted Period you have a Termination of Service by reason of Disability or death, then the Restricted Stock Units will become fully vested as of the date of your Termination of Service and the Vesting Date shall become the date of your Termination of Service. Any Restricted Stock Units becoming vested by reason of your Termination of Service by reason of Disability or death shall be settled as provided in Section 8.
5.Retirement. If during the Restricted Period you have a Termination of Service by reason of Retirement, as reasonably determined and approved by the Committee or its delegates, then, subject to such approval, the number of Restricted Stock Units that become vested by reason of your Retirement will be prorated to reflect the portion of the vesting period during which you remained employed by the Company. For each Vesting Date occurring after such Termination of Service, such prorated portion shall equal the number of Restricted Stock Units scheduled to vest as of that Vesting Date, multiplied by a fraction equal to the number of full months of that portion of the vesting period completed as of your Termination of Service, divided by 12. Any Restricted Stock Units becoming vested by reason of your Retirement shall be settled as provided in Section 8.
6.Termination of Service Following a Change in Control. If during the Restricted Period there is a Change in Control of the Company and within the one-year period thereafter you have a Termination of Service initiated by your Employer other than for Cause (as defined in Section 7), then your Restricted Stock Units shall become fully vested, and they shall be settled in accordance with Section 9. For purposes of this Section 6, a Termination of Service initiated by your Employer shall include a Termination of Employment for Good Reason under - and pursuant to the terms and conditions of – the Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan, but only to the extent applicable to you as an eligible participant in such Plan.
7.Other Termination of Service. If during the Restricted Period you have a voluntary or involuntary Termination of Service for any reason other than as set forth in Section 4, 5 or 6 above or Section 9 below, as determined by the Committee, then you shall thereupon forfeit any Restricted Stock Units that are still in a Restricted Period on your termination date. For purposes of this Agreement, "Cause" means any one or more of the following, as determined by the Committee in its sole discretion:

(a)    your commission of a felony or any crime of moral turpitude;

(b)    your dishonesty or material violation of standards of integrity in the course of fulfilling your duties to the Company or any Affiliate;

(c)    your material violation of a material written policy of the Company or any Affiliate violation of which is grounds for immediate termination;

(d)    your willful and deliberate failure to perform your duties to the Company or any Affiliate in any material respect, after reasonable notice of such failure and an opportunity to correct it; or

2


(e)    your failure to comply in any material respect with the United States ("U.S.") Foreign Corrupt Practices Act, the U.S. Securities Act of 1933, the Exchange Act, the U.S. Sarbanes-Oxley Act of 2002, the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the U.S. Truth in Negotiations Act, or any rules or regulations thereunder.
8.Settlement of Vested Restricted Stock Units. Subject to the requirements of Section 13 below, as promptly as practicable after the applicable Vesting Date, whether occurring upon your Separation from Service or otherwise, but in no event later than 75 days after the Vesting Date, the Company shall transfer to you one share of Stock for each Restricted Stock Unit becoming vested at such time, net of any applicable tax withholding requirements in accordance with Section 10 below; provided, however, that, if you are a Specified Employee at the time of Separation from Service, then to the extent your Restricted Stock Units are deferred compensation subject to Section 409A of the Code, settlement of which is triggered by your Separation from Service (other than for death), payment shall not be made until the date which is six months after your Separation from Service.
Notwithstanding the foregoing, if you are resident or employed outside of the U.S., the Company, in its sole discretion, may provide for the settlement of the Restricted Stock Units in the form of:

(a)     a cash payment (in an amount equal to the Fair Market Value of the Stock that corresponds with the number of vested Restricted Stock Units) to the extent that settlement in shares of Stock (i) is prohibited under local law, (ii) would require you, the Company or an Affiliate to obtain the approval of any governmental or regulatory body in your country of residence (or country of employment, if different), (iii) would result in adverse tax consequences for you, the Company or an Affiliate or (iv) is administratively burdensome; or

(b)     shares of Stock, but require you to sell such shares of Stock immediately or within a specified period following your Termination of Service (in which case, you hereby agree that the Company shall have the authority to issue sale instructions in relation to such shares of Stock on your behalf).
9.Settlement Following Change in Control. Notwithstanding any provision of this Agreement to the contrary, the Company may, in its sole discretion, fulfill its obligation with respect to all or any portion of the Restricted Stock Units that become vested in accordance with Section 6 above, by:
(a)delivery of (i) the number of shares of Stock that corresponds with the number of Restricted Stock Units that have become vested or (ii) such other ownership interest as such shares of Stock that correspond with the vested Restricted Stock Units may be converted into by virtue of the Change in Control transaction;
(b)payment of cash in an amount equal to the Fair Market Value of the Stock that corresponds with the number of vested Restricted Stock Units at that time; or
(c)delivery of any combination of shares of Stock (or other converted ownership interest) and cash having an aggregate Fair Market Value equal to the Fair Market Value of the Stock that corresponds with the number of Restricted Stock Units that have become vested at that time.
Settlement shall be made as soon as practical after the Restricted Stock Units become fully vested under Section 6, but in no event later than 30 days after such date.
10.Responsibility for Taxes; Tax Withholding.
(a)You acknowledge that, regardless of any action taken by the Company or your Employer, the ultimate liability for all income tax, social insurance, payroll tax, fringe
3


benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you ("Tax-Related Items"), is and remains your responsibility and may exceed the amount actually withheld by the Company or your Employer, if any. You further acknowledge that the Company and/or your Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including, but not limited to, the grant, vesting or settlement of the Award, the subsequent sale of shares of Stock acquired pursuant to such settlement and the receipt of any Dividend Equivalents and/or dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, as applicable, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

(b)    Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or your Employer to satisfy all Tax-Related Items. In this regard, except as provided below, the Company, your Employer or its agent shall satisfy the obligations with regard to all Tax-Related Items by withholding from the shares of Stock to be delivered upon settlement of the Award that number of shares of Stock having a Fair Market Value equal to the amount required by law to be withheld. For purposes of the foregoing tax withholding, no fractional shares of Stock will be withheld. Notwithstanding the foregoing, if you are a Section 16 officer of the Company under the Exchange Act at the time of any applicable tax withholding event, you may make a cash payment to the Company, your Employer or its agent to cover the Tax-Related Items that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan. If you are not a Section 16 officer of the Company at the time of any applicable tax withholding event, the Company and/or your Employer may (in its sole discretion) allow you to make a cash payment to the Company, your Employer or its agent to cover such Tax-Related Items.
The Company may withhold or account for Tax-Related Items by considering applicable statutory withholding rates (as determined by the Company in good faith and in its sole discretion) or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding from the shares of Stock to be delivered upon settlement of the Award, for tax purposes, you will be deemed to have been issued the full number of shares of Stock subject to the earned Award, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items.

The Company may refuse to issue or deliver the shares of Stock (or cash payment) or the proceeds from the sale of shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items.
11.Nontransferability. During the Restricted Period and thereafter until Stock is transferred to you in settlement thereof, you may not sell, transfer, pledge, assign or otherwise alienate or hypothecate the Restricted Stock Units whether voluntarily or involuntarily or by operation of law, other than by beneficiary designation effective upon your death, or by will or by the laws of intestacy.
12.Rights as Stockholder. You shall have no rights as a stockholder of the Company with respect to the Restricted Stock Units until such time as a certificate of stock for the Stock issued in settlement of such Restricted Stock Units has been issued to you or such shares of Stock have been recorded in your name in book entry form. Until that time, you shall not have any voting rights with respect to the Restricted Stock Units. Except as provided in Section 9
4


above, no adjustment shall be made for dividends or distributions or other rights with respect to such shares for which the record date is prior to the date on which you become the holder of record thereof. Anything herein to the contrary notwithstanding, if a law or any regulation of the U.S. Securities and Exchange Commission or of any other regulatory body having jurisdiction shall require the Company or you to take any action before shares of Stock can be delivered to you hereunder, then the date of delivery of such shares may be delayed accordingly.
13.Securities Laws. If a Registration Statement under the U.S. Securities Act of 1933, as amended, is not in effect with respect to the shares of Stock to be delivered pursuant to this Agreement, you hereby represent that you are acquiring the shares of Stock for investment and with no present intention of selling or transferring them and that you will not sell or otherwise transfer the shares except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Stock may then be listed.
14.Not a Public Offering. If you are resident outside the U.S., the grant of the Restricted Stock Units is not intended to be a public offering of securities in your country of residence (or country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Restricted Stock Units is not subject to the supervision of the local securities authorities.
15.Insider Trading/Market Abuse Laws. By participating in the Plan, you agree to comply with the Company's policy on insider trading, to the extent that it is applicable to you. You further acknowledge that, depending on your or your broker's country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to shares of Stock, or rights linked to the value of shares of Stock during such times you are considered to have "inside information" regarding the Company as defined by the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a "need to know" basis) and (ii) "tipping" third parties or causing them otherwise to buy or sell securities. You understand that third parties include fellow employees and/or service providers. Any restrictions under these laws and regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions and, therefore, you should consult your personal advisor on this matter.
16.Repatriation; Compliance with Law. If you are resident or employed outside the U.S., you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan in accordance with applicable foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and its Affiliates, as may be required to allow the Company and its Affiliates to comply with local laws, rules and/or regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal obligations under local laws, rules and/or regulations in your country of residence (and country of employment, if different).
17.No Advice Regarding Grant. No employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock underlying the Restricted Stock Units. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.
18.Change in Stock. In the event of any change in Stock, by reason of any stock dividend, recapitalization, reorganization, split-up, merger, consolidation, exchange of shares, or of any similar change affecting the shares of Stock, the number of Restricted Stock Units subject to this Agreement shall be equitably adjusted by the Committee.
5


19.Nature of the Award. In accepting the Award, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and limited in duration, and it may be modified, amended, suspended or terminated by the Company, in its sole discretion, at any time;
(b)the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past;
(c)all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company, including, but not limited to, the form and timing of the Award, the number of shares subject to the Award, and the vesting provisions applicable to the Award;
(d)the Award and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company or any Affiliate and shall not interfere with the ability of the Company, your Employer or an Affiliate, as applicable, to terminate your employment or service relationship;
(e)you are voluntarily participating in the Plan;
(f)the Award and the shares of Stock subject to the Award are not intended to replace any pension rights or compensation;
(g)the Award, the shares of Stock subject to the Award and the income and value of the same, is an extraordinary item of compensation outside the scope of your employment (and employment contract, if any) and is not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, your Employer or any Affiliate;
(h)the future value of the shares of Stock underlying the Award is unknown, indeterminable and cannot be predicted with certainty;
(i)unless otherwise determined by the Committee in its sole discretion, a Termination of Service shall be effective from the date on which active employment or service ends and shall not be extended by any statutory or common law notice of termination period;
(j)no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from a Termination of Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and in consideration of the grant of the Award to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, your Employer or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer and all Affiliates from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim;
6


(k)unless otherwise provided herein, in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of Stock of the Company; and
(l)neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Award or of any amounts due to you pursuant to the settlement of the Award or the subsequent sale of any shares of Stock acquired upon settlement of the Award.
20.Committee Authority; Recoupment. It is expressly understood that the Committee is authorized to administer, construe and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, including the enforcement of any recoupment policy, all of which shall be binding upon you and any claimant. Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.
21.Personal Data. Pursuant to applicable personal data protection laws, the Company hereby notifies you of the following in relation to your personal data and the collection, processing and transfer of such data in relation to the Company's grant of the Restricted Stock Units and your participation in the Plan. The collection, processing and transfer of personal data is necessary for the Company's administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of personal data may affect your participation in the Plan. As such, you voluntarily acknowledge and consent (where required under applicable law) to the collection, use, processing and transfer of personal data as described herein:
(a)The Company and your Employer hold certain personal information about you, specifically: your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all entitlements to shares of Stock awarded, canceled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan ("Data"). The Data may be provided by you or collected, where lawful, from the Company, its Affiliates and/or third parties, and the Company and your Employer will process the Data for the exclusive purpose of implementing, administering and managing your participation in the Plan. The Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations in your country of residence (or country of employment, if different). Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought. Data will be accessible within the organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and for your participation in the Plan.
(b)The Company and your Employer will transfer Data internally as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and/or your Employer may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Plan. You hereby authorize (where required under applicable law) the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, as may be required for the administration of the Plan and/or the subsequent holding of the shares of Stock on your behalf, to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.
7


(c)You may, at any time, exercise your rights provided under applicable personal data protection laws, which may include the right to (i) obtain confirmation as to the existence of Data, (ii) verify the content, origin and accuracy of the Data, (iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data, (iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and/or operation of the Plan and your participation in the Plan, and (v) withdraw your consent to the collection, processing or transfer of Data as provided hereunder (in which case, your Restricted Stock Units will become null and void). You may seek to exercise these rights by contacting your Human Resources manager or the Company's Human Resources Department, who may direct the matter to the applicable Company privacy official.
22.Addendum to Agreement. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as set forth in the addendum to the Agreement, attached hereto as Exhibit A (the "Addendum"). Further, if you transfer your residence and/or employment to another country reflected in the Addendum, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). The Addendum shall constitute part of this Agreement.
23.Additional Requirements. The Company reserves the right to impose other requirements on the Restricted Stock Units, any shares of Stock acquired pursuant to the Restricted Stock Units and your participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.
24.Amendment or Modification, Waiver. Except as set forth in the Plan, no provision of this Agreement may be amended or waived unless the amendment or waiver is agreed to in writing, signed by you and by a duly authorized officer of the Company. No waiver of any condition or provision of this Agreement shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.
25.Electronic Delivery. The Company may, in its sole discretion, deliver by electronic means any documents related to the Award or your future participation in the Plan. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.
26.Governing Law and Jurisdiction. This Agreement is governed by the substantive and procedural laws of the state of Illinois, U.S.A. You and the Company shall submit to the exclusive jurisdiction of, and venue in, the courts in Illinois, U.S.A., in any dispute relating to this Agreement without regard to any choice of law rules thereof which might apply the laws of any other jurisdictions.
27.English Language. If you are resident in a country where English is not an official language, you acknowledge and agree that it is your express intent that this Agreement, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English. You further acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement, the Plan and any other documents related to the Award. If you have received this Agreement, the Plan or any
8


other documents related to the Award translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
28.Conformity with Applicable Law. If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
29.Successors. This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder.
****
    This Agreement contains highly sensitive and confidential information. Please handle it accordingly.

Please read the attached Exhibit A. Once you have read and understood this Agreement and Exhibit A, please click the acceptance box to certify and confirm your agreement to be bound by the terms and conditions of this Agreement and Exhibit A, as applicable, and to acknowledge your receipt of the Prospectus, the Plan and this Agreement and your acceptance of the terms and conditions of the Award granted hereunder.

9


EXHIBIT A
ADDENDUM TO THE
WALGREENS BOOTS ALLIANCE, INC. 2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
In addition to the terms of the Plan and the Agreement, the Award is subject to the following additional terms and conditions to the extent you reside and/or are employed in one of the countries addressed herein. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in this Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan (or the Company may establish alternative terms as may be necessary or advisable to accommodate your transfer). All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.
EUROPEAN UNION ("EU") / EUROPEAN ECONOMIC AREA ("EEA") / SWITZERLAND / THE UNITED KINGDOM

Personal Data. The following provision replaces Section 19 of the Agreement in its entirety:
The Company, with its registered address at 108 Wilmot Road, Deerfield, Illinois 60015, U.S.A. is the controller responsible for the processing of your personal data by the Company and the third parties noted below.

(a)Data Collection and Usage. Pursuant to applicable data protection laws, you are hereby notified that the Company collects, processes and uses certain personal information about you for the legitimate purpose of implementing, administering and managing the Plan and generally administering awards; specifically: your name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares or directorships held in the Company, and details of all Restricted Stock Units, any entitlement to shares of Stock awarded, canceled, exercised, vested, or outstanding in your favor, which the Company receives from you or the Employer ("Personal Data"). In granting the Restricted Stock Units under the Plan, the Company will collect, process, use, disclose and transfer (collectively, "Processing") Personal Data for purposes of implementing, administering and managing the Plan. The Company's legal basis for the Processing of Personal Data is the Company's legitimate business interests of managing the Plan, administering employee awards and complying with its contractual and statutory obligations, as well as the necessity of the Processing for the Company to perform its contractual obligations under the Agreement and the Plan. Your refusal to provide Personal Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan. As such, by accepting the Restricted Stock Units, you voluntarily acknowledge the Processing of your Personal Data as described herein.

(b)Stock Plan Administration Service Provider. The Company may transfer Personal Data to Fidelity Stock Plan Services, LLC ("Fidelity"), an independent service provider based, in relevant part, in the United States, which may assist the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Personal Data with another company that serves in a similar manner. The Company's service provider will open an account for you to receive and trade shares of Stock pursuant to the Restricted Stock Units. The Processing of Personal Data will take place through both electronic and non-electronic means. Personal Data will only be accessible by those individuals requiring access to it for purposes of implementing, administering and operating the Plan. When receiving your Personal Data, if applicable, Fidelity provides appropriate safeguards in accordance with the EU Standard Contractual Clauses or other appropriate cross-border transfer solutions. By participating in the Plan, you understand that the
10


service provider will Process your Personal Data for the purposes of implementing, administering and managing your participation in the Plan.

(c)International Data Transfers. The Company is based in the United States, which means it will be necessary for Personal Data to be transferred to, and Processed in the United States. When transferring your Personal Data to the United States, the Company provides appropriate safeguards in accordance with the EU Standard Contractual Clauses, and other appropriate cross-border transfer solutions. You may request a copy of the appropriate safeguards with Fidelity or the Company by contacting your Human Resources manager or the Company's Human Resources Department.

(d)Data Retention. The Company will use Personal Data only as long as is necessary to implement, administer and manage your participation in the Plan or as required to comply with legal or regulatory obligations, including tax and securities laws. When the Company no longer needs Personal Data related to the Plan, the Company will remove it from its systems. If the Company keeps Personal Data longer, it would be to satisfy legal or regulatory obligations and the Company's legal basis would be for compliance with relevant laws or regulations.

(e)Data Subject Rights. To the extent provided by law, you have the right to (i) subject to certain exceptions, request access or copies of Personal Data the Company Processes, (ii) request rectification of incorrect Personal Data, (iii) request deletion of Personal Data, (iv) place restrictions on Processing of Personal Data, (v) lodge complaints with competent authorities in your country, and/or (vi) request a list with the names and addresses of any potential recipients of Personal Data. To receive clarification regarding your rights or to exercise your rights, you may contact your Human Resources manager or the Company's Human Resources Department. You also have the right to object, on grounds related to a particular situation, to the Processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting your Human Resources manager or the Company's Human Resources Department in writing. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to administer the Restricted Stock Units, or grant other awards or administer or maintain such awards. For more information on the consequences of the refusal to provide Personal Data, you may contact your Human Resources manager or the Company's Human Resources Department in writing. You may also have the right to lodge a complaint with the relevant data protection supervisory authority.

CHILE

    Private Placement. The following provision shall replace Section 14 of the Agreement:

The grant of the Restricted Stock Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.
a)The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean Commission for the Financial Market;
b)The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;
c)The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean Commission for the Financial Market; and
d)The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
a)La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la Comisión para el Mercado Financiero en Chile;
11


b)La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la Comisión para el Mercado Financiero en Chile, por lo que tales valores no están sujetos a la fiscalización de ésta;
c)Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y
d)Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente

GERMANY

No country-specific provisions.

HONG KONG

1.Form of Payment. Notwithstanding any provision in the Agreement or Plan to the contrary, the Restricted Stock Units shall be settled only in Shares (and not in cash).

2.IMPORTANT NOTICE. WARNING: The contents of the Agreement, this Addendum, the Plan, the Plan prospectus, the Plan administrative rules and all other materials pertaining to the Restricted Stock Units and/or the Plan have not been reviewed by any regulatory authority in Hong Kong. You are hereby advised to exercise caution in relation to the offer thereunder. If you have any doubts about any of the contents of the aforesaid materials, you should obtain independent professional advice. Neither the grant of the Restricted Stock Units nor the issuance of the shares of Stock upon settlement of the Restricted Stock Units constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Affiliates. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Restricted Stock Units (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Affiliates and may not be distributed to any other person.

3.Wages. The Restricted Stock Units and shares of Stock subject to the Restricted Stock Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

IRELAND

No country-specific provisions.

ITALY

    Plan Document Acknowledgment. In accepting the Restricted Stock Units, you acknowledge that a copy of the Plan was made available to you, and you have reviewed the Plan and the Agreement, including this Addendum, in their entirety and fully understand and accept all provisions of the Plan, the Agreement and the Addendum.

You further acknowledge that you have read and specifically approve the following provisions in the Agreement: Section 3: Restricted Period (terms of lapse of restrictions on Restricted Stock Units); Section 4: Disability or Death (terms of payment of Restricted Stock Units upon a Termination of Service by reason of Disability or death); Section 5: Retirement (terms of payment of Restricted Stock Units upon a Termination of Service by reason of retirement); Section 6: Termination of Service Following a Change in Control (terms of payment of Restricted Stock Units in the event of a Termination of Service following a Change in Control); Section 7: Other Termination of Service (forfeiture of Restricted Stock Units in other cases of Termination of Service); Section 10(a): Responsibility for Taxes; Tax Withholding (liability for all Tax-Related Items related to the Restricted Stock Units and legally applicable to the participant);
12


Section 11: Nontransferability (Restricted Stock Units shall not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated); Section 18: Change in Stock (right of the Company to equitably adjust the number of Restricted Stock Units subject to this Agreement in the event of any change in Stock); Section 19(j): Nature of the Award (waive any claim or entitlement to compensation or damages arising from forfeiture of the Restricted Stock Units resulting from a Termination of Service); Section 19(l): Nature of the Award (the Company is not liable for any foreign exchange rate fluctuation impacting the value of the Restricted Stock Units); Section 20: Committee Authority; Recoupment (right of the Committee to administer, construe, and make all determinations necessary or appropriate for the administration of the Restricted Stock Units and this Agreement, including the enforcement of any recoupment policy); Section 21: Non-Competition, Non-Solicitation and Confidentiality (the receipt of the Award is conditioned upon agreement to the Non-Competition, Non-Solicitation and Confidentiality Agreement attached hereto as Exhibit A); Section 23: Addendum to Agreement (the Restricted Stock Units are subject to the terms of the Addendum); Section 24: Additional Requirements (Company right to impose additional requirements on the Restricted Stock Units in case such requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate operation and administration of the Restricted Stock Units and the Plan); Section 26: Electronic Delivery (Company may deliver documents related to the Award or Plan electronically); Section 27: Governing Law and Jurisdiction (Agreement is governed by Illinois law without regard to any choice of law rules thereof; agreement to exclusive jurisdiction of Illinois courts); Section 28: English Language (documents will be drawn up in English; if a translation is provided, the English version controls); and the provision titled “Personal Data” under the heading "European Union (‘EU’) / European Economic Area (‘EEA’) / Switzerland / the United Kingdom", included in this Addendum.

MEXICO

1.Commercial Relationship. You expressly recognize that your participation in the Plan and the Company's grant of the Restricted Stock Units does not constitute an employment relationship between you and the Company. You have been granted the Restricted Stock Units as a consequence of the commercial relationship between the Company and the Affiliate in Mexico that employs you ("WBA Mexico"), and WBA Mexico is your sole employer. Based on the foregoing, you expressly recognize that (a) the Plan and the benefits you may derive from your participation in the Plan do not establish any rights between you and WBA Mexico, (b) the Plan and the benefits you may derive from your participation in the Plan are not part of the employment conditions and/or benefits provided by WBA Mexico, and (c) any modifications or amendments of the Plan by the Company, or a termination of the Plan by the Company, shall not constitute a change or impairment of the terms and conditions of your employment with WBA Mexico.

2.Extraordinary Item of Compensation. You expressly recognize and acknowledge that your participation in the Plan is a result of the discretionary and unilateral decision of the Company, as well as your free and voluntary decision to participate in the Plan in accordance with the terms and conditions of the Plan, the Agreement and this Addendum. As such, you acknowledge and agree that the Company, in its sole discretion, may amend and/or discontinue your participation in the Plan at any time and without any liability. The Award, the shares of Stock subject to the Award and the income and value of the same is an extraordinary item of compensation outside the scope of your employment contract, if any, and is not part of your regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of WBA Mexico.

3.Securities Law Notification. The Restricted Stock Units and shares of Stock offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, this Agreement and any other document relating to the Restricted Stock Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and WBA
13


Mexico and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of WBA Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.

MONACO

    Use of English Language. You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

SWITZERLAND

    Securities Law Notification. Neither this document nor any other materials relating to the Restricted Stock Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, or approved or supervised by, any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

THAILAND

No country-specific provisions.

UNITED KINGDOM

    1.    Indemnification for Tax-Related Items. Without limitation to Section 10 of the Agreement, you hereby agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, your Employer or by Her Majesty's Revenue & Customs ("HMRC") (or any other tax authority or any other relevant authority). You also hereby agree to indemnify and keep indemnified the Company and your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, if you are a director or executive officer (as within the meaning of Section 13(k) of the Exchange Act), the terms of the immediately foregoing provision will not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to you on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or your Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or your Employer may recover from you at any time thereafter by any of the means referred to in Section 10 of the Agreement.

    2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Restricted Stock Units, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Restricted Stock Units. Upon the grant
14


of the Restricted Stock Units, you shall be deemed irrevocably to have waived any such entitlement.

*** *** *** *** ***
    By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Restricted Stock Unit Award Agreement to which this Addendum is attached as Exhibit A, and I agree to the terms and conditions expressed in this Addendum.
15
EX-10.7 5 a11302021exhibit107.htm EX-10.7 Document


EXHIBIT 10.7
WALGREENS BOOTS ALLIANCE, INC.
2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT









These materials, which may include descriptions of company stock plans, prospectuses and other information and documents, and the information they contain, are provided by Walgreens Boots Alliance, Inc., not by Fidelity, and are not an offer or solicitation by Fidelity for the purchase of any securities or financial instruments. These materials were prepared by Walgreens Boots Alliance, Inc., which is solely responsible for their contents and for compliance with legal and regulatory requirements. Fidelity is not connected with any offering or acting as an underwriter in connection with any offering of securities or financial instruments of Walgreens Boots Alliance, Inc. Fidelity does not review, approve or endorse the contents of these materials and is not responsible for their content.







WALGREENS BOOTS ALLIANCE, INC.
2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
Participant Name:
Participant ID:
Grant Date:     (the "Grant Date")
Units Granted:     
Vesting: Three years from Grant Date (the "Vesting Date")
Acceptance Date:
Electronic Signature:
    This document (referred to below as this "Agreement") spells out the terms and conditions of the Restricted Stock Unit Award (the "Award") granted to you by Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), pursuant to the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (the "Plan") on and as of the Grant Date designated above. Except as otherwise defined herein, capitalized terms used in this Agreement have the respective meanings set forth in the Plan. For purposes of this Agreement, "Employer" means the entity (the Company or the Affiliate) that employs you on the applicable date. The Plan, as it may be amended from time to time, is incorporated into this Agreement by this reference.
You and the Company agree as follows:
1.Grant of Restricted Stock Units. Pursuant to the approval and direction of the Compensation and Leadership Performance Committee of the Company's Board of Directors (the "Committee"), the Company hereby grants you the number of Restricted Stock Units specified above (the "Restricted Stock Units"), subject to the terms and conditions of the Plan and this Agreement.
2.Restricted Stock Unit Account and Dividend Equivalents. The Company will maintain an account (the "Account") on its books in your name to reflect the number of Restricted Stock Units awarded to you as well as any additional Restricted Stock Units credited as a result of Dividend Equivalents. The Account will be administered as follows:
(a)The Account is for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company's general assets with respect to such Account.
(b)As of each record date with respect to which a cash dividend is to be paid with respect to shares of Company common stock par value US$.01 per share ("Stock"), the Company will credit your Account with an equivalent amount of Restricted Stock Units determined by dividing the value of the cash dividend that would have been paid on your Restricted Stock Units if they had been shares of Stock, divided by the value of Stock on such date.
(c)If dividends are paid in the form of shares of Stock rather than cash, then your Account will be credited with one additional Restricted Stock Unit for each share of Stock that would have been received as a dividend had your outstanding Restricted Stock Units been shares of Stock.
1




(d)Additional Restricted Stock Units credited via Dividend Equivalents shall vest or be forfeited at the same time as the Restricted Stock Units to which they relate.
3.Restricted Period. The period prior to the vesting date with respect each Restricted Stock Unit is referred to as the "Restricted Period." Subject to the provisions of the Plan and this Agreement, unless vested or forfeited earlier as described in Section 4, 5, 6 or 7 of this Agreement, as applicable, your Restricted Stock Units will become vested and be settled as described in Section 8 below, as of the vesting date or dates indicated in the introduction to this Agreement, provided the performance goal in this Section 3 ("Performance Goal") is satisfied as of the end of the applicable performance period. The Performance Goal will be established and certified by the Committee and cover one or more Company performance goals over the course of the Company's 2022 fiscal year. If the Performance Goal is not attained as of the end of this performance period, the Restricted Stock Units awarded hereunder shall be thereupon forfeited.
4.Disability or Death. If during the Restricted Period you have a Termination of Service by reason of Disability or death, then the Restricted Stock Units will become fully vested as of the date of your Termination of Service and the Vesting Date shall become the date of your Termination of Service. Any Restricted Stock Units becoming vested by reason of your Termination of Service by reason of Disability or death shall be settled as provided in Section 8.
5.Retirement. If prior to the end of the first 12 months of the Restricted Period you have a Termination of Service by reason of retirement from the Company's Board of Directors, as reasonably determined and approved by the Committee, then, subject to such approval and subject to satisfaction of the Performance Goal, the Restricted Stock Units will become vested on a prorated basis as of the later of the end of the performance period for the Performance Goal and the date of your Termination of Service, with such pro-ration based on the number of full months of service completed during the Restricted Period, divided by 36 months. If on or after the end of the first 12 months of the Restricted Period you have a Termination of Service by reason of retirement from the Company's Board of Directors, as reasonably determined and approved by the Committee, then, subject to such approval and subject to satisfaction of the Performance Goal, the Restricted Stock Units will become fully vested as of the date of your Termination of Service. Any Restricted Stock Units becoming vested by reason of your retirement shall be settled as provided in Section 8.
6.Termination of Service Following a Change in Control. If during the Restricted Period there is a Change in Control of the Company and within the one-year period thereafter you have a Termination of Service initiated by your Employer other than for Cause (as defined in Section 7), then your Restricted Stock Units shall become fully vested, and they shall be settled in accordance with Section 9. For purposes of this Section 6, a Termination of Service initiated by your Employer shall include a Termination of Employment for Good Reason under - and pursuant to the terms and conditions of – the Walgreens Boots Alliance, Inc. Executive Severance and Change in Control Plan, but only to the extent applicable to you as an eligible participant in such Plan.
7.Other Termination of Service. If during the Restricted Period you have a voluntary or involuntary Termination of Service for any reason other than as set forth in Section 4, 5 or 6 above or Section 9 below, as determined by the Committee, then you shall thereupon forfeit any Restricted Stock Units that are still in a Restricted Period on your termination date. For purposes of this Agreement, "Cause" means any one or more of the following, as determined by the Committee in its sole discretion:

(a)    your commission of a felony or any crime of moral turpitude;

(b)    your dishonesty or material violation of standards of integrity in the course of fulfilling your duties to the Company or any Affiliate;

(c)    your material violation of a material written policy of the Company or any Affiliate violation of which is grounds for immediate termination;
2





(d)    your willful and deliberate failure to perform your duties to the Company or any Affiliate in any material respect, after reasonable notice of such failure and an opportunity to correct it; or

(e)    your failure to comply in any material respect with the United States ("U.S.") Foreign Corrupt Practices Act, the U.S. Securities Act of 1933, the Exchange Act, the U.S. Sarbanes-Oxley Act of 2002, the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the U.S. Truth in Negotiations Act, or any rules or regulations thereunder.
8.Settlement of Vested Restricted Stock Units. Subject to the requirements of Section 13 below, as promptly as practicable after the applicable Vesting Date, whether occurring upon your Separation from Service or otherwise, but in no event later than 75 days after the Vesting Date, the Company shall transfer to you one share of Stock for each Restricted Stock Unit becoming vested at such time, net of any applicable tax withholding requirements in accordance with Section 10 below; provided, however, that, if you are a Specified Employee at the time of Separation from Service, then to the extent your Restricted Stock Units are deferred compensation subject to Section 409A of the Code, settlement of which is triggered by your Separation from Service (other than for death), payment shall not be made until the date which is six months after your Separation from Service.
Notwithstanding the foregoing, if you are resident or employed outside of the U.S., the Company, in its sole discretion, may provide for the settlement of the Restricted Stock Units in the form of:

(a)     a cash payment (in an amount equal to the Fair Market Value of the Stock that corresponds with the number of vested Restricted Stock Units) to the extent that settlement in shares of Stock (i) is prohibited under local law, (ii) would require you, the Company or an Affiliate to obtain the approval of any governmental or regulatory body in your country of residence (or country of employment, if different), (iii) would result in adverse tax consequences for you, the Company or an Affiliate or (iv) is administratively burdensome; or

(b)     shares of Stock, but require you to sell such shares of Stock immediately or within a specified period following your Termination of Service (in which case, you hereby agree that the Company shall have the authority to issue sale instructions in relation to such shares of Stock on your behalf).
9.Settlement Following Change in Control. Notwithstanding any provision of this Agreement to the contrary, the Company may, in its sole discretion, fulfill its obligation with respect to all or any portion of the Restricted Stock Units that become vested in accordance with Section 6 above, by:
(a)delivery of (i) the number of shares of Stock that corresponds with the number of Restricted Stock Units that have become vested or (ii) such other ownership interest as such shares of Stock that correspond with the vested Restricted Stock Units may be converted into by virtue of the Change in Control transaction;
(b)payment of cash in an amount equal to the Fair Market Value of the Stock that corresponds with the number of vested Restricted Stock Units at that time; or
(c)delivery of any combination of shares of Stock (or other converted ownership interest) and cash having an aggregate Fair Market Value equal to the Fair Market Value of the Stock that corresponds with the number of Restricted Stock Units that have become vested at that time.
Settlement shall be made as soon as practical after the Restricted Stock Units become fully vested under Section 6, but in no event later than 30 days after such date.
3




10.Responsibility for Taxes; Tax Withholding.
(a)You acknowledge that, regardless of any action taken by the Company or your Employer, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you ("Tax-Related Items"), is and remains your responsibility and may exceed the amount actually withheld by the Company or your Employer, if any. You further acknowledge that the Company and/or your Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including, but not limited to, the grant, vesting or settlement of the Award, the subsequent sale of shares of Stock acquired pursuant to such settlement and the receipt of any Dividend Equivalents and/or dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, as applicable, you acknowledge that the Company and/or your Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

(b)    Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or your Employer to satisfy all Tax-Related Items. In this regard, except as provided below, the Company, your Employer or its agent shall satisfy the obligations with regard to all Tax-Related Items by withholding from the shares of Stock to be delivered upon settlement of the Award that number of shares of Stock having a Fair Market Value equal to the amount required by law to be withheld. For purposes of the foregoing tax withholding, no fractional shares of Stock will be withheld. Notwithstanding the foregoing, if you are a Section 16 officer of the Company under the Exchange Act at the time of any applicable tax withholding event, you may make a cash payment to the Company, your Employer or its agent to cover the Tax-Related Items that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan. If you are not a Section 16 officer of the Company at the time of any applicable tax withholding event, the Company and/or your Employer may (in its sole discretion) allow you to make a cash payment to the Company, your Employer or its agent to cover such Tax-Related Items.
The Company may withhold or account for Tax-Related Items by considering applicable statutory withholding rates (as determined by the Company in good faith and in its sole discretion) or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding from the shares of Stock to be delivered upon settlement of the Award, for tax purposes, you will be deemed to have been issued the full number of shares of Stock subject to the earned Award, notwithstanding that a number of the shares of Stock are held back solely for the purpose of paying the Tax-Related Items.

The Company may refuse to issue or deliver the shares of Stock (or cash payment) or the proceeds from the sale of shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items.
11.Nontransferability. During the Restricted Period and thereafter until Stock is transferred to you in settlement thereof, you may not sell, transfer, pledge, assign or otherwise alienate or hypothecate the Restricted Stock Units whether voluntarily or involuntarily or by operation of law, other than by beneficiary designation effective upon your death, or by will or by the laws of intestacy.
4




12.Rights as Stockholder. You shall have no rights as a stockholder of the Company with respect to the Restricted Stock Units until such time as a certificate of stock for the Stock issued in settlement of such Restricted Stock Units has been issued to you or such shares of Stock have been recorded in your name in book entry form. Until that time, you shall not have any voting rights with respect to the Restricted Stock Units. Except as provided in Section 9 above, no adjustment shall be made for dividends or distributions or other rights with respect to such shares for which the record date is prior to the date on which you become the holder of record thereof. Anything herein to the contrary notwithstanding, if a law or any regulation of the U.S. Securities and Exchange Commission or of any other regulatory body having jurisdiction shall require the Company or you to take any action before shares of Stock can be delivered to you hereunder, then the date of delivery of such shares may be delayed accordingly.
13.Securities Laws. If a Registration Statement under the U.S. Securities Act of 1933, as amended, is not in effect with respect to the shares of Stock to be delivered pursuant to this Agreement, you hereby represent that you are acquiring the shares of Stock for investment and with no present intention of selling or transferring them and that you will not sell or otherwise transfer the shares except in compliance with all applicable securities laws and requirements of any stock exchange on which the shares of Stock may then be listed.
14.Not a Public Offering. If you are resident outside the U.S., the grant of the Restricted Stock Units is not intended to be a public offering of securities in your country of residence (or country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Restricted Stock Units is not subject to the supervision of the local securities authorities.
15.Insider Trading/Market Abuse Laws. By participating in the Plan, you agree to comply with the Company's policy on insider trading, to the extent that it is applicable to you. You further acknowledge that, depending on your or your broker's country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to shares of Stock, or rights linked to the value of shares of Stock during such times you are considered to have "inside information" regarding the Company as defined by the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a "need to know" basis) and (ii) "tipping" third parties or causing them otherwise to buy or sell securities. You understand that third parties include fellow employees and/or service providers. Any restrictions under these laws and regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions and, therefore, you should consult your personal advisor on this matter.
16.Repatriation; Compliance with Law. If you are resident or employed outside the U.S., you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan in accordance with applicable foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and its Affiliates, as may be required to allow the Company and its Affiliates to comply with local laws, rules and/or regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal obligations under local laws, rules and/or regulations in your country of residence (and country of employment, if different).
17.No Advice Regarding Grant. No employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock underlying the Restricted Stock Units. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.
5




18.Change in Stock. In the event of any change in Stock, by reason of any stock dividend, recapitalization, reorganization, split-up, merger, consolidation, exchange of shares, or of any similar change affecting the shares of Stock, the number of Restricted Stock Units subject to this Agreement shall be equitably adjusted by the Committee.
19.Nature of the Award. In accepting the Award, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and limited in duration, and it may be modified, amended, suspended or terminated by the Company, in its sole discretion, at any time;
(b)the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past;
(c)all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company, including, but not limited to, the form and timing of the Award, the number of shares subject to the Award, and the vesting provisions applicable to the Award;
(d)the Award and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company or any Affiliate and shall not interfere with the ability of the Company, your Employer or an Affiliate, as applicable, to terminate your employment or service relationship;
(e)you are voluntarily participating in the Plan;
(f)the Award and the shares of Stock subject to the Award are not intended to replace any pension rights or compensation;
(g)the Award, the shares of Stock subject to the Award and the income and value of the same, is an extraordinary item of compensation outside the scope of your employment (and employment contract, if any) and is not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, your Employer or any Affiliate;
(h)the future value of the shares of Stock underlying the Award is unknown, indeterminable and cannot be predicted with certainty;
(i)unless otherwise determined by the Committee in its sole discretion, a Termination of Service shall be effective from the date on which active employment or service ends and shall not be extended by any statutory or common law notice of termination period;
(j)no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from a Termination of Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and in consideration of the grant of the Award to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company, your Employer or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company, the Employer and all Affiliates from any such claim; if, notwithstanding the
6




foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim;
(k)unless otherwise provided herein, in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of Stock of the Company; and
(l)neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Award or of any amounts due to you pursuant to the settlement of the Award or the subsequent sale of any shares of Stock acquired upon settlement of the Award.
20.Committee Authority; Recoupment. It is expressly understood that the Committee is authorized to administer, construe and make all determinations necessary or appropriate for the administration of the Plan and this Agreement, including the enforcement of any recoupment policy, all of which shall be binding upon you and any claimant. Any inconsistency between this Agreement and the Plan shall be resolved in favor of the Plan.
21.Non-Competition, Non-Solicitation and Confidentiality. As a condition to the receipt of this Award, you must agree to the Non-Competition, Non-Solicitation and Confidentiality Agreement (the "NNCA Agreement") attached hereto as Exhibit A. By clicking the acceptance box for this Agreement, you also agree to the terms and conditions expressed in the NNCA Agreement. Failure to accept the terms of this Agreement and NNCA Agreement within 120 days of the Grant Date shall constitute your decision to decline to accept this Award.
22.Personal Data. Pursuant to applicable personal data protection laws, the Company hereby notifies you of the following in relation to your personal data and the collection, processing and transfer of such data in relation to the Company's grant of the Restricted Stock Units and your participation in the Plan. The collection, processing and transfer of personal data is necessary for the Company's administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of personal data may affect your participation in the Plan. As such, you voluntarily acknowledge and consent (where required under applicable law) to the collection, use, processing and transfer of personal data as described herein:
(a)The Company and your Employer hold certain personal information about you, specifically: your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all entitlements to shares of Stock awarded, canceled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan ("Data"). The Data may be provided by you or collected, where lawful, from the Company, its Affiliates and/or third parties, and the Company and your Employer will process the Data for the exclusive purpose of implementing, administering and managing your participation in the Plan. The Data processing will take place through electronic and non-electronic means according to logics and procedures strictly correlated to the purposes for which Data are collected and with confidentiality and security provisions as set forth by applicable laws and regulations in your country of residence (or country of employment, if different). Data processing operations will be performed minimizing the use of personal and identification data when such operations are unnecessary for the processing purposes sought. Data will be accessible within the organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and for your participation in the Plan.
7




(b)The Company and your Employer will transfer Data internally as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and/or your Employer may further transfer Data to any third parties assisting the Company in the implementation, administration and management of the Plan. You hereby authorize (where required under applicable law) the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, as may be required for the administration of the Plan and/or the subsequent holding of the shares of Stock on your behalf, to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan.
(c)You may, at any time, exercise your rights provided under applicable personal data protection laws, which may include the right to (i) obtain confirmation as to the existence of Data, (ii) verify the content, origin and accuracy of the Data, (iii) request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of the Data, (iv) oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary or required for the implementation, administration and/or operation of the Plan and your participation in the Plan, and (v) withdraw your consent to the collection, processing or transfer of Data as provided hereunder (in which case, your Restricted Stock Units will become null and void). You may seek to exercise these rights by contacting your Human Resources manager or the Company's Human Resources Department, who may direct the matter to the applicable Company privacy official.
23.Addendum to Agreement. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as set forth in the addendum to the Agreement, attached hereto as Exhibit B (the "Addendum"). Further, if you transfer your residence and/or employment to another country reflected in the Addendum, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). The Addendum shall constitute part of this Agreement.
24.Additional Requirements. The Company reserves the right to impose other requirements on the Restricted Stock Units, any shares of Stock acquired pursuant to the Restricted Stock Units and your participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.
25.Amendment or Modification, Waiver. Except as set forth in the Plan, no provision of this Agreement may be amended or waived unless the amendment or waiver is agreed to in writing, signed by you and by a duly authorized officer of the Company. No waiver of any condition or provision of this Agreement shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.
26.Electronic Delivery. The Company may, in its sole discretion, deliver by electronic means any documents related to the Award or your future participation in the Plan. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.
27.Governing Law and Jurisdiction. This Agreement is governed by the substantive and procedural laws of the state of Illinois, U.S.A. You and the Company shall submit to the exclusive jurisdiction of, and venue in, the courts in Illinois, U.S.A., in any dispute relating to this
8




Agreement without regard to any choice of law rules thereof which might apply the laws of any other jurisdictions.
28.English Language. If you are resident in a country where English is not an official language, you acknowledge and agree that it is your express intent that this Agreement, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Award, be drawn up in English. You further acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement, the Plan and any other documents related to the Award. If you have received this Agreement, the Plan or any other documents related to the Award translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.
29.Conformity with Applicable Law. If any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement or the validity, legality or enforceability of such provision in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
30.Successors. This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder.
****
    This Agreement contains highly sensitive and confidential information. Please handle it accordingly.

Please read the attached Exhibits A and B. Once you have read and understood this Agreement and Exhibits A and B, please click the acceptance box to certify and confirm your agreement to be bound by the terms and conditions of this Agreement and Exhibits A and B, as applicable, and to acknowledge your receipt of the Prospectus, the Plan and this Agreement and your acceptance of the terms and conditions of the Award granted hereunder.

9




EXHIBIT A
WALGREENS BOOTS ALLIANCE, INC. NON-COMPETITION, NON-SOLICITATION
AND CONFIDENTIALITY AGREEMENT
This Exhibit (the “Non-Compete Agreement”) forms a part of the Restricted Stock Unit Award Agreement covering Restricted Stock Units awarded to an employee (“Employee” or “I”) of Walgreens Boots Alliance, Inc. or an affiliate thereof, on behalf of itself, its affiliates, subsidiaries, and successors (collectively referred to as the “Company”).
WHEREAS, the Company develops and/or uses valuable business, technical, proprietary, customer and patient information it protects by limiting its disclosure and by keeping it secret or confidential;
WHEREAS, Employee acknowledges that during the course of employment, he or she has or will receive, contribute, or develop such Confidential Information and Trade Secrets (as defined below); and
WHEREAS, the Company desires to protect from third parties (e.g. competitors and customers) such Confidential Information and Trade Secrets and also desires to protect its legitimate business interests and goodwill in maintaining its employee and customer relationships.
NOW THEREFORE, in consideration of the Restricted Stock Units issued to Employee pursuant to the Agreement to which this is attached as Exhibit A and for other good and valuable consideration, including but not limited to employment or continued employment, the specialized knowledge, skill and training that the Company provides Employee, and the goodwill that Employee develops with customers on behalf of the Company, Employee agrees to be bound by the terms of this Non-Compete Agreement as follows:
1.Confidentiality.
(a)At all times during and after the termination of my employment with the Company, I will not, without the Company’s prior written permission, directly or indirectly for any purpose other than performance of my duties for the Company, utilize or disclose to anyone outside of the Company any Trade Secrets (defined in subparagraph 1(a)(i)) or other Confidential Information (defined in subparagraph 1(a)(ii)) or any information received by the Company in confidence from or about third parties, as long as such matters remain Trade Secrets or otherwise confidential.

(i)For purposes of this Non-Compete Agreement, “Trade Secrets” means a form of intellectual property that are protectable under applicable state and/or Federal law, including the Uniform Trade Secrets Act (as amended and adapted by the states) and the Federal Defend Trade Secrets Act of 2016 (the “DTSA”). They include all tangible and intangible (e.g., electronic) forms and types of information that is held and kept confidential by the Company and is not generally known outside of the Company, including but not limited to information about: the Company’s financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs or codes, and may in particular include such things as pricing information, business records, software programs, algorithms, inventions, patent applications, and designs and processes not known outside the Company.

(ii)For purposes of this Non-Compete Agreement, “Confidential Information” means Trade Secrets and, more broadly, any other tangible and intangible (e.g., electronic) forms and types of information that are held and kept confidential by the Company and are not generally known outside the Company,
10




and which relates to the actual or anticipated business of the Company or the Company’s actual or prospective vendors or clients. Confidential Information shall not be considered generally known to the public if is revealed improperly to the public by me or others without the Company’s express written consent and/or in violation of an obligation of confidentiality to the Company. Examples of Confidential Information include, but are not limited to: customer, referral source, supplier and contractor identification and contacts; special contract terms; pricing and margins; business, marketing and customer plans and strategies; financial data; company created (or licensed) techniques; technical know-how; research, development and production information; processes, prototypes, software, patent applications and plans, projections, proposals, discussion guides, and/or personal or performance information about employees.

(b)I understand that this obligation of non-disclosure shall last so long as the information remains confidential. I, however, understand that, if I live and work primarily in Wisconsin, Virginia, or any other state  requiring a temporal limit on non-disclosure clauses, Confidential Information shall be protected for two (2) years following termination of my employment (for any reason).  I also understand that Trade Secrets are protected by statute and are not subject to any time limits.  I also agree to contact the Company before using, disclosing, or distributing any Confidential Information or Trade Secrets if I have any questions about whether such information is protected information.
(c)The restrictions set forth in this paragraph are in addition to and not in lieu of any obligations I have by law with respect to the Company’s Confidential Information, including any obligations I may owe under the DTSA and any applicable state statutes. Nothing herein shall prohibit me from divulging evidence of criminal wrongdoing to law enforcement or prohibit me from disclosing Confidential Information or Trade Secrets if compelled by order of court or an agency of competent jurisdiction or as required by law; however, I shall promptly inform the Company of any such situations and shall take reasonable steps to prevent disclosure of Confidential Information or Trade Secrets until the Company has been informed of such required disclosure and has had a reasonable opportunity to seek a protective order. Pursuant to the DTSA, I understand that an individual may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a Trade Secret that: (A) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, I understand that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the Trade Secret to his or her attorney and use the Trade Secret information in the court proceeding, so long as any document containing the Trade Secret is filed under seal and the individual does not disclose the Trade Secret, except pursuant to court order. Nothing in this Non-Compete Agreement is intended to conflict with the DTSA or create liability for disclosures of Trade Secrets that are expressly allowed by DTSA.
2.Non-Competition. I agree that during my employment with the Company and for twelve (12) months after the termination of my employment (for any reason), I will not, directly or indirectly have Responsibilities with respect to any Competing Business Line. As set forth in paragraph 9(b) below, I understand that the restrictions in this paragraph apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary. These restrictions shall not apply to passive investments of less than five percent (5%) ownership interest in any entity. For purposes of this Non-Compete Agreement, “Responsibilities” means the same or similar material responsibilities I performed for the Company during the two (2) years prior to my last day of employment with the Company and within the same geographic scope, or portion thereof, where I performed those responsibilities for the Company. For purposes of this Non-Compete Agreement, “Competing Business Line” means any business that is in competition with any business engaged in by the Company and for which I had Responsibilities during the two (2) years prior to my last day of
11




employment with the Company. Competing Business Line shall also include businesses or business lines that may not be directly competitive with the Company in most respects (such as pharmacy benefit managers), but only to the extent I am engaged by any such business in a role: (a) that involves my performing Responsibilities for Competing Products or Services; or (b) where I would be called upon to inevitably rely upon or disclose Confidential Information and such reliance or disclosure would competitively harm the Company. For purposes of this Non-Compete Agreement, “Competing Products or Services” means products or services that are competitive with products or services offered by, developed by, designed by or distributed by the Company during the two (2) years prior to my last day of employment with the Company.
3.    Non-Solicitation. I agree that during my employment with the Company and for two (2) years after the termination of my employment from the Company (for any reason):
(a)    I will not directly or indirectly, solicit any Restricted Customer for purposes of providing Competing Products or Services, or offer, provide or sell Competing Products or Services to any Restricted Customer. For purposes of this Non-Compete Agreement, “Restricted Customer” means any person, company or entity that was a customer, vendor, supplier or referral source of the Company and with which I had direct contact for purposes of performing responsibilities for the Company or for which I had supervisory responsibilities on behalf of the Company, in either case at any time during the two (2) years prior to my last day of employment with the Company. To the extent permitted by applicable law, “Restricted Customer” also means any prospective customer(s), vendor(s), supplier(s) or referral source(s) with which I had business contact on behalf of the Company in the twelve (12) months prior to my last day of employment with the Company; and
(b)    I will not, nor will I assist any third party to, directly or indirectly (i) raid, solicit, or attempt to persuade any then-current employee of the Company with whom I currently work or with whom I had direct contact work during the two years prior to my last day of employment with the Company,  and who possesses or had access to Confidential Information of the Company, to leave the employ of the Company; (ii) interfere with the performance by any such employee of his/her duties for the Company; and/or (iii) communicate with any such employee for the purposes described in items (i) and (ii) in this subparagraph 3(b).
4.    Non-Inducement. I will not directly or indirectly assist or encourage any person or entity in carrying out or conducting any activity that would be prohibited by this Non-Compete Agreement if such activity were carried out or conducted by me.
5.    Non-Disparagement. During my employment with the Company and thereafter, I agree not to make negative comments or otherwise disparage the Company or any of its officers, directors, employees, shareholders, members, agents or products. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings); and the foregoing shall not apply to any claims for harassment or discrimination to the extent so restricted by applicable state law.
6.    Intellectual Property. The term “Intellectual Property” shall mean all trade secrets, ideas, inventions, designs, developments, devices, software, computer programs, methods and processes (whether or not patented or patentable, reduced to practice or included in the Confidential Information) and all patents and patent applications related thereto, all copyrights, copyrightable works and mask works (whether or not included in the Confidential Information) and all registrations and applications for registration related thereto, all Confidential Information, and all other proprietary rights contributed to, or conceived or created by, or reduced to practice by Employee or anyone acting on his/her behalf (whether alone or jointly with others) at any time from the beginning of Employee’s employment with the Company to the termination of that employment plus ninety (90) days, that (i) relate to the business or to the actual or anticipated research or development of the Company; (ii) result from any services that
12




Employee or anyone acting on its behalf perform for the Company; or (iii) are created using the equipment, supplies or facilities of the Company or any Confidential Information.
a.Ownership. All Intellectual Property is, shall be and shall remain the exclusive property of the Company. Employee hereby assigns to the Company all right, title and interest, if any, in and to the Intellectual Property; provided, however, that, when applicable, the Company shall own the copyrights in all copyrightable works included in the Intellectual Property pursuant to the “work-made-for-hire” doctrine (rather than by assignment), as such term is defined in the 1976 Copyright Act. All Intellectual Property shall be owned by the Company irrespective of any copyright notices or confidentiality legends to the contrary that may be placed on such works by Employee or by others. Employee shall ensure that all copyright notices and confidentiality legends on all work product authored by Employee or anyone acting on his/her behalf shall conform to the Company’s practices and shall specify the Company as the owner of the work. The Company hereby provides notice to Employee that the obligation to assign does not apply to an invention for which no equipment, supplies, facility, or Trade Secrets of the Company was used and which was developed entirely on the Employee’s own time, unless (i) the invention relates (1) to the business of the Company, or (2) to the Company’s actual or demonstrably anticipated research or development, or (ii) the invention results from any work performed by Employee for the Company.
b.Keep Records. Employee shall keep and maintain, or cause to be kept and maintained by anyone acting on his/her behalf, adequate and current written records of all Intellectual Property in the form of notes, sketches, drawings, computer files, reports or other documents relating thereto. Such records shall be and shall remain the exclusive property of the Company and shall be available to the Company at all times during my employment with the Company.
c.Assistance. Employee shall supply all assistance requested in securing for the Company’s benefit any patent, copyright, trademark, service mark, license, right or other evidence of ownership of any such Intellectual Property, and will provide full information regarding any such item and execute all appropriate documentation prepared by Company in applying or otherwise registering, in the Company’s name, all rights to any such item or the defense and protection of such Intellectual Property.
d.Prior Inventions. Employee has disclosed to the Company any continuing obligations to any third party with respect to Intellectual Property. Employee claims no rights to any inventions created prior to his/her employment for which a patent application has not previously been filed, unless he/she has described them in detail on a schedule attached to this Non-Compete Agreement.
e.Trade Secret Provisions. The provisions in paragraph 1 of this Non-Compete Agreement with regard to Trade Secrets and the DTSA shall apply as well in the context of the parties’ Intellectual Property rights and obligations.
7.    Return of Company Property. I agree that all documents and data accessible to me during my employment with the Company, including Confidential Information and Trade Secrets, regardless of format (electronic or hard copy), including but not limited to any Company computer, monitor, printer equipment, external drives, wireless access equipment, telecom equipment and systems (“Company Equipment”), are and remain the sole and exclusive property of the Company and/or its clients, and must be returned to the Company upon separation or upon demand by the Company. I further agree that I will provide passwords to access such Company Equipment and I will not print, retain, copy, destroy, modify or erase Company U.S. data on Company Equipment or otherwise wipe Company Equipment prior to returning the Company Equipment.
8.    Consideration and Acknowledgments. I acknowledge and agree that the covenants described in this Non-Compete Agreement are essential terms, and the underlying
13




Restricted Stock Unit Award would not be provided by the Company in the absence of these covenants. I further acknowledge that these covenants are supported by adequate consideration as set forth in this Non-Compete Agreement and are not in conflict with any public interest. I further acknowledge and agree that I fully understand these covenants, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Non-Compete Agreement, and have voluntarily agreed to comply with these covenants for their stated terms. I further acknowledge and agree that these covenants are reasonable and enforceable in all respects.
9.    Enforceability; General Provisions.
(a)I understand that my non-compete and/or non-solicitation obligations in this Non-Compete Agreement shall not apply to me if I am covered under applicable state or local statutory law prohibiting non-competes or non-solicits on the basis of my income and/or position level at the time of enforcement, including but not limited to those addressed in Exhibit A-1.
(b)I agree that the restrictions contained in this Non-Compete Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Non-Compete Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place undue restraint on me. I further understand that the restrictions in this Non-Compete Agreement apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary.
(c)Because the Company is incorporated in the state of Delaware (i) this Non-Compete Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any conflict of law provisions, and (ii) I consent to personal jurisdiction and the exclusive jurisdiction of the state and federal courts of Delaware with respect to any claim, dispute or declaration arising out of this Non-Compete Agreement.
(d)In the event of a breach or a threatened breach of this Non-Compete Agreement, I acknowledge that the Company will face irreparable injury which may be difficult to calculate in dollar terms and that the Company shall be entitled, in addition to all remedies otherwise available in law or in equity, to temporary restraining orders and preliminary and final injunctions enjoining such breach or threatened breach in any court of competent jurisdiction without the necessity of posting a surety bond, as well as to obtain an equitable accounting of all profits or benefits arising out of any violation of this Non-Compete Agreement.
(e)I agree that if a court determines that any of the provisions in this Non-Compete Agreement is unenforceable or unreasonable in duration, territory, or scope, then that court shall modify those provisions so they are reasonable and enforceable, and enforce those provisions as modified.
(f)If any one or more provisions (including paragraphs, subparagraphs and terms) of this Non-Compete Agreement or its application is determined to be invalid, illegal, or unenforceable to any extent or for any reason by a court of competent jurisdiction, I agree that the remaining provisions (including paragraphs, subparagraphs and terms) of this Non-Compete Agreement will still be valid and the provision declared to be invalid or illegal or unenforceable will be considered to be severed and deleted from the rest of this Non-Compete Agreement. I further agree that if any court of competent jurisdiction finds any of the restrictions set forth in this Non-Compete Agreement to be overly broad and unenforceable, the restriction shall be interpreted to extend only over the maximum time period, geographic area, or range of activities or clients that such court deems enforceable
14




(g)Notwithstanding the foregoing provisions of this Non-Compete Agreement, the non-competition provisions of paragraph 2 above shall not restrict Employee from performing legal services as a licensed attorney for a Competing Business to the extent that the attorney licensure requirements in the applicable jurisdiction do not permit Employee to agree to the otherwise applicable restrictions of paragraph 2.
(h)Waiver of any of the provisions of this Non-Compete Agreement by the Company in any particular instance shall not be deemed to be a waiver of any provision in any other instance and/or of the Company’s other rights at law or under this Non-Compete Agreement.
(i)I agree that the Company may assign this Non-Compete Agreement to its successors and assigns and that any such successor or assign may stand in the Company’s stead for purposes of enforcing this Non-Compete Agreement.
(j)I agree to reimburse the Company for all attorneys’ fees, costs, and expenses that it reasonably incurs in connection with enforcing its rights and remedies under this Non-Compete Agreement, but only to the extent the Company is ultimately the prevailing party in the applicable legal proceedings.
(k)I understand and agree that, where allowed by applicable law, the time for my obligations set out in paragraphs 2 – 6 shall be extended for period of non-compliance up to an additional two (2) years following my last day of employment with the Company (for any reason).
(l)I fully understand my obligations in this Non-Compete Agreement, have had full and complete opportunity to discuss and resolve any ambiguities or uncertainties regarding these covenants before signing this Non-Compete Agreement, and have voluntarily agreed to comply with these covenants for their stated terms.
(m)I agree that all non-competition, non-solicitation, non-disclosure and use, non-recruiting, and disclosure obligations in this Non-Compete Agreement shall survive any termination of this Non-Compete Agreement and extend to the proscribed periods following my last day of employment with the Company (for any reason) and no dispute regarding any other provisions of this Non-Compete Agreement or regarding my employment or the termination of my employment shall prevent the operation and enforcement of these obligations.
(n)I understand that nothing in this Non-Compete Agreement, including the non-disclosure and non-disparagement provisions, limit my ability to file a charge or complaint with the Equal Employment Opportunity Commission, Department of Labor, National Labor Relations Board, Occupational Safety and Health Administration, Securities and Exchange Commission or any other federal, state or local governmental agency or commission. I also understand that this Non-Compete Agreement does not limit my ability to communicate with any government agencies or otherwise participate in any investigation or proceeding that may be conducted by any government agency, including providing documents or other information, without notice to the Company.  Finally, I understand that nothing in this Non-Compete Agreement is intended to restrict my legally-protected right to discuss wages, hours or other working condition with co-workers, or in any way limit my rights under the National Labor Relations Act or any whistleblower act.
10.    Relationship of Parties. I acknowledge that my relationship with the Company is “terminable at will” by either party and that the Company or I can terminate the relationship with or without cause and without following any specific procedures. Nothing contained in this Non-Compete Agreement is intended to or shall be relied upon to alter the “terminable at will” relationship between the parties. I agree that my obligations in this Non-Compete Agreement
15




shall survive the termination of my employment from the Company for any reason and shall be binding upon my successors, heirs, executors and representatives.
11.    Modifications and Other Agreements. I agree that the terms of this Non-Compete Agreement may not be modified except by a written agreement signed by both me and the Company. This Non-Compete Agreement shall not supersede any other restrictive covenants to which I may be subject under an employment contract, benefit program or otherwise, such that the Company may enforce the terms of any and all restrictive covenants to which I am subject. The obligations herein are in addition to and do not limit any obligations arising under applicable statutes and common law.
12.    State and Commonwealth Law Modifications. I agree that if I, on the last day of my employment with the Company (for any reason), primarily reside and work in California, Illinois, Louisiana, Massachusetts, Nebraska, Oklahoma, Puerto Rico, South Carolina, Virginia, Washington or Wisconsin, I am subject to the modifications to this Non-Compete Agreement set forth in Exhibit A-1 applying to such state and to the extent such state law applies.
13.    Notification. I agree that in the event I am offered employment at any time in the future with any entity that may be considered a Competing Business Line, I shall immediately notify such Competing Business of the existence and terms of this Non-Compete Agreement. I also understand and agree that the Company may notify anyone attempting to or later employing me of the existence and provisions of this Non-Compete Agreement.
*** *** *** *** ***
    By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Restricted Stock Unit Award Agreement to which this Non-Compete Agreement is attached as Exhibit A, and I agree to the terms and conditions expressed in this Non-Compete Agreement, including the modifications set forth in Exhibit A-1, as applicable.

16




EXHIBIT A-1
WALGREENS BOOTS ALLIANCE, INC. NON-COMPETITION, NON-SOLICITATION
AND CONFIDENTIALITY AGREEMENT
State and Commonwealth Law Modifications
This Exhibit A-1 to the Walgreens Boots Alliance, Inc. Non-Competition, Non-Solicitation and Confidentiality Agreement (the “Non-Compete Agreement”) includes jurisdiction-specific “Addenda,” which modify the Non-Compete Agreement as applied to individuals who primarily reside and work in one of the applicable jurisdictions, but only to the extent the laws of such jurisdiction are applicable to the Non-Compete Agreement. The Addenda of this Exhibit A-1 should be read in conjunction with the rest of the Non-Compete Agreement and enforced to the fullest extent permissible to protect the Company’s legitimate business interests.
CALIFORNIA ADDENDUM
No. 1:
The covenants in paragraph 2 “Non-Competition” apply during my employment with the Company, but do not apply post-employment, during such time(s) that I primarily reside and work in California.
No. 2:
The covenants in paragraph 3 “Non-Solicitation” apply during my employment with the Company, but do not apply post-employment, during such time(s) that I primarily reside and work in California.
No. 3:
Paragraph 5 “Non-Disparagement” is stricken and replaced with the following:
During my employment with the Company and thereafter, I agree not to make negative comments or otherwise disparage the Company or any of its officers, directors, employees, shareholders, members, agents or products, except as otherwise allowed by law, including California Government Code Section 12964.5.
No. 4:
Paragraph 6 “Intellectual Property” is supplemented with the following language:
The terms of this Non-Compete Agreement requiring disclosure and assignment of inventions to the Company do not apply to any invention that qualifies fully under California Labor Code Section 2870, which reads:
(a)    Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:
(1)  Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or
17




(2)  Result from any work performed by the employee for the employer.
(b)    To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.
While employed, I will advise the Company promptly in writing of any inventions that I believe meet the criteria in California Labor Code Section 2870 for a confidential ownership determination.
No. 5:
Paragraph 9 “Enforceability; General Provisions”, subparagraph (c) by this Addendum shall substitute “California” for “Delaware” with respect to the choice of law and forum, during such time(s) that I primarily reside and work in California.
ILLINOIS ADDENDUM
Addendum No. 1:

A new Section 9(a)(i) is added as follows:

Effective if I sign this Non-Compete Agreement after January 1, 2022, I understand that (A) the non-competition obligations under Section 2 do not apply to me if I do not earn the statutory minimum compensation set by Illinois statute (e.g., between January 1, 2021 and January 2, 2027, the statutory threshold is $75,000 per year or less); and (B) the non-solicitation obligations under Section 3 do not apply to me if I do not earn the statutory minimum compensation set by Illinois statute (e.g., between January 1, 2022 and January 2, 2027, the statutory threshold is $45,000 per year or less).

Addendum No. 2:

    A new Section 9(a)(ii) is added as follows:

I agree that before being required to sign this Non-Compete Agreement, the Company provided me with at least fourteen (14) calendar days to review it. The Company also hereby advises me to consult with an attorney before entering into this Non-Compete Agreement.

LOUISIANA ADDENDUM
No. 1:
The definition of “Responsibilities” in paragraph 2 is stricken and replaced with the following:
For purposes of this Non-Compete Agreement, “Responsibilities” means the same or similar material responsibilities I performed for the Company, including my representation of the Company or my business contact with Restricted Customers, during the two (2) years prior to my last day of employment with the Company and within the Restricted Area, or portion thereof, where I performed those responsibilities for the Company. “Restricted Area” means the Louisiana Parishes that the Company identifies in separate written amendment(s) in the form set forth in Schedule A to this Addendum, including at the time of entering into this Non-Compete Agreement. The Parishes include certain of the following:
18




Acadia Parish, Allen Parish, Ascension Parish, Assumption Parish, Avoyelles Parish, Beauregard Parish, Bienville Parish, Bossier Parish, Caddo Parish, Calcasieu Parish, Caldwell Parish, Cameron Parish, Catahoula Parish, Claiborne Parish, Concordia Parish, DeSoto Parish, East Baton Rouge Parish, East Carroll Parish, East Feliciana Parish, Evangeline Parish, Franklin Parish, Grant Parish, Iberia Parish, Iberville Parish, Jackson Parish, Jefferson Parish, Jefferson Davis Parish, Lafayette Parish, Lafourche Parish, LaSalle Parish, Lincoln Parish, Livingston Parish, Madison Parish, Morehouse Parish, Natchitoches Parish, Orleans Parish, Ouachita Parish, Plaquemines Parish, Pointe Coupee Parish,  Rapides Parish, Red River Parish, Richland Parish, Sabine Parish, St. Bernard Parish, St. Charles Parish, St. Helena Parish, St. James Parish, St. John the Baptist Parish, St. Landry Parish, St. Martin Parish, St. Mary Parish, St. Tammany Parish, Tangipahoa Parish, Tensas Parish, Terrebonne Parish, Union Parish, Vermilion Parish, Vernon Parish, Washington Parish, Webster Parish, West Baton Rouge Parish, West Carroll Parish, West Feliciana Parish, and Winn Parish, all so long as the business of the Company is transacted therein. I hereby stipulate that the Company does business in certain of the aforementioned parishes, counties, and municipalities as of the date of this Addendum. I also understand that the Company serves those counties of the adjacent states that border the State of Louisiana and that I will equally be bound in those geographic areas where I also perform responsibilities for the Company.
I acknowledge that the Company’s business and my Responsibilities for the Company are expanding. Accordingly, I agree that the Company may amend the Restricted Area by way of separate written amendment(s) in the form set forth in Schedule A to this Addendum specifying new or additional parishes and counties. Any such separate written amendment(s) shall have the same force and effect as if the amendment(s) were originally a part of, or such parishes and counties were originally listed in, this Addendum. The Company will provide me with any and all amendments that amend the Restricted Area. I agree that if the Company provides me with an amendment that amends the Restricted Area that it will represent as fact that the Company does business in all of the geographical areas identified in such an exhibit.

No. 2:
The first sentence of paragraph 3(a) is stricken and replaced with the following
I will not directly or indirectly, solicit any Restricted Customer within in the Restricted Area, as defined in paragraph 2, for purposes of providing Competing Products or Services, or offer, provide or sell Competing Products or Services to any Restricted Customer within the Restricted Area.
No. 3:    
The first sentence of paragraph 9(c) is stricken and replaced with the following:
The interpretation, validity, and enforcement of this Non-Compete Agreement will be governed by the laws of the State of Louisiana, without regard to any conflicts of law principles that require the application of the law of another jurisdiction.
*    *    *

SCHEDULE A TO LOUISIANA ADDENDUM – FORM OF AMENDMENT
AMENDMENT NO. 1 TO THE LOUISIANA ADDENDUM

19




The parties agree that this Amendment No. 1 to the Louisiana Addendum (“First Amendment”) shall modify the term “Restricted Area” contained in the Louisiana Addendum to the Walgreens Boots Alliance, Inc. Non-Competition, Non-Solicitation and Confidentiality Agreement (the “Non-Compete Agreement”). This First Amendment shall be read in conjunction with the rest of the Non-Compete Agreement and the Louisiana Addendum and enforced to the fullest extent permissible to protect the Company’s legitimate business interests.
    With respect to Louisiana Parishes, I agree that the Restricted Area shall include the following Parishes (IN BOLD OR CIRCLED) where the Company does business and I am performing Responsibilities for the Company: Acadia Parish, Allen Parish, Ascension Parish, Assumption Parish, Avoyelles Parish, Beauregard Parish, Bienville Parish, Bossier Parish, Caddo Parish, Calcasieu Parish, Caldwell Parish, Cameron Parish, Catahoula Parish, Claiborne Parish, Concordia Parish, DeSoto Parish, East Baton Rouge Parish, East Carroll Parish, East Feliciana Parish, Evangeline Parish, Franklin Parish, Grant Parish, Iberia Parish, Iberville Parish, Jackson Parish, Jefferson Parish, Jefferson Davis Parish, Lafayette Parish, Lafourche Parish, LaSalle Parish, Lincoln Parish, Livingston Parish, Madison Parish, Morehouse Parish, Natchitoches Parish, Orleans Parish, Ouachita Parish, Plaquemines Parish, Pointe Coupee Parish,  Rapides Parish, Red River Parish, Richland Parish, Sabine Parish, St. Bernard Parish, St. Charles Parish, St. Helena Parish, St. James Parish, St. John the Baptist Parish, St. Landry Parish, St. Martin Parish, St. Mary Parish, St. Tammany Parish, Tangipahoa Parish, Tensas Parish, Terrebonne Parish, Union Parish, Vermilion Parish, Vernon Parish, Washington Parish, Webster Parish, West Baton Rouge Parish, West Carroll Parish, West Feliciana Parish, and Winn Parish, all so long as the business of the Company is transacted therein. I hereby continue to stipulate that the Company does business in all of the above bolded or circled parishes, counties, and municipalities as of the date of this Addendum. I also understand that the Company serves those counties of the adjacent states that border the State of Louisiana and that I will equally be bound in those geographic areas where I also perform responsibilities for the Company.
By my signature below, I agree to the terms and conditions expressed in this Amendment No. 1 to the Louisiana Addendum.
EmployeeWalgreens Boots Alliance, Inc.

By:                        

Name:                        

Dated:                        

By:                        

Name:                        

Title:                        

Dated:                         
 

MASSACHUSETTS ADDENDUM
No. 1:
Paragraph 2 “Non-Competition” is stricken and replaced with the following:
2.    Non-Competition. In exchange for the Company providing me the consideration set forth in the Non-Compete Agreement, I agree that during my employment and for a period of one (1) year from the Termination Date – i.e., the date of my voluntary termination of employment, or of the involuntary termination of my employment with Cause (as defined below) – I will not, directly or indirectly, engage in “Competition” (as defined below) within the “Geographic Region” (as defined below).
(a)    “Cause” means misconduct, violation of any policy of the Company, including any rule of conduct or standard of ethics of the Company, breach of the Non-Compete Agreement (including this Addendum) or the breach of any confidentiality, non-disclosure, non-solicitation or assignment of inventions obligations to the Company, failure to meet the Company’s reasonable performance expectations, or other grounds directly and reasonably related to the legitimate business needs of the Company.
20




(b)    “Competing Business” means a business that is in competition with any business engaged in by the Company.
(c)    “Competition” means to provide the same or substantially similar services to a Competing Business as those that I provided to the Company during the last two (2) years of my employment with the Company. “Competition” does not include passive investments of less than five percent (5%) ownership interest in any entity.
(d)    “Geographic Region” means the geographic area in which I, during any time within the last two years of my employment with the Company, provided services or had a material presence or influence.
(e)    If the Company enforces the restrictions in this paragraph 2 for a period of time after the Termination Date (the “Restraint Period”), it will pay me, during the Restraint Period, an amount equal to fifty percent (50%) of my annual base salary. My annual base salary, for the purposes of this paragraph 2(e), will be calculated based on my average annual salary for my last two (2) years of employment, less any applicable deductions, and excluding any incentive compensation, bonuses, benefits, or other compensation, less any applicable deductions (the “Restraint Payment”). The Restraint Payment will be paid on a pro-rata basis during the Restraint Period in the same manner that I would have received wages from the Company had I been employed during the Restraint Period.
(f)    The Restraint Period shall be extended from one (1) year following the Termination Date to two (2) years following the Termination Date if I (i) breached Employee’s fiduciary duty(ies) to the Company, or (ii) unlawfully took, physically or electronically, property belonging to the Company. In the event that the Restraint Period is extended due to my breach of my fiduciary duty(ies) to the Company, or due to my having unlawfully taken, physically or electronically, property belonging to the Company, the Company shall not be required to provide payments to me during the extension of the Restraint Period.
(g)    I understand that if the Company elects to waive the non-competition provisions set forth herein, I will not receive any compensation or consideration described in paragraph 2(e). I further understand that at the time of my separation from employment, the Company shall elect whether to waive its enforcement of the non-competition provisions in the Non-Compete Agreement (including this Massachusetts Addendum). I will be notified by the Company of its election or waiver by letter, in the form set forth in the below Schedule A to this Massachusetts Addendum.
(h)    If I was already employed by the Company on the date of my signature on the Non-Compete Agreement, I acknowledge that the Non-Compete Agreement, including this Massachusetts Addendum, was delivered to me at least ten (10) business days before the date that this Addendum was executed by both of the parties (the “Effective Date”). If I was not already employed by the Company on the date of the my signature on the Non-Compete Agreement, I acknowledge that the Non-Compete Agreement, including this Massachusetts Addendum, was delivered to me (i) before a formal offer of employment was made by the Company, or (ii) ten (10) business days before the commencement of my employment with the Company, whichever was earlier.
(i)    I acknowledge that I have been advised of my right to consult with counsel of my own choosing prior to signing the Non-Compete Agreement and this Massachusetts Addendum. By signing the Non-Compete Agreement and this Addendum, I acknowledge that I had time to read and understand the terms of
21




the Non-Compete Agreement and this Addendum, and to consult with my own legal counsel, not including counsel for the Company, regarding the Non-Compete Agreement and the Addendum prior to their execution. I agree that I have actually read and understand the Non-Compete Agreement and this Addendum and all of their terms, and that I am entering into and signing the Non-Compete Agreement and this Addendum knowingly and voluntarily, and that in doing so I am not relying upon any statements or representations by the Company or its agents.
(j)    I acknowledge that (i) the Non-Competition covenant contained in this paragraph 2 is no broader than necessary to protect the Company’s trade secrets, Confidential Information, and goodwill, and (ii) the business interests identified in the Non-Compete Agreement cannot be adequately protected through restrictive covenants other than the Non-Competition covenant contained in this paragraph 2, including without limitation the non-solicitation and non-disclosure restrictions set forth in the Non-Compete Agreement.
No. 2:
Paragraph 9(b) “Enforceability; General Restrictions” is stricken and replaced with the following:
I agree that the restrictions contained in this Non-Compete Agreement are reasonable and necessary to protect the Company’s legitimate business interests and that full compliance with the terms of this Non-Compete Agreement will not prevent me from earning a livelihood following the termination of my employment, and that these covenants do not place an undue restraint on me. I further understand that the restrictions in this Non-Compete Agreement – other than the non-competition restrictions set forth in paragraph 2 – apply no matter whether my employment is terminated by the Company or me and no matter whether that termination is voluntary or involuntary. I understand that the non-competition provisions in paragraph 2 apply following the voluntary termination of my employment or the involuntary termination of my employment for Cause, as defined in paragraph 2, unless the Company elects to waive the non-competition provisions of [paragraph 2 as set forth in subparagraph 2(g).
No. 3:
Paragraph 9c) “Enforceability; General Restrictions” is stricken and replaced with the following:
(c)(i)  Because the Company is incorporated in Delaware, except with respect to the non-competition provisions of paragraph 2, this Non-Compete Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any conflict of law provisions, and I consent to personal jurisdiction and the exclusive jurisdiction of the state and federal courts of Delware with respect to any claim, dispute, or declaration – other than a claim, dispute, or declaration arising out of paragraph 2 – that arises out of this Non-Compete Agreement.
(c)(ii)  The interpretation, validity, and enforcement of the non-competition provisions set forth in paragraph 2 of this Non-Compete Agreement and Massachusetts Addendum will be governed by the laws of the Commonwealth of Massachusetts, without regard to any conflicts of laws principles that would require the application of the law of another jurisdiction. The parties agree that any action relating to or arising out of the non-competition provisions shall be brought in (1) the United States District Court for the District of Massachusetts,
22




Eastern Division, if that Court has subject matter jurisdiction over the dispute; or, if it does not, in (2) the Business Litigation Session of the Suffolk County Superior Court, or, if the Business Litigation Session does not accept the case for whatever reason whatsoever, the Suffolk County Superior Court. The parties agree and consent to the personal jurisdiction and venue of the federal or state courts of Massachusetts for resolution of any disputes or litigation arising under or in connection with the Non-Competition provisions set forth in paragraph 2 of this Non-Compete Agreement and Massachusetts Addendum, and waive any objections or defenses to personal jurisdiction or venue in any such proceeding before any such court.
No. 4:
Paragraph 9(m) “Enforceability; General Restrictions” is stricken and replaced with the following:
I agree that all non-solicitation, non-disclosure and use, non-recruiting, and disclosure obligations in this Non-Compete Agreement shall survive any termination of this Agreement and extend to the proscribed periods following my last day of employment with the Company (for any reason) and no dispute regarding any other provisions of this Non-Compete Agreement or regarding my employment or the termination of my employment shall prevent the operation and enforcement of these obligations. I further agree that all non-competition obligations in this Non-Compete Agreement shall survive the voluntary termination of my employment or the involuntary termination of my employment for Cause, as defined in paragraph 2, unless the Company elects to waive the non-competition provisions of paragraph 2 as set forth in subparagraph 2(g), and no dispute regarding any other provisions of this Non-Compete Agreement or regarding my employment or the termination of my employment shall prevent the operation and enforcement of these obligations.
*    *    *

SCHEDULE A TO MASSACHUSETTS ADDENDUM – FORM OF AGREEMENT
SCHEDULE A TO MASSACHUSETTS ADDENDUM

_____________ (the “Hiring Entity”), Walgreens Boots Alliance, Inc., and any subsidiaries, affiliates, or divisions, direct or indirect predecessors, successors, parents, business units or affiliated companies of Walgreens Boots Alliance, Inc. to which I, directly in succession after the Hiring Entity, transfer or accept employment (each a “Company Entity” and collectively with the Hiring Entity, the “Company”), pursuant to the Massachusetts Addendum to the Walgreens Boots Alliance, Inc. Non-Competition, Non-Solicitation, and Confidentiality Agreement between the Company and the undersigned Employee (the “Non-Compete Agreement”), in its sole discretion, elects to:
image_01.jpgEnforce the one year Restraint Period according to paragraph 2 the Addendum. As agreed to by the Parties, the Company agrees to pay me the amounts described in paragraph 2 of the Massachusetts Addendum.
image_01.jpgWaive enforcement of the Restraint Period. I shall not receive any compensation or consideration pursuant to paragraph 2 the Massachusetts Addendum.
Regardless of the election or waiver, I remain bound by all other terms of the Non-Compete Agreement, and also remain bound by the terms of any and all other agreements between the Company and me.
23




Accepted and agreed to:
EmployeeWalgreens Boots Alliance, Inc.

By:                        

Name:                        

Dated:                        

By:                        

Name:                        

Title:                        

Dated:                         
 


24




NEBRASKA ADDENDUM

No. 1:

The obligations under paragraph 2 “Non-Competition” do not apply to me during such time(s) that I primarily reside and work in Nebraska, but do apply, as stated, to other competitive activity.

No. 2:

    The obligations under paragraph 3 “Non-Solicitation” are strictly limited to those current and existing Restricted Customers or employees with whom I actually did business and had direct, personal contact while employed by the Company.
    All other covenants, agreements and promises contained in the Non-Compete Agreement remain in full force and effect and still apply to Nebraska employees doing business inside and outside of Nebraska.

OKLAHOMA ADDENDUM

No. 1:
The covenants in paragraph 2 “Non-Competition” do not apply to me during such time(s) that I primarily reside and work in Oklahoma.
No. 2:
Paragraph 3 “Non-Solicitation” is stricken and replaced with the following:
I covenant and agree that for a period of twelve (12) months after my employment with the Company ends (for any reason), I will not directly solicit the sale of goods, services or a combination of goods and services from the established customers of the Company.

PUERTO RICO ADDENDUM
No. 1:
Paragraphs 2 and 3 are stricken and replaced by the following covenants and definitions:
“Similar Business” means the same or substantially the same business activity or activities performed or engaged by me for, or on behalf, of the Business of the Company or one of its subsidiaries or affiliated companies.
“Engage” means participate in, consult with, be employed by, or assist with the organization, policy making, ownership, financing, management, operation or control of any Similar Business in any capacity (i.e., as an independent contractor, consultant, employee, shareholder, member-owner, or business partner).
“Goodwill” means any tendency of customers, distributors, representatives, employees, vendors, suppliers, or federal, state, local or foreign governmental entities to continue or renew any valuable business relationship with the Company or any Similar Business with which I may be associated, based in whole or in part on past successful relationships with the Company or the lawful efforts of the Company to foster such relationships, and in which I actively
25




participated at any time during the most recent twelve (12) months of my employment.
“Competing Business” means any individual (including me), corporation, limited liability company, partnership, joint venture, association, or other entity, regardless of form, that is directly engaged in whole or in relevant part in any business or enterprise that is the same as, or substantially the same as, that part of the Company for which I provided services during the last two (2) years of my employment, or that is taking material steps to engage in such business.
“Customers” means those individuals, companies, or other entities for which the Company has provided or does provide products or services in connection with the business of the Company, or those individuals, companies, or other entities to which the Company has provided written proposals concerning the business of the Company in the two (2) year period preceding the termination of my employment.
“Restricted Territory” means those municipalities within the Commonwealth of Puerto Rico in which I performed the Competing Business.
Non-Competition.  I acknowledge and agree that the Company would be irreparably damaged if I – in any capacity (i.e., as an independent contractor, consultant, employee, shareholder, member, owner or business partner) – were to provide services to any person directly or indirectly competing with the Company or any of its affiliates or Engaged in a Competing Business and that such competition by me would result in a significant loss of Goodwill by the Company. Therefore, I agree that the following are reasonable restrictions and agree to be bound by such restrictions:
(a)    During my employment, and for a period of twelve (12) months immediately following the termination of such employment for any reason, I shall not, directly or indirectly – in any capacity (i.e., as an independent contractor, consultant, employee, shareholder, member, owner or business partner) – Engage in Competing Business services or activities within the Restricted Territory; provided, that nothing herein shall prohibit me from being a passive owner of not more than five percent (5%) of the outstanding stock of any class of a corporation which is publicly traded so long as I do not have any active participation in the business of such corporation.
(b)    I warrant and represent that the nature and extent of this non-competition clause has been fully explained to me by the Company and that my decision to accept the same is made voluntarily, knowingly, intelligently and free from any undue pressure or coercion. I further warrant and represent that I have agreed to this non-competition clause in consideration of the Restricted Stock Units I will be receiving under this Non-Compete Agreement.
Non-Solicitation of Customers I agree that for a period of twelve (12) months following the voluntary or involuntary termination of my employment for any reason, I will not, either on my own behalf or for any Competing Business, directly or indirectly solicit, divert, or appropriate (or attempt to solicit, divert, or appropriate) any Customer with which I had material business contact in the six (6) month period preceding the termination of my employment, for providing products or services that are the same as or substantially similar to those provided by the Company.
26




Non-Solicitation of Employees.  I recognize and admit that the Company has a legitimate business interest in retaining its employees, representatives, agents and/or consultants and of protecting its business from previous employees, representatives, agents and/or consultants, which makes necessary the establishment of a non-solicitation clause in this Non-Compete Agreement. I agree that for a period of twelve (12) months following the voluntary or involuntary termination of my employment for any reason, I shall not, directly or indirectly, (a) induce or attempt to induce any employee, representative, agent or consultant of the Company or any of its affiliates or subsidiaries to leave the employ or services of the Company or any of its affiliates or subsidiaries, or in any way interfere with the relationship between the Company or any of its affiliates or subsidiaries and any employee, representative, agent or consultant thereof or (b) hire any person who was an employee, representative, agent or consultant of the Company or any of its affiliates or subsidiaries at any time during the twelve (12) month period immediately prior to the date on which such hiring would take place. No action by another person or entity shall be deemed to be a breach of this provision unless I directly or indirectly assisted, encouraged or otherwise counseled such person or entity to engage in such activity.
No. 2:
Subparagraph 9(c) “Enforceability; General Restrictions” is modified to add the following choice of law:
The laws of Puerto Rico will govern the interpretation, validity, and enforcement of the non-competition provisions set forth in paragraph 2 of this Non-Compete Agreement and Puerto Rico Addendum.
No. 3:
Subparagraph 9(e), subparagraph 9(f), and subparagraph 9(k)Enforceability; General Restrictions” are stricken.

SOUTH CAROLINA ADDENDUM
No. 1:
The definition of “Confidential Information” in paragraph 1 is further limited to that Confidential Information I learn about or am exposed to through my employment with the Company.
No. 2:
Paragraphs 2 and 3 of the Non-Compete Agreement are replaced by the following covenants and definitions:
“Competing Business” means any individual (including me), corporation, limited liability company, partnership, joint venture, association, or other entity, regardless of form, that is directly engaged in whole or in relevant part in any business or enterprise that is the same as, or substantially the same as, that part of the Company for which I provided services during the last two (2) years of my employment, or that is taking material steps to engage in such business.
“Customers” means those individuals, companies, or other entities for which the Company has provided or does provide products or services in connection with the business of the Company, or those individuals, companies, or other entities to which the Company has provided written proposals concerning the business of
27




the Company in the two (2) year period preceding the termination of my employment.
“Restricted Territory” means:
1) the counties or areas where I worked for the Company or had material business contact with the Customers in the two (2) year period preceding the termination of my employment with the Company: and/or
2) the geographic territory in which I worked for the Company, represented the Company, or had material business contact with the Customers in the two (2) year period preceding the termination of my employment with the Company.
I agree that subsections 1) and 2) above are separate and severable covenants.
Non-Competition. I agree that for a period of one (1) year following the voluntary or involuntary termination of my employment for any reason, I will not, directly or indirectly, own, manage, operate, join, control, be employed by or with, or participate in any manner with a Competing Business anywhere in the Restricted Territory where doing so will require me to provide the same or substantially similar services to any such Competing Business as those that I provided to the Company during the last two (2) years of my employment.
Non-Solicitation of Customers. I agree that for a period of two (2) years following the voluntary or involuntary termination of my employment for any reason, I will not, either on my own behalf or for any Competing Business, directly or indirectly solicit, divert, or appropriate, or attempt to solicit, divert, or appropriate any Customer with which I had material business contact in the two (2) year period preceding the termination of my employment, for the purposes of providing products or services that are the same as or substantially similar to those provided by the Company.
VIRGINIA ADDENDUM
No. 1:
    The geographic scope in paragraph 2 “Non-Competition” is limited to twenty-five (25) miles from any location where I physically worked and performed Responsibilities for the Company.

No. 2:

Paragraph 2 “Non-Competition” and paragraph 3 “Non-Solicitation” shall not apply if, at the time of my termination of employment (for any reason), I am considered a “low-wage employee” pursuant to Virginia Code § 40.1-28.7:8(A), meaning that I earn less than the average weekly wage of the Commonwealth of Virginia as determined by subsection B of Virginia Code § 65.2-500.

No. 3:

Paragraph 3(b)(i) “Non-Solicitation” shall be amended to provide: “ (i) raid, solicit, or attempt to persuade any then-current employee of the Company with whom I currently work or
28




with whom I had direct contact work during the two years prior to my last day of employment with the Company,  and who possesses or had access to Confidential Information of the Company, to leave the employ of the Company and become employed by a person or entity who provides Competing Products or Services.”

WASHINGTON ADDENDUM
No. 1:
Paragraph 2 is stricken and replaced with the following:
Non-Competition.
(a)The non-competition provisions of this paragraph 2 shall only apply when my annualized salaried exceeds the compensation requirements of the Restrictions on Noncompetition Covenants Bill 5478 as codified in RCW 49.
(b)I agree that during my employment with the Company and for one (1) year after the termination of my employment for any reason, I will not, directly or indirectly, engage in Competing Services with respect to any Competing Business Line. As set forth in paragraph 10(a) below, I understand that the restrictions in this paragraph apply no matter whether my employment is terminated by me or the Company and no matter whether that termination is voluntary or involuntary. The above restrictions shall not apply to passive investments of less than five percent (5%) ownership interest in any entity. For purposes of this Non-Compete Agreement, “Competing Business Line” means any business that is in competition with any business engaged in by the Company and for which I performed Competing services during the two (2) years prior to my last day of employment with the Company. For purposes of this Non-Compete Agreement, “Competing Services” means the same or similar responsibilities I performed for the Company during the two (2) years prior to my last day of employment with the Company and within the same geographic scope, or portion thereof, with respect to which I performed those responsibilities for the Company.
(c)I agree that, if and after my employment with the Company ends because of or in connection with a layoff or reduction-in-force, the non-competition provisions of paragraph 2(a) above will not be enforced by the Company unless and to the extent that it pays me an amount that is equal to or greater than my base salary rate that is in effect on the last day of my employment with the Company. Such payments will be made to me at regular payroll intervals for the duration of the one (1) year post-employment non-competition period or such shorter period during which the Company enforces these non-competition provisions. I agree that I must promptly inform the Company of the date on which I begin any other employment or engagement by, with or for the benefit of any other individual or entity, at which time I agree the Company may and will terminate all such payments to me. Although such payments by the Company will terminate when I commence employment or any other engagement by, with or for the benefit of another individual, entity or employer, I agree that the paragraph 2(a) non-competition restrictions will remain in effect until one (1) year after my Company employment ends. I also agree that if I fail to timely notify the Company of any other employment or engagement, and if the Company’s payments to me therefore continue after I have commenced any such employment or engagement, then any such payments to me will be deemed to be placed by me in constructive trust for the benefit of the Company, and I agree that I must and will promptly return all such payments to the Company.
29




No. 2:
Subparagraph 9(c) of the Non-Compete Agreement is stricken and replaced with the following:
This Non-Compete Agreement shall be governed by and construed in accordance with the laws of the State of Washington without giving effect to any conflict of law provisions. Any claim, dispute or declaration arising out of or in connection with this Non-Compete Agreement will be resolved exclusively in the state or federal courts in the State of Washington.
WISCONSIN ADDENDUM
No. 1:
Paragraph 1 “Confidentiality” is amended by adding the following at the end of Paragraph 1(b):
To the extent the above obligation of non-use and non-disclosure of Confidential Information applies after the termination of my employment and to Confidential Information that does not meet the definition of a trade secret under applicable law, it shall apply only for two years after the termination of my employment and only in geographic areas in which the unauthorized use or disclosure of such Confidential Information would be competitively damaging to the Company.
No. 2:
Paragraph 2 “Non-Competition” is amended by striking the definition of “Responsibilities” and replacing it with the following:
“Responsibilities” means the same or similar responsibilities I performed for the Company during the two (2) years prior to my last day of employment with the Company in which the Confidential Information I have would be competitively valuable and within the same geographic scope, or portion thereof, with respect to which I performed those responsibilities for the Company.
No. 3:
Paragraph 3 “Non-Solicitation” is amended by stricking the definition of “Restricted Customer” in paragraph 3(a) and replacing it with the following:
“Restricted Customer” means any person, company or entity that was a customer of the Company and with which I had direct contact for purposes of performing responsibilities for the Company or for which I had supervisory responsibilities on behalf of the Company, in either case at any time during the two (2) years prior to my last day of employment with the Company.
Paragraph 3(a) is further amended by striking the following sentence:
To the extent permitted by applicable law, Restricted Customer also means any prospective customer(s), vendor(s), supplier(s) or referral source(s) with which I had business contact on behalf of the Company in the twelve (12) months prior to my last day of employment with the Company;
Paragraph 3(b) is amended by replacing it with the following:
I will not, nor will I assist any third party to, directly or indirectly (i) raid, solicit, or attempt to persuade any then-current employee of the Company with whom I currently work or with whom I worked at any point during the two years prior to
30




my last day of employment with the Company, and who possesses or had access to Confidential Information of the Company, to leave the employ of the Company and join a competitor; (ii) interfere with the performance by any such employee of his/her duties for the Company; or (iii) communicate with any such employee for the purposes described in items (i) and (ii) in this subparagraph 3(b). This restriction shall apply in all geographic areas in which the Company does business.
No. 4:
Paragraph 9 “Enforceability, General Provisions” is amended as follows: Paragraph 9(f) is amended by adding the following text to the end of the paragraph:
“The restrictive covenants in this Non-Compete Agreement are intended to be divisible and interpreted and applied independent of each other.”
Paragraph 9(k) is stricken and shall not be applied or referred to.

31




EXHIBIT B
ADDENDUM TO THE
WALGREENS BOOTS ALLIANCE, INC. 2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
In addition to the terms of the Plan and the Agreement, the Award is subject to the following additional terms and conditions to the extent you reside and/or are employed in one of the countries addressed herein. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in this Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock Units and the Plan (or the Company may establish alternative terms as may be necessary or advisable to accommodate your transfer). All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement.
EUROPEAN UNION ("EU") / EUROPEAN ECONOMIC AREA ("EEA") / SWITZERLAND / THE UNITED KINGDOM

Personal Data. The following provision replaces Section 19 of the Agreement in its entirety:
The Company, with its registered address at 108 Wilmot Road, Deerfield, Illinois 60015, U.S.A. is the controller responsible for the processing of your personal data by the Company and the third parties noted below.

(a)Data Collection and Usage. Pursuant to applicable data protection laws, you are hereby notified that the Company collects, processes and uses certain personal information about you for the legitimate purpose of implementing, administering and managing the Plan and generally administering awards; specifically: your name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares or directorships held in the Company, and details of all Restricted Stock Units, any entitlement to shares of Stock awarded, canceled, exercised, vested, or outstanding in your favor, which the Company receives from you or the Employer ("Personal Data"). In granting the Restricted Stock Units under the Plan, the Company will collect, process, use, disclose and transfer (collectively, "Processing") Personal Data for purposes of implementing, administering and managing the Plan. The Company's legal basis for the Processing of Personal Data is the Company's legitimate business interests of managing the Plan, administering employee awards and complying with its contractual and statutory obligations, as well as the necessity of the Processing for the Company to perform its contractual obligations under the Agreement and the Plan. Your refusal to provide Personal Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan. As such, by accepting the Restricted Stock Units, you voluntarily acknowledge the Processing of your Personal Data as described herein.

(b)Stock Plan Administration Service Provider. The Company may transfer Personal Data to Fidelity Stock Plan Services, LLC ("Fidelity"), an independent service provider based, in relevant part, in the United States, which may assist the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Personal Data with another company that serves in a similar manner. The Company's service provider will open an account for you to receive and trade shares of Stock pursuant to the Restricted Stock Units. The Processing of Personal Data will take place through both electronic and non-electronic means. Personal Data will only be accessible by those individuals requiring access to it for purposes of implementing, administering and operating the Plan. When receiving your Personal Data, if applicable, Fidelity provides appropriate safeguards in accordance with the EU Standard Contractual Clauses or other appropriate cross-border transfer solutions. By participating in the Plan, you understand that the
32




service provider will Process your Personal Data for the purposes of implementing, administering and managing your participation in the Plan.

(c)International Data Transfers. The Company is based in the United States, which means it will be necessary for Personal Data to be transferred to, and Processed in the United States. When transferring your Personal Data to the United States, the Company provides appropriate safeguards in accordance with the EU Standard Contractual Clauses, and other appropriate cross-border transfer solutions. You may request a copy of the appropriate safeguards with Fidelity or the Company by contacting your Human Resources manager or the Company's Human Resources Department.

(d)Data Retention. The Company will use Personal Data only as long as is necessary to implement, administer and manage your participation in the Plan or as required to comply with legal or regulatory obligations, including tax and securities laws. When the Company no longer needs Personal Data related to the Plan, the Company will remove it from its systems. If the Company keeps Personal Data longer, it would be to satisfy legal or regulatory obligations and the Company's legal basis would be for compliance with relevant laws or regulations.

(e)Data Subject Rights. To the extent provided by law, you have the right to (i) subject to certain exceptions, request access or copies of Personal Data the Company Processes, (ii) request rectification of incorrect Personal Data, (iii) request deletion of Personal Data, (iv) place restrictions on Processing of Personal Data, (v) lodge complaints with competent authorities in your country, and/or (vi) request a list with the names and addresses of any potential recipients of Personal Data. To receive clarification regarding your rights or to exercise your rights, you may contact your Human Resources manager or the Company's Human Resources Department. You also have the right to object, on grounds related to a particular situation, to the Processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting your Human Resources manager or the Company's Human Resources Department in writing. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to administer the Restricted Stock Units, or grant other awards or administer or maintain such awards. For more information on the consequences of the refusal to provide Personal Data, you may contact your Human Resources manager or the Company's Human Resources Department in writing. You may also have the right to lodge a complaint with the relevant data protection supervisory authority.

CHILE

    Private Placement. The following provision shall replace Section 14 of the Agreement:

The grant of the Restricted Stock Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be a private placement.
a)The starting date of the offer will be the Grant Date, and this offer conforms to general ruling no. 336 of the Chilean Commission for the Financial Market;
b)The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;
c)The issuer is not obligated to provide public information in Chile regarding the foreign securities, since such securities are not registered with the Chilean Commission for the Financial Market; and
d)The foreign securities shall not be subject to public offering as long as they are not registered with the corresponding registry of securities in Chile.
a)La fecha de inicio de la oferta será el de la fecha de otorgamiento y esta oferta se acoge a la norma de carácter general n° 336 de la Comisión para el Mercado Financiero en Chile;
33




b)La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la Comisión para el Mercado Financiero en Chile, por lo que tales valores no están sujetos a la fiscalización de ésta;
c)Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información pública respecto de esos valores; y
d)Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente

GERMANY

No country-specific provisions.

HONG KONG

1.Form of Payment. Notwithstanding any provision in the Agreement or Plan to the contrary, the Restricted Stock Units shall be settled only in Shares (and not in cash).

2.IMPORTANT NOTICE. WARNING: The contents of the Agreement, this Addendum, the Plan, the Plan prospectus, the Plan administrative rules and all other materials pertaining to the Restricted Stock Units and/or the Plan have not been reviewed by any regulatory authority in Hong Kong. You are hereby advised to exercise caution in relation to the offer thereunder. If you have any doubts about any of the contents of the aforesaid materials, you should obtain independent professional advice. Neither the grant of the Restricted Stock Units nor the issuance of the shares of Stock upon settlement of the Restricted Stock Units constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Affiliates. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Restricted Stock Units (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Affiliates and may not be distributed to any other person.

3.Wages. The Restricted Stock Units and shares of Stock subject to the Restricted Stock Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

IRELAND

No country-specific provisions.

ITALY

    Plan Document Acknowledgment. In accepting the Restricted Stock Units, you acknowledge that a copy of the Plan was made available to you, and you have reviewed the Plan and the Agreement, including this Addendum, in their entirety and fully understand and accept all provisions of the Plan, the Agreement and the Addendum.

You further acknowledge that you have read and specifically approve the following provisions in the Agreement: Section 3: Restricted Period (terms of lapse of restrictions on Restricted Stock Units); Section 4: Disability or Death (terms of payment of Restricted Stock Units upon a Termination of Service by reason of Disability or death); Section 5: Retirement (terms of payment of Restricted Stock Units upon a Termination of Service by reason of retirement); Section 6: Termination of Service Following a Change in Control (terms of payment of Restricted Stock Units in the event of a Termination of Service following a Change in Control); Section 7: Other Termination of Service (forfeiture of Restricted Stock Units in other cases of Termination of Service); Section 10(a): Responsibility for Taxes; Tax Withholding (liability for all Tax-Related Items related to the Restricted Stock Units and legally applicable to the participant); Section 11: Nontransferability (Restricted Stock Units shall not be sold, transferred, pledged,
34




assigned or otherwise alienated or hypothecated); Section 18: Change in Stock (right of the Company to equitably adjust the number of Restricted Stock Units subject to this Agreement in the event of any change in Stock); Section 19(j): Nature of the Award (waive any claim or entitlement to compensation or damages arising from forfeiture of the Restricted Stock Units resulting from a Termination of Service); Section 19(l): Nature of the Award (the Company is not liable for any foreign exchange rate fluctuation impacting the value of the Restricted Stock Units); Section 20: Committee Authority; Recoupment (right of the Committee to administer, construe, and make all determinations necessary or appropriate for the administration of the Restricted Stock Units and this Agreement, including the enforcement of any recoupment policy); Section 21: Non-Competition, Non-Solicitation and Confidentiality (the receipt of the Award is conditioned upon agreement to the Non-Competition, Non-Solicitation and Confidentiality Agreement attached hereto as Exhibit A); Section 23: Addendum to Agreement (the Restricted Stock Units are subject to the terms of the Addendum); Section 24: Additional Requirements (Company right to impose additional requirements on the Restricted Stock Units in case such requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate operation and administration of the Restricted Stock Units and the Plan); Section 26: Electronic Delivery (Company may deliver documents related to the Award or Plan electronically); Section 27: Governing Law and Jurisdiction (Agreement is governed by Illinois law without regard to any choice of law rules thereof; agreement to exclusive jurisdiction of Illinois courts); Section 28: English Language (documents will be drawn up in English; if a translation is provided, the English version controls); and the provision titled “Personal Data” under the heading "European Union (‘EU’) / European Economic Area (‘EEA’) / Switzerland / the United Kingdom", included in this Addendum.

MEXICO

1.Commercial Relationship. You expressly recognize that your participation in the Plan and the Company's grant of the Restricted Stock Units does not constitute an employment relationship between you and the Company. You have been granted the Restricted Stock Units as a consequence of the commercial relationship between the Company and the Affiliate in Mexico that employs you ("WBA Mexico"), and WBA Mexico is your sole employer. Based on the foregoing, you expressly recognize that (a) the Plan and the benefits you may derive from your participation in the Plan do not establish any rights between you and WBA Mexico, (b) the Plan and the benefits you may derive from your participation in the Plan are not part of the employment conditions and/or benefits provided by WBA Mexico, and (c) any modifications or amendments of the Plan by the Company, or a termination of the Plan by the Company, shall not constitute a change or impairment of the terms and conditions of your employment with WBA Mexico.

2.Extraordinary Item of Compensation. You expressly recognize and acknowledge that your participation in the Plan is a result of the discretionary and unilateral decision of the Company, as well as your free and voluntary decision to participate in the Plan in accordance with the terms and conditions of the Plan, the Agreement and this Addendum. As such, you acknowledge and agree that the Company, in its sole discretion, may amend and/or discontinue your participation in the Plan at any time and without any liability. The Award, the shares of Stock subject to the Award and the income and value of the same is an extraordinary item of compensation outside the scope of your employment contract, if any, and is not part of your regular or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits, or any similar payments, which are the exclusive obligations of WBA Mexico.

3.Securities Law Notification. The Restricted Stock Units and shares of Stock offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, this Agreement and any other document relating to the Restricted Stock Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and WBA Mexico and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather
35




constitutes a private placement of securities addressed specifically to individuals who are present employees of WBA Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.

MONACO

    Use of English Language. You acknowledge that it is your express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez avoir expressément exigé la rédaction en anglais de la présente Convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relatifs à, ou suite à, la présente Convention.

SWITZERLAND

    Securities Law Notification. Neither this document nor any other materials relating to the Restricted Stock Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, or approved or supervised by, any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

THAILAND

No country-specific provisions.

UNITED KINGDOM

    1.    Indemnification for Tax-Related Items. Without limitation to Section 10 of the Agreement, you hereby agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, your Employer or by Her Majesty's Revenue & Customs ("HMRC") (or any other tax authority or any other relevant authority). You also hereby agree to indemnify and keep indemnified the Company and your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, if you are a director or executive officer (as within the meaning of Section 13(k) of the Exchange Act), the terms of the immediately foregoing provision will not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit to you on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or your Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or your Employer may recover from you at any time thereafter by any of the means referred to in Section 10 of the Agreement.

    2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Restricted Stock Units, whether or not as a result of your Termination of Service (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Restricted Stock Units. Upon the grant of the Restricted Stock Units, you shall be deemed irrevocably to have waived any such entitlement.

36




*** *** *** *** ***
    By clicking the acceptance box for this grant agreement, I acknowledge receipt of the Restricted Stock Unit Award Agreement to which this Addendum is attached as Exhibit B, and I agree to the terms and conditions expressed in this Addendum.
37
EX-31.1 6 a11302021exhibit311.htm EX-31.1 Document

EXHIBIT 31.1

CERTIFICATION

I, Rosalind G. Brewer, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
/s/Rosalind G. BrewerChief Executive OfficerDate: January 6, 2022
 Rosalind G. Brewer


EX-31.2 7 a11302021exhibit312.htm EX-31.2 Document

EXHIBIT 31.2

CERTIFICATION

I, James Kehoe, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
/s/James KehoeGlobal Chief Financial OfficerDate: January 6, 2022
 James Kehoe


EX-32.1 8 a11302021exhibit321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended November 30, 2021 as filed with the Securities and Exchange Commission (the "Report"), I, Rosalind G. Brewer, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Rosalind G. Brewer
Rosalind G. Brewer
Chief Executive Officer
Dated:  January 6, 2022

A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 9 a11302021exhibit322.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended November 30, 2021 as filed with the Securities and Exchange Commission (the "Report"), I, James Kehoe, Global Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James Kehoe
James Kehoe
Global Chief Financial Officer
Dated:  January 6, 2022

A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 10 wba-20211130.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Accounting policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Discontinued operations link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Discontinued operations (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Discontinued operations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Discontinued operations - Schedules of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Acquisitions - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Exit and disposal activities link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Exit and disposal activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Exit and disposal activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Exit and disposal activities - Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Exit and disposal activities - Restructuring Reserve Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Leases - Supplemental Income Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Leases - Other Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Leases - Average Lease Terms And Discounts (Details) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Leases - Future Lease Payments for Operating and Finance Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Leases - Future Lease Payments for Operating and Finance Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2125106 - Disclosure - Equity method investments link:presentationLink link:calculationLink link:definitionLink 2326305 - Disclosure - Equity method investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2427415 - Disclosure - Equity method investments - Schedule of Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Equity method investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Equity method investments - Summarized Financial Information of Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2130107 - Disclosure - Goodwill and other intangible assets link:presentationLink link:calculationLink link:definitionLink 2331306 - Disclosure - Goodwill and other intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2432418 - Disclosure - Goodwill and other intangible assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - Goodwill and other intangible assets - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details) link:presentationLink link:calculationLink link:definitionLink 2435421 - Disclosure - Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2136108 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2337307 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2438422 - Disclosure - Debt - Short and Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2439423 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2140109 - Disclosure - Financial instruments link:presentationLink link:calculationLink link:definitionLink 2341308 - Disclosure - Financial instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2442424 - Disclosure - Financial instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2143110 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 2344309 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2445425 - Disclosure - Fair value measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2146111 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2147112 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2448426 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2149113 - Disclosure - Retirement benefits link:presentationLink link:calculationLink link:definitionLink 2350310 - Disclosure - Retirement benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 2451427 - Disclosure - Retirement benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2152114 - Disclosure - Accumulated other comprehensive income (loss) link:presentationLink link:calculationLink link:definitionLink 2353311 - Disclosure - Accumulated other comprehensive income (loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2454428 - Disclosure - Accumulated other comprehensive income (loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2155115 - Disclosure - Segment reporting link:presentationLink link:calculationLink link:definitionLink 2356312 - Disclosure - Segment reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2457429 - Disclosure - Segment reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2158116 - Disclosure - Sales link:presentationLink link:calculationLink link:definitionLink 2359313 - Disclosure - Sales (Tables) link:presentationLink link:calculationLink link:definitionLink 2460430 - Disclosure - Sales (Details) link:presentationLink link:calculationLink link:definitionLink 2161117 - Disclosure - Related parties link:presentationLink link:calculationLink link:definitionLink 2362314 - Disclosure - Related parties (Tables) link:presentationLink link:calculationLink link:definitionLink 2463431 - Disclosure - Related parties (Details) link:presentationLink link:calculationLink link:definitionLink 2164118 - Disclosure - New accounting pronouncements link:presentationLink link:calculationLink link:definitionLink 2165119 - Disclosure - Supplemental information link:presentationLink link:calculationLink link:definitionLink 2366315 - Disclosure - Supplemental information (Tables) link:presentationLink link:calculationLink link:definitionLink 2467432 - Disclosure - Supplemental information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2468433 - Disclosure - Supplemental information - Depreciation and Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2469434 - Disclosure - Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2470435 - Disclosure - Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 2471436 - Disclosure - Supplemental information - Summary of Dividends per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 wba-20211130_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 wba-20211130_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 wba-20211130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Hedging Designation [Domain] Hedging Designation [Domain] Unrealized gain (loss) on available for sale securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Long-term debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities Amounts reclassified from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Letter of Credit Letter of Credit [Member] Long-term debt Amount oustanding Long Term Debt Net Discount And Fair Market Value Adjustments Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums and unamortized fair market value adjustments, if any. Trade names and trademarks Trade names and trademarks Trademarks and Trade Names [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. Total Net Income (Loss) Attributable to Parent Consolidated Entities [Axis] Consolidated Entities [Axis] Entity Emerging Growth Company Entity Emerging Growth Company Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Notional Amounts, Fair Value and Balance Sheet Presentation of Derivative Instruments Outstanding Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Gain on sale of equity method investment Equity Method Investment, Realized Gain (Loss) on Disposal Interest costs Defined Benefit Plan, Interest Cost Income Statement Location [Axis] Income Statement Location [Axis] Receivable Type [Axis] Receivable Type [Axis] Acquisition-related costs Business Combination, Acquisition Related Costs Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Others Other Intangible Assets [Member] Derivative liability Derivative Liability Dividends declared and distributions Dividends, Common Stock, Cash Investments in equity securities Equity Securities, FV-NI, Current Consideration from disposal Disposal Group, Including Discontinued Operation, Consideration Fair market value of equity investment Equity Method Investments, Fair Value Disclosure Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Entity Filer Category Entity Filer Category Conversion of Stock [Table] Conversion of Stock [Table] Restructuring Type [Axis] Restructuring Type [Axis] Restructuring Type [Axis] Operating leases Operating Lease, Weighted Average Remaining Lease Term Other non-current assets Other Assets, Noncurrent Components of net periodic benefit costs [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Axis] Expected returns on plan assets/other Defined Benefit Plan, Expected Return (Loss) on Plan Assets Segments [Axis] Segments [Axis] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Conversion of Stock [Line Items] Conversion of Stock [Line Items] Redemption percentage Debt Instrument, Redemption Price, Percentage Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Income taxes Increase (Decrease) in Income Taxes Payable Discontinued operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Amortization of intangible assets Amortization of Intangible Assets Change in Restructuring Liabilities Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other current assets Other Current Assets [Member] Variable Variable Lease, Cost Antidilutive securities excluded from EPS calculations (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Operating leases Operating Lease, Weighted Average Discount Rate, Percent Cost of sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Share of other comprehensive (loss) income of equity method investments Other Comprehensive Income (Loss), Share Of Other Comprehensive Income (Loss) Of Equity Method Investments, After Tax Other Comprehensive Income (Loss), Share Of Other Comprehensive Income (Loss) Of Equity Method Investments, After Tax Total £700 million note issuance Debt Issuance Note Five [Member] This element details information about the total 700 million pounds debt issuance. Business Combination and Asset Acquisition [Abstract] Accounts receivable from related party Accounts Receivable, Related Parties Business Acquisition [Axis] Business Acquisition [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Estimated annual intangible assets amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Share of earnings (loss) from equity method investments Income From Equity Method Investments Income From Equity Method Investments Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Operating lease cost Operating Lease, Cost [Abstract] Operating Lease, Cost Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Financial instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Opiod Litigation Opiod Litigation [Member] Opiod Litigation Total pre-tax exit and disposal charges Restructuring Costs Goodwill and other intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Preferred stock $.01 par value; authorized 32 million shares, none issued Preferred Stock, Value, Issued Summarized Financial Information of Equity Method Investments Equity Method Investments, Summarized Financial Information [Table Text Block] Equity Method Investments, Summarized Financial Information Entity Address, City or Town Entity Address, City or Town Operating Leases: Operating Lease, Assets And Liabilities, Lessee [Abstract] Operating Lease, Assets And Liabilities, Lessee Finance lease, liability, noncurrent, statement of financial position, extensible enumeration Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Retained earnings Retained Earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Other current assets Increase (Decrease) in Prepaid Expense and Other Assets Trade Accounts Receivable Trade Accounts Receivable [Member] Carrying value of long-term notes outstanding Debt Instrument, Fair Value Disclosure 4.650% unsecured notes due 2046 4.650% Notes Payable Due 2046 [Member] A written promise to pay a note to a third party. Non-current liabilities: Liabilities, Noncurrent [Abstract] Trade accounts payable, net Accounts Payable, Related Parties Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Pharmacy licenses Pharmacy Licenses [Member] Pharmacy Licenses given to the company. Other Acquisitions Series of Individually Immaterial Business Acquisitions [Member] 0.9500% Notes Payable, Due 2023 0.9500% Notes Payable, Due 2023 [Member] 0.9500% Notes Payable, Due 2023 Income tax provision Discontinued Operation, Tax Effect of Discontinued Operation Schedule of Redeemable Noncontrolling Interest Temporary Equity [Table Text Block] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Financing cash flows from finance leases Finance Lease, Principal Payments Entity Interactive Data Current Entity Interactive Data Current Value of purchase tender offer Business Acquisition, Value of Common Stock Shares Acquired Business Acquisition, Value of Common Stock Shares Acquired Total (in dollars per share) Earnings Per Share, Basic Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Pension/postretirement obligations Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Sales Revenue from Contract with Customer [Text Block] Sublease income Sublease Income Exit and Disposal Costs Exit And Disposal Costs [Member] Exit And Disposal Costs 2027 Finite-Lived Intangible Asset, Expected Amortization, after Year Five Currency Restructuring Reserve, Foreign Currency Translation Gain (Loss) Document Type Document Type Other expense Disposal Group, Including Discontinued Operation, Other Expense Information Technology Transformation and Other Exit Costs Information technology transformation and other exit costs Information Technology Transformation And Other Exit Costs [Member] Information Technology Transformation And Other Exit Costs Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Reporting Unit [Domain] Reporting Unit [Domain] Cost recognized in the consolidated condensed statements of earnings Defined Contribution Plan, Cost Weighted average remaining lease term in years: Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract] Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Total $1.5 billion note issuance Debt Issuance Note Seven [Member] Debt Issuance Note Seven Diluted net earnings (loss) per common share: Earnings Per Share, Diluted [Abstract] Cash used for investing activities - discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Entity Current Reporting Status Entity Current Reporting Status Adjusted operating income Adjusted Operating Income The total amount of adjusted operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation. Adoption of new accounting standards Adoption of New Accounting Standards Cumulative Effect, Period of Adoption, Adjustment [Member] Post tax earnings from other equity method investments Discontinued Operation, Income (Loss) from Other Equity Method Investments Discontinued Operation, Income (Loss) from Other Equity Method Investments Commercial paper Commercial Paper [Member] Operating cash flows from operating leases Operating Lease, Payments Net change in short-term debt with maturities of 3 months or less Proceeds from (Repayments of) Short-term Debt Other Other Noncash Income (Expense) Fair value, assets Derivative Asset, Fair Value, Gross Asset Adjustments to equity earnings (loss) in AmerisourceBergen Adjustments To Equity Earnings In Equity Investment One Adjustments To Equity Earnings In Equity Investment One Restricted cash Restricted Cash and Cash Equivalents Finance Leases: Finance Lease, Assets And Liabilities, Lessee [Abstract] Finance Lease, Assets And Liabilities, Lessee Share of OCI of equity method investments Accumulated Other Comprehensive Income of Equity Method Investments, Attributable To Parent [Member] Accumulated Other Comprehensive Income of Equity Method Investments, Attributable To Parent [Member] Transformational Cost Management Program Transformational Cost Management Program [Member] Transformational Cost Management Program Cash consideration, subject to purchase price adjustments Cash consideration Business Combination, Consideration Transferred Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Goodwill [Roll Forward] Goodwill [Roll Forward] Reporting Unit [Axis] Reporting Unit [Axis] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Fair value of long-term notes outstanding Long-term Debt Property, plant and equipment, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Level 1 Fair Value, Inputs, Level 1 [Member] Document Transition Report Document Transition Report Weighted average common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Operating lease Lessee, Operating Lease, Liability, Payment, Due [Abstract] Business, investment and asset acquisitions, net of cash acquired Business, Investment and Asset Acquisitions, Net of Cash Acquired The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. This item also includes the cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Average daily short-term borrowings Short-term Debt, Average Outstanding Amount Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities, redeemable noncontrolling interest and equity Liabilities and Equity Receivables Accounts Receivable, after Allowance for Credit Loss Weighted average discount rate: Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Total $4 billion note issuance Debt Issuance Note Two [Member] This element details information about the total $4.0 billion debt issuance. Paid-in capital Additional Paid in Capital Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Liabilities, redeemable noncontrolling interest and equity Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] Expected annual cost savings of restructuring plan Restructuring and Related Cost, Expected Annual Cost Savings Of Restructuring Plan Restructuring and Related Cost, Expected Annual Cost Savings Of Restructuring Plan Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Tax benefit (provision) Reclassification from AOCI, Current Period, Tax Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Impairment of right-of-use assets Operating Lease, Impairment Loss Treasury stock purchases Treasury Stock, Value, Acquired, Cost Method Ownership percentage Equity Method Investment, Ownership Percentage Foreign Plan Foreign Plan [Member] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four Minimum Minimum [Member] Primary care provider network Primary Care Provider Network [Member] Primary Care Provider Network Gross profit Gross profit Gross Profit 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance Sheet Location [Domain] Balance Sheet Location [Domain] Comprehensive (loss) income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Earnings (loss) before interest and tax Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Selling, general and administrative expenses Selling, General and Administrative Expense Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cash consideration for preferred units Business Combination, Cash Transferred for Preferred Units Business Combination, Cash Transferred for Preferred Units Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Leases Lessee, Finance Leases [Text Block] Beginning balance Ending balance Restructuring Reserve Operating income from discontinued operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Other comprehensive income (loss) before reclassification adjustments Other Comprehensive Income (Loss), before Reclassifications, before Tax Trading Symbol Trading Symbol Outstanding equity interest percentage Business Acquisition, Percentage of Voting Interests Acquired Delayed Draw Term Loan Delayed Draw Term Loan Credit Facility [Member] Delayed Draw Term Loan Credit Facility United Kingdom UNITED KINGDOM Business combination Stock Issued During Period, Value, Acquisitions Current liabilities: Liabilities, Current [Abstract] Receivable [Domain] Receivable [Domain] August 2018 Revolving Credit Agreement August 2018 Revolving Credit Agreement [Member] August 2018 Revolving Credit Agreement [Member] Cash consideration, net Payments to Acquire Businesses, Net of Cash Acquired Cumulative translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Debt Debt Disclosure [Text Block] Restructuring Plan [Domain] Restructuring Plan [Domain] 2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility 2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility [Member] 2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility Level 3 Fair Value, Inputs, Level 3 [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Promissory note Business Combination, Consideration Transferred, Other Number of reportable segments Number of Reportable Segments Retirement benefits Postemployment Benefits Disclosure [Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Total operating lease obligations Lease liability Operating Lease, Liability $850 million note issuance Debt Issuance Note Eight [Member] Debt Issuance Note Eight Total Right-of-Use Asset Obtained in Exchange for Lease Liability Right-of-Use Asset Obtained in Exchange for Lease Liability Continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at November 30, 2021 and August 31, 2021 Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Finance leases Finance Lease, Weighted Average Discount Rate, Percent Acquisitions Goodwill, Acquired During Period Basis of presentation Basis of Accounting, Policy [Policy Text Block] Reportable Legal Entities Reportable Legal Entities [Member] International International Reportable Segment [Member] Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity. Commitments and contingencies (see Note 11) Commitments and Contingencies Total non-current assets Assets, Noncurrent Leases Lessee, Operating Leases [Text Block] Transformational cost management Transformational Cost Management Transformational Cost Management Finance lease cost Lessee, Finance Lease, Cost [Abstract] Lessee, Finance Lease, Cost Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Leases, Payments Leases, Payments Amortization Finance Lease, Right-of-Use Asset, Amortization Total €750 million note issuance Debt Issuance Note Six [Member] This element details information about the total 750 million Euros debt issuance. 2022 (Remaining period) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Acquisitions Business Combination Disclosure [Text Block] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Document Period End Date Document Period End Date Goodwill [Line Items] Goodwill [Line Items] Class of Stock [Axis] Class of Stock [Axis] Finance lease, liability, current, statement of financial position, extensible enumeration Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Entity Registrant Name Entity Registrant Name Pharmacy Pharmacy [Member] Pharmacy [Member] 2.125% Walgreens Boots Alliance, Inc. notes due 2026 3.450% unsecured notes due 2026 3.450% Notes Payable, Due 2026 [Member] A written promise to pay a note to a third party. Treasury stock, at cost (in shares) Treasury Stock, Shares Less: Present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Cash used in operating activities - discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Operating Activities [Domain] Operating Activities [Domain] Retail Retail [Member] Later Finance Lease, Liability, to be Paid, after Year Five Comprehensive income: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Boots Reporting Unit Boots Reporting Unit [Member] Boots Reporting Unit Cash dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Accrued expenses and other liabilities Accrued Liabilities, Current Sales Revenue from Contract with Customer, Excluding Assessed Tax Less: Present value discount Finance Lease, Liability, Undiscounted Excess Amount Cash dividends paid Payments of Dividends Fair value of previously held equity interests Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Carrying Value Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Total $8 billion note issuance Debt Issuance Note One [Member] This element details information about the total $8.0 billion debt issuance. Payments Payments for Restructuring 2027 Finance Lease, Liability, to be Paid, Year Five Common Stock, $0.01 par value Common stock Common Stock [Member] Segment reporting Segment Reporting Disclosure [Text Block] Finance leases Finance Lease, Weighted Average Remaining Lease Term Operating income (loss) Operating Income (Loss) Employer cash contributions to defined benefit pension plans Defined Contribution Plan, Employer Discretionary Contribution Amount Operating lease obligations Operating lease obligations - current Operating Lease, Liability, Current Total depreciation and amortization expense Depreciation and Amortization, Continuing Operations Depreciation and Amortization, Continuing Operations 2.125% unsecured Euro notes due 2026 2.125% Notes Payable Due 2026 [Member] A written promise to pay a note to a third party. 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Hedging Designation [Axis] Hedging Designation [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Stock compensation expense Share-based Payment Arrangement, Noncash Expense Exit and disposal activities Restructuring and Related Activities Disclosure [Text Block] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] 3.300% unsecured notes due 2021 3.300% Notes Payable Due 2021 [Member] A written promise to pay a note to a third party. Paid-in capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Changes in cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract] Net earnings attributable to noncontrolling interests - discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Cash and Cash Equivalents [Abstract] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] 4.100% unsecured notes due 2050 4.100% Notes Payable, Due 2050 [Member] 4.100% Notes Payable, Due 2050 Treasury stock amount Treasury Stock [Member] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Less: purchase price for issuance of new preferred units at fair value Business Combination, Consideration Transferred for Preferred Units Business Combination, Consideration Transferred for Preferred Units Other income Other Nonoperating Income (Expense) Other non-current assets and liabilities Increase (Decrease) in Other Operating Liabilities Other Payments for (Proceeds from) Other Investing Activities Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Total liabilities Liabilities Net (loss) Temporary Equity, Net Income 4.400% unsecured notes due 2042 4.400% Notes Payable, Due 2042 [Member] A written promise to pay a note to a third party. Accounts receivable, net Increase (Decrease) in Receivables 2022 (Remaining period) Finite-Lived Intangible Asset, Expected Amortization, Year One Redeemable noncontrolling interest Beginning balance Ending balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Schedule of Aggregate Future Lease Payments Under Operating Leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Consolidation Items [Axis] Consolidation Items [Axis] Total Walgreens Boots Alliance, Inc. shareholders’ equity Stockholders' Equity Attributable to Parent Common stock, issued (in shares) Common Stock, Shares, Issued Preferred stock, issued (in shares) Preferred Stock, Shares Issued Equity method investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Equity earnings (loss) in AmerisourceBergen Income (Loss) From Equity Method Investment One Income (Loss) From Equity Method Investment One 3.100% unsecured notes due 2022 3.100% Notes Payable, Due 2022 [Member] A written promise to pay a note to a third party. Identifiable assets acquired and liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Dividends Payable Schedule of Dividends Payable [Table Text Block] Stock purchases Payments for Repurchase of Common Stock Components of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Debt redeemed Debt Instrument, Repurchase Amount Other Other Short Term Debt [Member] Represents other types of short-term debt arrangements not previously listed in the taxonomy. Fair value of non-controlling interests Business Combination, Step Acquisition, Noncontrolling Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Noncontrolling Interest in Acquiree, Fair Value Balance Sheet Location [Axis] Balance Sheet Location [Axis] Accumulated other comprehensive income (loss) Comprehensive Income (Loss) Note [Text Block] Operating lease obligations Operating lease obligations - non-current Operating Lease, Liability, Noncurrent Delayed Draw Term Loan Credit Facility, Three-Year Facility Delayed Draw Term Loan Credit Facility, Three-Year Facility [Member] Delayed Draw Term Loan Credit Facility, Three-Year Facility Total undiscounted minimum lease payments Finance Lease, Liability, Payment, Due Measurement Frequency [Domain] Measurement Frequency [Domain] Face amount Debt Instrument, Face Amount Interest expense, net Interest Expense Non-current assets: Assets, Noncurrent [Abstract] 2023 Finance Lease, Liability, to be Paid, Year One Total net periodic pension costs (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Discontinued Operations and Disposal Groups [Abstract] City Area Code City Area Code Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Reportable segments Reportable Segments Operating Segments [Member] Term of lease Lessee, Operating Lease, Term of Contract Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Litigation Case [Domain] Litigation Case [Domain] Cash consideration, gross Business Combination, Consideration Transferred, Gross Business Combination, Consideration Transferred, Gross Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Schedule of Identifiable Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Borrowing outstanding Line of Credit Facility, Fair Value of Amount Outstanding Total finance lease obligations Lease liability Finance Lease, Liability Cross currency interest rate swaps Cross Currency Interest Rate Contract [Member] 4.500% unsecured notes due 2034 4.500% Notes Payable, Due 2034 [Member] A written promise to pay a note to a third party. Business Acquisition [Line Items] Business Acquisition [Line Items] Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Equity method investments (see Note 6) Carrying value of equity method investments Equity Method Investments Amendment Flag Amendment Flag Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Weighted average interest rate Short-term Debt, Weighted Average Interest Rate, over Time Total Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Net (loss) earnings attributable to noncontrolling interests - continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 2025 Finance Lease, Liability, to be Paid, Year Three 2026 Finance Lease, Liability, to be Paid, Year Four Other non-current assets Other Noncurrent Assets [Member] 2020 Revolving Credit Agreement, 364-Day Facility 2020 Revolving Credit Agreement, 364-Day Facility [Member] 2020 Revolving Credit Agreement, 364-Day Facility Indefinite-lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Shares issued as part of disposal (in shares) Noncash or Part Noncash Divestiture, Noncash Consideration, Shares Issued Noncash or Part Noncash Divestiture, Noncash Consideration, Shares Issued 2024 Finance Lease, Liability, to be Paid, Year Two Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax provision (benefit) Income Tax Expense (Benefit) Total equity Beginning balance Ending balance Cumulative effect adjustment to decrease retained earnings Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Unsecured Notes Unsecured Debt Unsecured Debt [Member] Proceeds from debt Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Cash paid for amounts included in the measurement of lease obligations: Cash Flow, Lessee [Abstract] Cash Flow, Lessee Selling, general and administrative expense Disposal Group, Including Discontinued Operation, General and Administrative Expense Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total current assets Assets, Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Gains and (losses) due to changes in fair value of derivative instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Total undiscounted minimum lease payments Lessee, Operating Lease, Liability, to be Paid Inventories Inventory, Net Other International Reporting Unit Other International Reporting Unit [Member] Other International Reporting Unit Net investment hedges Other Comprehensive Income (Loss), Net Investment Hedges, After Tax Other Comprehensive Income (Loss), Net Investment Hedges, After Tax Entity File Number Entity File Number Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] United States United States Reportable Segment [Member] Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity. Later Lessee, Operating Lease, Liability, to be Paid, after Year Five Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Product and Service [Axis] Product and Service [Axis] Gross profit Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Entity Small Business Entity Small Business Restructuring Plan [Axis] Restructuring Plan [Axis] Pre-tax gain related to conversion of previously held investment in convertible debt securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Investment Transferred from Available-for-sale to Equity Method, after Tax Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] 3.200% unsecured notes due 2030 3.200% Notes Payable, Due 2030 [Member] 3.200% Notes Payable, Due 2030 Equity Component [Domain] Equity Component [Domain] Gain on sale and leaseback Sale and Leaseback Transaction, Gain (Loss), Net Walgreens Health Walgreens Health [Member] Walgreens Health Post tax (loss) earnings from other equity method investments Income (Loss) from Other Equity Method Investments Income (Loss) from Other Equity Method Investments Employee stock purchase and option plans (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Noncontrolling interests contribution and other Stockholders' Equity, Other 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Disposal Group Name [Domain] Disposal Group Name [Domain] Total AmerisourceBergen And Other Equity Method Investments [Member] The aggregate of all equity method investments. Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Total $6 billion note issuance Debt Issuance Note Four [Member] This element details information about the total $6.0 billion debt issuance. Fair value of share-based compensation awards attributable to pre-combination services Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Unrealized gain on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Domestic Plan Domestic Plan [Member] Gains and (Losses) due to Changes in Fair Value Recognized in Earnings Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Employee stock purchase and option plans Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Purchases, net Related Party Transaction, Purchases from Related Party Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Reporting unit fair value in excess of carrying amount (as a percent) Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Investments in debt securities Debt Securities, Available-for-sale 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Number of stores expected to close Restructuring and Related Cost, Number of Stores Expected To Close Restructuring and Related Cost, Number of Stores Expected To Close Debt Disclosure [Abstract] Debt Disclosure [Abstract] Acquisition-related amortization Amortization of Acquisition Costs Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Entity Address, State or Province Entity Address, State or Province Accrued expenses and other liabilities Finance Lease, Liability, Current Earnings (loss) before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Document Information [Table] Document Information [Table] Wholesale Pharmaceutical Wholesale [Member] Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity. Lease obligations included in: Finance Lease Liability [Abstract] Segment Reporting [Abstract] Segment Reporting [Abstract] Type of Restructuring [Domain] Type of Restructuring [Domain] Sales Disposal Group, Including Discontinued Operation, Revenue Net earnings (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest and Redeemable Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest and Redeemable Noncontrolling Interest Other expense Other Expense [Member] Interest Finance Lease, Interest Expense Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Entity Shell Company Entity Shell Company Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Local Phone Number Local Phone Number Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Finance lease Finance Lease, Liability, Payment, Due [Abstract] Other Other Long-term Debt Right-of-use assets obtained in exchange for new lease obligations: Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Common stock, authorized shares (in shares) Common Stock, Shares Authorized Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Debt to total capitalization ratio Ratio of Indebtedness to Net Capital Expected cost Restructuring and Related Cost, Expected Cost Geographical [Domain] Geographical [Domain] Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.: Net Income (Loss) Attributable to Parent [Abstract] Product and Service [Domain] Product and Service [Domain] Noncontrolling interests Noncontrolling Interest [Member] Supplemental information Supplemental Balance Sheet Disclosures [Text Block] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Derivative Contract [Domain] Derivative Contract [Domain] Term of renewal contract Lessee, Operating Lease, Renewal Term Corporate and Other Corporate And Reconciling Items [Member] Corporate And Reconciling Items Asset Impairments Asset impairments Asset Impairment Restructuring Charges [Member] Asset Impairment Restructuring Charges Total non-current liabilities Liabilities, Noncurrent Credit facilities Revolving Credit Facility [Member] Accounting policies New accounting pronouncements Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Equity Method Investment Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Short-term debt Total short-term debt Short-term Debt Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Notional amount, liabilities Derivative Liability, Notional Amount Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Supplemental Income Statement and Other Information Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Basic net earnings (loss) per common share: Earnings Per Share, Basic [Abstract] Geographical [Axis] Geographical [Axis] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Employee Severance and Business Transition Costs Employee severance and business transition costs Employee Severance And Business Transition Costs [Member] Employee Severance And Business Transition Costs Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Total (in dollars per share) Earnings Per Share, Diluted Delayed Draw Term Loan Credit Facility, 364-Day Facility Delayed Draw Term Loan Credit Facility, 364-Day Facility [Member] Delayed Draw Term Loan Credit Facility, 364-Day Facility 4.800% unsecured notes due 2044 4.800% Notes Payable, Due 2044 [Member] A written promise to pay a note to a third party. Segments [Domain] Segments [Domain] Service costs Defined Benefit Plan, Service Cost Income taxes paid Income Taxes Paid, Net Guarantor Subsidiaries Guarantor Subsidiaries [Member] Currency translation adjustments and other Temporary Equity, Foreign Currency Translation Adjustments Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Comprehensive income (loss) attributable to Walgreens Boots Alliance, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) Shields Health Solutions Parent, LLC Shields Health Solutions Parent, LLC [Member] Shields Health Solutions Parent, LLC Net cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Treasury stock, at cost; 308,671,242 shares at November 30, 2021 and 307,139,982 shares at August 31, 2021 Treasury Stock, Value Deferred income taxes Deferred Income Tax Liabilities, Net Term Loan Loans Payable [Member] Other non-current liabilities Other Noncurrent Liabilities [Member] Equity (earnings) loss from equity method investments Equity earnings (losses) Income (Loss) from Equity Method Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Net earnings from discontinued operations Net earnings from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Profit sharing provision expense Defined Contribution Plan Profit Sharing Provision Benefit Expense Amount The amount of the cost recognized during the period for defined contribution plans profit sharing provision benefit expense amount. Fair value measurements Fair Value Disclosures [Text Block] Schedule of Aggregate Future Lease Payments Under Finance Leases Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Other Restructuring Reserve, Other, Non-Cash Restructuring Reserve, Other, Non-Cash Costs Restructuring Charges Trade accounts payable (see Note 17) Accounts Payable, Current Tangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Lived Tangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Lived Tangible Assets Receivable for purchase price consideration Disposal Group, Contingent Consideration, Purchase Price Receivable Disposal Group, Contingent Consideration, Purchase Price Receivable Depreciation and amortization Depreciation, Depletion and Amortization Proceeds from sale-leaseback transactions Proceeds From Sale-Leaseback Transactions, Investing Activities Proceeds From Sale-Leaseback Transactions, Investing Activities Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Accumulated other comprehensive income (loss) Total AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Continuing Operations Continuing Operations [Member] Cost of sales Cost of Goods and Services Sold Expected employer cash contributions to defined benefit plan in current fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Equity investment, exceeded its proportionate share of net assets Equity Investment, Exceeded its Proportionate Share of Net Assets This item represents the carrying amount exceeded its proportionate share of the net assets of an equity method investee. Cash received from disposal Proceeds from Divestiture of Businesses Movement on available for debt sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Consolidated Entities [Domain] Consolidated Entities [Domain] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement Location [Domain] Income Statement Location [Domain] Debt term Debt Instrument, Term Equity: Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Bridge Loan Bridge Loan [Member] Alliance Healthcare Alliance Healthcare [Member] Alliance Healthcare Other non-current liabilities Other Liabilities, Noncurrent Operating Activities [Axis] Operating Activities [Axis] Net investment hedges AOCI, Net Investment Hedges, Parent [Member] AOCI, Net Investment Hedges, Parent Other income Other Income [Member] Long-Term Debt Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Treasury stock purchases (in shares) Treasury Stock, Shares, Acquired Debt Instrument [Line Items] Debt Instrument [Line Items] Payments of debt Repayments of Long-term Debt Period of reporting lag Time period of reporting lag Period of reporting lag for availability of financial information. Derivative asset Derivative Asset Schedule of Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Document Quarterly Report Document Quarterly Report 3.600% Walgreens Boots Alliance, Inc. notes due 2025 3.600% unsecured Pound sterling notes due 2025 3.600% Notes Payable, Due 2025 [Member] A written promise to pay a note to a third party. Other current liabilities Other Current Liabilities [Member] Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Long-term debt Total long-term debt, less current portion Long-term Debt, Excluding Current Maturities Liabilities [Abstract] Liabilities, Fair Value Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Delayed Draw Term Loan Credit Facility, Two-Year Facility Delayed Draw Term Loan Credit Facility, Two-Year Facility [Member] Delayed Draw Term Loan Credit Facility, Two-Year Facility Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Gain on previously held investment interests Gain (Loss) on Previously Held Investment Interests Gain (Loss) on Previously Held Investment Interests Document Fiscal Period Focus Document Fiscal Period Focus Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net earnings (loss) Net earnings (loss) Net earnings (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Acquisitions Temporary Equity, Acquisitions Temporary Equity, Acquisitions United States UNITED STATES Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net consideration Net consideration Business Combination, Consideration Transferred, Net Business Combination, Consideration Transferred, Net Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Other Proceeds from (Payments for) Other Financing Activities Gross amortizable intangible assets Finite-Lived Intangible Assets, Gross Leases [Abstract] Leases [Abstract] Entity Central Index Key Entity Central Index Key Schedule of Finite-Lived Intangible Assets by Major Class Schedule of Finite-Lived Intangible Assets [Table Text Block] Security Exchange Name Security Exchange Name Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Total return swap Total Return Swap [Member] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Outstanding shares owned (in shares) Investments in and Advances to Affiliates, Balance, Shares Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Total other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Intangible asset and other amortization Amortization Recurring Fair Value, Recurring [Member] Income taxes Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Finance lease, right-of-use asset, statement of financial position, extensible enumeration Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Components of Net Periodic Benefit Costs (Income) Schedule of Net Benefit Costs [Table Text Block] Schedules of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Unrealized gain (loss) on cash flow hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Measurement Basis [Axis] Measurement Basis [Axis] 3.800% unsecured notes due 2024 3.800% Notes Payable, Due 2024 [Member] A written promise to pay a note to a third party. 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net cash (used for) investing activities Net Cash Provided by (Used in) Investing Activities Reconciliation of Operating Income (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accumulated depreciation and amortization on property, plant, and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Notional amount, assets Derivative Asset, Notional Amount Redemption variable percentage Debt Instrument, Redemption Price, Variable Percentage Debt Instrument, Redemption Price, Variable Percentage Short-Term Borrowings Schedule of Short-term Debt [Table Text Block] Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Total current liabilities Liabilities, Current Lease Obligations and Other Real Estate Costs Lease obligations and other real estate costs Lease Obligations and Other Real Estate Costs [Member] Lease Obligations and Other Real Estate Costs [Member] Class of Stock [Domain] Class of Stock [Domain] Purchase price Total purchase price Payments to Acquire Businesses, Gross Interest expense, net Disposal Group, Including Discontinued Operation, Interest Expense Foreign currency forwards Foreign Exchange Forward [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Redemption value adjustment Temporary Equity, Accretion to Redemption Value Currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) AmerisourceBergen AmerisourceBergen Corporation [Member] An equity method investee of the company. VillageMD VillageMD [Member] VillageMD Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair Value Hedges [Abstract] Interest Rate Fair Value Hedges [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Customer relationships and loyalty card holders Customer Relationships and Loyalty Card Holders [Member] Refers to customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships and loyalty card, similar to a credit card, debit card, or digital card that identifies the card holder as a member in a loyalty program. Document Information [Line Items] Document Information [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2022 (Remaining period) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Title of 12(b) Security Title of 12(b) Security Proceeds related to employee stock plans Proceeds from Stock Plans Statement [Table] Statement [Table] Other current assets Other Assets, Current Other income (expense) Other income/(expenses) [Member] Primary financial statement caption encompassing other expense and revenues. Adoption of new accounting pronouncements; New accounting pronouncements not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Costs incurred Restructuring and Related Cost, Cost Incurred to Date Statistical Measurement [Axis] Statistical Measurement [Axis] Fair value, liabilities Derivative Liability, Fair Value, Gross Liability Cover [Abstract] Other non-current liabilities Finance Lease, Liability, Noncurrent Purchase Price Allocation: Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract] Earnings before income tax – discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Total amortizable intangible assets, net Finite-Lived Intangible Assets, Net Goodwill Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Others Other Investments Other equity method investments [Member] The aggregate of all other equity method investments not separately disclosed in the taxonomy. Net earnings (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income taxes Accrued Income Taxes, Current Schedule of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Depreciation and Amortization Expense Schedule of Depreciation and Amortization Expense [Table Text Block] Schedule of Depreciation and Amortization Expense [Table Text Block] Developed technology Developed Technology Rights [Member] Fixed Operating Lease, Cost Related parties Related Party Transactions Disclosure [Text Block] Purchasing and payer contracts Purchasing and Payer Contracts [Member] An asset acquired in a business combination representing an entity's purchasing and payer contract. Pension/ post-retirement obligations Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Deferred income taxes Deferred Income Tax Expense (Benefit) Net Cash Provided by (Used in) Discontinued Operations [Abstract] Net Cash Provided by (Used in) Discontinued Operations [Abstract] Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] LIFO provision Inventory, LIFO Reserve, Period Charge EX-101.PRE 14 wba-20211130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 image_0.jpg begin 644 image_0.jpg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image_01.jpg begin 644 image_01.jpg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htm IDEA: XBRL DOCUMENT v3.21.4
Cover Page - shares
3 Months Ended
Nov. 30, 2021
Dec. 31, 2021
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Nov. 30, 2021  
Document Transition Report false  
Entity File Number 001-36759  
Entity Registrant Name WALGREENS BOOTS ALLIANCE, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-1758322  
Entity Address, Address Line One 108 Wilmot Road  
Entity Address, City or Town Deerfield  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60015  
City Area Code 847  
Local Phone Number 315-3700  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   863,272,027
Entity Central Index Key 0001618921  
Current Fiscal Year End Date --08-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Common Stock, $0.01 par value    
Document Information [Line Items]    
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol WBA  
Security Exchange Name NASDAQ  
3.600% Walgreens Boots Alliance, Inc. notes due 2025    
Document Information [Line Items]    
Title of 12(b) Security 3.600% Walgreens Boots Alliance, Inc. notes due 2025  
Trading Symbol WBA25  
Security Exchange Name NASDAQ  
2.125% Walgreens Boots Alliance, Inc. notes due 2026    
Document Information [Line Items]    
Title of 12(b) Security 2.125% Walgreens Boots Alliance, Inc. notes due 2026  
Trading Symbol WBA26  
Security Exchange Name NASDAQ  
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.21.4
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)
$ in Millions
Nov. 30, 2021
Aug. 31, 2021
Current assets:    
Cash and cash equivalents $ 4,135 $ 1,193
Accounts receivable, net 5,960 5,663
Inventories 9,475 8,159
Other current assets 745 800
Total current assets 20,314 15,814
Non-current assets:    
Property, plant and equipment, net 12,295 12,247
Operating lease right-of-use assets 21,826 21,893
Goodwill 21,520 12,421
Intangible assets, net 12,770 9,936
Equity method investments (see Note 6) 6,367 6,987
Other non-current assets 1,413 1,987
Total non-current assets 76,192 65,471
Total assets 96,507 81,285
Current liabilities:    
Short-term debt 2,647 1,305
Trade accounts payable (see Note 17) 12,452 11,136
Operating lease obligations 2,266 2,259
Accrued expenses and other liabilities 6,973 7,260
Income taxes 110 94
Total current liabilities 24,447 22,054
Non-current liabilities:    
Long-term debt 11,199 7,675
Operating lease obligations 22,103 22,153
Deferred income taxes 1,970 1,850
Other non-current liabilities 3,422 3,413
Total non-current liabilities 38,694 35,091
Commitments and contingencies (see Note 11)
Total liabilities 63,141 57,145
Redeemable noncontrolling interest 2,787 319
Equity:    
Preferred stock $.01 par value; authorized 32 million shares, none issued 0 0
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at November 30, 2021 and August 31, 2021 12 12
Paid-in capital 10,966 10,988
Retained earnings 38,286 35,121
Accumulated other comprehensive loss (2,301) (2,109)
Treasury stock, at cost; 308,671,242 shares at November 30, 2021 and 307,139,982 shares at August 31, 2021 (20,700) (20,593)
Total Walgreens Boots Alliance, Inc. shareholders’ equity 26,263 23,419
Noncontrolling interests 4,316 402
Total equity 30,579 23,822
Total liabilities, redeemable noncontrolling interest and equity $ 96,507 $ 81,285
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.21.4
CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares
Nov. 30, 2021
Aug. 31, 2021
Equity:    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 32,000,000 32,000,000
Preferred stock, issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 3,200,000,000 3,200,000,000
Common stock, issued (in shares) 1,172,513,618 1,172,513,618
Treasury stock, at cost (in shares) 308,671,242 307,139,982
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.21.4
CONSOLIDATED CONDENSED STATEMENTS OF EQUITY - USD ($)
$ in Millions
Total
Adoption of new accounting standards
Common stock
Treasury stock amount
Paid-in capital
Accumulated other comprehensive income (loss)
Retained earnings
Retained earnings
Adoption of new accounting standards
Noncontrolling interests
Noncontrolling interests
Adoption of new accounting standards
Beginning balance (in shares) at Aug. 31, 2020     865,603,519              
Beginning balance at Aug. 31, 2020 $ 21,136 $ (5) $ 12 $ (20,575) $ 10,761 $ (3,771) $ 34,210 $ (3) $ 498 $ (3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net earnings (loss) (299)           (308)   9  
Other comprehensive income (loss), net of tax 90         88     2  
Dividends declared and distributions (405)           (405)      
Treasury stock purchases (in shares)     (3,000,000)              
Treasury stock purchases (110)     (110)            
Employee stock purchase and option plans (in shares)     1,298,298              
Employee stock purchase and option plans 4     43 (39)          
Stock-based compensation 36       36          
Business combination 117       117          
Noncontrolling interests contribution and other 1       1          
Ending balance (in shares) at Nov. 30, 2020     863,901,817              
Ending balance at Nov. 30, 2020 20,563   $ 12 (20,642) 10,876 (3,682) 33,495   506  
Beginning balance (in shares) at Aug. 31, 2021     865,373,636              
Beginning balance at Aug. 31, 2021 23,822   $ 12 (20,593) 10,988 (2,109) 35,121   402  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net earnings (loss) 3,552           3,580   (27)  
Other comprehensive income (loss), net of tax (196)         (193)     (3)  
Dividends declared and distributions (415)           (415)      
Treasury stock purchases (in shares)     (3,179,750)              
Treasury stock purchases (154)     (154)            
Employee stock purchase and option plans (in shares)     1,648,490              
Employee stock purchase and option plans (11)     47 (59)          
Stock-based compensation 35       35          
Business combination 3,944               3,944  
Noncontrolling interests contribution and other 2       2          
Ending balance (in shares) at Nov. 30, 2021     863,842,376              
Ending balance at Nov. 30, 2021 $ 30,579   $ 12 $ (20,700) $ 10,966 $ (2,301) $ 38,286   $ 4,316  
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.21.4
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Income Statement [Abstract]    
Sales $ 33,901 $ 31,438
Cost of sales 26,326 24,808
Gross profit 7,574 6,630
Selling, general and administrative expenses 6,391 5,792
Equity earnings (loss) in AmerisourceBergen 100 (1,373)
Operating income (loss) 1,283 (535)
Other income 2,617 63
Earnings (loss) before interest and tax 3,900 (472)
Interest expense, net 86 136
Earnings (loss) before tax 3,814 (607)
Income tax provision (benefit) 275 (207)
Post tax (loss) earnings from other equity method investments (7) 15
Net earnings (loss) from continuing operations 3,531 (385)
Net earnings from discontinued operations 0 87
Net earnings (loss) 3,531 (299)
Net (loss) earnings attributable to noncontrolling interests - continuing operations (48) 5
Net earnings attributable to noncontrolling interests - discontinued operations 0 4
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. 3,580 (308)
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.:    
Continuing operations 3,580 (391)
Discontinued operations 0 83
Total $ 3,580 $ (308)
Basic net earnings (loss) per common share:    
Continuing operations (in dollars per share) $ 4.13 $ (0.45)
Discontinued operations (in dollars per share) 0 0.10
Total (in dollars per share) 4.13 (0.36)
Diluted net earnings (loss) per common share:    
Continuing operations (in dollars per share) 4.13 (0.45)
Discontinued operations (in dollars per share) 0 0.10
Total (in dollars per share) $ 4.13 $ (0.36)
Weighted average common shares outstanding:    
Basic (in shares) 865.8 865.3
Diluted (in shares) 867.6 865.3
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.21.4
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Comprehensive income:    
Net earnings (loss) $ 3,531 $ (299)
Other comprehensive (loss) income, net of tax:    
Pension/postretirement obligations (5) 11
Unrealized gain on cash flow hedges 1 4
Net investment hedges 44 (7)
Movement on available for debt sale securities (96) 0
Share of other comprehensive (loss) income of equity method investments (46) 5
Currency translation adjustments (94) 80
Total other comprehensive (loss) income (196) 94
Total comprehensive income (loss) 3,336 (206)
Comprehensive (loss) income attributable to noncontrolling interests (51) 14
Comprehensive income (loss) attributable to Walgreens Boots Alliance, Inc. $ 3,387 $ (220)
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.21.4
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Cash flows from operating activities:    
Net earnings (loss) $ 3,531 $ (299)
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation and amortization 500 475
Deferred income taxes 164 (348)
Stock compensation expense 35 36
Equity (earnings) loss from equity method investments (93) 1,350
Gain on previously held investment interests (2,576) 0
Other 95 (71)
Changes in operating assets and liabilities:    
Accounts receivable, net (127) (259)
Inventories (1,352) (1,225)
Other current assets (58) 36
Trade accounts payable 1,335 1,398
Accrued expenses and other liabilities (399) (105)
Income taxes 79 132
Other non-current assets and liabilities (36) 74
Net cash provided by operating activities 1,099 1,195
Cash flows from investing activities:    
Additions to property, plant and equipment (454) (431)
Proceeds from sale-leaseback transactions 202 231
Business, investment and asset acquisitions, net of cash acquired (1,800) (77)
Other 95 19
Net cash (used for) investing activities (1,958) (259)
Cash flows from financing activities:    
Net change in short-term debt with maturities of 3 months or less 937 (347)
Proceeds from debt 7,940 3,310
Payments of debt (4,444) (2,807)
Stock purchases (154) (110)
Proceeds related to employee stock plans 19 4
Cash dividends paid (413) (405)
Other (7) 4
Net cash provided by (used for) financing activities 3,877 (352)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (20) 10
Changes in cash, cash equivalents and restricted cash:    
Net increase in cash, cash equivalents and restricted cash 2,998 594
Cash, cash equivalents and restricted cash at beginning of period 1,270 746
Cash, cash equivalents and restricted cash at end of period $ 4,268 $ 1,339
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.21.4
Accounting policies
3 Months Ended
Nov. 30, 2021
Accounting Policies [Abstract]  
Accounting policies Accounting policies
Basis of presentation
The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated.

The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2021, as amended by Form 10-K/A for the fiscal year ended August 31, 2021 filed on November 24, 2021.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of the COVID-19 pandemic (“COVID-19”). The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous factors discussed throughout this Quarterly Report on Form 10-Q including, but not limited to, the severity and duration of COVID-19, the extent to which it will impact our customers, team members, suppliers, vendors, business partners and distribution channels. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of November 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ.

In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years.

On June 1, 2021, the Company completed the sale of the majority of the Company's Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (“Disposal Group”) to AmerisourceBergen Corporation (“AmerisourceBergen”). The Disposal Group met the criteria to be reported as discontinued operations. Therefore, the operating results of the Disposal Group are reported as discontinued operations for all prior periods.

Effective as of the first quarter of fiscal year 2022, the Company is aligned into three reportable segments: United States, International and Walgreens Health. Unless otherwise specified, disclosures in these Consolidated Condensed Financial Statements reflect continuing operations only. Certain prior period data, related to discontinued operations has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. See Note 2 Discontinued operations and Note 15 Segment reporting for further information.

Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented.
New accounting pronouncements
Adoption of new accounting pronouncements

Receivables - nonrefundable fees and others
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other. This ASU clarifies the accounting for the amortization period for certain purchased callable debt securities held at a premium by giving consideration to securities which have multiple call dates. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.
Investments — equity securities; Investments — equity method and joint ventures; Derivatives and hedging
In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Income taxes - simplifying the accounting for income taxes
In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Effects of reference rate reform on financial reporting
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable, or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to the above the ASU to clarify certain optional expedients in Topic 848. The Company adopted the new standard effective September 1, 2021, and the adoption did not have a material impact on the Company’s results of operations, cash flows or financial position.

New accounting pronouncements not yet adopted

Acquired contract assets and contract liabilities in a business combination
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance.

Disclosures by business entities about government assistance
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021 (fiscal 2023). The Company is evaluating the effect of adopting this new accounting guidance.
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.21.4
Discontinued operations
3 Months Ended
Nov. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued operations Discontinued operations
On June 1, 2021, the Company completed the sale of Alliance Healthcare, for total consideration of $6.9 billion, which included cash consideration of $6.7 billion, subject to net working capital and net cash adjustments and 2 million shares of AmerisourceBergen common stock.

As of November 30, 2021, Other current assets include a $98 million receivable for purchase price consideration due from AmerisourceBergen that is subject to change upon the finalization of net working capital adjustments.

The operating results of the Disposal Group are reported as discontinued operations as the disposition reflected a strategic shift that has, or will have, a major effect on the Company’s operations and financial results.

Results of discontinued operations were as follows (in millions):
 Three months ended November 30, 2020
Sales$5,327 
Cost of sales4,818 
Gross profit509 
Selling, general and administrative expense415 
Operating income from discontinued operations94 
Other expense(2)
Interest expense, net(4)
Earnings before income tax – discontinued operations88 
Income tax provision8
Post tax earnings from other equity method investments7
Net earnings from discontinued operations$87 

Sales from the Disposal Group to the Company's continuing operations are not eliminated and aggregate to (in millions):
 Three months ended November 30, 2020
Sales$458 

Cash flows from operating and investing activities for discontinued operations are (in millions):
 Three months ended November 30, 2020
Cash used in operating activities - discontinued operations$(45)
Cash used for investing activities - discontinued operations(19)

See Note 17 Related parties, to the Consolidated Condensed Financial Statements for more information on the Company's transactions and continuing involvement with AmerisourceBergen.
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.21.4
Acquisitions
3 Months Ended
Nov. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Acquisitions Acquisitions
VillageMD
On November 24, 2021, the Company completed the acquisition of Village Practice Management Company, LLC (“VillageMD”). Pursuant to the terms and subject to the conditions set forth in the Unit Purchase Agreement, the Company purchased additional outstanding equity interests of VillageMD, increasing the Company’s total beneficial ownership in VillageMD’s outstanding equity interests from approximately 30% to approximately 63%, on a fully diluted basis, for a purchase price of $5.2 billion. The total purchase price comprises cash consideration of $4.0 billion and a promissory note of $1.2 billion. The cash consideration consisted of $2.9 billion to be paid to existing shareholders, after giving affect to the $1.9 billion tender offer described below, as well as $1.1 billion paid in exchange for new preferred units issued by VillageMD. Subject to notice being served, the Company has an option to prepay the promissory note at any time and VillageMD may require the Company to redeem the promissory note after February 1, 2022. The promissory note is eliminated in consolidation within the Consolidated Condensed Balance Sheets.

On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.

The Company accounted for this acquisition as a business combination resulting in consolidation of VillageMD within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. As of November 30, 2021, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired. As such, the preliminary purchase price allocation will be subject to further refinement and may change. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified.

As a result of this acquisition, the Company recognized a pre-tax gain in Other income in the Consolidated Condensed Statements of Earnings, of $1,597 million related to the fair valuation of the Company’s previously held minority equity interest. The Company also recorded a pre-tax gain of $577 million in Other income in the Consolidated Condensed Statements of Earnings related to the conversion to equity of the Company’s previously held investment in convertible debt securities of VillageMD, reclassified from within accumulated other comprehensive income.

The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):

Purchase Price Allocation:
Total purchase price$5,200 
Less: purchase price for issuance of new preferred units at fair value 1
(2,300)
Net consideration$2,900 
Fair value of share-based compensation awards attributable to pre-combination services 2
683 
Fair value of previously held equity and debt3,211 
Fair value of non-controlling interest3,257 
Total$10,051 
Identifiable assets acquired and liabilities assumed:
Tangible assets 1
$637 
Intangible assets1,982 
Liabilities(241)
Total identifiable net assets$2,378 
Goodwill$7,673 
1.Comprises cash consideration of $1.1 billion and a promissory note of $1.2 billion. This consideration was provided in exchange for the issuance of new preferred units by VillageMD. VillageMD’s tangible assets acquired exclude this $1.1 billion of cash and $1.2 billion promissory note receivable.
2.Primarily related to vested share-based compensation awards.

The goodwill represents anticipated future growth and expansion opportunities into new markets. Pro forma sales and net earnings of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported.

Shields acquisition
On October 29, 2021, the Company completed the acquisition of Shields Health Solutions Parent, LLC (“Shields”). Pursuant to the terms and subject to the conditions set forth in the Securities Purchase Agreement, the Company purchased additional outstanding equity interests of Shields, increasing the Company’s total beneficial ownership in Shields’ outstanding equity interests from 25% to approximately 70%, on a fully diluted basis, for cash consideration of $969 million, subject to certain purchase price adjustments.

The Company accounted for this acquisition as a business combination resulting in consolidation of Shields within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. Under the terms of the transaction agreements, the Company has an option to acquire the remaining equity interests of Shields in the future. Shields’ other equity holders will also have an option to require the Company to purchase the remaining equity interests. Considering the contractual terms related to the noncontrolling interest, it is classified as redeemable noncontrolling interest in the Consolidated Condensed Balance Sheets.

As of November 30, 2021, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired. As such, the preliminary purchase price allocation will be subject to further refinement and may result in changes. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified.

As a result of this acquisition, the Company remeasured its previously held minority equity interest in Shields at fair value resulting in a pre-tax gain of $402 million recognized in Other income in the Consolidated Condensed Statements of Earnings.

The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):

Purchase Price Allocation:
Cash consideration$969 
Fair value of share-based compensation awards attributable to pre-combination services13 
Fair value of previously held equity interests502 
Fair value of non-controlling interests589 
Total$2,074 
Identifiable assets acquired and liabilities assumed:
Tangible assets$84 
Intangible assets1,060 
Liabilities(528)
Total identifiable net assets$616 
Goodwill$1,457 

The goodwill represents anticipated future growth and expansion opportunities into new healthcare offerings. Pro forma sales and net earnings of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported.
See Note 15 Segment reporting and Note 16 Sales for further information.

Other acquisitions
The Company acquired certain prescription files and related pharmacy inventory primarily in the U.S. for the aggregate purchase price of $74 million and $38 million during the three months ended November 30, 2021 and 2020, respectively.
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.21.4
Exit and disposal activities
3 Months Ended
Nov. 30, 2021
Restructuring and Related Activities [Abstract]  
Exit and disposal activities Exit and disposal activities
Transformational Cost Management Program
On December 20, 2018, the Company announced a transformational cost management program that was expected to deliver in excess of $2.0 billion of annual cost savings by fiscal 2022 (the “Transformational Cost Management Program”). The Company achieved this goal at the end of fiscal 2021.

On October 12, 2021, the Company’s Board of Directors approved an expansion and extension of the Transformational Cost Management Program through the end of fiscal 2024. As a result, the Company increased its annual cost savings target to $3.3 billion by the end of fiscal 2024.

The Transformational Cost Management Program, which is multi-faceted and includes divisional optimization initiatives, global smart spending, global smart organization and the transformation of the Company’s information technology (IT) capabilities, is designed to help the Company achieve increased cost efficiencies. To date, the Company has taken actions across all aspects of the Transformational Cost Management Program which focus on the United States and International reportable segments along with the Company’s global functions. Divisional optimization within the Company’s segments includes activities such as optimization of stores. As a result of the expanded program, the Company plans to reduce its presence by up to 150 Boots stores in the UK and up to 150 stores in the United States over the next three years which are incremental to the previously planned reductions of approximately 200 Boots stores in the UK and approximately 250 stores in the United States.

The Company currently estimates that the Transformational Cost Management Program will result in cumulative pre-tax charges to its GAAP financial results of approximately $3.6 billion to $3.9 billion, of which $3.3 billion to $3.6 billion are expected to be recorded as exit and disposal activities. In addition to these impacts, as a result of the actions related to store closures taken under the Transformational Cost Management Program, the Company recorded $508 million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard (Topic 842) that became effective on September 1, 2019.

Since the inception of the Transformational Cost Management Program to November 30, 2021, the Company has recognized cumulative pre-tax charges to its financial results in accordance with GAAP of $1.5 billion, which were primarily recorded within selling, general and administrative expenses. These charges included $442 million related to lease obligations and other real estate costs, $292 million in asset impairments, $550 million in employee severance and business transition costs and $172 million of information technology transformation and other exit costs.

Costs related to exit and disposal activities under the Transformational Cost Management Program for the three months ended November 30, 2021 and 2020, respectively, were as follows (in millions):
Three months ended November 30, 2021United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$87 $$— $89 
Asset impairments15 25 — 40 
Employee severance and business transition costs20 10 37 
Information technology transformation and other exit costs
Total pre-tax exit and disposal charges$123 $44 $9 $175 
Three months ended November 30, 2020United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$22 $— $— $22 
Asset impairments(2)— 
Employee severance and business transition costs12 28 12 52 
Information technology transformation and other exit costs10 (5)— 
Total pre-tax exit and disposal charges$48 $21 $12 $81 

The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):
Lease obligations and other real estate costsAsset ImpairmentsEmployee severance and business transition costsInformation technology transformation and other exit costsTotal
Balance at August 31, 2021$17 $— $77 $20 $114 
Costs89 40 37 175 
Payments(15)— (51)(7)(74)
Other(72)(40)(3)— (115)
Currency— — (1)— (1)
Balance at November 30, 2021$19 $ $59 $23 $101 
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.21.4
Leases
3 Months Ended
Nov. 30, 2021
Leases [Abstract]  
Leases Leases
The Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. For the majority of leases in the U.S., the initial lease term is typically 15 to 25 years, followed by additional terms containing renewal options typically at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.

Supplemental balance sheet information related to leases were as follows (in millions):

Balance Sheet supplemental information:November 30, 2021August 31, 2021
Operating Leases:
Operating lease right-of-use assets$21,826 $21,893 
Operating lease obligations - current2,266 2,259 
Operating lease obligations - non-current 22,103 22,153 
Total operating lease obligations$24,369 $24,412 
Finance Leases:
Right-of-use assets included in:
Property, plant and equipment, net$713 $725 
Lease obligations included in:
Accrued expenses and other liabilities37 37 
Other non-current liabilities963 974 
Total finance lease obligations$1,000 $1,010 
Supplemental income statement information related to leases were as follows (in millions):
Three months ended November 30,
Statement of Earnings supplemental information:20212020
Operating lease cost
Fixed$805 $805 
Variable 1
205 158 
Finance lease cost
Amortization$11 $11 
Interest13 13 
Sublease income25 20 
Impairment of right-of-use assets68 10 
Gain on sale and leaseback 2
87 93 

1Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume.
2Recorded within selling, general and administrative expenses.

Other supplemental information related to leases were as follows (in millions):
Three months ended November 30,
Other Supplemental Information:20212020
Cash paid for amounts included in the measurement of lease obligations:
Operating cash flows from operating leases$846 $857 
Operating cash flows from finance leases12 12 
Financing cash flows from finance leases11 10 
Total$869 $879 
Right-of-use assets obtained in exchange for new lease obligations:
Operating leases$544 $787 
Finance leases— 
Total$549 $787 

Average lease term and discount rate were as follows:
Weighted average terms and discount rates:November 30, 2021August 31, 2021
Weighted average remaining lease term in years:
Operating leases10.210.3
Finance leases20.120.2
Weighted average discount rate:
Operating leases4.75 %4.77 %
Finance leases5.18 %5.18 %
The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):
Future lease payments:
Fiscal yearFinance leaseOperating lease
2022 (Remaining period)$67 $2,608 
202388 3,376 
202488 3,260 
202587 3,145 
202687 3,032 
202786 2,924 
Later1,054 12,801 
Total undiscounted minimum lease payments$1,556 $31,146 
Less: Present value discount(556)(6,777)
Lease liability$1,000 $24,369 
Leases Leases
The Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. For the majority of leases in the U.S., the initial lease term is typically 15 to 25 years, followed by additional terms containing renewal options typically at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.

Supplemental balance sheet information related to leases were as follows (in millions):

Balance Sheet supplemental information:November 30, 2021August 31, 2021
Operating Leases:
Operating lease right-of-use assets$21,826 $21,893 
Operating lease obligations - current2,266 2,259 
Operating lease obligations - non-current 22,103 22,153 
Total operating lease obligations$24,369 $24,412 
Finance Leases:
Right-of-use assets included in:
Property, plant and equipment, net$713 $725 
Lease obligations included in:
Accrued expenses and other liabilities37 37 
Other non-current liabilities963 974 
Total finance lease obligations$1,000 $1,010 
Supplemental income statement information related to leases were as follows (in millions):
Three months ended November 30,
Statement of Earnings supplemental information:20212020
Operating lease cost
Fixed$805 $805 
Variable 1
205 158 
Finance lease cost
Amortization$11 $11 
Interest13 13 
Sublease income25 20 
Impairment of right-of-use assets68 10 
Gain on sale and leaseback 2
87 93 

1Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume.
2Recorded within selling, general and administrative expenses.

Other supplemental information related to leases were as follows (in millions):
Three months ended November 30,
Other Supplemental Information:20212020
Cash paid for amounts included in the measurement of lease obligations:
Operating cash flows from operating leases$846 $857 
Operating cash flows from finance leases12 12 
Financing cash flows from finance leases11 10 
Total$869 $879 
Right-of-use assets obtained in exchange for new lease obligations:
Operating leases$544 $787 
Finance leases— 
Total$549 $787 

Average lease term and discount rate were as follows:
Weighted average terms and discount rates:November 30, 2021August 31, 2021
Weighted average remaining lease term in years:
Operating leases10.210.3
Finance leases20.120.2
Weighted average discount rate:
Operating leases4.75 %4.77 %
Finance leases5.18 %5.18 %
The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):
Future lease payments:
Fiscal yearFinance leaseOperating lease
2022 (Remaining period)$67 $2,608 
202388 3,376 
202488 3,260 
202587 3,145 
202687 3,032 
202786 2,924 
Later1,054 12,801 
Total undiscounted minimum lease payments$1,556 $31,146 
Less: Present value discount(556)(6,777)
Lease liability$1,000 $24,369 
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.21.4
Equity method investments
3 Months Ended
Nov. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]  
Equity method investments Equity method investments
Equity method investments were as follows (in millions, except percentages):
 November 30, 2021August 31, 2021
 Carrying valueOwnership percentageCarrying valueOwnership percentage
AmerisourceBergen$4,393 28%$4,407 28%
Others1,974 
8% - 50%
2,580 
8% - 50%
Total$6,367  $6,987  

AmerisourceBergen investment
As of November 30, 2021 and August 31, 2021, the Company owned 58,854,867 AmerisourceBergen common shares representing approximately 28.3% of its outstanding common stock based on the most recent share count publicly reported by AmerisourceBergen in its most recent Annual Report on Form 10-K.

The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings (loss) attributable to the Company’s investment being classified within the operating income of its United States segment. Due to the timing and availability of financial information of AmerisourceBergen, the Company accounts for this equity method investment on a financial reporting lag of two months. Equity earnings (loss) from AmerisourceBergen are reported as a separate line in the Consolidated Condensed Statements of Earnings.

During the three months ended November 30, 2021 and 2020, the Company recognized equity income of $100 million and equity losses of $1.4 billion, in AmerisourceBergen, respectively. The equity losses for the period ended November 30, 2020 were primarily due to AmerisourceBergen's recognition of loss of $5.6 billion, net of tax, related to its ongoing opioid litigation in its financial statements for the three months ended September 30, 2020.

The Level 1 fair market value of the Company’s equity investment in AmerisourceBergen common stock at November 30, 2021 and August 31, 2021 was $6.8 billion and $7.2 billion, respectively. As of November 30, 2021 the carrying value of the Company’s investment in AmerisourceBergen exceeded its proportionate share of the net assets of AmerisourceBergen by $4.3 billion. This premium of $4.3 billion was recognized as part of the carrying value in the Company’s equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets.

Other investments
The Company’s other equity method investments include its U.S. investments in HC Group Holdings I, LLC (“HC Group Holdings”) which owns equity interest in Option Care Health, and BrightSpring Health Services, and the Company’s China investments in Sinopharm Medicine Holding Guoda Drugstores Co., Ltd, Guangzhou Pharmaceuticals Corporation and Nanjing
Pharmaceutical Company Limited. The Company reported $7 million of post-tax equity losses and $15 million of post-tax equity earnings from other equity method investments for the three months ended November 30, 2021 and 2020, respectively.

During the three months ended November 30, 2021, the Company acquired majority equity interests in VillageMD and Shields. The Company accounted for these acquisitions as business combinations resulting in the remeasurement of its previously held minority equity interests and convertible debt securities at fair value resulting in pre-tax gains of $2,174 million and $402 million for VillageMD and Shields, respectively, recognized in Other income in the Consolidated Condensed Statements of Earnings. As a result of these transactions, the Company now consolidates VillageMD and Shields within the Walgreens Health segment in its financial statements.

Summarized financial information

Summarized financial information for the Company’s equity method investments in aggregate is as follows:
Statements of earnings (loss) (in millions)
 Three months ended November 30,
20212020
Sales$67,588 $56,088 
Gross Profit3,420 2,410 
Net earnings (loss)308 (4,806)
Share of earnings (loss) from equity method investments93 (1,357)

The summarized financial information for equity method investments has been included on an aggregated basis for all investments as reported at the end of each reporting period.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.21.4
Goodwill and other intangible assets
3 Months Ended
Nov. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and other intangible assets Goodwill and other intangible assets
Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit or intangible asset below its carrying value.

Based on the analysis completed during fiscal 2021, as of the June 1, 2021 valuation date, the fair values of the Company’s reporting units exceeded their carrying amounts ranging from approximately 18% to approximately 195%. Boots reporting unit's fair value was in excess of its carrying value by approximately 18%, compared to a nominal amount as of June 1, 2020. Other international reporting unit's fair value was in excess of its carrying value by approximately 29%. As of November 30, 2021 the carrying values of goodwill were $1.0 billion and $372 million for Boots reporting unit and Other international reporting unit, respectively. The fair values of indefinite-lived intangibles within the Boots reporting unit exceeded their carrying value amounts ranging from approximately 5% to approximately 27%. As of November 30, 2021 and August 31, 2021 the carrying value of the indefinite-lived intangibles within the Boots reporting unit was $7.2 billion and $7.3 billion, respectively.

The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions with respect to the business and financial performance of the Company’s reporting units, as well as how such performance may be impacted by COVID-19.

Although the Company believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions, including the impact of COVID-19, could have a significant impact on either the fair value of the reporting units and indefinite-lived intangibles, the amount of any goodwill and indefinite-lived intangible impairment charges, or both. These estimates can be affected by a number of factors including, but not limited to, the impact of COVID-19, its severity, duration and its impact on global economies, general economic conditions as well as our profitability. The Company will continue to monitor these potential impacts, including the impact of COVID-19 and economic, industry and market trends and the impact these may have on the Boots and Other international reporting units.
Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions):

Goodwill roll forward:United StatesInternationalWalgreens HealthWalgreens Boots Alliance, Inc.
August 31, 2021$10,947 $1,474 $— $12,421 
Acquisitions— — 9,130 9,130 
Currency translation adjustments— (32)— (32)
November 30, 2021$10,947 $1,443 $9,130 $21,520 

The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):

Intangible assetsNovember 30, 2021August 31, 2021
Gross amortizable intangible assets  
Customer relationships and loyalty card holders 1
$4,430 $3,522 
Primary care provider network1,660 — 
Trade names and trademarks708 361 
Purchasing and payer contracts317 317 
Developed technology290 — 
Others 75 221 
Total gross amortizable intangible assets$7,479 $4,421 
Accumulated amortization  
Customer relationships and loyalty card holders 1
$1,395 $1,335 
Trade names and trademarks228 226 
Purchasing and payer contracts284 227 
Developed technology17 — 
Others 29 37 
Total accumulated amortization1,953 1,826 
Total amortizable intangible assets, net$5,526 $2,595 
Indefinite-lived intangible assets  
Trade names and trademarks$5,208 $5,276 
Pharmacy licenses2,036 2,066 
Total indefinite-lived intangible assets$7,244 $7,342 
Total intangible assets, net$12,770 $9,936 

1Includes purchased prescription files.

Amortization expense for intangible assets was $165 million and $95 million for the three months ended November 30, 2021, and 2020, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2021 is as follows (in millions):
 2022 (Remaining period)20232024202520262027
Estimated annual amortization expense$462 $560 $541 $514 $490 $443 
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.21.4
Debt
3 Months Ended
Nov. 30, 2021
Debt Disclosure [Abstract]  
Debt Debt
Debt carrying values are presented net of unamortized discount and debt issuance costs, where applicable, and foreign currency denominated debt is translated using the spot rates as of the balance sheet date. Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):

 November 30, 2021August 31, 2021
Short-term debt   
Commercial paper$875 $— 
Credit facilities799 — 
$8 billion note issuance 1
3.300% unsecured notes due 2021 2
— 1,250 
$4 billion note issuance 4
3.100% unsecured notes due 2022
731 — 
Other 3
242 56 
Total short-term debt$2,647 $1,305 
Long-term debt   
Credit facilities $2,990 $— 
$850 million note issuance 1
0.9500% unsecured notes due 2023
848 — 
$1.5 billion note issuance 1
3.200% unsecured notes due 2030
497 497 
4.100% unsecured notes due 2050
792 792 
$6 billion note issuance 1
  
3.450% unsecured notes due 2026
1,442 1,442 
4.650% unsecured notes due 2046
318 318 
$8 billion note issuance 1
3.800% unsecured notes due 2024
1,154 1,154 
4.500% unsecured notes due 2034
301 301 
4.800% unsecured notes due 2044
868 868 
£700 million note issuance 1
3.600% unsecured Pound sterling notes due 2025
403 408 
€750 million note issuance 1
2.125% unsecured Euro notes due 2026
846 873 
$4 billion note issuance 4
3.100% unsecured notes due 2022
— 731 
4.400% unsecured notes due 2042
263 263 
Other 3
477 29 
Total long-term debt, less current portion$11,199 $7,675 

1Notes are unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding.
2On September 18, 2021, the Company redeemed in full the $1.25 billion aggregate principal amount outstanding of its 3.300% unsecured notes due 2021 issued by the Company on November 18, 2014.
3Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. Other long term debt includes $447 million of debt acquired as part of Shields acquisition.
4Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.

$850 million Note Issuance
On November 17, 2021, the Company issued, in an underwritten public offering, $850 million of 0.95% Notes due 2023. The Notes contain a call option which allow for the Notes to be repaid, in full or in part, prior to May 17, 2022 (the “Par Call Date”) at 100% of the principal amount of the Notes to be redeemed or the sum of the present values of the remaining scheduled payments thereof to the Par Call Date discounted at the applicable treasury rate, plus 10 basis points and (ii) on or after the Par Call Date, at 100% of the principal amount of the Notes to be redeemed, in each case plus accrued and unpaid interest.

Credit facilities

November 15, 2021, Delayed Draw Term Loan
On November 15, 2021, the Company entered into a $5.0 billion senior unsecured multi-tranche delayed draw term loan credit facility, (the “November 2021 DDTL”) consisting of (i) a 364-day senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the“364-day loan”), (ii) a two-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the “two-year loan”) and (iii) a three-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $1.0 billion (the “three-year loan”). An aggregate amount of $3.0 billion or more of the November 2021 DDTL is for the purpose of funding the consideration due in respect of the purchase of an increased equity stake in VillageMD, and paying fees and expenses related to the foregoing, and the remainder can be used for general corporate purposes. The November 2021 DDTL is available for drawing in one or more tranches until May 15, 2022. The maturity date on the 364-day loan, the two-year loan and the three-year loan is, in each case, the earlier of the date that is 364 days, two years and three years from the date of the first drawing under each facility and February 14, 2023, February 15, 2024 and February 15, 2025 respectively. As of November 30, 2021 there were $3.0 billion in borrowings outstanding under the November 2021 DDTL.

December 23, 2020, Revolving Credit Agreement
On December 23, 2020, the Company entered into a $1.25 billion senior unsecured 364-day revolving credit agreement and a $2.25 billion senior unsecured 18-month revolving credit facility, with a swing line subfacility commitment amount of $350 million, with designated borrowers from time to time party thereto and lenders from time to time party thereto (the “2020
Revolving Credit Agreement”). The 364-day facility’s termination date is the earlier of (i) 364 days from December 23, 2020, the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the 364-day facility pursuant to the 2020 Revolving Credit Agreement. The 18-month facility’s termination date is the earlier of (i) 18 months from the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the 18-Month Facility pursuant to the 2020 Revolving Credit Agreement. As of November 30, 2021 there were $800 million in borrowings outstanding under the 2020 Revolving Credit Agreement.

August 2018 Revolving Credit Agreement
On August 29, 2018, the Company entered into a revolving credit agreement (the “August 2018 Revolving Credit Agreement”) with the lenders and letter of credit issuers from time-to-time party thereto. The August 2018 Revolving Credit Agreement is an unsecured revolving credit facility with aggregate commitment in the amount of $3.5 billion, with a letter of credit subfacility commitment amount of $500 million. The facility termination date is the earlier of (a) August 29, 2023, subject to extension thereof pursuant to the August 2018 Revolving Credit Agreement, and (b) the date of termination in whole of the aggregate amount of the revolving commitments pursuant to the August 2018 Revolving Credit Agreement. As of November 30, 2021, there were no borrowings outstanding under the August 2018 Revolving Credit Agreement.

Debt covenants
Each of the Company’s credit facilities described above contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, subject to increase in certain circumstances set forth in the applicable credit agreement. The credit facilities also contain various other customary covenants.
Commercial paper
The Company periodically borrows under its commercial paper program and may borrow under it in future periods. The Company had average daily U.S. commercial paper outstanding of $712 million and $1.6 billion at a weighted average interest rate of 0.25% and 0.63% for the three months ended November 30, 2021 and 2020, respectively.

A subsidiary of the Company had average daily commercial paper outstanding, which was issued under the Joint HM Treasury and Bank of England's COVID Corporate Financing Facility commercial paper program, of £300 million, or approximately $401 million at a weighted average interest rate of 0.43% for the three months ended November 30, 2020. The subsidiary of the Company repaid the commercial paper issued under the Joint HM Treasury and Bank of England's COVID Corporate Financing Facility commercial paper program on May 14, 2021.

Interest
Interest paid by the Company was $153 million and $234 million for the three months ended November 30, 2021 and 2020, respectively.
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.21.4
Financial instruments
3 Months Ended
Nov. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial instruments Financial instruments
The Company uses derivative instruments to hedge its exposure to market risks, including interest rate and currency risks, arising from operating and financing risks.

The Company has non-U.S. dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.
The notional amounts and fair value of derivative instruments outstanding were as follows (in millions):

November 30, 2021Notional Fair
Value
Location in Consolidated Condensed Balance Sheets
Derivatives designated as hedges:
Foreign currency forwards$$— Other non-current assets
Cross currency interest rate swaps1534Other non-current assets
Foreign currency forwards17— Other non-current liabilities
Cross currency interest rate swaps633 Other non-current liabilities
Foreign currency forwards61017Other current assets
Foreign currency forwards85 Other current liabilities
Cross currency interest rate swaps1575Other current liabilities
Derivatives not designated as hedges:
Foreign currency forwards$3,900 $64 Other current assets
Foreign currency forwards2,968 Other current liabilities
Total return swap271 11 Other current liabilities
August 31, 2021NotionalFair
Value
Location in Consolidated Condensed Balance Sheets
Derivatives designated as hedges:
Cross currency interest rate swaps$155 $Other non-current assets
Foreign currency forwards— Other non-current assets
Foreign currency forwards23 Other non-current liabilities
Cross currency interest rate swaps801 23 Other non-current liabilities
Foreign currency forwards575 Other current assets
Foreign currency forwards31 Other current liabilities
Cross currency interest rate swaps109 Other current liabilities
Derivatives not designated as hedges:
Foreign currency forwards$3,636 $38 Other current assets
Total return swap224 Other current assets
Foreign currency forwards808 Other current liabilities
Total return swap37 — Other current liabilities

Net investment hedges
The Company uses cross currency interest rate swaps and foreign currency forward contracts to hedge net investments in subsidiaries with non-U.S. dollar functional currencies. For qualifying net investment hedges, changes in the fair value of the derivatives are recorded in the currency translation adjustment within accumulated other comprehensive income (loss).
Cash flow hedges
The Company uses interest rate swaps to hedge the variability in forecasted cash flows of certain floating-rate debt. For qualifying cash flow hedges, changes in the fair value of the derivatives are recorded in accumulated other comprehensive income (loss) and released to the Consolidated Statements of Earnings when the hedged cash flows affect earnings.
Derivatives not designated as hedges
The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of foreign currency risks. The Company also utilizes total return swaps to economically hedge variability in compensation charges related to certain deferred compensation obligations. The income (expenses) due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):
  Three months ended November 30,
 Location in Consolidated Condensed Statements of Earnings20212020
Foreign currency forwardsSelling, general and administrative expenses$55 $(29)
Total return swapSelling, general and administrative expenses(2)13 
Foreign currency forwardsOther income (expense)(1)(9)

Derivatives credit risk
Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.

Derivatives offsetting
The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.21.4
Fair value measurements
3 Months Ended
Nov. 30, 2021
Fair Value Disclosures [Abstract]  
Fair value measurements Fair value measurements
The Company measures certain assets and liabilities in accordance with Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2 - Observable inputs other than quoted prices in active markets.
Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
 November 30, 2021Level 1Level 2Level 3
Assets:
    
Money market funds 1
$319 $319 $— $— 
Investments in equity securities 2
— — 
Investments in debt securities 3
20 — — 20 
Foreign currency forwards 5
81 — 81 — 
Cross currency interest rate swaps 6
— — 
Liabilities:
    
Foreign currency forwards 5
$$— $$— 
Cross currency interest rate swaps 6
12 — 12 — 
Total return swap11 — 11 — 
 August 31, 2021Level 1Level 2Level 3
Assets:
    
Money market funds 1
$634 $634 $— $— 
Investments in equity securities 2
— — 
Investments in debt securities 4
663 — — 663 
Foreign currency forwards 5
46 — 46 — 
Cross currency interest rate swaps 6
— — 
Total return swaps— — 
Liabilities:
Foreign currency forwards 5
$$— $$— 
Cross currency interest rate swaps 6
32 — 32 — 

1Money market funds are valued at the closing price reported by the fund sponsor.
2Fair values of quoted investments are based on current bid prices as of November 30, 2021 and August 31, 2021.
3Level 3 debt securities are valued using standard valuation techniques based on income and market approach.
4Level 3 debt securities include investments in convertible debt securities of VillageMD which are valued on a quarterly basis using the Probability Weighted Expect Return Method with gains or losses recorded in Other Comprehensive Income. Inputs include the enterprise value, expected holding term of the investment, volatility and risk-free interest rates.
5The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 9 Financial instruments, for additional information.
6The fair value of interest rate swaps and cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 9 Financial instruments, for additional information.

There were no transfers between Levels for the three months ended November 30, 2021.
The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the Consolidated Financial Statements. As of November 30, 2021 the carrying amounts and estimated fair values of long-term notes outstanding including the current portion were $8.5 billion and $9.2 billion, respectively. The fair values of the notes outstanding are Level 1 fair value measures and determined based on quoted market prices and translated at the November 30, 2021 rate, as applicable. The fair values and carrying values of these issuances do not include notes that have been redeemed or repaid as of November 30, 2021. See Note 8 Debt, for further information.

The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.21.4
Commitments and contingencies
3 Months Ended
Nov. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
The Company is involved in legal proceedings, including litigation, arbitration and other claims, and investigations, inspections, subpoenas, audits, claims, inquiries and similar actions by pharmacy, healthcare, tax and other governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized.

Like other companies in the retail pharmacy and pharmaceutical wholesale industries, the Company is subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which it operates. There continues to be a heightened level of review and/or audit by regulatory authorities of, and increased litigation regarding, the Company’s and the rest of the health care and related industry’s business, compliance and reporting practices. As a result, the Company regularly is the subject of government actions of the types described above. The Company also may be named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.

The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. With respect to litigation and other legal proceedings where the Company has determined that a material loss is reasonably possible, except as otherwise noted, the Company is unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.

On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co. and Walgreen Co., as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. (Cutler v. Wasson et al., No. 1:14-cv-10408 (N.D. Ill.)) The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On May 18, 2015, the case was stayed in light of a securities class action that was filed on April 10, 2015, described below. On November 3, 2016, the Court entered a stipulation and order extending the stay until the resolution of the securities class action.
On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. (Washtenaw County Employees’ Retirement System v. Walgreen Co. et al., No. 1:15-cv-3187 (N.D. Ill.)) The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. A motion to dismiss a consolidated class action complaint filed on August 17, 2015 was granted in part and denied in part on September 30, 2016. The court granted plaintiff’s motion for class certification on March 29, 2018 and plaintiff filed a first amended complaint on December 19, 2018. A motion to dismiss the first amended complaint was granted in part and denied in part on September 23, 2019. Fact discovery and expert discovery have concluded. On November 2, 2021, the Court denied plaintiffs’ motion for summary judgment and granted in part and denied in part defendants’ cross motion.

On December 11, 2017, purported Rite Aid shareholders filed an amended complaint in a putative class action lawsuit in the U.S. District Court for the Middle District of Pennsylvania (the “M.D. Pa. action”) arising out of transactions contemplated by the merger agreement between the Company and Rite Aid. The amended complaint alleged that the Company and certain of its officers made false or misleading statements regarding the transactions. The Court denied the Company’s motion to dismiss the amended complaint on April 15, 2019. The Company filed an answer and affirmative defenses, and the Court granted plaintiffs' motion for class certification. Fact discovery has concluded and expert discovery is ongoing. In October and December 2020, two separate purported Rite Aid Shareholders filed lawsuits in the same court as the M.D. Pa. action opting out of the class in the M.D. Pa. action making nearly identical allegations as those in the M.D. Pa. action (the “Direct Actions”). On December 24, 2020, the parties to the Direct Actions filed a joint stipulation to stay the Direct Actions until the earlier of (a) 30 days after the entry of an order resolving any pre-trial dispositive motions in the M.D. Pa. action, or (b) 30 days after the entry of an order of final approval of any settlement of the M.D. Pa. action. The court so ordered the joint stipulation on December 28, 2020.

In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against an array of defendants by various plaintiffs such as counties, cities, hospitals, Indian tribes, and others, alleging claims generally concerning the impacts of widespread opioid abuse. The consolidated multidistrict litigation, captioned In re National Prescription Opiate Litigation (MDL No. 2804, Case No. 17-md-2804), is pending in the U.S. District Court for the Northern District of Ohio ("N.D. Ohio"). The Company is involved in the following multidistrict litigation (MDL) bellwether cases: (1) two consolidated cases in N.D. Ohio (Cnty. of Summit, Ohio, et al v. Purdue Pharma L.P., et al., Case No. 18-op-45090; Cnty. of Cuyahoga, Ohio, et al. v. Purdue Pharma L.P., Case No. 18-op-45004), previously scheduled for trial in November 2020 but postponed indefinitely; (2) one remanded to the U. S. District Court for the Eastern District of Oklahoma (The Cherokee Nation v. McKesson Corp., et al., Case No. 18-CV-00056-RAW-SPS), scheduled for trial in September 2022; and (3) one remanded to the U.S. District Court for the Northern District of California (City and Cnty. of San Francisco, et al. v. Purdue Pharma L.P., et al., Case No. 3:18-cv-07591-CRB), originally scheduled for trial in October 2021, but rescheduled for April 2022. The Company was also involved in two additional consolidated cases in N.D. Ohio (Cnty. of Lake, Ohio v. Purdue Pharma L.P., et al., Case No. 18-op-45032; Cnty. of Trumbull, Ohio v. Purdue Pharma L.P., et al., Case No. 18-op-45079), initially scheduled for trial in May 2021 but continued until October 2021. The jury in that case returned a verdict in favor of the plaintiffs as to liability, and the court will schedule a second trial regarding remedies to take place at some point in 2022. The court has yet to determine how much each defendant will pay in damages. The Company is unable to predict the outcome relative to remedies or apportionment and believes it has very strong grounds for appeal. In April 2021, the MDL court selected five additional bellwether cases involving the Company, all currently pending in N.D. Ohio: (1) Cobb Cnty. v. Purdue Pharma L.P., et al., Case No. 18-op-45817; (2) Durham Cnty. v. AmerisourceBergen Drug Corp., et al., Case No. 19-op-45346; (3) Montgomery Cnty. Bd. of Cnty. Commrs., et al. v. Cardinal Health, Inc., et al., Case No. 18-op-46326; (4) Board of Cnty. Commrs. of the Cnty. of Santa Fe v. Purdue Pharma L.P., et al., Case No. 18-op-45776; and (5) Cnty. of Tarrant v. Purdue Pharma L.P., et al., Case No. 18-op-45274.

The Company also has been named as a defendant in numerous lawsuits brought in state courts relating to opioid matters. Trial dates have been set in cases pending in state courts in New Mexico (State of New Mexico, ex rel. Hector Balderas, Attorney General v. Purdue Pharma L.P., et al., Case No. D-101-cv-2017-02541, First Judicial District Court, Santa Fe County, New Mexico - September 2022); West Virginia (State of West Virginia, ex rel. Patrick Morrisey, Attorney General v. Walgreens Boots Alliance, Inc., et al., Civil Action No.20-C-82 PNM, Circuit Court of Kanawha County, West Virginia, - September 2022; Missouri (Jefferson County, Missouri v. Dannie E. Williams, M.D., et al., Cause No. 20JE-CC00029, Twenty-Third Judicial Circuit, Jefferson County, Missouri - April 2023); Florida (State of Florida, Office of the Attorney General, Department of Legal Affairs v. Purdue Pharma L.P., et al., Case No. 2018-CA-001438, Sixth Judicial Circuit in and for Pasco County, Florida - April 2022); Nevada (State of Nevada v. McKesson Corporation, et al., Case No. A-19-796755-B, Eighth Judicial District Court, Clark County, Nevada - April 2023); Michigan (State of Michigan, ex rel. Dana Nessel, Attorney General v. Cardinal Health, Inc., et al., Case No. 19-016896-NZ, Circuit Court for Wayne County, Michigan - October 2022);
and Alabama (The DCH Health Care Authority, et al. v. Purdue Pharma LP, et al., Cause No. CV-2019-000007.00, Circuit Court of Conecuh County, Alabama - July 2022).

The relief sought by various plaintiffs in these matters includes compensatory, abatement and punitive damages, as well as injunctive relief. Additionally, the Company has received from the Department of Justice and the Attorney Generals of numerous states subpoenas, civil investigative demands, and/or other requests concerning opioid matters. The Company has also had communications with the Department of Justice with respect to purported violations of the federal Controlled Substances Act and the federal False Claims Act in dispensing prescriptions at certain Walgreens locations.

As discussed above, legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs and penalties incurred in these matters can be substantial.
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.21.4
Income taxes
3 Months Ended
Nov. 30, 2021
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The effective tax rate for the three months ended November 30, 2021 was an expense of 7.2%, primarily due to lower tax expense on gains from consolidation of the Company’s investment in VillageMD and Shields, as a portion of these gains is not subject to tax. See Note 3 Acquisitions for further information.

The effective tax rate for the three months ended November 30, 2020 was a benefit of 34.0%, on a pretax loss for the three months ended November 30, 2020, primarily due to the discrete tax effect of equity losses in AmerisourceBergen. See Note 6 Equity method investments for further information.

Income taxes paid for the three months ended November 30, 2021 were $34 million, compared to $16 million for the three months ended November 30, 2020.
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.21.4
Retirement benefits
3 Months Ended
Nov. 30, 2021
Retirement Benefits [Abstract]  
Retirement benefits Retirement benefits
The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan.

Defined benefit pension plans (non-U.S. plans)
The Company has various defined benefit pension plans outside the U.S. The principal defined benefit pension plan is the Boots Pension Plan (the “Boots Plan”), which covers certain employees in the UK. The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis.

Components of net periodic pension costs (income) for the defined benefit pension plans (in millions):
 Three months ended November 30,
 Location in Consolidated Condensed Statements of Earnings20212020
Service costsSelling, general and administrative expenses$$
Interest costsOther expense39 33 
Expected returns on plan assets/otherOther income(74)(80)
Total net periodic pension costs (income)$(33)$(45)

The Company made cash contributions to its defined benefit pension plans of $1 million for the three months ended November 30, 2021, which primarily related to committed payments. The Company plans to contribute an additional $40 million to its defined benefit pension plans in fiscal 2022.

Defined contribution plans
The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution is in the form of a guaranteed match which is made pursuant to the applicable plan document approved by the Walgreen Co. Board of Directors. Plan activity is reviewed
periodically by certain Committees of the Walgreens Boots Alliance Board of Directors. The profit-sharing provision was an expense of $69 million and $57 million for the three months ended November 30, 2021 and 2020, respectively.

The Company also has certain contract based defined contribution arrangements. The principal arrangement is based in UK to which both the Company and participating employees contribute. The Company recognized an expense of $25 million and $26 million for the three months ended November 30, 2021 and 2020, respectively.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.21.4
Accumulated other comprehensive income (loss)
3 Months Ended
Nov. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated other comprehensive income (loss) Accumulated other comprehensive income (loss)
The following is a summary of net changes in accumulated other comprehensive income (“AOCI”) by component and net of tax for the three months ended November 30, 2021 and 2020 (in millions):

Pension/ post-retirement obligationsUnrealized gain (loss) on cash flow hedgesNet investment hedgesUnrealized gain (loss) on available for sale securitiesShare of OCI of equity method investmentsCumulative translation adjustmentsTotal
Balance at August 31, 2021$(359)$(10)$(35)$96 $(29)$(1,772)$(2,109)
Other comprehensive income (loss) before reclassification adjustments(1)53 450 (60)(88)356 
Amounts reclassified from AOCI(5)— (577)— (4)(585)
Tax benefit (provision)— (9)31 14 — 37 
Net change in other comprehensive income (loss)(5)44 (96)(46)(91)(193)
Balance at November 30, 2021$(364)$(9)$9 $ $(74)$(1,863)$(2,301)

Pension/ post-retirement obligationsUnrealized gain (loss) on cash flow hedgesNet investment hedgesUnrealized gain (loss) on available for sale securitiesShare of AOCI of equity method investmentsCumulative translation adjustmentsTotal
Balance at August 31, 2020$(748)$(31)$(34)$— $(10)$(2,948)$(3,771)
Other comprehensive income (loss) before reclassification adjustments17 (14)— 72 85 
Amounts reclassified from AOCI(2)— — — 
Tax benefit (provision)(4)(1)— (1)— 
Net change in other comprehensive income (loss)11 (7)— 75 88 
Balance at November 30, 2020$(736)$(27)$(41)$ $(5)$(2,873)$(3,682)
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.21.4
Segment reporting
3 Months Ended
Nov. 30, 2021
Segment Reporting [Abstract]  
Segment reporting Segment reporting
In conjunction with the launch of its new consumer-centric healthcare strategy, in fiscal 2022, the Company announced the creation of a new operating segment, Walgreens Health. As a result, beginning in fiscal year 2022, the Company is now aligned into three reportable segments: United States, International and Walgreens Health. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.

United States
The Company’s United States segment includes the Walgreens business which includes the operations of retail drugstores, health and wellness services, and specialty and home delivery pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise.

International
The Company’s International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, the Benavides brand in Mexico and the Ahumada brand in Chile. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products.

Walgreens Health
The Company’s Walgreens Health segment currently consists of Walgreens Health, an organically developed consumer-centric omni-channel business that contracts with payors and providers to deliver clinical healthcare services to their members through both digital and physical channels; a majority equity ownership position in VillageMD, a leading, national provider of value-based primary care services; a majority equity ownership position in Shields, a specialty pharmacy integrator and accelerator for hospitals.

Selling, general and administrative costs for Walgreens Health for the three months ended November 30, 2020 have been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation.

The results of operations for reportable segments include procurement benefits. Corporate-related overhead costs are not allocated to reportable segments and are reported in the “Corporate and Other”.
The following table reflects results of operations of the Company’s reportable segments (in millions):

Three months ended November 30,
20212020
Sales:
United States$28,032 $27,163 
International5,818 4,285 
Walgreens Health51 — 
Corporate and Other 1
— (10)
Walgreens Boots Alliance, Inc.$33,901 $31,438 
Adjusted Operating income:
United States$1,690 $1,155 
International164 87 
Walgreens Health(13)(3)
Corporate and Other 1
(63)(42)
Walgreens Boots Alliance, Inc.$1,777 $1,196 

1Includes certain eliminations.

The following table reconciles adjusted operating income to operating income (in millions):

Three months ended November 30,
20212020
Adjusted operating income$1,777 $1,196 
Transformational cost management(203)(100)
Acquisition-related amortization(165)(95)
Acquisition-related costs(71)(21)
Adjustments to equity earnings (loss) in AmerisourceBergen(43)(1,481)
LIFO provision(14)(33)
Operating income (loss)$1,283 $(535)
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.21.4
Sales
3 Months Ended
Nov. 30, 2021
Revenue from Contract with Customer [Abstract]  
Sales Sales
The following table summarizes the Company’s sales by segment and by major source (in millions):
Three months ended November 30,
20212020
United States
Pharmacy$21,105 $20,869 
Retail6,927 6,294 
Total28,032 27,163 
International
Pharmacy1,017 895 
Retail1,796 1,522 
Wholesale3,005 1,868 
Total5,818 4,285 
Walgreens Health51 — 
Corporate and Other 1
— (10)
Walgreens Boots Alliance, Inc.$33,901 $31,438 
1Includes certain eliminations.

See Note 19 Supplemental information for further information on receivables from contracts with customers.
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.21.4
Related parties
3 Months Ended
Nov. 30, 2021
Related Party Transactions [Abstract]  
Related parties Related parties
The Company has a long-term pharmaceutical distribution agreement with AmerisourceBergen pursuant to which the Company sources branded and generic pharmaceutical products from AmerisourceBergen principally for its U.S. operations. Additionally, AmerisourceBergen receives sourcing services for generic pharmaceutical products.
Related party transactions with AmerisourceBergen (in millions):
 Three months ended November 30,
 20212020
Purchases, net$15,791 $15,441 

 November 30, 2021August 31, 2021
Trade accounts payable, net$6,909 $6,589 

See Note 2 Discontinued operations for further information.
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.21.4
New accounting pronouncements
3 Months Ended
Nov. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New accounting pronouncements Accounting policies
Basis of presentation
The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated.

The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2021, as amended by Form 10-K/A for the fiscal year ended August 31, 2021 filed on November 24, 2021.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of the COVID-19 pandemic (“COVID-19”). The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous factors discussed throughout this Quarterly Report on Form 10-Q including, but not limited to, the severity and duration of COVID-19, the extent to which it will impact our customers, team members, suppliers, vendors, business partners and distribution channels. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of November 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ.

In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years.

On June 1, 2021, the Company completed the sale of the majority of the Company's Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (“Disposal Group”) to AmerisourceBergen Corporation (“AmerisourceBergen”). The Disposal Group met the criteria to be reported as discontinued operations. Therefore, the operating results of the Disposal Group are reported as discontinued operations for all prior periods.

Effective as of the first quarter of fiscal year 2022, the Company is aligned into three reportable segments: United States, International and Walgreens Health. Unless otherwise specified, disclosures in these Consolidated Condensed Financial Statements reflect continuing operations only. Certain prior period data, related to discontinued operations has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. See Note 2 Discontinued operations and Note 15 Segment reporting for further information.

Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented.
New accounting pronouncements
Adoption of new accounting pronouncements

Receivables - nonrefundable fees and others
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other. This ASU clarifies the accounting for the amortization period for certain purchased callable debt securities held at a premium by giving consideration to securities which have multiple call dates. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.
Investments — equity securities; Investments — equity method and joint ventures; Derivatives and hedging
In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Income taxes - simplifying the accounting for income taxes
In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Effects of reference rate reform on financial reporting
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable, or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to the above the ASU to clarify certain optional expedients in Topic 848. The Company adopted the new standard effective September 1, 2021, and the adoption did not have a material impact on the Company’s results of operations, cash flows or financial position.

New accounting pronouncements not yet adopted

Acquired contract assets and contract liabilities in a business combination
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance.

Disclosures by business entities about government assistance
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021 (fiscal 2023). The Company is evaluating the effect of adopting this new accounting guidance.
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.21.4
Supplemental information
3 Months Ended
Nov. 30, 2021
Supplemental Cash Flow Elements [Abstract]  
Supplemental information Supplemental information
Accounts receivable
Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, including amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies). Trade receivables were $4.6 billion and $4.5 billion at November 30, 2021 and August 31, 2021, respectively. Other accounts receivable balances, which consist primarily of receivables from vendors and manufacturers, including receivables from AmerisourceBergen (see Note 17 Related parties), were $1.3 billion and $1.1 billion at November 30, 2021 and August 31, 2021, respectively.
Depreciation and amortization
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):
Three months ended November 30,
20212020
Depreciation expense$335 $342 
Intangible asset and other amortization165 95 
Total depreciation and amortization expense$500 $437 

Accumulated depreciation and amortization on property, plant and equipment was $13.3 billion at November 30, 2021 and $13.1 billion at August 31, 2021.

Restricted cash
The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):
November 30, 2021August 31, 2021
Cash and cash equivalents - continuing operations$4,135 $1,193 
Restricted cash - continuing operations (included in other current assets)133 77 
Cash, cash equivalents and restricted cash$4,268 $1,270 

Redeemable noncontrolling interest
The redeemable noncontrolling interest balance as of November 30, 2021 was $2,787 million increasing primarily due to acquisitions during the three months ended November 30, 2021. See Note 3 Acquisitions for further information.

The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):
Redeemable noncontrolling interest roll forward:Walgreens Boots Alliance, Inc.
August 31, 2021$319 
Acquisitions 1
2,489 
Net (loss)(21)
Redemption value adjustment
Currency translation adjustments and other(8)
November 30, 2021$2,787 

1 Includes $1.9 billion of redeemable non-controlling interest representing the maximum purchase price to redeem non-controlling units in VillageMD for cash. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.
Earnings per share
The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 16.1 million weighted outstanding options to purchase common shares that were anti-dilutive and excluded from the first quarter earnings per share calculation as of November 30, 2021 compared to 18.5 million as of November 30, 2020.

Due to the anti-dilutive effect resulting from the reported net loss for the three months ended November 30, 2020, the incremental impact of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding.

Cash dividends declared per common share
Cash dividends per common share declared were as follows:

Quarter ended20212020
November$0.4775 $0.4675 
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.21.4
Accounting policies (Policies)
3 Months Ended
Nov. 30, 2021
Accounting Policies [Abstract]  
Basis of presentation
Basis of presentation
The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated.

The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2021, as amended by Form 10-K/A for the fiscal year ended August 31, 2021 filed on November 24, 2021.

The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of the COVID-19 pandemic (“COVID-19”). The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous factors discussed throughout this Quarterly Report on Form 10-Q including, but not limited to, the severity and duration of COVID-19, the extent to which it will impact our customers, team members, suppliers, vendors, business partners and distribution channels. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of November 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ.

In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years.

On June 1, 2021, the Company completed the sale of the majority of the Company's Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (“Disposal Group”) to AmerisourceBergen Corporation (“AmerisourceBergen”). The Disposal Group met the criteria to be reported as discontinued operations. Therefore, the operating results of the Disposal Group are reported as discontinued operations for all prior periods.

Effective as of the first quarter of fiscal year 2022, the Company is aligned into three reportable segments: United States, International and Walgreens Health. Unless otherwise specified, disclosures in these Consolidated Condensed Financial Statements reflect continuing operations only. Certain prior period data, related to discontinued operations has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. See Note 2 Discontinued operations and Note 15 Segment reporting for further information.
Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented.
Adoption of new accounting pronouncements; New accounting pronouncements not yet adopted
Adoption of new accounting pronouncements

Receivables - nonrefundable fees and others
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other. This ASU clarifies the accounting for the amortization period for certain purchased callable debt securities held at a premium by giving consideration to securities which have multiple call dates. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.
Investments — equity securities; Investments — equity method and joint ventures; Derivatives and hedging
In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Income taxes - simplifying the accounting for income taxes
In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

Effects of reference rate reform on financial reporting
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable, or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to the above the ASU to clarify certain optional expedients in Topic 848. The Company adopted the new standard effective September 1, 2021, and the adoption did not have a material impact on the Company’s results of operations, cash flows or financial position.

New accounting pronouncements not yet adopted

Acquired contract assets and contract liabilities in a business combination
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance.

Disclosures by business entities about government assistance
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021 (fiscal 2023). The Company is evaluating the effect of adopting this new accounting guidance.
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.21.4
Discontinued operations (Tables)
3 Months Ended
Nov. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Schedules of Discontinued Operations
Results of discontinued operations were as follows (in millions):
 Three months ended November 30, 2020
Sales$5,327 
Cost of sales4,818 
Gross profit509 
Selling, general and administrative expense415 
Operating income from discontinued operations94 
Other expense(2)
Interest expense, net(4)
Earnings before income tax – discontinued operations88 
Income tax provision8
Post tax earnings from other equity method investments7
Net earnings from discontinued operations$87 

Sales from the Disposal Group to the Company's continuing operations are not eliminated and aggregate to (in millions):
 Three months ended November 30, 2020
Sales$458 

Cash flows from operating and investing activities for discontinued operations are (in millions):
 Three months ended November 30, 2020
Cash used in operating activities - discontinued operations$(45)
Cash used for investing activities - discontinued operations(19)
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.21.4
Acquisitions (Tables)
3 Months Ended
Nov. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Schedule of Identifiable Assets Acquired and Liabilities Assumed
The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):

Purchase Price Allocation:
Total purchase price$5,200 
Less: purchase price for issuance of new preferred units at fair value 1
(2,300)
Net consideration$2,900 
Fair value of share-based compensation awards attributable to pre-combination services 2
683 
Fair value of previously held equity and debt3,211 
Fair value of non-controlling interest3,257 
Total$10,051 
Identifiable assets acquired and liabilities assumed:
Tangible assets 1
$637 
Intangible assets1,982 
Liabilities(241)
Total identifiable net assets$2,378 
Goodwill$7,673 
1.Comprises cash consideration of $1.1 billion and a promissory note of $1.2 billion. This consideration was provided in exchange for the issuance of new preferred units by VillageMD. VillageMD’s tangible assets acquired exclude this $1.1 billion of cash and $1.2 billion promissory note receivable.
2.Primarily related to vested share-based compensation awards.
The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):

Purchase Price Allocation:
Cash consideration$969 
Fair value of share-based compensation awards attributable to pre-combination services13 
Fair value of previously held equity interests502 
Fair value of non-controlling interests589 
Total$2,074 
Identifiable assets acquired and liabilities assumed:
Tangible assets$84 
Intangible assets1,060 
Liabilities(528)
Total identifiable net assets$616 
Goodwill$1,457 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.21.4
Exit and disposal activities (Tables)
3 Months Ended
Nov. 30, 2021
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
Costs related to exit and disposal activities under the Transformational Cost Management Program for the three months ended November 30, 2021 and 2020, respectively, were as follows (in millions):
Three months ended November 30, 2021United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$87 $$— $89 
Asset impairments15 25 — 40 
Employee severance and business transition costs20 10 37 
Information technology transformation and other exit costs
Total pre-tax exit and disposal charges$123 $44 $9 $175 
Three months ended November 30, 2020United StatesInternationalCorporate and OtherWalgreens Boots Alliance, Inc.
Lease obligations and other real estate costs$22 $— $— $22 
Asset impairments(2)— 
Employee severance and business transition costs12 28 12 52 
Information technology transformation and other exit costs10 (5)— 
Total pre-tax exit and disposal charges$48 $21 $12 $81 
Change in Restructuring Liabilities
The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):
Lease obligations and other real estate costsAsset ImpairmentsEmployee severance and business transition costsInformation technology transformation and other exit costsTotal
Balance at August 31, 2021$17 $— $77 $20 $114 
Costs89 40 37 175 
Payments(15)— (51)(7)(74)
Other(72)(40)(3)— (115)
Currency— — (1)— (1)
Balance at November 30, 2021$19 $ $59 $23 $101 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.21.4
Leases (Tables)
3 Months Ended
Nov. 30, 2021
Leases [Abstract]  
Schedule of Supplemental Balance Sheet Information
Supplemental balance sheet information related to leases were as follows (in millions):

Balance Sheet supplemental information:November 30, 2021August 31, 2021
Operating Leases:
Operating lease right-of-use assets$21,826 $21,893 
Operating lease obligations - current2,266 2,259 
Operating lease obligations - non-current 22,103 22,153 
Total operating lease obligations$24,369 $24,412 
Finance Leases:
Right-of-use assets included in:
Property, plant and equipment, net$713 $725 
Lease obligations included in:
Accrued expenses and other liabilities37 37 
Other non-current liabilities963 974 
Total finance lease obligations$1,000 $1,010 
Schedule of Supplemental Income Statement and Other Information
Supplemental income statement information related to leases were as follows (in millions):
Three months ended November 30,
Statement of Earnings supplemental information:20212020
Operating lease cost
Fixed$805 $805 
Variable 1
205 158 
Finance lease cost
Amortization$11 $11 
Interest13 13 
Sublease income25 20 
Impairment of right-of-use assets68 10 
Gain on sale and leaseback 2
87 93 

1Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume.
2Recorded within selling, general and administrative expenses.

Other supplemental information related to leases were as follows (in millions):
Three months ended November 30,
Other Supplemental Information:20212020
Cash paid for amounts included in the measurement of lease obligations:
Operating cash flows from operating leases$846 $857 
Operating cash flows from finance leases12 12 
Financing cash flows from finance leases11 10 
Total$869 $879 
Right-of-use assets obtained in exchange for new lease obligations:
Operating leases$544 $787 
Finance leases— 
Total$549 $787 

Average lease term and discount rate were as follows:
Weighted average terms and discount rates:November 30, 2021August 31, 2021
Weighted average remaining lease term in years:
Operating leases10.210.3
Finance leases20.120.2
Weighted average discount rate:
Operating leases4.75 %4.77 %
Finance leases5.18 %5.18 %
Schedule of Aggregate Future Lease Payments Under Operating Leases
The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):
Future lease payments:
Fiscal yearFinance leaseOperating lease
2022 (Remaining period)$67 $2,608 
202388 3,376 
202488 3,260 
202587 3,145 
202687 3,032 
202786 2,924 
Later1,054 12,801 
Total undiscounted minimum lease payments$1,556 $31,146 
Less: Present value discount(556)(6,777)
Lease liability$1,000 $24,369 
Schedule of Aggregate Future Lease Payments Under Finance Leases
The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):
Future lease payments:
Fiscal yearFinance leaseOperating lease
2022 (Remaining period)$67 $2,608 
202388 3,376 
202488 3,260 
202587 3,145 
202687 3,032 
202786 2,924 
Later1,054 12,801 
Total undiscounted minimum lease payments$1,556 $31,146 
Less: Present value discount(556)(6,777)
Lease liability$1,000 $24,369 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.21.4
Equity method investments (Tables)
3 Months Ended
Nov. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Equity Method Investments Equity method investments were as follows (in millions, except percentages):
 November 30, 2021August 31, 2021
 Carrying valueOwnership percentageCarrying valueOwnership percentage
AmerisourceBergen$4,393 28%$4,407 28%
Others1,974 
8% - 50%
2,580 
8% - 50%
Total$6,367  $6,987  
Summarized Financial Information of Equity Method Investments Summarized financial information for the Company’s equity method investments in aggregate is as follows:Statements of earnings (loss) (in millions)
 Three months ended November 30,
20212020
Sales$67,588 $56,088 
Gross Profit3,420 2,410 
Net earnings (loss)308 (4,806)
Share of earnings (loss) from equity method investments93 (1,357)
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.21.4
Goodwill and other intangible assets (Tables)
3 Months Ended
Nov. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions):

Goodwill roll forward:United StatesInternationalWalgreens HealthWalgreens Boots Alliance, Inc.
August 31, 2021$10,947 $1,474 $— $12,421 
Acquisitions— — 9,130 9,130 
Currency translation adjustments— (32)— (32)
November 30, 2021$10,947 $1,443 $9,130 $21,520 
Schedule of Finite-Lived Intangible Assets by Major Class
The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):

Intangible assetsNovember 30, 2021August 31, 2021
Gross amortizable intangible assets  
Customer relationships and loyalty card holders 1
$4,430 $3,522 
Primary care provider network1,660 — 
Trade names and trademarks708 361 
Purchasing and payer contracts317 317 
Developed technology290 — 
Others 75 221 
Total gross amortizable intangible assets$7,479 $4,421 
Accumulated amortization  
Customer relationships and loyalty card holders 1
$1,395 $1,335 
Trade names and trademarks228 226 
Purchasing and payer contracts284 227 
Developed technology17 — 
Others 29 37 
Total accumulated amortization1,953 1,826 
Total amortizable intangible assets, net$5,526 $2,595 
Indefinite-lived intangible assets  
Trade names and trademarks$5,208 $5,276 
Pharmacy licenses2,036 2,066 
Total indefinite-lived intangible assets$7,244 $7,342 
Total intangible assets, net$12,770 $9,936 

1Includes purchased prescription files.
Schedule of Future Amortization Expense Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2021 is as follows (in millions):
 2022 (Remaining period)20232024202520262027
Estimated annual amortization expense$462 $560 $541 $514 $490 $443 
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.21.4
Debt (Tables)
3 Months Ended
Nov. 30, 2021
Debt Disclosure [Abstract]  
Short-Term Borrowings Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):
 November 30, 2021August 31, 2021
Short-term debt   
Commercial paper$875 $— 
Credit facilities799 — 
$8 billion note issuance 1
3.300% unsecured notes due 2021 2
— 1,250 
$4 billion note issuance 4
3.100% unsecured notes due 2022
731 — 
Other 3
242 56 
Total short-term debt$2,647 $1,305 
Long-term debt   
Credit facilities $2,990 $— 
$850 million note issuance 1
0.9500% unsecured notes due 2023
848 — 
$1.5 billion note issuance 1
3.200% unsecured notes due 2030
497 497 
4.100% unsecured notes due 2050
792 792 
$6 billion note issuance 1
  
3.450% unsecured notes due 2026
1,442 1,442 
4.650% unsecured notes due 2046
318 318 
$8 billion note issuance 1
3.800% unsecured notes due 2024
1,154 1,154 
4.500% unsecured notes due 2034
301 301 
4.800% unsecured notes due 2044
868 868 
£700 million note issuance 1
3.600% unsecured Pound sterling notes due 2025
403 408 
€750 million note issuance 1
2.125% unsecured Euro notes due 2026
846 873 
$4 billion note issuance 4
3.100% unsecured notes due 2022
— 731 
4.400% unsecured notes due 2042
263 263 
Other 3
477 29 
Total long-term debt, less current portion$11,199 $7,675 

1Notes are unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding.
2On September 18, 2021, the Company redeemed in full the $1.25 billion aggregate principal amount outstanding of its 3.300% unsecured notes due 2021 issued by the Company on November 18, 2014.
3Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. Other long term debt includes $447 million of debt acquired as part of Shields acquisition.
4Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.
Long-Term Debt Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):
 November 30, 2021August 31, 2021
Short-term debt   
Commercial paper$875 $— 
Credit facilities799 — 
$8 billion note issuance 1
3.300% unsecured notes due 2021 2
— 1,250 
$4 billion note issuance 4
3.100% unsecured notes due 2022
731 — 
Other 3
242 56 
Total short-term debt$2,647 $1,305 
Long-term debt   
Credit facilities $2,990 $— 
$850 million note issuance 1
0.9500% unsecured notes due 2023
848 — 
$1.5 billion note issuance 1
3.200% unsecured notes due 2030
497 497 
4.100% unsecured notes due 2050
792 792 
$6 billion note issuance 1
  
3.450% unsecured notes due 2026
1,442 1,442 
4.650% unsecured notes due 2046
318 318 
$8 billion note issuance 1
3.800% unsecured notes due 2024
1,154 1,154 
4.500% unsecured notes due 2034
301 301 
4.800% unsecured notes due 2044
868 868 
£700 million note issuance 1
3.600% unsecured Pound sterling notes due 2025
403 408 
€750 million note issuance 1
2.125% unsecured Euro notes due 2026
846 873 
$4 billion note issuance 4
3.100% unsecured notes due 2022
— 731 
4.400% unsecured notes due 2042
263 263 
Other 3
477 29 
Total long-term debt, less current portion$11,199 $7,675 

1Notes are unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding.
2On September 18, 2021, the Company redeemed in full the $1.25 billion aggregate principal amount outstanding of its 3.300% unsecured notes due 2021 issued by the Company on November 18, 2014.
3Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. Other long term debt includes $447 million of debt acquired as part of Shields acquisition.
4Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.21.4
Financial instruments (Tables)
3 Months Ended
Nov. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Notional Amounts, Fair Value and Balance Sheet Presentation of Derivative Instruments Outstanding
The notional amounts and fair value of derivative instruments outstanding were as follows (in millions):

November 30, 2021Notional Fair
Value
Location in Consolidated Condensed Balance Sheets
Derivatives designated as hedges:
Foreign currency forwards$$— Other non-current assets
Cross currency interest rate swaps1534Other non-current assets
Foreign currency forwards17— Other non-current liabilities
Cross currency interest rate swaps633 Other non-current liabilities
Foreign currency forwards61017Other current assets
Foreign currency forwards85 Other current liabilities
Cross currency interest rate swaps1575Other current liabilities
Derivatives not designated as hedges:
Foreign currency forwards$3,900 $64 Other current assets
Foreign currency forwards2,968 Other current liabilities
Total return swap271 11 Other current liabilities
August 31, 2021NotionalFair
Value
Location in Consolidated Condensed Balance Sheets
Derivatives designated as hedges:
Cross currency interest rate swaps$155 $Other non-current assets
Foreign currency forwards— Other non-current assets
Foreign currency forwards23 Other non-current liabilities
Cross currency interest rate swaps801 23 Other non-current liabilities
Foreign currency forwards575 Other current assets
Foreign currency forwards31 Other current liabilities
Cross currency interest rate swaps109 Other current liabilities
Derivatives not designated as hedges:
Foreign currency forwards$3,636 $38 Other current assets
Total return swap224 Other current assets
Foreign currency forwards808 Other current liabilities
Total return swap37 — Other current liabilities
Gains and (Losses) due to Changes in Fair Value Recognized in Earnings The income (expenses) due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):
  Three months ended November 30,
 Location in Consolidated Condensed Statements of Earnings20212020
Foreign currency forwardsSelling, general and administrative expenses$55 $(29)
Total return swapSelling, general and administrative expenses(2)13 
Foreign currency forwardsOther income (expense)(1)(9)
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.21.4
Fair value measurements (Tables)
3 Months Ended
Nov. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis
Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
 November 30, 2021Level 1Level 2Level 3
Assets:
    
Money market funds 1
$319 $319 $— $— 
Investments in equity securities 2
— — 
Investments in debt securities 3
20 — — 20 
Foreign currency forwards 5
81 — 81 — 
Cross currency interest rate swaps 6
— — 
Liabilities:
    
Foreign currency forwards 5
$$— $$— 
Cross currency interest rate swaps 6
12 — 12 — 
Total return swap11 — 11 — 
 August 31, 2021Level 1Level 2Level 3
Assets:
    
Money market funds 1
$634 $634 $— $— 
Investments in equity securities 2
— — 
Investments in debt securities 4
663 — — 663 
Foreign currency forwards 5
46 — 46 — 
Cross currency interest rate swaps 6
— — 
Total return swaps— — 
Liabilities:
Foreign currency forwards 5
$$— $$— 
Cross currency interest rate swaps 6
32 — 32 — 

1Money market funds are valued at the closing price reported by the fund sponsor.
2Fair values of quoted investments are based on current bid prices as of November 30, 2021 and August 31, 2021.
3Level 3 debt securities are valued using standard valuation techniques based on income and market approach.
4Level 3 debt securities include investments in convertible debt securities of VillageMD which are valued on a quarterly basis using the Probability Weighted Expect Return Method with gains or losses recorded in Other Comprehensive Income. Inputs include the enterprise value, expected holding term of the investment, volatility and risk-free interest rates.
5The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 9 Financial instruments, for additional information.
6The fair value of interest rate swaps and cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 9 Financial instruments, for additional information.
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.21.4
Retirement benefits (Tables)
3 Months Ended
Nov. 30, 2021
Retirement Benefits [Abstract]  
Components of Net Periodic Benefit Costs (Income)
Components of net periodic pension costs (income) for the defined benefit pension plans (in millions):
 Three months ended November 30,
 Location in Consolidated Condensed Statements of Earnings20212020
Service costsSelling, general and administrative expenses$$
Interest costsOther expense39 33 
Expected returns on plan assets/otherOther income(74)(80)
Total net periodic pension costs (income)$(33)$(45)
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.21.4
Accumulated other comprehensive income (loss) (Tables)
3 Months Ended
Nov. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Components of Accumulated Other Comprehensive Income (Loss)
The following is a summary of net changes in accumulated other comprehensive income (“AOCI”) by component and net of tax for the three months ended November 30, 2021 and 2020 (in millions):

Pension/ post-retirement obligationsUnrealized gain (loss) on cash flow hedgesNet investment hedgesUnrealized gain (loss) on available for sale securitiesShare of OCI of equity method investmentsCumulative translation adjustmentsTotal
Balance at August 31, 2021$(359)$(10)$(35)$96 $(29)$(1,772)$(2,109)
Other comprehensive income (loss) before reclassification adjustments(1)53 450 (60)(88)356 
Amounts reclassified from AOCI(5)— (577)— (4)(585)
Tax benefit (provision)— (9)31 14 — 37 
Net change in other comprehensive income (loss)(5)44 (96)(46)(91)(193)
Balance at November 30, 2021$(364)$(9)$9 $ $(74)$(1,863)$(2,301)

Pension/ post-retirement obligationsUnrealized gain (loss) on cash flow hedgesNet investment hedgesUnrealized gain (loss) on available for sale securitiesShare of AOCI of equity method investmentsCumulative translation adjustmentsTotal
Balance at August 31, 2020$(748)$(31)$(34)$— $(10)$(2,948)$(3,771)
Other comprehensive income (loss) before reclassification adjustments17 (14)— 72 85 
Amounts reclassified from AOCI(2)— — — 
Tax benefit (provision)(4)(1)— (1)— 
Net change in other comprehensive income (loss)11 (7)— 75 88 
Balance at November 30, 2020$(736)$(27)$(41)$ $(5)$(2,873)$(3,682)
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.21.4
Segment reporting (Tables)
3 Months Ended
Nov. 30, 2021
Segment Reporting [Abstract]  
Reconciliation of Operating Income (Loss) from Segments to Consolidated
The following table reflects results of operations of the Company’s reportable segments (in millions):

Three months ended November 30,
20212020
Sales:
United States$28,032 $27,163 
International5,818 4,285 
Walgreens Health51 — 
Corporate and Other 1
— (10)
Walgreens Boots Alliance, Inc.$33,901 $31,438 
Adjusted Operating income:
United States$1,690 $1,155 
International164 87 
Walgreens Health(13)(3)
Corporate and Other 1
(63)(42)
Walgreens Boots Alliance, Inc.$1,777 $1,196 

1Includes certain eliminations.

The following table reconciles adjusted operating income to operating income (in millions):

Three months ended November 30,
20212020
Adjusted operating income$1,777 $1,196 
Transformational cost management(203)(100)
Acquisition-related amortization(165)(95)
Acquisition-related costs(71)(21)
Adjustments to equity earnings (loss) in AmerisourceBergen(43)(1,481)
LIFO provision(14)(33)
Operating income (loss)$1,283 $(535)
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.21.4
Sales (Tables)
3 Months Ended
Nov. 30, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the Company’s sales by segment and by major source (in millions):
Three months ended November 30,
20212020
United States
Pharmacy$21,105 $20,869 
Retail6,927 6,294 
Total28,032 27,163 
International
Pharmacy1,017 895 
Retail1,796 1,522 
Wholesale3,005 1,868 
Total5,818 4,285 
Walgreens Health51 — 
Corporate and Other 1
— (10)
Walgreens Boots Alliance, Inc.$33,901 $31,438 
1Includes certain eliminations.
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.21.4
Related parties (Tables)
3 Months Ended
Nov. 30, 2021
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
Related party transactions with AmerisourceBergen (in millions):
 Three months ended November 30,
 20212020
Purchases, net$15,791 $15,441 

 November 30, 2021August 31, 2021
Trade accounts payable, net$6,909 $6,589 
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.21.4
Supplemental information (Tables)
3 Months Ended
Nov. 30, 2021
Supplemental Cash Flow Elements [Abstract]  
Schedule of Depreciation and Amortization Expense
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):
Three months ended November 30,
20212020
Depreciation expense$335 $342 
Intangible asset and other amortization165 95 
Total depreciation and amortization expense$500 $437 
Restrictions on Cash and Cash Equivalents The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):
November 30, 2021August 31, 2021
Cash and cash equivalents - continuing operations$4,135 $1,193 
Restricted cash - continuing operations (included in other current assets)133 77 
Cash, cash equivalents and restricted cash$4,268 $1,270 
Schedule of Cash and Cash Equivalents The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):
November 30, 2021August 31, 2021
Cash and cash equivalents - continuing operations$4,135 $1,193 
Restricted cash - continuing operations (included in other current assets)133 77 
Cash, cash equivalents and restricted cash$4,268 $1,270 
Schedule of Redeemable Noncontrolling Interest
The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):
Redeemable noncontrolling interest roll forward:Walgreens Boots Alliance, Inc.
August 31, 2021$319 
Acquisitions 1
2,489 
Net (loss)(21)
Redemption value adjustment
Currency translation adjustments and other(8)
November 30, 2021$2,787 

1 Includes $1.9 billion of redeemable non-controlling interest representing the maximum purchase price to redeem non-controlling units in VillageMD for cash. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.
Schedule of Dividends Payable
Cash dividends per common share declared were as follows:

Quarter ended20212020
November$0.4775 $0.4675 
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.21.4
Accounting policies (Details)
3 Months Ended
Nov. 30, 2021
segment
Accounting Policies [Abstract]  
Number of reportable segments 3
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.21.4
Discontinued operations - Narrative (Details) - Discontinued Operations, Disposed of by Sale - Alliance Healthcare
shares in Millions, $ in Millions
Jun. 01, 2021
USD ($)
shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Consideration from disposal $ 6,900
Cash received from disposal $ 6,700
Shares issued as part of disposal (in shares) | shares 2
Receivable for purchase price consideration $ 98
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.21.4
Discontinued operations - Schedules of Discontinued Operations (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]    
Net earnings from discontinued operations $ 0 $ 87
Discontinued Operations, Disposed of by Sale | Alliance Healthcare    
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]    
Sales   5,327
Cost of sales   4,818
Gross profit   509
Selling, general and administrative expense   415
Operating income from discontinued operations   94
Other expense   (2)
Interest expense, net   (4)
Earnings before income tax – discontinued operations   88
Income tax provision   8
Post tax earnings from other equity method investments   7
Net earnings from discontinued operations   87
Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]    
Sales   5,327
Net Cash Provided by (Used in) Discontinued Operations [Abstract]    
Cash used in operating activities - discontinued operations   (45)
Cash used for investing activities - discontinued operations   (19)
Discontinued Operations, Disposed of by Sale | Alliance Healthcare | Continuing Operations    
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]    
Sales   458
Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]    
Sales   $ 458
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.21.4
Acquisitions - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 24, 2021
Oct. 29, 2021
Nov. 30, 2021
Nov. 30, 2020
Nov. 23, 2021
Oct. 28, 2021
VillageMD            
Business Acquisition [Line Items]            
Outstanding equity interest percentage 63.00%       30.00%  
Purchase price $ 5,200          
Cash consideration, gross 4,000          
Promissory note 1,200          
Net consideration 2,900          
Value of purchase tender offer 1,900          
Cash consideration for preferred units 1,100          
Gain on sale of equity method investment 1,597          
Pre-tax gain related to conversion of previously held investment in convertible debt securities $ 577          
Shields Health Solutions Parent, LLC            
Business Acquisition [Line Items]            
Outstanding equity interest percentage   70.00%       25.00%
Gain on sale of equity method investment     $ 402      
Cash consideration, subject to purchase price adjustments   $ 969        
Other Acquisitions            
Business Acquisition [Line Items]            
Cash consideration, net     $ 74 $ 38    
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.21.4
Acquisitions - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Nov. 24, 2021
Oct. 29, 2021
Nov. 30, 2021
Aug. 31, 2021
Identifiable assets acquired and liabilities assumed:        
Goodwill     $ 21,520 $ 12,421
VillageMD        
Purchase Price Allocation:        
Total purchase price $ 5,200      
Less: purchase price for issuance of new preferred units at fair value (2,300)      
Net consideration 2,900      
Fair value of share-based compensation awards attributable to pre-combination services 683      
Fair value of previously held equity interests 3,211      
Fair value of non-controlling interests 3,257      
Total 10,051      
Identifiable assets acquired and liabilities assumed:        
Tangible assets 637      
Intangible assets 1,982      
Liabilities (241)      
Total identifiable net assets 2,378      
Goodwill $ 7,673      
Shields Health Solutions Parent, LLC        
Purchase Price Allocation:        
Cash consideration   $ 969    
Fair value of share-based compensation awards attributable to pre-combination services   13    
Fair value of previously held equity interests   502    
Fair value of non-controlling interests   589    
Total   2,074    
Identifiable assets acquired and liabilities assumed:        
Tangible assets   84    
Intangible assets   1,060    
Liabilities   (528)    
Total identifiable net assets   616    
Goodwill   $ 1,457    
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.21.4
Exit and disposal activities - Narrative (Details)
$ in Millions
1 Months Ended
Oct. 12, 2021
USD ($)
store
Dec. 20, 2018
USD ($)
Jul. 31, 2021
store
Nov. 30, 2021
USD ($)
Aug. 31, 2021
USD ($)
Nov. 30, 2020
USD ($)
Aug. 31, 2020
USD ($)
Sep. 01, 2019
USD ($)
Restructuring Cost and Reserve [Line Items]                
Cumulative effect adjustment to decrease retained earnings       $ (30,579) $ (23,822) $ (20,563) $ (21,136)  
Adoption of New Accounting Standards                
Restructuring Cost and Reserve [Line Items]                
Cumulative effect adjustment to decrease retained earnings             5  
Retained Earnings                
Restructuring Cost and Reserve [Line Items]                
Cumulative effect adjustment to decrease retained earnings       (38,286) $ (35,121) $ (33,495) (34,210)  
Retained Earnings | Adoption of New Accounting Standards                
Restructuring Cost and Reserve [Line Items]                
Cumulative effect adjustment to decrease retained earnings             $ 3  
Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Costs incurred       1,500        
Transformational Cost Management Program | United Kingdom                
Restructuring Cost and Reserve [Line Items]                
Number of stores expected to close | store 150   200          
Transformational Cost Management Program | United States                
Restructuring Cost and Reserve [Line Items]                
Number of stores expected to close | store 150   250          
Transformational Cost Management Program | Retained Earnings | Adoption of New Accounting Standards                
Restructuring Cost and Reserve [Line Items]                
Cumulative effect adjustment to decrease retained earnings               $ 508
Lease Obligations and Other Real Estate Costs | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Costs incurred       442        
Asset Impairments | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Costs incurred       292        
Employee Severance and Business Transition Costs | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Costs incurred       550        
Information Technology Transformation and Other Exit Costs | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Costs incurred       172        
Minimum | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Expected annual cost savings of restructuring plan $ 3,300 $ 2,000            
Expected cost       3,600        
Minimum | Exit and Disposal Costs | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Expected cost       3,300        
Maximum | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Expected cost       3,900        
Maximum | Exit and Disposal Costs | Transformational Cost Management Program                
Restructuring Cost and Reserve [Line Items]                
Expected cost       $ 3,600        
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.21.4
Exit and disposal activities - Restructuring Costs (Details) - Transformational Cost Management Program - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges $ 175 $ 81
Reportable segments | United States    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 123 48
Reportable segments | International    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 44 21
Corporate and Other    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 9 12
Lease obligations and other real estate costs    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 89 22
Lease obligations and other real estate costs | Reportable segments | United States    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 87 22
Lease obligations and other real estate costs | Reportable segments | International    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 2 0
Lease obligations and other real estate costs | Corporate and Other    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 0 0
Asset impairments    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 40 1
Asset impairments | Reportable segments | United States    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 15 4
Asset impairments | Reportable segments | International    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 25 (2)
Asset impairments | Corporate and Other    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 0 0
Employee severance and business transition costs    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 37 52
Employee severance and business transition costs | Reportable segments | United States    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 20 12
Employee severance and business transition costs | Reportable segments | International    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 10 28
Employee severance and business transition costs | Corporate and Other    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 7 12
Information technology transformation and other exit costs    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 9 5
Information technology transformation and other exit costs | Reportable segments | United States    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 1 10
Information technology transformation and other exit costs | Reportable segments | International    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges 7 (5)
Information technology transformation and other exit costs | Corporate and Other    
Restructuring Cost and Reserve [Line Items]    
Total pre-tax exit and disposal charges $ 1 $ 0
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.21.4
Exit and disposal activities - Restructuring Reserve Activity (Details) - Transformational Cost Management Program
$ in Millions
3 Months Ended
Nov. 30, 2021
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning balance $ 114
Costs 175
Payments (74)
Other (115)
Currency (1)
Ending balance 101
Lease obligations and other real estate costs  
Restructuring Reserve [Roll Forward]  
Beginning balance 17
Costs 89
Payments (15)
Other (72)
Currency 0
Ending balance 19
Asset Impairments  
Restructuring Reserve [Roll Forward]  
Beginning balance 0
Costs 40
Payments 0
Other (40)
Currency 0
Ending balance 0
Employee severance and business transition costs  
Restructuring Reserve [Roll Forward]  
Beginning balance 77
Costs 37
Payments (51)
Other (3)
Currency (1)
Ending balance 59
Information technology transformation and other exit costs  
Restructuring Reserve [Roll Forward]  
Beginning balance 20
Costs 9
Payments (7)
Other 0
Currency 0
Ending balance $ 23
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.21.4
Leases - Narrative (Details)
Nov. 30, 2021
Lessee, Lease, Description [Line Items]  
Term of renewal contract 5 years
Minimum  
Lessee, Lease, Description [Line Items]  
Term of lease 15 years
Maximum  
Lessee, Lease, Description [Line Items]  
Term of lease 25 years
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.21.4
Leases - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
Nov. 30, 2021
Aug. 31, 2021
Operating Leases:    
Operating lease right-of-use assets $ 21,826 $ 21,893
Operating lease obligations - current 2,266 2,259
Operating lease obligations - non-current 22,103 22,153
Total operating lease obligations 24,369 24,412
Finance Leases:    
Property, plant and equipment, net 713 725
Lease obligations included in:    
Accrued expenses and other liabilities 37 37
Other non-current liabilities 963 974
Total finance lease obligations $ 1,000 $ 1,010
Finance lease, right-of-use asset, statement of financial position, extensible enumeration Property, plant and equipment, net Property, plant and equipment, net
Finance lease, liability, current, statement of financial position, extensible enumeration Accrued expenses and other liabilities Accrued expenses and other liabilities
Finance lease, liability, noncurrent, statement of financial position, extensible enumeration Other non-current liabilities Other non-current liabilities
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.21.4
Leases - Supplemental Income Statement Information (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Operating lease cost    
Fixed $ 805 $ 805
Variable 205 158
Finance lease cost    
Amortization 11 11
Interest 13 13
Sublease income 25 20
Impairment of right-of-use assets 68 10
Gain on sale and leaseback $ 87 $ 93
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.21.4
Leases - Other Supplemental Information (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Cash paid for amounts included in the measurement of lease obligations:    
Operating cash flows from operating leases $ 846 $ 857
Operating cash flows from finance leases 12 12
Financing cash flows from finance leases 11 10
Total 869 879
Right-of-use assets obtained in exchange for new lease obligations:    
Operating leases 544 787
Finance leases 5 0
Total $ 549 $ 787
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.21.4
Leases - Average Lease Terms And Discounts (Details)
Nov. 30, 2021
Aug. 31, 2021
Weighted average remaining lease term in years:    
Operating leases 10 years 2 months 12 days 10 years 3 months 18 days
Finance leases 20 years 1 month 6 days 20 years 2 months 12 days
Weighted average discount rate:    
Operating leases 4.75% 4.77%
Finance leases 5.18% 5.18%
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.21.4
Leases - Future Lease Payments for Operating and Finance Leases (Details) - USD ($)
$ in Millions
Nov. 30, 2021
Aug. 31, 2021
Finance lease    
2022 (Remaining period) $ 67  
2023 88  
2024 88  
2025 87  
2026 87  
2027 86  
Later 1,054  
Total undiscounted minimum lease payments 1,556  
Less: Present value discount (556)  
Lease liability 1,000 $ 1,010
Operating lease    
2022 (Remaining period) 2,608  
2023 3,376  
2024 3,260  
2025 3,145  
2026 3,032  
2027 2,924  
Later 12,801  
Total undiscounted minimum lease payments 31,146  
Less: Present value discount (6,777)  
Lease liability $ 24,369 $ 24,412
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.21.4
Equity method investments - Schedule of Equity Method Investments (Details) - USD ($)
$ in Millions
Nov. 30, 2021
Aug. 31, 2021
Schedule of Equity Method Investments [Line Items]    
Carrying value of equity method investments $ 6,367 $ 6,987
AmerisourceBergen    
Schedule of Equity Method Investments [Line Items]    
Carrying value of equity method investments $ 4,393 $ 4,407
Ownership percentage 28.30% 28.30%
Others    
Schedule of Equity Method Investments [Line Items]    
Carrying value of equity method investments $ 1,974 $ 2,580
Others | Minimum    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage 8.00% 8.00%
Others | Maximum    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage 50.00% 50.00%
Total    
Schedule of Equity Method Investments [Line Items]    
Carrying value of equity method investments $ 6,367 $ 6,987
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.21.4
Equity method investments - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Sep. 30, 2020
Aug. 31, 2021
Schedule of Equity Method Investments [Line Items]        
Equity earnings (losses) $ 93 $ (1,350)    
AmerisourceBergen        
Schedule of Equity Method Investments [Line Items]        
Outstanding shares owned (in shares) 58,854,867     58,854,867
Ownership percentage 28.30%     28.30%
Period of reporting lag 2 months      
Equity earnings (losses) $ 100 (1,400)    
Equity investment, exceeded its proportionate share of net assets 4,300      
AmerisourceBergen | Opiod Litigation        
Schedule of Equity Method Investments [Line Items]        
Equity earnings (losses)     $ (5,600)  
AmerisourceBergen | Level 1        
Schedule of Equity Method Investments [Line Items]        
Fair market value of equity investment 6,800     $ 7,200
Other Investments        
Schedule of Equity Method Investments [Line Items]        
Equity earnings (losses) (7) $ 15    
VillageMD        
Schedule of Equity Method Investments [Line Items]        
Gain on sale of equity method investment $ 2,174      
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.21.4
Equity method investments - Summarized Financial Information of Equity Method Investments (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Income Statement [Abstract]    
Sales $ 33,901 $ 31,438
Gross profit 7,574 6,630
Net earnings (loss) 3,531 (299)
Share of earnings (loss) from equity method investments 93 (1,357)
Equity Method Investment    
Income Statement [Abstract]    
Sales 67,588 56,088
Gross profit 3,420 2,410
Net earnings (loss) $ 308 $ (4,806)
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.21.4
Goodwill and other intangible assets - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Aug. 31, 2021
Jun. 01, 2021
Goodwill [Line Items]        
Goodwill $ 21,520   $ 12,421  
Indefinite-lived intangible assets 7,244   7,342  
Amortization of intangible assets 165 $ 95    
Minimum        
Goodwill [Line Items]        
Reporting unit fair value in excess of carrying amount (as a percent)       18.00%
Maximum        
Goodwill [Line Items]        
Reporting unit fair value in excess of carrying amount (as a percent)       195.00%
Other International Reporting Unit        
Goodwill [Line Items]        
Reporting unit fair value in excess of carrying amount (as a percent)       29.00%
Goodwill 372      
Boots Reporting Unit        
Goodwill [Line Items]        
Goodwill 1,000      
Indefinite-lived intangible assets $ 7,200   $ 7,300  
Boots Reporting Unit | Minimum        
Goodwill [Line Items]        
Reporting unit fair value in excess of carrying amount (as a percent) 5.00%      
Boots Reporting Unit | Maximum        
Goodwill [Line Items]        
Reporting unit fair value in excess of carrying amount (as a percent) 27.00%      
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.21.4
Goodwill and other intangible assets - Schedule of Goodwill (Details)
$ in Millions
3 Months Ended
Nov. 30, 2021
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 12,421
Acquisitions 9,130
Currency translation adjustments (32)
Goodwill, ending balance 21,520
Reportable Segments | United States  
Goodwill [Roll Forward]  
Goodwill, beginning balance 10,947
Acquisitions 0
Currency translation adjustments 0
Goodwill, ending balance 10,947
Reportable Segments | International  
Goodwill [Roll Forward]  
Goodwill, beginning balance 1,474
Acquisitions 0
Currency translation adjustments (32)
Goodwill, ending balance 1,443
Reportable Segments | Walgreens Health  
Goodwill [Roll Forward]  
Goodwill, beginning balance 0
Acquisitions 9,130
Currency translation adjustments 0
Goodwill, ending balance $ 9,130
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.21.4
Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details) - USD ($)
$ in Millions
Nov. 30, 2021
Aug. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Gross amortizable intangible assets $ 7,479 $ 4,421
Accumulated amortization 1,953 1,826
Total amortizable intangible assets, net 5,526 2,595
Indefinite-lived intangible assets 7,244 7,342
Total intangible assets, net 12,770 9,936
Trade names and trademarks    
Finite-Lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 5,208 5,276
Pharmacy licenses    
Finite-Lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 2,036 2,066
Customer relationships and loyalty card holders    
Finite-Lived Intangible Assets [Line Items]    
Gross amortizable intangible assets 4,430 3,522
Accumulated amortization 1,395 1,335
Primary care provider network    
Finite-Lived Intangible Assets [Line Items]    
Gross amortizable intangible assets 1,660 0
Trade names and trademarks    
Finite-Lived Intangible Assets [Line Items]    
Gross amortizable intangible assets 708 361
Accumulated amortization 228 226
Purchasing and payer contracts    
Finite-Lived Intangible Assets [Line Items]    
Gross amortizable intangible assets 317 317
Accumulated amortization 284 227
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Gross amortizable intangible assets 290 0
Accumulated amortization 17 0
Others    
Finite-Lived Intangible Assets [Line Items]    
Gross amortizable intangible assets 75 221
Accumulated amortization $ 29 $ 37
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.21.4
Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)
$ in Millions
Nov. 30, 2021
USD ($)
Estimated annual intangible assets amortization expense [Abstract]  
2022 (Remaining period) $ 462
2023 560
2023 541
2024 514
2026 490
2027 $ 443
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.21.4
Debt - Short and Long-Term Debt (Details)
Nov. 30, 2021
USD ($)
Nov. 30, 2021
GBP (£)
Nov. 30, 2021
EUR (€)
Nov. 17, 2021
USD ($)
Oct. 29, 2021
USD ($)
Sep. 18, 2021
USD ($)
Aug. 31, 2021
USD ($)
Debt Instrument [Line Items]              
Total short-term debt $ 2,647,000,000           $ 1,305,000,000
Total long-term debt, less current portion 11,199,000,000           7,675,000,000
Shields Health Solutions Parent, LLC              
Debt Instrument [Line Items]              
Long-term debt assumed         $ 447,000,000    
Credit facilities              
Debt Instrument [Line Items]              
Long-term debt 2,990,000,000           0
3.300% unsecured notes due 2021              
Debt Instrument [Line Items]              
Face amount $ 8,000,000,000            
Stated interest rate 3.30% 3.30% 3.30%     3.30%  
Total short-term debt $ 0           1,250,000,000
Debt redeemed           $ 1,250,000,000  
3.100% unsecured notes due 2022              
Debt Instrument [Line Items]              
Total short-term debt 731,000,000           0
Other              
Debt Instrument [Line Items]              
Total short-term debt 242,000,000           56,000,000
Unsecured Notes              
Debt Instrument [Line Items]              
Other 477,000,000           29,000,000
Total long-term debt, less current portion $ 11,199,000,000           7,675,000,000
Unsecured Notes | 3.100% unsecured notes due 2022              
Debt Instrument [Line Items]              
Stated interest rate 3.10% 3.10% 3.10%        
Long-term debt $ 0           731,000,000
Unsecured Notes | $850 million note issuance              
Debt Instrument [Line Items]              
Face amount $ 850,000,000            
Unsecured Notes | 0.9500% Notes Payable, Due 2023              
Debt Instrument [Line Items]              
Face amount       $ 850,000,000      
Stated interest rate 0.95% 0.95% 0.95% 0.95%      
Long-term debt $ 848,000,000           0
Unsecured Notes | Total $1.5 billion note issuance              
Debt Instrument [Line Items]              
Face amount $ 1,500,000,000            
Unsecured Notes | 3.200% unsecured notes due 2030              
Debt Instrument [Line Items]              
Stated interest rate 3.20% 3.20% 3.20%        
Long-term debt $ 497,000,000           497,000,000
Unsecured Notes | 4.100% unsecured notes due 2050              
Debt Instrument [Line Items]              
Stated interest rate 4.10% 4.10% 4.10%        
Long-term debt $ 792,000,000           792,000,000
Unsecured Notes | Total $6 billion note issuance              
Debt Instrument [Line Items]              
Face amount $ 6,000,000,000            
Unsecured Notes | 3.450% unsecured notes due 2026              
Debt Instrument [Line Items]              
Stated interest rate 3.45% 3.45% 3.45%        
Long-term debt $ 1,442,000,000           1,442,000,000
Unsecured Notes | 4.650% unsecured notes due 2046              
Debt Instrument [Line Items]              
Stated interest rate 4.65% 4.65% 4.65%        
Long-term debt $ 318,000,000           318,000,000
Unsecured Notes | Total $8 billion note issuance              
Debt Instrument [Line Items]              
Face amount $ 8,000,000,000            
Unsecured Notes | 3.800% unsecured notes due 2024              
Debt Instrument [Line Items]              
Stated interest rate 3.80% 3.80% 3.80%        
Long-term debt $ 1,154,000,000           1,154,000,000
Unsecured Notes | 4.500% unsecured notes due 2034              
Debt Instrument [Line Items]              
Stated interest rate 4.50% 4.50% 4.50%        
Long-term debt $ 301,000,000           301,000,000
Unsecured Notes | 4.800% unsecured notes due 2044              
Debt Instrument [Line Items]              
Stated interest rate 4.80% 4.80% 4.80%        
Long-term debt $ 868,000,000           868,000,000
Unsecured Notes | Total £700 million note issuance              
Debt Instrument [Line Items]              
Face amount | £   £ 700,000,000          
Unsecured Notes | 3.600% unsecured Pound sterling notes due 2025              
Debt Instrument [Line Items]              
Stated interest rate 3.60% 3.60% 3.60%        
Long-term debt $ 403,000,000           408,000,000
Unsecured Notes | Total €750 million note issuance              
Debt Instrument [Line Items]              
Face amount | €     € 750,000,000        
Unsecured Notes | 2.125% unsecured Euro notes due 2026              
Debt Instrument [Line Items]              
Stated interest rate 2.125% 2.125% 2.125%        
Long-term debt $ 846,000,000           873,000,000
Unsecured Notes | Total $4 billion note issuance              
Debt Instrument [Line Items]              
Face amount $ 4,000,000,000            
Unsecured Notes | 4.400% unsecured notes due 2042              
Debt Instrument [Line Items]              
Stated interest rate 4.40% 4.40% 4.40%        
Long-term debt $ 263,000,000           263,000,000
Commercial paper              
Debt Instrument [Line Items]              
Total short-term debt 875,000,000           0
Credit facilities              
Debt Instrument [Line Items]              
Total short-term debt $ 799,000,000           $ 0
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.21.4
Debt - Narrative (Details)
£ in Millions
3 Months Ended
Nov. 17, 2021
USD ($)
Nov. 15, 2021
USD ($)
Dec. 23, 2020
USD ($)
Nov. 30, 2021
USD ($)
Nov. 30, 2020
USD ($)
Nov. 30, 2020
GBP (£)
Aug. 31, 2021
USD ($)
Aug. 29, 2018
USD ($)
Debt Instrument [Line Items]                
Interest paid       $ 153,000,000 $ 234,000,000      
Maximum                
Debt Instrument [Line Items]                
Debt to total capitalization ratio       0.60        
Commercial paper                
Debt Instrument [Line Items]                
Average daily short-term borrowings       $ 712,000,000 $ 1,600,000,000      
Weighted average interest rate       0.25% 0.63% 0.63%    
Commercial paper | Guarantor Subsidiaries | Reportable Legal Entities                
Debt Instrument [Line Items]                
Average daily short-term borrowings         $ 401,000,000 £ 300    
Weighted average interest rate         0.43% 0.43%    
Unsecured Notes | 0.9500% Notes Payable, Due 2023                
Debt Instrument [Line Items]                
Face amount $ 850,000,000              
Stated interest rate 0.95%     0.95%        
Redemption percentage 100.00%              
Redemption variable percentage 0.0010              
Amount oustanding       $ 848,000,000     $ 0  
Credit facilities                
Debt Instrument [Line Items]                
Amount oustanding       2,990,000,000     $ 0  
Credit facilities | Delayed Draw Term Loan | Term Loan                
Debt Instrument [Line Items]                
Face amount   $ 5,000,000,000            
Amount oustanding       3,000,000,000        
Credit facilities | Delayed Draw Term Loan Credit Facility, 364-Day Facility | Term Loan                
Debt Instrument [Line Items]                
Face amount   $ 2,000,000,000            
Debt term   364 days            
Credit facilities | Delayed Draw Term Loan Credit Facility, Two-Year Facility                
Debt Instrument [Line Items]                
Face amount   $ 2,000,000,000            
Credit facilities | Delayed Draw Term Loan Credit Facility, Three-Year Facility                
Debt Instrument [Line Items]                
Face amount   $ 1,000,000,000            
Credit facilities | 2020 Revolving Credit Agreement, 364-Day Facility                
Debt Instrument [Line Items]                
Debt term     364 days          
Maximum borrowing capacity     $ 1,250,000,000          
Credit facilities | 2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility                
Debt Instrument [Line Items]                
Debt term     18 months          
Maximum borrowing capacity     $ 2,250,000,000          
Borrowing outstanding       800,000,000        
Credit facilities | August 2018 Revolving Credit Agreement                
Debt Instrument [Line Items]                
Face amount               $ 3,500,000,000
Borrowing outstanding       $ 0        
Credit facilities | Term Loan | Delayed Draw Term Loan Credit Facility, Two-Year Facility                
Debt Instrument [Line Items]                
Debt term   2 years            
Credit facilities | Term Loan | Delayed Draw Term Loan Credit Facility, Three-Year Facility                
Debt Instrument [Line Items]                
Debt term   3 years            
Bridge Loan | 2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity     $ 350,000,000          
Letter of Credit | August 2018 Revolving Credit Agreement                
Debt Instrument [Line Items]                
Face amount               $ 500,000,000
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.21.4
Financial instruments (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Aug. 31, 2021
Foreign currency forwards | Not Designated as Hedging Instrument | Selling, general and administrative expenses      
Derivatives, Fair Value [Line Items]      
Gains and (losses) due to changes in fair value of derivative instruments $ 55 $ (29)  
Foreign currency forwards | Not Designated as Hedging Instrument | Other income (expense)      
Derivatives, Fair Value [Line Items]      
Gains and (losses) due to changes in fair value of derivative instruments (1) (9)  
Total return swap | Not Designated as Hedging Instrument | Selling, general and administrative expenses      
Derivatives, Fair Value [Line Items]      
Gains and (losses) due to changes in fair value of derivative instruments (2) $ 13  
Other non-current assets | Foreign currency forwards | Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, assets 5   $ 6
Fair value, assets 0   0
Other non-current assets | Cross currency interest rate swaps | Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, assets 153   155
Fair value, assets 4   1
Other current assets | Foreign currency forwards | Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, assets 610   575
Fair value, assets 17   7
Other current assets | Foreign currency forwards | Not Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, assets 3,900   3,636
Fair value, assets 64   38
Other current assets | Total return swap | Not Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, assets     224
Fair value, assets     2
Other non-current liabilities | Foreign currency forwards | Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, liabilities 17   23
Fair value, liabilities 0   1
Other non-current liabilities | Cross currency interest rate swaps | Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, liabilities 633   801
Fair value, liabilities 8   23
Other current liabilities | Foreign currency forwards | Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, liabilities 85   31
Fair value, liabilities 1   1
Other current liabilities | Foreign currency forwards | Not Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, liabilities 2,968   808
Fair value, liabilities 2   3
Other current liabilities | Cross currency interest rate swaps | Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, liabilities 157   109
Fair value, liabilities 5   9
Other current liabilities | Total return swap | Not Designated as Hedging Instrument      
Derivatives, Fair Value [Line Items]      
Notional amount, liabilities 271   37
Fair value, liabilities $ 11   $ 0
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.21.4
Fair value measurements (Details) - USD ($)
$ in Millions
Nov. 30, 2021
Aug. 31, 2021
Recurring    
Assets [Abstract]    
Money market funds $ 319 $ 634
Investments in equity securities 1 2
Investments in debt securities 20 663
Recurring | Level 1    
Assets [Abstract]    
Money market funds 319 634
Investments in equity securities 1 2
Investments in debt securities 0 0
Recurring | Level 2    
Assets [Abstract]    
Money market funds 0 0
Investments in equity securities 0 0
Investments in debt securities 0 0
Recurring | Level 3    
Assets [Abstract]    
Money market funds 0 0
Investments in equity securities 0 0
Investments in debt securities 20 663
Recurring | Foreign currency forwards    
Assets [Abstract]    
Derivative asset 81 46
Liabilities [Abstract]    
Derivative liability 4 5
Recurring | Foreign currency forwards | Level 1    
Assets [Abstract]    
Derivative asset 0 0
Liabilities [Abstract]    
Derivative liability 0 0
Recurring | Foreign currency forwards | Level 2    
Assets [Abstract]    
Derivative asset 81 46
Liabilities [Abstract]    
Derivative liability 4 5
Recurring | Foreign currency forwards | Level 3    
Assets [Abstract]    
Derivative asset 0 0
Liabilities [Abstract]    
Derivative liability 0 0
Recurring | Cross currency interest rate swaps    
Assets [Abstract]    
Derivative asset 4 1
Liabilities [Abstract]    
Derivative liability 12 32
Recurring | Cross currency interest rate swaps | Level 1    
Assets [Abstract]    
Derivative asset 0 0
Liabilities [Abstract]    
Derivative liability 0 0
Recurring | Cross currency interest rate swaps | Level 2    
Assets [Abstract]    
Derivative asset 4 1
Liabilities [Abstract]    
Derivative liability 12 32
Recurring | Cross currency interest rate swaps | Level 3    
Assets [Abstract]    
Derivative asset 0 0
Liabilities [Abstract]    
Derivative liability 0 0
Recurring | Total return swap    
Assets [Abstract]    
Derivative asset   2
Liabilities [Abstract]    
Derivative liability 11  
Recurring | Total return swap | Level 1    
Assets [Abstract]    
Derivative asset   0
Liabilities [Abstract]    
Derivative liability 0  
Recurring | Total return swap | Level 2    
Assets [Abstract]    
Derivative asset   2
Liabilities [Abstract]    
Derivative liability 11  
Recurring | Total return swap | Level 3    
Assets [Abstract]    
Derivative asset   $ 0
Liabilities [Abstract]    
Derivative liability 0  
Carrying Value    
Liabilities [Abstract]    
Fair value of long-term notes outstanding 8,500  
Estimate of Fair Value Measurement    
Liabilities [Abstract]    
Carrying value of long-term notes outstanding $ 9,200  
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.21.4
Income taxes (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Income Tax Disclosure [Abstract]    
Effective tax rate 7.20% (34.00%)
Income taxes paid $ 34 $ 16
XML 85 R69.htm IDEA: XBRL DOCUMENT v3.21.4
Retirement benefits (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Components of net periodic benefit costs [Abstract]    
Total net periodic pension costs (income) $ (33) $ (45)
Employer cash contributions to defined benefit pension plans 1  
Expected employer cash contributions to defined benefit plan in current fiscal year 40  
Selling, general and administrative expenses    
Components of net periodic benefit costs [Abstract]    
Service costs 1 1
Other expense    
Components of net periodic benefit costs [Abstract]    
Interest costs 39 33
Other income    
Components of net periodic benefit costs [Abstract]    
Expected returns on plan assets/other (74) (80)
United States    
Components of net periodic benefit costs [Abstract]    
Profit sharing provision expense 69 57
Foreign Plan    
Components of net periodic benefit costs [Abstract]    
Cost recognized in the consolidated condensed statements of earnings $ 25 $ 26
XML 86 R70.htm IDEA: XBRL DOCUMENT v3.21.4
Accumulated other comprehensive income (loss) (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 23,822 $ 21,136
Total other comprehensive (loss) income (196) 94
Ending balance 30,579 20,563
Pension/ post-retirement obligations    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (359) (748)
Other comprehensive income (loss) before reclassification adjustments (1) 17
Amounts reclassified from AOCI (5) (2)
Tax benefit (provision) 1 (4)
Total other comprehensive (loss) income (5) 11
Ending balance (364) (736)
Unrealized gain (loss) on cash flow hedges    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (10) (31)
Other comprehensive income (loss) before reclassification adjustments 1 4
Amounts reclassified from AOCI 1 1
Tax benefit (provision) 0 (1)
Total other comprehensive (loss) income 1 4
Ending balance (9) (27)
Net investment hedges    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (35) (34)
Other comprehensive income (loss) before reclassification adjustments 53 (14)
Amounts reclassified from AOCI 0 0
Tax benefit (provision) (9) 8
Total other comprehensive (loss) income 44 (7)
Ending balance 9 (41)
Unrealized gain (loss) on available for sale securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 96 0
Other comprehensive income (loss) before reclassification adjustments 450 0
Amounts reclassified from AOCI (577) 0
Tax benefit (provision) 31 0
Total other comprehensive (loss) income (96) 0
Ending balance 0 0
Share of OCI of equity method investments    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (29) (10)
Other comprehensive income (loss) before reclassification adjustments (60) 7
Amounts reclassified from AOCI 0 0
Tax benefit (provision) 14 (1)
Total other comprehensive (loss) income (46) 5
Ending balance (74) (5)
Cumulative translation adjustments    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1,772) (2,948)
Other comprehensive income (loss) before reclassification adjustments (88) 72
Amounts reclassified from AOCI (4) 3
Tax benefit (provision) 0 0
Total other comprehensive (loss) income (91) 75
Ending balance (1,863) (2,873)
Total    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (2,109) (3,771)
Other comprehensive income (loss) before reclassification adjustments 356 85
Amounts reclassified from AOCI (585) 2
Tax benefit (provision) 37 1
Total other comprehensive (loss) income (193) 88
Ending balance $ (2,301) $ (3,682)
XML 87 R71.htm IDEA: XBRL DOCUMENT v3.21.4
Segment reporting (Details)
$ in Millions
3 Months Ended
Nov. 30, 2021
USD ($)
segment
Nov. 30, 2020
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | segment 3  
Segment Reporting Information [Line Items]    
Sales $ 33,901 $ 31,438
Adjusted operating income 1,777 1,196
Transformational cost management (203) (100)
Acquisition-related amortization (165) (95)
Acquisition-related costs (71) (21)
Adjustments to equity earnings (loss) in AmerisourceBergen (43) (1,481)
LIFO provision (14) (33)
Operating income (loss) 1,283 (535)
Reportable Segments | United States    
Segment Reporting Information [Line Items]    
Sales 28,032 27,163
Adjusted operating income 1,690 1,155
Reportable Segments | International    
Segment Reporting Information [Line Items]    
Sales 5,818 4,285
Adjusted operating income 164 87
Reportable Segments | Walgreens Health    
Segment Reporting Information [Line Items]    
Sales 51 0
Adjusted operating income (13) (3)
Corporate and Other    
Segment Reporting Information [Line Items]    
Sales 0 (10)
Adjusted operating income $ (63) $ (42)
XML 88 R72.htm IDEA: XBRL DOCUMENT v3.21.4
Sales (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Disaggregation of Revenue [Line Items]    
Sales $ 33,901 $ 31,438
Reportable Segments | United States    
Disaggregation of Revenue [Line Items]    
Sales 28,032 27,163
Reportable Segments | United States | Pharmacy    
Disaggregation of Revenue [Line Items]    
Sales 21,105 20,869
Reportable Segments | United States | Retail    
Disaggregation of Revenue [Line Items]    
Sales 6,927 6,294
Reportable Segments | International    
Disaggregation of Revenue [Line Items]    
Sales 5,818 4,285
Reportable Segments | International | Pharmacy    
Disaggregation of Revenue [Line Items]    
Sales 1,017 895
Reportable Segments | International | Retail    
Disaggregation of Revenue [Line Items]    
Sales 1,796 1,522
Reportable Segments | International | Wholesale    
Disaggregation of Revenue [Line Items]    
Sales 3,005 1,868
Reportable Segments | Walgreens Health    
Disaggregation of Revenue [Line Items]    
Sales 51 0
Corporate and Other    
Disaggregation of Revenue [Line Items]    
Sales $ 0 $ (10)
XML 89 R73.htm IDEA: XBRL DOCUMENT v3.21.4
Related parties (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Aug. 31, 2021
Related Party Transactions [Abstract]      
Purchases, net $ 15,791 $ 15,441  
Trade accounts payable, net $ 6,909   $ 6,589
XML 90 R74.htm IDEA: XBRL DOCUMENT v3.21.4
Supplemental information - Narrative (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Aug. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Accounts receivable from related party $ 1,300   $ 1,100
Accumulated depreciation and amortization on property, plant, and equipment 13,300   13,100
Redeemable noncontrolling interest $ 2,787   319
Antidilutive securities excluded from EPS calculations (in shares) 16.1 18.5  
Trade Accounts Receivable      
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Receivables $ 4,600   $ 4,500
XML 91 R75.htm IDEA: XBRL DOCUMENT v3.21.4
Supplemental information - Depreciation and Amortization Expense (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Supplemental Cash Flow Elements [Abstract]    
Depreciation expense $ 335 $ 342
Intangible asset and other amortization 165 95
Total depreciation and amortization expense $ 500 $ 437
XML 92 R76.htm IDEA: XBRL DOCUMENT v3.21.4
Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Nov. 30, 2021
Aug. 31, 2021
Nov. 30, 2020
Aug. 31, 2020
Cash and Cash Equivalents [Line Items]        
Cash and cash equivalents $ 4,135 $ 1,193    
Cash, cash equivalents and restricted cash 4,268 1,270 $ 1,339 $ 746
Continuing Operations        
Cash and Cash Equivalents [Line Items]        
Cash and cash equivalents 4,135 1,193    
Restricted cash $ 133 $ 77    
XML 93 R77.htm IDEA: XBRL DOCUMENT v3.21.4
Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 24, 2021
Nov. 30, 2021
Increase (Decrease) in Temporary Equity [Roll Forward]    
Beginning balance   $ 319
Acquisitions   2,489
Net (loss)   (21)
Redemption value adjustment   7
Currency translation adjustments and other   (8)
Ending balance   2,787
Conversion of Stock [Line Items]    
Acquisitions   2,489
VillageMD    
Increase (Decrease) in Temporary Equity [Roll Forward]    
Acquisitions   1,900
Conversion of Stock [Line Items]    
Acquisitions   $ 1,900
Value of purchase tender offer $ 1,900  
XML 94 R78.htm IDEA: XBRL DOCUMENT v3.21.4
Supplemental information - Summary of Dividends per Share (Details) - $ / shares
3 Months Ended
Nov. 30, 2021
Nov. 30, 2020
Cash and Cash Equivalents [Abstract]    
Cash dividends declared (in dollars per share) $ 0.4775 $ 0.4675
XML 95 wba-20211130_htm.xml IDEA: XBRL DOCUMENT 0001618921 2021-09-01 2021-11-30 0001618921 us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001618921 wba:A3600NotesPayableDue2025Member 2021-09-01 2021-11-30 0001618921 wba:A3450NotesPayableDue2026Member 2021-09-01 2021-11-30 0001618921 2021-12-31 0001618921 2021-11-30 0001618921 2021-08-31 0001618921 us-gaap:CommonStockMember 2021-08-31 0001618921 us-gaap:TreasuryStockMember 2021-08-31 0001618921 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-31 0001618921 us-gaap:RetainedEarningsMember 2021-08-31 0001618921 us-gaap:NoncontrollingInterestMember 2021-08-31 0001618921 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001618921 us-gaap:NoncontrollingInterestMember 2021-09-01 2021-11-30 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-01 2021-11-30 0001618921 us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001618921 us-gaap:TreasuryStockMember 2021-09-01 2021-11-30 0001618921 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001618921 us-gaap:CommonStockMember 2021-11-30 0001618921 us-gaap:TreasuryStockMember 2021-11-30 0001618921 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-11-30 0001618921 us-gaap:RetainedEarningsMember 2021-11-30 0001618921 us-gaap:NoncontrollingInterestMember 2021-11-30 0001618921 us-gaap:CommonStockMember 2020-08-31 0001618921 us-gaap:TreasuryStockMember 2020-08-31 0001618921 us-gaap:AdditionalPaidInCapitalMember 2020-08-31 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-31 0001618921 us-gaap:RetainedEarningsMember 2020-08-31 0001618921 us-gaap:NoncontrollingInterestMember 2020-08-31 0001618921 2020-08-31 0001618921 us-gaap:RetainedEarningsMember 2020-09-01 2020-11-30 0001618921 us-gaap:NoncontrollingInterestMember 2020-09-01 2020-11-30 0001618921 2020-09-01 2020-11-30 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-01 2020-11-30 0001618921 us-gaap:CommonStockMember 2020-09-01 2020-11-30 0001618921 us-gaap:TreasuryStockMember 2020-09-01 2020-11-30 0001618921 us-gaap:AdditionalPaidInCapitalMember 2020-09-01 2020-11-30 0001618921 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-08-31 0001618921 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2020-08-31 0001618921 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-08-31 0001618921 us-gaap:CommonStockMember 2020-11-30 0001618921 us-gaap:TreasuryStockMember 2020-11-30 0001618921 us-gaap:AdditionalPaidInCapitalMember 2020-11-30 0001618921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-11-30 0001618921 us-gaap:RetainedEarningsMember 2020-11-30 0001618921 us-gaap:NoncontrollingInterestMember 2020-11-30 0001618921 2020-11-30 0001618921 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember wba:AllianceHealthcareMember 2021-06-01 0001618921 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember wba:AllianceHealthcareMember 2021-06-01 2021-06-01 0001618921 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember wba:AllianceHealthcareMember 2020-09-01 2020-11-30 0001618921 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember wba:AllianceHealthcareMember us-gaap:SegmentContinuingOperationsMember 2020-09-01 2020-11-30 0001618921 wba:VillageMDMember 2021-11-23 0001618921 wba:VillageMDMember 2021-11-24 0001618921 wba:VillageMDMember 2021-11-24 2021-11-24 0001618921 wba:ShieldsHealthSolutionsParentLLCMember 2021-10-28 0001618921 wba:ShieldsHealthSolutionsParentLLCMember 2021-10-29 0001618921 wba:ShieldsHealthSolutionsParentLLCMember 2021-10-29 2021-10-29 0001618921 wba:ShieldsHealthSolutionsParentLLCMember 2021-09-01 2021-11-30 0001618921 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-09-01 2021-11-30 0001618921 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2020-09-01 2020-11-30 0001618921 srt:MinimumMember wba:TransformationalCostManagementProgramMember 2018-12-20 2018-12-20 0001618921 srt:MinimumMember wba:TransformationalCostManagementProgramMember 2021-10-12 2021-10-12 0001618921 country:GB wba:TransformationalCostManagementProgramMember 2021-10-12 2021-10-12 0001618921 country:US wba:TransformationalCostManagementProgramMember 2021-10-12 2021-10-12 0001618921 country:GB wba:TransformationalCostManagementProgramMember 2021-07-01 2021-07-31 0001618921 country:US wba:TransformationalCostManagementProgramMember 2021-07-01 2021-07-31 0001618921 srt:MinimumMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 srt:MaximumMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 srt:MinimumMember wba:ExitAndDisposalCostsMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 srt:MaximumMember wba:ExitAndDisposalCostsMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember wba:TransformationalCostManagementProgramMember us-gaap:RetainedEarningsMember 2019-09-01 0001618921 wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 wba:TransformationalCostManagementProgramMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:TransformationalCostManagementProgramMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:TransformationalCostManagementProgramMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 wba:CorporateAndReconcilingItemsMember wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 wba:TransformationalCostManagementProgramMember 2020-09-01 2020-11-30 0001618921 wba:LeaseObligationsandOtherRealEstateCostsMember wba:TransformationalCostManagementProgramMember 2021-08-31 0001618921 wba:AssetImpairmentRestructuringChargesMember wba:TransformationalCostManagementProgramMember 2021-08-31 0001618921 wba:EmployeeSeveranceAndBusinessTransitionCostsMember wba:TransformationalCostManagementProgramMember 2021-08-31 0001618921 wba:InformationTechnologyTransformationAndOtherExitCostsMember wba:TransformationalCostManagementProgramMember 2021-08-31 0001618921 wba:TransformationalCostManagementProgramMember 2021-08-31 0001618921 srt:MinimumMember 2021-11-30 0001618921 srt:MaximumMember 2021-11-30 0001618921 wba:AmerisourceBergenCorporationMember 2021-11-30 0001618921 wba:AmerisourceBergenCorporationMember 2021-08-31 0001618921 wba:OtherEquityMethodInvestmentsMember 2021-11-30 0001618921 srt:MinimumMember wba:OtherEquityMethodInvestmentsMember 2021-11-30 0001618921 srt:MaximumMember wba:OtherEquityMethodInvestmentsMember 2021-11-30 0001618921 wba:OtherEquityMethodInvestmentsMember 2021-08-31 0001618921 srt:MinimumMember wba:OtherEquityMethodInvestmentsMember 2021-08-31 0001618921 srt:MaximumMember wba:OtherEquityMethodInvestmentsMember 2021-08-31 0001618921 wba:AmerisourceBergenAndOtherEquityMethodInvestmentsMember 2021-11-30 0001618921 wba:AmerisourceBergenAndOtherEquityMethodInvestmentsMember 2021-08-31 0001618921 wba:AmerisourceBergenCorporationMember 2021-09-01 2021-11-30 0001618921 wba:AmerisourceBergenCorporationMember 2020-09-01 2020-11-30 0001618921 wba:OpiodLitigationMember wba:AmerisourceBergenCorporationMember 2020-07-01 2020-09-30 0001618921 wba:AmerisourceBergenCorporationMember us-gaap:FairValueInputsLevel1Member 2021-11-30 0001618921 wba:AmerisourceBergenCorporationMember us-gaap:FairValueInputsLevel1Member 2021-08-31 0001618921 wba:OtherEquityMethodInvestmentsMember 2021-09-01 2021-11-30 0001618921 wba:OtherEquityMethodInvestmentsMember 2020-09-01 2020-11-30 0001618921 wba:VillageMDMember 2021-09-01 2021-11-30 0001618921 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-09-01 2021-11-30 0001618921 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-09-01 2020-11-30 0001618921 srt:MinimumMember 2021-06-01 0001618921 srt:MaximumMember 2021-06-01 0001618921 wba:OtherInternationalReportingUnitMember 2021-06-01 0001618921 wba:BootsReportingUnitMember 2021-11-30 0001618921 wba:OtherInternationalReportingUnitMember 2021-11-30 0001618921 srt:MinimumMember wba:BootsReportingUnitMember 2021-11-30 0001618921 srt:MaximumMember wba:BootsReportingUnitMember 2021-11-30 0001618921 wba:BootsReportingUnitMember 2021-08-31 0001618921 us-gaap:OperatingSegmentsMember wba:UnitedStatesReportableSegmentMember 2021-08-31 0001618921 us-gaap:OperatingSegmentsMember wba:InternationalReportableSegmentMember 2021-08-31 0001618921 us-gaap:OperatingSegmentsMember wba:WalgreensHealthMember 2021-08-31 0001618921 us-gaap:OperatingSegmentsMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:WalgreensHealthMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:UnitedStatesReportableSegmentMember 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:InternationalReportableSegmentMember 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:WalgreensHealthMember 2021-11-30 0001618921 wba:CustomerRelationshipsAndLoyaltyCardHoldersMember 2021-11-30 0001618921 wba:CustomerRelationshipsAndLoyaltyCardHoldersMember 2021-08-31 0001618921 wba:PrimaryCareProviderNetworkMember 2021-11-30 0001618921 wba:PrimaryCareProviderNetworkMember 2021-08-31 0001618921 us-gaap:TrademarksAndTradeNamesMember 2021-11-30 0001618921 us-gaap:TrademarksAndTradeNamesMember 2021-08-31 0001618921 wba:PurchasingAndPayerContractsMember 2021-11-30 0001618921 wba:PurchasingAndPayerContractsMember 2021-08-31 0001618921 us-gaap:DevelopedTechnologyRightsMember 2021-11-30 0001618921 us-gaap:DevelopedTechnologyRightsMember 2021-08-31 0001618921 us-gaap:OtherIntangibleAssetsMember 2021-11-30 0001618921 us-gaap:OtherIntangibleAssetsMember 2021-08-31 0001618921 us-gaap:TrademarksAndTradeNamesMember 2021-11-30 0001618921 us-gaap:TrademarksAndTradeNamesMember 2021-08-31 0001618921 wba:PharmacyLicensesMember 2021-11-30 0001618921 wba:PharmacyLicensesMember 2021-08-31 0001618921 us-gaap:CommercialPaperMember 2021-11-30 0001618921 us-gaap:CommercialPaperMember 2021-08-31 0001618921 us-gaap:RevolvingCreditFacilityMember 2021-11-30 0001618921 us-gaap:RevolvingCreditFacilityMember 2021-08-31 0001618921 wba:A3300NotesPayableDue2021Member 2021-11-30 0001618921 wba:A3300NotesPayableDue2021Member 2021-08-31 0001618921 wba:DebtIssuanceNoteTwoMember us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3100NotesPayableDue2022Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3100NotesPayableDue2022Member 2021-11-30 0001618921 wba:A3100NotesPayableDue2022Member 2021-08-31 0001618921 wba:OtherShortTermDebtMember 2021-11-30 0001618921 wba:OtherShortTermDebtMember 2021-08-31 0001618921 us-gaap:RevolvingCreditFacilityMember 2021-11-30 0001618921 us-gaap:RevolvingCreditFacilityMember 2021-08-31 0001618921 wba:DebtIssuanceNoteEightMember us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A09500NotesPayableDue2023Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A09500NotesPayableDue2023Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:DebtIssuanceNoteSevenMember us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3200NotesPayableDue2030Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3200NotesPayableDue2030Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:A4100NotesPayableDue2050Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A4100NotesPayableDue2050Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:DebtIssuanceNoteFourMember us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3450NotesPayableDue2026Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3450NotesPayableDue2026Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:A4650NotesPayableDue2046Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A4650NotesPayableDue2046Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:DebtIssuanceNoteOneMember us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3800NotesPayableDue2024Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3800NotesPayableDue2024Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:A4500NotesPayableDue2034Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A4500NotesPayableDue2034Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:A4800NotesPayableDue2044Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A4800NotesPayableDue2044Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:DebtIssuanceNoteFiveMember us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3600NotesPayableDue2025Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A3600NotesPayableDue2025Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:DebtIssuanceNoteSixMember us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A2125NotesPayableDue2026Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A2125NotesPayableDue2026Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:A3100NotesPayableDue2022Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:A4400NotesPayableDue2042Member us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 wba:A4400NotesPayableDue2042Member us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 us-gaap:UnsecuredDebtMember 2021-11-30 0001618921 us-gaap:UnsecuredDebtMember 2021-08-31 0001618921 wba:A3300NotesPayableDue2021Member 2021-09-18 0001618921 wba:A09500NotesPayableDue2023Member us-gaap:UnsecuredDebtMember 2021-11-17 0001618921 wba:A09500NotesPayableDue2023Member us-gaap:UnsecuredDebtMember 2021-11-17 2021-11-17 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacilityMember us-gaap:LoansPayableMember 2021-11-15 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacility364DayFacilityMember us-gaap:LoansPayableMember 2021-11-15 2021-11-15 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacility364DayFacilityMember us-gaap:LoansPayableMember 2021-11-15 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacilityTwoYearFacilityMember us-gaap:LoansPayableMember 2021-11-15 2021-11-15 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacilityTwoYearFacilityMember 2021-11-15 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacilityThreeYearFacilityMember us-gaap:LoansPayableMember 2021-11-15 2021-11-15 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacilityThreeYearFacilityMember 2021-11-15 0001618921 us-gaap:RevolvingCreditFacilityMember wba:DelayedDrawTermLoanCreditFacilityMember us-gaap:LoansPayableMember 2021-11-30 0001618921 us-gaap:RevolvingCreditFacilityMember wba:A2020RevolvingCreditAgreement364DayFacilityMember 2020-12-23 0001618921 us-gaap:RevolvingCreditFacilityMember wba:A2020RevolvingCreditAgreement364DayFacilityMember 2020-12-23 2020-12-23 0001618921 us-gaap:RevolvingCreditFacilityMember wba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember 2020-12-23 0001618921 us-gaap:RevolvingCreditFacilityMember wba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember 2020-12-23 2020-12-23 0001618921 us-gaap:BridgeLoanMember wba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember 2020-12-23 0001618921 us-gaap:RevolvingCreditFacilityMember wba:A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember 2021-11-30 0001618921 us-gaap:RevolvingCreditFacilityMember wba:August2018RevolvingCreditAgreementMember 2018-08-29 0001618921 us-gaap:LetterOfCreditMember wba:August2018RevolvingCreditAgreementMember 2018-08-29 0001618921 us-gaap:RevolvingCreditFacilityMember wba:August2018RevolvingCreditAgreementMember 2021-11-30 0001618921 us-gaap:CommercialPaperMember 2021-09-01 2021-11-30 0001618921 us-gaap:CommercialPaperMember 2020-09-01 2020-11-30 0001618921 srt:GuarantorSubsidiariesMember srt:ReportableLegalEntitiesMember us-gaap:CommercialPaperMember 2020-09-01 2020-11-30 0001618921 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-11-30 0001618921 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-11-30 0001618921 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-11-30 0001618921 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-11-30 0001618921 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-11-30 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-11-30 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-11-30 0001618921 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-11-30 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-11-30 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:TotalReturnSwapMember us-gaap:NondesignatedMember 2021-11-30 0001618921 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-08-31 0001618921 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-08-31 0001618921 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-08-31 0001618921 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-08-31 0001618921 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-08-31 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-08-31 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-08-31 0001618921 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-08-31 0001618921 us-gaap:OtherCurrentAssetsMember us-gaap:TotalReturnSwapMember us-gaap:NondesignatedMember 2021-08-31 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-08-31 0001618921 us-gaap:OtherCurrentLiabilitiesMember us-gaap:TotalReturnSwapMember us-gaap:NondesignatedMember 2021-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-09-01 2021-11-30 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-09-01 2020-11-30 0001618921 us-gaap:TotalReturnSwapMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-09-01 2021-11-30 0001618921 us-gaap:TotalReturnSwapMember us-gaap:NondesignatedMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-09-01 2020-11-30 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember wba:OtherIncomeExpensesMember 2021-09-01 2021-11-30 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember wba:OtherIncomeExpensesMember 2020-09-01 2020-11-30 0001618921 us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-11-30 0001618921 us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:TotalReturnSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-08-31 0001618921 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-11-30 0001618921 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-11-30 0001618921 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-09-01 2021-11-30 0001618921 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-09-01 2020-11-30 0001618921 us-gaap:OtherExpenseMember 2021-09-01 2021-11-30 0001618921 us-gaap:OtherExpenseMember 2020-09-01 2020-11-30 0001618921 us-gaap:OtherIncomeMember 2021-09-01 2021-11-30 0001618921 us-gaap:OtherIncomeMember 2020-09-01 2020-11-30 0001618921 country:US 2021-09-01 2021-11-30 0001618921 country:US 2020-09-01 2020-11-30 0001618921 us-gaap:ForeignPlanMember 2021-09-01 2021-11-30 0001618921 us-gaap:ForeignPlanMember 2020-09-01 2020-11-30 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-08-31 0001618921 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-08-31 0001618921 wba:AOCINetInvestmentHedgesParentMember 2021-08-31 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-08-31 0001618921 wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember 2021-08-31 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2021-08-31 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-01 2021-11-30 0001618921 wba:AOCINetInvestmentHedgesParentMember 2021-09-01 2021-11-30 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-01 2021-11-30 0001618921 wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember 2021-09-01 2021-11-30 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-11-30 0001618921 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-11-30 0001618921 wba:AOCINetInvestmentHedgesParentMember 2021-11-30 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-11-30 0001618921 wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember 2021-11-30 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2021-11-30 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-08-31 0001618921 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-08-31 0001618921 wba:AOCINetInvestmentHedgesParentMember 2020-08-31 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-08-31 0001618921 wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember 2020-08-31 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2020-08-31 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-01 2020-11-30 0001618921 wba:AOCINetInvestmentHedgesParentMember 2020-09-01 2020-11-30 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-09-01 2020-11-30 0001618921 wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember 2020-09-01 2020-11-30 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-11-30 0001618921 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-11-30 0001618921 wba:AOCINetInvestmentHedgesParentMember 2020-11-30 0001618921 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-11-30 0001618921 wba:AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember 2020-11-30 0001618921 us-gaap:AccumulatedTranslationAdjustmentMember 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:WalgreensHealthMember 2020-09-01 2020-11-30 0001618921 wba:CorporateAndReconcilingItemsMember 2021-09-01 2021-11-30 0001618921 wba:CorporateAndReconcilingItemsMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:PharmacyMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:PharmacyMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember us-gaap:RetailMember wba:UnitedStatesReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember us-gaap:RetailMember wba:UnitedStatesReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:PharmacyMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:PharmacyMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember us-gaap:RetailMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember us-gaap:RetailMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:PharmaceuticalWholesaleMember wba:InternationalReportableSegmentMember 2021-09-01 2021-11-30 0001618921 us-gaap:OperatingSegmentsMember wba:PharmaceuticalWholesaleMember wba:InternationalReportableSegmentMember 2020-09-01 2020-11-30 0001618921 us-gaap:TradeAccountsReceivableMember 2021-11-30 0001618921 us-gaap:TradeAccountsReceivableMember 2021-08-31 0001618921 us-gaap:SegmentContinuingOperationsMember 2021-11-30 0001618921 us-gaap:SegmentContinuingOperationsMember 2021-08-31 0001618921 wba:VillageMDMember 2021-09-01 2021-11-30 shares iso4217:USD iso4217:USD shares wba:segment pure wba:store iso4217:GBP iso4217:EUR 0001618921 --08-31 2022 Q1 false http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 10-Q true 2021-11-30 false 001-36759 WALGREENS BOOTS ALLIANCE, INC. DE 47-1758322 108 Wilmot Road Deerfield IL 60015 847 315-3700 Common Stock, $0.01 par value WBA NASDAQ 3.600% Walgreens Boots Alliance, Inc. notes due 2025 WBA25 NASDAQ 2.125% Walgreens Boots Alliance, Inc. notes due 2026 WBA26 NASDAQ Yes Yes Large Accelerated Filer false false false 863272027 4135000000 1193000000 5960000000 5663000000 9475000000 8159000000 745000000 800000000 20314000000 15814000000 12295000000 12247000000 21826000000 21893000000 21520000000 12421000000 12770000000 9936000000 6367000000 6987000000 1413000000 1987000000 76192000000 65471000000 96507000000 81285000000 2647000000 1305000000 12452000000 11136000000 2266000000 2259000000 6973000000 7260000000 110000000 94000000 24447000000 22054000000 11199000000 7675000000 22103000000 22153000000 1970000000 1850000000 3422000000 3413000000 38694000000 35091000000 63141000000 57145000000 2787000000 319000000 0.01 0.01 32000000 32000000 0 0 0 0 0.01 0.01 3200000000 3200000000 1172513618 1172513618 12000000 12000000 10966000000 10988000000 38286000000 35121000000 -2301000000 -2109000000 308671242 307139982 20700000000 20593000000 26263000000 23419000000 4316000000 402000000 30579000000 23822000000 96507000000 81285000000 865373636 12000000 -20593000000 10988000000 -2109000000 35121000000 402000000 23822000000 3580000000 -27000000 3552000000 -193000000 -3000000 -196000000 415000000 415000000 3179750 154000000 154000000 1648490 47000000 -59000000 -11000000 35000000 35000000 3944000000 3944000000 -2000000 -2000000 863842376 12000000 -20700000000 10966000000 -2301000000 38286000000 4316000000 30579000000 865603519 12000000 -20575000000 10761000000 -3771000000 34210000000 498000000 21136000000 -308000000 9000000 -299000000 88000000 2000000 90000000 405000000 405000000 3000000 110000000 110000000 1298298 43000000 -39000000 4000000 36000000 36000000 -3000000 -3000000 -5000000 117000000 117000000 -1000000 -1000000 863901817 12000000 -20642000000 10876000000 -3682000000 33495000000 506000000 20563000000 33901000000 31438000000 26326000000 24808000000 7574000000 6630000000 6391000000 5792000000 100000000 -1373000000 1283000000 -535000000 2617000000 63000000 3900000000 -472000000 86000000 136000000 3814000000 -607000000 275000000 -207000000 -7000000 15000000 3531000000 -385000000 0 87000000 3531000000 -299000000 -48000000 5000000 0 4000000 3580000000 -308000000 3580000000 -391000000 0 83000000 3580000000 -308000000 4.13 -0.45 0 0.10 4.13 -0.36 4.13 -0.45 0 0.10 4.13 -0.36 865800000 865300000 867600000 865300000 3531000000 -299000000 5000000 -11000000 1000000 4000000 -44000000 7000000 -96000000 0 46000000 -5000000 -94000000 80000000 -196000000 94000000 3336000000 -206000000 -51000000 14000000 3387000000 -220000000 3531000000 -299000000 500000000 475000000 164000000 -348000000 35000000 36000000 93000000 -1350000000 2576000000 0 -95000000 71000000 127000000 259000000 1352000000 1225000000 58000000 -36000000 1335000000 1398000000 -399000000 -105000000 79000000 132000000 -36000000 74000000 1099000000 1195000000 454000000 431000000 202000000 231000000 -1800000000 -77000000 -95000000 -19000000 -1958000000 -259000000 937000000 -347000000 7940000000 3310000000 4444000000 2807000000 154000000 110000000 19000000 4000000 413000000 405000000 -7000000 4000000 3877000000 -352000000 -20000000 10000000 2998000000 594000000 1270000000 746000000 4268000000 1339000000 Accounting policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2021, as amended by Form 10-K/A for the fiscal year ended August 31, 2021 filed on November 24, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of the COVID-19 pandemic (“COVID-19”). The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous factors discussed throughout this Quarterly Report on Form 10-Q including, but not limited to, the severity and duration of COVID-19, the extent to which it will impact our customers, team members, suppliers, vendors, business partners and distribution channels. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of November 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, the Company completed the sale of the majority of the Company's Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (“Disposal Group”) to AmerisourceBergen Corporation (“AmerisourceBergen”). The Disposal Group met the criteria to be reported as discontinued operations. Therefore, the operating results of the Disposal Group are reported as discontinued operations for all prior periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of the first quarter of fiscal year 2022, the Company is aligned into three reportable segments: United States, International and Walgreens Health. Unless otherwise specified, disclosures in these Consolidated Condensed Financial Statements reflect continuing operations only. Certain prior period data, related to discontinued operations has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. See Note 2 Discontinued operations and Note 15 Segment reporting for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented. </span></div>New accounting pronouncements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of new accounting pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - nonrefundable fees and others</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other. This ASU clarifies the accounting for the amortization period for certain purchased callable debt securities held at a premium by giving consideration to securities which have multiple call dates. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments — equity securities; Investments — equity method and joint ventures; Derivatives and hedging</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes - simplifying the accounting for income taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effects of reference rate reform on financial reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable, or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to the above the ASU to clarify certain optional expedients in Topic 848. The Company adopted the new standard effective September 1, 2021, and the adoption did not have a material impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New accounting pronouncements not yet adopted</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired contract assets and contract liabilities in a business combination </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosures by business entities about government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021 (fiscal 2023). The Company is evaluating the effect of adopting this new accounting guidance.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2021, as amended by Form 10-K/A for the fiscal year ended August 31, 2021 filed on November 24, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of the COVID-19 pandemic (“COVID-19”). The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous factors discussed throughout this Quarterly Report on Form 10-Q including, but not limited to, the severity and duration of COVID-19, the extent to which it will impact our customers, team members, suppliers, vendors, business partners and distribution channels. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of November 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s carrying value of goodwill, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, the Company completed the sale of the majority of the Company's Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (“Disposal Group”) to AmerisourceBergen Corporation (“AmerisourceBergen”). The Disposal Group met the criteria to be reported as discontinued operations. Therefore, the operating results of the Disposal Group are reported as discontinued operations for all prior periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of the first quarter of fiscal year 2022, the Company is aligned into three reportable segments: United States, International and Walgreens Health. Unless otherwise specified, disclosures in these Consolidated Condensed Financial Statements reflect continuing operations only. Certain prior period data, related to discontinued operations has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. See Note 2 Discontinued operations and Note 15 Segment reporting for further information.</span></div>Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented. 3 Discontinued operations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, the Company completed the sale of Alliance Healthcare, for total consideration of $6.9 billion, which included cash consideration of $6.7 billion, subject to net working capital and net cash adjustments and 2 million shares of AmerisourceBergen common stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2021, Other current assets include a $98 million receivable for purchase price consideration due from AmerisourceBergen that is subject to change upon the finalization of net working capital adjustments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the Disposal Group are reported as discontinued operations as the disposition reflected a strategic shift that has, or will have, a major effect on the Company’s operations and financial results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of discontinued operations were as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:21.562%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income tax – discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post tax earnings from other equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales from the Disposal Group to the Company's continuing operations are not eliminated and aggregate to (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:21.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating and investing activities for discontinued operations are (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities - discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used for investing activities - discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 Related parties, to the Consolidated Condensed Financial Statements for more information on the Company's transactions and continuing involvement with AmerisourceBergen.</span></div> 6900000000 6700000000 2000000 98000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of discontinued operations were as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:21.562%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,327 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income tax – discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post tax earnings from other equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales from the Disposal Group to the Company's continuing operations are not eliminated and aggregate to (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:21.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating and investing activities for discontinued operations are (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities - discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used for investing activities - discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5327000000 4818000000 509000000 415000000 94000000 2000000 4000000 88000000 8000000 7000000 87000000 458000000 -45000000 -19000000 Acquisitions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VillageMD</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 24, 2021, the Company completed the acquisition of Village Practice Management Company, LLC (“VillageMD”). Pursuant to the terms and subject to the conditions set forth in the Unit Purchase Agreement, the Company purchased additional outstanding equity interests of VillageMD, increasing the Company’s total beneficial ownership in VillageMD’s outstanding equity interests from approximately 30% to approximately 63%, on a fully diluted basis, for a purchase price of $5.2 billion. The total purchase price comprises cash consideration of $4.0 billion and a promissory note of $1.2 billion. The cash consideration consisted of $2.9 billion to be paid to existing shareholders, after giving affect to the $1.9 billion tender offer described below, as well as $1.1 billion paid in exchange for new preferred units issued by VillageMD. Subject to notice being served, the Company has an option to prepay the promissory note at any time and VillageMD may require the Company to redeem the promissory note after February 1, 2022. The promissory note is eliminated in consolidation within the Consolidated Condensed Balance Sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for this acquisition as a business combination resulting in consolidation of VillageMD within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. As of November 30, 2021, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired. As such, the preliminary purchase price allocation will be subject to further refinement and may change. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this acquisition, the Company recognized a pre-tax gain in Other income in the Consolidated Condensed Statements of Earnings, of $1,597 million related to the fair valuation of the Company’s previously held minority equity interest. The Company also recorded a pre-tax gain of $577 million in Other income in the Consolidated Condensed Statements of Earnings related to the conversion to equity of the Company’s previously held investment in convertible debt securities of VillageMD, reclassified from within accumulated other comprehensive income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price Allocation:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: purchase price for issuance of new preferred units at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of share-based compensation awards attributable to pre-combination services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity and debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of non-controlling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.13pt">Comprises cash consideration of $1.1 billion and a promissory note of $1.2 billion. This consideration was provided in exchange for the issuance of new preferred units by VillageMD. VillageMD’s tangible assets acquired exclude this $1.1 billion of cash and $1.2 billion promissory note receivable.</span></div><div style="padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.13pt">Primarily related to vested share-based compensation awards.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill represents anticipated future growth and expansion opportunities into new markets. Pro forma sales and net earnings of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shields acquisition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, the Company completed the acquisition of Shields Health Solutions Parent, LLC (“Shields”). Pursuant to the terms and subject to the conditions set forth in the Securities Purchase Agreement, the Company purchased additional outstanding equity interests of Shields, increasing the Company’s total beneficial ownership in Shields’ outstanding equity interests from 25% to approximately 70%, on a fully diluted basis, for cash consideration of $969 million, subject to certain purchase price adjustments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for this acquisition as a business combination resulting in consolidation of Shields within the Walgreens Health segment in its financial statements. A noncontrolling interest was recognized at fair value. Under the terms of the transaction agreements, the Company has an option to acquire the remaining equity interests of Shields in the future. Shields’ other equity holders will also have an option to require the Company to purchase the remaining equity interests. Considering the contractual terms related to the noncontrolling interest, it is classified as redeemable noncontrolling interest in the Consolidated Condensed Balance Sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2021, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired. As such, the preliminary purchase price allocation will be subject to further refinement and may result in changes. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this acquisition, the Company remeasured its previously held minority equity interest in Shields at fair value resulting in a pre-tax gain of $402 million recognized in Other income in the Consolidated Condensed Statements of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price Allocation:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of share-based compensation awards attributable to pre-combination services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill represents anticipated future growth and expansion opportunities into new healthcare offerings. Pro forma sales and net earnings of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 15 Segment reporting and Note 16 Sales for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other acquisitions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired certain prescription files and related pharmacy inventory primarily in the U.S. for the aggregate purchase price of $74 million and $38 million during the three months ended November 30, 2021 and 2020, respectively.</span></div> 0.30 0.63 5200000000 4000000000 1200000000 2900000000 1900000000 1100000000 1900000000 1900000000 1597000000 577000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price Allocation:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: purchase price for issuance of new preferred units at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of share-based compensation awards attributable to pre-combination services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity and debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of non-controlling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.13pt">Comprises cash consideration of $1.1 billion and a promissory note of $1.2 billion. This consideration was provided in exchange for the issuance of new preferred units by VillageMD. VillageMD’s tangible assets acquired exclude this $1.1 billion of cash and $1.2 billion promissory note receivable.</span></div><div style="padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.13pt">Primarily related to vested share-based compensation awards.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price Allocation:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of share-based compensation awards attributable to pre-combination services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously held equity interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5200000000 2300000000 2900000000 683000000 3211000000 3257000000 10051000000 637000000 1982000000 241000000 2378000000 7673000000 1100000000 1200000000 1100000000 1200000000 0.25 0.70 969000000 402000000 969000000 13000000 502000000 589000000 2074000000 84000000 1060000000 528000000 616000000 1457000000 74000000 38000000 Exit and disposal activities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transformational Cost Management Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2018, the Company announced a transformational cost management program that was expected to deliver in excess of $2.0 billion of annual cost savings by fiscal 2022 (the “Transformational Cost Management Program”). The Company achieved this goal at the end of fiscal 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2021, the Company’s Board of Directors approved an expansion and extension of the Transformational Cost Management Program through the end of fiscal 2024. As a result, the Company increased its annual cost savings target to $3.3 billion by the end of fiscal 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transformational Cost Management Program, which is multi-faceted and includes divisional optimization initiatives, global smart spending, global smart organization and the transformation of the Company’s information technology (IT) capabilities, is designed to help the Company achieve increased cost efficiencies. To date, the Company has taken actions across all aspects of the Transformational Cost Management Program which focus on the United States and International reportable segments along with the Company’s global functions. Divisional optimization within the Company’s segments includes activities such as optimization of stores. As a result of the expanded program, the Company plans to reduce its presence by up to 150 Boots stores in the UK and up to 150 stores in the United States over the next three years which are incremental to the previously planned reductions of approximately 200 Boots stores in the UK and approximately 250 stores in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently estimates that the Transformational Cost Management Program will result in cumulative pre-tax charges to its GAAP financial results of approximately $3.6 billion to $3.9 billion, of which $3.3 billion to $3.6 billion are expected to be recorded as exit and disposal activities. In addition to these impacts, as a result of the actions related to store closures taken under the Transformational Cost Management Program, the Company recorded $508 million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard (Topic 842) that became effective on September 1, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of the Transformational Cost Management Program to November 30, 2021, the Company has recognized cumulative pre-tax charges to its financial results in accordance with GAAP of $1.5 billion, which were primarily recorded within selling, general and administrative expenses. These charges included $442 million related to lease obligations and other real estate costs, $292 million in asset impairments, $550 million in employee severance and business transition costs and $172 million of information technology transformation and other exit costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to exit and disposal activities under the Transformational Cost Management Program for the three months ended November 30, 2021 and 2020, respectively, were as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:48.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations and other real estate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and business transition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology transformation and other exit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total pre-tax exit and disposal charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-right:-9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:48.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations and other real estate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and business transition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology transformation and other exit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total pre-tax exit and disposal charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease obligations and other real estate costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Impairments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee severance and business transition costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Information technology transformation and other exit costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at August 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at November 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2000000000 3300000000 150 150 200 250 3600000000 3900000000 3300000000 3600000000 -508000000 1500000000 442000000 292000000 550000000 172000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to exit and disposal activities under the Transformational Cost Management Program for the three months ended November 30, 2021 and 2020, respectively, were as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:48.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations and other real estate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and business transition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology transformation and other exit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total pre-tax exit and disposal charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:48.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations and other real estate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance and business transition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information technology transformation and other exit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total pre-tax exit and disposal charges</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 87000000 2000000 0 89000000 15000000 25000000 0 40000000 20000000 10000000 7000000 37000000 1000000 7000000 1000000 9000000 123000000 44000000 9000000 175000000 22000000 0 0 22000000 4000000 -2000000 0 1000000 12000000 28000000 12000000 52000000 10000000 -5000000 0 5000000 48000000 21000000 12000000 81000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease obligations and other real estate costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Impairments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee severance and business transition costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Information technology transformation and other exit costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at August 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at November 30, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 17000000 0 77000000 20000000 114000000 89000000 40000000 37000000 9000000 175000000 15000000 0 51000000 7000000 74000000 72000000 40000000 3000000 0 115000000 0 0 -1000000 0 -1000000 19000000 0 59000000 23000000 101000000 Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. For the majority of leases in the U.S., the initial lease term is typically 15 to 25 years, followed by additional terms containing renewal options typically at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases were as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet supplemental information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,826 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,893 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations - non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,412 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfOS0wLTEtMS03MDYwOA_3e3f1ee1-24fe-4059-b7b7-4c6af3cb0f57"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfOS0wLTEtMS03MDYwOA_533cf0ce-c32d-4625-b124-06680c306ff9">Property, plant and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations included in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTEtMC0xLTEtNzA2MDg_041899a4-f90f-46de-b8c4-6ebecc8abafa"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTEtMC0xLTEtNzA2MDg_e52f5a24-c7f8-4179-aafd-2209c4b7a22a">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTItMC0xLTEtNzA2MDg_4e814d69-1c6f-4008-bbfc-a86ee8f19230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTItMC0xLTEtNzA2MDg_d6b647fd-d668-4fbc-81b3-057723ddb4c1">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental income statement information related to leases were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings supplemental information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale and leaseback </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Recorded within selling, general and administrative expenses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Supplemental Information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average lease term and discount rate were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average terms and discount rates:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future lease payments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (Remaining period)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total undiscounted minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. For the majority of leases in the U.S., the initial lease term is typically 15 to 25 years, followed by additional terms containing renewal options typically at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases were as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet supplemental information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,826 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,893 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations - non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,412 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfOS0wLTEtMS03MDYwOA_3e3f1ee1-24fe-4059-b7b7-4c6af3cb0f57"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfOS0wLTEtMS03MDYwOA_533cf0ce-c32d-4625-b124-06680c306ff9">Property, plant and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations included in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTEtMC0xLTEtNzA2MDg_041899a4-f90f-46de-b8c4-6ebecc8abafa"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTEtMC0xLTEtNzA2MDg_e52f5a24-c7f8-4179-aafd-2209c4b7a22a">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTItMC0xLTEtNzA2MDg_4e814d69-1c6f-4008-bbfc-a86ee8f19230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTItMC0xLTEtNzA2MDg_d6b647fd-d668-4fbc-81b3-057723ddb4c1">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental income statement information related to leases were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings supplemental information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale and leaseback </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Recorded within selling, general and administrative expenses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Supplemental Information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average lease term and discount rate were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average terms and discount rates:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future lease payments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (Remaining period)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total undiscounted minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P15Y P25Y P5Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases were as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet supplemental information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,826 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,893 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations - non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,412 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfOS0wLTEtMS03MDYwOA_3e3f1ee1-24fe-4059-b7b7-4c6af3cb0f57"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfOS0wLTEtMS03MDYwOA_533cf0ce-c32d-4625-b124-06680c306ff9">Property, plant and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations included in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTEtMC0xLTEtNzA2MDg_041899a4-f90f-46de-b8c4-6ebecc8abafa"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTEtMC0xLTEtNzA2MDg_e52f5a24-c7f8-4179-aafd-2209c4b7a22a">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTItMC0xLTEtNzA2MDg_4e814d69-1c6f-4008-bbfc-a86ee8f19230"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTA4ODQxNzc4MjQzOWRiODczZDMyMTNjNjg0N2E5L3NlYzozNmEwODg0MTc3ODI0MzlkYjg3M2QzMjEzYzY4NDdhOV81Mi9mcmFnOjIxMDhlOWRlNWFhNDQyNDlhYzYyMjBlMTAzMDJhZDEwL3RhYmxlOmEwZjQxN2RmNWM2MjRmZDY5ZDJlMGY2ZTU5MzNlNWUxL3RhYmxlcmFuZ2U6YTBmNDE3ZGY1YzYyNGZkNjlkMmUwZjZlNTkzM2U1ZTFfMTItMC0xLTEtNzA2MDg_d6b647fd-d668-4fbc-81b3-057723ddb4c1">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 21826000000 21893000000 2266000000 2259000000 22103000000 22153000000 24369000000 24412000000 713000000 725000000 37000000 37000000 963000000 974000000 1000000000 1010000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental income statement information related to leases were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.550%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings supplemental information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale and leaseback </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Recorded within selling, general and administrative expenses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Supplemental Information:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average lease term and discount rate were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average terms and discount rates:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 805000000 805000000 205000000 158000000 11000000 11000000 13000000 13000000 25000000 20000000 68000000 10000000 87000000 93000000 846000000 857000000 12000000 12000000 11000000 10000000 869000000 879000000 544000000 787000000 5000000 0 549000000 787000000 P10Y2M12D P10Y3M18D P20Y1M6D P20Y2M12D 0.0475 0.0477 0.0518 0.0518 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future lease payments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (Remaining period)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total undiscounted minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate future lease payments for operating and finance leases as of November 30, 2021 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:60.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future lease payments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (Remaining period)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total undiscounted minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,369</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 67000000 2608000000 88000000 3376000000 88000000 3260000000 87000000 3145000000 87000000 3032000000 86000000 2924000000 1054000000 12801000000 1556000000 31146000000 556000000 6777000000 1000000000 24369000000 Equity method investments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments were as follows (in millions, except percentages):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership percentage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8% - 50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8% - 50%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AmerisourceBergen investment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2021 and August 31, 2021, the Company owned 58,854,867 AmerisourceBergen common shares representing approximately 28.3% of its outstanding common stock based on the most recent share count publicly reported by AmerisourceBergen in its most recent Annual Report on Form 10-K. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings (loss) attributable to the Company’s investment being classified within the operating income of its United States segment. Due to the timing and availability of financial information of AmerisourceBergen, the Company accounts for this equity method investment on a financial reporting lag of two months. Equity earnings (loss) from AmerisourceBergen are reported as a separate line in the Consolidated Condensed Statements of Earnings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended November 30, 2021 and 2020, the Company recognized equity income of $100 million and equity losses of $1.4 billion, in AmerisourceBergen, respectively. The equity losses for the period ended November 30, 2020 were primarily due to AmerisourceBergen's recognition of loss of $5.6 billion, net of tax, related to its ongoing opioid litigation in its financial statements for the three months ended September 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Level 1 fair market value of the Company’s equity investment in AmerisourceBergen common stock at November 30, 2021 and August 31, 2021 was $6.8 billion and $7.2 billion, respectively. As of November 30, 2021 the carrying value of the Company’s investment in AmerisourceBergen exceeded its proportionate share of the net assets of AmerisourceBergen by $4.3 billion. This premium of $4.3 billion was recognized as part of the carrying value in the Company’s equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s other equity method investments include its U.S. investments in HC Group Holdings I, LLC (“HC Group Holdings”) which owns equity interest in Option Care Health, and BrightSpring Health Services, and the Company’s China investments in Sinopharm Medicine Holding Guoda Drugstores Co., Ltd, Guangzhou Pharmaceuticals Corporation and Nanjing </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Company Limited. The Company reported $7 million of post-tax equity losses and $15 million of post-tax equity earnings from other equity method investments for the three months ended November 30, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended November 30, 2021, the Company acquired majority equity interests in VillageMD and Shields. The Company accounted for these acquisitions as business combinations resulting in the remeasurement of its previously held minority equity interests and convertible debt securities at fair value resulting in pre-tax gains of $2,174 million and $402 million for VillageMD and Shields, respectively, recognized in Other income in the Consolidated Condensed Statements of Earnings. As a result of these transactions, the Company now consolidates VillageMD and Shields within the Walgreens Health segment in its financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summarized financial information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information for the Company’s equity method investments in aggregate is as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of earnings (loss) (in millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,088 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of earnings (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized financial information for equity method investments has been included on an aggregated basis for all investments as reported at the end of each reporting period.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments were as follows (in millions, except percentages):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership percentage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8% - 50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8% - 50%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,367</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,987</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table> 4393000000 0.28 4407000000 0.28 1974000000 0.08 0.50 2580000000 0.08 0.50 6367000000 6987000000 58854867 58854867 0.283 0.283 P2M 100000000 -1400000000 -5600000000 6800000000 7200000000 4300000000 4300000000 -7000000 15000000 2174000000 402000000 Summarized financial information for the Company’s equity method investments in aggregate is as follows:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of earnings (loss) (in millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,088 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of earnings (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 67588000000 56088000000 3420000000 2410000000 308000000 -4806000000 93000000 -1357000000 Goodwill and other intangible assets<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit or intangible asset below its carrying value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the analysis completed during fiscal 2021, as of the June 1, 2021 valuation date, the fair values of the Company’s reporting units exceeded their carrying amounts ranging from approximately 18% to approximately 195%. Boots reporting unit's fair value was in excess of its carrying value by approximately 18%, compared to a nominal amount as of June 1, 2020. Other international reporting unit's fair value was in excess of its carrying value by approximately 29%. As of November 30, 2021 the carrying values of goodwill were $1.0 billion and $372 million for Boots reporting unit and Other international reporting unit, respectively. The fair values of indefinite-lived intangibles within the Boots reporting unit exceeded their carrying value amounts ranging from approximately 5% to approximately 27%. As of November 30, 2021 and August 31, 2021 the carrying value of the indefinite-lived intangibles within the Boots reporting unit was $7.2 billion and $7.3 billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions with respect to the business and financial performance of the Company’s reporting units, as well as how such performance may be impacted by COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions, including the impact of COVID-19, could have a significant impact on either the fair value of the reporting units and indefinite-lived intangibles, the amount of any goodwill and indefinite-lived intangible impairment charges, or both. These estimates can be affected by a number of factors including, but not limited to, the impact of COVID-19, its severity, duration and its impact on global economies, general economic conditions as well as our profitability. The Company will continue to monitor these potential impacts, including the impact of COVID-19 and economic, industry and market trends and the impact these may have on the Boots and Other international reporting units.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill roll forward:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,520</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross amortizable intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and loyalty card holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchasing and payer contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total gross amortizable intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and loyalty card holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchasing and payer contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total amortizable intangible assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total indefinite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,244</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes purchased prescription files.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $165 million and $95 million for the three months ended November 30, 2021, and 2020, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2021 is as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 (Remaining period)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated annual amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.18 1.95 0.18 0.29 1000000000 372000000 0.05 0.27 7200000000 7300000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill roll forward:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,520</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10947000000 1474000000 0 12421000000 0 0 9130000000 9130000000 0 -32000000 0 -32000000 10947000000 1443000000 9130000000 21520000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross amortizable intangible assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and loyalty card holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchasing and payer contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total gross amortizable intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and loyalty card holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchasing and payer contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total amortizable intangible assets, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,526</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total indefinite-lived intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,244</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,936</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes purchased prescription files.</span></div> 4430000000 3522000000 1660000000 0 708000000 361000000 317000000 317000000 290000000 0 75000000 221000000 7479000000 4421000000 1395000000 1335000000 228000000 226000000 284000000 227000000 17000000 0 29000000 37000000 1953000000 1826000000 5526000000 2595000000 5208000000 5276000000 2036000000 2066000000 7244000000 7342000000 12770000000 9936000000 165000000 95000000 Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2021 is as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 (Remaining period)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated annual amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 462000000 560000000 541000000 514000000 490000000 443000000 Debt<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt carrying values are presented net of unamortized discount and debt issuance costs, where applicable, and foreign currency denominated debt is translated using the spot rates as of the balance sheet date. Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:61.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term debt </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$8 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.300% unsecured notes due 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$4 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.100% unsecured notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total short-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit facilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$850 million note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9500% unsecured notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$1.5 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.200% unsecured notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.100% unsecured notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$6 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450% unsecured notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.650% unsecured notes due 2046</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$8 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.800% unsecured notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500% unsecured notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.800% unsecured notes due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">£700 million note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.600% unsecured Pound sterling notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">€750 million note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.125% unsecured Euro notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$4 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.100% unsecured notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.400% unsecured notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Notes are unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">On September 18, 2021, the Company redeemed in full the $1.25 billion aggregate principal amount outstanding of its 3.300% unsecured notes due 2021 issued by the Company on November 18, 2014.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. Other long term debt includes $447 million of debt acquired as part of Shields acquisition.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$850 million Note Issuance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2021, the Company issued, in an underwritten public offering, $850 million of 0.95% Notes due 2023. The Notes contain a call option which allow for the Notes to be repaid, in full or in part, prior to May 17, 2022 (the “Par Call Date”) at 100% of the principal amount of the Notes to be redeemed or the sum of the present values of the remaining scheduled payments thereof to the Par Call Date discounted at the applicable treasury rate, plus 10 basis points and (ii) on or after the Par Call Date, at 100% of the principal amount of the Notes to be redeemed, in each case plus accrued and unpaid interest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit facilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">November 15, 2021, Delayed Draw Term Loan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, the Company entered into a $5.0 billion senior unsecured multi-tranche delayed draw term loan credit facility, (the “November 2021 DDTL”) consisting of (i) a 364-day senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the“364-day loan”), (ii) a two-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the “two-year loan”) and (iii) a three-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $1.0 billion (the “three-year loan”). An aggregate amount of $3.0 billion or more of the November 2021 DDTL is for the purpose of funding the consideration due in respect of the purchase of an increased equity stake in VillageMD, and paying fees and expenses related to the foregoing, and the remainder can be used for general corporate purposes. The November 2021 DDTL is available for drawing in one or more tranches until May 15, 2022. The maturity date on the 364-day loan, the two-year loan and the three-year loan is, in each case, the earlier of the date that is 364 days, two years and three years from the date of the first drawing under each facility and February 14, 2023, February 15, 2024 and February 15, 2025 respectively. As of November 30, 2021 there were $3.0 billion in borrowings outstanding under the November 2021 DDTL.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 23, 2020, Revolving Credit Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, the Company entered into a $1.25 billion senior unsecured 364-day revolving credit agreement and a $2.25 billion senior unsecured 18-month revolving credit facility, with a swing line subfacility commitment amount of $350 million, with designated borrowers from time to time party thereto and lenders from time to time party thereto (the “2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Credit Agreement”). </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-day facility’s termination date is the earlier of (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> days from December 23, 2020,</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-day facility pursuant to the 2020 Revolving Credit Agreement. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-month facility’s termination date is the earlier of (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months from the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-Month Facility pursuant to the 2020 Revolving Credit Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2021 there were $800 million in borrowings outstanding under the 2020 Revolving Credit Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">August 2018 Revolving Credit Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2018, the Company entered into a revolving credit agreement (the “August 2018 Revolving Credit Agreement”) with the lenders and letter of credit issuers from time-to-time party thereto. The August 2018 Revolving Credit Agreement is an unsecured revolving credit facility with aggregate commitment in the amount of $3.5 billion, with a letter of credit subfacility commitment amount of $500 million. The facility termination date is the earlier of (a) August 29, 2023, subject to extension thereof pursuant to the August 2018 Revolving Credit Agreement, and (b) the date of termination in whole of the aggregate amount of the revolving commitments pursuant to the August 2018 Revolving Credit Agreement. As of November 30, 2021, there were no borrowings outstanding under the August 2018 Revolving Credit Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt covenants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company’s credit facilities described above contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, subject to increase in certain circumstances set forth in the applicable credit agreement. The credit facilities also contain various other customary covenants. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial paper</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically borrows under its commercial paper program and may borrow under it in future periods. The Company had average daily U.S. commercial paper outstanding of $712 million and $1.6 billion at a weighted average interest rate of 0.25% and 0.63% for the three months ended November 30, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company had average daily commercial paper outstanding, which was issued under the Joint HM Treasury and Bank of England's COVID Corporate Financing Facility commercial paper program, of £300 million, or approximately $401 million at a weighted average interest rate of 0.43% for the three months ended November 30, 2020. The subsidiary of the Company repaid the commercial paper issued under the Joint HM Treasury and Bank of England's COVID Corporate Financing Facility commercial paper program on May 14, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid by the Company was $153 million and $234 million for the three months ended November 30, 2021 and 2020, respectively.</span></div> Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:61.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term debt </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$8 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.300% unsecured notes due 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$4 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.100% unsecured notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total short-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit facilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$850 million note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9500% unsecured notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$1.5 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.200% unsecured notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.100% unsecured notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$6 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450% unsecured notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.650% unsecured notes due 2046</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$8 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.800% unsecured notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500% unsecured notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.800% unsecured notes due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">£700 million note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.600% unsecured Pound sterling notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">€750 million note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.125% unsecured Euro notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$4 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.100% unsecured notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.400% unsecured notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Notes are unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">On September 18, 2021, the Company redeemed in full the $1.25 billion aggregate principal amount outstanding of its 3.300% unsecured notes due 2021 issued by the Company on November 18, 2014.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. Other long term debt includes $447 million of debt acquired as part of Shields acquisition.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.</span> Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:61.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term debt </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$8 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.300% unsecured notes due 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$4 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.100% unsecured notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total short-term debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit facilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$850 million note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9500% unsecured notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$1.5 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.200% unsecured notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.100% unsecured notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$6 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450% unsecured notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.650% unsecured notes due 2046</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$8 billion note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.800% unsecured notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.500% unsecured notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.800% unsecured notes due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">£700 million note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.600% unsecured Pound sterling notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">€750 million note issuance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.125% unsecured Euro notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$4 billion note issuance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.100% unsecured notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.400% unsecured notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Notes are unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">On September 18, 2021, the Company redeemed in full the $1.25 billion aggregate principal amount outstanding of its 3.300% unsecured notes due 2021 issued by the Company on November 18, 2014.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. Other long term debt includes $447 million of debt acquired as part of Shields acquisition.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.</span> 875000000 0 799000000 0 8000000000 0.03300 0 1250000000 4000000000 0.03100 731000000 0 242000000 56000000 2647000000 1305000000 2990000000 0 850000000 0.009500 848000000 0 1500000000 0.03200 497000000 497000000 0.04100 792000000 792000000 6000000000 0.03450 1442000000 1442000000 0.04650 318000000 318000000 8000000000 0.03800 1154000000 1154000000 0.04500 301000000 301000000 0.04800 868000000 868000000 700000000 0.03600 403000000 408000000 750000000 0.02125 846000000 873000000 4000000000 0.03100 0 731000000 0.04400 263000000 263000000 477000000 29000000 11199000000 7675000000 1250000000 0.03300 447000000 850000000 850000000 0.0095 1 0.0010 1 5000000000 P364D 2000000000 P2Y 2000000000 P3Y 1000000000 3000000000 P364D P2Y P3Y P364D P2Y P3Y 3000000000 1250000000 P364D 2250000000 P18M 350000000 P364D P364D P364D P18M P18M P18M 800000000 3500000000 500000000 0 0.60 712000000 1600000000 0.0025 0.0063 300000000 401000000 0.0043 153000000 234000000 Financial instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative instruments to hedge its exposure to market risks, including interest rate and currency risks, arising from operating and financing risks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has non-U.S. dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts and fair value of derivative instruments outstanding were as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net investment hedges</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cross currency interest rate swaps and foreign currency forward contracts to hedge net investments in subsidiaries with non-U.S. dollar functional currencies. For qualifying net investment hedges, changes in the fair value of the derivatives are recorded in the currency translation adjustment within accumulated other comprehensive income (loss). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate swaps to hedge the variability in forecasted cash flows of certain floating-rate debt. For qualifying cash flow hedges, changes in the fair value of the derivatives are recorded in accumulated other comprehensive income (loss) and released to the Consolidated Statements of Earnings when the hedged cash flows affect earnings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives not designated as hedges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of foreign currency risks. The Company also utilizes total return swaps to economically hedge variability in compensation charges related to certain deferred compensation obligations. The income (expenses) due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Statements of Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives credit risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives offsetting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts and fair value of derivative instruments outstanding were as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td></tr></table> 5000000 0 153000000 4000000 17000000 0 633000000 8000000 610000000 17000000 85000000 1000000 157000000 5000000 3900000000 64000000 2968000000 2000000 271000000 11000000 155000000 1000000 6000000 0 23000000 1000000 801000000 23000000 575000000 7000000 31000000 1000000 109000000 9000000 3636000000 38000000 224000000 2000000 808000000 3000000 37000000 0 The income (expenses) due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Statements of Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 55000000 -29000000 -2000000 13000000 -1000000 -9000000 Fair value measurements <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities in accordance with Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:</span></div><div><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Observable inputs other than quoted prices in active markets.</span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Money market funds are valued at the closing price reported by the fund sponsor.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Fair values of quoted investments are based on current bid prices as of November 30, 2021 and August 31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Level 3 debt securities are valued using standard valuation techniques based on income and market approach.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Level 3 debt securities include investments in convertible debt securities of VillageMD which are valued on a quarterly basis using the Probability Weighted Expect Return Method with gains or losses recorded in Other Comprehensive Income. Inputs include the enterprise value, expected holding term of the investment, volatility and risk-free interest rates.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 9 Financial instruments, for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The fair value of interest rate swaps and cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 9 Financial instruments, for additional information.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels for the three months ended November 30, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the Consolidated Financial Statements. As of November 30, 2021 the carrying amounts and estimated fair values of long-term notes outstanding including the current portion were $8.5 billion and $9.2 billion, respectively. The fair values of the notes outstanding are Level 1 fair value measures and determined based on quoted market prices and translated at the November 30, 2021 rate, as applicable. The fair values and carrying values of these issuances do not include notes that have been redeemed or repaid as of November 30, 2021. See Note 8 Debt, for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.</span></div> <div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total return swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forwards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross currency interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Money market funds are valued at the closing price reported by the fund sponsor.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Fair values of quoted investments are based on current bid prices as of November 30, 2021 and August 31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Level 3 debt securities are valued using standard valuation techniques based on income and market approach.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Level 3 debt securities include investments in convertible debt securities of VillageMD which are valued on a quarterly basis using the Probability Weighted Expect Return Method with gains or losses recorded in Other Comprehensive Income. Inputs include the enterprise value, expected holding term of the investment, volatility and risk-free interest rates.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 9 Financial instruments, for additional information.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">The fair value of interest rate swaps and cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 9 Financial instruments, for additional information.</span></div> 319000000 319000000 0 0 1000000 1000000 0 0 20000000 0 0 20000000 81000000 0 81000000 0 4000000 0 4000000 0 4000000 0 4000000 0 12000000 0 12000000 0 11000000 0 11000000 0 634000000 634000000 0 0 2000000 2000000 0 0 663000000 0 0 663000000 46000000 0 46000000 0 1000000 0 1000000 0 2000000 0 2000000 0 5000000 0 5000000 0 32000000 0 32000000 0 8500000000 9200000000 Commitments and contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in legal proceedings, including litigation, arbitration and other claims, and investigations, inspections, subpoenas, audits, claims, inquiries and similar actions by pharmacy, healthcare, tax and other governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the retail pharmacy and pharmaceutical wholesale industries, the Company is subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which it operates. There continues to be a heightened level of review and/or audit by regulatory authorities of, and increased litigation regarding, the Company’s and the rest of the health care and related industry’s business, compliance and reporting practices. As a result, the Company regularly is the subject of government actions of the types described above. The Company also may be named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. With respect to litigation and other legal proceedings where the Company has determined that a material loss is reasonably possible, except as otherwise noted, the Company is unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co. and Walgreen Co., as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cutler v. Wasson et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:14-cv-10408 (N.D. Ill.)) The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On May 18, 2015, the case was stayed in light of a securities class action that was filed on April 10, 2015, described below. On November 3, 2016, the Court entered a stipulation and order extending the stay until the resolution of the securities class action.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Washtenaw County Employees’ Retirement System v. Walgreen Co. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:15-cv-3187 (N.D. Ill.)) The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. A motion to dismiss a consolidated class action complaint filed on August 17, 2015 was granted in part and denied in part on September 30, 2016. The court granted plaintiff’s motion for class certification on March 29, 2018 and plaintiff filed a first amended complaint on December 19, 2018. A motion to dismiss the first amended complaint was granted in part and denied in part on September 23, 2019. Fact discovery and expert discovery have concluded. On November 2, 2021, the Court denied plaintiffs’ motion for summary judgment and granted in part and denied in part defendants’ cross motion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2017, purported Rite Aid shareholders filed an amended complaint in a putative class action lawsuit in the U.S. District Court for the Middle District of Pennsylvania (the “M.D. Pa. action”) arising out of transactions contemplated by the merger agreement between the Company and Rite Aid. The amended complaint alleged that the Company and certain of its officers made false or misleading statements regarding the transactions. The Court denied the Company’s motion to dismiss the amended complaint on April 15, 2019. The Company filed an answer and affirmative defenses, and the Court granted plaintiffs' motion for class certification. Fact discovery has concluded and expert discovery is ongoing. In October and December 2020, two separate purported Rite Aid Shareholders filed lawsuits in the same court as the M.D. Pa. action opting out of the class in the M.D. Pa. action making nearly identical allegations as those in the M.D. Pa. action (the “Direct Actions”). On December 24, 2020, the parties to the Direct Actions filed a joint stipulation to stay the Direct Actions until the earlier of (a) 30 days after the entry of an order resolving any pre-trial dispositive motions in the M.D. Pa. action, or (b) 30 days after the entry of an order of final approval of any settlement of the M.D. Pa. action. The court so ordered the joint stipulation on December 28, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against an array of defendants by various plaintiffs such as counties, cities, hospitals, Indian tribes, and others, alleging claims generally concerning the impacts of widespread opioid abuse. The consolidated multidistrict litigation, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re National Prescription Opiate Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MDL No. 2804, Case No. 17-md-2804), is pending in the U.S. District Court for the Northern District of Ohio ("N.D. Ohio"). The Company is involved in the following multidistrict litigation (MDL) bellwether cases: (1) two consolidated cases in N.D. Ohio (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cnty. of Summit, Ohio, et al v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-45090; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cnty. of Cuyahoga, Ohio, et al. v. Purdue Pharma L.P.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-45004), previously scheduled for trial in November 2020 but postponed indefinitely; (2) one remanded to the U. S. District Court for the Eastern District of Oklahoma (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Cherokee Nation v. McKesson Corp., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-CV-00056-RAW-SPS), scheduled for trial in September 2022; and (3) one remanded to the U.S. District Court for the Northern District of California (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City and Cnty. of San Francisco, et al. v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:18-cv-07591-CRB), originally scheduled for trial in October 2021, but rescheduled for April 2022. The Company was also involved in two additional consolidated cases in N.D. Ohio (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cnty. of Lake, Ohio v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-45032; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cnty. of Trumbull, Ohio v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-45079), initially scheduled for trial in May 2021 but continued until October 2021. The jury in that case returned a verdict in favor of the plaintiffs as to liability, and the court will schedule a second trial regarding remedies to take place at some point in 2022. The court has yet to determine how much each defendant will pay in damages. The Company is unable to predict the outcome relative to remedies or apportionment and believes it has very strong grounds for appeal. In April 2021, the MDL court selected five additional bellwether cases involving the Company, all currently pending in N.D. Ohio: (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cobb Cnty. v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-45817; (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Durham Cnty. v. AmerisourceBergen Drug Corp., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 19-op-45346; (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Montgomery Cnty. Bd. of Cnty. Commrs., et al. v. Cardinal Health, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-46326; (4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board of Cnty. Commrs. of the Cnty. of Santa Fe v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-45776; and (5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cnty. of Tarrant v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 18-op-45274.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has been named as a defendant in numerous lawsuits brought in state courts relating to opioid matters. Trial dates have been set in cases pending in state courts in New Mexico (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of New Mexico, ex rel. Hector Balderas, Attorney General v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. D-101-cv-2017-02541, First Judicial District Court, Santa Fe County, New Mexico - September 2022); West Virginia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of West Virginia, ex rel. Patrick Morrisey, Attorney General v. Walgreens Boots Alliance, Inc., et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil Action No.20-C-82 PNM, Circuit Court of Kanawha County, West Virginia, - September 2022; Missouri (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jefferson County, Missouri v. Dannie E. Williams, M.D., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cause No. 20JE-CC00029, Twenty-Third Judicial Circuit, Jefferson County, Missouri - April 2023); Florida (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Florida, Office of the Attorney General, Department of Legal Affairs v. Purdue Pharma L.P., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 2018-CA-001438, Sixth Judicial Circuit in and for Pasco County, Florida - April 2022); Nevada (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Nevada v. McKesson Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. A-19-796755-B, Eighth Judicial District Court, Clark County, Nevada - April 2023); Michigan (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Michigan, ex rel. Dana Nessel, Attorney General v. Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No. 19-016896-NZ, Circuit Court for Wayne County, Michigan - October 2022); </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Alabama (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The DCH Health Care Authority, et al. v. Purdue Pharma LP, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cause No. CV-2019-000007.00, Circuit Court of Conecuh County, Alabama - July 2022).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relief sought by various plaintiffs in these matters includes compensatory, abatement and punitive damages, as well as injunctive relief. Additionally, the Company has received from the Department of Justice and the Attorney Generals of numerous states subpoenas, civil investigative demands, and/or other requests concerning opioid matters. The Company has also had communications with the Department of Justice with respect to purported violations of the federal Controlled Substances Act and the federal False Claims Act in dispensing prescriptions at certain Walgreens locations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs and penalties incurred in these matters can be substantial.</span></div> Income taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended November 30, 2021 was an expense of 7.2%, primarily due to lower tax expense on gains from consolidation of the Company’s investment in VillageMD and Shields, as a portion of these gains is not subject to tax. See Note 3 Acquisitions for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended November 30, 2020 was a benefit of 34.0%, on a pretax loss for the three months ended November 30, 2020, primarily due to the discrete tax effect of equity losses in AmerisourceBergen. See Note 6 Equity method investments for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid for the three months ended November 30, 2021 were $34 million, compared to $16 million for the three months ended November 30, 2020.</span></div> 0.072 -0.340 34000000 16000000 Retirement benefits<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined benefit pension plans (non-U.S. plans)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various defined benefit pension plans outside the U.S. The principal defined benefit pension plan is the Boots Pension Plan (the “Boots Plan”), which covers certain employees in the UK. The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic pension costs (income) for the defined benefit pension plans (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Statements of Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected returns on plan assets/other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net periodic pension costs (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash contributions to its defined benefit pension plans of $1 million for the three months ended November 30, 2021, which primarily related to committed payments. The Company plans to contribute an additional $40 million to its defined benefit pension plans in fiscal 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined contribution plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution is in the form of a guaranteed match which is made pursuant to the applicable plan document approved by the Walgreen Co. Board of Directors. Plan activity is reviewed </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periodically by certain Committees of the Walgreens Boots Alliance Board of Directors. The profit-sharing provision was an expense of $69 million and $57 million for the three months ended November 30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has certain contract based defined contribution arrangements. The principal arrangement is based in UK to which both the Company and participating employees contribute. The Company recognized an expense of $25 million and $26 million for the three months ended November 30, 2021 and 2020, respectively.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic pension costs (income) for the defined benefit pension plans (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location in Consolidated Condensed Statements of Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected returns on plan assets/other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net periodic pension costs (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1000000 1000000 39000000 33000000 74000000 80000000 -33000000 -45000000 1000000 40000000 69000000 57000000 25000000 26000000 Accumulated other comprehensive income (loss)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of net changes in accumulated other comprehensive income (“AOCI”) by component and net of tax for the three months ended November 30, 2021 and 2020 (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension/ post-retirement obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on available for sale securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share of OCI of equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at August 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (provision)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at November 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(364)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,863)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,301)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension/ post-retirement obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on available for sale securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share of AOCI of equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at August 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,771)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (provision)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at November 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(736)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,873)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,682)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of net changes in accumulated other comprehensive income (“AOCI”) by component and net of tax for the three months ended November 30, 2021 and 2020 (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension/ post-retirement obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on available for sale securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share of OCI of equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at August 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (provision)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at November 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(364)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,863)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,301)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension/ post-retirement obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net investment hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized gain (loss) on available for sale securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share of AOCI of equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative translation adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at August 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,771)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (provision)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at November 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(736)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,873)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,682)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -359000000 -10000000 -35000000 96000000 -29000000 -1772000000 -2109000000 -1000000 1000000 53000000 450000000 -60000000 -88000000 356000000 5000000 -1000000 0 577000000 0 4000000 585000000 1000000 0 -9000000 31000000 14000000 0 37000000 -5000000 1000000 44000000 -96000000 -46000000 -91000000 -193000000 -364000000 -9000000 9000000 0 -74000000 -1863000000 -2301000000 -748000000 -31000000 -34000000 0 -10000000 -2948000000 -3771000000 17000000 4000000 -14000000 0 7000000 72000000 85000000 2000000 -1000000 0 0 0 -3000000 -2000000 -4000000 -1000000 8000000 0 -1000000 0 1000000 11000000 4000000 -7000000 0 5000000 75000000 88000000 -736000000 -27000000 -41000000 0 -5000000 -2873000000 -3682000000 Segment reporting<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the launch of its new consumer-centric healthcare strategy, in fiscal 2022, the Company announced the creation of a new operating segment, Walgreens Health. As a result, beginning in fiscal year 2022, the Company is now aligned into three reportable segments: United States, International and Walgreens Health. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s United States segment includes the Walgreens business which includes the operations of retail drugstores, health and wellness services, and specialty and home delivery pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, the Benavides brand in Mexico and the Ahumada brand in Chile. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Health </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Walgreens Health segment currently consists of Walgreens Health, an organically developed consumer-centric omni-channel business that contracts with payors and providers to deliver clinical healthcare services to their members through both digital and physical channels; a majority equity ownership position in VillageMD, a leading, national provider of value-based primary care services; a majority equity ownership position in Shields, a specialty pharmacy integrator and accelerator for hospitals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative costs for Walgreens Health for the three months ended November 30, 2020 have been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for reportable segments include procurement benefits. Corporate-related overhead costs are not allocated to reportable segments and are reported in the “Corporate and Other”.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects results of operations of the Company’s reportable segments (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreens Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Operating income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreens Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes certain eliminations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles adjusted operating income to operating income (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformational cost management</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to equity earnings (loss) in AmerisourceBergen</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(535)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects results of operations of the Company’s reportable segments (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreens Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Operating income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreens Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,196</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes certain eliminations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles adjusted operating income to operating income (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformational cost management</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to equity earnings (loss) in AmerisourceBergen</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(535)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 28032000000 27163000000 5818000000 4285000000 51000000 0 0 -10000000 33901000000 31438000000 1690000000 1155000000 164000000 87000000 -13000000 -3000000 -63000000 -42000000 1777000000 1196000000 1777000000 1196000000 203000000 100000000 165000000 95000000 71000000 21000000 -43000000 -1481000000 14000000 33000000 1283000000 -535000000 Sales<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s sales by segment and by major source (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.815%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retail</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,032 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retail</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wholesale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,818 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreens Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes certain eliminations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 Supplemental information for further information on receivables from contracts with customers.</span></div> <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s sales by segment and by major source (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.815%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retail</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,032 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retail</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wholesale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,818 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,285 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreens Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.75pt">Includes certain eliminations.</span></div> 21105000000 20869000000 6927000000 6294000000 28032000000 27163000000 1017000000 895000000 1796000000 1522000000 3005000000 1868000000 5818000000 4285000000 51000000 0 0 -10000000 33901000000 31438000000 Related parties<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term pharmaceutical distribution agreement with AmerisourceBergen pursuant to which the Company sources branded and generic pharmaceutical products from AmerisourceBergen principally for its U.S. operations. Additionally, AmerisourceBergen receives sourcing services for generic pharmaceutical products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party transactions with AmerisourceBergen (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 Discontinued operations for further information.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party transactions with AmerisourceBergen (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15791000000 15441000000 6909000000 6589000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of new accounting pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - nonrefundable fees and others</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other. This ASU clarifies the accounting for the amortization period for certain purchased callable debt securities held at a premium by giving consideration to securities which have multiple call dates. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments — equity securities; Investments — equity method and joint ventures; Derivatives and hedging</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes - simplifying the accounting for income taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12: Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted the new standard effective September 1, 2021, and the adoption did not have any impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effects of reference rate reform on financial reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates (“IBORs”) and, particularly, the risk of cessation of the London Interbank Offered Rate (“LIBOR”), regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable, or transaction based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, which adds implementation guidance to the above the ASU to clarify certain optional expedients in Topic 848. The Company adopted the new standard effective September 1, 2021, and the adoption did not have a material impact on the Company’s results of operations, cash flows or financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New accounting pronouncements not yet adopted</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired contract assets and contract liabilities in a business combination </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosures by business entities about government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021 (fiscal 2023). The Company is evaluating the effect of adopting this new accounting guidance.</span></div> Supplemental information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, including amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies). Trade receivables were $4.6 billion and $4.5 billion at November 30, 2021 and August 31, 2021, respectively. Other accounts receivable balances, which consist primarily of receivables from vendors and manufacturers, including receivables from AmerisourceBergen (see Note 17 Related parties), were $1.3 billion and $1.1 billion at November 30, 2021 and August 31, 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:63.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset and other amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization on property, plant and equipment was $13.3 billion at November 30, 2021 and $13.1 billion at August 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:63.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents - continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash - continuing operations (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interest</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest balance as of November 30, 2021 was $2,787 million increasing primarily due to acquisitions during the three months ended November 30, 2021. See Note 3 Acquisitions for further information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:81.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest roll forward:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes $1.9 billion of redeemable non-controlling interest representing the maximum purchase price to redeem non-controlling units in VillageMD for cash. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 16.1 million weighted outstanding options to purchase common shares that were anti-dilutive and excluded from the first quarter earnings per share calculation as of November 30, 2021 compared to 18.5 million as of November 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the anti-dilutive effect resulting from the reported net loss for the three months ended November 30, 2020, the incremental impact of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash dividends declared per common share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends per common share declared were as follows:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4600000000 4500000000 1300000000 1100000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:63.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended November 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset and other amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 335000000 342000000 165000000 95000000 500000000 437000000 13300000000 13100000000 The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:63.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents - continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash - continuing operations (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:63.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents - continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash - continuing operations (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4135000000 1193000000 133000000 77000000 4268000000 1270000000 2787000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:81.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest roll forward:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Walgreens Boots Alliance, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">November 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes $1.9 billion of redeemable non-controlling interest representing the maximum purchase price to redeem non-controlling units in VillageMD for cash. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.</span></div> 319000000 2489000000 -21000000 7000000 -8000000 2787000000 1900000000 1900000000 1900000000 16100000 18500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends per common share declared were as follows:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4675 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.4775 0.4675 EXCEL 96 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 98 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 99 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 373 464 1 false 116 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://walgreensbootsalliance.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS Sheet http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS CONSOLIDATED CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EQUITY Sheet http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY CONSOLIDATED CONDENSED STATEMENTS OF EQUITY Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS Sheet http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS Sheet http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - Accounting policies Sheet http://walgreensbootsalliance.com/role/Accountingpolicies Accounting policies Notes 8 false false R9.htm 2104102 - Disclosure - Discontinued operations Sheet http://walgreensbootsalliance.com/role/Discontinuedoperations Discontinued operations Notes 9 false false R10.htm 2108103 - Disclosure - Acquisitions Sheet http://walgreensbootsalliance.com/role/Acquisitions Acquisitions Notes 10 false false R11.htm 2112104 - Disclosure - Exit and disposal activities Sheet http://walgreensbootsalliance.com/role/Exitanddisposalactivities Exit and disposal activities Notes 11 false false R12.htm 2117105 - Disclosure - Leases Sheet http://walgreensbootsalliance.com/role/Leases Leases Notes 12 false false R13.htm 2125106 - Disclosure - Equity method investments Sheet http://walgreensbootsalliance.com/role/Equitymethodinvestments Equity method investments Notes 13 false false R14.htm 2130107 - Disclosure - Goodwill and other intangible assets Sheet http://walgreensbootsalliance.com/role/Goodwillandotherintangibleassets Goodwill and other intangible assets Notes 14 false false R15.htm 2136108 - Disclosure - Debt Sheet http://walgreensbootsalliance.com/role/Debt Debt Notes 15 false false R16.htm 2140109 - Disclosure - Financial instruments Sheet http://walgreensbootsalliance.com/role/Financialinstruments Financial instruments Notes 16 false false R17.htm 2143110 - Disclosure - Fair value measurements Sheet http://walgreensbootsalliance.com/role/Fairvaluemeasurements Fair value measurements Notes 17 false false R18.htm 2146111 - Disclosure - Commitments and contingencies Sheet http://walgreensbootsalliance.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 18 false false R19.htm 2147112 - Disclosure - Income taxes Sheet http://walgreensbootsalliance.com/role/Incometaxes Income taxes Notes 19 false false R20.htm 2149113 - Disclosure - Retirement benefits Sheet http://walgreensbootsalliance.com/role/Retirementbenefits Retirement benefits Notes 20 false false R21.htm 2152114 - Disclosure - Accumulated other comprehensive income (loss) Sheet http://walgreensbootsalliance.com/role/Accumulatedothercomprehensiveincomeloss Accumulated other comprehensive income (loss) Notes 21 false false R22.htm 2155115 - Disclosure - Segment reporting Sheet http://walgreensbootsalliance.com/role/Segmentreporting Segment reporting Notes 22 false false R23.htm 2158116 - Disclosure - Sales Sheet http://walgreensbootsalliance.com/role/Sales Sales Notes 23 false false R24.htm 2161117 - Disclosure - Related parties Sheet http://walgreensbootsalliance.com/role/Relatedparties Related parties Notes 24 false false R25.htm 2164118 - Disclosure - New accounting pronouncements Sheet http://walgreensbootsalliance.com/role/Newaccountingpronouncements New accounting pronouncements Notes 25 false false R26.htm 2165119 - Disclosure - Supplemental information Sheet http://walgreensbootsalliance.com/role/Supplementalinformation Supplemental information Notes 26 false false R27.htm 2202201 - Disclosure - Accounting policies (Policies) Sheet http://walgreensbootsalliance.com/role/AccountingpoliciesPolicies Accounting policies (Policies) Policies http://walgreensbootsalliance.com/role/Accountingpolicies 27 false false R28.htm 2305301 - Disclosure - Discontinued operations (Tables) Sheet http://walgreensbootsalliance.com/role/DiscontinuedoperationsTables Discontinued operations (Tables) Tables http://walgreensbootsalliance.com/role/Discontinuedoperations 28 false false R29.htm 2309302 - Disclosure - Acquisitions (Tables) Sheet http://walgreensbootsalliance.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://walgreensbootsalliance.com/role/Acquisitions 29 false false R30.htm 2313303 - Disclosure - Exit and disposal activities (Tables) Sheet http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesTables Exit and disposal activities (Tables) Tables http://walgreensbootsalliance.com/role/Exitanddisposalactivities 30 false false R31.htm 2318304 - Disclosure - Leases (Tables) Sheet http://walgreensbootsalliance.com/role/LeasesTables Leases (Tables) Tables http://walgreensbootsalliance.com/role/Leases 31 false false R32.htm 2326305 - Disclosure - Equity method investments (Tables) Sheet http://walgreensbootsalliance.com/role/EquitymethodinvestmentsTables Equity method investments (Tables) Tables http://walgreensbootsalliance.com/role/Equitymethodinvestments 32 false false R33.htm 2331306 - Disclosure - Goodwill and other intangible assets (Tables) Sheet http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsTables Goodwill and other intangible assets (Tables) Tables http://walgreensbootsalliance.com/role/Goodwillandotherintangibleassets 33 false false R34.htm 2337307 - Disclosure - Debt (Tables) Sheet http://walgreensbootsalliance.com/role/DebtTables Debt (Tables) Tables http://walgreensbootsalliance.com/role/Debt 34 false false R35.htm 2341308 - Disclosure - Financial instruments (Tables) Sheet http://walgreensbootsalliance.com/role/FinancialinstrumentsTables Financial instruments (Tables) Tables http://walgreensbootsalliance.com/role/Financialinstruments 35 false false R36.htm 2344309 - Disclosure - Fair value measurements (Tables) Sheet http://walgreensbootsalliance.com/role/FairvaluemeasurementsTables Fair value measurements (Tables) Tables http://walgreensbootsalliance.com/role/Fairvaluemeasurements 36 false false R37.htm 2350310 - Disclosure - Retirement benefits (Tables) Sheet http://walgreensbootsalliance.com/role/RetirementbenefitsTables Retirement benefits (Tables) Tables http://walgreensbootsalliance.com/role/Retirementbenefits 37 false false R38.htm 2353311 - Disclosure - Accumulated other comprehensive income (loss) (Tables) Sheet http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossTables Accumulated other comprehensive income (loss) (Tables) Tables http://walgreensbootsalliance.com/role/Accumulatedothercomprehensiveincomeloss 38 false false R39.htm 2356312 - Disclosure - Segment reporting (Tables) Sheet http://walgreensbootsalliance.com/role/SegmentreportingTables Segment reporting (Tables) Tables http://walgreensbootsalliance.com/role/Segmentreporting 39 false false R40.htm 2359313 - Disclosure - Sales (Tables) Sheet http://walgreensbootsalliance.com/role/SalesTables Sales (Tables) Tables http://walgreensbootsalliance.com/role/Sales 40 false false R41.htm 2362314 - Disclosure - Related parties (Tables) Sheet http://walgreensbootsalliance.com/role/RelatedpartiesTables Related parties (Tables) Tables http://walgreensbootsalliance.com/role/Relatedparties 41 false false R42.htm 2366315 - Disclosure - Supplemental information (Tables) Sheet http://walgreensbootsalliance.com/role/SupplementalinformationTables Supplemental information (Tables) Tables http://walgreensbootsalliance.com/role/Supplementalinformation 42 false false R43.htm 2403401 - Disclosure - Accounting policies (Details) Sheet http://walgreensbootsalliance.com/role/AccountingpoliciesDetails Accounting policies (Details) Details http://walgreensbootsalliance.com/role/AccountingpoliciesPolicies 43 false false R44.htm 2406402 - Disclosure - Discontinued operations - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails Discontinued operations - Narrative (Details) Details 44 false false R45.htm 2407403 - Disclosure - Discontinued operations - Schedules of Discontinued Operations (Details) Sheet http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails Discontinued operations - Schedules of Discontinued Operations (Details) Details 45 false false R46.htm 2410404 - Disclosure - Acquisitions - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 46 false false R47.htm 2411405 - Disclosure - Acquisitions - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed (Details) Sheet http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed (Details) Details 47 false false R48.htm 2414406 - Disclosure - Exit and disposal activities - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails Exit and disposal activities - Narrative (Details) Details 48 false false R49.htm 2415407 - Disclosure - Exit and disposal activities - Restructuring Costs (Details) Sheet http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails Exit and disposal activities - Restructuring Costs (Details) Details 49 false false R50.htm 2416408 - Disclosure - Exit and disposal activities - Restructuring Reserve Activity (Details) Sheet http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails Exit and disposal activities - Restructuring Reserve Activity (Details) Details 50 false false R51.htm 2419409 - Disclosure - Leases - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 51 false false R52.htm 2420410 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 52 false false R53.htm 2421411 - Disclosure - Leases - Supplemental Income Statement Information (Details) Sheet http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails Leases - Supplemental Income Statement Information (Details) Details 53 false false R54.htm 2422412 - Disclosure - Leases - Other Supplemental Information (Details) Sheet http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails Leases - Other Supplemental Information (Details) Details 54 false false R55.htm 2423413 - Disclosure - Leases - Average Lease Terms And Discounts (Details) Sheet http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails Leases - Average Lease Terms And Discounts (Details) Details 55 false false R56.htm 2424414 - Disclosure - Leases - Future Lease Payments for Operating and Finance Leases (Details) Sheet http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails Leases - Future Lease Payments for Operating and Finance Leases (Details) Details 56 false false R57.htm 2427415 - Disclosure - Equity method investments - Schedule of Equity Method Investments (Details) Sheet http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails Equity method investments - Schedule of Equity Method Investments (Details) Details 57 false false R58.htm 2428416 - Disclosure - Equity method investments - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails Equity method investments - Narrative (Details) Details 58 false false R59.htm 2429417 - Disclosure - Equity method investments - Summarized Financial Information of Equity Method Investments (Details) Sheet http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails Equity method investments - Summarized Financial Information of Equity Method Investments (Details) Details 59 false false R60.htm 2432418 - Disclosure - Goodwill and other intangible assets - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails Goodwill and other intangible assets - Narrative (Details) Details 60 false false R61.htm 2433419 - Disclosure - Goodwill and other intangible assets - Schedule of Goodwill (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails Goodwill and other intangible assets - Schedule of Goodwill (Details) Details 61 false false R62.htm 2434420 - Disclosure - Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details) Details 62 false false R63.htm 2435421 - Disclosure - Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Sheet http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Details 63 false false R64.htm 2438422 - Disclosure - Debt - Short and Long-Term Debt (Details) Sheet http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails Debt - Short and Long-Term Debt (Details) Details 64 false false R65.htm 2439423 - Disclosure - Debt - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 65 false false R66.htm 2442424 - Disclosure - Financial instruments (Details) Sheet http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails Financial instruments (Details) Details http://walgreensbootsalliance.com/role/FinancialinstrumentsTables 66 false false R67.htm 2445425 - Disclosure - Fair value measurements (Details) Sheet http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails Fair value measurements (Details) Details http://walgreensbootsalliance.com/role/FairvaluemeasurementsTables 67 false false R68.htm 2448426 - Disclosure - Income taxes (Details) Sheet http://walgreensbootsalliance.com/role/IncometaxesDetails Income taxes (Details) Details http://walgreensbootsalliance.com/role/Incometaxes 68 false false R69.htm 2451427 - Disclosure - Retirement benefits (Details) Sheet http://walgreensbootsalliance.com/role/RetirementbenefitsDetails Retirement benefits (Details) Details http://walgreensbootsalliance.com/role/RetirementbenefitsTables 69 false false R70.htm 2454428 - Disclosure - Accumulated other comprehensive income (loss) (Details) Sheet http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails Accumulated other comprehensive income (loss) (Details) Details http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossTables 70 false false R71.htm 2457429 - Disclosure - Segment reporting (Details) Sheet http://walgreensbootsalliance.com/role/SegmentreportingDetails Segment reporting (Details) Details http://walgreensbootsalliance.com/role/SegmentreportingTables 71 false false R72.htm 2460430 - Disclosure - Sales (Details) Sheet http://walgreensbootsalliance.com/role/SalesDetails Sales (Details) Details http://walgreensbootsalliance.com/role/SalesTables 72 false false R73.htm 2463431 - Disclosure - Related parties (Details) Sheet http://walgreensbootsalliance.com/role/RelatedpartiesDetails Related parties (Details) Details http://walgreensbootsalliance.com/role/RelatedpartiesTables 73 false false R74.htm 2467432 - Disclosure - Supplemental information - Narrative (Details) Sheet http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails Supplemental information - Narrative (Details) Details 74 false false R75.htm 2468433 - Disclosure - Supplemental information - Depreciation and Amortization Expense (Details) Sheet http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails Supplemental information - Depreciation and Amortization Expense (Details) Details 75 false false R76.htm 2469434 - Disclosure - Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details) Details 76 false false R77.htm 2470435 - Disclosure - Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details) Sheet http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details) Details 77 false false R78.htm 2471436 - Disclosure - Supplemental information - Summary of Dividends per Share (Details) Sheet http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofDividendsperShareDetails Supplemental information - Summary of Dividends per Share (Details) Details 78 false false All Reports Book All Reports wba-20211130.htm a11302021exhibit104.htm a11302021exhibit105.htm a11302021exhibit106.htm a11302021exhibit107.htm a11302021exhibit311.htm a11302021exhibit312.htm a11302021exhibit321.htm a11302021exhibit322.htm wba-20211130.xsd wba-20211130_cal.xml wba-20211130_def.xml wba-20211130_lab.xml wba-20211130_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/country/2021 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 101 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "wba-20211130.htm": { "axisCustom": 0, "axisStandard": 34, "contextCount": 373, "dts": { "calculationLink": { "local": [ "wba-20211130_cal.xml" ] }, "definitionLink": { "local": [ "wba-20211130_def.xml" ] }, "inline": { "local": [ "wba-20211130.htm" ] }, "labelLink": { "local": [ "wba-20211130_lab.xml" ] }, "presentationLink": { "local": [ "wba-20211130_pre.xml" ] }, "schema": { "local": [ "wba-20211130.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 663, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://xbrl.sec.gov/dei/2021": 5, "total": 11 }, "keyCustom": 37, "keyStandard": 427, "memberCustom": 56, "memberStandard": 52, "nsprefix": "wba", "nsuri": "http://walgreensbootsalliance.com/20211130", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://walgreensbootsalliance.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Acquisitions", "role": "http://walgreensbootsalliance.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Exit and disposal activities", "role": "http://walgreensbootsalliance.com/role/Exitanddisposalactivities", "shortName": "Exit and disposal activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Leases", "role": "http://walgreensbootsalliance.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125106 - Disclosure - Equity method investments", "role": "http://walgreensbootsalliance.com/role/Equitymethodinvestments", "shortName": "Equity method investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130107 - Disclosure - Goodwill and other intangible assets", "role": "http://walgreensbootsalliance.com/role/Goodwillandotherintangibleassets", "shortName": "Goodwill and other intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136108 - Disclosure - Debt", "role": "http://walgreensbootsalliance.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140109 - Disclosure - Financial instruments", "role": "http://walgreensbootsalliance.com/role/Financialinstruments", "shortName": "Financial instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143110 - Disclosure - Fair value measurements", "role": "http://walgreensbootsalliance.com/role/Fairvaluemeasurements", "shortName": "Fair value measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146111 - Disclosure - Commitments and contingencies", "role": "http://walgreensbootsalliance.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147112 - Disclosure - Income taxes", "role": "http://walgreensbootsalliance.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS", "role": "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "shortName": "CONSOLIDATED CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149113 - Disclosure - Retirement benefits", "role": "http://walgreensbootsalliance.com/role/Retirementbenefits", "shortName": "Retirement benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152114 - Disclosure - Accumulated other comprehensive income (loss)", "role": "http://walgreensbootsalliance.com/role/Accumulatedothercomprehensiveincomeloss", "shortName": "Accumulated other comprehensive income (loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155115 - Disclosure - Segment reporting", "role": "http://walgreensbootsalliance.com/role/Segmentreporting", "shortName": "Segment reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158116 - Disclosure - Sales", "role": "http://walgreensbootsalliance.com/role/Sales", "shortName": "Sales", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161117 - Disclosure - Related parties", "role": "http://walgreensbootsalliance.com/role/Relatedparties", "shortName": "Related parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2164118 - Disclosure - New accounting pronouncements", "role": "http://walgreensbootsalliance.com/role/Newaccountingpronouncements", "shortName": "New accounting pronouncements", "subGroupType": "", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2165119 - Disclosure - Supplemental information", "role": "http://walgreensbootsalliance.com/role/Supplementalinformation", "shortName": "Supplemental information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Accounting policies (Policies)", "role": "http://walgreensbootsalliance.com/role/AccountingpoliciesPolicies", "shortName": "Accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Discontinued operations (Tables)", "role": "http://walgreensbootsalliance.com/role/DiscontinuedoperationsTables", "shortName": "Discontinued operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Acquisitions (Tables)", "role": "http://walgreensbootsalliance.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical)", "role": "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Exit and disposal activities (Tables)", "role": "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesTables", "shortName": "Exit and disposal activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "wba:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Leases (Tables)", "role": "http://walgreensbootsalliance.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "wba:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326305 - Disclosure - Equity method investments (Tables)", "role": "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsTables", "shortName": "Equity method investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - Goodwill and other intangible assets (Tables)", "role": "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsTables", "shortName": "Goodwill and other intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337307 - Disclosure - Debt (Tables)", "role": "http://walgreensbootsalliance.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341308 - Disclosure - Financial instruments (Tables)", "role": "http://walgreensbootsalliance.com/role/FinancialinstrumentsTables", "shortName": "Financial instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344309 - Disclosure - Fair value measurements (Tables)", "role": "http://walgreensbootsalliance.com/role/FairvaluemeasurementsTables", "shortName": "Fair value measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350310 - Disclosure - Retirement benefits (Tables)", "role": "http://walgreensbootsalliance.com/role/RetirementbenefitsTables", "shortName": "Retirement benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353311 - Disclosure - Accumulated other comprehensive income (loss) (Tables)", "role": "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossTables", "shortName": "Accumulated other comprehensive income (loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2356312 - Disclosure - Segment reporting (Tables)", "role": "http://walgreensbootsalliance.com/role/SegmentreportingTables", "shortName": "Segment reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i7722a7d64cec4c548b7275257b93ce0d_I20200831", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EQUITY", "role": "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "shortName": "CONSOLIDATED CONDENSED STATEMENTS OF EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i7722a7d64cec4c548b7275257b93ce0d_I20200831", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2359313 - Disclosure - Sales (Tables)", "role": "http://walgreensbootsalliance.com/role/SalesTables", "shortName": "Sales (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2362314 - Disclosure - Related parties (Tables)", "role": "http://walgreensbootsalliance.com/role/RelatedpartiesTables", "shortName": "Related parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "wba:ScheduleofDepreciationandAmortizationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2366315 - Disclosure - Supplemental information (Tables)", "role": "http://walgreensbootsalliance.com/role/SupplementalinformationTables", "shortName": "Supplemental information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "wba:ScheduleofDepreciationandAmortizationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Accounting policies (Details)", "role": "http://walgreensbootsalliance.com/role/AccountingpoliciesDetails", "shortName": "Accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ic40d66b8d9e941668067b97b8d049be6_I20210601", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Discontinued operations - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "shortName": "Discontinued operations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ic40d66b8d9e941668067b97b8d049be6_I20210601", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Discontinued operations - Schedules of Discontinued Operations (Details)", "role": "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails", "shortName": "Discontinued operations - Schedules of Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i6981551f66cb440c828d191843b748fa_D20200901-20201130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i7fd70ce0c84349adb03f0762bbdc44a7_I20211124", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Acquisitions - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i7fd70ce0c84349adb03f0762bbdc44a7_I20211124", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Acquisitions - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed (Details)", "role": "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i20f4c994e40c46f1a58ef0b71e3c2574_D20211124-20211124", "decimals": "-6", "lang": "en-US", "name": "wba:BusinessCombinationConsiderationTransferredForPreferredUnits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Exit and disposal activities - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "shortName": "Exit and disposal activities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i6a7d65cad7ec4e299f1498f6a4203f4b_I20211130", "decimals": "-8", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i35a36b7467a4444b91584adf27b28eea_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Exit and disposal activities - Restructuring Costs (Details)", "role": "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "shortName": "Exit and disposal activities - Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i35a36b7467a4444b91584adf27b28eea_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS", "role": "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS", "shortName": "CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i8cfe0510b74240578dfbdd44884567cc_I20210831", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Exit and disposal activities - Restructuring Reserve Activity (Details)", "role": "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails", "shortName": "Exit and disposal activities - Restructuring Reserve Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i8cfe0510b74240578dfbdd44884567cc_I20210831", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Leases - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wba:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "role": "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wba:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Leases - Supplemental Income Statement Information (Details)", "role": "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails", "shortName": "Leases - Supplemental Income Statement Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Leases - Other Supplemental Information (Details)", "role": "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails", "shortName": "Leases - Other Supplemental Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Leases - Average Lease Terms And Discounts (Details)", "role": "http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails", "shortName": "Leases - Average Lease Terms And Discounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424414 - Disclosure - Leases - Future Lease Payments for Operating and Finance Leases (Details)", "role": "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails", "shortName": "Leases - Future Lease Payments for Operating and Finance Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - Equity method investments - Schedule of Equity Method Investments (Details)", "role": "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails", "shortName": "Equity method investments - Schedule of Equity Method Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i46ab28a7fffe49ccb3b095cc79360e34_I20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Equity method investments - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "shortName": "Equity method investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i46ab28a7fffe49ccb3b095cc79360e34_I20211130", "decimals": "INF", "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Equity method investments - Summarized Financial Information of Equity Method Investments (Details)", "role": "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails", "shortName": "Equity method investments - Summarized Financial Information of Equity Method Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "wba:IncomeFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - Goodwill and other intangible assets - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "shortName": "Goodwill and other intangible assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i1dfbd36df1f64f2db3ef702410626643_I20210831", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Goodwill and other intangible assets - Schedule of Goodwill (Details)", "role": "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "shortName": "Goodwill and other intangible assets - Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details)", "role": "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails", "shortName": "Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435421 - Disclosure - Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)", "role": "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails", "shortName": "Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438422 - Disclosure - Debt - Short and Long-Term Debt (Details)", "role": "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails", "shortName": "Debt - Short and Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i3ff68e6709884adcb0460fb593278990_I20211029", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439423 - Disclosure - Debt - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ida8ce2799fa84069a236f2ab5fa1971e_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442424 - Disclosure - Financial instruments (Details)", "role": "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails", "shortName": "Financial instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ida8ce2799fa84069a236f2ab5fa1971e_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "id837a08414054ea0ba9782561b39319d_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445425 - Disclosure - Fair value measurements (Details)", "role": "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails", "shortName": "Fair value measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "id837a08414054ea0ba9782561b39319d_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448426 - Disclosure - Income taxes (Details)", "role": "http://walgreensbootsalliance.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451427 - Disclosure - Retirement benefits (Details)", "role": "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails", "shortName": "Retirement benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS", "role": "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i1dfbd36df1f64f2db3ef702410626643_I20210831", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454428 - Disclosure - Accumulated other comprehensive income (loss) (Details)", "role": "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails", "shortName": "Accumulated other comprehensive income (loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ia5b882dd46ff47ddb72d87cc105d5db5_I20210831", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457429 - Disclosure - Segment reporting (Details)", "role": "http://walgreensbootsalliance.com/role/SegmentreportingDetails", "shortName": "Segment reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "wba:AdjustedOperatingIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460430 - Disclosure - Sales (Details)", "role": "http://walgreensbootsalliance.com/role/SalesDetails", "shortName": "Sales (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i379b46e51e984a6aa86e43750f1bc3b4_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463431 - Disclosure - Related parties (Details)", "role": "http://walgreensbootsalliance.com/role/RelatedpartiesDetails", "shortName": "Related parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467432 - Disclosure - Supplemental information - Narrative (Details)", "role": "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails", "shortName": "Supplemental information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wba:ScheduleofDepreciationandAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468433 - Disclosure - Supplemental information - Depreciation and Amortization Expense (Details)", "role": "http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails", "shortName": "Supplemental information - Depreciation and Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wba:ScheduleofDepreciationandAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "ieaa8e75c1d7347e78571b4ce4d809207_I20211130", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469434 - Disclosure - Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails", "shortName": "Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i94073e4d4c7c4bd081a24b665d77e33c_I20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i1dfbd36df1f64f2db3ef702410626643_I20210831", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470435 - Disclosure - Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details)", "role": "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails", "shortName": "Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "-6", "lang": "en-US", "name": "us-gaap:TemporaryEquityNetIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDividendsPayableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471436 - Disclosure - Supplemental information - Summary of Dividends per Share (Details)", "role": "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofDividendsperShareDetails", "shortName": "Supplemental information - Summary of Dividends per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDividendsPayableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Accounting policies", "role": "http://walgreensbootsalliance.com/role/Accountingpolicies", "shortName": "Accounting policies", "subGroupType": "", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Discontinued operations", "role": "http://walgreensbootsalliance.com/role/Discontinuedoperations", "shortName": "Discontinued operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wba-20211130.htm", "contextRef": "i85f804e0f3004fb8ad734a7763ec81a8_D20210901-20211130", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 116, "tag": { "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r174", "r314", "r319", "r327", "r528", "r529", "r534", "r535", "r626", "r719" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r174", "r314", "r319", "r327", "r528", "r529", "r534", "r535", "r626", "r719" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r174", "r212", "r225", "r226", "r227", "r228", "r230", "r232", "r236", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r324", "r326", "r327" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r174", "r212", "r225", "r226", "r227", "r228", "r230", "r232", "r236", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r324", "r326", "r327" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r0", "r179", "r184", "r190", "r257", "r477", "r478", "r479", "r491", "r492", "r561", "r562", "r563", "r564", "r730" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Adoption of new accounting standards", "verboseLabel": "Adoption of New Accounting Standards" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r0", "r179", "r184", "r190", "r257", "r477", "r478", "r479", "r491", "r492", "r561", "r562", "r563", "r564", "r730" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r0", "r179", "r184", "r190", "r257", "r477", "r478", "r479", "r491", "r492", "r561", "r562", "r563", "r564", "r730" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_GuarantorSubsidiariesMember": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "label": "Guarantor Subsidiaries [Member]", "terseLabel": "Guarantor Subsidiaries" } } }, "localname": "GuarantorSubsidiariesMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r332", "r366", "r469", "r472", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r696", "r699", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r332", "r366", "r469", "r472", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r696", "r699", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r238", "r386", "r388", "r641", "r695", "r697" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SalesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r238", "r386", "r388", "r641", "r695", "r697" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SalesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r332", "r366", "r420", "r469", "r472", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r696", "r699", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r332", "r366", "r420", "r469", "r472", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r696", "r699", "r720", "r721" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ReportableLegalEntitiesMember": { "auth_ref": [ "r174", "r314", "r319", "r327" ], "lang": { "en-us": { "role": { "label": "Reportable Legal Entities [Member]", "terseLabel": "Reportable Legal Entities" } } }, "localname": "ReportableLegalEntitiesMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]", "verboseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r239", "r240", "r386", "r389", "r698", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r239", "r240", "r386", "r389", "r698", "r707", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r67", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Trade accounts payable (see Note 17)" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r173", "r622", "r654", "r683" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Trade accounts payable, net" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RelatedpartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r56", "r671", "r708" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Receivables" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r31", "r56", "r244", "r245" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r55", "r173", "r622", "r623", "r681" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Accounts receivable from related party" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r49", "r649", "r673" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r71" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r102", "r108", "r116", "r117", "r118", "r533" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension/ post-retirement obligations" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r65", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation and amortization on property, plant, and equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r108", "r116", "r117", "r118", "r119", "r532" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Unrealized gain (loss) on cash flow hedges" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r99", "r100", "r101", "r108", "r116", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized gain (loss) on available for sale securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r59", "r105", "r107", "r108", "r677", "r704", "r705" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r116", "r117", "r583", "r584", "r585", "r586", "r587", "r589" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r104", "r108", "r116", "r117", "r118", "r176", "r177", "r178", "r533", "r700", "r701", "r731" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r97", "r108", "r116", "r117", "r118", "r533", "r584", "r585", "r586", "r587", "r589" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Cumulative translation adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r57", "r480", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r176", "r177", "r178", "r477", "r478", "r479", "r563" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r157", "r276" ], "calculation": { "http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails": { "order": 2.0, "parentTag": "wba_DepreciationAndAmortizationContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "verboseLabel": "Intangible asset and other amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r473", "r474", "r481", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfAcquisitionCosts": { "auth_ref": [ "r157", "r269" ], "calculation": { "http://walgreensbootsalliance.com/role/SegmentreportingDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of capitalized costs associated with acquisition of business. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Acquisition Costs", "negatedLabel": "Acquisition-related amortization" } } }, "localname": "AmortizationOfAcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r157", "r269", "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from EPS calculations (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r169", "r220", "r227", "r234", "r254", "r314", "r315", "r316", "r318", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r528", "r534", "r581", "r627", "r629", "r647", "r672" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r32", "r33", "r88", "r169", "r254", "r314", "r315", "r316", "r318", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r528", "r534", "r581", "r627", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "verboseLabel": "Assets [Abstract]" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r39", "r40", "r41", "r42", "r43", "r44", "r45", "r46", "r169", "r254", "r314", "r315", "r316", "r318", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r528", "r534", "r581", "r627" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r247", "r248", "r258", "r653" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Investments in debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r545", "r550" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BridgeLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.", "label": "Bridge Loan [Member]", "terseLabel": "Bridge Loan" } } }, "localname": "BridgeLoanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r467", "r470" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails", "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r467", "r470", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails", "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Outstanding equity interest percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r505" ], "calculation": { "http://walgreensbootsalliance.com/role/SegmentreportingDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r516", "r517", "r518" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Cash consideration, subject to purchase price adjustments", "verboseLabel": "Cash consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r516", "r517" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Fair value of share-based compensation awards attributable to pre-combination services" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "auth_ref": [ "r507", "r518" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination", "totalLabel": "Total" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombinationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]", "terseLabel": "Purchase Price Allocation:" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombinationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "auth_ref": [ "r520" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Business Combination, Consideration Transferred, Other", "terseLabel": "Promissory note" } } }, "localname": "BusinessCombinationConsiderationTransferredOther1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r512" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r512" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTerseLabel": "Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r511", "r512" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]", "terseLabel": "Identifiable assets acquired and liabilities assumed:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities": { "auth_ref": [ "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities", "terseLabel": "Long-term debt assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r508" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Fair value of previously held equity interests" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r29", "r63", "r159" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r153", "r159", "r164" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS", "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r153", "r582" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]", "terseLabel": "Changes in cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r20", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Cash used for investing activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r20", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Cash used in operating activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Gains and (losses) due to changes in fair value of derivative instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r167", "r169", "r193", "r194", "r195", "r197", "r199", "r204", "r205", "r206", "r254", "r314", "r319", "r320", "r321", "r327", "r328", "r364", "r365", "r367", "r368", "r581", "r727" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r76", "r309", "r655", "r682" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r306", "r307", "r308", "r310", "r709" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofDividendsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r176", "r177", "r563" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock", "verboseLabel": "Common Stock, $0.01 par value" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r54", "r369" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r54", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at November 30, 2021 and August 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r112", "r114", "r115", "r129", "r664", "r691" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss) attributable to Walgreens Boots Alliance, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "verboseLabel": "Comprehensive income:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r112", "r114", "r128", "r526", "r527", "r538", "r663", "r690" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive (loss) income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r112", "r114", "r127", "r525", "r538", "r662", "r689" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r126", "r138", "r661", "r688" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Accumulatedothercomprehensiveincomeloss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Conversion of Stock [Line Items]", "terseLabel": "Conversion of Stock [Line Items]" } } }, "localname": "ConversionOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockTable": { "auth_ref": [ "r161", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock [Table]", "terseLabel": "Conversion of Stock [Table]" } } }, "localname": "ConversionOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r135", "r641" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r421", "r553" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross currency interest rate swaps" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails", "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r166", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r346", "r353", "r354", "r356", "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r48", "r49", "r50", "r168", "r174", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r358", "r359", "r360", "r361", "r594", "r648", "r650", "r670" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r329", "r358", "r359", "r592", "r594", "r595" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r344", "r358", "r359", "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Carrying value of long-term notes outstanding" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r73", "r330" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r74", "r168", "r174", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r358", "r359", "r360", "r361", "r594" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Debt redeemed" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r74", "r168", "r174", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r355", "r358", "r359", "r360", "r361", "r370", "r371", "r372", "r373", "r591", "r592", "r594", "r595", "r669" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r157", "r170", "r490", "r495", "r496", "r497" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r483", "r484" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear": { "auth_ref": [ "r461", "r464" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year", "terseLabel": "Expected employer cash contributions to defined benefit plan in current fiscal year" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r398", "r434", "r456", "r463", "r464" ], "calculation": { "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected returns on plan assets/other" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r398", "r402", "r433", "r455", "r463", "r464" ], "calculation": { "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest costs" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r431", "r453", "r463", "r464" ], "calculation": { "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Total net periodic pension costs (income)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Components of net periodic benefit costs [Abstract]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r400", "r432", "r454", "r463", "r464" ], "calculation": { "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service costs" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r465" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Cost recognized in the consolidated condensed statements of earnings" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer cash contributions to defined benefit pension plans" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r157", "r281" ], "calculation": { "http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails": { "order": 1.0, "parentTag": "wba_DepreciationAndAmortizationContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r157", "r215" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Notional amount, assets" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r91", "r92", "r93", "r578" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails", "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r90", "r93", "r94", "r548", "r639" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Fair value, assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r90", "r93", "r94", "r548", "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Fair value, liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r93", "r546", "r549", "r552", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails", "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r560", "r566" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Financial instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Financialinstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r91", "r92", "r93", "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Notional amount, liabilities" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SalesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r10", "r18", "r124", "r686" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "totalLabel": "Earnings before income tax \u2013 discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r5", "r6", "r7", "r10", "r18", "r23", "r485", "r494", "r500" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Income tax provision" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]", "terseLabel": "Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration from disposal" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r19", "r26" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r19" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "auth_ref": [ "r19", "r26" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "totalLabel": "Gross profit" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "auth_ref": [ "r8", "r9", "r19", "r27" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 3.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r19" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "totalLabel": "Operating income from discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "auth_ref": [ "r19" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Other Expense", "negatedTerseLabel": "Other expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r19", "r26" ], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]", "terseLabel": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]" } } }, "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r28", "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Discontinuedoperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r467", "r470" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends declared and distributions" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r466", "r468", "r471" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r130", "r182", "r183", "r184", "r185", "r186", "r191", "r193", "r197", "r198", "r199", "r201", "r202", "r564", "r565", "r665", "r692" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Total (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic net earnings (loss) per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted average common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r130", "r182", "r183", "r184", "r185", "r186", "r193", "r197", "r198", "r199", "r201", "r202", "r564", "r565", "r665", "r692" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Total (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net earnings (loss) per common share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "stringItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r582" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r116", "r117", "r118", "r176", "r177", "r178", "r181", "r187", "r189", "r203", "r257", "r369", "r374", "r477", "r478", "r479", "r491", "r492", "r563", "r583", "r584", "r585", "r586", "r587", "r589", "r700", "r701", "r702", "r731" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r26", "r169", "r254", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r26", "r169", "r254", "r581" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r26", "r169", "r254", "r581" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "terseLabel": "Equity Method Investment" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "verboseLabel": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r131", "r132", "r157" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "terseLabel": "Gain on sale of equity method investment" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r64", "r221", "r251" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments (see Note 6)", "verboseLabel": "Carrying value of equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Equitymethodinvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investments accounted under the equity method.", "label": "Equity Method Investments, Fair Value Disclosure", "terseLabel": "Fair market value of equity investment" } } }, "localname": "EquityMethodInvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r576" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Investments in equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r344", "r358", "r359", "r578" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value Measurement" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r567", "r568", "r569", "r573" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r344", "r358", "r359", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r463", "r568", "r630", "r631", "r632" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r344", "r358", "r359", "r567", "r574" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r567", "r568", "r570", "r571", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r344", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Fairvaluemeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r344", "r421", "r422", "r427", "r463", "r568", "r630" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r344", "r358", "r359", "r421", "r422", "r427", "r463", "r568", "r631" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r344", "r358", "r359", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r463", "r568", "r632" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r344", "r358", "r359", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r463", "r630", "r631", "r632" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r572", "r575" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r545", "r551", "r558" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r600", "r606", "r617" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r602", "r611" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails": { "order": 3.0, "parentTag": "wba_LeasesPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance lease" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r598", "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Lease liability", "totalLabel": "Total finance lease obligations" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails", "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease Liability [Abstract]", "terseLabel": "Lease obligations included in:" } } }, "localname": "FinanceLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r598" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, liability, current, statement of financial position, extensible enumeration" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Aggregate Future Lease Payments Under Finance Leases" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r598" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, liability, noncurrent, statement of financial position, extensible enumeration" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total undiscounted minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Later" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 7.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (Remaining period)" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Present value discount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r601", "r611" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails": { "order": 2.0, "parentTag": "wba_LeasesPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r600", "r606", "r617" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, right-of-use asset, statement of financial position, extensible enumeration" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r614", "r617" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r613", "r617" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r275" ], "calculation": { "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022 (Remaining period)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r270", "r272", "r275", "r279", "r642", "r643" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Estimated annual intangible assets amortization expense [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r275", "r643" ], "calculation": { "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross amortizable intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r270", "r274" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r275", "r642" ], "calculation": { "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total amortizable intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forwards" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails", "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r466", "r468", "r471" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Foreign Plan" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r260", "r261", "r629", "r646" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and other intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Goodwillandotherintangibleassets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r133", "r169", "r220", "r226", "r230", "r233", "r236", "r254", "r314", "r315", "r316", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r581" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r544", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r134", "r158", "r182", "r183", "r184", "r185", "r196", "r199", "r524" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r522", "r525" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Net (loss) earnings attributable to noncontrolling interests - continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r122", "r220", "r226", "r230", "r233", "r236", "r644", "r658", "r667", "r693" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings (loss) before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r220", "r226", "r230", "r233", "r236" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings (loss) before interest and tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r169", "r180", "r220", "r226", "r230", "r233", "r236", "r254", "r314", "r315", "r316", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r525", "r565", "r581" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net earnings (loss) from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r120", "r130", "r180", "r182", "r183", "r184", "r185", "r193", "r197", "r198", "r565", "r656", "r659", "r665", "r685" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r120", "r130", "r180", "r182", "r183", "r184", "r185", "r193", "r197", "r198", "r199", "r565", "r665", "r685", "r688", "r692" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r10", "r23", "r26", "r501", "r686" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings from discontinued operations", "totalLabel": "Net earnings from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r4", "r5", "r6", "r7", "r10", "r18", "r23", "r522", "r525" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Net earnings attributable to noncontrolling interests - discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r4", "r5", "r6", "r7", "r10", "r18", "r23", "r525" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "totalLabel": "Discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r124", "r130", "r194", "r197", "r198", "r665", "r686", "r688", "r692" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r194", "r197", "r198", "r539" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r123", "r157", "r217", "r251", "r657", "r684" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Equity (earnings) loss from equity method investments", "verboseLabel": "Equity earnings (losses)" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r467", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r12", "r13", "r14", "r15", "r16", "r17", "r21", "r24", "r25", "r26", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r284", "r293" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails", "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails", "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r171", "r487", "r488", "r489", "r493", "r498", "r502", "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r172", "r188", "r189", "r218", "r485", "r494", "r499", "r694" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r160" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Trade accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other non-current assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r271", "r278" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r278" ], "calculation": { "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "order": 3.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r271", "r278" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r268", "r273" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r121", "r214", "r590", "r593", "r666" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r150", "r154", "r160" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Rate Fair Value Hedges [Abstract]", "terseLabel": "Fair Value Hedges [Abstract]" } } }, "localname": "InterestRateFairValueHedgesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryLIFOReservePeriodCharge": { "auth_ref": [ "r84", "r85", "r86", "r259" ], "calculation": { "http://walgreensbootsalliance.com/role/SegmentreportingDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.", "label": "Inventory, LIFO Reserve, Period Charge", "negatedLabel": "LIFO provision" } } }, "localname": "InventoryLIFOReservePeriodCharge", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r30", "r83", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of affiliates held for management investment companies.", "label": "Investments in and Advances to Affiliates, Balance, Shares", "verboseLabel": "Outstanding shares owned (in shares)" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesBalanceShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Supplemental Income Statement and Other Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Aggregate Future Lease Payments Under Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Later" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (Remaining period)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r616" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Term of renewal contract" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r70", "r169", "r228", "r254", "r314", "r315", "r316", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r529", "r534", "r535", "r581", "r627", "r628" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r62", "r169", "r254", "r581", "r629", "r652", "r680" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable noncontrolling interest and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Equity", "verboseLabel": "Liabilities, redeemable noncontrolling interest and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r72", "r169", "r254", "r314", "r315", "r316", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r529", "r534", "r535", "r581", "r627", "r628", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities [Abstract]" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r35", "r36", "r37", "r50", "r51", "r169", "r254", "r314", "r315", "r316", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r529", "r534", "r535", "r581", "r627", "r628" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "verboseLabel": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Borrowing outstanding" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Term Loan" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r50", "r343", "r357", "r358", "r359", "r650", "r675" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Fair value of long-term notes outstanding" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r74" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "totalLabel": "Total long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r74", "r312" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r82", "r169", "r254", "r314", "r319", "r320", "r321", "r327", "r328", "r581", "r651", "r679" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]", "terseLabel": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r153" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used for) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r153" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used for) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r153", "r155", "r158" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r110", "r113", "r118", "r125", "r158", "r169", "r180", "r182", "r183", "r184", "r185", "r188", "r189", "r196", "r220", "r226", "r230", "r233", "r236", "r254", "r314", "r315", "r316", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r565", "r581", "r660", "r687" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.", "totalLabel": "Total" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Adoption of new accounting pronouncements; New accounting pronouncements not yet adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r176", "r177", "r178", "r374", "r522" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccountingpoliciesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r220", "r226", "r230", "r233", "r236" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/SegmentreportingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r607", "r617" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Fixed" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r596" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment of right-of-use assets" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating lease" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r598" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "totalLabel": "Total operating lease obligations" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesFutureLeasePaymentsforOperatingandFinanceLeasesDetails", "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r598" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease obligations", "verboseLabel": "Operating lease obligations - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r598" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease obligations", "verboseLabel": "Operating lease obligations - non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r603", "r611" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails": { "order": 1.0, "parentTag": "wba_LeasesPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r597" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r614", "r617" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r613", "r617" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r225", "r226", "r227", "r228", "r230", "r236" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Reportable Segments", "verboseLabel": "Reportable segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r87", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r66" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r99", "r100", "r105" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Movement on available for debt sale securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r108", "r116", "r117", "r583", "r585", "r589" ], "calculation": { "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive income (loss) before reclassification adjustments" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r98", "r105" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Unrealized gain on cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r96" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r111", "r114", "r116", "r117", "r119", "r126", "r369", "r583", "r588", "r589", "r661", "r688" ], "calculation": { "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r111", "r114", "r525", "r526", "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r103", "r105" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Pension/postretirement obligations" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax": { "auth_ref": [ "r109", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for unrealized gain (loss) of investment classified as available-for-sale transferred to equity method.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Investment Transferred from Available-for-sale to Equity Method, after Tax", "terseLabel": "Pre-tax gain related to conversion of previously held investment in convertible debt securities" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r545", "r558" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]", "terseLabel": "Other income" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Others" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r75" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r50", "r650", "r675" ], "calculation": { "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-term Debt", "terseLabel": "Other" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r158" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other non-current assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r137" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r140", "r143" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r147" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Stock purchases" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r151", "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r147" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Cash dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r141", "r519" ], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "wba_BusinessCombinationConsiderationTransferredNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Purchase price", "verboseLabel": "Total purchase price" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r141" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "terseLabel": "Cash consideration, net" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r142" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "auth_ref": [ "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.", "label": "Postemployment Benefits Disclosure [Text Block]", "verboseLabel": "Retirement benefits" } } }, "localname": "PostemploymentBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Retirementbenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r53", "r364" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r53", "r364" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r53", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock $.01 par value; authorized 32 million shares, none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Cash received from disposal" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r145" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r146", "r149" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net change in short-term debt with maturities of 3 months or less" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r144" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds related to employee stock plans" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r26", "r110", "r113", "r118", "r152", "r169", "r180", "r188", "r189", "r220", "r226", "r230", "r233", "r236", "r254", "r314", "r315", "r316", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r525", "r530", "r531", "r537", "r538", "r565", "r581", "r667" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings (loss)", "totalLabel": "Net earnings (loss)", "verboseLabel": "Net earnings (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r89", "r283", "r606" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RatioOfIndebtednessToNetCapital1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indebtedness divided by net capital.", "label": "Ratio of Indebtedness to Net Capital", "terseLabel": "Debt to total capitalization ratio" } } }, "localname": "RatioOfIndebtednessToNetCapital1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r108", "r116", "r117", "r583", "r587", "r589" ], "calculation": { "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedTerseLabel": "Amounts reclassified from AOCI" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r106", "r109", "r116" ], "calculation": { "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Tax benefit (provision)" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r226", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Operating Income (Loss) from Segments to Consolidated" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Purchases, net" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RelatedpartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r620", "r621", "r622", "r624", "r625" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Relatedparties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r148" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments of debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Reporting unit fair value in excess of carrying amount (as a percent)" } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r38", "r159", "r164", "r645", "r676" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r290", "r292", "r295", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Exit and disposal activities" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Exitanddisposalactivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r291", "r294", "r301", "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Costs incurred" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r291", "r294", "r301", "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r157", "r289", "r298", "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r291", "r292", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]", "verboseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Total pre-tax exit and disposal charges" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r292", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r292", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetailMember": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Sale of product directly to consumer.", "label": "Retail [Member]", "terseLabel": "Retail" } } }, "localname": "RetailMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r58", "r374", "r480", "r629", "r678", "r703", "r705" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r176", "r177", "r178", "r181", "r187", "r189", "r257", "r477", "r478", "r479", "r491", "r492", "r563", "r700", "r702" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings", "verboseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r466", "r468", "r471" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r466", "r468", "r471" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r211", "r212", "r225", "r231", "r232", "r238", "r239", "r242", "r385", "r386", "r641" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r387", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Sales" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Sales" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Credit facilities" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r612", "r617" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails": { "order": 2.0, "parentTag": "wba_RightOfUseAssetObtainedInExchangeForLeaseLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r612", "r617" ], "calculation": { "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails": { "order": 1.0, "parentTag": "wba_RightOfUseAssetObtainedInExchangeForLeaseLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "auth_ref": [ "r610", "r617", "r619" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.", "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "terseLabel": "Gain on sale and leaseback" } } }, "localname": "SaleAndLeasebackTransactionGainLossNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r108", "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r74", "r174", "r358", "r360", "r370", "r371", "r372", "r373", "r591", "r592", "r595", "r669" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Long-Term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r447", "r448", "r451", "r452", "r463" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Gains and (Losses) due to Changes in Fair Value Recognized in Earnings" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r12", "r13", "r14", "r15", "r16", "r17", "r21", "r24", "r25", "r26", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedules of Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "Schedule of Dividends Payable [Table Text Block]", "terseLabel": "Schedule of Dividends Payable" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r26", "r169", "r253", "r254", "r581" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r270", "r274" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r264", "r267" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r264", "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Components of Net Periodic Benefit Costs (Income)" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Notional Amounts, Fair Value and Balance Sheet Presentation of Derivative Instruments Outstanding" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Identifiable Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of Related Party Transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/RelatedpartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r38", "r164", "r645", "r676" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restrictions on Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r291", "r292", "r293", "r294", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r296", "r297", "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r292", "r302" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Change in Restructuring Liabilities" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r220", "r223", "r229", "r264" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table Text Block]", "terseLabel": "Short-Term Borrowings" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentContinuingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component of an entity expected to operate in the foreseeable future.", "label": "Continuing Operations [Member]", "terseLabel": "Continuing Operations" } } }, "localname": "SegmentContinuingOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r207", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r230", "r231", "r232", "r233", "r234", "r236", "r242", "r294", "r303", "r695" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r207", "r209", "r210", "r220", "r224", "r230", "r234", "r235", "r236", "r237", "r238", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Segmentreporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r136" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails", "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Other Acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r156" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r47", "r629", "r648", "r674" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Total short-term debt", "verboseLabel": "Short-term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time.", "label": "Short-term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Weighted average interest rate" } } }, "localname": "ShortTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShorttermDebtAverageOutstandingAmount": { "auth_ref": [ "r727", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.", "label": "Short-term Debt, Average Outstanding Amount", "terseLabel": "Average daily short-term borrowings" } } }, "localname": "ShorttermDebtAverageOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r165", "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Accounting policies", "verboseLabel": "New accounting pronouncements" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Accountingpolicies", "http://walgreensbootsalliance.com/role/Newaccountingpronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r11", "r207", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r230", "r231", "r232", "r233", "r234", "r236", "r242", "r264", "r285", "r294", "r303", "r695" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r52", "r53", "r54", "r167", "r169", "r193", "r194", "r195", "r197", "r199", "r204", "r205", "r206", "r254", "r314", "r319", "r320", "r321", "r327", "r328", "r364", "r365", "r367", "r368", "r369", "r581", "r727" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r79", "r116", "r117", "r118", "r176", "r177", "r178", "r181", "r187", "r189", "r203", "r257", "r369", "r374", "r477", "r478", "r479", "r491", "r492", "r563", "r583", "r584", "r585", "r586", "r587", "r589", "r700", "r701", "r702", "r731" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r176", "r177", "r178", "r203", "r641" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r53", "r54", "r369", "r374" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "verboseLabel": "Employee stock purchase and option plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r79", "r369", "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Business combination" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r53", "r54", "r374", "r475", "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "verboseLabel": "Employee stock purchase and option plans" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r54", "r60", "r61", "r169", "r246", "r254", "r581", "r629" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Walgreens Boots Alliance, Inc. shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r117", "r169", "r176", "r177", "r178", "r181", "r187", "r254", "r257", "r374", "r477", "r478", "r479", "r491", "r492", "r522", "r523", "r536", "r563", "r581", "r583", "r584", "r589", "r701", "r702", "r731" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Cumulative effect adjustment to decrease retained earnings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Equity:", "verboseLabel": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Noncontrolling interests contribution and other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r609", "r617" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "verboseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Supplemental information" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/Supplementalinformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Redemption value adjustment" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r77", "r169", "r254", "r581" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Redeemable noncontrolling interest" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS", "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments.", "label": "Temporary Equity, Foreign Currency Translation Adjustments", "terseLabel": "Currency translation adjustments and other" } } }, "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net (loss)" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r34", "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of Redeemable Noncontrolling Interest" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TotalReturnSwapMember": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Contracts in which one party makes payments at a fixed or variable rate while the counterparty makes payments based on an asset, including the income and capital gains derived therefrom.", "label": "Total Return Swap [Member]", "terseLabel": "Total return swap" } } }, "localname": "TotalReturnSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/FairvaluemeasurementsDetails", "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAccountsReceivableMember": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.", "label": "Trade Accounts Receivable [Member]", "terseLabel": "Trade Accounts Receivable" } } }, "localname": "TradeAccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade names and trademarks", "verboseLabel": "Trade names and trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r78", "r375" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury stock amount" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r78", "r375" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r54", "r369", "r374" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Treasury stock purchases (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r78", "r375", "r376" ], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 308,671,242 shares at November 30, 2021 and 307,139,982 shares at August 31, 2021" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r369", "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Treasury stock purchases" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r291", "r292", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Notes", "verboseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r608", "r617" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r192", "r199" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r191", "r199" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "sharesItemType" }, "wba_A09500NotesPayableDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.9500% Notes Payable, Due 2023", "label": "0.9500% Notes Payable, Due 2023 [Member]", "terseLabel": "0.9500% Notes Payable, Due 2023" } } }, "localname": "A09500NotesPayableDue2023Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility", "label": "2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility [Member]", "terseLabel": "2020 Revolving Credit Agreement, 18-Month Revolving Credit Facility" } } }, "localname": "A2020RevolvingCreditAgreement18MonthRevolvingCreditFacilityMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_A2020RevolvingCreditAgreement364DayFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Revolving Credit Agreement, 364-Day Facility", "label": "2020 Revolving Credit Agreement, 364-Day Facility [Member]", "terseLabel": "2020 Revolving Credit Agreement, 364-Day Facility" } } }, "localname": "A2020RevolvingCreditAgreement364DayFacilityMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_A2125NotesPayableDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "2.125% Notes Payable Due 2026 [Member]", "terseLabel": "2.125% unsecured Euro notes due 2026" } } }, "localname": "A2125NotesPayableDue2026Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A3100NotesPayableDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "3.100% Notes Payable, Due 2022 [Member]", "terseLabel": "3.100% unsecured notes due 2022" } } }, "localname": "A3100NotesPayableDue2022Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A3200NotesPayableDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.200% Notes Payable, Due 2030", "label": "3.200% Notes Payable, Due 2030 [Member]", "terseLabel": "3.200% unsecured notes due 2030" } } }, "localname": "A3200NotesPayableDue2030Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A3300NotesPayableDue2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "3.300% Notes Payable Due 2021 [Member]", "terseLabel": "3.300% unsecured notes due 2021" } } }, "localname": "A3300NotesPayableDue2021Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A3450NotesPayableDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "3.450% Notes Payable, Due 2026 [Member]", "terseLabel": "3.450% unsecured notes due 2026", "verboseLabel": "2.125% Walgreens Boots Alliance, Inc. notes due 2026" } } }, "localname": "A3450NotesPayableDue2026Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A3600NotesPayableDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "3.600% Notes Payable, Due 2025 [Member]", "terseLabel": "3.600% unsecured Pound sterling notes due 2025", "verboseLabel": "3.600% Walgreens Boots Alliance, Inc. notes due 2025" } } }, "localname": "A3600NotesPayableDue2025Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CoverPage", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A3800NotesPayableDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "3.800% Notes Payable, Due 2024 [Member]", "terseLabel": "3.800% unsecured notes due 2024" } } }, "localname": "A3800NotesPayableDue2024Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A4100NotesPayableDue2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.100% Notes Payable, Due 2050", "label": "4.100% Notes Payable, Due 2050 [Member]", "terseLabel": "4.100% unsecured notes due 2050" } } }, "localname": "A4100NotesPayableDue2050Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A4400NotesPayableDue2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "4.400% Notes Payable, Due 2042 [Member]", "terseLabel": "4.400% unsecured notes due 2042" } } }, "localname": "A4400NotesPayableDue2042Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A4500NotesPayableDue2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "4.500% Notes Payable, Due 2034 [Member]", "terseLabel": "4.500% unsecured notes due 2034" } } }, "localname": "A4500NotesPayableDue2034Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A4650NotesPayableDue2046Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "4.650% Notes Payable Due 2046 [Member]", "terseLabel": "4.650% unsecured notes due 2046" } } }, "localname": "A4650NotesPayableDue2046Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_A4800NotesPayableDue2044Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "4.800% Notes Payable, Due 2044 [Member]", "terseLabel": "4.800% unsecured notes due 2044" } } }, "localname": "A4800NotesPayableDue2044Member", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_AOCINetInvestmentHedgesParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AOCI, Net Investment Hedges, Parent", "label": "AOCI, Net Investment Hedges, Parent [Member]", "terseLabel": "Net investment hedges" } } }, "localname": "AOCINetInvestmentHedgesParentMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "domainItemType" }, "wba_AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated Other Comprehensive Income of Equity Method Investments, Attributable To Parent [Member]", "label": "Accumulated Other Comprehensive Income of Equity Method Investments, Attributable To Parent [Member]", "terseLabel": "Share of OCI of equity method investments" } } }, "localname": "AccumulatedOtherComprehensiveIncomeofEquityMethodInvestmentsAttributableToParentMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "xbrltype": "domainItemType" }, "wba_AdjustedOperatingIncome": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/SegmentreportingDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of adjusted operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Adjusted Operating Income", "terseLabel": "Adjusted operating income" } } }, "localname": "AdjustedOperatingIncome", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "wba_AdjustmentsToEquityEarningsInEquityInvestmentOne": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/SegmentreportingDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Equity Earnings In Equity Investment One", "label": "Adjustments To Equity Earnings In Equity Investment One", "terseLabel": "Adjustments to equity earnings (loss) in AmerisourceBergen" } } }, "localname": "AdjustmentsToEquityEarningsInEquityInvestmentOne", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "wba_AllianceHealthcareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance Healthcare", "label": "Alliance Healthcare [Member]", "terseLabel": "Alliance Healthcare" } } }, "localname": "AllianceHealthcareMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails", "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "wba_AmerisourceBergenAndOtherEquityMethodInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The aggregate of all equity method investments.", "label": "AmerisourceBergen And Other Equity Method Investments [Member]", "terseLabel": "Total" } } }, "localname": "AmerisourceBergenAndOtherEquityMethodInvestmentsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails" ], "xbrltype": "domainItemType" }, "wba_AmerisourceBergenCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An equity method investee of the company.", "label": "AmerisourceBergen Corporation [Member]", "verboseLabel": "AmerisourceBergen" } } }, "localname": "AmerisourceBergenCorporationMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails" ], "xbrltype": "domainItemType" }, "wba_AssetImpairmentRestructuringChargesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Impairment Restructuring Charges", "label": "Asset Impairment Restructuring Charges [Member]", "terseLabel": "Asset Impairments", "verboseLabel": "Asset impairments" } } }, "localname": "AssetImpairmentRestructuringChargesMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "domainItemType" }, "wba_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Supplemental Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "wba_August2018RevolvingCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2018 Revolving Credit Agreement [Member]", "label": "August 2018 Revolving Credit Agreement [Member]", "terseLabel": "August 2018 Revolving Credit Agreement" } } }, "localname": "August2018RevolvingCreditAgreementMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_BootsReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boots Reporting Unit", "label": "Boots Reporting Unit [Member]", "terseLabel": "Boots Reporting Unit" } } }, "localname": "BootsReportingUnitMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_BusinessAcquisitionValueOfCommonStockSharesAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Value of Common Stock Shares Acquired", "label": "Business Acquisition, Value of Common Stock Shares Acquired", "terseLabel": "Value of purchase tender offer" } } }, "localname": "BusinessAcquisitionValueOfCommonStockSharesAcquired", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "wba_BusinessCombinationCashTransferredForPreferredUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Cash Transferred for Preferred Units", "label": "Business Combination, Cash Transferred for Preferred Units", "terseLabel": "Cash consideration for preferred units" } } }, "localname": "BusinessCombinationCashTransferredForPreferredUnits", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wba_BusinessCombinationConsiderationTransferredForPreferredUnits": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "wba_BusinessCombinationConsiderationTransferredNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred for Preferred Units", "label": "Business Combination, Consideration Transferred for Preferred Units", "negatedTerseLabel": "Less: purchase price for issuance of new preferred units at fair value" } } }, "localname": "BusinessCombinationConsiderationTransferredForPreferredUnits", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wba_BusinessCombinationConsiderationTransferredGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Gross", "label": "Business Combination, Consideration Transferred, Gross", "terseLabel": "Cash consideration, gross" } } }, "localname": "BusinessCombinationConsiderationTransferredGross", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wba_BusinessCombinationConsiderationTransferredNet": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Net", "label": "Business Combination, Consideration Transferred, Net", "terseLabel": "Net consideration", "totalLabel": "Net consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredNet", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongLivedTangibleAssets": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Lived Tangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Lived Tangible Assets", "terseLabel": "Tangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongLivedTangibleAssets", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wba_BusinessCombinationStepAcquisitionNoncontrollingInterestInAcquireeFairValue": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Step Acquisition, Noncontrolling Interest in Acquiree, Fair Value", "label": "Business Combination, Step Acquisition, Noncontrolling Interest in Acquiree, Fair Value", "terseLabel": "Fair value of non-controlling interests" } } }, "localname": "BusinessCombinationStepAcquisitionNoncontrollingInterestInAcquireeFairValue", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wba_BusinessInvestmentandAssetAcquisitionsNetofCashAcquired": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. This item also includes the cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Business, Investment and Asset Acquisitions, Net of Cash Acquired", "terseLabel": "Business, investment and asset acquisitions, net of cash acquired" } } }, "localname": "BusinessInvestmentandAssetAcquisitionsNetofCashAcquired", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "wba_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease obligations:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "stringItemType" }, "wba_CorporateAndReconcilingItemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate And Reconciling Items", "label": "Corporate And Reconciling Items [Member]", "terseLabel": "Corporate and Other" } } }, "localname": "CorporateAndReconcilingItemsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "domainItemType" }, "wba_CustomerRelationshipsAndLoyaltyCardHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships and loyalty card, similar to a credit card, debit card, or digital card that identifies the card holder as a member in a loyalty program.", "label": "Customer Relationships and Loyalty Card Holders [Member]", "terseLabel": "Customer relationships and loyalty card holders" } } }, "localname": "CustomerRelationshipsAndLoyaltyCardHoldersMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "wba_DebtInstrumentRedemptionPriceVariablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Redemption Price, Variable Percentage", "label": "Debt Instrument, Redemption Price, Variable Percentage", "terseLabel": "Redemption variable percentage" } } }, "localname": "DebtInstrumentRedemptionPriceVariablePercentage", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "wba_DebtIssuanceNoteEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Issuance Note Eight", "label": "Debt Issuance Note Eight [Member]", "terseLabel": "$850 million note issuance" } } }, "localname": "DebtIssuanceNoteEightMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_DebtIssuanceNoteFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element details information about the total 700 million pounds debt issuance.", "label": "Debt Issuance Note Five [Member]", "terseLabel": "Total \u00a3700 million note issuance" } } }, "localname": "DebtIssuanceNoteFiveMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_DebtIssuanceNoteFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element details information about the total $6.0 billion debt issuance.", "label": "Debt Issuance Note Four [Member]", "terseLabel": "Total $6 billion note issuance" } } }, "localname": "DebtIssuanceNoteFourMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_DebtIssuanceNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element details information about the total $8.0 billion debt issuance.", "label": "Debt Issuance Note One [Member]", "terseLabel": "Total $8 billion note issuance" } } }, "localname": "DebtIssuanceNoteOneMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_DebtIssuanceNoteSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Issuance Note Seven", "label": "Debt Issuance Note Seven [Member]", "terseLabel": "Total $1.5 billion note issuance" } } }, "localname": "DebtIssuanceNoteSevenMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_DebtIssuanceNoteSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element details information about the total 750 million Euros debt issuance.", "label": "Debt Issuance Note Six [Member]", "terseLabel": "Total \u20ac750 million note issuance" } } }, "localname": "DebtIssuanceNoteSixMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_DebtIssuanceNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element details information about the total $4.0 billion debt issuance.", "label": "Debt Issuance Note Two [Member]", "terseLabel": "Total $4 billion note issuance" } } }, "localname": "DebtIssuanceNoteTwoMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_DefinedContributionPlanProfitSharingProvisionBenefitExpenseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the cost recognized during the period for defined contribution plans profit sharing provision benefit expense amount.", "label": "Defined Contribution Plan Profit Sharing Provision Benefit Expense Amount", "terseLabel": "Profit sharing provision expense" } } }, "localname": "DefinedContributionPlanProfitSharingProvisionBenefitExpenseAmount", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/RetirementbenefitsDetails" ], "xbrltype": "monetaryItemType" }, "wba_DelayedDrawTermLoanCreditFacility364DayFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delayed Draw Term Loan Credit Facility, 364-Day Facility", "label": "Delayed Draw Term Loan Credit Facility, 364-Day Facility [Member]", "terseLabel": "Delayed Draw Term Loan Credit Facility, 364-Day Facility" } } }, "localname": "DelayedDrawTermLoanCreditFacility364DayFacilityMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_DelayedDrawTermLoanCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delayed Draw Term Loan Credit Facility", "label": "Delayed Draw Term Loan Credit Facility [Member]", "terseLabel": "Delayed Draw Term Loan" } } }, "localname": "DelayedDrawTermLoanCreditFacilityMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_DelayedDrawTermLoanCreditFacilityThreeYearFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delayed Draw Term Loan Credit Facility, Three-Year Facility", "label": "Delayed Draw Term Loan Credit Facility, Three-Year Facility [Member]", "terseLabel": "Delayed Draw Term Loan Credit Facility, Three-Year Facility" } } }, "localname": "DelayedDrawTermLoanCreditFacilityThreeYearFacilityMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_DelayedDrawTermLoanCreditFacilityTwoYearFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delayed Draw Term Loan Credit Facility, Two-Year Facility", "label": "Delayed Draw Term Loan Credit Facility, Two-Year Facility [Member]", "terseLabel": "Delayed Draw Term Loan Credit Facility, Two-Year Facility" } } }, "localname": "DelayedDrawTermLoanCreditFacilityTwoYearFacilityMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_DepreciationAndAmortizationContinuingOperations": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation and Amortization, Continuing Operations", "label": "Depreciation and Amortization, Continuing Operations", "totalLabel": "Total depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortizationContinuingOperations", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationDepreciationandAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "wba_DiscontinuedOperationIncomeLossFromOtherEquityMethodInvestments": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Discontinued Operation, Income (Loss) from Other Equity Method Investments", "label": "Discontinued Operation, Income (Loss) from Other Equity Method Investments", "terseLabel": "Post tax earnings from other equity method investments" } } }, "localname": "DiscontinuedOperationIncomeLossFromOtherEquityMethodInvestments", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsSchedulesofDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "wba_DisposalGroupContingentConsiderationPurchasePriceReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Contingent Consideration, Purchase Price Receivable", "label": "Disposal Group, Contingent Consideration, Purchase Price Receivable", "terseLabel": "Receivable for purchase price consideration" } } }, "localname": "DisposalGroupContingentConsiderationPurchasePriceReceivable", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wba_EmployeeSeveranceAndBusinessTransitionCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Severance And Business Transition Costs", "label": "Employee Severance And Business Transition Costs [Member]", "terseLabel": "Employee severance and business transition costs", "verboseLabel": "Employee Severance and Business Transition Costs" } } }, "localname": "EmployeeSeveranceAndBusinessTransitionCostsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "domainItemType" }, "wba_EquityInvestmentExceededItsProportionateShareOfNetAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount exceeded its proportionate share of the net assets of an equity method investee.", "label": "Equity Investment, Exceeded its Proportionate Share of Net Assets", "terseLabel": "Equity investment, exceeded its proportionate share of net assets" } } }, "localname": "EquityInvestmentExceededItsProportionateShareOfNetAssets", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wba_EquityMethodInvestmentsSummarizedFinancialInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Summarized Financial Information", "label": "Equity Method Investments, Summarized Financial Information [Table Text Block]", "terseLabel": "Summarized Financial Information of Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsSummarizedFinancialInformationTableTextBlock", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsTables" ], "xbrltype": "textBlockItemType" }, "wba_ExitAndDisposalCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exit And Disposal Costs", "label": "Exit And Disposal Costs [Member]", "terseLabel": "Exit and Disposal Costs" } } }, "localname": "ExitAndDisposalCostsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance Lease, Assets And Liabilities, Lessee", "label": "Finance Lease, Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Finance Leases:" } } }, "localname": "FinanceLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "wba_GainLossOnPreviouslyHeldInvestmentInterests": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) on Previously Held Investment Interests", "label": "Gain (Loss) on Previously Held Investment Interests", "negatedTerseLabel": "Gain on previously held investment interests" } } }, "localname": "GainLossOnPreviouslyHeldInvestmentInterests", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "wba_IncomeFromEquityMethodInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income From Equity Method Investments", "label": "Income From Equity Method Investments", "terseLabel": "Share of earnings (loss) from equity method investments" } } }, "localname": "IncomeFromEquityMethodInvestments", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsSummarizedFinancialInformationofEquityMethodInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "wba_IncomeLossFromEquityMethodInvestmentOne": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income (Loss) From Equity Method Investment One", "label": "Income (Loss) From Equity Method Investment One", "terseLabel": "Equity earnings (loss) in AmerisourceBergen" } } }, "localname": "IncomeLossFromEquityMethodInvestmentOne", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "wba_IncomeLossfromOtherEquityMethodInvestments": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income (Loss) from Other Equity Method Investments", "label": "Income (Loss) from Other Equity Method Investments", "terseLabel": "Post tax (loss) earnings from other equity method investments" } } }, "localname": "IncomeLossfromOtherEquityMethodInvestments", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEARNINGS" ], "xbrltype": "monetaryItemType" }, "wba_InformationTechnologyTransformationAndOtherExitCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information Technology Transformation And Other Exit Costs", "label": "Information Technology Transformation And Other Exit Costs [Member]", "terseLabel": "Information technology transformation and other exit costs", "verboseLabel": "Information Technology Transformation and Other Exit Costs" } } }, "localname": "InformationTechnologyTransformationAndOtherExitCostsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "domainItemType" }, "wba_InternationalReportableSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "International Reportable Segment [Member]", "terseLabel": "International" } } }, "localname": "InternationalReportableSegmentMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "domainItemType" }, "wba_LeaseObligationsandOtherRealEstateCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Obligations and Other Real Estate Costs [Member]", "label": "Lease Obligations and Other Real Estate Costs [Member]", "terseLabel": "Lease obligations and other real estate costs", "verboseLabel": "Lease Obligations and Other Real Estate Costs" } } }, "localname": "LeaseObligationsandOtherRealEstateCostsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "domainItemType" }, "wba_LeasesPayments": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Leases, Payments", "label": "Leases, Payments", "totalLabel": "Total" } } }, "localname": "LeasesPayments", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "wba_LeasesWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases, Weighted Average Discount Rate", "label": "Leases, Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted average discount rate:" } } }, "localname": "LeasesWeightedAverageDiscountRateAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails" ], "xbrltype": "stringItemType" }, "wba_LesseeFinanceLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Finance Lease, Cost", "label": "Lessee, Finance Lease, Cost [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "LesseeFinanceLeaseCostAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "stringItemType" }, "wba_LongTermDebtNetDiscountAndFairMarketValueAdjustments": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and after deducting unamortized discount or premiums and unamortized fair market value adjustments, if any.", "label": "Long Term Debt Net Discount And Fair Market Value Adjustments", "terseLabel": "Amount oustanding", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNetDiscountAndFairMarketValueAdjustments", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "wba_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest and Redeemable Noncontrolling Interest", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest and Redeemable Noncontrolling Interest", "terseLabel": "Net earnings (loss)" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFEQUITY" ], "xbrltype": "monetaryItemType" }, "wba_NoncashOrPartNoncashDivestitureNoncashConsiderationSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncash or Part Noncash Divestiture, Noncash Consideration, Shares Issued", "label": "Noncash or Part Noncash Divestiture, Noncash Consideration, Shares Issued", "terseLabel": "Shares issued as part of disposal (in shares)" } } }, "localname": "NoncashOrPartNoncashDivestitureNoncashConsiderationSharesIssued", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "wba_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Lessee", "label": "Operating Lease, Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Operating Leases:" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "wba_OperatingLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Cost", "label": "Operating Lease, Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCostAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesSupplementalIncomeStatementInformationDetails" ], "xbrltype": "stringItemType" }, "wba_OpiodLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opiod Litigation", "label": "Opiod Litigation [Member]", "terseLabel": "Opiod Litigation" } } }, "localname": "OpiodLitigationMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_OtherComprehensiveIncomeLossNetInvestmentHedgesAfterTax": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedges, After Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedges, After Tax", "negatedLabel": "Net investment hedges" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgesAfterTax", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "wba_OtherComprehensiveIncomeLossShareOfOtherComprehensiveIncomeLossOfEquityMethodInvestmentsAfterTax": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 6.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Share Of Other Comprehensive Income (Loss) Of Equity Method Investments, After Tax", "label": "Other Comprehensive Income (Loss), Share Of Other Comprehensive Income (Loss) Of Equity Method Investments, After Tax", "negatedLabel": "Share of other comprehensive (loss) income of equity method investments" } } }, "localname": "OtherComprehensiveIncomeLossShareOfOtherComprehensiveIncomeLossOfEquityMethodInvestmentsAfterTax", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "wba_OtherEquityMethodInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The aggregate of all other equity method investments not separately disclosed in the taxonomy.", "label": "Other equity method investments [Member]", "terseLabel": "Others", "verboseLabel": "Other Investments" } } }, "localname": "OtherEquityMethodInvestmentsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsScheduleofEquityMethodInvestmentsDetails" ], "xbrltype": "domainItemType" }, "wba_OtherIncomeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense and revenues.", "label": "Other income/(expenses) [Member]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherIncomeExpensesMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/FinancialinstrumentsDetails" ], "xbrltype": "domainItemType" }, "wba_OtherInternationalReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other International Reporting Unit", "label": "Other International Reporting Unit [Member]", "terseLabel": "Other International Reporting Unit" } } }, "localname": "OtherInternationalReportingUnitMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_OtherShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other types of short-term debt arrangements not previously listed in the taxonomy.", "label": "Other Short Term Debt [Member]", "terseLabel": "Other" } } }, "localname": "OtherShortTermDebtMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "wba_PharmaceuticalWholesaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Pharmaceutical Wholesale [Member]", "terseLabel": "Wholesale" } } }, "localname": "PharmaceuticalWholesaleMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SalesDetails" ], "xbrltype": "domainItemType" }, "wba_PharmacyLicensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy Licenses given to the company.", "label": "Pharmacy Licenses [Member]", "terseLabel": "Pharmacy licenses" } } }, "localname": "PharmacyLicensesMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "wba_PharmacyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy [Member]", "label": "Pharmacy [Member]", "terseLabel": "Pharmacy" } } }, "localname": "PharmacyMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SalesDetails" ], "xbrltype": "domainItemType" }, "wba_PrimaryCareProviderNetworkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary Care Provider Network", "label": "Primary Care Provider Network [Member]", "terseLabel": "Primary care provider network" } } }, "localname": "PrimaryCareProviderNetworkMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "wba_ProceedsFromSaleLeasebackTransactionsInvestingActivities": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale-Leaseback Transactions, Investing Activities", "label": "Proceeds From Sale-Leaseback Transactions, Investing Activities", "terseLabel": "Proceeds from sale-leaseback transactions" } } }, "localname": "ProceedsFromSaleLeasebackTransactionsInvestingActivities", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/CONSOLIDATEDCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "wba_PurchasingAndPayerContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An asset acquired in a business combination representing an entity's purchasing and payer contract.", "label": "Purchasing and Payer Contracts [Member]", "terseLabel": "Purchasing and payer contracts" } } }, "localname": "PurchasingAndPayerContractsMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" ], "xbrltype": "domainItemType" }, "wba_RestructuringAndRelatedCostExpectedAnnualCostSavingsOfRestructuringPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restructuring and Related Cost, Expected Annual Cost Savings Of Restructuring Plan", "label": "Restructuring and Related Cost, Expected Annual Cost Savings Of Restructuring Plan", "terseLabel": "Expected annual cost savings of restructuring plan" } } }, "localname": "RestructuringAndRelatedCostExpectedAnnualCostSavingsOfRestructuringPlan", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wba_RestructuringAndRelatedCostNumberOfStoresExpectedToClose": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring and Related Cost, Number of Stores Expected To Close", "label": "Restructuring and Related Cost, Number of Stores Expected To Close", "terseLabel": "Number of stores expected to close" } } }, "localname": "RestructuringAndRelatedCostNumberOfStoresExpectedToClose", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "wba_RestructuringReserveOtherNonCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restructuring Reserve, Other, Non-Cash", "label": "Restructuring Reserve, Other, Non-Cash", "negatedTerseLabel": "Other" } } }, "localname": "RestructuringReserveOtherNonCash", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "wba_RightOfUseAssetObtainedInExchangeForLeaseLiability": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-Use Asset Obtained in Exchange for Lease Liability", "label": "Right-of-Use Asset Obtained in Exchange for Lease Liability", "totalLabel": "Total" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "wba_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for new lease obligations:" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesOtherSupplementalInformationDetails" ], "xbrltype": "stringItemType" }, "wba_ScheduleofDepreciationandAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Depreciation and Amortization Expense [Table Text Block]", "label": "Schedule of Depreciation and Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Depreciation and Amortization Expense" } } }, "localname": "ScheduleofDepreciationandAmortizationExpenseTableTextBlock", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationTables" ], "xbrltype": "textBlockItemType" }, "wba_ShieldsHealthSolutionsParentLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shields Health Solutions Parent, LLC", "label": "Shields Health Solutions Parent, LLC [Member]", "terseLabel": "Shields Health Solutions Parent, LLC" } } }, "localname": "ShieldsHealthSolutionsParentLLCMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails", "http://walgreensbootsalliance.com/role/DebtShortandLongTermDebtDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "wba_TemporaryEquityAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity, Acquisitions", "label": "Temporary Equity, Acquisitions", "terseLabel": "Acquisitions" } } }, "localname": "TemporaryEquityAcquisitions", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "wba_TimePeriodOfReportingLag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of reporting lag for availability of financial information.", "label": "Time period of reporting lag", "terseLabel": "Period of reporting lag" } } }, "localname": "TimePeriodOfReportingLag", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "wba_TransformationalCostManagement": { "auth_ref": [], "calculation": { "http://walgreensbootsalliance.com/role/SegmentreportingDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transformational Cost Management", "label": "Transformational Cost Management", "negatedLabel": "Transformational cost management" } } }, "localname": "TransformationalCostManagement", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "monetaryItemType" }, "wba_TransformationalCostManagementProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transformational Cost Management Program", "label": "Transformational Cost Management Program [Member]", "terseLabel": "Transformational Cost Management Program" } } }, "localname": "TransformationalCostManagementProgramMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesNarrativeDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringReserveActivityDetails" ], "xbrltype": "domainItemType" }, "wba_UnitedStatesReportableSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identifies division of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "United States Reportable Segment [Member]", "terseLabel": "United States" } } }, "localname": "UnitedStatesReportableSegmentMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/ExitanddisposalactivitiesRestructuringCostsDetails", "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "domainItemType" }, "wba_VillageMDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VillageMD", "label": "VillageMD [Member]", "terseLabel": "VillageMD" } } }, "localname": "VillageMDMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/AcquisitionsNarrativeDetails", "http://walgreensbootsalliance.com/role/AcquisitionsScheduleofPurchasePriceAllocationandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails", "http://walgreensbootsalliance.com/role/DebtNarrativeDetails", "http://walgreensbootsalliance.com/role/EquitymethodinvestmentsNarrativeDetails", "http://walgreensbootsalliance.com/role/SupplementalinformationScheduleofRedeemableNoncontrollingInterestDetails" ], "xbrltype": "domainItemType" }, "wba_WalgreensHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Walgreens Health", "label": "Walgreens Health [Member]", "terseLabel": "Walgreens Health" } } }, "localname": "WalgreensHealthMember", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "http://walgreensbootsalliance.com/role/SalesDetails", "http://walgreensbootsalliance.com/role/SegmentreportingDetails" ], "xbrltype": "domainItemType" }, "wba_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Lease Term", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted average remaining lease term in years:" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://walgreensbootsalliance.com/20211130", "presentation": [ "http://walgreensbootsalliance.com/role/LeasesAverageLeaseTermsAndDiscountsDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32804-111569" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.L)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r28": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-10(d)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=d3e168853-122756" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668" }, "r397": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r521": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125514181&loc=d3e34841-113949" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r566": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r618": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123417830&loc=SL77919786-209982" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r625": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14.Column B)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r722": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r723": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r724": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r725": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r726": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r727": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r728": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r729": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(1),(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" } }, "version": "2.1" } ZIP 102 0001618921-22-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001618921-22-000004-xbrl.zip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†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

2[/HT M?FQ&'4&V'L$$ PY:%-X(R64!<"81J)"1 IOD;NP M8"3A"V$IXSCAU3C(C;=8Y CJ":Q97G<6I76,/"A2>B1BO/$MWM5J$,$FP/98 M[!5GTJ80>/]X0E&'/(>X 5L@NYJ%!Q&PF :QC04#:.C JX'H*'"T#>2P6/LZ M&?&O8;M:NFT43YP$TGI36,@/>?\9;RDNIY)MV7_C%\5%2+S[$ALU M08;3(!DXJ'D *#>^@WKQ%%FT9(I$7,*Y$W[G<3( +NL/TK(\4;8G8E"LSU7+ M8M5.I;6OM5YBJL:*F.6 ;KW;G#AX-]MUJ>,XCU=_8@7YQ>]!KF\..D>][@A<-4].KFX[("!<'H" M?_GPX02,A.Y'E>?+L5S1^=GGSL7G?>GGTXOK[>$?BY+,SH&X"J@ M?2I\D%MLAAICS;O/YQJD&2@F%#,\PPOBA6--R6C"/6.TH&>\1SK-?,=9;Q46 M29U5[J&BJP;.,GP1@^V%M1T1AP_V3-*]"+W.^ZU@S>Q5J6OT5I32Y^7SG,[/ M_SH]EI0V^$F Q*'OY&9-]DENJ83"8YR+9!0.0;JI=W,1'7B=MA[%O7!*3@*HW%*%Y[*-OLN[1KP M@@E+7YS&!\B L_44]ADS&J.:@+V\0R;&.:DI/,'DBE SOR/.@([Z/.Y$;MC( M#:,&@&H*>,'#@Y>4@ 46B1@5PF3@C]/(%8N&XB<:QR% DD!7C&T)U',!0?W M53#X SM)\&U]@#Z?J2LRLNFW2[.L&NB9938@_/8C]&$9V%;"0TA%8*E8C^<) M[11NL\<)Z.T,R*^:O29)Z"_\('MNY@NP*,8S$C!_/6_FJ_R3 @A _\DM.G)\ MU@V#[8:1 M!B2JD ^R0@-:W$D*J.'YX9FSB)@.OHF/W\TU!!SI"!U59,1NHLQ'.GR,X(^])IF,V27PG M)I\^'2$$\P5L(%3/3TIQL5SI?'Y_ENO$-'D 7!>$L1@E5PAP5.+(Z_!7>,[F MO(S1+F2 BCT+X0('S]SU8O4LI'#QJQ0SY:=HI!$RBL)G%-YPX4.&HQA^$$(3W@7(5U5"X#!-"IM%L M-)700W#D-/? VY'G-]$DQ^*NZ31IDN98TKR4Z#:>Z7GD =7L4;61VR@9A!RN MI1 Y!3$KT4EF:8/H30W_,FSR'.*<28(-L7G7.7J1"$<1 MROJB@^@A9K'!+K+,\J(D16QXF08-6F)S,+9R" M(LM"(<;!&2*D<\,%+$<\&4UR=LR?%QG[=A%+A-,@,)!P0( MFGOEL,-X GZ6D[ET<&YP0= ZQ>$I8+8C_$I/@^<#!AD&3!NEBBOA,&4AG2T! M IAJT62<1N4P'!5A\*6?_BY\H]O,A 6/4/P%P41=>#A&BLE"^ 7%T#ZOG9E[ MHL&]+S"1)W%*#D@B\*?,4RH9_DWR0:2*&J48.8^21^*/0!2B\1RTWF)G#O MH(%E-^CP)@.G0G] MW<=FC7SY// .9_" .$5 %)W;K+!M(8B4^^'4%7/$TF!O:1(B1JG"Z*>$<69I M@*45XQ2D.^&4GF+=2#P&@'*)EJ.3&H_\\M)7_ E=0Q>#.$D*PS0- M L3)7(S4-D1E(?\,\160?@C$/TIG,07 4>EU#\0P1UFCB$\7<%2.&2R^C2<^9Z#,R4\5J_(,LFBHH<1R$4P8J"H=MQ1,>(\S7 M^D^:(/+$;M'^;RSH:C G(K\;!CR.Z>&7 ML]C<0JIVD410>N&PI:RN_HC;M2*V=.QC,HA7-N!E 6D@G.=IRBG5H^.C++K= M$+F[8X:4QT/@0&JB](-_^U\3@ CI9='J;(5__:N7Q\JRLX(T ,X2H;BFO/2UM3$38^?;8B.L^P"> DD?+ MX3$>'2VV@U$YR:5"U-S2X*>$5@10/K!7VH@P#$'Z,(S\CGP'JY,%FT2<[>'P M1689W!91B,]U[/+[19ZG?$A=S7O>9/EM,B^F\C2MIK'* M<79!Z*X-\G+!"EYUXD9@KXQ0_;%?S)ED+L49VFP\!-NNIEIJ@P M3S''FPP:9>.3%X8X(7=1L&&C7!S1A%\%O'N95&J4P_[EY'",K3@!-P[0U8N+ M7J)LQ"U(S*&(YQ>'JJ26IB Z\8Z9_2];&\T_+P!G"(]O1R$%K<\?$P<&H<@3 M4!2-)*Q-";FC5-#DH- K:,:)_%)JB"#=^VF/$DV$93Y+E4WRD2\/)A#:&<4F M\^F\N4[$3(A$^V$.E (4:8+3G]@C+[KY!;"[0 ;/DHSE+E6%_UFW/P6Y6%I\U>8&XS5YD*9!_V< M<7CU40$UT5E2LD86C-"4\$(G/7F64LZW5B:@G3$]8S\M 8(#1UD?3ADP0]%\ M%TQ\-Q-0V+V&&YGHMQ6$NCB-N4 M"D^XA3Y!7_RW "1XN"A)08F.^539R3C=4U[QDZ7;.61%+MI%\16.A9S(>+P4 M!>%V,DUIN3%7HPKK_#,L50S.%"B43+#&8LJ[(2Y \W"J;;9.59.<'Q<14]$3 M6@0&@/1@Q4E (P FUO2"Z!?\%$P;*1/:K"B>$(*6QR!W1OC,ET)4U2UCT">[ MEL[&2B/NNRWO!<["K$L[?7>D5W?=5MVZRJ*NLJBK+.HJBS\UO:ZR>%B5A557 M6=15%INNLGA@CUWO\J)S>?+Q](AGW]GT+E*4(HB./Y2[WS%\@T&.B/;3 M)%CNF$B\+!_;KY@S& &\^L+_R^- (Y9@;H4GG])*]QN\&%L2,2Y\3T7DI%12 M7R2ODJP%*-T!['"F\#R-"F6E S/+YM9S/T071>2.Q/&S_HCL2*7 4WQWZ3Y8 MLFGA_M:UU:S+&870^M=)Y]/EO[:$,SIIM$!T'61Q@CF45G 8GB^Z;K!NTEF MR;91HEN)C5"=N^7U\C(4[@6Q49_/6\E6*7H(*,:^14OD;RP["8_E[ M\]X'/MF'/RZ298QW7;)$= Z!J\R#^7R"1PK:6>F$\<> H;,WI#]$3C'M42U' M'\$/2Z\T)Y_YU%Q8L]2ZE\<(/GTZRN.=^1WH,RG1WL!G@9M#J8?.%'> /].( M1_C+2Z0/SRQ0B--B@SPI =\_XD3Q*QU=DN=UBT_R 5S;Q>RK-6!G16R4JXTB M'),G1RH81@Q/&8''S@T1#C6>6%XVYV0V'=R8"^WC>O-O:9(/1<\/<6E"RT&H MV7EN*=;S'6=]Y9@%"H!N?<\O8L[K#"(0_<(+ ^V$ N(J)]U+%GQ)&T723I"' M3"W8QJD.6S_"036W>83#Q/]:F*4X ML@;MF&4W=3JEK-'Y5M=[ MGWL2<1CYF#7EJ86L1S//,OVA-^5L&2'ST4S"HL@P"S[C4\K\RRI6X[_%?-XA M?$-MMO-U18/AF/I<@;%?ODBJ\FO]!F$@BCMYF(3T?9Z4R?H>!=W Z]OB2H%\ M12;&(/"I)D6DGX?29\HWX:M*O@^^ U[T+,8(<."BZA_S,9)HZF&#,5AG<3P1 M.?H2F?<*8@:X('!M)JR%Z 8MW(7RFE%ZR;#PK!A8HFGF=Q:^6*0*7^%Y-,1 M(30P^9".B)Q9792Q H-4K\.OBX0)I)^2 M4$E@<#I#CEE>8#>#7ZS@B=Q4[BZ^@\8I^KFA.0I'DB/J,$5!;BJ!4J%0/@ 6 MOP@A@\,'L^P8'_^1).G@W6/FI*"QQ-:6KI--^N6B A+7.:>.EF=U'2R:=H&( M GJ;E0V0S"2/^"0<49*;]6YQ;9!-NLI&S CI&_#9 R$';EY5D(9=BD/EHV.+ MJ^3+JC%O%REVB,-8JA]>#SSB8ZQ#YJ[>3DC@W.722&=F)%4^0Z]%3BKF>N6% M6UOMDJFF;IEF6S85U6IOHU>218RVTB?)P_[MM5V2]%Q/Y)#TBKO?G\4M27?[ M2*>D%-"#IU?P2%2CP@C#.*LAV=>3KL_)BDSKZOP MZ_J3NOZDKC_9S_H3HZX_*?ZM*TGJ2I+-5I)LS/?-S-.->;Y7/-11&(ZI;U>> MQEC,\KLG[I>Z:>E /&R*N,<>G&M%7C#PN ^3?C^-G0IOEU>)B-%XY0TLB1_F M)MG=&VMR-ZL\U2^;%HA%T@(\<[G))3!OX&AKH)!25G(ACE6)J[7BCSL1/SH8 M][=M;*/[6ZI>V$X7N,?&B0BZ5:;E1.X+WB:\8 SR^ GQ?81+I,U,P%T[3<-!N'5![7M)P;>8271M7LEZT% M5CF[P1BX*&,O-1ZO'7-=C;CASRU-,U5%5BUK&XE[^>#[[2'E//M>7*M;G?Z8 MO1R DW/U303+"5H'=3[T1Y7&(!+LQ\(D?GO4M2!(G(YXOSCQ>=LRTD6)7+ M7L5:UJI#BV:5K/:9W^]0,M?3F7.BLP!#-&7K.VN5$>5;? XF5IF14N$-%==8 M\V5C>L,GX8,T+-V*,'.)]*KWYY3OF"X'OP8^N^&)2#_MH:&B-8.-W-G+&)2= M< Y*N5=%K1 ^>4+R?8BZ!TYXS"=U\.Z*<=J104=BQ%E^WR\?,)8-6,355KZU MJ+A!M *D>L4(A@PSI:E"O(Y]D2@2&O495Z5_:$TM)Z%4XV51:?7+S,U4Z4B/&.SZ)+],:.[/ M8=2GH^S;62W,K#A8ULE4"E>5&^I>GUZ^ 7=_+,9LBDDBL[-I^4C 9)%A9^8Y M 7 8CGS%5J3L;B"7#VZ9]TP3^I.-\O&:I0%4-+T(;%WR%@CP0G"*\C$I,W,# M$4ZSO2(5W26P!1RF6PQIG._M$VCP0 :G;M;Q$J3.E'K.+I*_+*<,A,.-J(W@ MMXG@O>?EQ0 8?"QO/,.F&8SR(8CCC!IGBBFR1L=T4JN?7R\BC%M1>:D8:>#D[2&G*P<_V^'K/,1JJ=CI_-Y\6+)12R!)FB5"];A][R O5'<.3:C M,,1CQ=>07N8BAGDI+S=GTK&UXN;%=%SO3>J4E:$V!ZO9G5I@MV?7].6 X//7 MZG*9NERF+I_YS7OM>;Y M?#ZJD)?E\LFHKL]O;FZ4!O.6*C/R2?G\"AL>*.;#]/-I#K@9/^WCB[&LY?1R MWD7CXQ7XQ-8BIP.,%J"Y(F[XG#XD>;+%1JJ?)TG36B%"^WTVFK+2>W$)2K*9I[;&%M" I.?17)JM.[H(\SGX2 M]+95,+C@/;Y8'R 8<^: ]^#:IL[//I]K+*7;=1S&/.]=RD%).'X+$" \L4RR MLSS"OMR,%?F)B_/T?N1\ZO6B:!?S=)[E(H96TUAAJQ4^*Z) TIH58@D':8F$ MBK*RD?SD"(]P[UOE-?VA-#"\A(&QAE;<6/$XMO#X_W:/\CO81LEG)ON1B&[N M'G6KCZ#N^_&VA01LJ :2KV$:3T.\*8MOIV*OAL')FH;\"EK](7#90N)0&DHF MW3#DO@W2;1-P.*W.F%7X>&@*Q**:$GD3XE"&D (3>_W715S7CG7.(L M1I8>+7X>#*(M%$ZJR8T<37U:(R<%41K,J8#2GDFO+)3GYL+KJ435TX-P*V59 M2\BR]G)9EJ6/JN.0/O:DP7KJM8&9#2E23\RU/#8P4'37U\ M^&%S";;3K&:G[.J64Q'%V%L1V^>T*(6>-$D#_2*$S;+0OYB%?# H5!>RCYO MY>>JG(ZX^3R],+T MY7ZJ+..YY,]BW@>OO'.P&$ASQ#%'HB>_2'TC2K"HZ4II']63R(54:K MEQ7ES<8Z.;GCP<9#^XI+$X_*K<7%+#4.E;1RT"5_Z+J:WP9;HN5@G4!T@_RA MMHME$++S% ^/&*5+>;%J?.T,Z!^*6;P$[Y=XL&?-__B'JIK%@O0F4GY?!M9S,AJ->*FXFUZT@0=PPQE!@X-C4YTH>A/3^]A$ M;];KRW#L.\32U3=8WUOT=//&'J6]$R@_"O.Y8>FU(_S>V.QJP_A!R$HOXF41 MFRE52+&V[F6PHA]TM?N8^4+P _S*7U^DU,EK>&]**_&;MU4=I^UVLM?^N#-*DVM]3 8;&2SEFP]PV8M[6&K MW@O9U8HT]JF:8@7ALG?E$S.-!VN<;J;,=!\ ,=.%<\B R/KDA>7,@[F'#(ZB M\UFT]V1-T>*VI(/+3*]52S1/-T^6)9+)+L#JC^<[_[;$E:L/;IDBB/%LY\=/ MUX3#8THCYH5:3<>'0<=J3<8U&>\^&?,>;_5=3\^,5OM+:7C0R@[7*BG M7NH9JNL=O)+IMH_X%&--XJO&\;/*R;E7+G7(]Q-#:HVA+17P5<=H3\U'7)KYH$-NF1[#F&E!I#6XZA!T9A:P2]%(*T M#6+H$-S59^B2VT]C3ZFM\>U&T+J"HD90S4$U@LH(6C=L7+NS#VC'6[.#>&]S M-DO:[?8_9U-]<$75-M17E48PR=;AVP'NI&/ XTV\*Z2SP, M?5,3U1[O83P*+[OAP==<>9!<:>QN"J=FRIHI]Y,I=S>>7?-DS9/[R9.J7&O* M]9WBA2G3:XV2YF]Y*[6KI@F]>N&5ZFN8LS?7US#OUEB\^AKFI7T:]37,]37, M]37,JU[#O*92??&ANY;V(&VEMYHMZV%S6N\9NJL^<.+L/7-L+?-91L.J#[N_ M=P.;59MRRWB6H;L/6_5>R+;WU[IX\-!=N1ZZNZ_#5>NANV_KH;OUT-W[_(]Z MZ&X]&._^BI=Z6FE-QWM Q_6TTIJ8:V*NB;DFYFTCYJVU, ZA^^;01^_J]8"5 M[4;0:_5-C9QM14X]='K9^[>37T/M.^VR!79:C&T&PCRP8Q= B.:CUT]YEG"M3F^(NYM$;MTFXM.\QPV$B/8*JZT:J?N'U'KJ[MZB5GG@+6OUU-UZZNX. M.!'[/+:LM;O^13U+L&;*_61*U:R9LF;*FBFW"B8[',VNF;)FRCUE2EFNN?+Q M4W>S+3]^'.YF!EU>#ABA0P!U(F;D)/X0CD%"C]" C\GQASASB]"(D7AB_V!. M0I*0. ,ZZC,"7_,#XODC..9OYC8)7\Y))N!:5ZPZI%-R0Z,IP34C']XP)3:- MF4O"$7[@AY.8>/#],(J;I,<8P="7*K\[HA,^\@J^.@H31B+6IQ'"FWAA= L_ M2D$8_L3?^5P?WN[+OZJ\(S8+PMOF$G O&Y7IN__WRM=:5+8L73%-2]6UMFM; MIN9JJJ(Y+4LW:?N[8IBO7A"#56,G!96YS,%A6#@"&9B&1?C4JS]/NW^=]"YQ M("4Y[9+.V_\ZN+HY/W)Q<>3[I908"=&:IN?8:=PNNE,^I,X(9HB_M8@ M"=#743B$;4Y)>#L"RC&LAF7H#:MEXC*=(6PB#B>1P]ZSJ,\PZS,< G7% Z#@ MN &4,X;_ GT@L=#Q. I_<0H'2E2MIO8W7,0'J@TG"9#2B--8MD02.C\+>L6M M\%7A#Q=()'7$QPA>_\WNS*$<(N"P&D..,B(K')M<^1F'YAR))! MR.&>+@F?-\IPI"2Y#24^FS.5 KA"0.&IG)=&@ =&HQ%\$I/701C';PA-DLBW M)V*L;\H6I=TY 8UCW_,!F[A,05DH\N$%@+YPR++%8'LEEOE'3&:&9Y*8]7'1 M)CF>1-GYDOMGB@IYC,-%9SD2Z"_LCU#Y%V#ENX%M_ &F'@'D!EG_4OH$[I/% MXHFF3FSQ1*,2"RBQXS$*I!N0T8+,9Y=!K.*. !P^8&?)2%1R"VQ'QA$(^PC( MC;@3#NF%]P&\TB-Q$0A[Q-?PO1K-5K%71"-"FO["'08T%1I<=8SZ(;>AQGX( M!F@ *XDIA)GL1WMIY(#Y4[)6\F-4X*+'QLGL:7:&!XNC GIX*0:JD4I%?0N@ MY>-:D)<*"LN%'M#!)$@X*E+2#T<@]SJY5 ZF#52/$QL%58+O1)J+P8 &09@ M!,F&F\PD,]#"DJWDKYQ1_,#Q > 8#/P^8 + 68R6(>R&!A.:40PL56)?3K,Q M6@FCV'>SC7-;N&0&XU:I"PY(C*8(]3RV! P%1&%! 9Q?H!*P=H/<( M$9,7ZX!8!2[HHJVODF,_AK."J)L(?1:59GKR1UKD9$9"%\ 'BR^5IT?P#70( M.:?"+RX;H2'W(0=G+^?%=9V%%%[U/2;9F^M[3'9KTGA]C\FR>TRL629;=[3T M?MUCLD9@I"7G@9'Z]I-*S-2WGVQMW.SDOR='5Y>G?YT !L[..A?76V(H<8,: ME'AXRQTWKNO3:%:<^^H_V73.P?!C$+=@*6>GV!DCH=5J&@^\Y^7.>T/TIJ$_ MS$BXYY(3]>E-#[[9U4R/:KV4X7$4(FEOPY-/:R(EX7AC9;E5*:S\1.T=O4KB M-0B1-&@#WA/[Y;!Q@MY[&NQ.TSJSLL)!P._3W+<%2[RT M)(ZC-=KRNK."UP+ ;M3ZU22\NR2L-'3M@=-L-T'".Z??=DF-?8PP*3V.0L]/ M5NAHW\'&2+-AF'??8/%\I+M&E^H.0K;5:&EW#U*MA<*>&;TL"'BI4I^-6)36 M15!WZ(_\.(EX;IJP7V-,B!_:!/]60VL_T"[<(NMOSY%D-,SVUDV)WSE1MDL2 M*RWGF:^3K"H0W$_S!_ZMC9_G&%"N-#136S:DO)86^V7XG%>72!^8C:,T5&O= M85^UC?/2@LG0UK@[H;9NGK#H<$/7D[H_)G%2%#27A%0W'$D?.YW/9,AH/(E8 M3A=/NL]6TUAAHQ5ES!A&E+1F1?4/]L:)$BKEGKK)G38BE(9IFK5Y]BR05=IW MCS"L1=Y^F6@GS3S1"I(P[$KEH:I4+N*U M#??2-IQNKG&E4G60=J'>O.<^ MDMHL?*!9*#?UI8F%6IKLLUWH5@F=U:5-;0'NJ'&A-%L/K!.O#<"7PY&\[LTO MAVH!+HSH&6:]7B#@W);]K0=_C.+<%>TS_+)IV#O9(-/ MGW6T08W.>KK![E+(7C;KUP,.UH=9/>!@6SFXM]!:317D9%[P.\[>-GY2IW@CSOS%E(DN(WJ4YSV0=R]DQ![K387:]/VDXMW M46L_18?VXV"RA32KR$U]TSI\MR#V6FDN-C?N)Y?OH*Y>MQUQ[Y10]ZQ6VNNQ MLV$U%ZLZ]Y.A=S[?OD(C']F_'/K>Z5#=:AJUU;&>F%*:\H%(J1TT.YZ\Q6[O M]&QMEZS+\'K[8!R-'0PG;*XY;>]TVP-%PP'; H;N9O0=M[E6YH#_1Z#M@(,IKZ@0BZ';2!7J+E:N^T=VWMK"T#U(-QA';>VJD; MHAX3S-U))0UF35THLJ9(4W?:?ZMH%]JECB"U_2Q--BVK_0P=0<]TX6FKO?*& M=HB M2\C4;Q4KPY$/OL0H>2OA7YX:&RL$>M7'!WI?F(#XCF=@J3=- X'7 P_M[__/ M4E7YG23EH?0S$4J/^2?*.V*S(+PE7A@12B+FA"/'#WP>@$??/!F@EQW_/\$87'0>ZE\7D"@'$F #2&]8V$.@YH82Q@(+=^,B#\_2@B M.6!Y>B!V@I!OITD6*.4Q9"2P@UD(WYN^/%>K(K5')/"*$X0.9CZ\2= DE9-0 MJ V^,U%!%A# P^V C0@P&29*_)!7B@83%QY+2T81@B$@)EIX '.M!#,J@,;8 M!_L'4R^S&U@*R'3KNLJIIX()\ECKWU[-?#&-U,K%5Z@-YM8D6?S*OLR1TM2F MJCU](/8YEUUMXM,>A56^ON^0+PHPE:J2#V$T)(HL?5E!R3XBV9HML6!L; @$ M6GOEY&.ES36CW3G?050P M"%9\MAM3A>TNDW_+L'V/XGIY(EF(+'$8?^U\^GAQD=_6^=WI\VKDX/>EM_7G..MW.QY.SD^[E/WKD^+1W=-7K MG9YW^4'@HT_7O=->%9'<95/<@U'?_;]7OM:BLF7IBFE:JJZU7=LR-5=3%@(8>:"E2=*+-Z"X\0B8;\NHP-R<=*[^@1_./] SC^? M7'0N 9J+9'"/:G^FL_(5W_H)T)USOYE\Q^EGZO>]*!Q6EZ2\W,GNMBSO*B)& MD_T(C?31E)OU^'MR=[H&M:1";FE,_M":+6+[08#VOS#UX5E8E?(:'FY@AAX\ MUE;(,'TL>\D8C-&(3&%CJ6':))4E@5C_(PI_^!MQ$/G,J\I%0_R%Q1?PU3A> M^ZYW7@[*IC6X(;,EUZ,[JI+$2R+F!>#KP)'_4)M&#@VN*B3LU^I36-6=Y-". M6.K_##&C"7LLH> ?."J&W?CA) ;G:< "%^ V"B-^V;:X?T$VE&8 MYIV9:;168-1JY8A#D/RA:*T%3*Y$'_AMS. U &7Q&&0+^-/!5* \&X****C< M!M *>+=P[A3G\23@R.8X!(T&")GX\4#@$0DO8#RV(E#E^3$X*\4V@O"64U7Z M(M!K $DX#Q 1T!=^ ]?="<1=SE [\SP!6-Y2B^=:GX?A#!GD < FR,BQ"- M)EX%<@$#//'$_H$J"P4#_=4D&/KKA@ "C70<8'L1F(&USZE:TYMR 77D/)1C MN#@W!=99O )I^%4,.L**8L=B__CB5#KB6UBU4@&]8^*S6T/=@6SPS!%R";6(90W!S0BG9I+F=P>/K MRRR+^\OQA>'[\!VJ_9D^),XDB-G) C4: ]V"K&.Q.4COYA>']S.X21T*)576@AGBF[/[0:IY; M!]>%',U\HSB)0MA0OG:_-!03?[D%G%.'_]$&0Y:, 4M#ZDS3]$]"_2#S%:Y& M/J[ I6&*]$P8,'S6QO0N/GR*1LN('Q.D9\SZ7&_RZE'^-?%V"KP!DED(Z]U) M?ST\JM1:C"IMB'S7#3E51I;(^VO2._F( ;PU,X*K JS](F&XI3JS.FPYPP5; M(GAF#>Q9/LW8+\\](JL4_>OV)(;E@/MO![XSF'VJI-Y!BJ7"P(TF_3@)@14: MX*W2 .4'L,HM"P*^#ASAQG?P4_SS$+^"/Z#.P<(;]*J $\$BRR7-[#?\)(]@ M+-ALRZP]+EDR09D=&+4-R$-@_#$-T+*$[]T 7/*("0HD/!B8K6!H^F,N2_CQ M4N%VZ[L,C/H8+/K,<4^! !+,G3AH0PJ H^<:71X[ M=WYY'7K=BQ;(RDO0GJ9'K_)^Z:T#P!_/=/CMOE1;M1JRIC[L6NV5.S0W>2EZ M3<)[3\)F0VEIVTC"A]!!N])E>NIZ9Z[DMNTCO%9#T\TUZ:X:P\\J(%=MRMU/ M)!F-EM;>')(.PG1\BB;ZNZBO B8[0WUR6WF8:MHB&VK/D:0W3%/>')(.P4HX MF6L]2(=*5Z7M#\R(@']K$V*[4?1::6CFXL3JVGS8S!6?^ZF$@,:,5FTI;#>2 M7AORXO45^V@C;'[P_ HW@^[?+/G]U)]*H]6NC9RM1Y)B&!N/D\R5JBI\#-8F MID]N]1H'HPVZ$UX_,%>+'>_@E=#J04I^5;&:M>3?=B3)>G-=SV.'7=R-"3-- MEEPJ9H;J#6T1XBUW74#-45K6K6OOMU(4MMF\X%5 ;OHL6_6/,M* M=[&!/AMJRD;N@<7RK49;7[>6JC9W7AA)[88LKYN2?6IS9[V!V[O4M&(V9=7: MG:85S5JMNV3MS1I[VK3RTCT-0]]U [:A0O#*4=^OLWE?\1LR<^(:F5M=U5\W MJ.Q3@T;=H%(WJ*QYV'VY4.JAUS/7=W-5@++].#[:0:=]I8+]_;N@26VVZBNM MUJMZ:VIK=6#OAY9Y[@OA[H?)%M)"JVEN6N7L%L!>RTWKDP^=\UO.#H[L[ M:?@JS542&+6G4#32/S92NP>J;SS#++4.W'ZJ;36M6@>NQ^:/3&SNH Z\$%<' M')H&E&L5N*:WK#;5 PV5E91@5.*66@5N/]4"GS\L\7JP.E!NZAO5@=O Y:/* MQL\=Y'>U\1B.WTD]9=:*?6W%;M2*?2_;(Q_%_3NIO5J;KT[<+8"I56'?ND&H M;A ZH$:$7>TI^5SL9^?O_LU15?B=)>=WY MF:@[C_DGRCMBLR"\)5X8$4HBYH0CQP]\<5DG^#[) WI."&N#Q\FP12H.X_K M>?Z(PN/\!GN^* ' .!, &EC<_HA0QP&M 8\P ,D!J(BYO]?F?L7OAZ/ROTV-):39+R#I-A&J$ KL6#S(75^Q$#+HO@>3B!I1.73N.,ITNQ^-"#OZ##G(;I9Q9I MDLN!'Y=?%S$O $D@MN%1)\'U\1\6L[D-"/J!S8['4?C+'\)N0("(ER4<7OPH M_$I@D1 ,W0DLR#<:3\;CP&=N*G#@!]@Z):,P&H+ *;_H<(A2WSJB7"C?!TP1 MEX%F (31./VC%X5#V&X8<90#M0PH6)PV8R/LD!H)[9.0 +0(4-(M"^!3H.F8 M.1-NFZ:A'%0BX20AJ<[@7XO9#:X2P3/1[)>0BLHRS)TP)*$@#'E#%GX7=P3/ M#6F?-;ABRMY P?O\ 4]$;!BZ+,"';8;?BB?V#^8D*2W29(+6-*@QV#B+\&V< MI,>E)7]B4QH:E-57M8!F%3RZZ6F7C:V.5&/8NO[SODBT)4 M657)!Q#Q1)&E+X^+9MZ7%L^66'"Y-M5DN'I;Y?*6LWD%\>I/LO[_YDY< M^G<0%8?M,\D&6^:G1#U SUL:W()H?_7/&2P.09ZDNS%5V.XR^;<,V_=XJR]/ M) OQ8 [CKYU/'R].3KH]\O[\_+)'.I\^G7:Z1R<-G)[VM/\]9I]OY>')VTKW\1X\7,&UP>7Q:=\6C1Z/"$_8^UM=D<7R 2!XS_Z,E? M0W%985/@485/$L-O#7([ !LM/2PLB7_PG0%8;A$!YP)C 5&3S)N2C?(F9AMD M9CXJEPW/?%!=:1AS0Z_RL?OJE,#U07""!Q4"HK,WSF]M=C]W;6+E-^.B\1CL M3K#L@ND,J&:*IA%)\,4;/YS$Z:SFN&1KPR()IR\X0F9A+AJCEQCR86 'N[BS M+**#QN\"4=S0R$<"-'_>TP 4@A%='=];[HA4=(](Q+I AR&C.*MFMXD M:)+*D:74#@&[*J@YY#G.9R&(FG1.MY^%#-+I$QP;');S#^ T%RX(T(/RP90' M*AG-;F!U0-ZM4I\-I'S%MRB#?>=^?Y8CVV5.&'&Q^'8R@E,+-[LW(_&2NZL) MT&959H(4*WQ!7O3L-D-I#SAJ1GPNL:=$:ZI(2UFIS!^JU90)Z+: :YJ%Z,#, M=\UF.__N.CM8D]\W ]C9]N?9@RM-Y4$'3V/GJ!K09G.):32U?"4>QP- LS[& MZ5(9&>(1 +^YM&;4)!"%DR>B3;S9Q)04#Q/"50#%A3:4J'G MQ2S!]T?,']J3*&;#3#]B$*B)[N*J$)3O.*%1HL8%.+>*L]\#Y^5-O<6KRJL] M6,H 2><(@"T9P'?9FFD4:LIH)-%^2/XW 7"BB?753P;PX;S:;!D,STK J]P6+F\O0K*DOK+F(T1T6>ZR5NPHA9> MH#[#IAI:&T1BX/>WD:'0U#-;YI>&Y9\L MW?/GU?9'LU%HL/*"EQ,+!/!+E^;?N#:H^:U ]^][%XR'79))4UR,\#@/)'$S15F 22 M?D!CT!E(2Z&-M2?;XB@\F6.Z,(7U67W4+1&&CSLTTO@?"G!XZI26R?@/12Y4 M(+($Q,9[%H&]D59*Y$#F M%4]4!%9@B3\,69]73L![BM+R[8M>IT9OO+-T07[QZ,X6_AV\JV'3A MT89X(),B"*_4F>N7QLGC+[=X(!'JLT/X.?=OA+N$\F9;..Y.@BJ7EPM;2"UI MCP>S%%86WV_J+;P\\WTP;\"Q)&KGJN0UB+TE%OS*\J M-K:&#YX:+*5CC5B?SA\+%H@'X%/^)"(\D&EO>"",T+'C6 *@HN)8*R*T$U;= M.E78A/MKXR+D"ZR;>G)HPV'I\L/-0"SC?:I"&K4NI*D+:>I"FE4+:;;?[UWK/H6US:$M\G67'_3A*5J\O& F1ZLT MS2)%>SGO_"WX$WD$=U_]P=WJDUK3S/7=_WOE:RTJ6Y:NF*:EZEK;M2U3HH-?RWA%HN9[R3F1WF.3=>1(,^$N9Q4JZ0 M,$V31E81MVGD,XW3VI/8QR@K5@M.$JS X21UU>PU17!4K,(FW @CMX,0?$$: M\/3IB!-($OGVA)-CMA:2UD<&7QM-F^3SNMO("L3>AR$B*IBR\I M@:*(= N@-.9"TD7U%.)W,L0R*M&QM"Y7;HYRJ^E5:!N!5Q%TPNQI>EC>/I83 MHXO^Z$R_D/^"+F83=. M51H(,#<)$H'K8%?5I9:486%UU>45SY_'RE\'Q.;?$+[)<0 MFDE>EL%U@!> D)C0K"MR-5I=;I(T4^"L2RD[$VAJM9I&>_G'6S=*SE*?/GS% M-[N)\-5+S+"J'G;TX;0++OAIYQ/Y?'+QX?SB#!WRO9M.]AH$0)H(Q *E7PX; M)R3KSDB[H>.UAL9N(8+K>7/UO+E=1&4];^X Y\WUJNYG>9J!:#+9!0#\\4R' M+Q\ZPO=MU:F-AJ58U7+L:YABVB(#:L^1U#;4S:'H$"R$^F-F[D>$X5/S-WD+0-; MN<8AN(K=?*Q#ENB-<>!Q.H6+C=P#\P_UAJRN&YVH)>B+(TE16AL6HA5WB]15 M3'45TPY71NQJD4OE^,G7V;"7NF!IEW!9%RSM4\%.7;!4%RP=Z&V.FC%WFV-] M,^;#8UI:4W\<)^U@BF:E(HZ]N\=159KM^N;+=2#VNM5LKV7B[H>>>>Y[8^^' MR1;2 G#/*B;7LRJ=W8(8<(_\2.[90=VR!4+1FJW8@UN(/N:D=J/]PUY5;M7K<16'?;JJU M=EPKX-(T#TXWEB]).B#-:#W0_5C-8B MZR]4%<_%V>K;0.K;0.K;0/;D-I#_O[UO[6[;2-+^*SAYLQME#T43O(B4O9MS M:%G.:&)+CBA/=C[M@8@FB1@$&%PD,[_^K:KN!AH@*($4)0)4SX>)3(*-OM2] MJY[JZ&X@NAN([@92OAM(;320+K#1!3:'4Y3Q)6W1LAK3T&=7Z;/3!36'5%"B M"VI>6Z*SVI57U]4@$>P_SG0P>]G)I8N_ALN99Z\I?=RRZ%RVO? M2?%0":5=.4(IE\B*_=YL!F<.!V>%XDEJ["?:$$8S*S)F%NB26\8\K!_P.%U% MA@OT ;[T/7/A6QR:C6/2.L))0_+ ?FZRNQO^+&1W.$H SP39']G6,E1[WHG6 MJ*[O4[D"_A9G!,_-K2EK\':"X@T6V)5_PA,!F_LV<_'A6X:_"N/;/X'"J<>J MX5E1C'H2"-3"_GD-V6-QH:Q#S!WV GL5XG\92/?Y'",'?'M*=D)+&I7)1I+* MPTG+R//M'EGBRD7]5VLQ7/@ ;N0"Z!;YPEYFU//Y&W-I%P.X$D[JP NUN*UL6<9&CB(.!C ML$[Y3OIQ\*2WS*TED=JMZ&EIS1E2&^^IR5\(-"-Z7(HWP>(V;._[L,;BB@"K MJYS)\N4M.+J*N/QL'!N7L!&@L3V8XR1VFT8AF)!UZP,AM,'N0Z8B1O)!F B0 M/$$/H:P-2[NQYA]P\5@M(<$=\"&!H+SL!!Z^P!&*OG.2Z/F7;KY)(^ZBJ3COT6/](;L0:H08$!]9Z7,!+X. M_3'7@V1V1ID>T6MZ-R-]SF_)N"GLV(QB;F+=^5S2\+ZW)(JDA $_V@O=I(LL MGPJV<#>;)W(QR&$+W_&BTI9!NBE8I"+':8 \<[RT*?P,=AZV,AF'=XG^^IOL MU2R,%T54+ID%BG/J'_\56T%$37#37JF6C0I4727VLX:_SJ[^=?'AV#PEU8"? M$'0FKI;LK0F\=@*62 -%*^](;9 3BZH=[#E8GFTD[8[!+OAF^_?8H3:E!B3A M6O3<_9(W ?@Y&5@KD="NV/=2Y,\UNVC?B^?=;_:2@> (BEHQ*RIX$]K,V11( MI-U'B;2,S9-2ZVFSG1+K(G#FH.7)0DTZE8.YXZ+=@J9W%/C>%#;#9G/QX,X9%SF(%:2*ZZS-E?#N(.7=S81BGBHZK>;I,U%%QE[D--%]A"8>-S&5 M/>@T^\G,E<,7LBL_E"23U,OCX0F03$1&68F349/6BG0C@50LO.Y!.AFN XZ$ MW30^RN%\.0&:'A(HPS;C#,5N*$(F<"C'R9@N^!1N96AT9P9+'C3C5=@N3UNT M8L:*[P$1R+LB %+J9 M%+,I2C.'2R6@J,BA<(<_F83 E;!!0H:,_3!ZS/Q+[;TB,^\I_+LVQO]2=,NO M3?<77?SA%X[-_J%O-'I;\@<-Q1Y0 $O2)P3 M?I;(L_9V1F>AIBYER*B<$OE31EYS0JFJ.S-5MV!+KV:-,_,X,UW^8P0+=.:W M,;@"."&AX^3TI8XUA([=D'=TCK_.\=9X]_-,IG.\=[YW#!X7+!$7KGA2 M?(I3=,4\LN7">+'P@VA'QMQ^*'B(=* 0"\:I^9UHN EM$S6:JJ^^2=A6/6U, MC\H/DC_]JNSLSD)$&^%%OH;PT?H-V3*.A B.F3B2>:($DM:_3E"@O.&A ),/ MK ^ZTIF +>E%.>'['%$C:^WTRH2/GN1H;WI]OR\]7.LLO8>-3L?^GQ^Y5Y:TQ4RYT"HWJA\0]F MN=&L(@1SDQH&R95/?JKR3D@P*:<(+W0P/@JLFW\<4^0,/YA:'KJ8&.?"4 ]P MK$T_B^<8$8%A F=L^'//.1[/+,]C;FJ,4.X?/ NR "TG(J2%M?0#SJ^+P+_# MW(\0J=5FKH,96&-8&T6K9C2),2:))$$R3M4.9OV@7 R3%#;P?&F;@%GPJ.)] *#ETU!4B*K MH]4R'C.7\7\C^\_\<(%+W_RNJ39A+EU(?."%Q,6E;A\O+H>79Q?#3\:7\^N/ M5]>?,1QP<+6I1R A.T&$H!]'[-%E+2A-:RY'X./J=OWU>A$=;7Q(57;ZFKC MUU9M7-B^;S?EL(6MI2NW 3\^T^*KW4^[9V[73+MT(?0^>Z%K\CUT\B77O_VN MBC3\&BKJ2W6J;&^VYD)VJQ[EM5L;$EWQ\3ZK>"Q;H7^8)[2=;-CA,;T*LW$7 MF!H/T5_!GM2$_DYZVZFE"AE0!WY"G?T=T&NP#M+D_B,L?_WYE5D(1]W>RI*U M=5"9T^GLY7!>39>'@H0,+@4*$F+JU^3AL?ZIAZDOC\P-F$9;,Q66:+NW9'*5 M++HK;"6ZPNZ##B]CNO3S)SSUY4V2/X)E5B(3)$0X+(&1PCS[E7F&;>T85ON MGA16UN[AIG)")GZ(C+F5-+XS/T"YL0.945]_I;MI-$E[E+40&C7V+?6 #*G[JGH M0C Q?FR?R*?5ZNZT/#)TD- (>UB!UK"!T/#G*3IP5X%%%664ZEMZ3WG+U3CR MZ26G K#DT*CZE8-Y$A#]9I1NA<:/W82H&D86998&1+KK)&17<="/W0$"<2%P MDC+78H3 M.Q^.OEX7.*K[@S-)P: =#TAGSNE%I$^$.3H*$]S[>+%P)8Z:)PERA8I"0G^7 MGLW9@E1#E58YXHD<<@WE1BS @,B=:; M0KFM68^8I.R$(KMH*1/@?9T>?C_M2F8+U;W')1!ZD^VHO%LP&4)^L;+,6G(# M4*+ S!.T%RE>+EEDG%L! C&',G?R(S::.P-J'\5U67'#(OQS@)^ $G*B(QEP_+L1\2A+G-LQ?!SF 5XB012A,3/$&"'=QO+ !^F MXW'$QY # "EM(6!C60:B+($<-^'I881\ MX\-FA^0]1_Z,/6H30+*%0] ]?AQZBE)Q,'IH.H6YS#QU:8FL[.7'0&Y0@['-$KH,:'?'9I\U*< MT!(TA3\F^6 W2(#AI+)\EH"O$>R93WLSMCQ!]\GTETASMH,8BPVQ!_"F>R)F M :;XL*F1.[)BRI9#W0YE0Z_;.$I,!!>V031TG+-@2FV_.-H8'H9TEAN\ M]48\CF+"D1V#>IR2&94Z'\=2EU'/#61G[!Z ZW$"KMC2CH *X*2ZV0HT7;)K MR58]1 @A-NH)TCZ._(&PD1&"&5(&D1LPT5T2R/J67Z,GTTI%*/PD(46%3NF% MF5-X2 #B[M\A/APR7L#;*Y!,%F(<.W;ZGKW^,"L34"\ME2PW]*5L!89@060Y M7H;3);W :8B#EXII1>.@5!2Q+\V1TUL*0:,Q!TN^1;LPLH9%MC32Y^U M,:^$@Q'2[,1<#[X1QX$\ (:;^?K)ZLC6:K-D\:>_4 M]MP 079]I4@_+17ATDG(FX>A_2H.1:OB9&\%A_T\6_LX9&+%]_41M&IC!0+Y M!;>[\QR[/7=LVV5[VNVO'L5;1Q&&B$KX:VO7K2[]%>W?A2Q2<0XGO?CT)C")H=+U[ ,??&S4T43LV* MN8NW8\6SE0AAE,I2AKZ>L[#X">C@U2LY-AN=WDD58;+UP3X1P+^K3_7P3G4C M[%!]HG4XT4%;G^A!G:C9: ^V1)#6G2>>NODWF+&2Y(!@VTO,'$NS:;7!\/\VX].&4ZI*HG>6*GU!;AP4K?D*F#JU7_(3Z M>SRA5Q%O4M!^(M]@8#Q%RQ2'R/&,X1Q&#OTX&+/W",N@0U!;E(?NL:6Q/B'M M/NMCTL>DCTD?4X74TFN(17VZ^'C%06C";:_N7K?U;VH/NN(GI!-K]#'I8]+' M]*J.:9]JZ1&[22*]>#["JC]TJ/K)*CVIC_4@G]3'>I!/ZF,]R"?UL1[DD]O> MXVT%;U$Y-(<'VF$)6(>5UB+/<<.WF\TN=! JM^4_/D_AZ0:NPCY6;39.3I.6 M9_OQGJM7]*NY1W-/.>XYZ6K>V?LE7DV1$-:@5)H;Y._6Z42U-#QT:7ATHDE7 MDVXM2==L]/M]KK)BLGV M2PVK,?8UQGXE][4$QGYK7]M]>-#2&F-?8^Q7 ]I<8^QKC/U*$*+&V/^/?6#L MZ\C3H4>>CGJMKHZ::MJM(^UV3G7(5+..9IUMQ+Z^*M.46T_*/3G1I*M)MY:D MV^M4K170:ZBHU_U%=KZE)YNB8^MRTQ<^H?:FZ-CZA%[DCZF@C9[N M,?+B1I3N,?(RC:6T2_;2T2=]0-4^(!U\JL4QZ>!3U4^HK7N-/*_9]'"O$9$! MJUN.[$;<-+J#3>E9.VJU4-WZF/0QZ6/2QU338]JS9GH- 2K=>.2IS54W[8RC MG;5:"'M]3/J8]#'I8ZKI,>U3+6EP](-\4A_K03ZIC_4@G]3'>I!/'M;MC^Y# M49$M?YVEF6;#[/4TFH0N;-;M25>3;AU) M%ZS]TQ-MLNRHW8;^LD9?2B(3Y-AM-_O8863A\]*DMU2:Y-RQM+$(=B=0?BC: M!+32GUBW0(EQM/J31V99GQ8I[6:[T]EY8XCG'+9<&XN2*/W54F3%$O6/]T/C M=Q,;$;2-CWXP-\S6\>\E8H';KE'AB!4,[3UM0;>?9;(2J\Z8/AD%\,(+X'V4 M-O]?;L7*_\^"=+%3=GP;,.O;L36!XWEKN??6,OSA3>84YR!/Q&SZ;9CN.OFW M[K0?D;GY]?CHSW5U'E M!V/T]?WHXL/%\/KB?%3Y]7P>7@Y_/?]\?GGST\CX<#$Z^SH:75Q=TD+@JT__ M'EV,BHAD;YW$:,2W3@1[-RZQODL6&>>RVB7RC>1&Q(,ODC*8_[3FBW?IK7[DYHX-"[:6F2*"]!#H4DP&\QG](@:$_=@?:]9QLUG3N(C)A+ MU>P323"3P)_#@KW(\6),D1'),J!>=&L@'27?OKU*HS=(&*PZ"D/?,6GNJ0'W M''5.S8K=CPK]F+L",'M$F;LNIM%CO Z#) ?0LB91]^VSHK'4?8R7+B]_SOCF MDUIQ&,]B;IPT>R5F5W 'BG+XN-,LB&K>6B'# 7[XQ2Q]Z:(+$_/^FRZ8K_@1 MO2IH_;U)QVX;0;HI@ZU-AU?VKJO-(YE]4 NGA$.HZZ& M<3%.9WW$N]'3UO"VTJ.KK>%JGY &V]N'<*_>A/727O72GI[@49$[_S77N'YD MN895ZN9_WVU8UNYXJ62JZFF8[K;1Y](;42,/\- .UVST.UNZA\]^O#I[3&>/ M/7OV6#1C@= ?.F5,IXR)@@?'NV.<2HP9LZ=H8Z!M4M1797T=Y7QZ21=^4Y>IGVHU> M_V3C"IJ:.K(U/*"]=T[44G]%F1YR>%%Q#??=G/#0PDXD:[OE9>VFVU CP_O0 MCG9+J[P>T<0Z!&JJ,L;KU9;5F[!>VJM>VLZ#LQ6(W(L[W\CZGN:F&4>WS&,3 M)]JR_+L.ES0O<-%3/?K6X:L5=CCG*?ES%LU\VX M.!Y;X8SXH7Y1JX&.6FU[ M2S'0&?C5/J&C3G<_4<57DTV=W3/B#W8'RO7286Q_K^F/MMOK5.UB= M,ENM2,HAILPN$$$/E8< 4A 3"=ANY,628TH>33Z Q;G6'[.+C$XW140[_N M5/MUVT:X-BT_TK[=2Y]0=6N07Z-_MU9!4]N&DJ)5^PE[DE[:!ZS/V6Z)?K0O M-["MW<#G= -76EGG]E^W/M:MCP^BKYIN??Q+M_P]W>,"XX47H%L?/W_@3+<^ MSK<^KHT&TBU_J]_R]Q#CZMA?.^^Q6U$4.+P[6( [,)QCT 8@.>N M ^LZL*Z['>FH;/:&>C\)-_IPGJ^6N0)Q\]K)1-WK2.=B*[G8;0WP4-W3V: B M7.?)[T84Z@Y'K\WT.#(W2%S4AJ$V# _4,,RVM:BA"'Q*6XO7;6CL'4E*'U,Y M:[V*]F#U:MZ?'R=BDXR5BL3<-TB8>TKD72.#[9CG>RT-"W:(Y[I!&=Q+':N& M!*O)15P-U<]#5[[,)I6S5M>N>(];GPO-(XN?>_XU^'PBS%G5A@' M;+M2W4=DU//*I]\$%'8)/:7ECUC N MO''3.#; =1]S&P!,!5\Q 5#]5PFAXY%3JHEO\J1PX$8T6Y=@X<$=\>#II5K/ M=+JOYO99)R?J:\[J7'/J8RI5YJ3OH9]]CW6"HK[RU#?3]3JF]I8]D[7!J-,5 MM:6H+<7#.Z:VMA2?WX->AW->0X&H.SYH$_&@C^FH5\7DQR- \I4T[:.YI\73)9N M'5*JM#:TZCB&-K2>;&AI5J^MN>?YS*GU.>N5L7 . M<(H'F)95S+\?'&Q DK/$%BR 5<_G/DQG9@7,.#9$1 NKF%=*F%XJ8:%H!=OF M^K>>+X7KR?E ]5=M-5)@W:;9J9_^JI&-I\F]2FL[:C6[&^2R[)#<#JL)1*E> MN$)3$L(4Z%.V[UK?&B9>M9J]ODZ.J_89M9NMUNNIH*B"7*&NKT^0*8^H]%+T M6E:]5X]>C]K-4XV:7-WS:35;FU9DO9R=4CT8T&<$#*V_"<:%)#703M&ACVZ9 MQR9.M'?PE1HRYQ%RIVZ[4>7SZ6Z@W&ILB.VOE#4K8A:(?((")H\Z/ G\N;#5 MV%^Q$RV-.8MFO@U"Z8[5M]CK5%>_;F_8[+&R4I]1[8W/0[307ARO_=7;!ZT3 M;;]5^GSV8U_KG$3*2;2?=B.NLQ+W?1MW&'E5S9-#PB*ND@&KF>?PF:=UJIE' MYR0^"O5;PUD>UG7GTY(2GP%972<['5"R4VTK96MD+6F*K]+:6LTTL_EUD?MK MP TT>Z50L38LI"0I:;Y[%!1+0_MI:+\#/*96L[5E.Q$=='WQH*O&UJFLE700 MD:/:>@PZ\JKYIP*K!O]#5X/OOG_BZU'Q.U+DCYBTN]GZ0Q-$FRV^VH*H9O>G MF[+\/OU!S3R'SSSM.FGQ%V&>ZCCJ>\M[_X/^@0WM8&K6E&4T=VCX<11&EH=K M:B3:_LCQ#)B*BU[ZBP&%[+(I:$6Z@I:X/-E6?V@C:I0D?VA' MVVMN&D]]F:,E"?Z&;D4D-\/_Y1)BNNUF'P7"JK2X=^QH)A:I_I"_Y&TK_8EU M"U(>I-_*3_B)_/+?M\&;7[)BA?Z/7]@DP])FP ZYUB)D;^4?[V1AI^/1YM./ MWLVM8.IXQV(N!1*-MHI_G4ZKV>)3$VI-O%E\W:2OPC2KZ:?O<:9?U^:/QN&NU6NVU\](.Y8;:.?R_A2S_!*I%#*#\9 M,RS5V-,6=,M7JJU/M9("XX47T,8%&)O_+[=BY?]G0;K8*3N^#9CU[=B:P/&\ MM=Q[:QG^\"9SBG.0)V(V_39,=YW\6W?::\3<_HADQ=>A/?YC^.G7Z_/SRY'Q M_NKJ9F0,/WVZ&%Z>G3>,B\NSIC&\_&",OKX?77RX&%Y?G(\JOY[/P\OAK^>? MSR]O?AH9'RY&9U]'HXNK2UH(?/7IWZ.+41&15$\#/23O0:0/>CO7%*79-+OU2(M+#-O06R%H3]VJ"?QO1/-#,N@<5P#JPR#>!S% =;Y M -5[3>-FQD*6&601.$#^L"!X?HQK MP&18&NS[@GDA"Y.1:4HV5CU&,.#$9>/(&,=!@&M((<7@#YJD-V9\5)@([R<* MK[]=&M&,&9$SI_JD26XA\)!SYT3+9N;X#X2FVP=$TT5=LZVY#Y/[FZ@<\4W< MV$8Z5#_%AK(%OW2\R/*F#LIXH'B&A.]Q- (O\H.E<6>Y,1] 22\#';C5T&MG MECX:RF?#> Q,%P*5AZ >6&!PK\OWPIFS"!L&L(K-#,^"C17_ '[[QJ=/A<'8 M15<9MVE[?H(O%L [/,\.GH,_'/@41HN]:(7= M\8DS'YC06U(F0?]=:-!H$\<#1G5 (01O$=L[ V]&'8_9D) *+RKR*35S9W! M9J%XN&5LD]7D#U.(GH81@RK_QC*_%1-K& Y_E369,"E;E,P;I =O:2PL9)C8 MM0(43(YOXY LQ"-:F3[,&D%Y0A)7L)MVP_ #OKLA2"QZ>QRR2>P:KC-A_!6K MH\"\8(Y.R.SGE,GOXQ"X$A8"4[Z%4^3L,1[C^9,8!H$Z=A9(S &B?,"K8TK) ME 1$W!(PE<^LR)C PHG?&">#]-^X7-R+]'&A T+2# D#YH;$-1@+/%O.9;2= ML HZLD7@3YS(X#8:?V$Q$S\H"22AA0\,CMNT\#U4542-&Y;J)G(#/T*RR#9Q"YF7AQF]KH,D(3&'- M@58;XG5(P/SU\@<$298NG$W@5_ U_A:4X!@8 <5>J16K*SWG[R5Q3,HTNVB; M@9BCCQH@_O#V1EJ-H&_'WXAI0=[1G%[*P,5Q0Z!79P*TZT4P]AKKE2MY7-YW MQ% 2LHTDB+O$![:D#_Y,ULPN4N /FMX'*92ZAR24LH42 H@KWT$<*'D(9.2$ M?AR,V7LD*)1*7NAP]55$%Z#WA+X%PA+I2_!H8G.IFA.L2'B4D_;:%R&1D> K M>EN!*7>3/D9\";ST-[Q"+!$71C*NX(4PS1_-1J??D7>SALT=0V*[6<"8,8>= MG8'*]Y#9+_T[-K\%C=UI-3"DW)*LG'U75E38,56?K+S]IU#.5MHJ/_::)\8M MGTF#$L1PRZWOC40(J>(3MM/WICX'WG!\QP8K,7*FTA^B!XKL;1*R*PL4UBI? MYX@MHMQ"#Y&_>P?$WS<%O/(52 M/$X\>G$LVI?!/:MTZH;0PT6D"JD ;E!._ M:X71L>,=3YP _O#CR#C"8=NM=Y\N/E[1G^:[GP60'W(!CI4P>MY;Y!K-$!9. M:@>#]^9PH;+E5/GT@-A7Y_FQ>)[,P 4H(*@XLN+2 :=YW"92WOY7#)I9F#?P M2SN&QWHNZ-' M#F,(=,3O$0LP8N=X$_" 0*URZ09:V0_ F%+DH0&V BIL 0?&/65RQD-5!B*G M)[&OB$05[//\,'V(DV>\UGM1CCX]A=7\BE8XG!_J%-4P!W//N>,&I>-A,),+ M]3A$HPX4%5"$/W?&QHS94VX(%ZI1%F7@-Y&%@,9@S6 WWX:.[8#R4DQ5Q0C. MF[XJ"KNP(YK&'TR:E+?,=<#4AED I]WY&,]R456>RK 8?\$+?"QE 5;PD8PJL0&Q1%#<) MI;0P.R'#;"*@]#=]D?X5415[1K04>U-I? M8Z(J\X 9T%,C%ZO02Z-(@U0W3C@&PN0S(MM!B>E\;8Z:](5KW2>6$_XZB_., M+QE;X0P?+:-1'MZ#@Z3HT\.EZ*?A@N>"#VN"#9):B\9A+!260$J(G)#1C?#B M, :SP$<+9H(W%^1WT-<;A2,R-X6/D_B3-J5I#%WX+)YFYD0NQLRZ$]LR\UV\ M6Z"$4,Z4M[X5V*EK)D/.>9% @85[CP5XZ:AH0WZOEP8[\IO+6X-&(KZ%-"9*P/G"Q<"GE0E#TE6?[024!""<'M"N%,D =:SP=?'7#;&DY!C3@(F,+_$M=<&+BL0+:"/X[);YP"F&U8M> MF?I?:W;O(*6:TEZT_F+M0VI38C3@F$H[**Y/X0.%YI3[9Q'N1'<+&;V1"8> M+>JC> %RPSBA'$^Q-H7_@^6A7-9)'Q^Y@2Z]P=>+(O7.^Z_8@E>"MV3 GN%- MM(PNWHNRE>-'RU;(M)25*^=?1L41PW4AT8,DY$-*$$L&^LD"MGANC9<%7Z$WZK@%7W@Q;2_WI,$Y M7^D5W$(U1AHM7#!V>5;CDY M)^2,V4X:7I*^M[C=#[D!=C]CZ,-;[O)O&3 BY"M263,1NVX_/V..9$&AY-E(WML ,2[<= M ^).,@J[8B886>PTAN>HUIRNK]+U5;J^ZJ#KJWHM75^EZZMT?57Y^JJ'SLVQ M_^<'IW-BM0:#KMGO#]K=SJE].^AW[$[;[(Q/!MV^=?I_YL#\X05-]*(]X"++ MQL >&9AO^2TEP25\NOC]*QSES;]I/\Z&7RYNAI^,Z_/1U=?KLX+3W;N+\5-H MN+XW/0:"FH/+M7 07'?AN\Z8$M7O>\,M-F>D7\M/QV#!HHT6>^+>#6US M' >L,#3!5D?AR1@X$W!=XL"3>>@4:7PGPH+T!=B+"S>& 3 4/'']>[+X, .4 M!TT3?Q3FETT@GD.^G@D>^:H56VT_.5TL'JQZ_#S+-K[]DY);?7%7 MA3Z+M(Y*47/TQ<<'>9X;:?"B;- MW5)'8/.5Q HI&RP"U2+11LG%$K"(2&])$6]Z8Q('([4G*26&0*4@M&<)((XC) MV_Q,^9=: >!SX>\Z8S8&WL0_Z2+)YDG\L$6, M!^I5=FYD6O'=NB(5F =+0<$P*BZ0[&WG?ILJ%&N99@&([)?@SL&@E#HF1J32 MDQ1GIY9[)+J5WV@F83A@OCO+<27G\0HHL!5"HDS01S @GC1^[8C0XYP%9%0L MK 7E6%+],D9\+?DG7$(T'I3.X=UU4BA2"&4B$3HTDA8]FIP,),/*!^"M/L@"PV/5I4$Y&! M3,BU@P=VKF&V19B]:8R ,;]8061<7#0YAW8:QN\Q."61E00^1'W]PQ,E1^[S8ZL!$#L.,E5/[8')TD"&.P+WEM3$LZ?,>R& M[5 P-?P9#1O8O97T,Q'DY/?L/YKKWM'JEG_',)[&0"<=D[\!J&,&]A+W(Q06 M\\GTPD*D7'4$IG\Z'MA28+S@@8H#%JY&(F& -7ULZ&$E60CIB WU1711+U[B M6F->U)9F1X-ML%R(T'P8QOP>([WH0K,]FYT@ZB[I9@S>31MQ$U#,>8D(%X*(3CG*F:0D MV$^TEDE+IT,B M2S< ]BU$D2A3"+#@P?@B-W.(C6F0Z+(J"&^VR 17D4+/4,VIY(!IN0.5G\$#@?(?#R9C14OIFG :9@;B(L110.$QJB0/[ MCMHZE%>2."-43]F5"77L2ELH]47()\494QU$PM<%V17R14ENF#*CS*N!H,4% MU"V+[LF<7\ I?:<:>Y@"2L(<@6&RK2FQ&<6GM>#M4NPULVRZK)M.T9P'<^36 M#P+_7M@98'OQ^M(?3]-JM%0_<*O%'/%-6>N"_P1&J3 M@V""N0GB3\1H(V=<@ZSR;>;RFB_IEZ3QPGQ@,:TU5^*'3=B0*-$B^=5D=GZ3 MS!>3U!2(,3-EXYP!V$X,0#GN@N[Y,?HGT@RXW+:9C!1Z)2>:5.3,X,2D/@*6 M5TA+%MC)X"U\DRHNY3EK/ Y0'"3)E&G)G.MP#XR7YB'X"EEJH*4)8&7)$5/2 MN1<7KQMGJU5_VT3P20*DDP)N52*)NG _PO2(KA&0NF/L\N1\8-#/SK%U/KTUC9,7N0&)] M=(QA9NLWMD+6&2$Z?TCG#^G\H=>2/U2^MX+.']+Y0SI_J![6,[^@.4\O:"IB M+)^M7AVEQID:"(G8>.;!I*9+]/;^)&;^FVU,8QZ@V:WU=[*@GGX MNUYG_4NWM8O,0;/3+6<7;?;=2;__/),M-VSE2^.>U*6LK/&B/GI:9O%<:U6J M3]S-PVY[O0HB7_S4E?92ZWK$M59;'U6<)#!04*9C:YD5O[J=:VW",8_V[:R# M%YR!OZM4I]\\ 56M7VGQ?NZN7^G*^JO==J[3Z^VX:VB!!*EEUUU-R/4BY.ZF MW1-?BI"W[8!;)WUTX8DR;DP%VDH?[; Q:!V[?W:W:_U9T]:M-3RAWNG^3N@U M6+1_6"[F-'JA\0]FN='L.8S:4B1:L'G*LQ=O"W=7M(K MJSJ742]T-/4(B&KV?,WLV3$U>VYC,^PUJ[+"N6W9RI!LZ5O%*T.*)KM%555' MJ5?(5(9T>FVU>GY-8N$&4C+9<+L4IY+#HX1BGT+ZV.OPW6GI;0%+Z:+[Q,^\0G[4.WVWH,5L!$::'4+VFG%3'($Y5;\]-+5M44CN4Z8LK[0 MEA#O$;H(!/%@]KIY(BU%^EC.&!,BED &P6/'7O;8%7N^U XCB3"TC[Q6RJR41NJP-$:BJS(R:X%'_RI '80 M/B,\A#L"_%C+:TC.!Y8ZCF1]04TK1&4/^ %#!)9(2U$L M60CTG\*D*P"],"D1S$,,J&(/%&5K!3BD"!V!2\['%T6 '![(P 4;.Q.'5P4[ MHHH1);> ?01E@\(^"X 0QN&""Q@5.I)#'! HN7A)5HSG0>>42?%9(O(4KW9& MAL5Z]J2W DDHU,E)9SO,]T.&)N%<%>R^%S1T2R.TV0P1C+"D-=^"G4-4(!DI MQZCB8ZBGN_WA-+"5&Z] )3PC;"P=RA:&=V#0^'$H ?'4MR-2C.6X"LI?"FS9 M2.#Y&=K#'%X,TG]FZ[1V;Z*XUGUUT,B 7#H1,YMK'<%0ZHQ''(&D)Q M1*(SMH&-3>#?A)0[ 8L'1A.]<>!1@Q0",9AT(@IA$[*"5 M19HJ\(+0\I;;(06-:&\1@\H!WERFI%,2SPM=9H<[RJY#_B6UFL-N:;Q/C3+/ M9.AZLM89WU&.,E(5UN*']$_+B_'T>G1$;7Y$X\Q\\;$T=>>][X/N&;KRS,"1 M*BJ*JTW=6[O3/&WMOD+M8(>M)QP2XZOY6)'Y-P]M>^NG+6&O"OOW&G(N^H+?PUY]TNO MG64R#7DG%ZLA[S3DW3K(NSUD$?![1YDLL^96)L0NY%-LX$T7(H$::E-ZU^=N M+95+RZ*Q$T1APE=/.QXA /\8+Q$;2K=)ZH(H<[B4CU6,[QO*'!O#-MXRZC40 MAG% <6WJ/8'7% 0@/HY=2X:6>/>F6\2("X%^\#XV2&Z%F)VY#X1.Q(*);'KSX%T%X"5LX[HM&/^#NS>RQ?A2#D>).$[5.PA8MM M)6A\M_&R880,5@,K0#3Z]4T.E#M./UC)B&L:Y\HABYX?RBT5=BKAZ3\!7?)@ M@PCXK=AAN@M&9/29W%.Z,L^L)MLSGMU9;DP7:(YG,\J@(!!GT>F0WTSQ 3:\ M,2K;:O:T]<,+LN*FK6;/KB]N+LZ&GXSAV=G5U\N;B\M?C?/1S<7GX4W%&LV6 M;\W!&R\QGG-'#6BP'5!Z;_CK M) L!3DD+3*F1%N^>@YV#TKX[Z10H55I=N979F :(CWM8+%YUVW_&LKU0T:V[ M REIA4L21:& M+#./Y"G*_L7<0YYRPO,R0][9,I^GB#M*PF@"!C1BE?)W4D*-4"V9OI39S+2T M$:4Q\N=)/Z(Y]2=61DVW6-*MTGUV?NMXLD,BO0C^._5]FS00IW4;&P([$3MV MG3MBC,CRI@Z2&*KIB"C$"7 ;&J0KJ+>9Y0JU*!M;@!X0*4=S!K2H=D+D+01# MV08 B DT>R3:IL*>>C !V?G&&^-2(^L[VS@+IK3@[519\%Z>_Z'*W"_75Y?P M]QD9>%41O,,XDX!%[W.T^: 75^ MS2BK'*:9N,2B2Q^16K# $X#AT(ASJ+E*P$! 86.?YU+[)U6FOK/AUQMP'H;7 M_S8NKV[.C>OS7X?7'Y 0/UY=_P%_'G^ZNOH-_SVZ 4N@2D1Y@R@U4"R\5('S\'.F([H;3XZ/TLRE,"^O[<"^Q@O3"EC+R4R7OZ1 MZ[L76A,&JC4 4YSW, K)0A8B^TO@W&%VY"@U@3_!?WAK5*!1:@@_Y!V/S=/3 MGE1 0IXW:(Z8'T]M*.E7#3('E&EE.R@K75^YGE([Y:9Z'6:;>@.)(I9.@^6Z M_CAYFY)HBN:\"[K:%;U&\1D;J\RY_:F\L*IBSIPI;5T'^ L1>*Q+!0IISS$1HBKUQ^ MZCK?F+O,?^KS"_3\Q]A7=VR%*X. J8GGY8%%L?*5X_H%SQ,:>OYCZL5HKSP, M6YO_;.I;;OXSOB'Y3RUGGO](9H/G/Q&(]) MCFBC.Y,E_^UZ[JY,YNUCC@](AP=DE/38U;:($X4A9/B"IYX'64\;ZV<:!FIB M2@9-BM@PLC%?"!GRS?/OR1V(/?JSP>4K;XDYMF(TG[..#PQ]AVF"TO.0]8/< M<0$S%*S9B(="%!DA1:&8E3('FE-VEM+^Y4-FC(["EN\-+#NZ8TDQ"6]9\*!5 MT!!FZE;JI6E<@%/@T?=DQG/]()?'MU-=D-PKH V8+/;YFO#,<7=)D0UE-ZC2 MAD\?ZV\:^>U'OW.+_\9[R%)5FQ6)IG9P3L+IO&4SRYW0 MQW]AO1B5P/!H#H:G+*IJP*EGWDG..[P)6\HN_5C&=I#LJ44S;E2,-0$BS=27 M+9[7SU020KA@UC?X ?;%390X6J#XQS*9?U52B1^4%7_ S'W:%2*<" Z"T[ 0 ME]A9$.OP4"6036''V*8U4)JW(^O&"UK_(H9/Q]0O>+E^(PVZ94AW3=KEW#K# M76;$/=B'6!"H=".4PM/4H+@3V?1I.T65\G&NLO!"=SC3U[WZNO>U7/=V]'5O MYCZO= SB-(E!Z$OB5W%)?'%S_MGH-(W?OPXO;RYNAC<7_SJG5< 'G^2_\?+X MT]7HZ_4Y+/C]U=<;X_/P^K?S&^/Z8O3;FBOD'(,=HPQYV^M*P>+0O=K;8_QD M+TM_*-C%00J:!L8+4U0" 5/@KJ(4K((45*!<;,UY(ZVQD*Z+V0M/M70U-%B$ M8(3ZH7#1,U.^\]$L<_$^@3PH'M[BQ8P.[W1,00&0W0Z11Q3W@9.-7YF%)-LY9@BB@TTA[EST*JGD-1J\-'ADO\*5F"DBG'KKL MKOA)+7S3*\_X; 7 )CVUNO?K;\KM#M[XQ$"10P[T 7NK H9\/!OF$4% 4,2" M4>&Y3_!SV"82A[>6]\VXHH.PC6N,4H(,J,A.?+IX?W7=(.[!>#F>)B4%EW^PJ#=L\L,-?1U?+S.&UW72WC8E" MC-^+V/2BBNPZ<7&Z2 PD!'SZG@\["]R+P:G(XOL.7R$/?*Y=7RT$SYG M.1 Y&JMP!8)6B:RE(B@!CD Z?V6T!D9 !?Q)139 H7HBZ2ER,X:(+SXZKL@,R@32)<*(P2&#\. ";8NS MXQB%E.AL\LXI7"9Q\U4B$F@98 VI;U2';Z71X7'GQP6V)\C,EO3H\Q\+XQ! M"K2GERV,YW:B@0*&E4?0-ZE-Q\^?\#_XI9%5%?B*T=5'T+D9!8B+^2A >:Y! MY@>P^O=H-R 8";SUWW[PK182[D+IN+TN-0"XWPOQ;E[>F&9D&:7IG"JFF.)< M;9.=(V_R)D4#BM=[&&&_(X-!"?9G/:N2V#"(VH:0HEFD-OB=FP4U2*\Y"-!) MVN$K+T7'55KC8-LGI)]Z3&1-A*$/:^-9$I3U@<(J"J%<@BI#W_@ M6DDH885X9!*R>)YTOHU7>D%V? H"4P3'7QU%Q&]2>9$&:ZRIA>*2YU3S?4.D ML P?9O:#@@/>\01\-1$B2%Z3[I.4R2N:P'+GF.E+@BZD$([A4DD)O,XPVQ+9 MUL&4^ ASVI:$48E!8'YU&SUAS3)' "^M,90S]42A!NT%3U7C9Q'.G(4"A]C@ M>,UXQ9R*YE!%C"6I/I8!G!2I^RCE=D6$$^-G?I*:->J6_5R;M*&5TIR5\U#4 M5EG]G)6$BDWRL1M8GE8/S6C9.\^ =6 M$@+AN/8ZF%:T^PBI]CNET0,)_-A+L)@Y]SXX=C[7C,J]*+]&L*Z23:-236-U M6/@:DTNM);I=(KF2C1F\*OEW5E*&ZT1E32V-Q: XYR%$.931R4E*FW44HVTV*:8AA/05E43KKYP-9W^Q#A?7WRQC:V. M(-XBR'I\?/'P?)),34RFVS1M7J?GZ/0 S2CTW-> M87I.MVF<75W>7%]]&M$*OEQ?G9U_P&R<0\V]Z3:?)US1?N+D4CZNUJ:=H8_L MBZHKZH]D8_.4M>2]0A@;KBQ)D\$F3BP0.!TXJZ3VA2.@H ^\VH,E"46DX IJYPF,#I[- M'#8QSK^S<4SAAZL)^%/PSB/AH9R=7\DT$'HO?SYU;%:>_Y@\7X_(S7"#,Y5% M%OG+$$+)9Y'HE&.-P5^4H X3 H3XD^?7)#ZHN/\ C^]?#C@_4_;Y ^WN"';7 MM7-Q4U'(+;KA\9PIY1U$EH6P!*+^@U^Y*/@31&= /^(2-46/_P>S7""K$9NF M_0;",7 *KB.EH9_RW4W6\EMZ(5:"NVR'EQBIMY^T511AE3_"(U$NNOB1T+WR M)-U].C2Q)?R&R0EEQ!7[LX1%&"6R4#F,K,D$ICSEZ6K&-'9L%74HMWB+XDB4 M\+/R;HFVX\^=*)*-2J(RNTKI(![C'O'&@?FU)[S?'>R*MY&>Q_LS7=8>J@^!Y M3WF'E&H8%2N#!IT)2& N>3]>\;@7/"EVFJ?0;**5I 0KJ?#H8)/3H@BLR-Y1 MT')RL%Q.YGI<, 1/4Q-OY#2"4SB7$6JLT.=S(U +I.C QOY$-)F06A6%\1SO M$?XFC6^+Q\55@FR)B,F]HBI=Z?DEL@^ N1LB60CF20E%ZF0=0JZ)YS&_WY*9 MQ+$GLE"HO4R1'B7J34^)3H2BW@LLK:9MPWK_>YH>%@7"O$(AH&7Z0+)3Z:E4 MC(J+[HW MF+:\UL&$?!@B7(;@J"DL%X9,N:%3KSV8-R/^XCEP*J\F'888VF$.W72 3'99 M@GG'YZ P\[;X [1SWQ09GZ@/E$Q7EAK2MZ+"U^"':$";&D) M*)MPSS(- JF 6R)RC-7;/]#4^+! %4AN6K^Q93JNO(5.+IS3WZ=FE'R=3=@B M@345!A-!BB&1W?O!-W@'9EW>.1;JBL ^Y@GW?ASQ&PD@RP"'%K>6N%@T,D*) M;B;>X* M/.> M<#BR5I:H$7E+\ ,F'C/K&^X6)3A%F6WR0>0'="8\N5J %\KN8)BC(DJJ.?D8B\8C-2LF1"ZCA*KP3JS)8$/C2 M/42\DL"*;8RIJFSB\BUF!'&3 MO PSNH@AA9+$, OH05.(!&$/_+F M\=BYFR?H";GH%)$XQC9<-[>,D+8_&R=-IJ)NM]S9_,;.G5 !GK&Y[4(G3Y@\ M>.:RP"?B6C5%I5%F0W58TGB5E1Z8]X<#-!"%!V150W7JTD@;YF%+)$5DE@>F4& M\ZX0VJMI7*'TY*7%*9]3#)# 5T&LVN#H\RJ>A'04BS^=JQ2Q\#9Q3R'8P688 MK>5SS39G33#5.5*BD/0Z:TAG#>FL(9TU],,OO9[.&MHN:ZBGLX9>5];0E^'U MC7%Q 0K]YA_GU["(CU?7GX>(W_Q@OY>G 5BW6X,J UASG,^F87QB4QG597:% M>J;?D!&M7.AD0X9T >;@(DI E.,/.)JZB0X(N!4I] V/=4YEU=4.T=1K$=P; MAA0&0&0>B7#ITP5=UED+N:_.>-"]!+]&1D17_A%$OL%Z$A4L;A7MTAHBE M?N Y5J6JNUTV99BJX.4-<2+\GQ_J2;ESNF MH-*KL;I)S#NE$*KV0MZ)9*[;N!1%%U)01N13PZQTKW@)"VSOCYUFKR*[D)1O M77DI5(O9IWAVJR% "Y(5W,O+\#L>Z;!4KN84CQ>OO/S%M>;,AB=0*"R-HR\4 MU!"1BXJLOD@XW363)"J8>[,!WX'*N?2;QO6O[59K8)K]]L\"WIJ"3@6DDX0D M'1F@%NE>Z.QC%M#&CGQ)H\,T?R@PQ&J;^&P.P4)1D<@K0C=*":^T&'@A=^9F M5$6)R"3L*##<8PNLE!AO>63D.(E*8Q1>](_A$3-';HE(SU0W1M:6":V;]$22 M65T%'/,T>51G\$T<_CA\(2KPJE\ZK>)&.1@GCBDP1[%?PFU[IO &-2_[MD(2+K MDX#X)WG02:A/+'A2P"][6X5_'_[NI-_?>5#9[#9/!J?/,-E!>_<1<+/= M[ \&-=G9=J=YTMINV)??69RL66Y"N[U;B/S%GJ+J67"@36/JZJ-ML\SJ>5QT M3W9':KEQ5+QXK_0A? NSC]]5*@E(.JW\*Q!<45# M+J5>M'%#(0TO)H,-8R%HJ(0)K9!)1I!')7:PU+:\KNT=4CHO$]@H"PL6@HCG MM,LUV-'J7J$^D9HQ+YKGRTS4SDX__B-/:(\7!KC;]- P2//!9KPP2RR>3=+JEG?_9FZ_1-RWS3 M-HUC _[LX)]E!/VZ37G<*MWAQK:,@NT-<'&5RA6BC.'VNV++?I=41MO1*K\9 MNSS@YSW4RN5__?ALY[C!^6EB?B9BUM+JP ]82ZO7(:W:C5:KT^B:IXW3DU9% M27IC^W-"_ZN/B6FV$A,3_MS>Q,RM>RNA7;!W!RV7BVGE646O/B9]3/J8]G=, M-3R-\FIZ+PHW9TQ67^&:J<(UWW1:%8CIU) H.PVS?]KH][:T&ROD[1SX074' MSY_'M.B_C0@H+;ZL)-MV//UO3S'FN- MPX(;K[_:Y+R-Q5 S4G[-TNI)SGU=#EC+JM@/!XNH#('^0(J M_&37>[N:1%14\?'4)**7KU%YE]W++J$I437@/V,/B^[,04-!X'_O^U%H#%U1 M56[%T&WV?>$(C"I$/Z!VI?^,W:52$)ST,D@R(#E6>$3]$\(8!J/2 M+@5E6*:QI6_>M*%$Z2K"_D%5$?::AG&5+RVM2,'6I>\5X)JOW?)R(#@:JJQ\ M@8Z&*JN^Y:2ARG[IG6BHLJV@RMJMJD*5P4Z.C^&GV(G\+>_EL5PMKM'X9?O! M+WOPE&IK"IV *73^?>;<.M&ZDO6*J/33TV:?5_ENJM%/FR>M9RCD;?9.MJL] M?VA4--&ZV]4K/SQ9\+9W;WSTFV:__)VC, C8!=SR*%N';-V_N[^^;,,_FU+][,PS&,VR\\(;94RMX8UN1]<8\ M,0>G;?,-S--INS".BXW33_^XWU2VFO M8/LT@4/**QNE:$A?9#!P*(&!J*$ (>80ND\6P8ZC^-U1 TP!Y3#S71N[0/H3 MV: MQ4' ]5^F,?3@^#?CZ"/V[D/D2/.X<]+OG?YL3. 3.]NA%JF?+2(.@M8V"YN> MOGREBM:E%=.EIP/0IJ!+VX/N22>C2]M/U*7/D+Q5>5UZYEIA:'PPOI @0##! MKQY(@"*]RC' >5]>"7!L=CF;YK7N^Z$Q5!J&=Z6.@L\3Z'#YV9K+.BY>&K*7 M.,P0K]% 4'U.VP")"SBNF0G$7 !PSTF*T%1+_QY4V'.6@SVC@-*J9%65Y"ET M)XI$.V754R1;Z1&SV^WU3_KF&WO0[?0'IZ!'.D*/=+1/MH4>&PFU&@<)7$J,![)T^#BH):&_0OOO=DK*X@[64&\M00VV^_+"^$$2+]# MYKS9;3XM**8-^>K)W^T,>?,$/NJ<@@ V6X/^:3/'FBC-4V;OUE+/^S;>+D![TW5O>OMBG6U34[7,QV MM9V[H0# 6_./3A!&QDAM?71!"2-QP-:$2#JY$,DMB^[Q1N)A^\T? %,TGEMKC. M"7%L/",:'O%V1Z+7QS">8IOTC@AR[R*JH>WI5RKK96"\TVEW!P.PISMFI]T# M>[IK2D%?=WMZ'R%.+NV1B4&6MYJGO=9_4.O,T+!C:BO5*8HHZAW=D=1]80,Z M:;XD.O[I<+$6KSGQB@*VA3D\X EBN,)L"?EJMFIO2>]-'(P8]MKOD4K)LUDY3N=NKW^E4-M"!E/_"@CKIK'LJY+2A+6 MHH6( M[IIFMP,6L-EOM_HY$:UMX*U%]!W#UB]/D=%E)J=?[1%555@G5G7[1%O5 M6F27$]GM1&1WM%6]G3P8+A:^XT4D7BF,;,%9!.MR^5(N79/,]TB"7C[9KY>F MXY66^S4^Y2I;Y^WJ"'QMG1^ J+=,L]/"$0]SX?W5F"G[D\3"BB646@6":2UP MV-Z1> IE@X Q^$'#]&B8'@W3LU.8GKZ&Z4G_7P/N:,"=TH [&F!& \SL#&!& MA_[JYP_V$G^P5_/HW3[]P1&!XEX1Y,XSNX*O6-W._W6R4DN%6]0,^!-:]<<- ]'WR819G ;-1VCV2WF'VMDKOP.O]#RR$Y?.2WNV8$N3#K'W1 MS#ZN)E-$)0&A1&VH9@Z;*(;MU02> ,Y:Q$$86\":P,LC=,KA)W :\F7WUWV=(8CBE5N]UJM>MI >]-+:_SV#5BZ0'+L78BQ^I>65(Q.9;@@^Y+ MCKW&\]!!Q]#4,4:&O\[_OK3\:%%T84QTUZEAW= ,=.?-?U[V$UQB1A=J77M@CA8^?R MWV,K &IPEP5X=[\G>'=_\:<$Y%T2[^VT!.@='QD#T8YGJ/,[.O\>,2]$*^I] M',+'82A>A)/[9'G3V)JRG^%G8S>V6?C6.')^%@W9O=!W'7[] ?^P81B\L[!< M45K%6!2^@\/I3_2-]W[\Y,?53A6E[NCL'UI1 M;R%U;ZSOON?/EX:0;J+9V]Q*Q+#>UFI&JZK(A6?#3UIH[X8+SRQW'+O-]NL>_5DWCR-6ZRUHS-#^XQUI--C\-WVL)OAN6 M_&3=,E70'R MV@\*S_^M_]\*\,N#T#?[F?Y_J6"=8W@<*=[P _A[O@ M9$5^L#06+LP,/K2" MP/+XPTVC%LO[KV2:NWV]6>KU9Z)1>3B>,3MV86"4#2*/(:0B&;QI2VL79Q8( MFUOL&^;/'1(RZ@7\1<3FH7'2,H^LGX]Z/_.2R*F,:HV.?VL((-B'6X[AE_3R M";]A-D*ET9F[Y--B>&L?!^"=BUF??Q_/\/#QZFKNA&2?6$ FBR7. \' Y93E M:O%G;X!JQ'J-> $_"=A?,0OS=3T:AT_C\&D)PS?0.'P9=#7#L?_G!Z=S M8K4&@Z[9[P_:WCB MU\OAS=?K KR]"MHE7Q2MCKH6M:(3I+D=.?V;Z%Z18&>>=KH-\<,I5M=\^HI5Y^40^E26_05%V?<&5/^(=?CJX36?FS/K6ZKD@<5LY;-'MD$&Y@ M-FYJ81Z&O_$!,TK?&O^TO!B\68.#,K0/BM$?$N5OPC>P=GS5;VSF,RT%ZG&D M/_RB#ZV&AY:62?X+NT+A9:9CRPN27UW_UG+7U1WI0Z[+(7\)'#BY!1Q=J4/< M@][6IH(V%;8S%3Y;WMR?P:P^6S/K3\O;1BIM0$G5W[ ??M%;LK(E(^8Y?I#3 M<8U$P>&=JN^Z+""UQ_7=<#SV8X\*W9Z@\ YL'U--4F9[UES_/W*GM_?+17U_ MJ.\/]?WA3N\/3_7]H?+_M[Z]A/_,HKG[R_\'4$L#!!0 ( ,^%)E2_ZHD$ M$B>P2Y5E<,B MT0^.I]%H- [^^K?7A6<\8Q80ZE\>F1^Z1P;V'>H2?W9Y]/O33>?\Z&^??OKI MU__K=/[Q^?'.N*).M,!^: P81B%VC1<2SHVO+@Z^&5-&%\97RKZ19]3I?!)" M [I\8V0V#XU>M]?;?LL^6F:OA[%M=BRGBSNV?3;I3,Y=MW-R=GHQ/>U-7=QS M?IE]Q!>6A<_11<<\LU#'QMUN!UV@TXYMG3JV>7$V-;NN 'T-/@;.'"^0 17S M@X^OP>71/ R7'X^/7UY>/KQ8'RB;'?>Z7?/X'_=W8Y'T*$[K$?_;1NK7"?.2 M]-8Q?SU! 4Z2OTS0.C7R9@QC/YA0&@;(\PCR'?S!H0N0[9FF:743,0Y*%-D0 M/PBY<)+>#5DG?%OB(%\&7A_SUSR?;J=K=GKFD8'"D)%)%.(;RA97>(HB+[P\ MBOR_(N21*<$NL.QASN-&@M3K$+$9#A_0 @=+Y.!:%?WTDV%P(LAB25EH^!F0 M*0HFHO !"X48+[<%Y9;4W5$'A4(?>?H !$1M,U+'V L#_JNSQOCP&KA'Q]5+ M$ 6=&4++!J5(2\J2Q$_JER:EF>;%Q<7Q*U>U_'+DJHQ(W^%_=LQ>O6R+=*]Z MWO"KD\CMHPSK;E:O#(G/XF?+9?$GU+Y !YQ_CXF)#[B M:6(N,U8YIZ>(_WU$S&'4*^E6QTM&EYB%! =IBRX Y@Q/+X_ KG<26_:GAR8? MH"!)B@S^IB+RU\<@@KV[=4426:X+ETUJT]B!"?-*@\EWZ"]P9Q+X\&%%S1$9I!X?CSWQ]O MJS@>H@!KT00_R6%=M$]=\/O@'Z.S]F,[AI TN.BOQ]L"6U!1@-VA_TG\O:WN ML7"<1"&XI2B5Y3:;.%[?]1\& MU^,OU]=/XP84E&,JN#$%-ST@9 R-BA-R4IC&"M2(40T)>^ MU<8CQ*!Z=X?$3_+R_?G@:#V^N__[[[=,_]\1L#K": M4:O;M:LQNH8VAC>&!#_PF&KN_N/#[<-O^S*TN=!J+NUN]Z01ES'\@*B?[XR\W=\.M[ M=-\UMIK;TV[WK!&W@&^(#%K$:-\1,1'BSY;4(PY,A>HSEX.A8*AG=DU3SC9( MX'@TB!B&'VL0(T%I-0VC/=(QJD(+7XFH1 MXH?%?;7) LZUZA4-$O+T0E$"I M^+&[EEV1GQBN3?3P1J&\'2+L\J".*$X#;@IPU/;,-L4,?8.8-)"Q1FH])4]H MXC6Q:DHT%3U6]\3*]IL">HR?)>*AZSP@QO]ZQHW-7$5+R6G[T)5NC,26T^DH8LX^M"7^'\'/#7U(Z0Q3/6)?/ M@#(8Z1(:LHA&4D:1(%5*(RYF*U7R^I6$T!XN"984- ,YT#E%J]37HF(HY9AJ M\JGE-O$<2_"4H!EKN ,[N/& 6P:H''U-R\IZ/RJFVC@:%[;P[D-S=6BUI;5M ML2Q4G<:VC]N%#?^(@Y!%3A@QXL\&- B;3S,;Y*%F^<06"T1U6-[(RA!Y'?@N MY )^8/:,^_+MVSLS7Y";6@=.[>[Y3CH0YVHDV;92'>XP^)D-B(WEU-[/F9EU M>Z5@ZUJXJ5.S(:WV8,ZMK*\IQ=OHJ\B:[^Z8%."H;=.%W;THH*+M_H9LAG&T M7,J#6LC[#.,"-/EXCG%XZT\I6X@B[LA8C1R47/;XVF AE^EB9INTS8S2XWY=,N<4KN4#HSS9AJ&<\PV&=D7SU6@ MU>R";<[$V%?L"OAMC@^4XJ#_C!F:8?'C";-%T/==L407^3O,"FM@JTFU;#,3 MNEF1&N/+!X;(P8 LC%4>+>;U)H*ID&SZ$7KC*A^ NL?KK?X,)E(WQ.>DR>0[ M,MTP-S7WMFT6.;T=0^884Y_D:4"FQBI7,5N,\UUYRP>%J$71G^;W50G([Z 4 MWT,IKO^*2 @-%,[YQ1G/. A%8S4( Q4 *<,'O1,S)Y8KD P)9:2P#K0T7C=1 MPBEC#KU3*QOA*:2HC6&(@L9=KT3+!/TZ0?.(ZXX9JBWKF6W6X'MS53M. M)W,V;M-Z<;"M25OL826M(K":Z'/;K&Y[6Q_4*NITT6*!&/DWCMT8LC%C_7Y] M?[=BJ!7EPC:S2W$JB[ JC+$JS<8T^V IMI3K-TK=%^)YX)12'J$@4!-_1F D M16+S3WT]*454^F56U\RNOB:0PG46H,8:U9"P!\Y6+=S45ZN(JW3:+& P8]NK M\-=&_ZVLP7QL/:@TY2OAOEQ5FIN;=L,[/L M6)'[M*.^$CFH@8J;&YXIOH/^ EY3DDCNQYV\W:-_43;P0.8[:$G-DJB5R+9[ MF?7.!DHDR]01A3+6I4HV+$_ O>,%,T3)#IK6E%\9S>PO* O)OT6%KE^7H%/O M-Q[MIUAJ'3RQ>YE%V+WKX"])*#A=3",N9RLU\@I/P@:'"+F4>L9P:F;WZG&Q MEK5MXY/3:UFU9W]F96=F7+B-GCNO]W@./9N?VZ'^C"_]\F?-#\N6 *I-VKG= MRQZ#YM2 R>*@\N0.P'8X;LQ:2VW0'DZNYZ&H";JP>]GCRI*@=D^,5F$Z?ALV MBQHN >:B*$<-NVMF=U&N8X8IG):3T71846 IAQG;M++#>2XQ;1QW\EJUL1U3 M@2G-F M(>_2F6&_V76$*C"UK3LULYOI4VABSK.!UR**Y/&!$+TVH20MK*;@S,SN>(]/ M+@CQ=K9X8YN5@Z&V5##OSRRVIMN_E>;I$8=$FN<)]@&XB>^5@Z'N"1=F]IC M&L1(4%I-0U./JQ!)Z6Z==*VL+YQ#21M=K6R+-K99Q5!*TW5BVKU,-#F7G19: ML+[C1 M>"BQ7R:"QH4)S(($\8R+L.[19LZN%*P$K;=U)S\R>@$@AQ^MG&]B& M!#=^YO '*C,MWOP>P#KP:GMI65E_NA:M;;2D%0G8Y3+P.OAJFVO;O4QHM2;# M+;3&8SSC0Q+#_!.0,)FL3V(&06U?3\SL.8@8PEAAM)B IL:R $=M%4^M[!0W M0T8;+=]V:S8V<45 :EMV9O 7M/Y4%J,^_.DTW6RA E/;+=O,GHD"- .E/KVU@=G,MK+!D2+ZVK[5N:#)KS!4RR'B;^2[^SQMM7..:O;/;2L[12UF M/YVMV)QS.!JEU@QYF\4;G0Y0,.?_\JLKGF$V*O=*B0O'B0-N('^W;R5IE+E: M7RYL*S.U4.A+7 )^UH[G\8OXKY$JAE"B=4'D^X/^K"E<':9\Q"[&"SYZ/E"? M[XD#<4@YN_5###5O?FQI;SDK->>L:UO5W83-8YKK AB;)3"2(AQ4)J?77Y%G MXF+?#9:8C>>([7T0*L])K1*F;65#T96,R2I#8\EOY.59_J^KP*_'K\%'M%SR M-N%/Y&_?I[+LXA$\P;+QA(*\3-"??:O7[3[0$ UVK>X\7$\R. M##0!VXN<\/(H9!$^,GRTP)='95(^/_\-CQ.IUPGSR$?@@E"7%_GRR(U8/$\, M(LB"A!'_]1NCT?+R2"8G(5X<&:%,'K(._ROXZ-(%(OXMO.- 1\>%%>M>G.24 ML6>5U*Q,3(.J\4'PQJ,O=S@(,.[']2BJ45'JO5=$/N%#-=C^4&JUDT!Z[2&?#>1WU2 %WA" MPEJ:O* ^C!CLK8(NN_^*DEM/J;Q\[AHQ'PH/U9"_UY?0#7UF8O*J[@D) @SZ0][DI<=T_.)S/1>NY3'G<1 0HG_!K^-FCSK="WG>!?$=] M#Y-R&^K0]NNOZU>V!*U<30U\I_YW.]:/9C#0]+KF^2-^IMXS_WRB,"9]/M'C24N\L2AE=*[KM2=V0YY*YE4I" P4>+B&O.VCVF"Q!I4XW,4$!\FX0.Z MF! _&0 #/NF3JZE\]C/%#'3CAK(1P_)O/G(4:^ANH)H.M5?80V_8O6+HA5]F M=4>1+XUM8EV?7N@_,6+5K'93- U49O5%&>%+RVL'P8>Z(VC"BPISXFHQH/HX M/SHZM#ZR(D:;0?K BAR-"N^=[X>0R20*A5=-1XB5>S/OE)L.&E10'SZ6/_"O M6285^8+=&0[ZTQ"S)_1::&\:XVEJ:FY2WX=JWK_JHOS@WC6:([9 3HG=W$ZE M@39+7>-QPV8>K%)25W_ND0=0AM/?8]4:3D)H*WYE[O6K,T?^#,/ +C0O4;BW MXFA4 RA-.VZBG7?$X3&4H)HN;Z?60*=K>'!@8/?A" H8;;4]'3#M\UTH8EP> MT"!\B#AIP^DXI P'/'C&]X0\T8%'@^*8>G/ =[+2Q _Q#+,]N,%U8A<-P33H M('W+S%N1[94M4:NE-*C8%0F6-$">@!PDUUB%&]UV%#&PS $>,;!9OP>Q^1'WY72[^][@5C%<8NC%IA,&)4Q%\2^X? /?@EA:BVXL/;-P)IK\?LO. XG7ARY MXUM0Q6SS$2/O&LH38CYFESAZ-4%T& 7*!N8=QW6-JMH?#FYS@@250C151#6H MXCH:4CS75.T J2ROJWVK,0^!/(.]1+9C(%V;1+5>5K*844%2 Z67.SV2;Z$7 MCU9;R73E*]&\=6/S?1OKV']?5JP!KT!KZVAMTQ]S7B_1^\0/'%->H&J"2J017["\@MH#"/Q)\Q@PEF M/W:S&EFYIF@:-$1FY1QJ47.M/26A084*FES]">B*>^+V@JW'YK@F;JT+P+EI@\2TH\8FYIXU/X-5QC/:?MYZ1#G&>2U89 M>35M:S59#;J@L!"K[ZOPPVV+I0C;\7#=']!3>/E&&*PE.!(S12BP+LX[!7^6 M$<,5AA0[+UY[4G80J41* SK[]NE)MHCV:5G%U%(:5&P0!2',59E84.$>[)PL MQ;HW?4->R ^UN%^H!].UDN&_/HX&E=\>QF%.7F_<3PEH4)V^=9ZW6F*7K;&H MI32HF(@9)2$5^,N+7)@[C&2,?W/O3O[I9;%BJ#[@7&B!OT_FNDZCKQ=+C[YA M&&'YT0_(#VJ3^"XB>$-D3*^> \\&3%RTTE8IJ&.7+\['&(EZF837Z/O/5CEQOS11BQ_%+'EV^>AZZ& M0,SEI2&,3SQ5"7OF"VC0"S@C*)@/V0BQ,/YQ1<1I5?XY\/C)1JQ:K"0'O&LK MPH0[X[[7KD*9204?PLYQ67MECFZ)E :$9^)3 \KXL1">3T!]>J'U1N"4@ ;524:+U/ @3/]PRC^*QX<.ZGR3-J'RHD0M M+%U'F'2\$#MSGWIT]K;I=JQBRJ\DK.!S[H*H@:;T;3NG;]IE>^9*I#2HF-CB M(DX-K_;\4']ST;S1"<>=<77M&LF(@\5<$NK(U\OD(8&RN$P%20TT0K&_-]G1 MV_?]2$X[QH@O'09\VUM*:@1$--D_7 ]?5PWYFMSN):_642M%06(-]& \)]AS MXW*-J2?PXPU"=W<#=;4J"FM036&%QG/*PF3C7X6Y5&YZ#2H3[T26'0O&''ZT MS!>5*#O/42ZH0?4R=]K@9UPR8U"*:%"E^" -!EP'>5_GU,,!\DIBWR5"&E2K M^-!>Q;7MZ@!Z+&#W[;QK[JRR@'^)E 9,EI_VGL/XM<_3XT5X&C3&;Y"*NZ]# M?\3P,Z%1X+U]@8%N[;DF <5BS[@6AJX^SA^\7#-\?Z4F.Y-, P[[=MXBFUW: M4]52&E0L;X,O"N9[NP:C%$O3=0<>3X"!)#G)566!3"&A =%]R\H+%)IEX46U ME 85JW^*3=*HDP\(+-G:YDF(_&6MJ*(2*W"Z6B#"Y MPRL5IEY!&C,X86Z@K7@M"@REN79SYB+I9STEV+%84U8'3S)B:N?_7N;MJ4^,&&ULY7UIDY,YLN[W^17< M/E]O#MJ7B9DY0;/T$$$W!- SYWYR:$F!3[OL.K:+97[]3;FJP%6XP(MDOW B MNJ%L7'X?*1_E(J4R__J?'\XF]][A?#&>3?_V$_\S^^D>3M,LCZ=O_O;3[Z^? M@/OI/__^IS_]]?\ _-?/+Y_=>S1+%VPQ'SO_7CY]MZ_,B[^N%?F ML[-[_YK-_QB_"P!_7_W2P]GYQ_GXS=OE/<&$N/VO\[](+@2BXB 30U#*1H@N M9]#6^&)$R2C2_WWS%_12H@L>N)4!%#(&P0<#2IJDN+>%L[SZTLEX^L=?ZA\Q M+/ >#6ZZ6+W\VT]OE\OSO]R___[]^S]_B//)GV?S-_<%8_+^]:=_NOKXAR\^ M_UZN/LV]]_=7__KIHXOQI@_2U_+[__7KLU?I+9X%&$\7RS!-]0&+\5\6JS>? MS5)8KN;\F[CNW?F)^@JN/P;U+> ")/_SAT7^Z>]_NG?O?'QDF;^:(TT6/G[UC\>/7[^B$:V>L/QXCG_[:3$^.Y_@]7MOYUC^]M/[ M& B8X)Q+5F']QQ9?>O\S]!0FZ6*RFJEG]/KJJRNZ;J/ #TN<9KRS.>T9$8B2%EXI@GA MG+@N44!4,4&,UN7"4+#";\Y>'>*"QK@2>PF+N)+]U2/NUWF]CY/EXOJ=U4P# MXU<4^(^[L5S.\?ZC>WZ.;9YR3"OSIWGNL"NM*&UZ"#/-TDW1?K,6K M3]Q?7)R=K;X3QDL\N_[]JAJ;\F,YZR:02P[0> XER8.4YA>8GY(].=D+:AAO@^J=%&#"U9,;N8+A":#*!&"LP2$6TY <@%R_+-/6>6X>%;W$A$1!\LL)RO70-C3:A&I([W(X)S>30V!$:V6@(DO" F5PYY0E M0%T G"X""ZFQ.E% MQ_%\1C(\MV0K0A&8\J9]8G/UT <[*// MSL[&R[.5^T<.X6Q:-]1QFNKX$CJ,+!50)FE001B(LG@:KG,EHG0ZN#Z>^=V@ MAJ2Z]N7"%]YX(QGT(/GU8BNL+EI'B\UD\A"=$Q "K3@N4BI*92-TGZ!]OTW) M$YQ;'$2! V>\A^37[&DPW*(I&D10Q$2=2]T7H[@0&0V36QNQCS.^$T'PD&8WK[[ZG01*8R*34%ONX M.E]BV=&\P?=$@0-GOAD#7N(RC*>8'X?YM)[W/$CIXJQ.,^9'6,9IO!PI=*D8 M+4GC,D',M*1[,Y(V+Y*"#L$E\CXV[]O8AF0 &Q.DL6!:[E5>XUB=KI#+?C[' MMSA=C-_A99K)L]EB\1LNGY?7X<.("^9940%BT@32!0U>BP(\1 &>1@[*&T>F,4JPR7$CM2G2=#H- MNX5D2 ?^C9EQT*2W4RDYC^O8P^1%&.>GTX?A?+P,DQ&S)B2#2'$^_4&C"S4] M7$.6B5PBR81PG78.-P/:A@CF^R1""Q%TC+M(24TNZK6$%[/Y:L*7R_DX7BSK M$<_*G P6>OJELMC=)8# MLS;X.T2OV9@B!$7CLE K3P%&AXS1=&AU:-%==[Y]D7EU MF+":+;U?Q]/9?#4!5X.2ML@<,0*S-!XEB@87'0>3H\HF(0NR3[+V;21#VNL< M &$.$E3CD[[U\T:7*"3Q!K01'E11#@(WF2(4X9-UT:K4YR#HZP>[NX_LE]DL MOQ]/)J-DN*A'^X V*EJ&MCK#DISA@CZB\>PT2@&=34*"*S0LI3V#8(T&&941"KVVO(^-O /0D/1> M4_&W$$ S-KR8S\YQOOSX8A*FRP?37,&=5SST\Y/QM%XJ7-VM>EEG^7GY?8&K MN7A02/O>V)FAP#J-+^4SS0_.JC7X]^KEB/OH@U>*%+2BN0H^0\Q*0BXJEN*3 M**G7WGKOL0UI&ZXI1P=&BX:II?"'O1#O=9P-F&W1#VJYK2KGFHFE&FINW3&]1?B2BDUBB)],= M(_&XID>*D@F7U$Q:YJ/IL\_[55A#VKMK2I-VPFC'C\^7+=8&*5EPGCL'(F " M"D4*..<]2"U09BFL[G2I82.<(6WAM>7#P9/?(W.&C-V&G8UD@X^Y2#)T-9-+ MBSI.^D.1"63<%NU]'T_H6\@&LG$I7"A)>M+NMJ9S&DW:79I(;G 1203F'@X%[^]:===W%VR=TM-+] V@$\UOTX5"U%;!0&+22'[4$+WC,8A MA;E=2;/OQ+?+^<&S\]D\S#]>#N;ZHAL%)1?3Y3X$7HR,2H7E>MW&UQC&)0K9 M9?:0K7*(B16,??;(VH]E2*%L5QZ>F :=\W2+YDP$JR$;K+=\$6EFI I?6EQ)!\[G,4 MF@9KG5A1I(XMVMG4V?5/+P3S"N%S?53!,ATS$+)$&IHS0X&EPP*)&%911 MOG2Z[;<1SY"V@MMSHH$,;O'AK_=O3]0S>MVI8NBKU_3RU\>_O7[U_,GC!R]_ M>_K;+\T*AV[\[B/4#_WVF!J5$7TQGY7QLN;FCESVG.3MH3 MR9D0%IQCY%MS M;HH-2-:BCXOW&8KTSB;KN4@6U$DN4@@'47% MBM.@8_$!Z >&-'KI3)\*<+N@'))_NR=7OCQ^ZB2DAF>7ZP@O[PA?D%OU&=]> MNW#92F6+<4"N.2G4.G,NQEKB)Q3I#5KGY!$(UVH\0_*ENU#S)()O'Z9]'M3( M!Q1,"W69M:U,0/#.!9#!25YLY-JHOH'99S 'GX3@:I)_P2E]]:3F/.2S\72\ M6-8'O/&#FF0:52P&G5"1TL;!DM,LL M?\.KW.%Q0]*GK9C0:[:;:%:, MR'U4Q1J((>T^M%8'^\[UT/TZ;0M3L=ZE]JK6PS6Y9DEQ&@L&*5S*)O?*8NOO MU^T[R^2\7^GWGTG]KT2N6,F&/+'$ ZME\Q*0GX8T*([:.Y)\IWL>=P :E.D= M #4W.\.'R?&(2_=G++,YKG4A>/R!_ R2XW@:YA^?TNPO[I@D)&]#RR2 6:LH M8N"DTZ(BG69D-M(SFW,YT?K=>U!#9V_ MZ9O'] O+CP1?"A6-!S3>@XK:08PN00PZJ20M=^48"O: (1QU8]IFFJ):AXZC MHT"(UZQ[XR0$JY"7X+SW?9+EOM>-Z=,P]:!][5UD/( 5?8?J\Q3T98^L[FEF M,G4.P6$40-:"2:<,BM2G_D'KD0RJ#MCW1^?F9.FRO^.E$5PS"8778E8N1? Y M&IH<9Q19;.Y4'[;>N;^S^W@>SA8TY?66UBIA$^?OQ@D7KV:3/$*#Z)PWD+6B MX:$B/T05!9(9)H)QELL^65=W8QI4B+TO%;ZL:-1$! WKZ[U#6I;7/NT\I.6_ MQLNW#R\62UK \T]7^^K5'?HOK\Q/(;5@6:X515*F9HA V2T#R#'04)F79IR7F$090"L[7B/'!;KT 'GWUU!6"$<620;M "UK6XM*UFIP3M+YSDC*0\^O% M41[1W[P-TTNG14$'6AA>2PE;J)MG8&(6/)HB@SV5 M%[D'V8X5R/0G6VO9==/E/X?%.(UX%H)++NLN6:A'++6.17) +@D+9&3(4/6I M!+P1SI'U^.J9ER*Q-@6736UN*%(]O300F2I@I%1&)9-T,>L@[?G5L' M:O ])7E<_;T&DCRY;&)-C3:RWB_/#LBV<+(T)2I=KWO;/HVW=P0Z9-W=FF1M MI7;*K:B]PU29L]"RQBI1U+N0*, S"E@D8X:L8Y&E'.,(]HA;(WM>ZZ6 ;W8S M3?0Z3K/1V1)E!AYES1252(YD9."80%Z/HG3NAV!@J3VF#QCI1 JHU5%2UD MIQ)D9Y*H)2-CIQN'G5+_3JO(>S'O6!(^8BPPRAF]\JY>)Y.KJM<6HI,24 M1 M;]Q&G4X56?8?_=<2LJ[D9F7@);H"4M<6;$60H:X'<_7JE7#)HC[9K:5OHQ]4 M8E%C,NYN)!I+>^CW[81-,6E,X%0] <3,@&RD!ZE"L,(&*U6?R/+'KZ-P/_T'O/_WGXZ>_T?H MM0>S%ZNLYRY&R2 +OLI7*1!S0+!,9R8RBS+TN0[>>" -&M= MYK6-$K<4EL<(&$5VD?F0V'%+1)TV$#PEXS;TD=E'2FV+/'ZK[:\O@2("U,"= M8*!XL1 X0Y LVIRS*,7V*3O?JCWSL>SPD)C57+(M&SK?-4NC(I+Q)9(GD*J; MDKFDL)1&S%B20G!?>*?S_*^ ZCC>_6ZNIH"6U[KPW-3N[CX"D<1!4(P'9:Q- MKD_UU:X6;K V82=.;NBC?3+9'V/!;J?&A,U6)IHVK%?KB^?@#!I@AC,?.<<< M^UPD/A#XH!)]3\#0YL(]KMMB52HT,PDD&C)NBM-:\2P!BL9)41,!LA;RS0@9V2G8\16(QA2;X>3*L%N M8C\*:0DT26CZ<-6\(GU\/2?_(Z3EI9^R>G4EU0T^B8TJVQ2 E9HH'RGZ<#2X MV@Z>FQ(XB_KXNY+[CV=(#8E/2N@C4:*[<5_EW#\O7_O(\W)'/N9G=R6XA+D$ M<*K>YK,,R/?]7 MEP8^G[_\V"?@FT?5Z-R;F%CCEQ?SV;LQ?=O/'W]?U(Z!EY2H-61(Y;V[[ 9K M67$Q:PN8Y MSIA5K\#A7$ M4-UG9:.0GBS([6NU&\WOOL\?TDY/9QH=34Q-"/7SQ6(\Q<7BLP$/TURK?BU7 MY%^,KS.Q9Z5.VM6*R".1ZY$(,=\P4XV[U."#=Q2)1@$@01$Y@L=YSYW5 M'8$.*<>F$^,VI%1V$V5S=?^\/!K7V9CFQ:@8H0E)A*Q6E3\2H\B_=G+67F9I MDE.ESY[\!C"#2GTY%G$.E$D[?X+UZNULOKQN^3P*W/%@> (62KW1 M82PX82(PARB8\H[E/GU)MX+W'?B:/15/&[%U8=2KY2S]L4KT&$ETCAQ:BI96 MM3VMR!0W^9I?[',1JEAO^ARA;,8SI#.]$W!F3\'T"$&(OA?S]);"[^?EX>SL M;#9=@1NE&+5D@FREJ)ZJ$@HS:9O/BF_I!T:;R,4SSF-N'9YQN@!"_=.>H;(^V07WH5H4 =71V)-$^ET M,4U/%XN+>DAS"Y=+45BM:V4T+*0-8P;OL@>6")VRQK/8W]/9C&T;_M@?UV0U M$%CO#8U/U8G6AA]1,\X%(Y%SK"6/.'CKB/),&,]91 )XS V-#1@;7O_T,I@< MZYT 9+[>LX[@8RB0>6(A%,--IV*-P[S^V8DG7[G9N8L FBV'1W@^QS1>S0C] M/,&K#)H'9_6ZT;]7[X^P>!,=+V!TMJ!*++10F8$E7 M:](T%UI#.A6 M82Q!9.0_:*T*#Y%AXMN%ES3 MXRAT5=R!HN 50I !M)0F!R.SPSY5+#;C&5*^[I$42P/!="I2=5=9TX16U+)' M%-&: "I% TYX!IJ&K%(6T=D^CGZS+E>GWGQHS:'V_OUT M^A(3CM_5NS@TT(0Z%T]C3%A[^":RG*N.:=%;B<*3ANRS9_556-O0QOU@M&DG MIX[4J^VY8VU#'__#4 MV5=.':E#7OQY&.?KJ.]*)UY?\U_E.RY&KEZ-(BJ3Z ,Y\B:0AM2UPSAW(67E M.'8JZ[ ?WJWV"]D/S[;FHNU(PPJ02MUB$@\"% .6S!N=+@$1SI')P/*MNO;FW!;D5Z7ZP+?%>,NRM^3[- MP_HJX(H5CLJ0+E:% -)/(=,J8#$I&:UESG;KXQ712P??TAO MP_0-O@Q+?%P*IN7(T=@DEP68+0Y4S@8B+Q0I">>DTCJZU*D2]U''><2+.!9# MB2PI($U$3AG-($1R\R%[%GSF6KO8)XK;]R+.B8NZ#I?OMW5')Q+T3J[:=)O- M&2V5*)ZX%,E^HK5 ZLV#2BD8':S'3E>C]JU6<.*:X=\]20\EP2DR !D&[K-" MD*GNW;G$R?[6+,A@$EE^Z\OMZGHGS@ \;>;*]T_20TG0KH_]:HC/R_JPGT\/ MFN 1@ -I/JOV7@=)9D%V^=\LL-@AG0)Z#NB_:EI=:125.LM M#V>?VD^]2F\Q7TQP,2N;>R(^PF483Q8WP6Y5GNK ![8M6=5R](W*6-$3SV<$ M]9?Y[.+\$[DWXJ"/+!9K:='T/EE-LN+5[-)'F6-M."LAL!UJ+U:!,2:^RN4<2)FU.3YGWJZ M;H,>5"&L(U'UBW3<(\F\7:KW]H!?XCND-T8";9'%19"V-J!0(D ,PH+E1F@9 M,^.YS[[W[EB'%/L-GY'["+@E$;]$M$4+Y,L2\)^V]D>)D9N?7#TL0O*FDDS@ MN"J0C=.9U08FIAL[6PS@B MZM6-]G5:GD@]1ED+QD?"UXY"&:+0%J:P*Z&4* MJ<_I_9Z AV9MCD[> Q;ZWH(_A=GY%,Q_GL^1X4I&GP.8Z T%\Z* 4UE#8EF: MXKSSOD_6W&&X!V:.OBO*'LB"4S#W^FK-]4J3&8OV/H,1CFPYLQZB\AYR23IY MJ]'R/IOE^V,>5&N0[XRRAXB_T]69S5L&G^JDA\2Q<)% 9EI&"DN];*HT<&L2 M0ZSWPOIL+>Z"\I#+B5LPZ-(VWG%5Q7AMI23CZ%FA"0JVGE+X?9E;KY9?'3ML_/=19,&3#3. 9%UINLBJ^GJJH:U( M"7-V,O4Q'GO!'91C+Z8CQ,^F*R6#GTB3//3 M3)'+N(Q7]V-6=_^N6U;0/ZXEE]._79QAWC_GX4C VN9&G&(V#\RA6&]2\G!V M%L?3JU/@Z6*W.OZ\;A8&9]1<0F5LXYT1&2D(U" #X[^,-7D4+PC3:=N"M] -@1O MHC-+OMG'ZQ!A-6VVM,7@5QU7KFY+_SX=UQRV&'-QSH*.SH!*ABP/0T9F0'A& MWHQB9ILVVH=@&(0U/Q*+CBJO9M[G#H@_YV^N-A:O-_3KA<+5:L%:2HVLS6S^ M>K;V=7P40B%/AW,PJ:90*IXA6.7!UH:>3LO,.Y7:/,+@.LS_JR6>KYGTNP ] M">/Y/\/D OE(9*M$L0A.2%NO'"3P,@D(*27KBY36];ENU@+]$ S-4%?#;0MU M=+:<0L_PD7&9,>9J7==:G@@#!U?0D['-0OD@G0U]$AIV03FDG?SOD+=MI'\* M?MZ:80HA$$7@8),1D.I01) MN(N-VNX7<>P+:4A7JH9*XU.RH*?^?HEI]F8Z_C=^94H4C$4;(686P5NEO>P-I39)>39^A_EUF+X9?_J=42A: M!.L3*$&A+A&6R")YH7D6+G*3L[^=H+ZMRF@-=>!QRM'8_@VU<5*&#%*=/*W= MM]=&M$K.>OTV3.MEI_?CR63D$2US/(*5NA8*<'5T24+V.5LCC4O'HTE*,Q]#GVLZG08TJ#RL M'W6-[$N@(YV-/ZNU$A:O+L[/)UB/H\+DYS"I'WGU%I$<[C*;7XIO_U/NG1_1 M]KSZL!$VNKW_N39=17/-B8\C(XD%EFE(:"EZL59 C)F\#\=%-LQ*T2E5[@Y M![=VV/RU-9R[H%!SNAP5G0I%90)PE4N+PH./I5YYJRV^K24;T2=KZ)O0AN1R MM^#+%VT=FLJF73>0S; >7F'25EGIDP.=+.G,P#PX64NE2)E%41)YZ%.-X>NX MAN1>'I$L^TBE&5,NB_3AK5'6?1]F,YGW&,C0NHM G(%"1E.-0$$/ I*2C2%(V%AR3Z%*3]&JHAJ22>["F5H[K^JYA] MW3MNZ/-O\]T]G/V=Q]0@O_1EI>WS\OOB,BA\'NDQT[I%0ZN+K)@#7/,F-C'AAT >@@F[@@Y$'4'@!26\C.B?+[=WCC=K^YK>V#;X_864L2(EU9]*RJW)X#DV$$(O-%$=F MI;'+0$NW$T(49UTDX5XB>3S^K5AZD")JT%>:X:G2/ MX'5)('PV5O-(L7 ?=;$=OB%D%W;D2B/!'#7J?'*QO)CC#=U7UIS),,WK(SR@ MK/1!C^L1F[88>:-#J6?ULAG>X<%?@WMT@:.0C4/)/7 I%#GSP4)TV4(.R5BN M+.=:=%G?VR(\5,]M^YS_AV'^FD:((QEB\#QHR*XVAPGDPSI.X8Y5DF,4*:#L M4W%E9ZA#<)ZZ,NZV;NPKS&:V=2>8[VG6T/"CD3%>F3\3LQB/M+&8,)Z!(.U^EK)A%=%"X9GZ8.B M*$CV:3.\*](A7?H8%.OV$N71"?<;.=.OW^/D'?XZFR[?+L@9T&BL3&!831QD M-M#RR C,%:%HII25?=*C]T6\#0'U_T8"'B3:XQ+Q)9Z%,85T\^?ER7A!,JR+ M9Q11,.]]@5"8JH4A'+C,&006(O,B2%E.:'XW8MZ&C.9_'1D/%^]I#'%U%[A' MC)(+<#%(6C2A7K4SM:H74??.5UJ< A4"T%BGZ MKFDW%FD%^%P@<^2"%1.T[M,UYEO(>H_\.B"TM/1#R!F*T0Z4*0*\]!R\,;'4 MLMF9C+L(8"%G3I.2DP9D0(:)G.3F'SO>I MC[ [UB%M!YV.;(>+\6AZ[;/6-=PRQS3$5"_)% K,'.,$5G*.1DE&NO=D;MBV MUO)8&STG]\-V%MEQ"57W/5.F7_8<(651R$W,Y"$J7J!PYT-.7*E.G?*V13BD MS9K3$VI7D1V54)<'U:$(GS)1/=K("9X+%'A@[1M0I(S9>2;[](G8&N*0-F%. M3JG=A?8=)&&-^$VPW=.P1GQ B5BW1W_L5*Q(YBT124'(2B8R=!!KODHVCF/) M&&0\[6YLI^O@HRPI3LE) 8?:> A0(C6@&56(Q.!,WN,E/1!W0GJRIXM;X3O M))CCG&+\/LVU<\G%=(GY\8=$'WUP5E^-BD69@]3 /"E]I1$I]+ 6K Z.F>@B M&?SC+YZ[X YI<^PH#.LOU.,=:L@HR>@G"SS7)*^@"P2+!2A@X<%:K0KO?VOB M:(<:(X6"6X<>I-:F3-G*"=U)&'U7Q)V+ M-F;T(L=(/K$,!#&N&M_7GU+RR>4<69_TZ9U@#DD#'Y]'381WI(#FNN @>>VS M>OE__*DR85B5:/O05&TJ[ZV#0/*HERC11Y.T3-V.![Z"JX%*O>O;+SM$ MF1)HQ()!$'4AHI;U#C4C_R?)K&DNI.NV'?159 ,SP*VXLT%MMA-02TM\%ZH' M*5V<55%@)ET^7X[_O9K!48I>QU@WP@22QR"%!A=E@F(MEX73A(AN1[D[8AU$ MDZ_3NF0,KVZTZVK&(\4MS_"N'SUEA9$[04] MF[YYC?.S^M[^X?>WOK%M%+T3_E9GA6O/6:LP27&%=EP5('4B:^D@DFZM;V6, M"J1&HA2\3\;O9CP'5L]=[J+HET=\;J+ MM0YW%#D**XFPJ<18"^Q$<-D9L%FFX)CP)74Z,KX-94@;R0T)TF;JCV1J7N)R M/%_5@XTX)<.Y/&"/]^[O:FM>ML3/JMDZ,$F+F-!O,.Q]Y9CGTT2M?A34D(]2%2;>U3CLA-;-!7T*Z M+LZVPF2S%CG1:)FM2!36J[_%0I(Q.G*_Z>]C$6<=UY"LTXF8L[>8.E+G\8=S M3$O,9 0NYM/GT_K>59?"K$0.QFH0Z )1VM2S7B7!1IF]*\9ITV>_?A>4@VHO M=B)>-9+AD5RDM5VJU9DP_7:,=4DP7&99Q6PGQ"*W5-,'=!N.JXO[AC^)=]OXU]\ M7@9*Y<*CCN!C\#0M@8&7"4%KC26*0O]WW.K:$_603FNZD^]HXCV2K_@*W]1] MJ3F>U^/,Z9O]G<*[OJFM][<5WM;=7C^+>!084UR1"%&77!O+%W""?HJH,#)I M4.@^(=L&,(:L^';\/\#8ZXB10V6PZVT&I1 M+@B(V6C@+FLC18ZI4_'.;R$;EJMU($V^/!!N*)8F+7!>S\-T\:GU6IC4"/O7 M, UO5GO:(\Z,Y$RPVIZ;8FUN/3EO+$,AK\YKE(A\FR.[KS]E4#DHK43>>'*; M.3$;.J>ONJ,OQI=-U%?7V M& >U@]5:6W0253,JK>=)/2]KT"XQ&6Z2<#J %ED2$F/ D8L$DD+ @+$DEO:DQ6PV%.LJE>3U[#&1;/GQ<9A/"='BZ?3R=75U+C_R?(JC MZ&RRLN9.)JVJ?J+!:F<@LVQ0ARR4_OG#JE\3GLB=)K_8X6G:]U_Q^O= M?RG^3N-+CVEZ(Q>W'M5,%WA ''OH(QL'O$UGH$&'Y/4G/[CYY(>S*7'W@AAV MQ>/9=#%RLN9&!P-,AD)>[.I"JTNU64I.EH>LH]IB5>_XV,//<3\_;F0M%IU2 M 118W:4R>4FCGOGY2HD]F\QLY M_X:TI8N> SK.*0JO)\R:QJ6EDB)B%JET\ESO@C2$4X!C,Z2-?+:T9E?OUS]B M6.#?__3_ 5!+ P04 " #/A2947H<+9XA\ "R9P4 % '=B82TR,#(Q M,3$S,%]D968N>&UL[+U;=UM)+UYNSU))56VM44D:26W/ MG!>LR)L$-PC( *@J^=>?2)"@> '(#>R= (F2O4I-@N3.+^.+G1F1&9=_^9]_ MG$U^^)+GB_%L^M<9G3#[^/EY]^^(^4%__XHRNS0 [<2067& #T:4-)$Q;TMG*750R?CZ3_^N?X3<)%_H,E-%ZMO__KC MI^7R\S__]-/OO__^ES_"?/*7V?SC3X(Q^=/ZMW^\_/4_[OS^[W+UV]Q[_]/J MIU>_NAAO^D5Z+/_I__SVZGW\E,\0QM/%$J?QVP T?%I>_>%U-/JGBQ_2KR[& M_[Q8_?VK6<3EBIX'I_##UM^HW\'ZUZ!^!%R Y'_Y8Y%^_-=_^N&'"\GA/,YG MD_PNEQ\NO_S[NY=WD8ZGRY_2^.RGR]_Y"2<30KQZPO+KY_S7'Q?CL\^3O/[L MTSR7K>C74ZZ@=(7S/^K3?NJ-Z1,!F%X2 '?>?0 :%3Q:;T$OIV4V/\/+6>67RWRV M&!5+.T$H!HR/%I01$E GVE0T;14J8LJH[M*\6*O-(L>_?)Q]^8G&^:F*M7ZQ MDN\%T0^,?B'R?K/Z0+\["DIAMJ@@.2]HD_.*9L&0UFMF':)$D>4@LZBCW43] M356>S=?X+U^@/=^P:A8T8&\Y&T!X%\P0_!]_F,U3GO_U1S8$B?_['.?+/)]\ M?9<_S^;+D4G%E\P-)"X5*,$CA!01K&+.*1."9G80/F\-?$+4]A'I79;Y$"R_ MS?/Q+/TR32_($AXYJTB]0@"428)"(2!X,FP9S8RSP*3T;A".;PQ[0@SO+\Z[ M_(I!EN(YD@52)WFI<\49XVD)@2($>2$A(03.,VC,D72/J\3X,,ORK9%/B.5> M0KU+M.Q#]"_3Y7CY]=?Q)+\^K^(8%;)>O"H1F!.)L&1';F82P'SP$8WFFL5> M!-\>\02([27$NX2J_H2^RQ_'BR7IV?(UGI$]P((G,U2 %K).3!7PBEE(LA3G M&2^9Z0%(O3GJR1#;0YAWR=7]R7TYC;,Y+1RK2;Y?TE;Q?'8^7N[S;_KP_ M2VF>%XO+_ZG3Y:.$62?%::Y:#*$Z5G@[6UJ%/AN^^8KW+ MM1N,Z^?TY9OYA]GOTY%BOI!K@*!Y-D ^@@.?#!F.Q>6S+^-IS*.T/('WCI8=9QR*(:SQ MS:.?&M]]A+OA_*37,=D-8&]GBR5._K_QYY55X;,L#(L$9ABM.$($\*QPL,;Q M8ITH5O<[O]T^]JDQOK]@-_#=Z\"LKC7/YAE70#@FX3UY$)[I:C_0DH.ID!N! MV7(;HV"L]&+X^F@GP.G>PMO 8J]CL7H//7G[:39=._H\(!:-"DHPGAQ]22KE M7 "6$NTH,:'J>5IR>\038+.7$#\=,\*"# M$V3OY:I9$D$8R:/6-BDO>C%Z>\038+27$#AUUKK?KEC_@)IQ_S MZO#-9..4L@*23@X4(Y/=YQ*!/M;6\LR8PD%>S^NCG@"MO86Y@=T!#K">G\_G M--6+>Y"J=F2BGR]&,66O'%?@HR1++695=P32/S+T.<5V\>_038'DRX M&U@?X/CJY729YQB7XR_Y!2[Q$N?(JQQ<1#+(,Y(_9JT"-!@AR0O<*H_< MBZ*9&>B>\6K0D^%X?U%NH': TZOW9SB9_'R^H.DM%J/L350*/<1SL\\X M_3HRW++"' +7CE:3I&K$0M' N->Z9,-T'.+MW3CXR5#=7[0;*.]U2G6I@I_R M9+*&@YEK5LB5(TTD&[%81"A;F"ZU^G8>J;?4/U*GRQ&MEA: M0@Q-+3M:7JP2X#PM-%S+J'DA1<1A G1O#7P"/ \AT@TT]SHFNXGI(C[\ E7T M6B5M(PCI KD& @%=4L #\P*C(=>AWVG)UJ%/CNI]Q;J![%ZG8\\(4EK!FN#' MD:HWU)Y;T$;2FA*KH: #;2M,A*1%B(%O2-?;@> ;PYT J?N+;P.1O0Z\-DSO M X8)[1A2TZ[@2)T$EZ 4R[246-I K#6,?#NOPN"Y>:N1!Z3W6J;S =_47J+< ME/WTPT4.ZS_'R6R1TU]_7,[/\[]9"Z ,F MT*V!7#HF32, MO9XM\^(M?JW[VHOS3$SH2V18$_71:) U"EG1GD?6D0P@&>U\Q12?PJT7_D[I MBX='>;*,#BS 5_D"V1*;T!F+I'%5*Q+HB8)>EJQ0N 0F#7 &$/-2DP64R=J M[QOEB5,[F "WYL+_RT^W)$/NR3\&J%7SYO7[-Z]>OGCVX9<7]/6+7UZ__^7% M^P_T[6^_O/[P_LVOO_SOO[_\\']OPNM6R:;CDX>M<[//=&Y5P1'%>YW1"2&8 M"F2Y"[1%%UIH-;/%] M-]<#.%I76/H:#B^G<9YQD5_DB_]]>;'/?9I-2.D7O_S7> V%)($%BT%_9OO.S')-\4$HW6ZS]N.C M@;-R=]8DF M99,D1"<"*%O3>3"1$8[<>:M11WU?!E2?57@(_*>M?T?@>,#R1=68?)V7M7+# M67XU6RSV ?]LFM[EE/-9_:5M\RMDX,BL($41:8>( 4+BY%+2>R@*O8;6QPXV M_2&PGJ:^/DJF!ZS/M);EF^6G/*]A9//\J9Z=?!0"5"8$J!&!I$,62^#"Y'? M5YYH?Q6Y!]1I:\E0; Q8Q6HCM'_'R7E>(WL^6RQ_R\M/LS3B5AJ%44)9)12+ MS -&93&9!\DFL1RF^OQ+NC^1*HS!#\#5L2ZX;&\7"S.EK7855S!":[SRL8!PVI-15TSMIY# $21HY!M'JX'E7K']*=1N* MNP'+@ZT1/TO_>;Y8UO/IQ8?9LY169.#D+8[3R^ES_#Q>XF2%/-Q&_BZ3Z!;C M97Z?YU_&,5],]5V.LX\7E*YF/6(B^"B-AU)(A51B"8+Q",F4XC#99.]-\MI? M-UO/[+0U^5'IQ9 5TKJ\JBLKY**,]F*D+'-<9PE690)JI*NW-0*2Y85EE[/# M-D<<71&>MB(VX6G($FS;C[97QS"CDF((I@A %A4H*VI$67$00]5SQ[#$^]*C MAKR/6 'Z$ZA+3Q:&+.W6Z>)-UD*@-&-(WB2:,&>DNE( #T8G2RLEZC:'%MTO M0H]VG>=0Y!AK<'_.I2;-)/"6RTI<\=QR>W_%A\=UG=C2/"Y4LAI>LVFUTE;1R])Y M\AO00DBEUE]R])4L' *B,"PKP7WC"*1-L Z=[C$$W=LTI[?8&P1.W,)T&2W9 M!533?(^-L(Z<\M&?OEDKV1],,]!T>!JX1^RFYV7NK 2VU@; M!U2(KOD?!]*'741^F#20&#U9F YL$J5>S"!X)S2@D%QXEK5V;9S:1Y &,@!% M#V>"["#?!F&7-RY6+B$5Z6.V9$AK5L/=TE^#(XF',8 "NHX!:20;(FT+@-8#>"2^L4U"%X>0^ M8+#B%;@8S\_.)[6=_+:XH$N@6ACEE)504LVO245 ""Y#+(2_Y!K7<5_%^1X* MTA7B22A+$SX:Q :^RTN::TZ_X'PZGGYUH2NB)WSTU$3H ]H77?!=O@]= M$.YR%#6(>ASC/*H-ISLH3 ]"!O17=D"*V7/!F0$OF0/EBZ>E5&5:^Z0PAC9( M:SM9&X]>9;:<6#T6C=F%AP-KRK=0E75"/RVJ/M=RR(Y[PDK[I??D=:$.,AKA M@_$'W(5NH3N,:9,NHX M1N]*!.017]E3/^.D3O3]IYQK?MVWDY<*9C);G).U_/-7^N;SC*3RM_GL_/.W MW+WK@-]< 7YU=;,Z <66S /3-:>H?*MKD^/> D^R=G71OU M_D&?T[CC=/G-B,S<>C2J(:M:'*GVAO(F>Q#6,6-D3"FTN7;:%_%1 J4>I:[? M30P[@ XTN!9Y.Y_%G-/B5Y+\"UJA%LOQDH3XIJR;HN3%B,> (EH'IC895-H9 M<)9V*(/,^QBB<(UBZ3N ^ZZ1VS1R:&8'+N%5#W5P\>G-_"W.EY??7(-Y^51M6$/8DX0,Q?))WIWA'K "!D QG?UNZU^A^9V MX%H6-R3U?"6"].8[G47!I60&BI0#FG M@&3-(?JB+>T$+.HVU6\/-,%#1><^]M?A,>O58XDGOKE'6L&(O0 MD0D'LM3Z-%PA>.\28,Z8?0C,-@H4>P#8L2YV'J4NW>>>]>2T0932/? NCR.[ M &P:NOP@Q..$,0]*;'>EZ<'*4=1',5$$EV1"*U:3R&P"YX(#9BW37H605)L* M@$=2FP>"G8^K-;N0T49;-JRQ%[#ID_+SU_:RE [P 1 M+="K:86,B7/=IF;"8>;WW7;;;KL]0@UK$).\$^#7>);7]]0=8!_.,.P._#CF MXF/4I?OLA\:*T-H6W05^]B5D@U!LHCD4EZ'6,@,?HX@LZ&QEFQCJ1Z6_#]BM MIZR^._ _=#>9RU"1?\LX67Z*.%^;5LEYX6K-=T;#@[)6 MG^ D1.IAAD*?E; MQ54W]Y'9\OPCFZVMR)D-+-G'$?3T/G[*Z7R2%[.RQ3P?.!BJ\X '")+:;_*W M@J>T$:A55EB,5UK:4(^I99)<%RV\#UN"ISJ/_=C]F&\G]]FR++5/9 VS5"OO M)*#WR]/FQ$A C >43]69>=4DJ.KU;+EQN%OSN0;[65@LYQB7(^$D.N8DN*1J M [H:7Z-(,L:(&*RBQ28?(,9J_PF<]I7N+F_"O9;&@32DP0'*#I%C[_*73!^, M:GM>9VKN6RW?I730@%P;0&EL85&H>#OVY?!Q@Y=8CVSC'$HM]H\&W(?3UF[; M0_&+B^7B3?G;;)86[V>3-'(>C8_2@9%6@//,@BR>)""-J%C MZ^*T=D&>I_359&5*G1&M56ZK=*$_:KW@/!))YU*, '*7:D!X M+;HD10%$2:77]2T_'4[I9$J6B=9$K#: M.5$%(DAUN39M:'7L"_JZ;K=AMT&-I!]CK8B9KY"X46O=E@(PF@(K& M 2::2-%1V2RD8.7H>GD+\W?5;,AQ@^Y-]TBKKN@7Z6(;?N7G7&;SRVI<'_"/ MD2=-BDQZ*(J6?U4;=@9#%G?AUG+.9,JQF=<_Q 3^M'I[+/YIFA4KZX+$YDV@EH]3DI+@JN%AP*/40BMC76'4]F'X'Y7T#;,#M@RZC*[ M[*$WZL(X6=5%N^C@]W):DR%7K81&@1-R5CR@\;0=E,(!9:G; 6;HV@3 M C'4#+[?RP_@&@VG(\>]$EU?XG+NN(G*U_SVA$]_?SU[XM,^^-FQ;JBE%EE8TV#L3K4SL5)T?99- 2> M-*-U+?/;$95#U_097R)L07YUI/XO+\1>2;EYLGL0H>1-* MSA((-KW;3B6H!?K U":+SO#,L OW(PN MX+V7*#1WP)QF]1BF;CC6 9FAY A;;8)NTTFS%^P_JU*VX;7!2GFHM$ 6:BHL M&4AE5?M4>P8^DCLCHX@Z.M3TQ1,-A#[9LC-]S(;'J%=/I>P,I\7&5VG;6!LI M^:C)$;*6OG4Z,LEUO'U.^+WLS,%U:<>R,[MP>I2Z(5T ?B\[TY/8G0N([,/* M4=3'*31*U98L2FC:*R1"T(F#+E[:(+FD-^N4U*9GV9FV6K,+&<(\Z;(S.Y'S,8]:E@>IV[*,( MCZCLC*NWYEH)$$H*4-P[<($L,)$9.IEC$(>XL3NV_CZ.LC/'4-]=^#]8V9D0 M.!>"-BPF:S!;$O5&@C96&8(P]!_CMW3R1,O.[$1.I[(S.TBV@=%Z]09MN)UZ M?W&*N'H1/"9=,C)PV=&+P"R'H&IP8\&4:E0$:]1TJ2/ [V;C=K.Q!<<-$E8O MH6RZ)KUX][K@:VK@/83P.)9<$WIOJU +;AK87 _B9-;Z1 LU>.YK \[$ +E4 MX&D1S\D67AH5ACB.[CQ@13T*U=F%DG8J\_QBY26 WY;>RRU:AH(^.$6O8J8] MWY4(WNA0ZR8G7[C@B&VNN1Z$=GB[:5@V-ZO*0%00G9#J#$K"P(=$:RC/9V=A/+VLS'6M;]V'.4X7)<])ER^P\N*T M""X#Y[6E)_FK$+15X#Q/JKB@3 @/;(;[C'L"ZM!D'ZI!D!^F%V7S;.R MS/-:FL'Q%%4F.\V5ZB0J3L8:JCDX&9Z MU)2:QY*6NV%JJRB-E+54*&E9M3J#"K3 AA0+:,%BI->BN$9Q"EL '2LFKZT2 M/'S)MS,9#:):-L&Z6#_7D:Q= #:-IGL0XG'"Z08AM(.2]&?C*&JC@Z=E64G@ MV84:"J; HRH016;9LZ1U;I-^=B1U>2""[CC:L@L) ]_^_OMX,L&/^;<7EQ%9 MT49C.=EAP3,%2G!![J$O8+7C,8M 4^U2*_;68Q^%:=M'Z+-A)#9@?$>%\O[3 M.$_2XB()X?UL7P+D)A;44A*L6*O!UZZZ03B"ZBT3AF7# ML0.EG08[):*'EVZ3<-?Y."_>E)?3-/XR3N=DIW]]>7:&2_H<)YL,IDO<9 9Y MQX4DHFOIR^(#>(D:8JDW?0Q9J^+Z^R(^%=4Z*'-; T(.$#2[MMMGY>WY/'[" M17X['\?\;++2ZII&,TTO$[U,XS*N=ONSQ2)_BYNC'[ZBC\>3530R_>S\+*=A MPF\; FL6R'LH8=X.":Y]V;/$4E)0K# D!PH+\Y&G8FF&HP-A;!A<3"\L*]9Y M2"S51O'9T%+.$(+Q0J/0SK(V^;F'""[N<))[E:]V<5VP#F!]>;76_1OM@D3D M;/YA=NUQWTH8ABBS* H<\YR6(^YKM;8,:'5Q0EE60IN"NX>;XZ/8>O;3V!Y' M_(=4C&,$/ENEI./6@A I@ .?'YM6[!I&O0NE MQPNCOALN8Y5&SY.#C$+5L#L#F(VO9;DRLRB+BZJ#B]8'PW>EZQ<]V8_4 0.W M]XCZU$D;1.\NRV)$1$!7\T')FXA<&,^]&%;]CAI@>QH*MRMQ#5+\=XH7,,87 M65.@Z+W0H(S3@"+;^DX$G8NQR-OD&3V-8(Y'JI3-J6[07'H'K#+_/G:_[C-OG^BN/Y*N:?CU22B0<9P=I40[ID 1=1@!1%T\=>6>\/ MI>P[H_^NY=VUO*UJ#!C0O\4FNH7_]6Q:8W.(N\FU%.P-\QC%*(K4C$%TGFSR MXB0$'AP4+;3G,6+17:XW!X3T76V[F<$'H;Q!UD![:?-13"Y)AAR23O4.,G#P MM6:+$1BDB"Y9?W0C9=_)?7\_CG:2NYMB'299X%V.LX_3FB"T_2;IV::;)'*7 MOS539=G[8DG.WI&MIC'4D%0.D<T_IU6SZ M\=7X2TX?GYX ME;K?N#FJ/C2,.QUBBK1;W9C;*H/NPR><_FTV2[^/)Y/:$[+M-H8)=FC?V&N??+]U7@LVG*82Z8^HAX51&%<=F"4)>L4;14QN6"9 MLY*%U[P4_>B5_['Y MSXE%4VH>>XYR=*$D5Z^%=.#5-O"U%IB&5>7HF (S^6#!TT\J1WDG)>B8H[P+ M&4=)-NT"\'N.\IZ$[IQUN@\;1U$;C]$X)A58+VL/ H(<,-6>%=('+#R1;79* MZK)GCG);;=F%A,8YRCQY*PD-D-6507E!4#C/P()SKI@LM+QEVSS5'.6=A'Y/ MCO(N$CM*CK+GDI0V6HA8^["AY+7^>8#L0U#:"Z]\EP#X)YNCO"_1PTMWZ[O; M*&/TES_&2YRF=%GD$:\:T S0>OWKV!)-SCLMZ C$]QTG] MY#U^H=]:O"DW_NKM!.D-E_3&Y11!HJFA^L$"*LE 6)NDL,1O9AU6N('@''X- M'%R+KB^#QR!IX'WRGBF\/J^B?5/>TU_GQ7I"'V;/ZP' B-/";H7UH%4R568" MG!8(!-:8D()/J?13K'O'__-HTG T-/"B.KP!]6L^"AJ-RC)#+=Y)EH;2X&4J M$)F7TBI79&D3X]T5X0DI5%-R&MPWKZK]?YI-Z&F+=:C@9>3@V]E\1<)R.1^' M\V4]P_HPVQR$.Q).(?D8 8IP*T?4@#/) S+'2^0)F6]SPS8,_A-4P",0V^ F M^)[7J/Y'4SJOT:X?9B_H8SXR(G/MM8? DJY.;P%?8UE59AB*J"7;U*%7N@TX M3U#=&A+5X,[UV]G]/;@O^W:KF)(QM,M;SRO H,"K@A"T"MD+)YUI7?KW09"' MNE%KOVHU(N;8EVJ+^7+T#J@$(2@%BBM.R$.!PF1T/F;!5">5 MHJ=>4R?Z[K8JW1CV^!=E W,ZZRO; 8WR*Q#K-L<=8.QR[]6=ZN%//!^^U>I! MP6T2>\BO(9UHLTS><.#)U6*PCH%3M@"SRBK)D2U-GYV260;)DIG@P,F3+M1,5*0$U.>TY:>VNMO%-MIP=_-X8^G*W72_BS M(20WX/G8"@C^<0U($3)XSVG+<=68<+'4<"P/QL<8O2\8;Y^F]J'P^M!/D,*] M)=?ZG.JFT;A::)3AWH;HZO(B::%)%@+W&6*17F%FV32J)O@ L%.UEUKPTN!D MZ@/]WBT17-Z<=@'6-*9H*[3CQ!(-2N2L)0L-5I?M )E0/'I+KX6.M.P9C8"V M:)"HLD2KF;-MRET?6#T>B!TZCG;L(OR!8X?J)3G-<=U#;*G ?/'$+-=3$\T60[W7GV&Y3SC_F-<@$[B16L==K>JA#*^*)#R M35\M+5(H,P-30B%]I:\\.JQ@7T[+ M;'YV41,GQT_3V63V\>M%=9SUY\\N5[:ZV]U [;73W)/+G2UM<<8K<%IJ""4% M*[0FI7XH!K$?@E-0E@/)O\'-X)T L96-'%*.I1@#9 T[4)'6.Y\#HU7.&\N9 M8;S;A4V_(XHUG#_5P<1>'+2.1*B@+E^1+K":'D9L ?8(CB+VH^XA9>@A]]:' MF]?@,24\-S8!N4>Z5H2-I/K%@RA*"!48(Y/YZ:O#+DSCW-@&)"^62O9 M-S K-H,SQLLH-?E?@A8UY04C=TP9X#P2N&19$ M(J=?<#ZM&4SK?2YJ5K(N4$RM;X,T66>J7YZY\D$:$T)L9%UNPG-X(V, LNY8 MEKTE/7#XRY6J_RU7&^?SIW'$R4K-+6HA3>T]G)RG_5#3/*-BH)R+D06?8APN M?G0KC%.U'(:3_8!5H5:@+F*0KT.Z5/PNH :/-MT*Y_"QIP/1-6LEZX%C&[># MH\4O:^4*H"BD[U)S"$DH8 RMY4$5^N%358![HE8/R?\N(AZ0]S@[GR[G7T=_ M^WG$6.0.50(NF:Q1@1Q\L0*D=J5XB2CX?0%SBQS_\G'VY:?+)U[P?/G-BN85 MP=_&.VSXXT""G_62VH [^1K!W]^/HA#.2K)'(E.DD#PJ0)<"<$\32%IPK>]+ MDMR-M[^_/P7>=I3:P.OL\_.S\\FJK,8OI>2X?)OGXUEZ4YZEV>>K&DPN))I? MG8^I^#R2A9@4!Y$E*]&6+$*G[.I.2VX71*=LEPW.R("-J[K@NWPENB 8L1<&/=*@(ZLQNE9VH&+0_ Q>U.T95EU M.C<<9HNZA>ZP9DH+=G?9G_I0L]4J/72=MCLAY8L&!=NV#W*8RFT=)WFKA!N9 M-0XU^98Y.I5D1)-$5-)J*XK146TOX;9]O /4* MP3N4W@@N6QTHMZOEMG6,Q8A+QY7,!2Q-&)1+],:)R$#3I\Q8:7ANTP[N+I9' M6@QD%XUX,+-L-X&WN)G?P3="?N M.\63[L+! 0,'N\#ZL\>3[D1=QPC"?>1^0+6P3HNL,Z?]4Q(\IAEX:1&,9X+> M 2UM.% $^J.+)VVA#;N(^XCQI"P[KTW0@$DBK8JLWFGX#%8G:7-1LH0N9?&? M9#SI3A3M&4^ZBWP;6*T/I6X')F64QD,)N9:03[H>H),(LM#%66$.4N[P:5;. M&,R@Z,G+02MG= 'VO7+&GD1VKHVP#PL'K9RAM;%<"@D278VPDX[USBA6T7>JJ M/,D:"_NJ01OI#EU+9^>L?\VE$L(X6@4U@Z@(Z=18V%?93F0 M_ =,I5]=D-.&-YN,TPK?ZOI@94IE[QFJ3$N<,K3+I<0 0_+@:@Y/2B9RV^D^ MKEN$PD8,I^JT#B3UYGIP^3ITP31\:-P6-$<(AAN J7N)[R'FH<.8MF%S:%P@ MY08?=2&_RB-A,P90"16XYAGM<$D,AZ7^OJ"V S&_BW0;G#J\H:61,$T_7@:, MK_>D:+DHF@M:RQ+!$LJ1D2L48#+!V!!2UFVZ"6X!=."PM$'8F@TOZH%=RN>S M^><9@V&ZHS7E?]#--Z1/12SRJ 4#^"D3A"=RRRR1,B[W&D\ M/-(39KB!*!N\ZE=966L?9JV'JX5-8(H\N$3SYK2PN9JUK:T&EGC.G&F969NN M=/?".E4K<'A.6K1ENL!R^6)T =/TLN(&G".7O^A/UVU%Z"WK%BO *N486 M!/!DD$#)&F%F.626@C#(R7%M%(C7GOBN92X:\[Z+B <^6OP[B3&GU407[S)M M9:M&A)?PUI9*C)H;QB!@K3=-2QMXYSSD5'A*-G-?L(,MT&&HPY\(]2!BUDZ* M ]M[JSZ2T\M(BVWX:F7/A$8!#\A Y4SJ7*_5DM4!@\J*JRX5FKN,]51I'ER. M6U_FH^:2K&]7+W[ZM756R9;ACI!?TF7BMS)-A6L2,DQ1)=4 MS+IKILF6D0^0<^(4DXE4'HHOY)TDX0"]5Z"C8EX:JUDYD9R3RX>_FTTFO\[F MO^,\C:SF$8OUX!(WM"9+\L&##H#:6\5<"E@.D(!R%]@CS4;915?NC=;J247K M(+]+>".44F0E+:2B$NT33 -RFG[U\#0/,>E2#J8>1]:)OI1U4(>=Y-V\1=K% MY?](!&85;=S$$B%1P=33FT2O@#!!,!."\P<(^;Y$<\(ZL(^\&T1MOL6O*P^/ MYG<#WLB[DK*S%FQD I11=>V+%KQ0T6;&;'%M]LEMB$Y+%P:1^\#]*S;-=W63 M_WHV?8Z+3R,99#3!*G+I"OD1N::-FY1 RIP4ZARDZ]+)Y*%Q3H/IP27:NN_$ M);Y5,,<$;]8-&"E"4E3MLT/&/RCE22VU=9"#*#&N9-#I=G00TV CQ-/0FK;, M#%@:\B'#)L9"RBRCLZ"\ITU-:U\;JV0R;4J6L4W1\8<-R3V.AW>X)/$RE,1% M!F9L;5^-K)8-RY"S((_9QVAM&^OIJ69Q]W&Q6A'S*+.X-V0"1%.PB.+ AAJA MZ[, -*$6.^!&>,=%]/=5]OM3)V+MI \[)F+MPLM!,VRZ /N>B+4GD9U3;?9A MX:!J@L+9$*4$(1/9+=8X\$PJ8%GQ8HM,A;7I(O2T$K'::,G&PGZKHVN]U#[@R)+O(Q@ .+6T4 MY(J1?<0X\C:A_(^_.%D+;=A%W$"+Z5A MEM7&4MIY54+V6J-3B/2]RM'GT99G]EM_7Y'[D?/JT2_R(L['GR^G?7F%XZ5Q M*814HY@TJ.C\13%YE:QSN3;*$6TLMP> ]=UW+AY_ERJ;1N+M;%D7DS#J=^'[?"KTI!Z^H4[)P)-+R4)(F*M*FL<(&WH4-"[H(W,YG9P5=-E]*"A NU5HK_,CQT5 M4-.YW^'TX\7EDT=F@S()I,Z.).(]U#[38)G4RG,A,P[7_^UJV&,=BPS&X:RO M+ >N1K("L3[,[0!C\!HTUP @G2.'>DCMX4N]_G8^77\_R\M,LC:=?\D4< M]&)]=3(K%[_PV^H77G[[A1YYO3U''#:U=\CIWSI@XC)@D39;ZZ526@?.,S+F M%">[RAL[ZCOX4)'86X:YYC&@$BS5D!G4!F@UDN"SCL!T35\VRIC4.A#[(8Q] MGVB[_%C'D45"CU%C=N%CX BF9V=Y/E[, MSLFJ^SG//^;INHXNR7'=]0 ^)6TS"8HBWNRANI/OA MD4Z"[H$%VOKMOHJ\OQ>QI<4L>)M)+14)PVD' ;T"HZ+4M/1)CUTRZ/8;_234 MX@""'S#._>9EF5(YII0]7*M8%QJE>YN]$P99KX'WDU_ RG[MHG3>NMC/PH&0P$)@KP&*VRD2D]>G4 M+O.'8'$7L36]S,]&Q%"P@.&6T&0IP=7#-G(HB@C!61Z'Z_3U2"[S=Q+^ULO\ M7237]#)?V8P>O:O])\BF)\L>0@P.>&$Z<%N*BIWJ\C^ER_R]*=Q;2WLRK())6>06%LH>\^A%G.MU5V]T)Y[$=L$_.\,]5%?LNZB M6[>OR=J2=M2K>UM[-D3RC- &36MZ(8ED^B&HE 3C:DU? MS J\X0F9:V5IORNN\7!5!JZ)1U=12(%EM%99L(M'4FON*;!5*+(X[_.Z>_D73KDOIF^N*RP=2(U12%X@.@\V1D,<7 MN9HE&I+(GDG&=)L<_%V1GIR:'82RNRIF#A32JKWE(GA:/UT0]02. WHI 0LK M,M%B2B_(]Y#6H92H 2E//J35*&]U,A$DFEIK1]<;:YJVXTP[6H83RDY!U7_V MD-:=E&:HD-9=R#ML7&(79-]#6@?CMGN XC[$'%9U2I%.6V^A**UHA7>JUD\) M8)1Q@CM+;]5P02NG%-+:2&-VX>/P(:TI*NXQ%++S7(WC]3417&H0VF")+'J\ MW4_R%$):=^)DMY#6701Z^)!6X8OFHA@PI89M:ZZK@<_ !.V"#L$&WZ5O^A.+ M7=R7[H$%.O#;_>_CR00_YM]>K(NK9"R2!P_2V% 36Q-93R8 3RH'BRE@[A*N M?.NQ)T%D'U$-7)3]_:=QGJ3%OY'KO?ST?C8Y7W68>(MS4JI7KYZO(Z6==,Q; M!3$6 IA-J=M0@&(E?6PU@3<=N.PTV$DP/+Q8&QSE7QT&__SUZLM_&^OE%=P#8MS;X3W.,4;&_!^S;5:D9:@\H"NX%6WH2LO8'D MHZAQJ!R"0 /:2)9#07*B.H5_/D4->Z &_*-3L%VX:JE8+Z>?SY>+E03X55Z! M%I8G#S5ZF4SJVF^T%LKBO# ;= I6M;DMN@?4X2^&&M*Y37%ZT MD^^BJ4V9+E6\"Z;!C\2WH3G\87A?EK82WE/$ Q]N;\562@G2" $^.MH0)4;2 M;O(.95*%ML>(6MLG2OL]!]J'8'T7R0Y\A/7F\WB6O@&[W'1D248:EB!C+2#. M(RUD"C5D)[T/)C@C;X6Q;3ZDW/3PPQYV#"/SV9 ".W3#EVWE*,_/SG!>@T]^ M'4_I+\8XN=8N[X %0OOA.$C9T %%=2N/R9&>%6^TU,DKSY17.3 A0D(?2@AF M:S'1?I .EO4D#&J4D=ZK&#B9QU*7%] M\+.PN.BU8I)@K'9]2M+2"L., J>#A, 3ERY))E6;A*\M@!YU:-TN>K(YB+P? M 0WRE-Z1&S<]SS6P?=U_YS_&RT_/SQ=+@CO_Y8\X.4^U;^5B43LWI _XQTBH MXE4AWY&V#%ZKHM;@,"W!^8A2,2=4:%-L= ^PA]>G08B^T\FO+4L-CF[^-I\M M:GQR&2]'F&FZ42!HQR*HI.F]X:%>V2BR<)20)78RRG=6F&L@3D,1]I5J@^N% M"Q0U'GBD7>1,* G2L7JL1/\$IA",T.A+*ER%-B>ZWS"'.AILSJ\+ =,\]GQU-!* M^C^=&=A4K\05[2N^=J0MG&EI9)2"M7G%GVP(?1]CL0$IQPZAOS_%Y/6,WI/I M8C89I]H;?1WQL3K)2BISIYD':64!93(9,MPJR,5[B1AB=S6!7+3&(@]0!\G$J*Q.O11OAY.V#P+_\+Y#IA+%:.?1>AX!7@[WS2?"R)1,44#V5H"B)1E"9!$LLR$9X7U2;2JI MW8'2_]S\LGC0WTD!OA6*>E.NA4G50@V+Q9ORG,3ZM9[.GLW.I\L18[7Q8N&0 M GI0Q4? Y!449Z.)EBEAVI1?V1_SX=?2?KIS]_S\(&PUN)]9RV%4!+W.3C*( MGK8'57AUWE"#E[F4J(+.I4VT_QK!4]>!O239P#9[.;V477Y%*RWMS^LU^*)J MR]5=SA5>%7DD7 J8JD5?'7. C";-M?&\ =9R3[9YTW4=^#UD?2 URR=Q$5)"SK)N7B!!X M3."#R-%'&)RC)8N(@\ARXTLO/]=!Q M$R86BC*^.$B\7H?$6.I^QFG:Q:M@C92Y2WV7;<]_VK0.(K46':PN@%BTX$4QF&Q(K'0R@)]2=[F=A+^UN]PNDFO:70Z9X:%V\BC12:@' ML>"X99 \^HAYO2G<6W*'[B[WT-7UVE"871D*[4("MH]UT-B MCE.^W9..L629UD4IJ9A5S@BE;6(^JAJ"$A\,$M@^[-#1 N0U"519@V9>U?X% M"%[1/Y:3.G.OBM%MVMT,'BVP?N"[V63RZVS^.\[3R 2N:F-[X )IP?2ZOFWT MRD5![ 23(M-M(NHW@'D,=S*[L+WM;G=?^;:\N#="RJ02+:A6$@YD CQ-"3(O MBNS2:$5LG8=G6_BRQ;Y#1>XG@6_^M\/,_IQ3FMCA\O^HF-"E?2 M"VU!AGHZH(2!H,D8]HE;GB)'>;NNZL \;T)U.MSWEGF#"_@U-IIG'G^/PG8\AYH.I0,# @D^T''K:?GTI@#X),+5VK4JT!^?A MSLD/2_T]A^8'8WX'Z39PD][0,HCU[O3]Q<:QSC0R1>A2\XM27EW:.5K:=*T7 M*X1#0X:8CVUB$+< .NQY[3!LS887=8/#CZOZ&3^?+\@.6BS6\%;Z[G4)%K,' M$6L@'.< MF,,!Z;JM"+UEW6!_N E*25]3)0HXEF(]V"L7'C!#'5E$'G)LDQ-X .(?B#8\ M%.^[B'C@F,,:/I73:J*7,55U<;N$=Q7#X;*EU0X$Q]H+#0T$KB0(9:(-S&IY MN][!QFBT#D,=H;KD_D3,VDEQX#C##3&0=_&9$E+"$,$I7_X0O;$CJIZ-?+8/]NV@G*6D?/5X MR!FFU\,)#2XQ"3JFG(N(WLUS/1-Y M%'6*7!.[.5A>;YDT>%M+"@D=M!'">=&F2N+N6/]<"C4$82U:JVU'_#HO1SJH M:D\*D-Z1\YE,3; P%LB5\(K7-B*WFZNT5R?"]>=2G5V):'!8MW--#!NS0ZLM MI"1IY92T:"+# D9('[02QC2J!?[XJY4T5Z6F9#6(@MF@[QN*K'BC0RV$SJ.H M^9.ZIO'5@)F,W&3:B*-NOBGKH]7G ML[,POCA;N;A?,=%HD4CW+4^*3#SDX!R/((.U,C&GM6*'-YBZ@3]4,--Q[:8& M1!X[%JK#O'^^YGQ?U*XU1COC/401"BW2F@Q%D1%*2.2(),3L&S6Z[0[R6)>G M!]>?[OK;B\?#&OS?@+[&LZL"VAW@MFT(OQO@([6$;Z4 W15M,/8>@=()6TJV M]34TW(+218!'KT$R;U00.K)R\$.PPRG;0]WA'ZFN[4+:P#=2ZPYH[_)%?/_B MT_CSXMDTO9I]Q,>6W\]F7,3V1O)O?9_-_K/.H,TLF MN 0^TBJABF3@I:[AF$H:QJ*37G;0CH?&.5UM&%3"#?:C#W-,F1#^HZKHZILZ MZ;5J*E)$P0M9@F65 ._JHLDR6%UBTCX6Q=J2Z+N!-(5SN?S++F*T!V@89J&@3.,YJ,J U MK"B;7*L">X ^SLE@4V783?$&8_+P[5 V0D?K MLA;HP=H:.E.3(D) #=QA2@PE!M_FZN[1*-\#)X6/7?=V(?#@IP"R6.^-1T@: M RB."#YF4:, ,?%@>, V)MHC.P5H3NQ.)P&[L#+TL>$GG)]A_/IJ'.G]NT)D MG5+9* 2N(B%*08(7*,$8GE 33)YO%9K<[/YO?/KITCV01 ]=@/)%#LOWGVI& M3CW;GG[\D.=G];/]TQP>>N*@V0H[P;^5=$"OFY5YX71SP)YT2TECE? M_.BAA_<]@PG+E]/%(R]>7<6=)'3>&J4AD?<&2M9*[$(4<$%XC%(IR]JD MD6\!U/^LZ?IC?\68+UL0>NT1LXKTEJ5,"UYRY)(P R)&;6RT(36J';8-T>$7 MIR%TX.XIT@#R;A#\?Q/7*B_CZR%9*,:F-E$5&\"?EBO(AU)2,[NC:X M_8ULZKQV9I4+$+:6GLF6?*LV)M0=*$]; M(X:1<(.KJ!MJ.IO&5474Y4C3$I6YM6!*/>\1)0&2MP9)9&>#8"&Y-B'%F_&< M!OD#R+K!'=/-F;[+GR^NW->VKC4I*LA$0/*_JYFF+Z:L>$*[%V.LX_3\7_G]#(1XG$9X]T;-/+QZ>/QA C)"_H9 M32Y]T_=K/QN1L9M3)J.AZ,Q :6T ZX4:2UI'9$R3()LH5_.IG89^/BX-N*OB M=MC%[^*"UQLOR11G(*2MZW&UOV1VD")*IZ4U7'?J#]1SQ3MH'E?[Q6UWV3Z6 M5*PK5ZY.Z /]T>I&3$?+K(T%N)6DN/0UU$,A2*XP\N-0%-MFZ=H(YU@!%;TY MWN8V[RWKEBA^T:&,Q'U0='JI<>3!MV$7<#;2 3*,S6B_'.'F+M'!>7E1R MSBV6(B!AK<''8@2?:P]:I;C0M9QSHTI5&^$$&3-AI9T@[N8=_G+;/)E M//WXG.S><;TDJI;MUW5#Z,134J3JI/2LUF;)Y-I;!.>UT3*Q$&R;!G7WPCH- M=1A.\@U6A7K4L[R]^J7()9,BD#M/3KPJDN8=O0##F,K(2(U5FT(EF]"P=43>W%S;B.8R[VY^T!1>@A] ,L")?HBLNU7UD"6[*ON:X, M4#@&1=MA?P.8PUL%0_ T&U;(S:-UUOU\D&EGP:V:KWCB M)P13R%8Q16J=HW&'B,HY)3.@IY2;9(9>1W0])K8#KJ9FP#9DQS$$^C)WKR+T M%'N#;6 K/L.<%)J3(ZMR!.5D *\=!QZDIO6J9-VH+N9AU>$!8^!0VK"+M SY9Y\1:_UH7OQ7FNU%QN5UF:S!5#B$$J0J9#O6TI-53,\IA2]O:6 M'FR,NKI_E&-?3^[+Q*R)& =.!WDF^29DXA)94(PE[ATPA;5B@<@0D"O0(88L M:.]+N4L-F?M'.0F"!Q/CP&_P*HKKQIG6NAJ)4=E+1Z:K"[5='UF9 94'9@I7 M(CK/6)=&1=N>?P*D#B*Z@8-C5Y-<+,YK0DS5MU]JJ8CU.6)@WG.=0%J7"1:C M>=J(-%DE$AHG-(L=&+UGB!,@=2@!#FB%KQ80YO6F%41>0J/50A86:\2)=*!X M$8"6],ZS; )#R>3M*_S-"_']PYP OT,*(4Z VZ$$.&!DZL7F+S9HG&3K,QW&?)!!@/-U M54%%F[_3!1C2_SMC$+7O9$/=-\H)L#N@& <,,%TA4YNL.[U&9E-PS'H)@;P\ M4)$I0)=6*XRQ6>@862J1)R")[\>$^H MG+4$2'@@/S\;# 5EZ))8M'V$$R!V(/'=)=7U6Y:5WF (F+6Q9[4C0\"#6V6X M9>[HJV"!2^\<^>N&W;[/V+(LWS?*"9 [H!CO$NS[+6T-B.1\S ZR M,V0-Z(2 M6*'\Q0&1,NJ1YK9'<:5F^;Y138'@X,6Y@N-]AE=JD?&H-C:'D/!B: ML50$C5M#UE]M%,V3=X:I)&[W^-G"\'VCG 3#@XEQ \.#'E7].OZRWCQ*=)QV M?@>%Z5H9PHNZM" DCL&$[#)V6J&WCW "S XDO@VL]CRH,ILV#;U>4IB2+)"' M%FS-;PR1@Q&_90&;"'1SD!=@<4XP:&>YU4W3DA'?^Q1A6\C#S6 M=IBTI"BL065"&6 F._HBY4Z/+2WCO*"9 [H!@W,-SKH.JVWGWX?;:^K#*% M,68(1JX=0WR4X-"259]"2AJ39V*?P\>K 4Z UV&$MX'2GD=3:I-IMXX'X62\ M,^\2H#=D!"AFP*FH(# N"_GDTI9.<5/WCG("Y XHQ@UQ&+W#I6]F1'.F^G_^29^M^>3D1&GG&G@AYI)#& M=NP3HBY9$HXI0 N LN5?OUFXD!0(@ V@JT%"X]T=#REM]U>97U=E9N5E%[9B MA"]*!. F*F)[%K1#,00,,18K6")[\853X(G4Z"$8<(R4&VC^<$UO5#*%9!7H MK#@Y@0HAJ,* 3B1KHN,VRS:->9Y9-?7YFCNJE/H8L3>HG]KTH%HVEYJO1%NY M[[,CR\U[<$8[(!N(0]#* VH;$6/) MNTIMP#Z%I,@S[DW:!-X2Y8JW9C&X.X M"\"FQL*3$"]C.?2BT XD.5\;#4Z4IX$F[K./Y.&D+ 6=H2)!])%V3Q.#U9D' MF]IT9;@079ZP,B[#EF.4T',QQX=/8[S)\[]@N%E\^C"]N5T.J7X7EIT*W[S> MN,4:C?,&@07RL>G@8Q 5H4REE&S)\DJF2]2HT\N&MRAZ5M"TI73WFA@-Y[K\ M%F:SL!A_Q?.&N3QZ3.\37 X#W1K;8BU]T((7K@TJ%6+(@JLDT)/\M2NK.."C M)[:9U8(F9)6=!)]8( 8$ =&2S9FE+3PJY:)M-2=WV%DM7&+AADN0D<>Z4 L! M-0-'3"<3G848\;/7ZJ\W\W&"1_ S)P;PW(F!X_ J6SI M8.8Z019%&&:"8&J8)NU[ %XC;_K11HM2UGT0_QYFRV;=#Z"R:)TV,8'5-;83 M4JB5(@E"YL4ZJWTV7484'OG:ETV'UG)NWHNF5EZ/HC &34;PEOBI7*%SD8E" MIKWE+-$QJ<(06T;%\K+IT).,>ZZ+/6G\D$B*6VTD<)<]+;_$>NU+W[M&':UF MA4RI#KO!RQ[X=.J6T%SB#8*J==5ORU;4/_Q[_/GV?F[9Z_"%_F3Q;>0%HE D MF%A\S0PP&7S6$K)%@RF9Y$J;H=K'H'S9/&JNEP938G9AK8Q?5_' MS+PM==IT)&>LAB5_G]*&2GP?+\(-']$YRH7R$@QME:!B'?2MA0!NLR?$,3'1 MJ*GV$\BN@R^]RK_'\N,-OF7SH$W;T%=?<4;V]0/ZKL,^&:V-O!A(NC:-R\% M].B!HS3DSQM79,.)ID_!NPZF]*^)'HN9OP.YL8UV(>AG[?TJ]_' MGW&$7FK!,H>0:KM8Y1UX7SLHB!)**?2&[:XQ+<9W=$!Z121JI9\^:Z@ MWH5QIFUQI%.*"6T!6FO-M? )HJ$?72AU@AER)ML,7]\"Z?995'\JN ML1KI^-,9&#IB8$H:8M81>.:9_+DH([9QA': N?2 N!XC)D?+=E? _1(#XG8D M9J9"SGNJ?3M2O=!FDFPDE2U8Q24:;YUI-?_G6:>L'Z7=IU/6CY'R4'G*73#] MN"GK1VFL2\+R*>(>B@K9>QZM*Z!SHKU1*;)\ZR!?3+H&_3Q7<8BZE>>5LMX[ M XZ1\D!C/21:(S@O@%[4X24B@C,L@7%.QX#!)MUF>OJS&.MQOI8Z#/4X1L3# MCWV+B$EY\G;)8*VMJ1.XS KDXF6R7#/AVIS^+Z%0X1PF]"?V%JG&LW'^B&^F M8=,^E59D3$T]\K84PF-]+[\O256;R%Y HT?Y9P6XQXPQKY MVL35-]71*0F7HP*I>5K7SC+RB%RA8TW2?R)OL^_O0G,%2C];R U2*79.*PM9 M9RL343 +1YAB *=II:9P$P7C432J4'[NDQW/I;=N M\_Q.$?J DQV+RK1,QM+J">^V3'!DPX1M9#N8 F M1^1T2M&15!.^%()SECP54^_643L5VUQ2/PL7L \]=7$"CQ!R R>P6J.;)BJ; MB0E&&UUD L9"[5,6$$+DC"P4'X)$:;&T&>CY&,M5:/U,$3=/R5_N:(*<3,^E M :VB)$290^3.01'%6:T5QT8W@(^Q7(OM=Z:4FZ=0/^C#U 77CSW.\RC-=1W@ M>(K8FV\'#_!EB]F%%*'4T94JRSJU4BLHBBF%D8D&)8.QX_S;,*&8Z3= M<_WX4\.Q+.?"1PS@2YW6$;R#P+R%$);V260Y=^I+]V*FC!VEBR.FC!TCR!ZM MO56YSTWX1J;G+/RKIBI5JV1G!%H+[0,+"J+GH0K ]?]]/0I1&_2E\VP),.UR)P3 (R/@'X]W]-_QO#; MQ2D%IB1J(Q^3,J"(@U@$$Q1#C:YHL MW\X3.HTF.]_^(_#D?+'WZ$MT0TQZQAV8K<@H#?E/K"@2$9V+X)*T@(S3J:B\ M=JS+!(A3W_]#D*4'T?=^^(K($A;8?=8O_DD6.[^.ITL/AW.E\C&.HTV@R 2@S*& M0XBB /%;J!P$=[;3;(IS@5P[XH,9\B]07A[+[P44"5C(5N.M!^2N^U,RL +,IM=2BK:ET^')X+; [+A"'$W M27%Y= O+N2WT'S)24!5:I1+@ZWVLM$EXXQQS6)H0X#E<=/>BIJ=ONH^1<8/T MAM?3SY_IE!R'FW>!CLM-WJTO0NMD(/!E/\6\S,"54%QPQH6,UC_SHY[/%Z'V8?%SM9H85C,X)2+D.WN,Q0Q352]%93%QC'F'+=5=K_M_JTR7:&"K:5>(;\6GR7 MF^EZVDLG' (S] ]5F("0/*'3DA?FO/7=>GX^#S7N,;7ZU^(Q8NM9>^L.7FL@ MPBBN.'.0L C:WI&V=\QT?GC:[W..3N5.!VDG_7WWZN$.S;.$/^U#B@I9,:*XMEU&DCU+"EPX'P>D@''R+AGS?_Y-LS"A/[\PVV< MC_,XS C6W5CIKV M+^1FQSX)<]GX:$GP(J4/M?] 4H7..$X^?_31 BM"69^RTKQ3D<^17_Q##-=U MY)\LW1ZOQ'8CVM2R=,#4\+C_'LTE#_O3-750\6>(N=E!OX7-%A9$\APPE'JJ M(;%<20%"\A@(ES&ZY4=_\4.^K>:/D6[?P17\,ITMZD[V!C^&F\V)MLGTB3$& M)A"$KQ,<6"P09"E@) ]2>+3,]G?$'X1RJ4/^'$U-6XBYP9W'ONF'QB9/"\Y MBY:@BBO@O$\@#!D?6.J(H.&&1%[!L=^GO!OTF'YZ'F(7@'\,FSU1H4>/#SU% M&RTZ0#T)U 6#*6@#>CD:2@L&W@@!+D;C=!22CM%KHLN)PV;;LN48)?1<3/3W M\/8R">R2U+_UV. Z'1J-A?QA/ZQ3C00S9'Y/STB;&'GM;KX-C.L+?FQR8C99+:<)ZX?&[9]6S\=3F6=GXWR^3-?5-J2^:():ZEHDSM"Z(@^% @ M)T]&J5 LY3;9:0=AG5]JOGGXJ_D<%[]-J\[#S7K,0DK0#Q"A#K43PY(GE M"-HGIH36DILV#6<.PKI$"G=?S'A<73Z*Z3+CUIHT'/PRM@I@XIE2\\:)-:FA7A#\0[- M=#Y_.[E#_A?,'\>3C_>1I3D?&5*V#:3O7$PBX9 C&$S00&M1)=9+1-LFP_Q4 MQ-?$KD&TUJ",Z0[;_(%L?@HWU>'Y\ EQ\:8^@I3RT[?[O_!Z.EG,0EIF<__T M;;VJ/^%\_'&R_+NK,*=3.6E!MAWWCE;&)8DS.0&2*>.-U:&$-B'@=FL:;GA0 M*YX^$WWOLM,N,8EHU\J7 ;6L6;!11MK_-7DGW-9.F5@7HV6Q+-!ZVGC$^Q!= MZ@+CN1!F.VC9A^):1+1WX-J41'= UO8&9"^V"UU]]*+##L0X0P'#4L1H)C2/ M#DQMV$4P$T3O,_"(#(M4/.M>*@-(MD: L-12D1C$ 6>)N;C(.PKHLY3[SOQ_=I7K]]Z7+O23I21%-+U)W8/0^**6RAYH5 TK&!$') A*1<2>2R:G- MZ,?A2?+D!(!+<.08^3?@QB_3&=*6^?._T_(>A7[\5YCES9C2%*)-P=/N2:Z^ MRD) L+3\XJP)DA65MG/^^KI(.(#JDI=7Y^IO^TZ@+^&WZ*DTF\[G*]LJ??MU MLL 9SA?OP^).!IMVD#:PBH<^C%";B)&C'@O9;\6K@LYP9*J-5]P1X!71I85* M&FPIOT\7X>8]+FYGDP__"E\V49V8HPTV@,QUF(KE$J)3'B*QF1&5=>A6@7HT M3W;"N2)6G"_N!O;I8WM\>8HJJ366I,%+ST QK2'HX(!,])B=)*8ZU80$N_'\ MX?#TK;0&?O1C5.N/I@NNIF[./F27<7'ZT-Z3A#A#] U.FKWX.!8KT-!VIZOM MI*("YTL&9IFR67%;L$U6Z+"4>,*A&9(1QTB\B8N[ H3YU?Q1LM=F,I-*@3'+ M 04!4ZC(+&*%3EK)LLRACF=B34C1 =SP]D@_FGSDZ?:KA@9^S6_32;Y#N6GV M9D.RC,YN7UBIAZ8F2(:#+=&0OY\URC;,V 'F2IAPKI@;[!&_3M+T,WY8$*)* MQ^_2&XJ4*483@?/E?&9:+SE+%ER(VBJC'8]M$L(/@/K#.FVBO@:YO'N@W;>( M>1)<4SOU(+S+&*N]*;,;2<[0Q' ;T:9;"3<2=62@@Z)=UP@Z'U$[H.?DP&SQ MUK6Q72] DR<,V,NPY!@%M!AD@3?T1Q__C!.*.F1Q5O3[YHII\> MK=W:CV"9';&2PQ:H%&1DFT:JW ]EO7ZO]]AG#_':&YS9W./2X?KL[= :^W=Y!9L-\<)+7*'H= M0E8\2X+IDET1!D<'G]Q3'=? MPGP\?W-78>1HNT!:!F".M4M=':1BK(3 Z12U-(@2OXGSI98R\%JB]UI "^:=*)H2H> 9CG=$L$WNWQY?W)*:?:/GUOW[^GUMR76_J1K #\ @E9HLJ0#;DI"H7R+)D00 & M*[AR*8A&?04Z0QR>:#VK=_MVNXEN&ACH%=WBVX?Z_2P_L5^^_C8>N<*CDTR! MRYH, I$-D'.20#K&F$^%3M,V98N[T%P;-(,;[E=?R7BH0:U?IK,/Q-5[ M=+7SY/U/HZR\C )YM1)=Q5E]U)2@Z&B$EEEZTR:XW!7AM;&EB6::)HBOY#&B ML];I8FB5VM.B8QW=*^I0QI28T*4V+>W4N/>,5,P5DFMCQ%F2;A O?F"?'5IR MDBK:@(H6&@VHVJLBEE1 !B$L*Y%IU:8HM1N^']G2;:#!IHG?#_".@D.-+F-= MLJ2]3TOPP43(*H=HE*3OJ77MR0,XP[.HA>Z>[*UVK.";L.%A1^R[I8^8I-TN M&4U@1!WHG@($% A<8RXQNE)\JWZ,.P']R/M*'SIJ8.R^F4X^;B;)CI*0.LCD M018REE049(*3QP5:B%@PVJ1]HV/I 8H?F20G:Z.!$=N'5%:Y 29D'8NK6>MD MB*L0'7C!&2#SU51CP?$VQU)O2QBJ2=7S8>)EM/]<>EC=K?ZG;W^]OU=8+FIY M1:VM*Z9@K=M1-4XER+],T@*+Q=C@/406/5[WHQ+ MXDZB4%D 1W2@;(ID40CZMR"9#E8'G1K?01Y =Y$\I)8LZETE%]Z3(A-19:G M,ZO)'O4:8JCI$<*;DB++RK9)2+K07G2D\]";EL_8C(Y149-+V-GL&YWGJ_%J MF%=".+!WYH#44ZE=5W6F8U\$4"EHH1$98IOXQ)% KY!5+575XF9VOAA_ M#@M\6SI\!0*Y1S\N[.4/ ^ O6LG9:>W0&H++GL3%!D[2F"BCQ#=+8 M+ZA1T >F6B>7#DV@D_RZ8?ESC%(&XLW\;E_>9+MK(71F$:R-9,RQ4""J@."E M]I$'\AA\XR/N +H+FDA]J;4#;<[22=,I;CN:I=&@4?7U8SRV8<.4;^0S>SE!AHW4*3(>=-/9%= M[24?: M-+'GF579MPH@OJ)GE4?H[IIGE,<*_8#-+E8Q+/ADZ4B,'I1C!C)D^ M#.F]=4P7*]MD8+_,9I;GT*6%2@9K9ADYEYA3 ;8E#17WVPNZ6*NYIN_=^)3KET??8!0&M. AQ2B*,XT:P5^>8=UCR,^#8,?H MJB6Q?IU\N5W,EQ+@FXD\(:I8K )T6(NV$U1'R5ALL3)YL"J%L*ED9)H(QKG".$54J M7+#1_L>>&Y.G!6/^:?70=S=A:NT$C%0(Y:K>!'3EL)V@A><@^F<@29 M$Y*U*8?I!._\>XGME_R&BWEJZ8 ME*!,G7EIPG@-O^M3JDQ0Z525-;DFWP6U"[$MTD;%: M2!X ZW H\@,8>!L8%&8=BY(K+*WN20_A^N$8<[)2FHP4W497>YZF!>95//[M MI/YNW4!')3([?+(@0E:5WAF"DQITSE;6WJA1MLKPZ8[RAZ-33PIKDN+333 C M32Y(%$I6_9,CX8G_T?D:[;>VL,QL&6QGVHWPAR-5#XIJ<%.RQKF\?AS'VZJ! MY1= /MST&\ZJO3C#^MLP^_;P+ZWJ6$:>6Y5%=N0'VT*V(WIP25D@IXE[75PQ MO,W4RO-P/P?R-3+%A]#D((;69A/^Y98V8=PLXR'R^7NLLB< ;\LOM+QP\]\8 M9B,>BQ06%>C$Z(M2+D-$'^K(1L5*],CT4/[QJ6NX8GX.K>$>+;S:RG[/5_9N M-J5%??@4ZE4[_?!U7"^]UFM=][Q??VC1RT+60H3B:A(&JX40R2N0)C'A,4B[ MG=2]]@&HEO,MHP=DZ MFI9^C;Q8SD.;2YU.\*Z)5.WTTL".^Y ^8;Z]P;?EL4#F]Q*9;^:'<6\\+Z 9 M2V1TLLKTXB'KF'F)+&&K:3?'P!RJ#UA["K73SG/IX75_);*,X'VALWLZ>_-P MT)0,PDAT$3#4!-1H) 0O!-A0O*NS7G*C:XLGH5TJHZ\A*Z8MM=/ _#\(<%,X MTP%BTS2]#B ODYS7LWJ/(<\9NKD0C9S.6C@>@(YK?+N\5HX5;]O]FWTMP^CE$R0 46=>U*K+21" M((L/G#&R'K;HW"'S9([I_WZ*#]425A*H+L)PA$'HB)2T#LC(BZ2QC:%N:>,T?[7G2'G@,>39>!*,)">B&ULCC*3AZ[;3)%ZAF/(A_,R^M)(@TOYPW--NX#[8[+XB$ES59O!U+CE' Q2>+*Y5X M2):!S+P:6=&3@:0#8&*A#E1.*K;I%O:R)XL?H^*S)HL?HY\&&:G+V=AK2!NS MG#NF73U^4W6W,62()F<(IJA0NSPPW>:*YS&6:Z+%F9)NL)$\F(N^*1.RRD?A M$:QBM&?60K+E;$Z-(B>GBDFE39#\$92KT_S)?;V](#'E:@=,? M?)GAIWHB?\7Q3*V>)D"0(]FN22 MU3F-CGS7F7-L[U^VI-OKAR];<>\-O>S^/M$K)WBTML[%\[5Y% =?;((B?*:- M1XK8J!W[L4C/GO#[]O6OKQ:KN_/J8_X^?1=F]('_AHNWY??P[_?3FYMUEZ.1 M4*AY0@;,I@"*2PX.I04A6(X^%F8;.>Y'@+S 5->6W'HT]K>1NAK83A\6T_3/ M3],;>MI\-=N:A'%SFVNFSV:.P\.%_#:=U.MO$GVU#S=% R--9P>MQ /SM!A MD O$>B(DZ>@'CRGI-E]B/_@OP,=6%-DVY(?7;RLK;\\G^Q.6Z8RLA'03YO-Q M&:],GO6O29(CIX32@A!S:>O5FQ?D1),5Q+1';J703K;Q'L]!?;V,'$R7#6*@ MV\A^(2EV.%E6O>76M0OWB]$VNQ(M^ +FO7M'"1[ <1<@(D\B*V.+:G.4=T7X M@Q'N7!TUR)0]M(5O9#)228A<#6@OC*ZE7Y[XGLF 5BK)(HM6>?AC=X/N>CG4 MNVX>\T<_$Z>C6,*J=*0M5$C:436MQQ3Z*+"X9)'9(-J\$*"#0%5"(3*DAF0"H5,"BC8F[33O@8E$-EJP\;#&BEIN>2MWX7;EY]"G5] MTTEM_;2\PBRH4]#& BO1D<6>R>Q!VM4X1BFC,^17MOI(#\"Z5"9).S(\\OO[ M4DJ+X8C?8]HT!.L JFD*R4Y8ETD=Z5%]VS,/>Y/]8,2(')TTZ,C+IT] :9T@ M,*S-EJ7E$0O/I8U',B AGD@2&9H/QXB\ 0\>;),[,NY>Y?]_.U]4::RO(DM& M;^NHZ\@"@I+9T/'L%0BG2R;<,O'0VKCI@'-XIZ,'Y>ZW9OK63(/;C0=H_TPK M7_M K\/\TR\WTW_]!?-'7'EA:[B>\^A*HA/7,?J05!'@O'&@4^(Y\)B+;U.S M<"30*V-2[[KI<4NJ=?'5=R=LOTZ^XHK=2W3S[^ 9KKQ#AX!2)E#&(P1>+&0C M%;-,%ENVJ+.S)T&'5[UDY;>09H,X_P-N$M*_3688;FJ)^CWF#64W&7#%:NU] M!LZ,H'W.U*%"52 ZVH3>6#J>6V\0^]+LC_M\$W+2D1_Q<6G MZ8-%S'>%"S>%(S9$(Z(";VNK!$O$<+(0.W*(2HHDQ?88U-V[31-T+YECST1G M#8+V#U;U^XQLM9M5FOFVQ>:$LD9K0?NMJ*$N32BYU_0/432B]T:U::?8#=]+ MYE9#330(TG?X"C8=U[66+$L'O&ZJ*J9*\9A J&"LEK[VYKM4;/DJ6=.C/AX3 MQS3-S/VPBCG/\$N]*)E\/#T%=]^3>LVU[01W*ZE6*J\-H^^SZ*2<-5%('[A3 M*C'A,G>C?0\]MZ1F^=3WFZ?^.BG3V>>P7OW=18;-6=B5Z5,C1;7CFU)@R-J. MT6KC>9OQZ5W0G9_B\!4GMUAOS3>S /\Q7GQZ3=LJ?1RSG_^]OJ.K?6CI?Y0/3:01!D,\:B-$]M;JE/ #O\+M8[IQYG/+1568\QI:5E MN#RC:0/^@K40J@JD[KLCP5)A$B/XY#DHSNHE=*9]W2B+27GAMQ/1=YOCNQ]_ M17KO2X@]!WB69MC=$L--;4SWUS )'Y#[7)?]GB>UM>97(6ILOI5UAU@L5P2)##D+H2%N, M]G7 JP M- _)1%T:%9P>QG5%%&F@B 9)DS_=SFF5\SG9VG$\6;EI]Q#?X](: M7R'-=::B(:5*0TM7Y*2!*X5!RJ)PK4,=B-2$,MTQ7B%]&BFHQ_#+_8FWC _] M/EUYAC^'V80$,O]ULDD@VX20WDYP) ,W665!NZ.M 4OR&&.1"6C#%$[I(MCV M%)T#]D3W]UX109J+O4'$I8*9T%_Y]N;77]Z^QSG.ON(JY_?UIS#[B*.L$%T= M;6<24[7@6H!7]4I5,FVLRSF'5ETS#B.[(N(T4<;>*,L9.=C?6\_UMF.4="K9 M,E>S/SQ9T($\(VD"2"4U0^LS5VUNH7: N4)*G"ORQRRP_?6L/K#ZG[ZM_W#= MG\HFZ[0B/RL8),B6DTT5)6"1BCPMFTLJ35AR MBA,H*;UHBZ=##R?+4:O M:\.\FW%>KF4ILF5VF@E>B=JUJ*;\U'A-S4ZC\]5[%[00,>72*?6<7O& :_33 M-L_V8[A\X[A&6I_V*OT>HRJ[$:VO0;I@.B;3]T1F7"+!MR]-'53\&6(>B@*N M%N\XC9!<+7'RM:*"ME$Z/!7C3+N02R=3Y1FJ?D\J[Y":/T:Z+F/; MY.&PF"5F)B#97+.ZC*VQ7@2>79;1",>P37KE'D##V:C]:6N?37J&J'N^)'D] MG=$A%Q;X:I+K=)=)&M_4$Z^N>(V.K&(NN/%D)@<&REERM&748 *G\XZ\;56Z M!-2??M,+UG #4;9HY+@I3-A$XC8\7&YLR;',E/.@H\]U(EZM>2^*]CE:M>6Y MCIEM6_RU"]:U6X/]ZZ;!#W7=W N7/-UOKH>=?,\5]9-6L ^ M!&5+8KDP [5;:(VF*2"7V@-C3!1A=;"RC6DP@.*[UG8UUOLQ(N[Y?OUO)$;, MRX7.5YM>W=S6\#9)VE''&*0$86LDC6P4"#9&8"$ZE$ER.C$[V 0=7G6QT.0I MBIBVDV+/=M^RK\%D?=V_#U\RAMO !3#':P_21/BB;B+L7V*.6ME&;;+,M 550(GJ;LK6) M/@D?):;1=T\Z<^K5>!X^$NR/Z_25=3;C_8T!!F^<-0:*$;'V::*O5'@-!6,L M-HNHZX&I=M[Y+'RBFV2MG:=!V]K)_- YG&TL0 W)!P5,4C7Y@KS$*K!9NVV M9$IO8G_&%Y)!!32!1!-+"*!L79! )%UG$VAIWOE._41>X(5D?^I]^N;Q&#$/ M=>W4!=./=_-XE*:ZW#^=(N:A*("N!)<,(2KU9D1[8GFA8TYD%YQ6PD?L='8\ M0]4??_/8N^:/D>Z -X].*DQ2"C I,U">UPL8ZVBG(Q^:_# K;)L64L_[YO$H M;76\>3Q&U,/?/&K-78HA@S6!7'DRCB#4(B.C4K(^:T%_>$TWCZ=HN($H![]Y ME(5KFPJIKIHQ*M,6%ZQ/D%2Q=39OTK*-Y_TL;QY[-_OZ5T+S*\8N8'[L*\:C MU'7PJND463>_8J0MR06;&!3.R2WVPD#,)0'9/\:+J'/"-C,!G_L58W]Z/T;$ M%[AB)--$.#)& 'T-:3FC"%[DX)+W3#I+9Z7L,9ZJR?,EU:/A53V1=[-IODV+M[,/./LZ3KA* M<(Y>"QD5H4#R":4G%D46P):$.JF@5;>2HTXQEUT(KL;P[D7$/5;*/\ S)U=Q MC>BN J$#J-[#K7OA#!]O/5]3C]7>DYA[#K?N!Q="MMP90^>&K+=1M+,%'P5D M[V-0.B7G.\UC?HZZ/Q!P'4CUQTBWYT/ZW:!V08R32@-JK@B+ M->"T+& 3"E>\"U&UF1/\$,5+UN_94FWS/>+M8IS"S3\^D5#FX6;3%))Q'9G$ M#+S483*NYK!Q5R#%XJU7U@?9)?!]\"4O69O]2G#PO+W;+U]6B1.!GG-73/); MF-4[FJ]X1DI?QR?WF^UWRG*VVW"*VE69,YZ95LA[T=K*8_S9=8*7JFVF8S-]CPO'7Z@2\N<_:\1I]SIS<[7IOIHEC/A-ST5F+ M4J$.C7*:NB+LH:'P\CWWC_X-%R-)9U_2INZ5DI-)I SXZJ_2AY9$"MHYT>9F M=B>CXA$#[=Y FSFOV[@"KYR& M*+)"):0-MEDK\H/(?AB6G*&0UE.AOLPPC9<;-OW[#2[%/\D/VPF2?? %9XMO M=3+1@OZL=OSZLFP^Z9SVZ,E(8ZR0?9"9A*AY!.\41JZDC8V*S?I:P?42<'@% M-[AX_AT_U^2)V;=U%WBR*+[5[.K/582GC(J=UXF]&246"-G4>GZ6P LM0#&/ M)BM%WV6;O;#_M5PI>2^L] ;=3U]-%N,\OKFMQO '3+>S<3T%5L4"F%?%!)^_ MT")6L>U-;\5W./M CA2N5C[R.2;.576!9;TNE ZBD8H<9&6RMU$8WN;:O1?X M5TK6X57;8*+-?3^%[V2V%!@)[I?QA+Q*@GTOO/6]BS(VNV#!U+;3BCL&#FV] MY^0A6F-1-'(Y3@0\X%CL]LP;0FF7KCW9*= #*_SIVX/5TK-7A?\J%\5EK3+E MM?[*&(C6"4(?33@R.^SD/%Q(&E]A6)#CB%+0B-9+3MID&(KB@@.=?6T51HN/QB6(.F 2PN40VEPX/X7LNLC2 MJQX:6&P[-O!'D+__Q4/P4=MH-0;(RI6:P^S >6M!)..E=C&31=MLVSD9]G4Q M;#@-MBC2O(O<[!;1N@VNMX)K$DKQM8R9APQ.,P->^%2BRL'F1HV$N\ ;*D#; MDD3]Z^&Y1&'OBA_O.A:\2HOQU^6-Q[H(9^F*,U[0&?H09$QUO OY7YX+!)N% MM[4$>Z$5U\%$UJ+O$7$ M 5P7,"DAX7<13_.+)V8SW$Q?Q7G MRV$U;>HSBKKEIW+@=>>72)$'EQ^_ MH%5ITYZW#4[2IS6XH][HL*B./=;6OZ[_B$3T__=__A=02P,$% @ SX4F M5)$D-#;\/ $ =MD, !0 !W8F$M,C R,3$Q,S!?;&%B+GAM;.2]>W/C.)8O M^/]\"FS/[+W5$485'R )])V9&\Y73T9D969D9G7?B8H-!9XVNV7134K.='_Z M!?B09$NB JDN;$1W5FV3/*<\X/XPP%P'O_^OW_<+<&#+*N\6/W''\*?@S\ MN>*%R%EWT:1$$4/?]K^:75OFQ"_5CPU_^SZ\?OO);>4=AOJK6 M=,6-@"K_4U5_^*'@=%UC?E8OE5,;^]&7 MCGV8?O2F[C?-#W)\A??$7*QR\X5ZNQ)3?7>WHBY6?7R-?7TMBC5=3O"UV(G9 M4WEI/OB@?VK%F ?UD&DMIZ7N/57EC[5<"=FPY9-'@US\QQ_T3XM-!6\HO5_\ MEQ0W>E9\(ZO\9E5S]YOBCN:K12HBS%,]<85I'$&4:!MPG&50/Y9R)F).,[E8 M;[_;"[F"OWWMU*AEV0GZ@X.EZQ-O;"FK8E/RW5QWMSPV@>FYR\QV^)<5O9/5 M/6UOT-H:MZ QX#];/<&>HN#W1M7_Y]]_V5EW ;3+R0!;SA"K@C_19VEM7_.M98;\<#/AU MV5E"2WYF--HK?N&%]ICNU_#)P!@/T\WD=>'V76F@UDK\ 12ED*7VB8\8=/ - MON;:+=XLVVGWMY5VCI?Y/Z5XOWJ0U=HXS'_60CX45?6KO&.R7&#&52P#!%F4 M9A#1.(,L00',<,H9RF*!T]B%-%P5F!N9[#0&-UI1\--2J_I'H%\3^D!S;>E2 M E64H*+ZATKR39FOO[\">P: /]?H&V7_>*7I MBJW!URW:^LIN,* >#&@&XPI\IJ59$/[>&.>1SH;BZI7FG)68E/Z&0O2<%@<_ M9QA=OMI4^4I6U>OBCN4-#7^1O+A9U3*%%I>KW'S-KJM*KJMK_H]-7DIQK7UL M_7&^K+^-^F^;.ZVO1FI3FJ_@WM\64N&,!=JG3+@>4R12"4F4,(@12AA'E!*F M7/AU=(WG1L@?BM4-U(+N@# D0!O5W?AV_&&V(^A9#=[(C-[9"O:,O0([<\&^ MO: Q&'06 [H28,\NT!I]!79F[__=']=/-D1>)X?QM9YT-IEL$)Y//],)'C9? M:666F@&U$LVN[3L-W=Z4^6E]*TNM^WTI;^6JRA_D^Q4O[N3K1H]F@^B5U"Z3 M_$9_+-(P28F4$11AQ/7572BM'L=@F] M^JMWQ6:E":O>Y7>V8[*TK:M/ $]M M8]P5:,T#C7U7@-46 FVBOPEF%.2]3B9^-9QTXA@%W.>3Q#A"ADT('^1:^\:? MU&L]"^7K=K> ))(G,HP@"TG-ZRG$H4P@B06.28@BP9PV@H\)F=TRH=81% HT M6KI1\%$8[9CT4G!&)L3GN(RP/=*'@%=B.BIH4G[I,_4Y3?1>Z_:V?V=T8=;! MVK.Y,UMA'^7Z35YQXX)HU_,=S&+P &!".4** M0))JV%$L*<1$29A&B&6AHE*%U(:*IX!_"IIN_&90;$PDB@GN&1G_?@Z? M6Q M^5VK#XS^S1ZYM@!T)@!M S!&@,8*4)L!]NP8&7S1QFC57M*+#L(33<8;#.WH M+3?F6PVZ/2JSC[7:;5G=%Z71H+H"].:FK)>K@-.R?#3WT/;=4&"YI2A6E&7Q M7?^U K0R?]+.)6!T:<*X0'4K]:@*_9"?]1 _@KP6+[7 M:S /7TT.Q5Z%5.L MQ-ZOVA>]DR7/Z5++H4:7.ZW5#;V1W>]Z,M14O,[-QISAR"M0;;0BPNR(Z!54 MLP^K#2OJI92!L5:MN?3[;RU -E4'SD1N.\04265[58JHQ'(Z38\/JJC1X2@ZO95!3= M=U\_63O@=_GFKJIOVK](F7?BKGDG'NIW@NZ^5K4XNGK\^7('Z=)O=N,\Z:?4 M#E$8QD'M#@U^["2NTJ5&=V[4Q<\9MJ#Z5E(AS7>CTE+J7SZ:%[Y=$HB 9(1F M% 9IK%=6D@M(0T1@+!F.$BPXHDXKJUYIU<5N\@3^.?3@.SW>+6&W0C>T$[/6O( M&@AK54=8[UJ!XG7AVR]QTA6PE?'/E\)V-PTC;#,3U'/ KY)6&SWEFTE@^^%_ MY=J7*/GM8QO(IPDZ25480!&2%**()9#(D$!&,A;C5(G(+4;22?K<"+U>&S2+ M@JVF]?OS\?HO R,HW4;#CH1&PWAD4KH,7F=:&@235YIRTV!2VAH$SG,:&_:0 M8;2FW=WFV,#$.BU"@HE@+(!<9F8?3V-/)*8PE8G, BF2.+7:1CKZ]+G1DMG# MT(O#5;WJ;>,OZ7I=YFRSKH-%U@7X*UWJ];-<5>!549C D>4R-VOB*W.6=WKI M9@$U07',*1.0!P&%"*4,:G?4.*&)2-/(G)*KQ7J;"C BU">R&KSZ34;&)6C9 M,?A@#$9F:/--:Q1K(TW!];/O61-3ZH^DCR+AE82?2IB49(\:]YQ$CU_D1I)5 MN5Z\+E95L:^GJ!3%/QN5+5TX'HA[7_+?0$U\LL^""/K%]P&A+[W7-^_]X[K MWYZ_W[T")GG-;4SLWG:K:]U>>B'S1?V8Q[=WLC3),W\NB^_K6Q-J05>/"Y;& M)$VD@D+[2GKBUE,XDRF&22 2G/ XR9BP>>_/R)G;J]^H"CI=0:,L:+6U>_G/ M0=O__GL$;&0*&(B5-0E8(G&$!RK)?[XI'G[13VAH0/]0,T#][I][[B2OOZ5Q M'0/87CYL>?2I.R/ZH)=B\HLI[/!)_58U<;F+1$0)HBR!D?8!($K2!&*%4BAD M0'"@1!!FW&6YU"MM;H2P518LC;:@KGH!"P4W^A=:QRV[>?S]6-NM +PA.#)# M[,"K%;T"7SKTM+)-EH*_Q8 5*%X7!_T2)UTL6!G_?/%@=],P2C%%4L1F*3^I MCX4YI*?+-LC[D_JT67?Q*F]DF3]H%1[DYZ+*Z\/\;V:Q^$W^6+_2]OU]02@/ M>9Q%)N^>0:02!JE"")&Y@I[Q)MVUK6>Q54S CTAGACV*'PN>52YV5F)0TAT+TG!T'/V<8#;Z1 M*E])\4JN] _KS_J;]WZEV4.+?5U4ZP7/),58*)AF6+N[5!!(0ZK7VCP22:JX MB%/D0GK]XN9&<9UN@&OE'-?59X"UHRU_<(U,4JVBH-44&%7-:6V+G]'6'QO9 MH>*5>\Z(G)1I[,Q_SBN6=PUCD>;,[ZM>P-5A$UW9T?IX244DUJOC$&*&B=FN M"R&A0D(L,R63*$X(PRX4TB-K?OQ1GSYO=06=LDZ'=S8@V]&))^A&YI+!J#D3 MB04>7EFD3]ZD%&)A^'/^L+EE<%6[>OGWT22V?#!)*B8%(%_1%=?KP"^22[T0 MU"N_5X^[G[]I4?47/V213'"$8:)I!J(X2R&+HA02&6>2)(FDSA7N!BLS-_K9 M:0B,BH-(YZ+!L6.EJ2 ?F;84B5 MLQ/"K=[-LT6IO>8G[Q2%9:/ID*6= _YV#.@9TYG-V@5KU=_XQ9Q.X/6 MV-783HE_Z;)J9V"QJ(]V[@D#LWI,\K#\D#^8TI]K_:7*]XJN;4OM7#I*8@A=1ID(4R!BK*'1*[7%686[>W7[9*[JGIV-*C_M0 MV'':N "/S&V-\K#6'NS4;PM9/BUE?&V#O7N^SV#X_";]N*LQ;>;/8)@.TG^& M/\D]O/V+?KYL'GUT+H@:[:_WS0#E&X$$DH)(H)C*D*(.*FSE.2)#!A-*$T00$G5LY' MKY2YO;!M.'6KXE7W S#*@D\KZ1I\?@S8_M?7&UQCG] /16I Z'D/$A<$GA][ MZL1AYSV&'0:=]UT\,.3<5#MZ/O&WDPS/6*@P1E#&F8"(4@DQRO2OF<@TEHD* M$N84<'Y:UMQ(H%;5-:*\!TJ[M8,G@$9^[9M:PP>K@Q%JDEC@X3>0O$?>M&'D MYPT_""*WN&5HJ$P7D;C?&T);I62H&&0I-N5X(^V^(^W#QPAG62H%39E36.!1 M*7.CA;T8WV6KI64R6C^8=O1P,40C$\,>.A_.HC,@^J7'>L]!+\3E5.BYG>.LM44"%,MO6OI(O2*MJZO8(*U'>G@%,R6C' )=!.1 M0J?B%6B4!+66^C>MIT=V.(.$7X(X)6Q:CCAC\@%-G+O^DH2"71N[=P\?\T6* MI.*$91I!$D#$ @5IPBC$-%6Q"E/*4Z=.:TC!BHR-S9YHES3\$>(_NHC0F@-J& MNMA:6_!\WPRPM<-X,GN6^'1B+L/2LY,S4)F)G:#+(#MTDBY\GL^LS%T91J/ MLC#'90M$48(CR6&*%(((9QCB. FA"&68A&%(@M2J(I"[Z+E1Y+N#BO>[=$R_ M>9A'!\+%&?,-[S0NVD'NY=-Z!CO5Q\ZX[(-K@ES+H^)GD&79!XM=?F7O$X9V M\WR0FB=-_SC-D.N2\O5?\_7MZTVU+NYD>7J^US:R9ZX@Z43((>]*=UN'QH#\RY?RO(U7QW2 G2 9$M1PU_()XEJ?/FSB2Y:@QAS$LQR\;YFN\KGMZ57K]]4G5^]EU MJ9Q%(A 7@4RAB(B"2,H 8LF5_C4,(I(F@J=.J=?'QPN58C?Q2#X')V0/H1\'KA']"U*3S>[^YSZ?S,UGG<-.5; MW9ADG>N5T)_)\J')R16(R)BF$901TIS 2 8)23%DF!&:TD21T"E>Y8R\N9'# M$W6'IT6?0UDOZDA"*8(J4+%FWDRC'(D4RC06J08]2D+DUN?,(\[3=#J;"&G; M-9LW]$9?J[G"-F!99@6&Y^58O\R)EV%6 !PNO^QN\U'T^J_2E+^5XEJ_K/1& M?I$F+:3[H^F:&2YP@D4J@@123*1>EVEZP4FBB9TE&<\H25":#J^#?5Z!N5'[ ML]+8%]7!MH#?CGC&!'5D)CJHEMUI#UKUP5;_YHJZ4_58!;3MH1NQIK:%$B]8 M9ML>HO[*VP[/N2#9HHG,_KAMG[V(*%8JX E,D5ZHHC2@D,11!@,1<?MI[5QUIS)FO41XS" 1'$%$(_U3 M1"+M['"2ICR3>B5[60W2?@7F1AFFQTJQDFWI]95<@_M6><#:\IMU49O!QV7. M(V1'-&/B/C(''2]O:AH,=OIO_V0L #^]+J7(UW\H7#XJ:S[;->;((0IQ0,:PP3'IDPS-;7IE80A2X( M21Q*1&QK2%RBR-RHGN?+?W_[XU[RM11?Y'I3KCZMS&?-HF%!11HPK@B4(4D@4BJ#.),,IM0< M33/3U5,Y9DDZB+=Z$2?-G.QT!66M;&7:==SK*]I5_R^%67!=ZJWWC,=03_U" MC%_22]]"WNB^UR?%_+W=6!C3.S^/W>8\"+^R5GX?FO$=N\8R!+0.[6N== M7CVXVK'4-[0&IF2;(%R;WIG X#?5G:]$J=M4&=C_$';.:N;AL;?W=W+5=64 MS#6'PNN\*>BWRR;8;I;%89!E&9?:$8HI1"S6:W4:(QA&"68)0OK_3I5L'63/ MC49VNG9S]O!-2Y&#NLHE]QX5.8/38C+W@=[5S8;H>]7O#0'PV]D\]]MLNC; M'_S6%.;\HGGWK5+:25N0+%!AQ 44"J<0A3B"-)4<1FF0H2"5$6;98EVLZ=*2 M^R95WXD^MT:,]ZJ;\X>\5=]4VN#:OJOZWSK[LS6S+LU3;D&H_^Y(K=-^22S9 M>;9#/S+!OZY'V?P+]BPRW4"W0US_T0S[\\^>W-" #H4P$\=#G_<3_WOL & M#-"@X7$6>9%1]#L136O"M'/9BPS/P73X,EIX2L7YH!<;[_7*HUJ($-$TC!5, M(A% )(,(,I:FD*@D"$(5$DX6U%S<_2/YIH8;4&M[J5Y.3N(;3U['\"- MS?-#,;L\2>< CG$3=7;B7C99Y\#LLPD[AW<,/5-AZ_-'L6\N[>./^? M-:5)S6!@'7 ZX@24YX,1.]D3 MGXDX 7)X'.)V^\ .K>)OF[9.RK?B6HBZ'QA=?J:Y=JQ>T_MV-?)"]N5O53ZIHKBY#1$&-,H<1,0(2U4T1C12%# MC+(P#7"0.1VFC*WPW BQGHQ@;0S@>]8X]GH=>YCMR'1.@S[?796F6)0TW;Y?HJBB; -,]FSQVF)T(>+]=:,=6>MI.M1,-P4$W MVZGD#IN #I?OUYR7&].JS70E_T9_R$J_.75Y!AQSR7FB8!@&9BX)Z[D$0Y8F M08QCA8A;&I&#[+E-"XV&8&U4=)L*7 "W8_618!R9H(]LCIJ=]A;86FG0:NV/ MAP= Y9527>1/RHX#@'E.=$,>X:$2=-5?0K7:'>Q]DS_6K[31?U]D.(W2,&-0 M<)1!E*69]H>%@E&*5$ DY5A:U=WRI=#)BJ_D%5:&'C)+E!L&$V(^] M<_"D2G1UODRTOF1G$?C=V 1JHWSF1'G"=[S*T4.4>KD*TA= V%M)^I+G#MR[ MV#7OK;-9C>]:REOMON8/LB%]$Q#\4:X_*WE[Y1]ZHKDK6G\@4A+N M^Q>VMPU=W%>9'$4"VX**F!)(4HIAT1%"K*$)(0&,F.Q M4\N??G%S(YI];8T+G^\ZCP^I&78&:\OEDS<$QUXE/0/OH&V[QR60%29^5SK] M(J==T%B9?[!NL;MK8";OMEK"DQ*N;>W65X^FRNXG90[6=_NZ,6)2(2Z@S @V MRQ?MWR@D()99R!%+!$N=@G4'Z# W GK=) +D*_"T2/%>MVW'3. !XV+'2R.C M/3)9==H;HGH*=6L 8(]-:6A]01T/TA3N!Z/LK5^ I=\$Y %Z3)N6/!RH@V3E M"QXUC".[K.C7Q1W+5VUH1QW$\4\IW@N]JLQ53K>,?,W_L[Y<+JB,]:J1"LVI2GMRH1YPC 2'B4@I(VE($^RT M9IQ4^[GQ\OO+',%I1]Z.OV<[GB,S?V'WNY5>U2PUC" #@=_4\:+#)_7R69:"R:=IEYD<)Y/<"^CQ 7ERE\WQ8\; M";_*.R;+!<*4BC#-8$BC1*\15 *)8A+&&<]0RA.,L5,OG5."YC;A--QQ<<'R M8Y#:30\^@!J9R=NCV!:CEJE_;]3TZ)R?0\)_^?)CPJ:O8-YC\M$BYGW7#V.% MO]"R)JAZ+]1XXHLD"W"*F/9GE100Q0Q!IM((HBRBE&(218%30Y8#"7/C@4Y! MMW?_$#B[E_XB.$9^VSO=N@,,HYZ_E_RDY5[?[D,ID[[6)XU\_CZ?OG#@H8/V M-42^W*SS!_E5ZEFM]BW>_C"!:E(TS7;O[C?K=F_R+2U-,Q136*#.B+B^*S:K M]2*4$9P;!:JM54"V9C4= MJM]^_@HX77(3QF*" L%/^0I4QJKJCXYG'%Z&UO(H9.H!&_O$9'^L=@:!MT_& M:L\FLQG96662AYN\MBO06.;Q?,4GT'Z/8;QH-NUIC4\P#PYUO#Y\A+9Z=1"R MEF&JO[39T@N*$YY(%L-(FK9Z2C#(<( AP9('5*HT#+BWMGI'%)@;9X_85N\8 M_)8+P!%!'7MA>+:M7J=_77)K6X=AHL9Z/>!-UUCOF!+S::S7 Y%38[V^YWC( M.>M/M3".<_5)F2VRZFNQ%(L@CE,:9P)B3C.]>@VI_BG&,,5$LC0.24"=FL5? MH,O<*+ ^8M7>C;;&E?\N&1$[*IP(YY%9\6E6V?FDLF:)77= J\T!QIZ1\LF& M@3I>*IFC/B^7138,N-X$LH&/=*/3[XPN^K(G:N_TD^J[Y%1CENI::<;Z1G\L MYPAQHB1((N"E-NU1IE"72NJF+252FV5>?^+YC3B M2=+33\NZR4?>Y#[IBV1M'KBK[=.?;PVTH_-)OA']?#^;49[T_*0OE:WY!GQ2 MY]/>S$6-Z:"Q'>P9?P5J\TU*W(R^#*+-Y:AY[?\S7XHG6O__Y48'8NR:0RW7V6NAI@56VH!NYCL9;OM.3V7)UP MAI)0"*@"'&MO@V-3.11#)53()0EB)JRZCO2+F=O"[9NIP@_^Q[^&:?R_LB M=_ER:7:J5UIKD+#UQPP$7)-\V6E/4U5E'?-^0AEQ68--#> NCL$V/]&WA>;E5[% M"H-_]\7\V<^,$",YRF1 50*)5"E"48DI02*!%#@12A"F+J6)&G M5^#)S/0?)5$TV[.MBKTK4EB]>G0J M;UB_"2Q1,4:4PBR1@3GX22"A+#2]#V0<99(I&3L6J)Y [;D1UM,#8_!17SJ( MKR8:=#OZF]]03GKL;S6*0\II3PBJ[TK<4Z@^=1'O"8?C2/WO*:4/FXC>Y:M\ M+3_D#X>YC>\VZTT=&;NMEO+VA^G%L&MNS2/,TU3/)S1%'*(@XY"JA$.EYYA, M!"H.D5/ADDN4F=ND\;9:YW?U2H^N5AM-.P%)/\E9I"&>O'4?8JO00AG4>__-GL5Y1'9D9VUB5=W5FW*DP%9_P MV1_/>H5QHE/:R^!T.GBUAJ?G_/7\,R8[AK4V9_\TUOZF@>VV2ZE=]G>4FY(@ MCV^*.YJO%I',PB0F$D8QU2ZPV5PA<<9@+/6'5-"(":=%3SCX5,>U9[%'S#DY>CU\U[%W=.[1]_%;25:4?66^3 M=5]&A'@</8%_CP=M. M9S&W(P"?2(Y,"9>!Z$P3MLAX)8ZS0B>E$EL(GI.+]7T#4O:>)%N;7,"]37&! MDR@D$"6AV9)A :14AA"1! O*">;":E.\7\SJ#K9:I-?%*_5VUDLOLUG^]@>O2_F_*\IW^D :'F;'NH+'64*"+)20 MB"B#*.4$DB2A4(9IF# 1I8%;IZI+E)DGA^9U],76%L>J.I>,C1V;3H7XR(2Z M,P/LV5$G:K66@)TI$_1I]X"JW\(ZER@T;64=#] =E-;Q\ MM9^NM?LN''K"L=>AJZY MF A9E*P$++$N'\RPQ!'6$&L6)AD$5%$.:5X'(J8 M&Y0/_)U[6.(+KY?N^KEC?.*^1!9VY.+2_ :_:QBOZ-?K9W/ MDXE3EGL^BS@0,_'IPRDS#\\;3EXY['7OF@II-^EYV.FQU0:.69BF*85<:H<& MQ8)"$@L.@S3!VO(P"R/F0@5NXN=&$YWV-3DTA?LN;&/L.!QV_#$>R"-SRQ-\ M#\+HQU_?#0/.*S4YJC I;0V#YSFE#7S*,+K[K,=&EJ447]?Z87^ARXUC M[?\"=+.^+!577JL!R-G/NI!P2OI'),S*;/T&/J,G9_- M-H^P]FS-^9 RV4:>1TCVM_U\/M9MBA0R7[Q=K;7T:R%*4TM/__BI_%9\7RT2 MCF4FHPQ2' B(4BPARZ( 8B(5Y[%(16:5IM0C8VY36:,F:/6\ D93C2,PNMJQ M7Q^@_;./)YC&GE&&(&1-.Q88'/&+*\E_OBD>?M%W-RZQ_J$FFIID^IXY"7%8 M&-61@M^D33SJ5?]"BY*ZT Q42$2X4E))A[?#*!.)$I% IHBF!TB!) MK#*6A@B?&R4\"R2M_C0TZM8"=YL3TO'0'/WP]%E$;KOII]4'>_I?@<8"#W'. M%H@/C7[VB_Q+Q43WC\ 8T=+VN%G'4%L\\H4BJ^V-/1UO[?",P<6<#F,3/VI3 MFX[TVU)4G]36"?U<-#4-W_Y8F_81IM=U7JT7)**AGBHPE*'^!R4D@"00"4P3 M+@61*(F84YZK-\WF-J4\B=*^ LO.MGHCMK7N"E2=?6;_1&V7>?>MB5= ;HT$ M<'[='\[=JKVS#OR^LP^\ MW0VGW_I0?K'W72S*DW935X[R"^J1,E*>!0P-(VH"V[LNV&WD&L8!D5$801YB M3?I1PB U)6.9Y&&:1J%*L=-9VW$Q ME$,2ZF57'(5!%"2*:C07#[)DQ71H[HN; ,^W/O&TFY(NQVCD^>4 G/-AIP/B MLOI \!R;=534Q/%9?>8>QFCU7CTT?X>M=U'M=1%F'F28$AQ"G@3(.- "XD!@ MJ!WG,(MX(J7D;EDYST7,C4>;?EY;%0=5R#X"I-V+?QD\([_TCL@,R'0Y9;SG M_)4#,1-GI9PR\S#7Y.25@\OUE\9I>R.;_[Y??2[E/02O@7(.B[LOT0 M5::N5'\!7$H5A8<:0?F1GG]"-LQFS?<1B:PDY"-L&"RPL0K)?5+G)1Y MK(Q_3C!V-_E83+VC>=E&@G,1Q\1L3"FJ5U0HH9#@+(:>,M8Z[ "1$1=C.UDON"([,+A_679XN7LTS#5*D\!T7JX^ MTT?#0&\V,@I0VDZ)D2(TPHK!)(N%J??)(48$PU2D,6-$K[XBJZBW\Z+FQAKH M9ZWM_PTVVLG3BRPI6JH0^IMOE+:/PCB#<#]5^,5M9+9H(:M5!:VNX$T+V(#J M &>0LX]6\8?@1+$IU^![F:_7<@7N-67DE6E"#^[I(Z#UU]#\1L'Z-B_;/L*> MFL_;X=03BW+F 9-%GM@9LA]G8GG',(=L+UIE=U:YBR],5!@$20*SB$?&-XL@ M"Y6$:11DF8HRK/_G=M#5*V]^YUU:1]AM9"UWJEO&%MJ!;.>1>0-N9*9]$I^V MTW24\LE6F'CUS/HE3NJ?61G_W$NSNVE@-X5VR=BRU-,NVZ];42NQD[L(8YZ@ MC&=0"5-26>E_2!HKB' 8:=*+:"")4\,%5PWFYMDU&R.TVQBY;^RX BMI66]Y M^%C8L="H"(_,3-O]IL\=K/O5WO.>HC+N[1^&PN2W0X2S%M,VD1@*TD&?B<$/ M&M@KJKB[R]==C;O7=>O6&[GB)^I$,A+' G$%,3>U#1#-($U#!$,>H)!IX*+8 M*?+*3?S<*&Y/^_J$BN_K[]ADRFT<[!AN/'1'IK?GP#Y1??R*+<-P\]O/RDV% M:3M=#8+GH ?6L*>X[[U]OJ7E'>6/'W)NSA*[0+U$2I$R0F$@0M/T H>08:$@ M92K(HEC(&%G5HSLM8FYTU6FI5W^-FO9[1"

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

?\X'!HK!N^UYP9\7%9LOFOJ^73XYLY*\M"%SL= MSS0GDAK(#?<08\4Q'<,<)03B*"-:9XFFRJM;^(7YID8_K;B@DA?L"]RKR=PE MP-WX*"",0Y^JKT&P3YU!%UQ"EQGLG'/L*H,N )PH,NCTF!_)2%7,WC8^B+I$ MS[N%?,O6:D9(GD4T3R")J_I;UA>'8W-6S#/!-.6QRJ@+K9R=87)$T@C9U(\" M1DQ@Y70CC_- =M-%$'B&)@A?9)Q)X:+V)VB@5.+GN^7SOYIG:P8P/U0;O]KR MYT<<99-?5*C=UI<_>%U-O8^;RKA$Y4F>IPE$TNQF%!G[@#(L868.+#$F2N?* MJQ[HT0Q3V\BM@%>4&SY&T>VE?Q4V ^]B/UAZ5\D[4GV0TG@?7Z="\%DESQ7! M._Y@OVW]=6VHP7)%]>;_I*MJYI4U*BF7)!G6EJV[R2SSH!*PE[6?KG477;[D&P&GC;^\'DO>TO0A!T^Y^?;50:N*CT M(1U]^K&V4HZUU593K&=<@3YA.<:8YI#0F$,51!#E/!4PHDRS)(AE'3LT# MPP(_QOL@_=E(^\_@:6$,A2?;SF4@A"^_-L+A-O!KI(&L$A4TLMZ MPUB/5XN M%Z!S?]F$@W"DE\\M^+XJUN9 !AX-*1=EU17ZD;T 5B=CF-\86-\7*VG;Y :K ML>R&4\?+ZL( H[V\W!39?9DY/M'/,?IM94[C3ZN7RM'ZM>I:/(NIRE.-1*9Y @PI.,H3A-M5LAQ*OD<-H- MH]9(M&K\%7RNVX?5G>%!*WO 5)BS"^-&+,.!/9T$F%TU0*T'J!49*>WE$H[C M9;R_BB5_+#82'"[Z5]2-7VU MU>F?E&S^O%R4,XYCEN'4&%!9FAE3BF:0&@L*VAJ(TMA30E*O#HM723,UH\LJ M YZ,#K8GS'*SJW>:PL":1AM-VL]XY\] MH;_L$.]6GQNPJQ'X='F%_/MEA$ V;$>-JR0:M^=&"/".NG($&;1G@%_=2.C4 M=$N;X#ACN# [-40,Q8WDFO*AD=_"IT48MFQ\_[('EQ@5](1AXW]=B M!;Q0[=(WZ*[>FV#4'7Q*MO(S 4-XV^(&;Y_4K3;;Q-8T>%\\JUG$8BGR MC,(DUAHB\^J'+$4V-<_\;\PP%[F7#]MK]JGM[8_,S!(@=O8LVFY[?S ,!R:' M\Y&PN_56F)6^JK "K/P#Q[A>@FWX4-:S$KQ^Q.HE<)P"4R\.TKMYZ6'MY+9N M\J8G099J90@*PYQG'*(X%Y#B5, H2:2B6<03KOSJN3O,.KWXDOUZXD4E]5^] M6Y=>1-O1OQ,6P:&].&ZEV&_ [7J]*OA3W1;;T-EG5K6"=&BTT:?OJ2N"H?N? M7IQW[#ZHKD"X#062B[V2840 /3RREL>D11 MG07)/7XJ!%@C14YY?:&\@J,N@= 1%G7VT=$"HBX)OQL*=?&S_1O*+Q=5>,7; MPGJU%[+\K%95J,5;)>;F/W*&I1!$4 (SVPL212B&3+$49@F)(IDF&&FGPLL^ MDTZ-$ZO+(=E*"V0C9A4F)9=S\TMI2X#6(5,]NLQ?7 1G6RTHM,,;:T;<-J)J M(_&-+2-3!UB9?VW$#MN&WA6DX/WH+TX\>F-Z5RA.=:AW?K;OE=?<_/7N5[50 M*S:_70HV2%")KL.521Q!E$4ZX MQ$F<>/&4U^Q3(ZQ&^!MP5XL/V$("MJ< 4(T&OG=C/HOB>E$V$-0#$]@&Y5]W M4-Z7';3"#^!C[P5;X*LU'PE&OF?K <[QI5N?07HW/UP]*=GZX0I5-BGB,ZFB MG#.6VR1M>[-OZ(WB*(.4<)ZP%#.BN0^SG9UI:BS6"+IAJFI_U5T-YUOAO=L9 MGH'9C:N"@#F6WLSH+=2I_H(7CA@;X7]L]J M\:3>&PG?+!>5!^SOQ?K^S5.Y7CZHU;L?8OXD;9Q 6=KH46E; [,.HWTP&X: MT,H/OAL%0*O!#=CH %HEPK9&O0+"P.$)_G*,',70&ZCC8(?^0P6,B3B;)D)B MFHN(48@E%X;V9 89(Y$M@YCA+$(QX:E?_H[7_$Y;]+]IWH[?0KBQ8'AP7SM< M8HSLG%ZH#1\M,8ULG%[@.$5+#)1]TP9A?-(;Y]HL325F"680IS0RQT">0!9+ MLQ(DC7":IHA$PH_&3LPR/;(Z\+T_LN*\,]@92S(:2M?VW&7[;[ZLMX$BB.,ME"I&V!;PP$9!G"842VP;7&F5:>]72 M]IQ_:KS!WC&*8CA !_? U1+76(+?JO(I=:'J\+>//6$*G)#L)\/( M*64(NDT[->[:&AY@(VQU1_G[[=]Z]1MQ1-_1CQ8\O\T(GK*/,;>IQ/61>]J.FO5DNRN6\D)6%5_5+:JL> M8)U$/%%0I8)#E* 4TD1D,$18ZZ(2TFUU" M 34PE_3"R)E$7$#HH@SS_ Y=F-\.J:)S@E&(P47%E@:_;)>5B[=WXPL ;>^E9&T I9U3X&1LP>:3KG@7+/ MTPD"V$B).M_NBQ*H>7U@E%4%@Q(4"[U&S_EG1TOQN2C^;H[/Y0]?=Y7X?KGZHLKUZDFLGU;F/#EC M:1XG,>4P51F!B&4"\EP1*(B4@J2"81RW]XG?W(]RY^;K<;/X;016;<7M=Z=X M!*K?Q6(OC$:^733;'^P)&?Z*\1P,@]PS'DWV*I>-YU0^=^-X]O/#%)795#BA MQM122B";2Y- I+"$3&8I)#E&3.:2QZE7R*CKQ%,SOLR7*@M;229P$9G_MO5C M7J%RS*L6C9EFO9AK2\6$JQ+39A6VUV4QR[E*)50LEM9*22P599!(E&D418PJ MXET39G\.GRTS6@68G9K0P& M,3>GZE2F!*5^M9FOP7,(9R3A!.4YAJFD/$XQC22 N8I5%"N4Q(SKQ*,?A-/S4R:H]!GZYSI M,4H_6ML44Z\K"MHRD3.E$,948B@XT1!%F8(\UA+B2. 4Q8G*<#:KKC_L@"71_MM]7?*ETLE*SRDVW=UV*Y^&S6^=W#XWSYHE;69%HI^Z]L M];+[H29S-8V(H%(@J#**(,KC''*62Q@I+N*,\Q@CIT*@8<29FH73B@V$S=43 M._*6UM4K:V4!5POSTQK88B[VQOC1#.)I#UVYC&Z$--[B#,Q=C2)@5TA@5;D! MFR7;TV;_DZ%3E,/@&I04KQ1I5/X, ]\AU08:]4H#;/]>H:W()!(B.<]3J'$F M#.O:PE>,24AU+'(549%;6\R==;NGFQJK;BV/ZN0(EGQ>W/5I W@!92RT-# + MLSU8"A&3$60)CF#.!3;_CVB$A=\-2SB@3M.JW'MU,-##*@]N_!]#NRGX#MM*[]&^]&FF?H.'!$!\I ME#@H\IXAP[VPZPPD]AMQQ/#B7JKN!QWW&\+_/7&;Q FV<-L UB/;XP)R M[NP=#L&1R/H6?%\5Z[5:@$?#+T59-<1Z9"^ U2E&YC<&UO?%2MH@M/5+H.0. M-YPZB/G" */QL)LBN[3K^$3OR_IB;4S\9]N>?&T6NC 3V-J;ZW*7WYOBY39P M\]OWY8PE49I1P[VY$,Q S[>0%ZR3$]YX!9E]3[TK[' M CC?W0\+ZO!7^$9^6"D MAI4U8#7-U6W!%%=Z>_9BU6,N%$DZ&5^?QQ#W^GW MD&3LJ_W^8)VXX;]BL)YAD^)>R:>Y^J1M-4ECZ-K_V,I0SVQN ]B_60Z>\1S% M*K%W_=@8HD@3#+EU4@A)%$D2S>/,J9: UZQ3,T=;H6V5O*KTICV]53_L2 [^ MK&3WK&[BM@IN/!@[D=3_Z[D MG8W?5&5Q5Q>SJ\K]\#2A69S&4.61@ A)#9DM(!<1>T%#4JDB[<-+IZ>9&A$U M4H(=,7O55#H#JAO-7 _5P+S2 R5O$ND&(2AKG)EJ5)KH5O>0%RY\NA\1?%B( ME;VG>:OJ_WZH4TCNEW,S1EF7M/RRG,_?+U??V4K.J"V'8D,5):>&(6@>09HD MU):8I.;_F,()\F$(S_FG1AVM^."G5H&_V(JQNSK\2UM2]D^K!V@4\:06WV5R MXYP!P1^8C ; W9NL>J(7E,5\91B5WGH"=,A[?8?I>8"S;45_,=-(VPG>' QK M-VR<)X+35,#8P\S]T=4(3]I1U M>JIQCU6=ZAZ=H[H_W;<9WDYI%',V^Z+FMG[0K5@7SU7/O5,9G'$6)U(R K,X MRB$B!$&N$@)C@1C"C#'A1QY]A)@:M;S[4:PKUX0LRL=E:5O:;L3W[9+78TG< MJ&=HH EJ24E8]M=C< MEF[\L'C#'HLUFV]">%42IU)"%1'99.MQJ6&B.1&4B$2RR,MV[)IM:C1K183% M HA:2$\SL!-71\,O%%I#FWH;.4&+62/J ,7HG$ ):\EUSCBN[>:B_)&UYO10 MWTYYIP(G;M=MAZNJ;"C,!41HIVQ_/'$:3%#'$(X:H9W\\AUFG M1B>;$*'*0ZVVM"K--?YI%,LE$BC)(8UOC!6GSDXQL%^5(IB36*N*>-5ZV M@T^-7_;R\WI='NY!Y\8@?0$9F"AVQ0I9[.18V<"E2W8F&+D0R;%JQV5%3GRF MO]EPP *5%[VPB0(-2^S_P\XG/ZM5L93'P0IB_B0-B;S[(>[MC? 7ME;OM%9B M?)71?1TUID8\;RHY;5NA MRK2Y.3)PJE?V:H-#]?>_^EL]K_"%<3>CIOTU&,$NNSEAE&V5W@;('_[;W@,U M&.!$T-D-V$ "6DR !074J( _6UR"]D-^S84-;DJ^@BJCVZ:OMURGC-U7E*9W ME')3G/&]@==>7-6\>7)\N]E0P M+]Q:!UO12NX@ 9:>I4\&6WVW]^=KKNG ;\:] K/ 4A;8U6^G5,KNI?C-T<7Y MOJ*@U31HC/4@:Q Z"#NLD&-':0\"\8DP[F'F">HB]C>QSP\RH0W?D0@ZD(%Z M&98Q?)*O9O!=5M_1"QG&@/JX7-R9;?-@6[]^,T,T#=B5P)*F*8-2" :1S4C/ MN?DUQU)J3EG$B5,MI.YIIF;,6"FA%1-8.6^ E=2SK?T%7-W8XWJT!F:-?D!Y MTT4W#D%IXLQ4H])#M[J'M'#ATSWBUU!\(FX#1VT71$51:K._MLX, MD!KS%&$>IRQQ.AE=GFIJM(!^CL_'K^'((PJK&^%N<@B+V\ $T4"V%[]VTP2P MX:A/ %LW=!X!;,$@'"F K1O*0-%J3J!T1:MU#S!>M)J3(GO1:FY/]+.NOEDW MV-/J9;=]IZ2Y,9X(AAE/;<*H3"#+L8"(YQFA7"HLO3J3G9AC:@3:BECW/[75 MA;N:.C@CZ69,78G/P$2Y@6:H9J@=Z@G4]=%^&[U.-O]- MK>^M%_Q9E6O[9JC]$^5R7DB;857_0:FJ^ M11'&5QI ;72'2D3&G8I5!IE)) M98:9B+T:2WA+,#62:(HRU!J K0HWX$ )T&K1JQ:/_TJYT^RD(UO]]N*+4JM M5N9@]7ZY^FR6L_KYCT6Q+F=,B$Q@JF%B;"2(2,HAY6D&9:8QS2A)XD3,%NK. MROO-[>QYC3Q.>Y;6>_9(J@'=,4:=OX)',]R]C4)X7!5" ;U<@:(LGZIVI4L- M%NJ[^4NCC3G,%C;090TT*U;@N3,"->R27C[E#KY"X[!JJP;8T:/J.[#5!.RH M4BW81AE0:3/2DKB?GL=:FI'.UD,ND= H3=HWV0\7IV ME5O?JY5YGR[WNX@V=7YF.6,113&U*6H*HIBG,)>:PB11C'+!(\V]HDRZIYN: MI5])VS3Z]6QIU@VKFZ4>#JR!7R U3KN2;AH -\*&[ 'LA$K8EF;=4X[;TLQ) M_:.69FY/A:K 64VW;:/6=% KE'F#VW#P&#.82:PADA3#'"429A3+2&*513&[ MKOKFV;FGR2Z+Y0(V71,!JRJ[5U$.\ZWBI4R66ZJE;T?[SDL MB!_E!0)Y9+8SX#9B@\\;D"O);RJ4WUU$N3?1N0,V",W[G26Q MS!*4FUV:9;:&#R*0X5C"F.B8$AYE0GO=[9R;:&JO3)L.^M/ ])M MXX: 9^!=O!&Q:3Q4I\Y^Z+[_\@_TO !$V&C/6CN,]+G^^3-(-. MA(^CI#68L20I1>94SU(!$3''?1YG*4RS%&,L8L$RITJ"EZ>:&AV@G]'YI!F4 M^&1^="+]=D)I\X\FLX!1LRC M<5%D/X_&Z8E05^%?E%#%LYVGG,4\$RGF! HL;&5]1"'C*8=28!S35%N>]?.D M=LXW0>>I$#:CI@2KC90W8*$\7:7=(+M98]<#]ZK7V#O"#GEM?0*3@2^J=V=\ MY:OI$\I?OHP^]5 _*GE?+(JU^E@\VP#WM?E.%&;0VRI"Y/9AN5H7_ZA>34T( MS^_JQ_K;=S5_5K\M%^O[,C:HMFW5?;O MIC3@9RO&B*+59HHJ(S%9RP]C& >(0%3SA'/5(0BY)4T&5[$J3'R M%R65H6/+"&>J\5WEK0NQJ"B+$J)D"H4BQ+Q28YL3JRB,LE0G,964"CJKWR1? MU^:P]M]A:0_%'6Z!?U%WQ:)ZV7(VM[E>K[Z><2)RI+B&/(^MSXLB2&5J#F:8 MT%BC.*4X;=;SW<+Q0#:%U6R%'6XMS0Q36LA>#OB1EV9TU_VF:T>MX&Z=YT9' MUV*8 8^8PZW!D+<&(<1\S?N&@#!?N*D(.5//. 1EK$:U#0>WQ_+V,O7E-V:; M":]?OE42;%II2RKR."(""JR1>1'P''*12JA4QF/;C"W37IU\>\@P-7/LJ[A7 M\FE>)63?WMVM*O<@>/^TMEVV*X7 )E;OCX7RJJJ#$LCK73&8!2)&"(6(\BE-O9RCK'@*L]2A5Q#*4]/,37N MVY,25&)Z5?#I +.;LL) -# C]4#'*P2S&X"K8S'/##]:4&:W>KO1F1<^V<\\ MJBJ)W2_GYHFR-MEF>202%&D-J8X(1#3'9H-3!E.&TY2S.!)*^$1K'D_AM<%' M"]K\.YL;NT8M2O#+X?VG.G$?GR;IY?3@;Y#PB04V,$].,:D&<5_/00.CX M9,^> LN'A^6B&O:K_?Z7'\KR29XE4,8"Z8BK%#$O M?_:9>:9G"5@QZVJ@-U61*B7!3\6B)@?? -)SX+K100#(!K<,*K2^UFC50AHR MK<0,V)JA&X>P/1G.S#5N,X9NA8^Z,%SX>,]\T;;HT/'7UYP.**.9@!HI#I$P MIP2.*8&1P@G+,,9Y+'RXX?Q44Z.';86M0 S1@;(;283!;F">V,*V1Q7!F>(R M&&$3.,]/-V["YD6UCQ(T+S\1LMIP:5LGS9?ETVK7!YM(K% L8)08XP)%-(4L MD2F,$3+TPC(2Y4X9F_Y33XU5&F/ZH2YR6VQE#U$_^"3V;MPR#*(#<\VYBL%U ME:7_LRP6:_ W\_N3):"M*N#/09RH_A".4#7XY/03*!?#.$?HQVEM5 M%G<+&RI]6_Z[DG?5S56Y7E6Y FTN#R4$>L+5D1GH.M)H*8*>JNWF"OH^VB,M M.SW5U2MI,U^1%KF*!84J1ABB7&!(99["-$]H1O,,*>H4F71YJJEQ=]K5RS#Q M2\S?SU9._ MJ_6FQSK*2,0R9/A8Z 0B0G+(DT3"*,E)CC.-\RCQ.>D/).?4N'U7DTW1\T:7 MP^KG]N]6G;_ZN0R&6G$W-\,$UG'@=\WIAC1;)<'>&M=JMA4]ZS7>T10TJM;U MAOYLU0WHUAAX08*Z0H:2=53WR<" '[I:?6JOB%;XBBH.L\7W;VHN MTT6 Q7'C_<$@'YC-@Z+M3G4#GR^J M;3K[2>\$2,XD(8GY>O-;PN17BZ>%I;G=NU;['S/&X4O=J41;/:GNG=)B%3C(B1)Q!*C2Q5?,S MF!,D(*,Z2U+SAPS)?D91+WFF9C!9H9>+:L_9G/2M2DT7K#VEP-XE:E]SJM\Z M^II:@Z_.B&:8U[*,9*)=A>] YEL_F5[)M+L*P/-FWW7#]@W?Y.MM+-;V/5#7 M*YD9HHTQXSE$"3'GTB16D')M?HU2FB/**>5>]SG=TTV-8:VT8%758>M(P^B# MJQLEAD-K8,:K@-I*>K-K -;"A@S(= $E<"QFYY0CAV&ZJ'\<@>GTE'^X3D54 M7^^7J_4WM7JPTS2Q$(0AS+#MFB"%88X4:\,<'$'"29:36.NB:9&E]X M='?MQ*Z;'4(A,C GU-9.)2.P0H**)/QC;LZBY!YM$P*MD>)LS-8TP]5&?06@ MG:(R\$LK/UQ;)*5%DJU6YD%5'[H7RS4P#SX7RZ=R_@+F16D-SF(!S!A@S7XL M%\N'4#$YE]#LB,8Y^^AH<3B7A-^-P+GX67^Z/'$M^W6M'JOKU[)JHWJZ"-R' M17-#J]ZS8O4W-G]2LP3K/$%<0$$B#1&/!*2(4)CFBL=Y%'.91*X,&U"NJ9&R M%0P\6\GL+EHL%_!4+5U''U_H-;S,]*^T,@._'$Y'RUC%P(YF-^<*<%89"XUZ M-Z!:X4K#UUE$]Q?1*RWF2.^NL1?5ZZTU /0=+[J0LXWV;AP HMW7Z1##]XQ^ MK;>F&?.J>WIN MHJF](QLY024H:"7UJO%W$5LWET<(Q(9^=_4"RS]"\P(284,LSTTV;HSD!96/ M@APO?;YWS:]#OZN-P]]>:,1IGBLA>Q=Z.1D(@.3"==]T%6YH$J;[@B%+I\6/>D M8]<15Y77EWQ>W%7T[QFKXX!UA.(H,5_EF*0&ZYP;KJ=8 M0Y%EF N&&2-D]JQ6?/DJ:._._"IX UC[5&K10Z/OQO9!$1W:+=Y1MWXK<#B> M=\8F*-%?GG54IG<&X9#JW1_T]P6_57/VHN3;%?MN_'W#$70)EM"Q!B%C&7&&M6<*2%X1-WJ2UXCQ-3>"(T> MP"I27S=954"M"VAEOP&5.K!JHMC^H[O3L/>*77;SCK$.@P"O=?" MW5L[QIJ,Y)H=8GMXN5^OQ;+#U]I[Z-$-_)6%5R"MC]V@B9T M@^/N2<=N8>P$P8DFQ6[/]>2<]KKG-S/!TZH*=7F_4O_UI!;BY>W2MBJ?48XU MU32!*>,"HDA(R%)N?HT-&1%&^,"N2/C MA 5R8-+IB:$_V;BC$I9O'.8=EW+<@3AB'8]'0P3%&SNJ#=L6+,[,^5K9FG,Q M1%SDD#-CY* T(PKE!%.M^X?#;R>:&L58R0#K#N3V0]*-1$+@,_BI]R#TO<)J MV*#W8R &#'??F>P5 ]V/5>X.<3_Q^7Y;?,K^,F(/QI[;S-\%9JI;O!BR4)P<<(NBV]:_ 9> =OX&D M$2W<+C^C<]#-?3C'J'OZC(*'6_G)XC#"YNP0)YKBR"N,X]Q$4]O3OV_OZYIB@YZU!,\BZK:U0^ T\!ZO1=R] MD1NDT-,E)(+N_+.3C4H!EU0^Y(*+GQ_&G_F[^K'^]EW-G]5OR\7ZOIQIC"(4 M*P)EA)0ABRB#7" -<\WB*,Y2,XM7#Q-? :9&(N9+EH9U91Y!'L:U>0V0K^;J M7"\!5^ S*^0-J&YC@M2UOQ:R45V@1T),RB5Z#B)?%^G9)I7MN8,PUX;(0%UN:T =W"B%O:UI4VP,\SC-5Y'5S](.'1'=PO4HD, M&NF %;HN9]S*O?F3E1S\5-]BGL>YA\_$#[3 /A3'R4?VJ?A!U"FC\\+DLV_W6U?'HL/8\=GJ-.:2_M2 ZVHE?%:5OA M02W](,>4GLB%W5">,HR[K_H!=+2]>@[CM\ND*F9OC!5RNU+LS5(J8PLD$A&* M(8]B6_/1]JO. M:5_4FME7Y[NF]=Y."I5]J8IB/8W >UJ=W2"&@ . MTX[ZSG>'X? U[_'DU17GCPSVG?KV=27!&"?431]C=W@]E4Z_3,\;*;W7<&&LPS %0F! M"$L-\YAD4'"99IS@7$1>QFH 1,>Q4#=X?@V*IQO-!T!I8$+?IK>V(E[.[>J? MTWH:AF$R60_F>IW\U=,*G\U:/?/Q?O3Z496E4OL9L38%R;8,6#01-9BEA$IB M6,$0 HJ1-$9EG$"5*)QAII3@R(<5+D\Y-8*H/ZS50SE#6BI;D TF.:,014D&F1($1DI3)"(9D=RK2EOG;%,CF!UA=XLD M@C^MQ* 2V?,\V@VVZP5U( @'OY6^ KT>-] .J 2^=NZ:<>2[9@?ECR^871[R M(Y5RM9Y]+-9-P9HWEJO, $TRF^(YT1E-H:R13+3,KJBDWCGYU,C!K,(]$+L2WX [*^A5M;6[\>]FC:%1'9A- M3E?%WI,>[(A_ WX=&.VKRI4'0_U5:Y+W1O_:DN-.\/G5%>\>\C6+ASLI>Z%" MN-L8/:])S9>ORA[_I*MVE_?+N7FX?/=?3S;NHPTNI#DB0G$):4801'%*(,NS M"#*1B(CEBRMLA+8>F5VQ_P74@KO$'5ZQ"(ZWH*&A'?KV,P2J M_I>>/BB%O>QTFGG<2TX?,(XN-[T>[D=2]6"_J?7]4GY8F'/QNO+H;PMB4ZH% M8B2&>0':68H M=*%DG9/;=&61MPO99K85JC1_,W:]/&@!S1C!)-4"4I:GYH2=,4@C<\QF",M, M8TVY[AEC%D2^*7-:JU:U#6O-VC9)LLH V5$.--KU#4@+L]B.QMKK+>'09MW. MZFUU UOE7)=QI'[@0?$?*#HNC(RO%#\7%.#S$79AI^D9)&(.\)_T?D7:S4W. M)UV79/KTM"[7YCM?+.YF&98JIDQ!H2B&*%(*,J8D9%KG<6;>%''JU\X 4O)S%@DTAC3"**,9,;B911RGF-[NT2R MU)S752:NKH?M15ZC55/035F3*WOSG,95<(5%FE.HTL2<)"+-8"YU9OY'2ASE M"1:Y4[)J.%S'N+&OD)RWXH7 T8WSKT9G8&(_5T%GX%HY@Y#SZ9E>O^K-.9KM M_G#/UHOV6N=-5>E+O+1E +^PM6H#"YMP>4(SI+@D4'&40"13"FDQK/5N1M M9VHK]"80>8"$!D^DPO9D=)Q[W-:,?H <=6CT?-P_QN@6X2BR71_+S^S%'J#? M/JDD2E&S02*6(Y%H#+G*-40H,P9*)C'4E'!CO%#-<.P:4=0]U=0H"?ULI/UG M\+0HE>$E)<'"2@ZD.6%9H=WC6BX@W$U!87$;F'4:R"I102-KU>2D0JQ';ZP+ MT+D' (6#<*1PGUOP?56LUVH!'@VG%,9H7B]MYQW JN^A_8V!]7VQDN9?5^N7 MG\-$^KCAU!'7?&<*FB^%,@=NF@F5,9RF3FT072:;&LMNPMIVA+TB!:039S=C+Q1Z W-M M?^"\C3H71():[!.CKBOKBZK M'W8TZ'_][+HZ_E?, V ^,%4YPSW:-;$GAH-=!;O*\6K7O9Y =5WI^@[5M\N- M+7*\B6?0.( M9Y7X;/3+ M_# MU;VSKP)AX+WLJ+]7J>Z3NO:JU;T_TFC%ND\JL%NM^_0'>AH_Y;IX,/;4)[T) M'-O\L*U:V=RG((9SPB,$(VU#$'!B#DD\)A CA*)<&XL(*R^+R&/RJ6W=5G;[ MYMX)KMQIU>SYVO99",=W^4#P#OV"OXCL ($)?; *:P?X"#"N<= #FB.+H<\8 M/7W@]\O5VA9ILWV2_ZZ*N_NUDK?&J&=W:C="XI/YIV_%@YI%L;$IJ- PXEI" M9*G-6!\93!*FC+'!21PYA3#T%6!JS-:*#%@M\WZTE:?+VW#L6[ TOPSL$H$='7WA"^LG]M7B'&=W#TA.O)P]QWG MNC@"A\(B'Q9B_F2S NK37"O,AT630Z7^75?-EW' -O1 MPO+08D^/C>%? @C$!@2PW*#0YX[XRJ7VN5 >;P''N7W^Z6.U?)9AP%:GG4:I M==_AI0;?V(\;<'NPNOM*;MY+H>^OPZ ^P&7WE8*]PLUX&"A/7Z,'&CM@*O%. MM_C_,!3US7P%U(Q)F<68Q-#\Q]:M9A*R2&8P40IKE>C,'$:N3H,]-?/4^-M\ MM7& ?-B3(+N1ZB#0#G/WU M\VZ[0''*Q>T<8#B">F^^I3.J-65:QY#F++()N@QRE1'($Q*E'"%*Q?5I^BK1_7]VIE M#;(JYW==5[UJ;H6%K>*?8 9CE1.(XEA!9KL'92+*D!:*2>UUD=4QU]38IQ+5 M'E]A(RQ@E;2>/0L[P'4CH4"0#<2=.I[VFGUJQ&+E!QL%VKIJ&Q5N@%$"&BTVI=8\ MDM>]5Z:;@P;'>V!6\H:Z3\$ ;\P]:@@,B?U(907"?=W]R@KTA:ZKTH#WF.,5 M'^BK[EX]@MZ#]+VHD;:Q>;$VYNVSO2Y:FR].P>>J?E&]^]%<'_VZ7,KOQ7P^ MRS4G22PC2*AD$)E7BC%'=085IY$@0E")M=^EC)\ 4WN5;.6'R?%)R MQNU%12PBB+,LARA/$#WO M!]MT[K^,X"-?S6^1&O]BWLP]N.1#S M%U#)#RH%P)]6!<_:/SX+XTQE0\ ]/)V%0[H/J?EB%IK8G./?C42U*]8M:*%VL9PH++2-,H6(8&4)3&/)$F$5 2@E%\HSF7C;6 MF7FF1EY-X/.:_;!UCI^+TJ;;_,1K83V+$)V#UM4M>C5@@WL_*ZR,B*"1$?ST MRR6D>L9XG\5A@+#MX[E>(1+[K,*G@ZO/?[QO!_?#KLN;=)W/RY4]]W6%;+>1 M_K,DHCKBAC:HE E$6 ^R M3$IQ(;#9#RPC&"),S5D:8P&1SA1F:2)3DLT>U:I8RJ]KMEI/=;$.11QNR7Y1 M=\7"YC0!SN;V+/(JZ\9E%O.8<1A%)(4HECGD<2(A%CF)511++O)FW=XMY+17 MK15PN#5[5_6D>]4%(R@GC%()A8PU1(+P.HP[BC7B4:Z3E,C90MVQM9K>ZL)OUELCE5A5O=M6:LV*A3D M4F& MK[*P;C;=^'MK8!-P5Z%_:?+/=S/2&ZW&SPP,BW38.B1A1!NW.DE0.(]JEH0= MO9_%>RN$[5Y:?C''V^+93O2[6M>=K@QO1RKAE,<0$YV9TS#-H'G#)E"R1!"$ M&(NU5U)@UV13.Q*WLAJF;86] 0OE66ZN$UXW]@P%VL"3)NE K?S M^?)[=0.AK5NN#G:T>;$W36N\@ SH@E907NN<<%2V)U7W!BCJGQR$;$NA^;'WV< MPC!A"F>Y,:95EG%S^HDB2)4M#I5'>4H9%PPQOV+>5Z(X3B'O+8Y6RNMA="/? M*Z$9F'/W,1D@KZA#_: D>FJ>4;FS0]%#RNSZ:#^F_+Q:"J5D52;"1I385^4G M_7&YN&LKVAGBS!15D88Q)@HB1A+(A% P5E(@A&26I5Z5=RY/.34>;26NR[)( M;PYP -F-$L)"-S!#[*/6BFLC/ZW V_J8X2C#'9Z@#.(P[:B$X@[#(;]X/-GW MDJ-I[%(?.M\L'QZ7"QM"4D4.,!RC-$<8V@,>1-J8:!0S#=,\)1*Q7./$J]!" MYVQ3(YFFE.!6R%Z!&MT N_K, L$V,,%X(];#I^6 1&!75=>,(WN@')0_=BRY M/-3;7U2[J)6L$JGMX"MUKQ9E\:RV%:^J!H*S-(JC3'(-$Y11B$1,(-4L@R@3 M@@JD5$20,W,H(^8HEB,J5*28:YK9Z2FF1EU5?]A'5LC*?\L>:C]O45U65/FU MP*P">-AI'&+.%_/JFG+)Y\5=7>SPK^Z)2V>0[Z:L,'@.3$P5E%;"&U#+Z-T) MM ,?]WRMZW$:*0WK"*\PZ53=^G=D29UY<+3DIV[!=W.:+GRRG_7WMDD7_76U M?'K\J"&:D#Q M1C5CP\-Z:.0.,$//?+#C!F+EQN1(G$KHE HM"09!KC3 I"VUOR^K=74UTO9SVG?B['RL"H+>\ >EGL#U.?5<1"3T.>;\A&.?3"ZJ?N*L M5ZZ#J,J;*OP#Y M5&67B$I#ZY@'VEK8SY6%;8N\J57Q7/L7BJUF?C35>QW=*&R,U1G:M5^I8-'? M*@&L%NTUH^&\G9-/HPSXX+ BWOQW+9Q!N;&W,*/RYK60'7+JU>/UX]O:W=^X MAA9W9VL%S3@3+,MC"6/%#+]B1LU9#"[ ?%B+? ,V0G?6'PO'?;Y0!>4Z MY\E'Y39?2 ZYS/OYOD5YC-EI%O?E=[6>I2+%LR^+-=0Y=JHQXF,A=.1S7G&J>WC.M1P3VJP$1M8N=UC?-P@[][S@P Y,!%< MQK!'/QHW,-WCIX*#.E(XU15?4*_X*B]\.L*MW,89+?K*2ZW=8"R_!WOR\YDP M6,/\]BU0UY"Q!TY5WMJT_&_LQTQF<<99GD%,4E*G%5*L&10H%HA00BFF;H5Y MKI#":9^,6H7'=GTN!:.@0G> PEG6NA2^<1AOE3BY[OE\[^:Q^ISO/FA M8H.*"4X.-LH6[U*CW;N=G^GG5JNS0']3Z_NEW.[[NII8N9P7TEI4]1^4>KM\ M8,5B%L4IRI6Q!+DP-B%2&$&>ZP1FE!&AA,ZT3'R\;SUDF-P6KS.=:QUVWH,W MX$ -T.H!_JPU\8P(Z;->;KZ_@5=A:&898 &\_8E70!C4[=A'CE&]DU< =>C$ MO&:H*V/>ZXBZVX5LKSL*5?Y6)SK*3XLOMA#0RASBS0>,.*OVUU]8690?BX7Z ML%8/Y4SB*,5)HF!.&3:&4&X[M'("(XHR$LD4,1SW"I(/(=W4:'8;(G'3=O2P MP2X[&H)611M1L5&R^M2NFJ#2$_QI-065JGT#\H-\"=P8^M66=F#N?I55[9\M M$!+]8=(+@DCX.OD((<$]F\ 0=)*0=K>5Z?\LB\7Z;^:7_5PJ*5-!*8<1P;9_ M+8MA+A&%F$>YP$FL$'$Z+_>L=;_TMS>O"M935+6U_$V MW^6KNK-3MB$A"4L31CA,:1Y!) WJ7"ELSN]:LEPQ@1*G*B6.\TV-CFJ102VS M^[VK"[*7+[L#XS4PS^Q!!;;R@D;@'E%+3E]0YZOJP'".="W]09HY"FT=!+)H M&E,:(F= M%4MJU\70-7W3NM[MC8_W[$Z%8<_E>8T5QKS5:S-XY6CH2J%_/V^ M$/>V;MD+>& O51--7.K /"T,ZBM,,M%R7X7JSO MP;*Z.A?;$JA&(EL1K31Z-7+]'.9NW&,-.^[!7489[<[;0Z7=^VV?QX;-I*FN MSFWK[??%LYKE<8(%QAC&FA*($I7#/,XQI$FB"4NCW%BS/D9L+RFF]AKY:%;) M\4+\.O3=+-C!,1WX5>.76=-VX;&* *O)^*DV)X%\E;R;?4DFF81S$JR^&3FG M!^MYB!?W2C[-E(A@3IK#4$4[\NOWX"C U&FSEKTL?U-6)*Q7 K@Z>!WO?17$\Y \( M]= '?B>4FYH3P&H *A5"GO][HA?6%^ KQ+A^@9X0'?D(^H[CQX'E:FT;<\@G ML?ZT^JI6SX5053<'2I6(=,*AXH;94)PCPW%9"A,..S?!U#BL MD;$Z(S5B>O7(. MD-R^%@&=@WNF!C#.Q7%*_BSC,LSND87X[)(RS@X]"")=4 M:S?\Q<\-7]%XM2Q+(X(NUC:*>J;2/%4TCB%"60:1CA#DJ32&#HXQ3R.BJ/4- MNE=0Z"^*%TF,4%.A$@\\5O(-5Y+X8#G<#)MQ0!Z8:GJ4'*Y6I%:FR>=XG1K# MIS%]M9K"!^),MH;P:=BNJ1E\9L1^+&J;QK+RWHSW7$@E?WGYH[01F+N M=N-]?5-+8OYM(\HVNB))S29SQD0LXICXM38-(YC/ MUA^G&VK5%T'/E]\;=[9N%=IQ=#LVW B\AFXT//ZZ#$S)-C>N6I16)M]4/ILPN'I< MUL-6-RUO;(&LUTOL$WN:\F!%=TW$[ ;]VY^'0#-@8DS!) ]$@F=X+DBM[![ M_)'3#9V4/*VC+*=9FF#(,8LJ,<9A[7:OZ33\U\MEU<5=&A_4Y53_LJ-#W'L%I/7QO$4*C/.(= MPEF 1[I"\(%NH L$)Q%>Z?K !Y[SEP=>H_0UJ+X^L/G\ER8B:18+@C6B$SO*XA32B,;0T!GE1"0LUDY9@6?&GQIG->_Y2D;0"NEK&NTCZ&H*]<9E'-/' M$9(>1LY)Q:\P:O;'&]F(.:G,L=%R^F/]C)0ORM9E%NLGFQOVV:Q==5.%5((Y MD9F]\DL@BI,$,DTB*$2D"8_BB"BOSH4G9YG:]MT3$E@IO:[]NA%ULR:NQFG@ M[>P/D;=5T E!T)?_Z9E&?<=W*GOX*N_^<+_MWU5#Z8L2F\4N5V*XOURM4VLJ@(2M%JME*S^_LR*N34NS(>^&EOCVW(W'VM3ARS) MD#9DD\ X2VUP013!G$@."3$'H"S"%*5> 52OK=#42.WS2L$U^P'N;)>&51,K M9#MI+(V>JS;6W*#U7"R?ROD+N%=SN5L9T#Q6?W9=V). 5'P-2IM,7'GG_*CQ MM1?'D85?6\P)$;Y#R;Q#1, 6DOKBYO;3FP]56_6=PGH[N#0?:I&!YI.P--C8 M;^E>KFX;Y1ND#-_4UCKHF^W5E1KU)?KJVIYY7T]&KGZF@7ESU#-^72_%?WYF MJT^KRD$JJ^(3G]7JZSU;J1F*)(I8DL%4(?,"SP2&G/(."7 MT!;^W MHNIQ9(](J^7"_"A46_:A[E=5?ECL?J98B.)QOE/_A*512J2(H1 IA8@;0J,R MSJ'":4H(B6CDE@\=4*:IL9U1"6SE!?M*U1<)VT9]_Y^Y=VMN',?21?\*'L[$ MKHXP>G@!"6#.D_-2U1D[.S-/I7MW[*@'!:ZVIF7)(\E9Z?[U!P!)B;(D"J! MFGMB5SMMD6NM#^+'M8!U.?A@8UGO+@\Q5MB/)D=>MX$YM+4*YK%;2K:6&_"/ M)]M7L+5@Y]9KH(2=: !'SM:Y7J^14W6B 7F7U59MOK$7 MZ^]^>%99DB=U8P#&$IP;MQ,*)#5$9:H@X1Q#+G&N4I%PBKEOYXIN45,CX/RO M1MY_@.>EVXDQ/M#2:NZFI%JE_?LO7$"XFRGCXC8P =:0.55!K>L-^% CUJ-U MQ07H_+M6Q(-PI(85W5#&:0/A!TI'!X@+-QBM^8.?(>V^#YY77-.Q\7W3R*/N MK4U*RBG% F)<8USH-\WI-2ID:B]>;B3LNK>IF_1M3/ MQ[P:IZ&/[X,AZMD-\0P$ _0\?"WI#3H;GC'V=/_"SF^V<38V(X0/*(*(%A@BE%!+-L$&4"*F+@N4R:%//3^S4",)--E\M M@3N-L$'2HM$_,/'0#W0_RH@/Y< <\KU!;Z=RNTO!37M^?.3!J&%0Q4TL]!,] M;D)A$!Q'B81A5X<'>_]DB_NU4LO-WQ1;;!]J-QJ+7&"48(BY,'2D"(=$Y"5D MI:!%42J92>\8[Z2$J9'.3DE0:>D?D)P&\'((=S4L Q/(:T1ZQ&JGH?$/T:Z& M:*3(S/O+$Q2+=5K?$8*=OFZTR*M3[7; U?W!<";;'_-:A=PQ\)E>U+-<<:Q* ME$.6HA2BDMK=*\U@PK3D0AJ+"^U+;_YBI\9YWU:;+;!92K\LK!O@6E7.E_=U MX6_5>U)5HI.Q6Z58;/V:;X@Z#K3[S# MH#Q68]=X: ?Q=3AH'20><+/1F#W!:%SF=BIAB4U4@8I40GQ>I%J2J]!CR9^SX8K5U6 TLK'(U?UVM MM9K;.1LQ1P_TQC/R)()P/48>3- ;J.,Y!?UO=05Y/JP6YHI-1<^.J6=%1D5. M$85,,V0($MG&T[2 HD T(R+-,T9G2W5O4XON0B:IG!3G]2#2ZD$\$CI@ HX; M#+DU8A6EM@/OMG#\[1G3D:*WHP80GD ]@NYY CC4N9:_A_ZI] ML9O*,XM,4N=AB$]$)V2-3S;G#3Y)*!T?'[:A_1?U8P*)M"T/\ZQD7"\:O:?UVMU?Q^^?YYO59+T6ZC?[N4[E^+5Q5Y7]3VJ[;5PV4ABE0F M.4QTH8QKF&M(D>)0)AHEF*0D$T%9,<.H.37F;$RHIHI56@.V4SMB"?D52^O' MJV^_8 ,SL$>Y=VTGV"UKRU*WX]"RM54*[E)[+'^/5KU]_8*,5I-]A:J3J;2^ M'NZ0^ND(TJYMZEC7O&Q*5QW2E'E-[.;2[$#:&W%25!28>ML8X3MGWEM[;4_*TPQ3W.=*:AXB8W+R8C=R-4P*?(LETE!RLP[ MM[2?"E.CPCL[&"R@PK4?=5AA\4>U]WIVLW M,9/QFEHH<%ADN(5*%@(QI!E6&&,W3E!6EUPLD3.S47AKMB+B#VZ[; MC.A3%3HR/G MPX+_IP1\OEC8,Q;;^@?,:]W]7:L.8"\[L''@&CHO9P0SNP M\GG^[G^S5S0]ZO'OE\Z1;S_6JYF7=4S2),]XB04L><$@XAF&3,L2BH252:F%(!R% M.(@1=9L:;?_*YDU#8./N;%K5,Z)5,P'8GZXQ(]M66?SN6&6[LOWYH=B# C;5 M[,ZZNIG(G:8U]\1S< M 4"/Z@7'U&]45WD 8%_[TT.(Z%M_Q;;N]?_9*/3)_+B9)0*)C&<,FL"_@"A! M.>18&>)/L48,YS350?G QR*FQMH[#<$?5D?@E P-\H^!] SHKX)GZ. ]#)D> M]5/GC(]<.G4D9N2JJ7-F'A=,G?UDV .^66]GG^?;^7W%+L8'<0/*A"A59APV MR&590E3*!'*19)!JG:NDR'7IUTSW].VG]F#O-;0S3U70H+XVJWEX+WPJ?G:[G>[ZZV+UY]^4 MO%=-7[9WRL3MZFCD3#,42Q,LI0F7H0F:,XB(X) D10;+),]5F>=%PE2LM/8> M^DV-.OZQ7"NVF/_;^._W=8-(8<+!V14QI[[.>?M[%&Z[2P$SFD<3N MYEQ;"X$S\5432NXL/1IL-OK\L2N68;34]3XZ3B9G_0J 0Y+5KQ'3=W;7ZDFM MMR]V2NC6Q(0V5GRRSN,N:U.YBM/?Y_/J_5V_N]JJSLKB4X)S\WWA4EHPK\,,L0X% FAA60JI3PH&!Q> MY:F]2!J+;USKHJW;#5*-U3=@V=$*]ZT6W>_5,JVE'/AMLU]%9^Z-6\:=Q:UD M>565^0-G-5QI:.P&SO#FQ=*R';2-=S=IFQ]SQ-E82Q5Y/-K@:H\\6FVL93@> MRS::Y)[5 .8ENMG.A56P/G-5G-.$"PK+M$ 0:85,P"(*F&2LI 4CMA0W*-'_ M2,347A6-AHYC I/VC_'S8_'K4!GZ;+\-R!"] ,X:'S=__EC,N*GQ9\T\RGH_ M_\EK3ORNW+?&-K;?MYC#?ZL=\\ZLQ MMOV9&2F92%,[ ;/0$B([<8H29L]$M<@Y+A.L@IH'A"HP-4]_IVB/C>A@\/TX M<$A(!V; 6BW@]#H(S7%[NH?!>LQ*ALUQ>BUUS7^SX]/<*' MU7I[I]:/MF+@SMS#)2-Q13/)RA1B.\87V?1\SDL!=4*3+,L5I2ILR^.4E*EQ MEE,2&DF/P*IY ZRB0:E=W:!ZNFK70C6X-]8#I7 7JPN%N%[424GC.DI=QA[Y M0IT?[NON/-D#E^7]/Y;SK?&MA*T0NS?AK-V+BBAAB2(**DNPQR?OJI,C4YVEH!G8PK0 M^PJ>^1(H9X+=YQ*U$8 Y*\ O; ,8>*HL#QQ"=,4Z^OI08ZS.X-Y4LS#6BANP MM\/M.^ZWG^V>\VZ=&G- 94],W^I:3"-[6;W5&=G?NA:V8\_KZCOVH]_;'VR^ ML-M\OZ[6MHGU=R5,E+N=JXWE^/V_9B+A+,$IA<*U9-*20IX1 5DA=*:E5H@& MN66^@J=&K>T&#_.Z7GBSTS:,,[W!]V/((2 =^C#"KQ]V.)*=-V/+S6=2)R57#-D4SP2B-!>0)R2% M--.B2'BA94*'&(K4*# UUC)?RG*884@[R/TX:D@@!^:J7L./K WC3S]ZC=Z; M3#W:*3'):4>O(>H[Y>CH/N&-@GY7]K16;-WQPNU2UEML[U>;[9=GFZ_T57\W MWPNU^?CS20D[IW'U?K':J)E,-$ER4=BV9H;E:)H8EDNQ<!N!=Z/M!+^38[&6)&16B -N#)!C8^NA;2C+5+O6X_6-.E:X]LM ME:Z^5\\$=N/#V^;0YE;/:W7+C1),;&>EU#K)\@0FC.3&N2XE9"K)(*/F%538 M MPLK%O]23%3>[&X4'6O)OBC432T%?UI4/WZG M18V;Z=YI[E&V>_>G>^X2MHIB[$2-_WF>5YF"EH$VLT+F"A5<08%M!DJB*:0E MYE 2) I>H@++O!EL[KD[V"G0Z_M^.-I\8')H:0C7];N6^92]]8';@C' MZLB^5[2:W;-3U?DKYS=5PW< O3")N^_7+7+\&-&8!MG'I6_8Q/-4JL%^O M\!AK[,=Y(Z_1ZJ$I2OZV_KU8^Y@666*7 M!$V-A"M=0:WL355T9B %C<)^M'H1WVZNC(G:P 38'S!O2O-%XP1/;93XZ_WJ MQW^:6U0497YPS.0XZ>*-1R$:7_,:]O#^?&]O;]>687>84DW"WRS*H+4^7L*E1PZT0:]M6V1Y6+&U&O2OF4=IWJ3DXCZUUC>KZ7$0DMD]S7N#8SLI%TT]X(9>OZ<Z._;2[X]LU,S*,4NL7UXCVBS'=7&E@,)+N MFX[4,\(8ICC-8)J4PG8($Y!@E4'%TXQ*E1)-341IIT?X4=& N@8QV4[C =_9 M=:<$\,O"MB1L.A)N.SH/CKZ\?N0WD44;F#L/VDM6A5Q[4\'>UF8AZ\\[<^UT M[;9YNS$!\?AVA$6(2M=#ZCLJVX\ _.N7Q1@B>_JM^RSLI^?MYK/ZH199T])+ MG7(FIK7ZG0#6:!;VH&EIU<:!Z&A MG=)=,<<-J!0UGFD%V !=OSPPB>N6=L@;URN];/B14^IQ2?B6UX8:@H32B1$/$>0RA+!$J&LQ"I55'FY QV1WZGG MG]79C63W0QX5GX&?]$,]P4[1'O,\NR'SSW:-!MU(*:V?I)$QUW.U 7+^8[ZI MV^0<8&_#G?/M3[ MM3N%7.FN'3.Z,7;5>D6:*.JU>AW9L]W7CY8BZV5&.P_6[X*(9Q.[],Q4Y53H M@D)"90J1U!DD2'$H2YD5F)9%F01-FNF4-C5JK[J_K_BBG@:TJ1\#UQOUOR*< M2@1FP48#;\QSB?VQQ"!)L5Z8#'\R\38ILE[&>YU-1$J8_:[N[4MQ5]:_^X)+ MCAF1)@1$DMB2+95#3J2)#7.J,IE*I#$.ZFYT1M#4**36$^P;8/3-GS\+K1]W MQ !L8-KHA55XFZ,+0,3M='1.V+C-CBZ8?-3OZ-+G^Y&#[9ST51_4]'Q8/;+Y M7",OXRX?5J[]42D; M2!#GX?5CB"B@#4P1/?$*)HF+6$1EB?/21J6)BT:_YHG+%_2LOYMOGE8FP/EM MO7I^^M1$GK:ZISH;4W)W-/9[%;/."DW,-Z;$D+%$&"<#FSB%I!AF!2D19IK) M,JPV+UB%J5&+;4L2F#G5 W<_:AD6S:'WJVOE@=/>'FHU6R%M _8I S>@MB%B MY5]O_.)6!8:K,6[%8&^8CJH)^]\I?&/]B]KN4P!VPKY9WVNUO-UNUW/^O'4C M"5:G3_E=9;14ZM%^Z$SN3Z)15G)50L(TADCI I(<"YAQ@@NEL"J$%T&.I?#4 MZ-38['9)6SE>_KO7HZSPY7.#J:W;P,1ME^S5%.$]=]=6@[;9ME7*FKXT!E%#5&.Y<9$]3V\^*AQS0DQXP^\/VGFR9GUIS]Y_>EO M0Q7U_6>"J5+D.(_KV1-[4D/\^=\P P_ MX;T"HC'/=V_V#M#'"\QXU>'N&3@&.]I]+>_-#G;/&-YUK'ONDKZC*EH;O+;Y MB7,W-FK]0WV>+Y4K/YCQ%)2)BE&49YRE!0YV$?H5-C MC<-3":MT'1,XM<$?5G'@- \\VO%: 3^&B8WKP%03 ](>XR'\,8H\",)#\,@C M'_RA.![N$'!M[V+8M26\#ZKZWT_+6R'L>(C--_;B(J8UDVJF2EZB$BN8I<*0 M4YF4D$C#4!AE.28XA27B0K!)+00I<$P5*5F7F450$)0054LLPQ*@KS5QF4R1JHP-0> M]D;_@S9\;1-N '\Y:&[:JYEB\#KYN2!#HC\PJ\0'/CR7MB=Z<7-L0Y48-_>V M)T1'.;E][Q/NOWPVZ[[X]K!:JJK)_BS+2:%(F<)"91@BCC$DHI0P%075ME<9 M2KR]E]%^'ON1P!=]EON0:.@?DE (D@G^6:O MG#.C[:V<_O.'EOPYY)#%E5RR%*Y>MO@ MKE[7KES 6?$XZS'*P?*!*:_S=+Y42V%,NCF;J5/9%?D\^GJ XQ]>7Z'3^"?= MUP-X\E@\PFWC55#/U:8U+&]7JX<+SFBFI$% @KLVCSKD) PL!2<+*3.5)GA*ON4'7J3$U/G"6P)6&SQL%6#5J9E6; M8P]Y56T0T*NUB0/_K#R7=G<8SXXP5ZY>-^6,MR8#\U*U'%\U-&94DW] 8XB) M!$%C"C"V].DS$W-% F;MCK(R8TW;[;]"D<;L7HUFUZ#=_CWW1:'C[0\,##NZ,KJUN..J#PPYV@4Y>%?PQZS MS7H[^_@_S^9Y_;O:/JS, _U#;;9*?3&K53>($51D2!4I+&6"($H2 CGB)63F MF22$*(8+Y.,17A8U-:^OTK#:+K%:!O;>\<"V^WF-B]C SW X6-Z/M3\.78^Z MN4OK,3?_>OV(>X@9Y;'W-[>A@H K^KV%WZ\>'U?+[]N5^-?W!V:^-K?/1LYZ M_F\E9R(KDE+D"A88"8@TI9 5!8<)+00AF&4B MK/3BX/Y3HXM=+>23T2^TM.(0.3\2N */P;V%&@JKVHW=#ZC[:KQG3W,3!#D6 M;3YTT_3/,G^_W?4JCUE!<1*FR*42AS)&KHDX:>!Q\2WB2AN9P&(YHM?S3QQ_<,""T$O >Y'&C%A''H?V*IJ$WW:RKHN/&K;,$G$ MRD]/8.)6?5X2.F[%IR<$1]6>OM=%*$)WA:0+9L38LE);Y2[JG].92$3&%2(0 M$8GLZ58.N9+"Q"HI+9,\$S0/&J?L*WAJU-,H!\0JM(^%-]:>;#, @D.SSD'9 M>55Q[I1V)>@W8 ?N^RYPKRL\]T!JN.+S+N%O5X#N 4EG$;K/]>&;JW6[]-_4 MZG[-GA[LB)9Z[X]+2D69$9A@XP,AE&A(-,-0EX3J1*>1_/R3FH4C :FEC!X@C90+YI_]=[I>0FC;9M>-+*]8WKYP_V\D8..??O$ MFC(S\4Q&3: C,$0""4A)(B'">4;2K$ H34-J:D89"TWDYP MHKH:IR6-ZE=T&OO:B>C^<+C'\&V]DL8GV1A_Y+M:_Y@+M:G?<2K%,BWLG"21 MVSE)=J]$2 W+1&E",5/,;ZIVIY2I44BMJ/.S:TU[. [G0;WL.$2!:F!NZ(52 MD/]P$86K_8?S$D;S'RX:V?8?+G^XI_]PLD=OW1A6,45IRKB;E&TX '-(F9)0 M":'*A&4E1D%EFEW"ID8%KYIFSVME U.E.N'U]!0B@3:TPW"F%WG\7KP^@,1U M$KH$CNLK>)A^Y#+X7-.S9EMG8\B?&_GXV@._5S M^\Z8\*\9P90PGI2PS#2#*%&V^CN3D.HLEXE*"0H;K18B?&KDTM;=4,MN,GI@ M)YH0^/W(9BA0!R:? SQKO8%3'+0T!W]8W8%3/F;OF1Z8Q>T[$Z+ N#UG>D!S MU&^FSSUZCGM3W(17=IO6BFNH\G>V5=^W=J_VFS+?5Z/'O9HE&4](D3-(58*A MS0F'!.,,(MN=7!>BU"(H$EOX'?HRUWK^P[@0/]1[ MZ^LQL;4C,>M=AXRDO" DA9+HQ'A>A$.NS3)D.,,)ITCIU*O,TD?8U-AIKRMH ME.TYU;838E]>B@/I',9C,@TTR%P9&*Y;/HQE7AUKE0$HL8_C#XN@>S'(!&A&YA$*DW;V;1U?YA:76#UC<K]9/*QL,N%P7:\7<;4#980OU!FB9%X)E0L "$P41 M2Q'DJ5)091PSPRU%Z7=,[2=N:KRRT]@=I 1T@?%$MYM1XF,V,*'LX;IU67 [ M=:NI*YZ()(:EXU!I02"2"0*\CR3L,PQ2Q C1.=> M[;6"I$Z->JLF(7O-/4_UPI#.5)XJRACD)2,0E3J'A&L*,<>XR#-%$Y',?J@U M7[T9UFWI0Z,]'Q;MRV^[01 <^*7W^HL*7HTAJ]3N\>[S!];_%3@(P".]"?V MCO-"#,:IX[WH?Z_17H_!YK7?DN$7]]SSV#>UM ?DSVO7W5KQM,B*C,)?.4(B55*;*0SC\GI02]#$=K!+1<+6&M(%CLU0[AHE)1*IADG!)42Z1) 3I2$N$1$Y3XA(@^8T=DJ;FG=H(:M$;3 ?+>O#")7(C7)7'DZCL/XX]+[GPNZIG[-K]? MSO59BWDZ[D@AE92$(3'%:0B3S!%(B!*2)RK'024EY4-\! M/[%38Y2]JN"IUC4PUKKU=+\+%1 _!V(O1^QQ\=S8(9O*0Q:7^-&Y:%R"H-@BIM- MZ"=ZW#S"(#B.,@C#K@ZOHGK__/B\<&?S'[568OM-K>&4S$ZR*[*\]&]NZ2=R:N^!O=:@4OL&5(K;\_5&]1X5 M5YX+T$U1P\ Z]*E8'$2#JK/"0+JZ5,M3W&AU6V'FMXNX J_LYY@>]^:T[_RJ M"F1C2$_:Q,.F:>?7]6_KU?.3[993_:+9]26*YRA%##)I#R\H828 +@0LTIQG M0@N5ET$!<@==Q2?/Q!' M,_@"+NW=/.@]VSQ\6Z]^S*62[U[^L;%$M\L&W?>_G14)I4AS@[DH%$129I + MKB#'#+&\2"E+<,C)J+_HJ1V7VLXXPJAN]]2<[H"_@-4NRYE=[AE\[5KXT=(P M" _,3E4O50/NMQ:XOUC-P7SYEX%;,XK_ZTGTZZJ\Y! M-E]66V5[2GU>L>7F=R74_(?M[_=YOE0N,7V&4HQ3G4N8$2H@(@I#X^X5D',I M!%982.1U9A$J>&I4T.AM-Y:V-@/,*>XJ=ZI9V=8IV=L!_K"65%44@8&I]]+X MT<@0@ _,+8-@'3[7+Q"XN)/_?(6/.QLP$)*CZ8&AUU^YEU9-*[2"]@F$=2@M MORZ-X.=UW8S[RVJY;O[YCFWFFSNKT$QF-"^UM)/&D&VF:Q:*,9+"C)<():HL M$0_J615-LZG1HS4,.,M :Z]B8ZM]:]W=X]LV!OSA+.F[;7?UV@9N[HVY8@/S MZWZQKEJ?_IN"L; <9NOP:NW>9H,Q%JAGMR&C";BVQ",F8*&"JLQ(B7)H(M204Y@G#)"NE8*IGGYLS$J?&PHUV@#GU;OH7\0_6\N0#-0$YQS4M^H$\X%$,ZWP[ET88Q6 M@)7'@!)=YH1(*+6=JD!H"2DW$&.>ETG!I) E[=_S;Y)^W7?QH.2SB;%6VD1A MR_O]CD^K5=VFGRMW"F)?5KD*N*&WQN)@=F47O^$22IF5:(BAS MZU@P*FP?+ T3KK' O$Q2X=63Y:*DJ;%'I2PPVH)#=4&EKQ\]7 :XFR"BPC8P M1?1&S)LDO-$X01,;)?YZO_KQG^8>%4.8'QPQ.$JX?.=12,';P(86_"_HYU+8 MW(C;I;3_8U-1?["%=1#W!SU0DQ+DH3=Q %>8(UU"R5@LC",$?0Y/H+ M\J9&$BX?R'H/[H>6QE<COA-K;\_L+6R>[-B-[@PSS!*;6VZ9H1#1-,4DJ0@4%!EXIJL MU%K*H)*?+FE3(QFG'%B>&"'Y9"(6$\H\FE?LQIH1."2R&W,_GHF&Y-#.20.= M410X36] !>P04R*]4(E;.-,I<=R"&!_CCPI=O"[J,7>Z"?+;XVU=!47*L##^ MBNT5SNV8%%% DID8A[!$,,YPJ7.O79%.*5/CDL/!R@&U*=U8=G-%-(0&YH@0 M<,)F3E\R_OJ9TVS?1Y545'[UY.3RUX M]_(W)>\-$WU0F_G]TGVVVO_GAC4-K[+VQA16G!GU8HZ],S8G_M?!SDZ:QV /SYZCKW#_% M9[ E&";G)[ZZ;Y,$-!CL9[."AI,8W@7]X^/38O6BU'?U0ZVM)B:4?O>\,='S M9G-G?K&96REV8W\W@8*G99YF!4Q8:F)>NZM&95;"-!,RP;GD*M'^/;J#Y8?P MRCAE0XT)8&>#VS9JK ![,]PQ54 K[_#%P2GA>8G-4YMEMANO+B$M$8>I'3U- M<9(KY)5O,?C2C')4TBS,YF!A>+,PV_W"B*$7IOMU/#C<0^]B'#\"MUV/0(_N MZ^&0^W=A'Q3ZD;JQARY!G+[LO9'KZ,\>?L_1^K3W-K?=K[W_3?K%GO]4\_N' MK9*W5MR]JL[?OFJWG;7Y^KS=; TKUFG'8I8KB07/S+I@6D"44Q-88J%@DK.4 M)*(0D@4EY01)G]H;I-J)_65>[V-O_A(6WH4A[Q>Q#8;GP*^(1F]0*UX?OKLD M**<[:"E?[X''"[)ZH18U;@K38-10J!) M[7?FU@.N-SAMJ[4<[I#M%0R#'J\ULM[T8.V5P9>.U%Y_/'P3XX-:L!V[+=HJ;V3D%_ M-=K^!WA>;FQULWF>EE9S()\5L$H'3%_L1OCR.R(>;@._#&K(G*J@UM6XJ35B M?097=D,7,*TR&H1CC:@$?Z[GVZU:VLZ3C_.- ML5>#)LS=SWT/Z+@>W#?"W- M;]?;E[]&FE;IA5/7B,KN&XPWE]++D(-AE'Y7].Q5J.[MEZ8>3<$+G6JD-<0* M8XAPRB'/< %-G)^7AE)S1H(ZS1S'WH&$<;OGG3+NJ&_>R0_U;0B@YTLEWZFE^6'[S2SB=[7^,1>N3G"6 ME5SJ@J9Z=:R+FS'ZI^CW8TK :/ MBYV>H%846$UO0 .>539F+P /3")W!>B2.')_ _CCSL%^%S4CSNJ6O@[]M,Z M$G/Y16UG.A-2FU@)HI*6$&6E+;8AN6VOGFI9ZE2BH%D.QR*FQA)U0X"M5=$X MJ//SF]2^&/K1PW7(#,P)-2A..V#5NP%&P7@\<-[XJ __"3&C/O'GS7S]F'=\ M,KSNY;=GMF9+LP+?G_EF+N=L/=_-8Z**,T45@ZE0'*(B28PSD!20F-_C)%$, M*^);^=(A9VI/^4Y5T-;5O_RE"]+NYSTB4 ,_]*\G?J\6FU9NN7:I[4KZNUFM\OW[MI]>+%)4,MW!;1K?SOYVK& ME)WIE.8:(0D%Y0@BDF!("U%"4A9:8R;S3 ;Y 7V4F!J'--I6.:V5NH#M]76) MKRO;2BC,A>BU0'Y.QM"P#\Q(._5!I?\-J"T N[5HV0!:1L1S5:Z!,*HSTTN1 M4=V=:Z!Z[1!==:^>.Y]US["O^G=E6[.)[7/=./9WM;"S]ERZ:%7YI;DHLT0) M2# 2QHU2$G***>12"Y+E-"&:!^V+^LN>&BVV6ZT=*._XL%:_24GO4\ 7LBZ> MNZ[#H#WTGFQ$H,-W;<,AB[NG&R!_W!W?<&".]H-[W*)G2Z?5X]-:/:CE9OY# M53&G"36_:A-XSA*29)10;'P\93M%%LAF:140X82J$IO_R_*0Q,X.64$4-D)R MYX&J8%YM?M1]5MAVNY[SYZUK>[A=@7^RQ?U:F8^"=ZN5>=)N%XNY+3"XL:TE MSY]M!B^''Y-% GE@YCK$M]Y<^N6SQ==M+%E&,QK?@-M78']CZZZYU>']GR[# M%;?W4X>\3QR5]]YVWYMLQ-VM<]>XWM_WX4RR>;>KZ;ZN5_'.^ M6,Q$SE0N,@:9D-1.>,HAU2R'+,,9QQE-\CQP)_JRT*FY5GN= 7-*W]A64*$; MU#Y@8Z2%+ACD0F00(5) HLU_F,Y(JK%"BI0AW!\=[-$R_.=C0>Y[2A 7R,'/ M#7;HW=;H67K_9:@D<^;?"^J5[PGS^_K_?2,T%5EDD)95%(.]Z*&/[/)$P19E0@ M5&2E5Z,=;XE3H_Q::5!I#79JUZ[0#3":^V346#0#ETJ.R!8H\D3S\X M_7,]H\,Z4LKG55_2H"S/((0ZDCW][C-:SF>06>W4S[ +^[GG9\9B[V9&G[FP>P8Y@40I9L+U:_P7HW810=GE$_+7+XN=;#@/VP,QN<7;-HK^U<;::&]?]+ZU!K+>780[V M-,,1B^IO!H@?U>L,A^6U[]GC#OVXS4UZ.;&S8?>BFMV-;VH]7QGI8FWG;7Q0 MU?_N>B-KFM 4,PYIFAFFRV5J8F4J8(*Q3%*-,-%9R,;$]2I-S8>MQNF(@TV_ M>C>UVEMU,;7=]-NRGX%]JR,LH!\[CKLL [-FM2*>V["#=,6.!V=42HV@UJA4 M&P_&UQ0<\ M(#\J[0GZ2#E&#=K?*[2=?A'3A\[:'C%5!JO;;N M8IU"W9H#;=/Q!66E4"R%-$N0B5&Q@CQE&)9)(4J%J%8*!=9 =!$9937 M93WGJ:[8LBFO;O9UTS0A"6.P*%(-$<$<,HT9E!274N24)$G0(*)C$5/CCEU+ MEL!YJ,?8^5'$=8@,S I.N:971,2JB,O&QQU\>BQFW)FG9\T\&G=Z_I-7;/Y\ M,6JZ+.)MBR_J;VF:BR+#J8 B%8DMCJ(V(2*'A60H+U,F<%D&;^UT")S:\UYM M$RQ72UAK#!9[E7OLTW1A'; +$PG!4?98]KJV788!Z,(7F?C;)5U"Q]\,\8#@ MY%:'SW77E%7;?9-?C?95K4"NMP2>/KW+/JGI/E 8HM+\D^0UJ[SW!.%V.[WMQ MO]=$,X[@5IC;5_,(W(]KI>H64I@+PS\8,3E88N2QV5@KQ! M>$T__A?&\%#M^+/Y\MF\ZK\^J36K,LK4V@T1<,W#9YG,,9&:09E0:N)B.Z\D M*01,&1,E%4F"TB2\*Y"W_*G1TEYAL-II'&4V0.C"]/&>HL(]OA_5 G^O_XT; M-E!-DG$V#.54>8,WH'MU68IVN?QO$X,!/\PWHA*HY%[>KA23I2I+JK![8B:_R3F@2'CS%HJ'\OBO MH+;N!R^A=BFSN:XN>?NV6E?M:5X5-]L=2#MYUO@,]F.?EN;Y53&[;?9!?,#W MU@4%WO"EY0=-]QO+\QY]!N^X#J!N2+']^IC;VC:@W]8K/=_:=Z'Y\KC$Z8T= M:USU"?WX\TDM-^KV@ '/*N>S]AZJY-E@KL;I?SO]M%E-6 M'8GLGYY#KW_/%ZK>OGL)8;:7I$M,7IG -TK8P1 M9P)%@N-P/E"LF_:+\7YE\[5+,+6OYL5J\VR>A#OU<_O.6/VOF:2%R!67D*9$ MFJ!.2Q/4F7_JG&"4Z83A)*B,IU/:U%YZ5EGPPVH+'ETZKNIQJMJ-KU]0$ VU M@=]5#C"G*&AI"OZPN@*G;,3-_,]NC;?OBFK+MO_0Z%RHM,@'SLA 0Z;* G'(,%4XUHD62"^+5OJ*' M[*E13+M;X>W]_=KEDH!?GXWN"CB#;"YEU3CW'TNS''7M;OW'4"X*6"1/9AH& M^J%YJHWAS2X%S7;.-4\&6X#_J]@:-&;4;2+!,"P6#F!<3@N0/R[#A0-SQ'<] M;G&E$U4U!;I=RH-T.><[R*_+W^WDP;IIY9?50H0(W#F(==SFM=;X#3]L92(K0*1T3/ M?WB6;0_JHO/!W;IQ=O,=KNJ*\Q[4'MW__P-;W:C.3 M5&#)>0(S:@!% @E(N50PUTI@;KX4(@LJ4#TE9&IN\OOPX9XGL?/S3*]%9%2^ MK/6+YQQV61_5R3LI:%1GK M3C7E .]7CWR^=%[B[[L3]T_2W'RNYVS7N+LN%9"'T9_YFW$RY>?5\O[S_(<) M;@Z:?<^TR$W,E2&8J Q#1'AF? >M89YAK:C@JLR\)H6/I._D..IP:(!_2#+& MVEZ."2>V8@,3Y*X:JF7N#=@;#-H6-UMUCW:UV3? &@Z=Y6#W=;B=X-?! M/\B=V-=BI#AY.E^/H)![Q,7JB-K'T&*TP']$2-M[!V.*[9&//-\\K39L\=MZ M]?Q4U>G<&Y7,3YNYK/.>OYEG\8%MU+?U7"BCNYK_<.,9<\1SJ4L.,1:I"6"P M"6!PF4$3M^@R3SDON/#.1.ZOQ]2\A[UF+EORJ=8:/%FU;=+DWJ* 7-DO#U$!RD!T>X7=^.L4]K)>9.@OEYH5R!_5+>/MI*K7]7SQC2 M C,M"DC2PC;?P"4D"2DAIK@HA$Q3QKP"XA"A4WLOM75VCBUK*1O:0]8#<[\- MN-A(#OV.::E[ W8*.SQO??#LT5'6'Z#(;64]!(_<6]8?BN,&LP'7AOO1W]8K MH91TQ8/?V:)*YN-,_,L-M[=3@@P35NV&#J?[E"Q5EH6@*)1QHDO"(2-4PC3- M%"V+G*C">ZNNKQ)38ZK&CJI U[Q5%%PTIH!MRQ9_=ZWW^EQVGL= ?6!6VP%N M;0#6"+BS K3-N $[0WQF,L5;!G^7>8SE&,E?'FI9@GSE:_'L<)1[WWHT+_E: MX]LN\M7WZNMQE]_/EWVPQ!WX]MM>Q M=]YWG>8]8(W.(/!'#2GB:CAJ[#$(N*^#E&&$]*Z4G&^5.VUX/4R\'3/5-=ZV M$NW.?%?4K,28YAD7L.#F"X *Q"$7U,0W"2JD9%25A0QKO-Q3DQ "&:<5LWDJ M\N!*R%Z+X,?7(P [,#-7%M0'L7L;*F:^<9U%Q%8=;LW<5&63SI2H!9+78!F[ M6+*7+F,73EX#V(DBRJMNUSNU\_GQ>6'K2\Z-7*PG9!!28I3R DJM%42:$LA3 MA&'."")I*8E@01TJO"5/S2EN*0Y6)V;+UI/-JA&SP9F@GJN1YUCE)6%VP#F' MJ-2VBE6D4"B&,B:Q%B+P)37(>HSS6KJSG0V'0MKO330(>@._>VZ_OO]TU ;P M&W/38N)/B E&*';>KJ?TL5-YPT YD=T;>(/>'6H/INQ^6MJ-GJ59 M4:PI3!*90Y1F!61Y*J$@BA<:(ZH)"YX>US,TZM28EG+!G4T[P Q_L^C0;O8Q)[.ZB'1+';B=ZV?@3_4,]+KIV"_>@.NEV M*7]7CKM.9*J%.&3.^)LZ@B;N-KZE)I@OC<*9E4(?_0/E3\S@/ M"^GL;EVM-NA1;QBZ%J$[I]$1'IB5+H [TH9G$&H#;6GZZ?!&FY9! )W?E@R[ M33^V,S[8XVKI)HJ[X0";K\_;C8GH;?OMF18ES;FT@_8*$[@E60YY23&4I?EM MKAF50L^J7J7?MVR]]2.X+I$AS]IKP<,]=N_4_7QI^\0#SA:N29B=6.*FE(1& MS9UXRS1+4$ISF&.6VWGK&K*TH%"KK&0HH:P@I,;[X]+3.8V+=B-V.*P_.LT& M!MKO/1$+NH%?"I6:P.EY4\UPV=R EJ[QW@$^B$0E_$Z!H[*[C^FOJ=SKFE@Q M[IUZ?%JMV?JEFKGW^VJQ^'6U_I.MY4R0A*28I+ HBA0BP3+(29I 37.5RXQ* M1;RZV/<1/C7_]$Q@MS.@F3;YA[4!U$8$-GX+6IR^<7,!]&9K+<;C'/7J&Y>K^L:IQ.)INU1SZ*)5BBAFDQ#BJ*),I)+E MQF7-4IF598&%"@K$+TF<&K6=G.\6&'!?1-DSQ(Z)W>#^TPG8!CA4\,8D;LA\ M4>JX0;(O"$=AL?>%?0/AS?:K_FVUDC;_Y[M:_Y@+M?F^6ACW"7-*B.T=I+6$ M"!$,B4H0+ 77>:H+JG"0^W1>U/089>/&E=BJ@$ FZ<#3-_J*@=+@W%$!Y-1T M&W*-HL!J&C/RNH1&Y+CKK+B1HZY+9A_'7!>OZ%OZZ&:RU--6[#B6)N&IZLS_ M\?%IL7JQIYK[H2V;WY6=.6R$?-55%WF;"S/3"B5(HPSJP@Y0$2F"1+,")HSA MPG!,(8N@])1XJDV-@'8Y9:HV 0BV>3@8AK2QF0#-E*1F\I$=D&0##5%UD *Z M:N'_8DP,+;Z,MNI^M/U@K-G&]H^IK7,I MX?MA##'+/F.#'KDX-)IZ(Y>0QH;UN- TNH0(767W9S7[PJ)=(_]4ZEPR)B'+ M2D/^.M>0ZZR$$I.$HR0728IZMYKMDCPU;C]_F+G7O??L!?_U\*/E05!^L]/B M,("OZW;K ]9P+7 [I;]=7UP?4#J;Y7K=(+RROMJUJ^HB;;C]\:>MHE3RTW;S M;;UZJL8Q&ZGN...K_J*V=6>\DN8TS3B#I:$U&R/GD&I,(1=2V :9A41>FV_7 M*#$U@JOWMN<[0VZ JDT!\ZV;W[DWICKEM![.4FV#>V'V7K=N]AMK-08FPGHA M/K46XF-[(0[LJ$Y0[4+8F>2A72A[+X1_S?T8"S+:4-SYQJR >@1KVS%DXT;: MN=FX;+U^<6^M:F2NSW-CK]L_._8W)@94U=(_JNW#2M:/HE*11N%>NQ(=U?J] M;SU:M?ZUQK>K]:^^5S^GO=TDX,/<]0*P0<-7W;215)M91G*-:((@226"B*@4 M\D10F"N19CDEB9)!F[\>,J?V'K-#-^R@:N4*_UR;&%EW( MSRGWP]G/'(Z,X M\/OGL,5.2U]+4GN-XSG@ ?!$=;U]Y([J= < \=K=#KFT'_V<*X+YO-IL;G^P M^<(F\_ZZ6MO^)=]M[7GEYIH:>EW&C*C9XAS'26I!)FFF40"2$@P[EQ+ N<,:($+J3VX>MN,5-CW[:FH%$5_%$I MZ[F]>P'8;NZ,!]?@606]D/(F-C\@NFC*W*%%4>9?K^GI@HA1R,;/S(8Z/#_= MS]4S?&*C*.-3_IB;N/;=RS\VMG7&B09TIQ*<=F<5E$BE\D1!2I,K? MQ87SM7<7^>Z]*W",0_E]:]X5UF-\5Q6L?7]0:FL[74LY=YN6BP_SC5BL; NY MS;N7@\[]&W.+Q;,M!K*?J315MPJ(9K!5S# M -HX'+"5A0(X+,++B$;[AOF]E2;ZO1GXU37-KTR?6JBQ%R]V*=5H^H]=B37V MPIPHY!I=A2BOW<_V:V^G3%0; )RGG(C$OAZIA@AS\U.*<\C*,BDPXPP1KREI M7M*F_FH#C;J!FRQ^4/=Z8_0'<&2.#\#N6B(^CE3:VSM[Y3Z\=9PC*B4%%"0@L&42(E9,*P",UPIO.T2'))PNHS7HN8 M&G6X8Q%YB7S.F1[^S4;+U?Y;5?,[]7Q=NLP M\&NG;=C_JANCM'<+:NN.NB ?&@@:"P?9)A\&_+@-#^*J.&YWA$'@/6JE,(R4 M?N_J=^NYO%>?5VQ9-QCA(J,D2S.8JTQ!E#(3OH*]HOZE0V>1['ZN8^$S\+-] IK+S[@_1O[E4S&P&JD\*N3K%%2X= F# MCL*DLY>.5GAT2?EV8='%SUZ1N=^:$6<]I*K3R$SIA"9(9Q ++>S,3@DYE@D4 M@M,"D42629#[4- MV.L9.7V]$XOX">FGQ8V?8MYI]LFD\>XK^NY'U@<7]7%H.T.I[FMW^W.^F>&" MI88_$E@B8D*?/"\A(9Q"F;.B))GB4GB-IP^4.SDB:;0][%-A- T\P/3%W7?C M*3J:0Q-,#R![; D%P1)YK\=/]LB;.$& '._.A%W>(V3[^O[3%[7=EUO_39EH M<%--4ZO]Z3+-".=E"EFI$43VN(-0$\+),B.8(5[JW,N-\90W-0JRV@ S]7O6>#V"H-*XQOO27V]D R(_>(B.E88>!G92&&A M/SQ=$:+'7<8+%OU-.H@; RZ[(H0\&-XI,XY*DB*8$%9"Q(L<4HHHQ)SD+,$X M3709'#E.>3AM%?]4(VA[Q(<])I]>!:90E96 6R46AT\L, M^;Q:WD.;XN,J_?M. SP+LFUS7*7&^6^.ON'*)-Y9OP0 16UVU"(%9#F>0:U)*3 *264!E6;Q51N M:CY,^^FLVUBW;0"U$?V(+LIJAE'BV<(GE6AD%G&=B;5K=XO.E:OE'8-2;T M@_!P% 7?A+%C0GN.VZ/*Z/<6N+-#N)[7+ZV)@[?B?Y[G:R5G:9*R1&D-BT)P MB/*40XX+XX,F%"4<"4D2%#;VOD.:%P.,.O2^419LK+;@R=SW@6W4IO^ T2ZP M_3CW6@#'H= =JC/NPKQC.1I MEF-JW$";ETD$@;10$NJ"JT3Q4F0H*)_^C)RI.7BO JTKROG/ >M'%A'@&I@H M>B%U9?74$0X#EE!]?IOJ\ L&=Q=3'7^\[WB3)_;B(M:OVFY"V!T<*VF&"Y%A MJ@4LTTQ#Q(3=T,H3J+4@*<,E+F6@6W%.U/1\BF^UGC:XD,&[66.#JV : M:_[(4PNAP[VKF,-&NH&(/%ODC+"11XETFWP\.>3"Y\-S".[FC^J;6L]7\JLV MM[=QS?+^,[N?89)FF7$1H&"40*33 A)!#3\HSAC-4RRTU^91EY"I^0B5CO9+ MOFZT! MV[W_*?1;-;BZ(A='0$811$3P-AI'_\7\,K$8Z\S_SE7+-JNO6U39+ M\<5^0L^7;"GFS."U-']_=*I%&G%Q";*./("SEXYV^'])^?:)_\7/]HVFUO,? M9D%^U!M!,YWFA=0Y,7%3AB&2:08I424T;$FU+'(D95".YVL!4^/&O7[58);0 MF.D5?+[!4G]0!H^2=GC<=N+1(S(Z;73DD.B5D)%CH=,F'@=!9S[7(UG2W>!V M*5N)X9_M](?7YRR<"T4+E4"5I3E$A6:0:ZRAP#3'O%2L\!OJ&R)T:@][^[CE M^_/3T\(ELIH7TV'#O$_[UU1 )J#O0ESVF8: =V#:J%0&1N?#@I%*[9#SJ?[ M!N19#@#P6,F6G4!'RK,,A* MH%+4CSNZT.SFX$@8#>VI! )SPVC9*_/5^]>,_S=65PV9^<(S@V*#K MGJ,\_!Y&-<^ZST=[N&IYF21?5EN;I_UB^>+#LS+P%$U)"]%%PDKCU4J[55VZ M$W 3?B&<$2J3+",J\TO O"PLY&L\3N)E_E>C[W^ ?[+%_5JIY0:\6ZWL>ZXN MD':-AOX*EM8@()\5L+8$^!#=T!O$RR(M"\BPS7U-A8EW<_-/F164I4FBB?!J MJ!@7^#$XMH;]>>GFBBD)OJV>C6NQL=]XNZ/G T& >FX1I!IRJH=;T! M'VK$^I04=4,7X.5&@W LWQ;\N9YOMVII1^@^SC>N?=@3>P',?0_MOQC8/LS7 MTOQVO7V)M(?HAU.7D]M]@_%<6R]##AQ:ORNNF1]95:BW'.;F=9H8J1+F PP)O&8?7C!^-,##2]==$U+?3L:L9IU>ZI]?S,0\9M:OV.; MN7 I9S-DXF0E;18I0A@BEB60&C<:8D3*A!228Y:'M]OOH /\#<@#[:O,%,@2M .SUOX)H;AF], M?K3S)E_>KQX?5\M65N_7Y^UF:[ZC)EB<%525(B\U+&U7()1Q KD@R/Z$L%)Y MEB/DNT=Y6=S4.+72&%0J'V:C@Y;:X1G]GNA?WM.,B^G %.D)9YS-3G]D>NU[ M>MQ^M"U0?U/;NZ$!5_5S\MIY?ZUV>@5B2!>40EXJ$R52962IT7 MA'B=6G>+F1J5['-1P_-VSP"9) 8MV[M-E-0>_U,[FI=KB))4I25E2I1DMEUM MV6(T('?"A@/RSLH BP,X;\!";3:[X/NI:BD>!60_!_9ZZ :FWL-4Z!OP\6?3 MX[\)O__.MO5,^GBN9309+H276Q=M=@H M6F?4A3:.;, M![5@+TI^6+,_K1-D!X.\7RLYW_[*A"LSN?MS]7\56S?_;([*N18D*Q*8E$A! MQ',)&9;2CEC#:5G05"7>(S[ZJ3 U*JFM -8,-S:R&F9360(:W6^ ,09::W:_ M\D]?Z+E6W10TS@H,S$Z]P>^11-+WB?%.+AE^-49*.HG_2 0EGUR'8T=22L\; MCY:L]^H/Q,Z9)@QH@=FV![E><44D[, MJ[Y,A2("2RV",EW\14_M]=/VSRK=0:5\JW/TYHH6)@&+$NKRQH1Z1"_X2I2O M\(U] 1O(7;XH_HT\:%]8SCO5WG?HG6UC>S>I#ZKZWT]+E]MS*\3JV8BI\P1O ME]+\9OVLVJ4PLXP4N28%@AP5.42*%9 3QJ%*L, 8%U*&#::_0I>I45^M(5!5 M7[TJKV/ERQ-GQR::T&-G4736Y^Q\VBN!>Y$)LW5MPS?S_B-S9^?K\MM:_9BOGC>+ ME[^I18O.FRG&QGM$F*] MGN+#KE9W(["IM0"L;)U HS]X, :T9^+,&Q/\@^:09;F\7Q$;Y7&XTB%;YR4: M@/>J ZM[>\++IV$!]M^*& CHD?8?8@(>M//0 [:.[8:0NXVVQ]##Q/;&0I_+ M^U=\_SK?"+:H>OS\:GZWF9DOC#">-(?4ICRAK,PA*U(&TX0CE9(\21(O=[I3 MRM0TF[FA0#;V7W >E7O7?9U&XJ@+\^*ZCUX"? M->Q4%?CY#_>+LC]JK>S81%6E MQ;H*Q:@-K-[@=V4?'Q/>.)U=%8F(,KRO/UY1 ]T \:/&M>&PO YC>]RA'V]] M6Z_T?&N=HAEB14EU*:'FLK1I@1PR)1(H5$%009'6)0O)*-[?.HAW1L@BMI55 MBJV7!L@-^&5A7?4PXFFA9H=DIY1SF$G)()(9@90E.2P02@7C68YQT!9I3]1& MFE$;"S6N!"NR!$.![+A?CC&D.)&PH(2B5 KS[:-AP^GZX39.+Y28R/F]R/JA M,?"+JIHHVRJ4=$U@ZDST;U7:/KC=;M=S_KQU6[?;%;#)T8;VC'X+^[$F0(OW M#CN&*NH[JG7[4=]!QV:]?L><^$2_=\B[Y\U\J3:;]ZM'/E^ZUY+U/.Z7\W\K M^4D:CV.NYVPWFZB9&W+8=LW\S3CF!T<:/.$DHZF"16(+6U*FZA9I5(NRY"I- M,A:P4SJPNA/=6?4Y\1AU5?T(["T7:1PV;"P$+1-OP-Y(T+82-&TB:SO=H5:[ M@J$V]6:8$ZZ!5R,JX0ZEZZCL/3#@KU\%0XOK]UYYSS8/]O_;!(D?;&&3(GXW MK_[U7!CNM'\P\@]_T?KD3!":BR3+H,Z4L$WW,.0#[ MEJVW?B^/JW0*89_7F@U'1%;)&R#,?X':Z^H89KVSI/H[VP*N[N=+Z\G:;*1* MR;#WRG6KFK D*TE90%4($VX5BD%>E!H61""NJ8DJ1%&OZL>EYP2@D=>TT6LJ M*ZJ6\FW6,F.(TT)1F"%A@D"4,4BD=?)R4C*>YSKW&]TR^CJ.$6W[K^&82^;G MO(VV$ .[:-4:V/^"EH+62=LM@/NC7937OVM=$,\/BP)L5&_K.HU&]:FB@/?: M6H\'ZT2$S?3Q,3-"14R M9Y(QKP.F"W*FQIAMW0+&/'4 V$9F,=V6M;IX_4PW:A8!4S%BH/92.D\ M/;$+&WIU&9&NN5<=5X\W^NJR"0?3KSP^'D:*+K]S_3+[Q_=91D3"LDQ#PK$M M$RTII(PG4*&4\9)G.4&%#__M;SDUJON''?PN@8D.M[[;>BU\NFFMG]4#,]@_ MOGRZ^_@!?+^[O?OX_?J'[MC&CN27^L.53U3_8Y\$T[K5* _;L>K-U^YI)UQKBFUI7K3W3#".1F8B-)D)"I'@*24H(S!$K,$))J1D+ MBMTNRYS:0UAWLMM4G>R>V!K\<.U/8O1<]5D"SU@L+K!#1UP'W0&-PN:+6]&< MK)O+V$ZHD7N@!D 4-W;RD#MNA.0/Q%$<%'!I>+1S8G_ZO7$5YK+.@KE;L^5& MJ_5:R2]J.V.E(C(WL4^64N, ,"DA$\QN$MI=0YF4B'O/! X3/36.LD?NHJVN MO[,?B#E%!FN1I[#496[GC")HLX:@IJ4FF*2JL$'GY>RA@3$?*;MH',POQZ?# M(?DFIZ,'NH.6\JY;]F X^\>VP^$]4K@;%?>@(+@?=!UQ<> -1PN5^QG:CIY[ MWJ'O1&EMA,EW:FE^V'XSWY9]?[C/N_8+A K-2V;IGQ80%8F$Q.;W:41RFR I M. [J*>DE=6IOVUII4&L-K-H'W1 _]VV$X;<(?A%!=&@'?A5$0;7'=.L E"*/ MO/:1//(<[ PCH=CAUS<5OY!.HP;C^??@ =-?7I>9M^I%>.67_*XRC3N/HQT17 MHS,PWU3ZW>P:_0_!+IT81.60TY)&98I.8U_S0?>'>U?L":6DFQ3UC;VX7F&_ MKM:NS@977P4A[L<< ^(X,*MVF'[&9.\ZW)B+\H>2GY=9\X>:[@H/?UK;TD2"5 MRS)74&>Y+1HM,>1"VSVF3 F*D"Q5$L)DEP1.C;J<4H ]VDK)?[NJH/E.[=KS M"2.VBXC[,5E,' >FKDI5Z'0%>V5!XR8Y?>,1E2\R49GIHM!1J<@7@M?BDS7$G$AV*&'?RT$GSCB8,G?Y4[X&UQ@E9L\6G MI50__[=ZFO M';?0\:)W8X;NU,_M.Z/SOV8959DN,@IQCK4;0@T9YP7$*BV(4%)I$=0XK8<. M4R.#]FB ;M\6\!?P=_;?JS5XOV =/FZTU?(\R1EV#88^S?&'OYI:!JP5P)DQ MR)"&8! 'FM;@K\<;C6T(!NK\_(;P6X7[/M^5L/-Y7S[^% ]&@OIBOI0SPHNT MH)F"%-N=7<0SR/*:) 61OJ[/*0&3([M:1] H":R6_G[/21 ONSW7 M0C,T!X6A$N3S=)G>R^4Y>I[5"O'\^+RP2?%N^_3$J;#M MQ/5YE\N5"DS-G4HH=O],N^"%\CPG'A#^H8^0XR,??L3<$[ZXI\^A2HQ[,-T3HJ,SZ[[WZ4>, M=[8BXW>U?5XOO__)GNJYE;E,RUPE"!(N;?,FQB!-[3]3)!.D\S0O@B9#GY0R M-8IS2H*UTQ)LC)IAS'4:23]ZNAJ?@3FH@J92$%@-+X]0#>:83@RB$LEI2:.R M1:>QKRFA^\/]F[O9[+C#CB@G9M#/--,$YT)"0?,,(I5KR&6"H109+7%!! UO M$^4E>6K\\/?54KV 1[;^E]H"_;R4@;LX_I#[D<8@0 Y,)+M^3<==G:SB=9'Q M7O6XO9N"T(K>I\E/^N@]F8) .=5_*>P&?:=H[@9S?EK:\7'R!S,6;NY6MUJ[ M"0MJ\XXM[.]; .(<_= M.)W0OSYO-UOS^-G,,-<780-6?]KB'MLTH?I%8*>$\(7Q([=!P1Z8Y-IC@0VN M;@!FK;YMJ;XWX ;4)MQ4/16B#L7LB5_D49BA6HP\ +,G2,=C+_O>J&=1Z'SS MM-JPQ6_KU?.3.U":Z[EPQ:F^$\LT 4E3C- M<9('-8BY*'%JWEJC,' :@T.5P1^5TJ%EH!=A]R.WJ& .3&97XAA>^.F+3=RB MSXM2QRWX] 7AJ-C3^\+>T\SK#2B;E&S=NVHFDI+[D4A?U/:KOF,_VZ-$[E:_ MJR>;.+N\K](99IKBC#%I"$H(;F>;,TB9L-./BJ+@:4D*+$+&'473+(C(1NAG MTC8%K':V!(\VC[1NON[;&ZS&X&Y=>Z/=%5\,M>6PR8E&.MNCD;J?&/K MJ%/@HF,=>QIZ).W&GHT>%]03D](C"^C'Z/]4\_N'K9*W)@)E]^K+L]U<_*H_ MS!?/YK>5M]H*&V:_OK?IQW)=1ZD-R\Y4FI)$9 )*7%"(L&:0YX;I4)[)E*59HA*O'GHA0J?F M;58G?2N79R .\@RJP8E@[DP(XS@O]/V(+3:F [/9Q82-MJL8C\1"4(K*7%Z" M1Z6K$"A>5=:Z3?2*E5A+\<#NLM'$SNBX9?92Z=?&"GI7YS7'JWQ6S9ZF/U9@;\;Q>&\^H3C0J M5"%4)@J89Z5Q63#'D)=V$#;1.L\3EA19%E2=[R%T:L'83KW .GP??/TH(C9J M [/%/N?"C3ZMM!P@MRL$EKC%^#Z"QRW(#X#BJ"@_Y-IK-OB-7[-/W=C7E#&A M4VJWZP7)F.$895P232A,C5_".>,L+8.ZS'8)FQJWU%[[EOT,G>3<"6G(=OKU M0(VS0V[T/&@0.TC1G0\D VQDGQ'X!GO3W::?WFZ^<$W/7AZKY;UY A\_*+Z] M,[>X_3G?S+ N2Z6080E6(HB(0I#0M(!$T\)V>96(!VT3___-?5UOW+B6[?O\ M"@(7=R8',,\114JB9H !W$ZZ3X#NQ$BG!Y@Y#P8_;[&T1&[NO?:Q099&$=9&:(T$ULHK8.T$_["6^BI\'$/4 MC2DNQ2DP0XR!R%_W8P"#:=4_C@TTKP;(@*L'2B!#G_6OB6UD%7\V?,)6_ZG8 MYL-:OF<[=9?@.,\R)*!.D=F)4$8ARQ,%>:(QYTG&9.24,#XTR-(>_5;?LS84 M6$N!,1586]TK9$]".OSL3P54X&=_%$9>];+G0!A5,WORIK/5S9YSJU\[>_:S MH\4!;?)B)2;TQ1[ 8147&L#$M>^"I\>\*J,Y#H-;/CUZ-D*:=PR=P3&3JNTLSAK_4I795E8^L>):M]D&U;2]:G@H4*Y' 7..D7NW27&8P5IBK-$H2G'J5 MX/P 'Y;&JBT$%:F>2+X>2Z3S?3%\27F1TQV8X%^7'6VO0.?VJ7F?B?5GGXQ M;Y#Y_/A!;Z/9)^KTFVU^4RY62?N%%>LFS:7(B:,H2 M*7(%$Y7G5A$V@BQ-,:22RU1K01+DU^O*;_REO9W^6&\46Q7_:VCIWIC?9LR: MS;RP:A?:^ >K!.>[RC?:7%[OP0$._"[H:^(]DL%]#Z5]JI6%K$N@,J'JZ;> M*D!6RT@$0XFB.=GPHS31? :D$3SNLV%V78_O?32;'YBVV);G<-J(7C$\PQF M<9I"PE1D%O@HA9(JI#*N$HGHJ$2[X^,MC>1Z-H+*R%$GW.= =@P;3P==8,KR M1FU\BMTP%F&RZTZ,^6,2ZX8!.)E3=^8R/S*Q;>*O,8VB3^5.;6_9B]V:O']6 M!DC2O*4SDN::&!X1G#';.0-!2JF%.9.,QI13Y10>.#_4TB@$_]58^W_!\WIK M4Q?-2WQM+0?R60%KM!N3." \3"+3XA:8/QK(*E-!8^L5>-\@=GYMXPN=+,TK MUSP'=7G$/!"^&C/@ZA'\N2EV.[4&3X9#BFU5D__$7@"KOH?V-P9V#\5&FK_= M[%[^>CE'N^-4T[/Y?$6Y".&H(ER'&\S"M>Z.M#3K<<7D;0O[)1@?OC\IPSO>\^:JSHRRGLS2"=$!R;GZ(PZ9LI2NB0YP M>?12=+G;R!.O?6) NU/>]PR4'%."%8=YSBW[12EDD10PEH)13A#-J%=W@Z'! MEL9QKQ)ONF#1^':,@T ['O5,!%_H0_?QR/D?N#A ,NW)R-" \QYA.+A^<-;@ M-_9"-BV"B_;\\B/:X-SM7/Q(XYCP+KQQ85P!:8)%Z0"1.,'0)F4 M*(Z-,RL_##CZEA:&/CJR;\!&R6+W,Q/%JMB]5+%:%"=F\9"8=01)N?E#8,A$ MHB%#*D-II..(::\& 0=#+(T+:@M!:^*H"/@1(-T>_LO@"?SL>R+CK^)_TOEI MY?H/AYE7E_^DFP<"_*<_.7D\I>I?6HG*VHYLC>*QC&2.\XQ"@>+4+ 42"CE* M%=0\SDFL8IRXA;%'CK\T:AAN0WK5[P%;-0HVU MV!7?BEVAMG=QRGG.8@:%M-5M":8PCS&&>40Y5JE2-$4^\H'N0WN1X PB@C8C MOTIY>O=L3 :ZW%C=P,9LP#J[/?=+[E/AN(T* G#HW97!MHJ]M&;;SN+OK.4& MXK^ SGAP?1YF_SV6-V+3;KW]>_JOA(7^EK>E.MMN2JDW4'N4]AIID4F;5/<)&&0Q+E5]N#F M5X6BB"4J1]CK^&P:LY:V&'SME8V:=GZ]:=M:JC\ M\Q:87H>FK/;):\^CO5O[2ECN;[>==EN M1UKT-2'H-.$L122'+!<*DC2*(),B@G&2Y#*-E!;82[G)8^RE\7=C.F"[?G?* M7IJ@'S/[S((;_0;"-C#'GH4UP.G "*0F)4:?\6=EOQ' O*6X,;<8K4ZYL2(( M[U7]_X_KCDYOV%-A=K;=R3NF,HHT0S#F5H".)?94(J6V^M9LS[59J%)?K4K' MH9?&8CRI>MTN/%9&) #TUEK M-'C7FFVC';UU8V-ZD#P)?\2F%L5T'7YNB4Q/6(X(9OK>X>*BR_?J::-$O5(T M/Z]41:MKV<\2,\M&8\?NY=9\!VU!J&V[_&1?FG=!/!0 MA:*7&?>C*D@G@72@M'2:^X^-RNZ*>NMC[_S[DPT!;'XM7[46CK36."$*HC1) M(-%Q!CE+S#8]3A&-"-72[Z#=8Y.I)!HW1H+5ZY&&Z"_JNX=!),0T> MZ[P4SA&A2V> )HY+GA]WYJ"C,Q"'$47W2T>VEU>;XINYW;?Z7/U362N.&"9\ MMNO,5$J91W93+2DD2F/(4QS!/%4ZR;*$L1QYM98?&FUI%-1:9Q>*S]5:HMI( M>_:1'\37C6HF0RTPR>SM;*N>.@AK6R=L'>\"R;1MXP='G+=EO(OS!^WBG2[R M+WVW$O/[9.\O2JK'IWK]5 CU'VQ3V,.Q6V6^8NL=NU=W0E"L$HIAG-I:>)J8 M36R:F/TK2R*.2$XI=3IS&#'VT@AF;S#XUA@+GCIKW0N\?:=@F'4" QN<@_BN M5WQ@>UUU(%?67X'6?G [ ];NU?4!,9^IW'YB[+UJ[D>B-U"$[WO'V:KR1[K: M+],?>XM+%5E_?S ;[*]M8Y(N 07%D8@EBR&1*((D-LM,QK,8)HF@C!"=Z,BK MK.3<@$M[$5160FLF^*G<;,H_B_7]:''3$QB[+36G1"XPT_=UH6L NV9#,^F# M#D,42,SSQ* _2'ES&(+3,IEGKANYE^UK;YH%[E'1S3>:FSUIS>X ,\HYCU2* M89[0!)*<($-'"859&N8R+9Y(PC3 GH0:YCX]B.;5>Z379I6 M67#C-O7\J3;AYTI3S]2?^X M8]4AZ3-?%?>UECI;R\^[![7YHMCJ0]4UK6HMTN38YCE/L5F]018Q 8E.%>2Q M@5/)7$58DXP0=CUE:"5>S4;Z9C;*: M#2LR#U0]&R+D;)P/"0?#.#3'^WS91ZBK^N'L'@X.AO=,P>")_V0+!H]SLAX''W6"DFI"MU?^L?]^5XO\UB39:D@QKA&"6*O,*$#R&.<(8 MZI3F2% 95T_HI)L'>D*G/SFR])"]-(6-U^)_GHN-^NEY6ZS5=JNVOVS*[?8N MR6PW/$Z@B!,,26)VWER8W;BB/$^9CI'(O$K)SPVXM,?_UMSHP;X6G^PYFV=% MX3EPL\CJ,TD!!7>&>M=9*H&HSK\!:>58673!+(TZXI@=]N8=:S=0TS@0ZO1H% M:+@#*S]S?MP9U2C8!H^EQMUQI-!FN5'%_?K#=U'59YM?_V2;5@<:8T)IGD50 M"I&813&*((U1#I'9_A*5IR*.O&HYAP9;VH*XL;4YGQ(O5C_.6NMY.C6(KQOK M385:8%YK 6OM!(VA 60T7!"95M%R:,!YY2L=7#_0JG2Y9NQ!]EI]UJ_E?W]C MWXO'Y\<:#N MC]G$1^T>!LQ\".\/S>'Q_(A[C%8>MYW.?ZW5-NJE5K.[_;QNTP1>[K(814PG M9AZ$PF9;21BDF,20ZH3'*H^Q%E["/F[#+HW%]NHR76_Q;2U)J&M_P,HZY+MF MU+=< ^8II8+=QEZ;I5P#SB.B(/[ M7#V.J+ZJQZ=RPS8O5OYA]W(MQ*82B_A:[HMF*O6S.Y%IGC"!H%!"FG478I#1 MV,;!&(HB2:C.O?JL.8^\-+IZ5=5HU?Z8_._G[S>2"H)H8)[J; :U MT5>@,]O&ZWM85Y9/1U7>8$W*5NZCSTI8WJ"\Y2S_&XRCK5_*4OY9K%;-IO2F M":]\W;#U=E4%N'YAQ=H*TMX1E&"4ZPPJ$0E(LE1!ED<*:BQCE<:(:^PE\> ^ M]-*(JS45[/:V]LC+C,'_ M)N4PC^%G)3%_6-ZRV(@[^.=W7S^J35%_$7]2FWNUOBDWECOM[9O(+A4)S=,( M0ZUT! D6=F=HE2681BA"2$6)1U+W^0&7E^]P8+-[WJH#OL.\-#UF@;GHP%C0 MLW9$YJ\#@N[IOM,B.5..[_6ZTL?]^V_XUI)%":0:QY!@GC M E*N[/M.1BKG+$HSI]/)(_=>VOJO,\^= MZB=9XQ+\ @,#UVEHV@PK M!7C,1'+GOQ9>)';"X0'&>GO%;/1TPM0^%YWZR$BAF+HSRA?U9'58U_I;&.(Q)K[54UX#+HTJBJ ML1ET1H.>U> ?U2E=9;AG:8'3!+AM5Z>&-3#[38"HOY*,!T33JLFX##ROHHP' M% >J,C[7CFU&4I\O?&&[?<,3V^J^IQ_"),HXJ_2:)88D3PTE61$917"&4T$D M2;SRN!S&7!HM]5K\U(:.%G5Q =R-AR:&,3 -=0>1UEPP"L\1?46<$9JXH_F1O4I&%^J+BB8HDSMYV%&-Q<:[G M\=/^,9F;Y^VN?+1EV75T??M0/&VOU_+7\H6M=B\W;"/_7J[,O5J5@0BK!"G) M(=*)U=-,!6081Y!KK1A/9:*14YWEF,&71A6M_6#3=Z#NAE:[ (1-H'ZHG7"/ M>7C/ROG@4$BL ]-,!_.7 Y@;ZX$U'S3VCX@Q>>/M'H0*B?M,4:HO2EM8=R40 MQ[[P8/? ;-598<4VN-K]J91MGP14_7:PTU28?VFOO;*%&.;C[/%II:X ?]Z! M=6GEPQX+VX]I5UZ!G5HSLU\>?JJNP-9]FUMEX8#CR+[_FU\52H!7YMC0?,:WWL@L:H%?+@C6=;([NX MUU\E.WU^;#^COK+])S/UC40.2RAGVO;(Y%$&21(SR#'54$49RH0]S-1>=5&G M!EH<);QMRF!-':D\=!)8*)9E L$<2:M"D3);-LY@)!4C$2%""><=T]N; M+XV]*J/L@X/B=_POH#77?6]T@-[Y_= EF 1F'%\XO'8^I_P>M=LYN-EL.YQ3 M;O1W-2<_,U)-<5,*I>3V9V-(I=%H6\!N[UB&6488@1GG"!)LZW4XDS"-"5=I M1J(D3KPT%(\.L[1'MK6RCC=6(4B@'I]6Y8M28%LIACY9NSW%_HY#[+;*N!RX MP,]UAUE5*U[+JMX.@N0OYC>(P;02?L>'FE>X;]#= [F^X4^/3)%L^Z54'<[N M4IU@036%6B/SVB8&.B9Y!&.EXD3G4[OKG*,9X MJJB"/!$*$I8SR'*EH8@2DB6$I,RO\/9PB*4]OK7X?]N+:$PW]2,PNCW%EX$3 M^$FN<:FM"]"'Z+3ODS[11X:9]:D^[>;;)WO@D_[).=7-ZEYFC5ADFW^0<(60 MMIJ.:6S5BY" /$;<5M9'>8SB..?.63@G1UGF,U[4'0+?-3*WCH'!83B''_3) M0)KE6:_Q^5N+S_8O(_)A3B/EGO@R"6(S9;C<;HI'*X12BUX5; 6VW0I(L%H$ M1:VKBM/MU@:EZQ9*#<15:LI&?5/K9[6=*#WD+'H#>2"GKYTMX>.L^?W,CO,? M'KWY:H0+_6?^S[6*I(("Y[ +*$I)!'" M,$ZU+.OO?JG!6OT)6.>,38;J>?-OX-/0/U<) M7B_*K,OL#97T6YAY3Z/;LBWDY 0F>@OVWG;PVGB;AFT-!_]H_A^D4_E8]"9= M%GH;,>NB<2Q$;Y>4H^\SCC6_*'LN+G;/&S/<]5I^J:.BMEN7_<_PM%W7RJ_E M>_/7Z YA@G+&)20$19#P/(&VQ3E,;=L=CG$<$:^MIM_P2V/,NN- MP+NQ7#@X W/<*\.K%59C>M75[ZKZ$[3FVY"]=6 Z?AN'VZ3LYFG"K-PV#IZW MS#;R+GZ\MMWL[KY8V?3K[\7V3C 6D0SE,&/8+/%B9.DJD3##G*F(T!RE3C5M MK^ZZ-!:RX<5BNRMLYL9OBMG&YW4PUQKKN U\#=LPV8P&8X8P]@@WS_[K.\[R2!]UHGU2C__CV/393?'-3,BW?17K9[W_R[TNM.14 MHPPI2!*108(DA50S 3.M$"(%E8!;86]?/>-O7OS=MZ$*(;U_ MM- M^4UM'*4@#CZ_H"]^9=>DL@XGO1V5T[05(.B4H3R! BD-$TPU+G*95>(<_Z,XA M[?9^FQ"_P$_WZ63NO;F!4[8/<0F?G]T;\\2R<>S2-FF]*1^Y M&<;[Y3%\:YW6=NF]M"VEPO:J> M/F/PO_H1WHR3[\:=RYS2P#3<.@UZ9MKH9,]OT'.\WRZV]GW?(*A8MTVRK2;7 M2H(* !O;[-T[B$S7_#,WZ8MB1O-G?>?,/RUO7U\_P(+1#<:/==JU.06V68#- MDS[ZD9^4+C>J_N!7]OT.:REPK%(HI="0Y'$.:U1:F+.$Y]M)GAY@KCWJ3=RZ?$>^I6YI/8-G=? M\RD!/=+D?-+;CPZI%#NSF?IFWSD[\VTO^$K5*;>?E-FH,"42I"*8Y7D&2:0U M9''"H,XH4G$N.17*A\&'AUL:,7^U8P#V:.6*_]<6%QAJ;HUNTN*OP%IYMLL[ M [ES:&4B(,-'5HRAL+(4[$WMLN@_#< W)K#B@,K4<96A(><.JSBX?R2JXG+5 M90WN[K!")$\$@TAD&!)#'Y"A-(69I(G,L2$2F;GU@'I[:Y\O^SS=GEK+QC6B MNQ-)AC-!&$Q)G!C2C2+(>)Q!+CE+8Y7D>>*E@#0&J#EB-Q?"A&(JF182"DZY M@0DSR 7/8,:SB*0)%I*0NUKPY/<=V^S"@?5VD/"0V97D?;&N-%TX6]FHZ.@O M&Q%,QAHF68(@$4D"*=$,QBA*.=,H5ZQ%\<-:AL:P'6(.!-5:7@Z?V]MZ#""! MW\MG'[[1;1R#O&:[F_^0%HRG7IT'_S[N)?E;L2XWO3"/>5DJ3C-$84)X#DF: M2I@G2D..=(HY-A!A+^V(MP,L[4U@SW#,1L>,M[*/9-&8Z1G?.(#1[>&\!)S M#VFE1M (7O]+&^*^WNTV!7_>51N270G>@->Z,=V#?0J@21_P@T%F?=!/N?CV M@3_YN9'UJ/64_E8U9?Q8]62L2A&:^L!8,HDI(C##20Q)9A;.#)G==Y*@B.8<*?'+##]UF =ZYQ:5^*-K 4>QM"S*'@R+&>J#O[Z MH "[O]^H>]LXJ=2 K59M!?!)H&W)XU8]L8VY9O52G8:LS+-B/U1)SN_8]W)= M/D[5O]8=V'.%P\,WF;>"V,FA@U)BMZO&=FOK1[MOZE"W6<-TL>YM=PYZ:V.P MY;J_]OE:OE[Y=,L^GFN:<6WS_ABU6DL84DH(%%SGF":Y%%CZ!*W#F+FT8/EC'6RWE/N5?>^G MSC1>S[^Q"#LS$_? "V+JS&WS0L)]V&DOZ&CCWCC70FR>J_2:^O14=?)4F6V4 M3JB$<2*D[<_'84YC 1666!"$.,9.M8QG1UK:-NMCEVWBFR1^&DPW8IX$HL#< MVMC8R]A0(:2_SD(Q*9F='FU6/CKK]%M*.7_!2*U.\:#D\TI]UFU =Z]_(G&: MQFD8PR2;V$.T^/M31F:$VU2X9Q9W5#P+IQQ$1P MA8[3'D&J4?L,HQCC ,NT*J #X\TK"7K>\0-]4(=+_,.W[5U+_5X];90HJC4- M6\OK)EW(_MHH<%5?A/TWGZA(QCF-8$ZPK&9B1P)S ]V&W*>?#/3HZS[S,%#4-.C]> ML='+81V(F5YP\]EBJ9<#T(^Q3G"WL0(BW]2J?%+RJQ(/ZW)5WK]\*>X?NF,( MN]*EBBF8I-CJAJ1FW1LS"3'3&%."$LIB/]V0P?&6]C;JS 6[SEY?K9!A@-W6 MOQ/"%O@5LD=L;RJH;3U_4#9"#,0)EXDU0(;'G%GZPPF 0\4/M\M&JN?7L;WU M?56B;67'[AA/D(X,V6N;6DB4K2#(\AAFF8P%B5#$%?92SS\88FG4\7/QW5>M M\ AN;O1P&1JAC\];XUI9!6O?A'+Y)WV?5B[_<)AYY?)/NGD@EW_ZDV/52RL) MP5NVV;U4Q:E,5('[]_7Y^_.FMS#/-$YXC 1,:P5 M)_,8>VD$T&IK/AG;O957?#!WXXA 2 8FCQ;$RFS0MQOL#3>[G!#1M1&(32Q6 MZC[^S$JEWL YS(G3_L9IM*4QU-[@*H#P9$VN\CPJF]T#.>=A/A\_FQ2\ MP*3T!K?*6M"9.R(?\#R [@&O28&<*:YUO:[K: &K=2VJC#X&>*L#(WI:+1L; M(-FJ6J:?V1XBNV+W\B];\#3T;9XH)= 9W('HUOE[S!;$GBOM/D"R)_4VORPJ_HQ7LO_?JZ3#UL&1UQ)JC&,<4H@216'%$<24JET M)%F.99QY9FQX#+\X2E?KK7E*_@:>S+H?;M2N:/292[XJ[L-Z76S5K W_B"3SJQV*JGLR<-@X^"<.IG$QX2Y,TQ&P',D[63, M7<;&Y3L%J#K)I0G^-T/>Q9PF2F4,YA'&D&"6F)\R#161DC*%(D*]-$[/C+2=@)H[,#X\Y M"8##R+S;96/;M^UNV/;A=E-^*Z0AL)<_MG:HHPI#VTZJDB"):(PY5,(F MOV6VP0_[:#=BF]=+*M>W+W,R_V-\M'+;+ M9D:;NJT4NVX>V.9>W6G$TSS6U.P/I(0D3Q-(N7U]*1;A3"<\I?AN717] M.XJ(G1O2B7GRFGGZ XLMC8#9J)RX;/##IS ; ;!(>EO([7G2*7_BS^:G[Z]W]J_\;\P=E6 M_?L__7]02P,$% @ SX4F5%Z[%[D%O0 NK,( !0 !W8F$M,C R,3$Q M,S!?<')E+GAM;.R]VW:;27(F>N^GJ-USNZ,KSP>O\S MG[[DQ7(ZG_W+G_B?V9]^RK,X3]/9AW_YT]_>_PKN3__S?_S3/_WW_P?@__SR M]N5/S^;Q_%.>K7YZNLBXRNFGWZ>KCS_]6\K+O_]4%O-//_W;?/'WZ1<$^!_K M_^CI_//7Q?3#Q]5/@@EQ^V\7_RRY$#DK#C*R#$K9 ,&E!-H:7XPH*8OX_W[X MY^RES X]<"L15&8,T*,!)4U4W-O"65I_Z-ET]O=_KG\$7.:?B+G9+#SX(Q^?/E;__IXM?_^.[W?Y?KW^;>^Y_7 M?WOUJ\OIME^DC^4__Y^_OGP7/^9/"-/9OOBV))Y] M6.0\6X;Y?+7$L[-II?+/X(=*^/J#5E\_YW_YTW+ZZ?/9 MU<\^+G+YES_]'I#6%YQSR>KJ_^W;?_OS-T(^+_*2L+-F_"7]X.(CZF+'$I7_ M6.59RANV+]<[F\<;OW16A3Y?7/Z79QCRV?JGDY2GD_4G/PG+U0+C:F*4+#*) M!,4[!81+!L%;"R(HY7(N:$VZ*8/*P)(X6.MHF>.?/\R__$P?_',53/UB+:&U M=+Y;;B.EP^B^W)(O9F6^^+06[GL,9WFBI/8>B7HNN*2]11O,>:O 66M8-LRK MH(YBX:Z5;W)S7>M/%O&G^2+E!=F:RZ5Q$6\BX#N<7_S&SY]Q01\$\>/T[$KV MU>@,H?V;AZ+B? D?$#]/ MWI'0]%= M!,.!R$Z@6#+@DHQ0-!H;3#',RB;@^9Z6<5 SL)+G@TJ\!\S,/WV:S]8, M_#5_"GDQ<2H*K80!71AY;88KP&P14D@A6A,R*M$&,K=)&19]*@O>$$EO4*C05I.DB%S#$'+ M )*142ZF^!3D V[HPZOLA ?1.1X&%F8'P%!Z"R_F@I>8BG5)6$C2DW4-@4-@ MU@!C##4K,5E,.P'COE5V H9\%, 83)BC N,.7XT"R?R"CN'EI%C.$IVL8'RT M9/N$!-0I$,Z5-"IB(N,W=+QSM?HX=F1P_W50(8_HBESGXSW][H1"OGH0*DC. M"ZC&D.AF2/X"LX[<-13Y/J=U=W#4U;H*9@[4W19 ["W(3@#PO\]Q09]X]O5M M_CQ?K"8F%4^.N8'$I2+OG$<(*2)8Q9Q3)@3-["!8N+5P5S9B.%@<(]Y.$/(F M+Z;S]'R6GE%$-W%6$91# )2)#"<* <$K"B]($IP%)J5W@^#CQK+C.!S-T7&X M:#O!QOL%SI;3*I0+?!=GC"=3!T4()(\I(07W/(/&' GG7"7&ASE*;JV\$T+4 MHT/(40(>&23/9ZOIZNNOT[/\ZGSM3I+1)*: MENFFA.#"3@I.EE")#"P6LI-2*]H.Q%)T2E@555:6#8"?.Y;?"3GND2%G"%%W M@9DG*9%&EA?_JN+ADX19)\7I-#44H"D7,Y#/%4%[EH,H3I4C@^ [E]X)*_Z1 M8>58$?>$DZ?TY>O%^_GOLXEBOE#(AJ!Y-D"QFP.?##GEQ>6<+*IX9-KLCH5W MRZ"QQPF2 ^7;$T36Y^CKQ9O%_,MT%O,D)Z^$RA8(U0R40 ]8+YJ\=V0?G7$H MA@A[MJ^^&U@>3[YU,$GWA)@W\^4*S_Z_Z>>UV^6S+ R+!&88F48A GA6.%CC M>+%.%*N/NZNY>^W=T/)XTK #27EDK%2;^&21<4TWQR2\I]#.,UT=+#*-F K% M=Y@MMS'2XN6XXLMKJ^V&A\>3>#U8DB,CH)9$G[WY.)]=9GYX0"P:%91@/*@@ M";W.!6 IT:D9$ZHC4VFW5]P-"8\GP7J41$=&P[L$9"["^^GJ+$]T]HZ9 MX$$')\B9SA7$$D$8R:/6-BE_7PG9PVBXO>)N:'@\F=6C)#HR&MXOL#Y)>??U M4YB?30J:B+*R' TYS8+^"%8+*%B40RF4CN$H*-Q8;C<VR9T5RDKV)2J&'F O6 MO'\B$Q@LA5G#Q6/+@1XNURY@\?Q37GR@\_&WQ?SWU<>G M\T^?5/1P+C7NF3#=!S":FQ=?#>8/+;DY_%R[@(N M[S[FL[-+ZC%SS0I%YP1ZC#2:/)_$ZC(Q'!LH3XB"MN3C##Q-5"U(\ MMZ"-)-,7JQ^E YV<3(2D18B!YZ/ <6.YW0#Q>/*JA\MR,!#\]Y^_DR7Q]??+RR:NGS]_]Y?GS]^]N\K);2[J' M/W3H7G5[LG%D$[OOVA*]+K].9T32E S&?//"[JHWF@Z81/(:"IKZK IKHQAI MH4CCLM'*1[S/QQN@ ]@]U!W;@.C)8S B(>$A(*;ZQJ->23D&17,3 M=.39^OL2;H?S>I..3II5#86*V\V(CA!Z!SVK-M1?..Q73&25%2]TK!I6*_@5 MT8^QT+=&^V0+,N7OXO+CDUFJ_WK^'^?3 M+WA&S"R?K)[B8O%U.OOPKWAVGFE'Z50P)/+.%(FI[BWOK*@UV\QH%NEL;F-G M=R*O!T0=!8/;#=$&UTD'0'L28WVPN'R;8R:6PEE^E5>7-^@R"X=",!#>D^.7 M,P-GO0+-7&8JLXSVO@CK" MU#U7C-E4;'E:#:: #-+V8?2&JYXNOQ,(D%)F4 M(.4ZESDHKQQX[^N>X!Y5(+'8^T*PP]%SG8IQ.ZT-CY:#)=P!.EZO/N;%#9%, M@K!CA&/F>EG$:H+1#RI'2[@ O-XDO MM2>81096N$+$&SI398C 8XE28V(*VT!E?Y0,?L_4\/0Y6,:' V2^PK,! ?)J M/HNW)*)0>V MY2Q MG7\Z/ZLC2IYE8B!.-YJ?:LWR?ZZ_G1CB.#,2LPZA]E05"8)1 I@Q,0OF M76)M0-B>MQY"NV,Q..\:$!ULD=X&&::?OZV-XA.=V'UD]V-F!@3F<&CK U&_S>?I]>G8VT<$59C'7DGR2B"!_ MU!?.P,@?7\CWAV M7DOBKKCR7">*:AE(+2693RX!@P[ +6T"^I]/V&;.PR[4]1 ]#@RGP972@?VI MI_KJZU_SZN,\U53*4R>!J8BYK[KR5TL;2YB9F*SGC M=.ALZP4=+?8.L/,=_4YF0?Z;!IU%!H4R@JOOY36KG6>-TL&T<:(/0LS@=8]- M$7.4L+M);DT"LLB]C6!<;;)CR% ZEPV(FITK)(%T;R';L1#IP4T>,'&UES@[ M ,'+*8;IV70USU$S M$S*/]$\3F.Q*X;B1>?,"I2:*ZB(VN\;9[8N':&G/>:\@*DW.?Y0"G"T)LO), M1<\X;Q21W4W3N)G)-BBX&VK'**0#?^C=Q_EB]3XO/OTR7RSFOU->;001.)0?')U#Y)\[FLU?43MZ/?$= .FH_1\>WKLD4+OPBA=%LU< M3)V[NK]TFBB*!:02M2=E4!!4*N"9B%9Y:4ML=.^WE9YQS[Q&^!E ]!V8GIM9 M]4M1738?FG#E!/U_!I;H#Q4-Q0H4:T#B*$U2)FG3J"[E7KK&]<8; 6I 570 M+-H>BW-:]3M9323WR01.\:._H]42Q>! MW,OY[$,-1I_EL+J6JV<4B&;F=7VN3 :6D;_GL\V@C? N>99CHY8E6O.0LA&GE?M__!P[D] MD74*BS4PLH;520<@>W:Q[)4W>%UVF8(+KPSJ+*$HBC 4RX9.]ZC :^6"CAFE M:^-0/4!8-RF#@0$VI#XZ@->ZOF&KM";$"$/)"Q3/$B@5$[C"'92HC,T^UV> M[6I+MM+43>)@:*LUC!8ZP--V)DRT@2OI0,KZ3##J B&Y BC($9619>&:WQ+O MB:)3) V&]JJ.EGT'X5_M4CG=E.C51^_S63W,\RP24Q.#=3RV9K50+]7V81)0 MH@))HA&21\O=?2.TCN@[<#=1W9QS[4*_H532EWF:.".,B8Q!LK65<@RU/Y40 M8"5/F3O+Y+TMJP"/83M*V4X8M4FNNS,?2-2C^G0-B0?W5P=M(/^B(KO(D'\YG+EM2 V/98X$1]$ MD9 +*Q2+622W)Q?(%*0YJ:,QO$V-V!9BQFZ\-QXZOGM ?9RB.C"RUSKS;^BW MVFF5I802)&U<:>ILA^2 G[O;.0BLC8E&[ MO<%I>C%[BI^GY"9/,(6 .:^OA,D=D59!J$.J @M%*I/1BD9M1+<3-&XXW1'@ MAE!8![A[FU7T'!>S6O)[HV5%F<9I?6S%0A*9.$+K 0V/$&7,-ABE MBFES2?8P;>.&YQVA<6 U=@#,:QRLL^]UF-(B?\RSY?1+WESNO)POZY7.Z_(> M_YC8S+6V+('068'RB8'+7$'AL4@7G6>\6>W;/H2.&Y5W!-F6"NXB0GF_R+@\ M7WR][I0(;IEC&HQ) I0.'#!Q04)SMCAF1.!MRE>^IV7<$+DC'!ZIIOVAYC=0 MF^4/%?N-LD 35$J8;#4@3[D.(DQ$OG80DG?DB@A9Q*DR.>,^(N\(:D>JJ8., M^U^GL_GB4DF1*%H.B+R;JQ(E((IJ4%Q14/VM?<0)NH91CZ=X+SX(.# M.H3S"'#HP,X^=(4PX<$Y)TJ!1#(%9:6J'7D%1..]0QZXP.;O-+92-NYA?^H; M\^.5,QC81AR,]6:MFX]Y-8UX=I.Q@:9DW5SAY".S[F'PE/.SF,IDIAR%)(P@ MI6Q@$(*48#7#3+&PLMCJ3&L_/VOGK9N8%U*$ DYS7\=I"PBU2CRE%+DD(R]+ M&RD,VM)FW)E;^R#IX)8V^RCJAW$\O_4HDT5C0$^NCC7D9TA.;C<&$%*CYD($ MX]I$1B.44HS?.&;$>1C]1P2F1 M2+:6Y G*DV.#/GE@VGD,"I5R;5*7N]$WMLT=#T'WEEL,HL[N0+IF8?GD?/5Q MOIC^9TX3;B.17%BMRD=0M7NC]YG3MR9X;0MSI=5(A?OH^J&J,X8#Y5'JZQ2, M+Y;+<^)$R"B+M>12H8F@HE?@:X\:07_JH%*0J8UO>C=-/U3%QM @/$!M'0#P M6K'3G0:^F& C)HJTBZ0]%9D!GS5"$"4S+NO]?YL>C#L0]T.5;1P#R:$5V1QCO<0]4/58PR$Q:,4UR,&+\R\ M-CE[H01X$S,HQB+X4FV]"4S'D)6.;9ZYWD'0#U6#,2CV#E!8![B[44JR8612 M:N.O2.;;R?J>2-668$DGX*E8+IPKJ=$DTRW$_%"%&,?@[5A%#8:UTU[:O'M/ MW_[U^:OW[U[_^OQ__^W%^_\[U&7-ED\^Q27-0PP-?SES3PI2!2^DU0:XKT,I M/(6R(10!&K,K*B:K=:N*JQW(.SX[?K'(^[H[)T)$I56J$\=KQ$1N*+AB(SD( M,J6"T@K>)KRX2(A#,M*<-_F:< MSB8,BQ+>.\@U?UT= JBCRL&J[+S4A978YKWG5G(Z0<[QZMXZH.T8V7< H&L1 MQE_SIY 7$Q>CUU(XL&G=JY<\/^^$!A22"\^RUJY-^ZSO2!D7. .H]^YH[@!9 M=P"6&^'!!0M%^IAM,62*O;RH80RUW7Q0UC.*#10_01RW!V":W2L-#YACY=T! M9.YX#GK!#)W!JBTM.)KDX"JY"HZ[:]Y(U[LW0\# :3@<] M .KAYW$7C&EAE%-60DFUQ5>BT"*L<[6%^"VYF!#;9-5W)G'<^YX&0&NBFPY M=_L9\2472@8TFD&QF;Q'I1T=WY8#%BVYD]K9W.;LVT[/N%1X-I8$0T+1>K MR=.-<25;^KR4'%=O\F(Z3Z_+DS3_O-9.C6B%"T9J*VK[54V"XA9<1H3HF&;6 M.LYQIUZCM. U--%WMY&T*T5C%WL=G3AJ(OK.H72QZS![+GBMK)"LIFB+IUVG MZGM<*8PA.VSM3@?<(& :,YO4!@-[ .P A70.L2?IW\^7Z^Z\%Y8XTA;T.7@Z MS6NINB>;[#U%(ZB#C$;X8/P)+=R':.F#MROJP/@);F2+^C+ MY21GJY1-Q($P6%_Z)'":PI!D+?-%Q9*P\07+%2UC%Z$.?ZMRF)@[ K%IS7= MEI_ES;]?S+Z_NWQ++N2O\\7ON$@3'YG.KA!GF2(0E6L'<1L*<5L#$4%_YC8/ M/_8DM)/KEP-Q,3^=DCK X'?U7J_/5\L5SFHMT 2]0F-"@B(H\%%1D6MA90#) M=*W25I%CFSJ*^Z@:%UU-X?!0+=ZANCD89Y_71S/MJ,6JHX>=DXS>99,D^;@B MU#>SH@ZF0DC(G;<:==1MIEN0=^C8_WW@)-7>?6M;]Y!M96S M]#:GG#_57[I+*B77@3<*4JSSW%D,$!(W=0QJ$86V_WTNBL:]G#LE! ?121?M0[<\AW@225:+^@1'!$S2&G"H1"W=2H :&41R M^[T,+L1&,S7N(6KGL[K/>7JX[SV I!&8:QS&VI[ M(I$9H"'7VYCL@T236&Y3*K4+=>,^H!H->$/HJ@L$KKG9O"U\=KZH;O(F_%IO MK/6?OY!<4_4KR*E8*W:"UGCE8P'AM"?7MQA B@/!Q,[;A/< MD\?X#37910?Y.YA<;\>[>/2Z2$:[45LDF6JAP04;R*\5)FGD&!K-B]F?UG%; MW'8 UJ'TV 56O]V?+M_/[ZC$7?,:;O/Z-I.PE]-5?I<77Z8Q;X3S-L?YA]GZ M4S9-^9D(/M8Q3J74'@2))0C&(R13BL-DD_6A40UU6\YVNUI@/\)&Z HD'83U M]QF&M;^U:=NYG"C+'-=9UCI XLM(5^\2!23+"\LN9X=M$E*[4K@;B'^("[(F M2NL%C#T6:0 'HQ.ENPZZC9YIN-O_1_U%=+@RCGR M*O3YK-5(I(,N@1V*'"-%BB;G LJ)!-YR67=:\=QR:[%-9]$37OKS'^)&: 2% M#PKU$5L!/7G[ZL6KW][=9&N@9D"7GWWR=D!;F1JH(=#FKO&JYN^JU0N/)0=! M+E[TM3S*9@\^"PLZ2D*20ZN];&(M[B#H^/> 7_+L//]*&_MIW2OTD?\V77U\ M2D$<+;=X_L?%!GNR7&;Z7ZIS&DTM!TB* ^UC!HJ[##[)"$D7[G7FPI@VHU78)*XRK* -X*3.HH!5X=!PTT\H[I:LWV29 V(F^ MT2O"!H=4 [V,:(IJ!>>WRK5Z;&]BE\T-^XO9E[S)E[^>Y8DT5C.)M1LN^>&J MM@-'Z10($766WMH0Y0/^^A[+C5[(-1AR6LFX@Q/L-462I),:OU[R-[%(/'!5 M!QHFLK,II76O> C<6 P"O9)M*FBV$#-ZI=;@YN=8B7=PLJUSR*_FL_E-5BXM M9XD4($?C@;&LZC265)]'3IRVQ:2BH:1:PBV-!J=5 ME;\3=-1+)79K_G%@GN4D3(Y>RS4XWGM%2 99K MJDG+H%$E!TQK \I'!&)SHN\F[5)&MO?&[ MW(D8**3#&&HIER1WPB$4U,(GBOZ#9=QHT@"V30G_/E2.7S+5 M&*H#*JD#^[NY7%RG85WB0FMT((+PM'5$!N], 8-<9I*G^C83?P/(I; MDR,%W)UMVF:A[[/(S^G75U\G(3D?(]/ #290O-12:^7 TW;0/O.$J5G[NZ.I MWPV.C^K^Y>1*[<#&[6._=W(RM$PJVNI5H'.@0C: 15I(,0:7)1?)G2)_?CPG MNP'\4=T*C:KL#L!^HY_5)$I1AY,Y,*&. 4)96PR42-%@C@J549*UJ2:]0<9N M,'M4ES&'B[DWC%R)PY9D='T09362.)"4ZF2R$!A7S,5$3#0:,K&-G-TP\ZCN M3HX7>P?8>=B!F#!>E+690]#K!DZ%F.&ULX[3FG/4@6 PDL\W;L7Z #8VYW; M2QO=11W[G-]O\^>:*+KR4E/1ULH<@3.F0(FUE\H,9*&T99HC+RU?DPS PKC% M[ZW1>BK==@#JF]Z"]TI%F034H7F@BE,04E"056)TEBB3&W4CV-\I:Y92'AY< MA\NX X!7'6VF\4HLU>'PQA@HIHK%5K2'X*!.,I,A%JM"FP/U7K)V MLTZ/JC9@.#4\"D^-V%QSN.9U4J(KPM@$/AC:,IK"F2!U!B&DL)HQ'=E8=V8W M"!UYWO-P$-G;ESM<7]W!\?[#_R:CC)ED(@8PAF5062; $C($9W1VJ#4V2F(< M3/+($Z9/!-%6.NP K%M%.!&:?)# +6TQ&^HX6@/.45#EO$TE"OJGM'FLMI6< MD>=/-P/9\;+OT*%[-CT[7^5T):"$P;I0R--5E1VN3)USE,GQ-8%A#D;R-G?Y M#Q"VF^5Z5*5V0ZJB ].TDYMPP>/&]@96,(;:4%V;.NDO%W(9I 094!E-6\>( M-AW(]B:U+]?N** M! ^UH#B:DI *) M5S;M^W(0T7VY>.V@VDZ3'8#V#C%.A' QHO(@@B'Q.14AL&P!9,.S=,'.NF*[[J2S^?*\#J&X$IU/0J6 4'*NXZ#J M1&B2%D0MDW!.Q,S;5)(<2/!N5N]1U-6?4G4=F+I_R],/'^NN_4(V_$-^=5ZG M-+\NWS6KW$1;VBH7'5GO4&J%5W 9'%(XQR/9]V"L4+S-"Z"]R.S+76P"G/FI MM-@O1*\[&#?:JI9BHTY.@BB!G(U0"F#A"-)CU#I)^DF;N&9/0OMR%4>$Z2": M' RHXW4,??KZKV_>/O\+_?S%OSY_\8J^?7Z3NV&:AVY;YM1]1!]D=:"6HE<^ MP>NR<1((X5OF&WY+4'*'VF4%T7+R&$3(@$Y)8,Z+HK+41K5Y[+ GH0,T#;_] MT5<5%I>RD,E[BL\0>'"T^Y+4X#BSM;8B.^-#G>3;1!8[$-?)6/H&J-K207Q0 M374QUN;:ZY>Q3U>O3#7+ M4FKN 0UZ4+3? 77MM8_),'+522-M\D:-&!K7,I\:EWMLBU.!I(OYHO<)HHZ& M_O5L_OM?$!WOCM:@&+G#S@.2_];V9R:B2TGDI=W=OI)U]P>E8?;?PZ M7[S#L_PNQ_/%=#7-VTXHY1USR2H0QLIZRR<@L$2<>^69*U%BHZD!0W$P;G_X MCBUS,QAT;)+7>>W7Y;Y?>5WNZ-MU90QM;U/UWX:?<5OY=WQ2G @BG2>#OO4/ MJ\]ZI H@7#T+"S> TE",$B3]FZ3.99O"\%VH&W>(0,<@/DA]'=2MW7,G<5#[ M14$G0N472-P&24V1;%M&WSSN(>HL8-)#L!XEZ:&WZHU=;%%!F;!A)Q!U8[O'ID KZ+A9*^RC,WK MV;ZC:H"V.?4SWRSF7Z8DOU^^_FV9R;>_FB'WA,+$+^NDXM9&II>R,4B^![<1 M,%>?/$4+WD8!ABQW'5>HD+?I03L,_=V4P!V'NBW]>DZMW Z.YVM%6I)IPDUF MX 6AI][R4"R:'#BKC.;)RR#:U'#T4A W!@+NKIG;1QT= .E;.FP]C(CDN!Y, M5%NED1<;IV?Y1D.L]_,=1?U-K(8S6XJ"@J6Z)*C ,;10I)<%F5E>]L4'?%70ZV$K/,JT M1-"F-A/6Q8&/CH%&E+&^>/[G<@;-U/?-4B'5^^H!36UO.BRB/GU[,TB M?YG.SY=G7_^2SZXQ='DQL9Q@0*ML]?Q%9.%1I-+F M6>>=)(U;:=4E2(=58Q=5A[=+?*X)[2E^GJ[P[$IBRNF$JB20&ADHDRPX:QQ0 M<(?,Y>)\NWDD.](X;F%5UYAMI.@^O--;G)&\\_1++4>@@X)%STTFMR7'ZFI7 M+[L$"<2*E9Q[Q7TSK_1NLL;--+7"PH.0.U0QG9K*ZIC,Z#^B/3J1Q:'1K$ 1 MY!0KN2YI()'Q%*2+T0>,Z40XNT;6N*FBT7!VJ&(ZQ1FYPY]QFBZ36Q?.QN5C MYB?+9:X>L;36\V A6&>(3UO(]6 23)1,<4?_I]H\ CN,WG&31J,AH-?UV6!"TQY8EGRU>A#\JGV)],1L+)IO [<&#H(PJG.XFWTC9LB M&@V21ZNJ2Q]PLY]NLE;OJV)KBZR\B6_DZRE$9YD:!!K5RH6 .O^ M9#H+(:5Q*C=K\[XKD>,FC\8TI0,HK4L\KK?>E1BO;S436"A!!))9B*!LE. C M*B@\N^R]-Y&=+"]T%Y'C)H;&M9='*ZT#/.Y>[C4Q.?M2AU]J[8FSQ#.X9".X M*.C?I;[[;O-V;G<:1Y\9.G;I7"-U=O 0[@[.-E=8NPO71V5$U@D2DPA*2P$. M=88H0TG1Q)1"FVS2,/1WTXOQ)+7V+97;1_M9_+J^U7@_?Q+_XWRZR"0!8FOU MM;;,6Y$#7FL&/M=?F6CCHE=>0,+:@CRJ&C<*!CFP(C#4B]DVSL#N-'99K=\4 M0[>K]=NH<_2B#V(CYIS652RU6=++Z@0%C'^_U@QCN470$SJ\?)"1TQE#QXNR M1I-S[C+PA(:[XHTNMZSMU@J00]?OLI+^%( \F=)&[G;UR_ER.LO+Y;="%IRE M=:YWO0&7T\MA8//U@76Q*],D&J> LY)J,CY\)SLP,N#UR^ M2R_U5+ \ALH M2:,I<%22U8H&2]NU1%G_CZ%K,_]U)_*ZS ,T1<[WK_8'5F(/'NTUIEXLE^>U M]\SK\G(^^W#%D6'"%$$>CLNHR$=7#C!'"Y)QSY76"5E[6&ZGKFV08.GR8-BCJT&8>VXS5N(NB+@/^4X)O$%5U M$1U="_^(J?-%_(A+VD=/YY\^S6?O5O/X]XESM(UT5E"")+O.O*E3;358EDNJ M.\ECFRNFAVGK,GH_J14<5GU]0/)ZHK>RL)ZW-#'D>W/A,_!L/45ST@(:Z2&8 M@IP'KX1J8P6WT]-E(#[6 7R@FCHX=-]-*:^<2 F_KHWJU+ M6IF#Y$.,FN>82YNZN2W$C%L?UP/,CE10=R;MFLE>)UFW"'/B(T,?,8 O0H"R M7H$/]%7267!;N->VS2R&/0D=MUJN!W0V5&P'UG%W"4\LL2&++H#"D=T/7 .J MY,$I';FN/7-TF^-Y=QIW0JO[@=':2)T=Y,Z?EY+CZG5Y_@=YP+,/^2V9[M>S MRFS]IY:I?,&SNCG?9I+C-))A7]_&SM+-'US[S4G('E76&3P7%,MARE"? )J MF:+QBIE&#F<#9KII/S]L5GULM7=@HH]B=OOTEJLY%-?%NA'UE=:03@^2^WQ29TCK/$HH:L4VT- M@V1[/'T; AJ4J'AA;?I4GY;/<6_5'@/R1]VL>\&P P_PN$-?1W2RT"F?$R-W MEQL)P>L$7!LO!3D!Y%;WM^?&O03\K[:%]@+)P3OB\UHP=.(O5AWL"VL%IH01 M7 AUNEA@@(P;L,5%H^I[5-7F[J?]OFAV/_E?;E_L Y(C]\7SV?6$;+.!2A>= M TC@G^=GTUAS1S?HWVEPTI8/&7A TD-D#C0(Z=LR;RZ6N0*=3%K+XC08"IG) M28BU9U)M:.ADCBKGXDJ;7D)WTW1T*^WIA]FT3&-]X?3=(N])I+^07%UP19)!F$%#F@#"ZB44C ;\+Y;O2-/*%@&,1\UR1[>-4,%EZ>T!:]&=(F MO3F9;=I.]@EL%.,Y%%5;$@E7^P<:\-8JD+G8@"X*[MN\\V]GHW[!Y73YNMQ: MX.OFSV\; 0/M+.DD%$U_J%H%[Z(JM.$\CUP'GQLU@-F-OGYMU!Z(N6VC&JBF M@Q38J_S[-8X6\QE]&=5V_G+TL=@2P9O:@=8I!*\H5A*>*^>M3]FUF@&X M'Z4CSTAI \*FZGJ,1^:SO,+IV3 GYN5G-3\PMQ+=_KQTT@4L]7)9<02%(9+[ MA 8,9A>*C=J(-M.,VIV7K\X_A;QX7=[FS_/%>OSTN_QA,ZV"T(E6(0>7ZJ ? MH^H=MV0@:4,$$H53C;+M=]/4[;FX#S*^,TG#J*!_X_-LNHR; HZM4P"V[QDW)/0H\?+W?C4JUS?=BKJ3\_FR_-%_G9Z6QNQ9I\A"4;[ MLD1&I[>P8',PAH446&K3+O=8RL>U="WQ^-V\N5/J^+$:R?>;D0=#F 5:*HN!!:]XFYSLB^[CSG7CE9/4EIW;,&S;YOP>FI1JSU_A8OZU9=\>/B]XP>?Q,;? MS\Y(UMZB2QSK@_OD:V F3>V_KP%%%@$Y8SJWZ5ES8FM_P&;[Y>M>VWE]A$^X MU%P:5D"0Y0!%P2?M2\,A^J*MCX%%W:QI^BD8?%Q6?1]T;Y]6VA=B.DCEW^#P MZ1DNE^LKU34"_I@N)[$('9EP((L@N?.:"O8N >:,V8? K&M3V?T 8:-/0NL/ M3/?%F$=JMF^@/IM_PNELHI@H@LL$4=68.-L$S@4'S%JFO0HAJ3:YVP=)&]W* M#@>$W4%V@%;Z@-GV% RQ23\IOWRMW6;_FFOZ>N)R5B): 5G7FI44ZK6MCV"D M\\BE1*;:> ?[4-DM^ X!R/?P:Z.M#I#8_HQ9[WZ4-F/4F@12A\9%[P 1+9 9 ML$+&Q+EN<[]W&OY&GV39O9_0((/+^YE\2GQ.T\4WDX(RVSIK(BOB3BD*B[RIC6.L8\;(VG2]637-013_ MZ([*@1"\SUMIA8<.<'^]T]:SZ;K9_XJ$3A'_Q0"6O)SP&)#B?0?&!%];85"\ M;TL=I+-[A877QSC:V+ MG]S8E^\^DD*7M:-U3I.@1&*H$B1>AP3E@A3&Y 0Q1X;TS?3N6I@?2"TW>'MST8CXS6(:\]L<\_3+VB44B"PD9$!;.((2 MO!XYG$,2*(*520JM=X#S$22,VP?M,4#Y5/I]K#5-E[5BRWFYXRYBX%JGG1<\ M20W48>R/]8" ,\S6:DB1L^KB.D"G/?B2-2;M!&?_J(W:(Z1GH5[/(4)QO'I> MG@$Y7,1]%%%'AYJ^>*3)F4=8&[4/NL>JC=H',1T$F0\53G#NN;#M7: M#@V=M?2MTY%)KF-J=OW_C]JHO<"T9VW4/IKM&Z@7EQ9.H5&J=AI7M4>^E0A! M)PZZ>&F#Y))$^8_:J".!L'=MU#Y:Z0-FNU?;V$ 'CN'U14,AR0F6 9.3M#V] M9CHD:VPSQ/TPM5%[ >28VJA]M-4!$D]4-V",\CG1$<.E)9\J*PW.%#(!)KOH ME;7"MNEW^(_:J#[\A YQUL'N.[1RPCFR*UH)$$H*4-P[<('.5I$9UGYO090V M(Q3^41LU$/8&JHW:!PC=UD:%P+FH'4J83*!D$A!DS'2 AB ,_!FO>D\)ETR,G#9T:9CED-0(@,KF))- MH;!&=4T[$OBCW_$=[QFTT'0/ -Z0OH6IBQW.K/44&-1Y.%[7#9,QXE;=R34H3X- M2KYPP1$;=55^B+21T38H$K;#;""U=("S4]ZS9\NRU)X\'LW(7ZF90U^")X@Q MK3+C >5C?4WUN*%P;0&EL85&H>+LV]/3U_!>T=I3:.!6D#J_2/T2_ MCPO!3^?+.L_]M_D\+=_-S]+$>30^2@=&6@4J&P-!!@&H(_T%$]$T"C&/('K< MJY1'ANFC-/ZXP$V_LER^62*2 MSJ48 49@?5"&EO:T*("8Y@\T>&^&/U_KCL_>O5Q[RX MW,P111":*Q!24312ZNB/C Z85]I;BE.L.<&(@=T)W@G7YA^X/D[3^P/:;P ] MRQ^([?1^#.O]8D:'1EZN+AEVH= Q)0-D- %4- XP$?]%1V6SD(*5T:%]B^:= MT&W_@>ZC]=T5P.\2%6\LYDRG'9KF6(1C8"?KN!X?^R9'0A^?R/4_$QV8,^NOMSU$GM==;8;7> MPMO*I+0D:(7@ H]1"*V-;5:!NC^Y.X';_Y<#]Z!:'K]_PD.[=^.._S&HKBI52YUJ7>GIQ9A-W&6\_0;RKA\(Q9.QV MH\-^1*2>6HD=I$9V.%R6KS+MSGJL1"]*\-&#E%QO!O$X'3@4:64M%D[%M$F$ M[$/E;OC]H:\DFRFU#U]AU^A@:^G#M_DC*90HD@>C& 7#P5L(6 R@"T%SM#DV MFH4[% <_^HNO!E4GI\)+!X;]@+($SATW4?FZ]>M8'JW!(2)H1$/1L_'Z%$^Z M'EO9R7'-XOYEVG*Z9>O?UMF\K6V6XLKF3*K;*PS M)ZRNHUQ%4N2*%5VG[VE&YUSFM_M<#S7U^Q!R?_3'.<,8\?9(Z #NVSC<]BI@ M*].3Y$TH.4L@-FEO.Y7JXSH#QC+'G>&98YM4]U%DCVO'3P"K^5@Z[A30FU!Y M%V:]ER@T=\"<9C6'60\KZX#"(6^3U29H/!F@=R9[7*>\#T"WT7'_726?Q/\X MGRZG&QS3=I _1LOFS@_G7\*T]D&\.1!+)?D27Q;^]M( M9X9&!73 0YT@H'--.I ?;+5CY 8C*:_-8\#]Z#S6 FY9[9LK]6U@M":OW"Q8]#X51F&[TIS0QF0M"1:0LV:,)ZZ5;9,1/ZT=NVP-_+J\S7'^ M83;]3SKG$ZET6J9YL^IRO2RAF\AX.<4P/5L?_/1WYY]R6FOLVPYRK$3F,P-3 M7+W48YG.?>VA:(RR&"8+/P M>S^NH5F]G_1Q#&RQ@DYMGL#:VOS ,$9AB.L45IC+ -[N>YUQ?SR M]=IWFQ?M@FD9G'(@@BZ@$KD?SMD,1E%,1?Z/"8WZ=>]+Z:,RD?N@[6X3V4"% M'61SMG"U[H*3LI8*901O=0852H208@$M6(Q9^>(:]76Y@Z"1N[DT1<$=\4O@F@6<7:J3L* #N MZG!MC%R2]Z_3LS/\D/_Z[*+;4;316)[(K)/KNQEC$Y@O-3O 8Q:!1+-+B=VM MC^T/!$E._F9^=K^_MF+="7+Y]>,,1-+*BE)#9B M?2]0)_\&X8@U;YDP+!N..\!AI\7&O1EH!Y+A)=W!D?0N+RAV?5U>S-+TRS2= M4^#T]<6G3T@K3/%LV]%^P2<=V-YQ(0DDM:*C^ !>HH9(@;<5#%FK-QB'4CQN M 4(;6)Y4BQV@=0LG+Z_J+B)Z9A(OD.2Z2R67@"DS\(4IEWV2W+>Y1[V/JG&- MX=A.^F'*Z1-H;_(B5MU](&G^ZWSS@GKS*.\J(3B)KN@LI*]3B"49?U6'!V*$ MI+BP&%/DNFV6?#]ZNW/G#L3+PT <6GD=0/0-?ET_Q'@_O^#@VWCA=3^7B?"Y ML, ,>%YO[Y(@SC*W8#RQR:-)NK2I^WZ(LNX*",B'L$&#LNVYW3MUQ4&HN^@[L MUA[\K=^?\0DS%K/W&;2H0R*)(PBR< ADE4V*&C-KZ]CM3.JXO9>:'ZAM5/9X M3-VKO)IX"N.-E@ZD%+4C%$,@WR! 2C5B2C8;888U=+3JN!V.QC9S^XJ]$T!= M$]>_XMDY>9[$ZZ?Y[-UJ'O_^[B/6]S&7OF=65F&T C*O<9?6$KP@H5KAC=4, M$?T^Q^<>2X_;9*@IM%HIH!-\7=\YN/QX;MPV/RL43FD8[9_,$0++L88Z5L?"?'"QB8^V+Z7C]MYIYJ(U M55@'@%S[E;3A:/V/F=R$+_G;V_^W.=Z<@9S^_7S#?^T*\&0>I[0?OPGE^CZM M?_\%IV_CJ?<'+-:](43,YD7/AZUE+P('TJ27#4 M09WLU':'T_376 PGMRK.L^+]4/N_+I38Y9)R$H2$PDQ)+HB',> M::^5@#HK;QMU\=F'RI&[^(R1#3].4X^K2O[R!G9>WIPOXD=+:& Q3;]^0L(:5^Z<2YSAO -#0)J@U&$ICHOV6R#G( MQ9!Y$1J+U6C4R1+=/;T!('O@DTD5S2A!B5C DVF"$)E*0CD4NDU5[ _]!F ? MM!W]!F ?%7;@9]Q5;QQ=*,G)6#L(<%#6^YHFU" 99D&N%#.Y3>>H'^,-P%XH MV/$-P#XJZ119-PL!/4;CF%1@O:QC<(FU@*F.7)8^8.&)L_*/-P ' F#O-P#[ M:*.S-P \>2MK:_B24@;E!9'.>086G'/%9*%E>L!C?(1O /92V#UO /:1WJ-X M ^"YI T2+424 A1*7LN/ F0?@M)>>.75#G#X(=X ' J2X27=YY'T+0?@4;%B MG8?$DB7KF@T$QB@^-Y[<1*&=92?S>*ZH>F15U0.[/8'IZ]/"9(.ML^#!<96*>FXM2!$HH@^1PD^U*;JF'1*PB4* M[?NM^#YE7J0+1.U;/[Z/>@^&ZY>\"//3EE5^7RUCE4;/DX.,0M5J/P.8C0<; M768697%Q%U?U&!KZ\& [A>Q)%3S^_+(#ZE5UT@;1.^#2,E 1$=#5X3[D D8N MC.=>#(O@7RD0?3T%^G"TQ*&@Z"!*WL/YNE3]?"]/OTL>O M.%VLWTGPB4HR\5"O5&RJ56&R@(LH0(JBZ<>^7K*<:J/L37T?+UH>WPYI"Y/^ M'LWQ*C*%(S!M%Y"EZ*DQ!X<%"TT)['B$7OTEMK M0)+Z>&33*>3'5'^?!\+ VN&3F%R2##DDG6K3J\#!.YG!" Q21)>L']VQ.I2Y M/AX,=;JW>@59G]'X]RW%OZ]1W=I4_%5>?9N7RK+WQ9)>O!.U=B_4HFP.D<WN#NST<+S?(1L5&WTZ:@>+A$[5&[)8 MOW9\_Q%GO\WGZ??IV5D=D5J<0XK8*((#A1S!!:MAT_:/L!]N"UWXR\3%%QED 9M#4$F4&+GL+WN@BK39&R39C@!HQU-U%XP^U MK0Y%SO@7Y8TT-"F(PKCLP"A+CCC:JAF*5#-G)0NO>2DGFQMX#"/=W6?^4/MF M7Z1TD"2X.BA9#$H&S,"37E=T*9*F<U,XK$6ZL&% MM@V.M8Q'$Y@ +^I8'F8HZ&;.@[#2AE1L0-[F">,AU(Z;F&F#M=NVK+D6'['= M.W@6\$.?>"H;V'!*\.[H-)PEY0P%^9GDI'3DX*1$*"IH3J=E$:+-.[&36<+K MHV&W+OETOEPMOVV?*+S2RDDP(M?N.5X""O(=6!!8,-BD5*,).?L1^ECLWSX( MNV^L[]"ZZR!O=0=[]$U>?,F_?'U/GU.[WRY7WU@4Z$EN)$29<^VH3&=*\"5 MX49('77.I?UHZAV)'3>-.RI$!]/A(SZA!Q@UO?MGG^K4/LD0ZMVAJW+QF0D& M(?G:CC(D<$EH2,+:DKB/TKHB@S3)YPX$G M5R<;.P9.V0+,*JLD1RYWZWFW.S#&;.]SA,IN*_T ^8VL]K].9]-/YY\N",^6 MF>*1]).J3U6'EGUARAN/H04QU8__G&-\")D M\)YG2$X2X2Z6>MG@P?@8H_<%8]XI+-M-_=>7'B?(&DS]!TNQ@_C]QCE83[_U M6;@._-8&41GN;8BNFD$*+GFR$+C/$(OT"C/+IE$WFP<(ZZ4/4QL_HH5V.@#; M)I%P@ZF+KFA,*!Z]Y35S0;O&: 2T18-$E25:S9QM$P/>25)',W!U8%8 M2LD$&+0 H3,O*>O,;L\)V0J2O18=]\P:'C?M)#YZ#ZEUL<^+3Y]QNMA,L[IN MCC_BXD.^9"MQ&Z,L"JS1K$JPCE:V#@1GWFJG?(EQ!R#MO."X!;##@ZB-I,<^ MG3Y]/IM_S?E=)D#6K#R9U\M"L_6#Q.GFG>*WW6')G*+,#$P)A78'?>6XU9", M1#0Z8+S=%&?[H;7OPN/6A38XRYI*?G2[]&)6YHM/FX>M.7Z M_OS)A16NI_H-/KUVFGL*;[.EH]QX!4Y+#:&D8(76M(4>NLHZCH)QZSR'A]J) M=-%%+Z0;19%(\B**$4($Q\AU/ ZCND@"' MJ?HA\!P@]Y%=JYL&=A.M_A5G^"%7]_'-8OYA@9>Y6*5K>H0.=&U8 $7>(@1$ M!P85&?RD@I=EAR-OCR4[ \PAZIVWEW4'%NA=#4\K%YM>('4R!O!KMX M$TQ]=Q%4B$!&F9@12@.2,^ 8>JE]F^+Z>\D:UU<_U0$WG&8Z@-DM'B[VHS%> M1JG)Q12T0Y07C#Q.98#S2$PDRXJS3>"UE9R12S*&4_?6P>3'R+X# +VM)7JS MG)[C8D:[[2J9%C4K615! M%?K+X6!T%QGCE0X-I-[YT+(>$3!Q?CY;+;Y.?OMEPECD#E4"BJ1DK:;AX(L5 M(+4KQ4M$P>\K'%GF^.&D!=?ZOF89^^G\;^_&*QMKH_,])3CRP?#T M_-/YV?H9R?-2E7]3^?%('E-2'$26K$1; ML@@[M?/>Z8S8A:)Q6W2?PNL87"^=X^QBX\7:H2AZ#:+6:RM3!&"6$J2RM7)?!((Q%\:]$J CJ[4LEJQ\ M<0@^9D\!H659[93 &<:LW:*N7]@=@HQ]+-LQ:NKOFO5FV>?+J][ .?K"59*0 M0WTA+I@%YVNMN3)>6A%]"&V>3^]"W;CS #JHRSY,3R-?JMTCK>=_?*:M5AM> MS<@I@D13QY8%"Z@D T'.JQ06A=NI]'8@D/DVS6R'H7_< M^H?FX!U!RL_)(3S2M?[^3/Z,9\8D;GVVD-@2==[W0*^SN91F6$H M@N([N=,K]2%M[!8ZQ[W>'-/2'JNT1]PNZCNQ+QOTC;I[D5,UD-J1S9-WDBK, M,ULK#Q,J )ZE]D'5,)ZE]=-:!7[J]0CT*C20:)3) MD]O-6Q6G'?HLI(N.4WLI?Z=G(?MHHD" MA*.E#2=Z9]1#Q>P JM[Q6<@^&2/MHX5&UOZE-NJ4L!6*)$I25 4*M563*.;+[R*-2.QR!P[>_&:%M MTEY*/KC]S3X2'QE*N[=DX3%X%E* I)VB8#A:8BK3Z6Z\=TZQ@G:7^_YAF]^, MT$'I4 BUD?3H74KV;\*BN51"&$?V6A-[N4YKK;VB@HV1++I23.S2CJM-^YL1 MNBD="JBVDA_9+AW1<$5P'Y.*#()8%WMY!\Y;!?2/KUU>Z =Z!WPU;GXS0I^E M0X%V(EV,71A,Q_K\;)K6_*POS=;.9O:>H3[.;0P*^@63?'7HN-IU#XP)) GS4A8(5C\2#,8!*J, USVB' M>SEY%Q4CEHD/H-E[@7* F#O(/;W^G.M8GMF'B]=EE_8R6BZ*YH)V3"(VA'+D M^@D%F$PP-H24=9MZ[SL(Z@DXAVAZ/KS81_>XG\X7G^?$1EZ;X#B?Q>E9+0JJ M,KK@1X9HO*.3/F:502D>P$F=(#J7662)>-TEZ_WP2N,]RQP4'PW$VH&1N7JT M?AD57*)^;8(%ILB#2R0G3B;8U<8KVFI@B>?,F9:9M:E?O9>LQ]/WZ)CD]G": MZ0%F&]HOMI]"KI$% 3P9).)E LN1X_F^S*6V?M6"6;S,9VG5AZP4[EZ=PC)H;1L$BU@;TM(7 .^H%+DJ 7O4'HC MN#Q!5=HQSV:[:(;5Z/[^,#WUB+WEA$O'E!$9:/HI,U8:.M-/ M@[21BQ^'U_=#@-I/^#_*2X/+0HC-WWYM_>;@CN5&>7VP"^LG?X<0DQ0H;0#4 MTA(&"CR$;U6'15/^?_:^K+NM(TGS%\69W)='6;:K/$>6?"1U M]>DGGEPB)4Q1@!H@9:M__42"!$F1('@!W,1->*:ZN]HK;BQ?QI:1$:&^,@,; M:_>$1P'!Q.HCN!'><9$:/7P=HVVSB[<)>P%BS[;-?;33 =B>OTP/PMF8I 0A MZU@#:QQX)A4P2IB*+3(7UF9]Q9DV;>ZE^,%-F_MHX:R:-KW0R9,' .\SA;:2 M"J$VDCZ[C84^%18H!@!*WB4HI>AL!$,6G%D3HZ7$VPP9 MJ_2W:=D\%$YM)3]Y!?_@-D&M47KO!62*,2DXB!%\8 508S2L*,UP6%W_[]:R M>2C03J2+#B+T[2]D8\!@,,FZ)#W48R/ NT0\"8*,\"7Q1G6(PY^E=_%B;[34 M[R!-] BGVX.(PABMR/ RE.3>;8K@@B4;1)D,N7G& S_!M+>^GZ7OI>J!S]+W MD?L9/4O7Q<5@*;M@*5"R49(&CSY#=-ES)M#23P]P>&?_+'TO]1[X+'T?6?=F M@9Z[2'.*R1RX@N(+@LK"0?!>@4Z*>6FL9J7S"^XNWBLTJG0>IJ?>L'?+S/O% MY>6OB^6?89DOK.8I%.O!94[A*)<.8M3UAL);Q5R.H9S@MOLI81T9MU&0L MJ M1ZJE4Y1=!"D%*FDA%T6>P#$-@9.X:JN)YC%E7$L4'2+[#JS0'^'[NB>;Y/$#.Q?>E8S.6K")"5!&54N=+'BADD7&;'%M8JOG M*.IHD/?(.!I%!\<.-OXX_LJ"6S&MZVMO%_/78?7Y0D:93*0PDP1"V3'6!34F M9Y 2LPH:HW2/!I:^O)I@RWQE^7')TH8B!HI(' M2EDU*.7I0&CK *,H*:U%-^@9\2CAT582.QJ"?8*8Z7@M=> "GPL&4RIT?F1R M%I3WY,:U]F2$/5(X6%"F$PQ6WB<0;[;"<8I ?+#LCPS$?YD_G.C?K*EYW8-Q M2'OR[;\XF[[LV83%%>)PI9,CDD&T0=>D(YE?(A.TOJ-+MV M(A]^C'ZDXU@3\097*\2[=_,W/_Z11/83_5/_OJ 'Q4*0Q9N_2*:T0GP+!%9 MZ&UF41K5)FO?3=>T^?L12'AL)484?P?^YH:;7V?S>B@?\Y)D7='($)P2NEJ\ M1.FC,9 9+\(*X9-I4UO<1=6T*?SH0!I!]/V_H[GEKA;X#W<\M_]Z$_>SC;0V M3LA'BDB94&!\9*!T(L0@4Z!523(SRHI2F\?XXSBANPZ\U2N*5F8ASB[73R1N MP+P6XSV(K68Z2(^@?=)U%Y(D6Y@%I!(MCYF7Z/P+JM_G>UVYF'WT_*2]<6SA M=N%H2#SU)N81&QS)N4B-:YG"6(%.HB(D.>O58B M2O N:B/1/+[.&M7M;26JJYA\'PQL=V_'"W[BH;COP_S3S>M/'YB-RF20&AVH MY#UXJJ++'2C] ?A.K_??9?/;E>M.%S4/F*EH! MF#P1;IRO0^D2).=M"<:GE,UHBO_ATQ.K_A#%+<:0XM3J#W\])!Q3Y#8:,GB\ M[I^6"#4? RRER+K"R>"@P=;#U/_PT].-*!Y%_0=+L8,4=KL'?'/7$^W)[^48 M<^T[U224BN;BZNI \H[(M=:B3;?F"X1-798;-VYHH8UNP/5C">@C+K^\*Z\7 M\]LLWQ9MF;I!6;,L7(PLY4;'>JS+\Q]/R/.WO7<\HPO68++ >5T1YI"! MYXY$4&Q=X8R)ER%-ZOM^=VIO>+#>'UZF-Q5V!V[PD;F=??I\]:[\QRVG%U+: M0OE- 23Q$3-%@DN:,M,@& \R9L_;Q%H[R9H&6.W1\-Q>HZ-5TQW.[F[87E\O MJ\POG&/**LIY)'.9?+L($)67P$*M@$AFDVR\(FLK7=,$6Q,C[2CE3+I(ZP5^ MWB[FZ9:E:+2TTB6PBK)MI3)""%D!>0)3A,8LQ2D,VQ;2INGFZ 5R!ZJH9]1= ML"*=YU* #G7V5DRBYBT6M!?:6Y:S:#14]AF"ING9Z 5A>ZGC<,>YH&SGZ.>G M#YM2!D@K!Z.)J019("7(K([#"<)"24'QY)0TC[?:;HWS]_OJU/6(4:+\AH+N M(/9ZR-WC,#(:%9TU=7FST:"T9-6W"RC(L3 AT/LVCG '4=/%]RUQL*/A[!BE M=(:O.SM[WS*#UD3T!JP(="99[196]$?&!)^+,T'P-J']3K*FB^PGPMAQBND5 M99L41?C,8L@2,@N4HA1CP/%B0!=MHW#"Z=CF8>8NJJ8M@(VH_"&P.D03O:+J M0182'&4:(2F(6"> >^+$V5#6PN(F%&9"F\4C+Q V;=AU8FP=J(]>X77!=>*JM,G9/$44 :$$&,!0RE1M%Z[:-N[ MQX/)GZXDUD<^T$C1O9K'VTAB#ZZ3LYC06Y EJ,JU!^I[6X863,E)4FSM=3AA>( M"]/,$NL!YLT5?H[M3K_-Z6_BG4 :=3R]_)7F34][,MJF[TFBRS$[#@%C'4+& M$T1C.!CI/6JGE7 ]3ZYZ>GNT'LE]5_OB%KGJ9]M'E\[U,!PNP [?ZE),+PY+/"MVMT489P3LM(;K @U#6,W&* M#I)*2R_]28=K>.=5ZM[B[@ P_PK+67UK<<^ *!8U$QZ$DW6PM== ;M] \4Z) M+$PTN0U>GI#22Y/1:' Y3MB3;W1]/%/M![D$SZQU-H,W!'EE @:D5&^!I=G^EJSOU0[W-B(+LP(#L*,^\^K)87LW^9ZV?BY1\8BR1M'0=WA@D MF41I/<3D(UE).D/#7L2.66E[2.!TOFE,/ ROG1VLG,XP]]N="!X4U8AO]VDLKPW4VWJR8SB M)C(] ;)6!,FB"N&%19!*NF!30-?HP=9X]>2Z8NC7R\6?CVY_2A#,">&(LU#G M&-")\RQHT";&H*SQWH@7(/+\KW=51]Y'AP\S^Q$$UX&?^M'G;I:6743N8Q1: M 6,Q@&.0>)O /@;,L(;WEY-[]O M-$M"$-&R/C<*O&ZN]CGS 2'.C[\Z71?;B)H_4E@3OQ=] M5/M^%RD=F&/^;?[+7^ESG5OXZV+Y3*-URLPPD1.P8NNVZ%BOU*GY,M")TEF3&\YT3@TR8S4= M+M^F7?<(HJ>+PT^%J<>K+$^DX#/!\O;')!*="=XK('N0:D 9P156$QFF"]J0 M9&FSWNY@DJ<+^SO&\?'*G3B^VU^V%]*X(HP,)--:\"V4?H=IQ>_/5J.UQ*)H0Z $]$CH3 8)G9(R%L%"$LYPT>AMR'C%^/_$>E(PWXKT M/7ZA@_)PTO#]431.15G'W>DZ!K:^ (Y(O(LLG=29UP%! PS7X ]V5;+?1],/ M[5 ;\780N_T8@K[()K^@O$XE[3@(90IY]3I;A1&G@8L:FK)H8YOD8U]*I\LX M&H%EYV7 R)KK )D/@\H!W.ED%!DH#D74=^DB" BI< C%& R\4/#1?B; 2*AL MDC^EQL1A\R:F N>CH3T4(0UD/0$C%G MITL\Q6S5ERF=LA>^"5CV\;#':JX#9.ZPU=NX*V@EXSR#<\*!(JE"E%Q!CM%( M[BF,.,$@NI%0V:B+_A2H;*BU>&[*O:& MKYN=<*CB3EK[ MF^$Y!FJ&#*T93X6]@Y3$^)9\RL<_\?(;_KZ87WU>74@AA5?%TPFW%';4^QB* M'Z!9*^QL$>FJ 'JN^,X!G/7(?_UQ<>&UE9.1\0JDM;3P8 M\!XE:"X*2AT#LR<<=/>4P/Y&B4X QD.4=2X8)%#AA6!66L=M';HG:IF #E=A M!4057@P\<=5FA]Y@$J=]&-H3#O=6V)D@\=?%-04ABC-=0P^ML@452(Y!*4W2 M8X%K::T4)YSZOH7":5^1=H3#O=5U+C"A;]\Q995(MW)=4)VT)K ,G) /)?/$Q MV:PGPN(/9 X"I/V; _)PQ9T!*B^R<,SR.K0_BPPJJ@@^* ;.LQ"8X:&8:8 X M"'ON;XZ]O=33V1J$.W[^8YYO+XPP__)7PM7JU9?Z9Q>91<:-\H L4O8?6;7P MR8#U1F3E6 :G#0=5&&/<([(3K-O8\^D2^SL";2]-=.!5MS^H>D9:2ML8M4>0+M8W M";7&&4P JXD[[[BC/SM!G\T(%W@GZ^TZX@*OF6HZ@-W-P^EG7O/MO@?2(F0> MM*>SA>NG?@C>U/J2L:PP%X*+K6[-#Z5YVBN]=CA:3*+4ATUX#=@?30]1W;NA*,;-,TL3>ITUX0]HG0O55X9AA=WT$ECHI'K8''VKE<@J[3WSG$ M:"P:6;)DTT-T^JO#+A&ZMP+/#:#U'D!(S!R3@HPY@)+!0F26@<.L;*:4E?D) M$ZIN+A7[!.B^"CPC@/YX6X4BU3L# 2B+H#311?(0Z$!&KIFT06!ITP)T$+G3 M7C=V!]7#57E&>+T0F)0RG!Z5?5Y1]@'14539 MQ67E<^/Z2N+<6BD!>?4 WA4@21KP*G"'D?N<3K';I9<+RY/!;@Q]_+V?O%X\ MJH+7\\M_7A+4O>/5YD6?S;[BZNIGBO+^\G_NE MD04YB."1G@;??.OW];=^N__6JWG^WXO9_.I?]">DS@?S@JV13'D%S+$Z%)#7 M49%%@688BBU.Z]"FJK0GH<=ZD&<^5]_M7RY6]*6/I("?Z-_X]P7Q+]%A "-# MH;0BD4BD42#(60J+!MWC&>-M1;*%QFDO@EMB[+&G::2W_IW/,T;C8UU//**M MN_V]TUB\;<1/9/<2.I$P(K!"X8H208)/64"1S$=3F_9RFVRF#[MW?VI0!"&U M]Q0&6J0PD$Y-2#F"RX:7#]=?OH3E M['_P-EJ<_;#];6T7[MGER5 2*CWPI RH$A-$&QW(A-HD;X5CY@5K-Q(ITW:M MG *#4^CL;)WOA_09\_4E+LIS8)I'/AA IC(Q6/Q/&! D,Q:4$D) M"-D6\-D9(Y-AWK7I,CZQB]\HY=US2ED?U0M4493L)6 () Y5F\L"MV!ERAA= M"=:VN5481M]YN?M]L/5DK^WX^IK0Z:^65R]R]/2O(KX-7_#57[/5!:\S;RTR MJ%L"R&M1QN89F4_"!0C&12Q1MJ%.!$2HC<)1&;<19X5]W(T,.ZF91JXG18+BR:*F3@% M>O4%E[/5XGJ9\"=BGZ,Q;]EI^2(Q<2.63& M;)W&1"9=! ^9VY"%#3%)-0 L+W]IFFRW(5A&%FYO=H6BTP$<6C*[T5ND0Z!( M>$X[B,$K,"I)349:^I /L36#OC[->XI3VI_QE3!QA/2^+O=:NW*E,.6,'KA- MJC[]J*Z<3*KEW.ED3+9FT+#30<'0W6>GK;DU#K,/$VX/B+@%,G?).F_(K]() M 26C@ICK>]3? TQ10>\,!VY+44-6_(T3/T//SU=5#J*^@^68@<=ZR\ZPS>S M.?YVA5]6%SXHP7).H((FSJ*5X"NPF:YK+HPBZ]CF&GDXC=.^[6T86#165P= M?(:?"X]U.S?J>B=>7\V7#"YI.E0R:N0HD\]MQO$_0U#G)>(#]3^L76$O94Q: M=]G-R+L_YX3;S[.OMWM\PB>\2"HB"IG!1*'K= 8-SG@$BVA]0A.D."7.MI#8 M>=;4$GG'*FQ$+)ZZ(>%M6-;2YS<8<"%D3A7IG MV$BP#[8.;"381U_GW$A@E+MN=D^(^Q +!N=IOX3WY#JE!:!-*8LF'QQ.C_VZM!'OI<[]6 M@GV$>PZM!,*7NL/)@"FU.4=S39QY1EF2=E'':*,/ \!RQJT$AX)E9.%.#I9_ MS2XO*5'^_>=;XCV&(GGT($T=">!2)D]O(O"L,-J08\ A32:/?K;;Z_]#87", MV";V)1\^S_ RK_Z)X?+J\X?%Y755P^J/M23?O'F]Z8=QTC%O%:14B"$TI;K; M",5*^LM6$[-#WMX,^M@THPP;HF-\$7=0>_\US);_"I?7^-/WNS_\YPR71-3G M[V_P&UZN@S5GHD?M!!A=7]\21W02L&X/S(S301 \IB'A[MY5@6'T=5X?/3SG M:JBFGL#W.X;ZVGLMK*?\W9Y;Y4W$.F\D^R3J[3J'*((!;23#6 (E#8,NJ0_' MX! R)U[,W GST%Q=*7UA,C?YE^OKU9KB?'-];[2PO+LH39S4 0H' 0;.'!> MF(TZ1ZO:O#C;050G:!L?"L^![DB]3%P!?3.[FGU:J^=U6-V405APQA3E(%M) MU ?AP==U:U'X'!4&G^6@G5"#"DE/OW\6;1.'5BN/%'=78/E(_\9= %NB-$* M3X[=#'@+GJ)8F54A"YZ"UH.F^AP F7LJIBL8':O59P%RH(@GSOS>?9TM\CTC MMT91EFRD81DPN$!^/=&144$#.NE]--$9^6B%R/9:T+8?[T7UA^IK,:;P.@A: M]NC/,"8;CBE!RMY3[BOJ7:2MKR,*CTQG442;^<@C-_(U6X%P@ERND;HZ .(# M'GZK3V=>Y6^U+V3UT7MA0>%!*@G'.TLE"BHL-S^!$HE XIJQ$FWV5PVF<=FW5I*[R M:)5U,73R05?97PDQ8_[M:O7'8M7KU8KO*JB5#4@54#) M&,6FV6829;*4LR4MO4R>!3G DQ[Z_6D749W TYY$,1UXXNT"?(_ALH[/_$>8 MS:OQ?S>GX_5UL0J7%TPDSHJ/M4.( E&F&#BGZFK-+- SR9@^Y6S"YRF==@'5 MI%9Q)/6=[[33G?-?3S@#]3@Z3C09=41A3?3,R1+R5*)T1RC/*3E."($\/2!B M?;&G=8Y_BY'H PNX5M)_*/,#FVN;EI(W(_%4,6K0F?21,?K MR*E:]-,2G$]!*N:$BFWF,AU [+18' 4DB]-JK -04MRPJE<5979U$9#$DT0 M[5@"E36=41[KTT!52E%"EM0F/'Q Q+0^LP6(#I5P!^"XH;I>#5QHES@32H)T MK+Y/Q2+_60<.S/.BCI^8 MT:_//\TH+0DW[0/[7[&]^),CWY;MQ\)(%U^;C[Z:$S@VW[MI++CO;[F?P%:L MTDC!B/9($8ETH;8:9$@Y!&;1@Q)D-1.>^=O!@]>B3[PAT]L$ALN2=\/ ML#DK4[0V8$6=>\^]A"!10XE",QD2][Y-"?&DAO&^2+/Y[/TY\MH(*0R=41.1 MHLY44Q&I*/24.AM1F--M;K1V$'5.)F\?!#U?/#U.+QWDB?>L_#J;SZ[PS>P; M/A'?HWW:(60;6(@@12%OD:6#4+0$9C K:Y27V*9!\ !BIRU*3 ')-GKL"*J+ M72S^>EV;>UY]J>V[_[/6\R]_?26'AX]X9T6+Q#$!J_FZ,AK!)T*<2+H$+C&R M1G.SQ^1BVK+*Z<%]D^R!D0ENZMCP[\_-VSU_\@6W^SW)!Y%LE[0%"&A!)L >?JX$NIG @\ M9V$'3<\_X"KU$2F]7-H?H> G%Z7'2+LWN-QV;Q$EW*2@ %%Z2L)$@LA3!A\% M)I^*3[;-D\XMQ$P+F2/5NPLL!\AZZF%3-7P@(XS+^5H!X?('AC9[,+TG?F0" M]"[55:H)0KVW49*ES'E@TH@70J;!'^L('(>H\_$0\E%E.S%8?JK1Z#8>6"S* M^.(@\]KOG%*IUI:3F(HGAVVDQ"&#ZI_[_6DK%F-"8A0)]K!?^F;JK"N)ER3! M)5Y'8WLBF@=*(RU#SI1AJHR\7;JGV=#'!QR'2[,'"-PB5UMK52*_&7.HQ0,* MU!WY3-!<.^N816,')7;GN&)\+Y4]LV)\'_E-O6/ZA^7827FR>X9!R"6 :XKQO=2W+,KQO>1XM3J_V$Y=F"&QSI]J20GZZT.!\,'J_]@*7:066Y\WIN[5OB0F)(Y"0I?+8F!.PTQL026 M$7:-\#ZKMJTG;WI;&#Y>(>(X:7< EQ\BW?O!?N_*@_'O=@JOS2XT,PK <4AQO9]=V M&OILH]A+M8M1Y=P=4FZO_D(,D46?067O0/E2(/@LP-0EBRHSDX>U>A^(E:F7 M=8VAV9U .4#,'43L[[YB[;B*=763U>0U_B,,:7PL]0.J&]LVJ5NEKE:.^*(^YK5@;KN2ZB&Z9>?6 ME#KGT-*I L&#)@,:#$2N) AEDHW,:OEX3NC6WJX!GYH8'H&RZO/MPR($)S. FLO(X5V00H(K'C@V151M-3Q\7CZK:#8^N,3W_2/@H+C MI=9!D/&TYIZ(Y*!0D]_TJFZ""> 5_9?EQAKN53&Z[7B6-WVW@QP3GQXG[8[@ M\GYQ>?GK8OEG6.8+0Z[/)#HUG+!/V9^N#5")0Q),ZVAR8KK-*+8MQ/11R#U0 MO<^ Y5!9=P27"R.DS"K+:EZ)[L $>!(!("\*2TA6I#:]0'O=G3<'QL&J?*XW M8Q^Y'HR'K^O5G101+Z]&1<6K]-_7,R+BY^OE;/[I9D'H1:$XV@MM0<;ZC$() M"JVU)QN;N>4Y\2"QK3791E4??3UCH^=H^7=D84@N./LT?WU--,S3]X_+,%]= MKC6TV29VH6+ &*P!DF!Q;G:) M&:.=\9Y<8*206FH-7F" $G-@=1HM^C:#D_8@A'8+V., ,QR81VMOXDNG MS=::]WB3"ZX^S[[6?;9O%M_#Y=7WUY1+_'-Q26J\VQW'1+&<2? EU\97'^H? M6>#9F\*<196'['#8][O= NUX "Q.I(V)D?;'U_5-(PEIST<@"R7OK.M%7$4R%I5&EWX$ _ M+D-&XNC?]3BL_Z0*:7,,%(%>\$)11UF__G?5N#,$JTO*VJ>B6)M$;B=9T]81 M3X&T\;4SM9&Z7J;/854?8<_S'^$[+C7B*^:/F#[/%Y>+3]_?SSY]OF,G M)XG.$2*<$ :4#Q:^X]RADFS[V%P@;!#=]SG!KH:$. +<9COBCT&Y] MO$29T!H@5\] )9O!<5;['JQA1=GL6CV:>)ZH04 S?P>@C:69#D#VPIR )\DV MLRXQPP6@BQI4)(G5%RC I7&98?0HVVR0V9/0;G.!D]3;6FJU?]!N/>_!.M0B M>+#6\OJL-]89Z1JX"SFS($/T;>XY#B!VZLW*#<&S'U"/UF0'8-V=0G[ MFUFJ6VPV/%BG%!H5@*M$/.0H*4\/$HSA.6ABC#]>7+0]M=WZZU.O\#X-6$:2 M;@<&:4=P\N:NL9KE3 F2CAX$EPT]^;;JFK-OKJP.Q,!QL M^RNF;Z"]2NGZR_5EN*+S^V"VV472.7%-R,!8O46V&KPM]5FJCMH(X;QHM J1WAK@Q=52RL9!L](H;:9AL\\QG-UW= M^N/FL-M7*8=#;'$5+J>9WVH3NF I5LE9DH679-P#"P6,D#YJ)8R);5X,-9G? M.L7%VC@P;*JX#FS?EK.U94RM-SH*)8$G47=!Z;I6J+YCP, -4K"1=)LQ+4.H MZ_:J;2P CJR@T:QAWZ]*GETR//$3DQ?IZO&]R7["G.3QB: /EH01ZEYH"@C0 M0#0J0N'(F,J<([:=\##UXY-G=70O(FDQ2*F *U=W^N@ (6&&6+)U(F(QH.<+7F21 M?8X$-./KA,/:6.]<'7J'*;$B3+*N3:WC,'J[+;_UAN*]E7NN(*9_]D)+[S2Y M&8BR3M!BP4,,.H&V)/.BT<9&#:.'T=MM":\[$.^KW+.+B%\5^O(=J[)$IK$V MB'M93ZD-)%AA "D98"4*R@O:-.H=072W'?D]@?EP-?>_MNQGC%<'5)?7_]K( MQ=^GI(Q4FZT_O*T %HL17"$DJQPH;C4EZU9!)N^:.7*M&]U:;J?G^-=G#W_U M(\GN)_K;_[Z(Z!F=D R$W/*<0'1,0\,E< Z609=FP+4,P1-6UD: 0M/'Y4= M+_CS,!3KSL1#+J,>_,L-C,8VLMJ:CF =I9(&P7N*992*'IQQ'H)*I'#%BVLT M(K6-Z;@?M/WA,WF_C[C\LI;K'92=$*@#<@K@T% J4@HX'2UX(7R0*(+%-B6_ MERCKTICL@X[G]P..H(H. NI[?BH;O\U)1-?KA3'W''$=DR+["C)6C@Q%5;[H M#$))DIK$H'.;P_0R;=,6CYO":Q1UC%AV:.JXUF_/P,V["V^\-#8S MH/RR-@&+ @1Z1Y%@D$Y+:^A\-&/Q$3%=>K=],+ M5#Y&X#TXM!_<,OU+ZQ>N M.EEF;2K K63DFDDR/@2$[ JSV051;)L:YE9RIL?-44I^[+..EGB/L+E]:)@- M%U(:"5%).DV%7MLU(*26PH14 .]8:(I00>F:9(4'&AZT;81D\PMY+3&70.4?1B M;*EW )WW^&UQ^6TV__2:OCV[^C6DV>7LZOLM,RSSG!4=*SI@M0N0THH0; #G MM=$RLQAMFT[4G61-O**P 93&TT('D*I9R-5C*YT3Y4>R]EQDD^M029)3\@(, M8PH#HR.CVO0B;*-F^L1]S CH:'EWB)G;,U4SR\ YP"A=P"=_YBO,%W7-5G$QF:(6LFA<.9!Y^CKL@0' MD>PON,24"8:%+-I4I+<0TQ=H#M'Q8ER!=X"9'TWP^B!5C\JTL^"0U>&.I-L8 M32&?:XK4&I-Q;5[I/Z5EVG;.L=W3D;+N#BT/Y@ 9YJ30G&)]A0F4DQ&\=AQX ME)K@7[!EC\ VBGHJ[>ROZ9W .5#L$T^-?B4E8V\75[CZ(WRO1^GG:ZPZO36; M* URQ0*D*&L3@([@(AVNR)7E*6?T]A& ML[5VOV5GD!QJ!87340Z.3CX-D[$ M+2=1,*,0[8>[/Y*3ZG0*. 83:03@V,](_B' M6L-F9KY1Z*6CT,U%BO@S15DQ* _,%*Y$2;VI#D7G/=09I'1(;C.1B4R#A*)&#<4*S- -.SXQ[;., MT0$QEC"G]AW,ZVV63MZR0E9-%I8,A")KRV(1$"QAW#,TD07)Y.,KQ^W.8_=G MIGWM,+[W&%&HG=F,#_@-Y[=L>%]X<$:#9C7Y=ZE R,25K5.8G96^Q"&!Q8Y/ M3/MPH+G-.%284]L,*;:@6[)-#83?'3;@DLO,)': S%"[I'"#4Y0K&,YL5A57<#4E: MG_W ,$R<3[5S'$E.;2RDVY9SJUM.4A3<^.3 :%/K^6@AYI#KBE"T,42/>4Z>3HV(9SM>&$!# MT+'K*\/0<49%T/%DVEF@40=T;'8')\?+7QF&C',J@8XFT\[LQ8?97QLFHI>)I[KZ@"R?"K6S42@#S*"C/\B(/!]@ M+NX^, P3YU/Y'$>24QL+P85^OAZC(F7:X2,&1$D*!\Z* =#I1O"1<5F*( ML=CYE6' .)_JYX@R[XTAR:F.AU+:H>=-XQBFG8MYE"-Y0C*28 :>2@LBX+,Z@ MM&50H^?.KPP#QCF5/$>3:0==Y#\^[5MW1[M:LT\:(0H505$<56\ (VB18Z"D MRA75YLW!4UIZZO(Z_LW!D;+N#BV;5SM&^*)$ &ZB(I%D0=AG"!AB+%:P1-'3 M"?#2PUN#8S6\$S 'B+L#R.Q^1!R53*$.+=19<F^7FFZ@P<9]]I'@M92G(7-<=?S[2 M83,Q6)UYL*G-1( 729O6*(T"@ &@.EP;$Z=:'S[/\#*O_HGA\NKSA\7E=66' M4H0JW#=O7F^R XW&>8/ J4:9& 91$5HIU>_ M!ZI[)X0.E'UW&/IM3K^,JZOWX0H_D((P_X'+5'7U"2^"YY(R Y(/5W7:KO$0 M,^6UJ$546G"=_"F&4NRBL:<'Q"UP-II^.D#>W3O8GQ;+Y>)/RE-7%\SQVE < MP*[;BEG0]:F\!*V]D"P6,OBN"<2V$-/3V^-QL'2LQ"<.M1\.E'Z+ZWF_U>*^ MFN=?PVSY>UC^&Z_^%2ZO\57^/]>KJ_6L\(N42N!!!/!!4YC@27(.:ZS O+2^ M[L"10R+O0[[=4Q7[. "=1/I=[(5;O]!_R.J%2=DY41SH((D%KBPXY04(*S X MM$4T6HK\A)2>2DOC&*3CI-V!#_OA4"SFZ7I917FAR9BN1XZ;$FMN4C*$( -D M@S,@OW2P1OJG.9'/D;^LOUBFB&*_I[)(Q\?[8>_+T+2B4P M(X5)1=?(S#9;M[":U[88=]$&I%"T([\G;&IT@2I8 !<;:_A#(/#;S3Z?9L&,U M*B]U!H:.LN.4*#O..@+/G'P"CS(B.X$+[G?#SCX8&+)A9Q^!=^!KMS3^I&(U M2_4]?*H74(S"3Z^R!:NX1..M,ZT671S61G?2W3I[J??E-KI]9-T=6C:;&KSG MT;H".J< 2BE#(J$X$Y/F5AO/53Q%VV4/S0;':GA(&]T^XNX ,MO&FTNTAD*- M NA%G;(O(I"I36" T/F":_C[B[J&&^L+\E(B;E*8]0 MH@[;%PE<9@5R\3)9KIEP;?Q3QUMT1L?1>"KHP ;]M)SE3_AF$393!DD"QA@2 MA;>E$/W6UZ94#B5:FY0PDC^>"[J.2:..EG>'F-D\EB@F)Y<31%N1 M']?%"&N *9(*6B5BH^Z1LUG0M9>>!R[HVD/H'4!G:X1OX2JC%T/"2EVD/@'6"F1F2;5[^;0=M&&UUD L9"'202 M$$+DC#RM#T&BM%C:['1[2LNT[JD!8HX4=P> V;)[2E""5_LS0:LHB8/,(7+G MH(CBK-:*HSQ%2W:?&]V.B6>.E'5W:'DPJB!;S"ZD"*4N+5-9UGUE6D%13"F, M9$)U&R-S-AO=]M+TT(UN^XA]ZD$?+^P(L9P+'S& +W6(=_ . O,60EC[V,AR M'C3I8X3%*Z>?]+&7'O=8O+*/4">?"W09OE/HM0Q_UG:YZEFW5B2UT#ZPH"!Z M'NIJ" -!ROJ<,RJI0@PE#9DU-_!S/274(^"EA9![QXTTZN?P_1 (E+#(9! M2(:LL0T2(@H+3!;/B&>7Q+!5/@=\O*>@YA28.EH!O2/LXY^+_\*P?,1A2D%I MB1KHS% BH(J 6*<#%T.G*WKT_'%WQ6$0V_KUGAYTG )CQZN@>Y 11G +CU9D ME(8R$%84B91\/[@D+2#CY/F5UXX-F=5\Z/=[>NEQ$J"-H(:I(W%2/GMT[?NJ MMF]6&6XUUB77^SN3P/!ZCM!+\,XG<'6V1D;'DAFT%''?#_?T&F2,:+VIX'M& M%7>_+^97GW?W&F1CG4:;0="!J8^".82Z@9K.DE Y".[LH"G2QQ+2TZN1UJ@; M73%3H_#ZT_7J2C#NGN-XPY,4S!I*;ES 6(?P(_AH(R3KO2A.6)4&E1L&?J^G MUQIC8*J%F#NH;_ZP\/KN*I(;SYDFP.M47WIBCL1$)E/L#0HNF/>Q34%\*SD] MA?;'U\2/EWB/L+D]7I1>H$K&0K:\[L6F3->9E($79#:[E%2TIP%.#T7Q$53] M$G@.D'L'\-ERB\BY+?0?VIP/-(2I^ M^=9V'WEW@)C7BR]?<)EFX?*/\!4W>U#1%Z%U7;/..3E;F]?=F!**"\ZXD-$V MFGJTE9QI2^$SFIY=?$^S#_=6%W#"D;G!*1<7\+RF"&*&N%KKDDH M6E#0-@0J]*L/8$)_]A@B/WRVIV+1X:'+X9+L0?V;C2':2R<< C-UPWIA D+R MQ(66O##GK5>#)C8,!\"4WN0(E3U6^@'RFUCMOX>_9E^NO]P27H= *,X<)"R" MS!62N<),]M"3_ !@Y'&.L1!D^T'(>$Y*GHJ\1[G$D:1 M9#"HV7#)D -RW=WD=(3: [1\J*%R#NHJ3ZW/\;8Y$E &4A(DA+&.K7< M^P3"D%/%DG*(I]NW,]0]G>@J^?C[OS&DWBEX?MPEXX+!%+0!G9BLDS08>",$ MN!B-TU%(LM@G@]$9K&W:"P![KVW:1QL3M[3\:W9Y&3[A[S]OMN$EA\%:">CK MA:E.=46\3F"= (A2W&D5X'=N6Y.:MH0E;92?")A=H^ M+X@-JR!+6WBM/D3;9J[-,4N73K1N?>R'FH=)O3OP/%C\PR467H?UR+B^L@P6 M FH&KI2,R%G(\13CNGM?NK27NH#@;33_=(>\]9OSRM6KJC^4LX0.V,N?&L)PAKR.# M; 4$3AX]BR(,,T&P83?91\+N60)[>N[7 G/C:&;RYU<[6/I76*[GSC]@C47K MM(D4-^I:VP@ID/A,@I!YL6G^/@U)KF7=GOVHKVD44QJ"I M/?"6SH)RA7P_$W6LD.4L42B@PBE,5:6EIU:L%E9I;WF?X\8X08F,U48"=YER M'%LB1,;)SFC4E-6R0J'F "O4;&/EN MR>+K\)7^SM7W"R\0A2)!QN*)-V4R^*PE9(L&4S+)E3;;)/:ALJ>+VG%L6#,= M=8J_>KK6Y^I=N4F/WUU?K:["/!.?%SF*.F-/@T9&^8IU"9P*#C3E*I@#)PX' M]:>-@L%=E/9T(],.AZ/IJ@,LOJ_:>5=^FV<2'N9:>OZX(,-/9VMV%2[Y!<4* M7"@OP9!)KU/\ G@M!'";/7$8$Q-MYFR^1%E/A=9QL#:J+CK UOKER6;.Y*MO MN*3DOS +]R$9LARRVW/HS(R^V?)G4 MT19;+F??UNLS[[&T>C7/_\3\J;JO1'_KIKO\Z>;#G#DZJ2R(X AI4EL(DF6( M+HNBT;.";<80'$'T\=77O3_]D53U$_W&OR\9K-=2_,6,;S]L=.8$*WD=V!(75:DIM6 M$0P+A)7^*Z\750UA\N;5&GUKCQ( MG^X)_&-QT[]WH\/[LU:D""E0,.LT.CIK&, Y5KOXG(@F\Y););SC,'"^YG4? MU#[)62;0?@>IS#W;]ZRM'DA^W5NS_J-WY5;D;RI M7Z7__T@RG%\@E$&=90S&091UZY$V&KPT=>R:+^BC#UJIOULH M\[#(=G>;5;^+JSNYF%@H'8D:3,I8V\8C!"X5V*)43#:@Z[6-9;6.@@O[MA8/7 -/X7+:DX^?$:\VMCYG[[?_P.O%_,ULW68V4_?;Z7^ M,ZYFG^;W/N'"J9S(-07@WI&DJQ!"<@(D4\8;JT,);0K\[7B:%O:CPV_1)18Z M.!7;F%X_!+>;I>5FF^6JWP:C,=06K*S(HA)X&5%:XY.'0,$N=9>^XB2VT<]0ZB M^@/3(7I?M%%"+WAZO84/QZR/.A7@(6N23YUJFR6K=\E99T&IIFD(IBT435OR M:8FD8\7?"XSN3\2;68BUP_-^<@L71>FB"Q@=!*C( OB<#!B57+%%(SY^W=3& M-CVA;-JW=*IHQ=XO7Z.&8-!&R=)/CIQ4)I1KI2$!DJ51# "6>!MWD#M M)&O:EW4GL%?'*:(#5&TK/[V?K?Z]#C=#0>0""SAEJI24 )*/A>0+-S($KW.; M=0F[J)K6!W::)8ZFQJX@^5!NMP?7^Z"4RAY8"@A*Q@1!R0(2D7$GDLFIU32$ MYZGJKX)\F.Z?!=61BN@ 5+\NEDC'[9>_TN_316=7<'5;V ZEC=/R[,CJ6(#D#U>KE8K6XB@?3] M845[([/-NC8;6*6_/MZJRY@H%8Z%HHWB54%G.#+5)H\<2& OG00C0ZV%>CI MWV-L M*SE33V=IA*CC1=\!?I[&G^M(04FML:1ZA>P9**8U!%W?F@KBSTDZ%:Y-Z\)V M>J9%4*=A_@BJZQ* FRUB6*Q 0R='5_>OH@+G2P9FF;)9<5M0GPB"/03V8VC[ M10 =(/H.(+1A /.KU2U/]\G/K5G6*@7&+ <4Q(A"16Z=E;1^!"%SB$JJ-L,V M!A#7&[ .0<&3;'%+>;[C:K/HRH9D6<0ZY*]4\ZV)!*D,6,G0!.,":S3%>"\RNX3=(?!X_&BF MF:XFGN^XOHN]D=LC)E*0D64*/:2E %,YH^JKN%"O0((W*MC@'STJW3K$\=D/ M3!M[C0^5\:39@6UZ$$K$6*FSU092J9?_1E%H7+>Y_?CT]R(E[F+R 6(D62GTOLY/B*!]8DIH+;EI M4\#?258OMY!'J_]98!VKBZZ M>E'^OZ(H<)3SLX[R"$[LM]<@XL6P:;@&#[QW8 &T,G78'LPJ/UQP MK/@%I5G"!L)*+H;B7!,D!!,T$.^JQ+I[W+;IECV4XJF75;1"YDDT> 8#/XC5 M;Y75+QCJV("#!SYN_9VQAWR\3.Q(XSWN$' _4.'^R;FSA6E1.!A,Y"4%9Q"Y MM) ],TI&PQ5O\T1G%U6CS45X\-OW4VZ2D2D+'PGOE.$H7K=4)X(_=PZMDM(G MT7BTP3:R.GD+?BQ&GAU+<+0JSM3^'#XY<<>OG<(6-9R=N!-M.421%'. KE;/ MR/%!K!MZ,_TIDT8A3VW:\EI:I/LA7G=?N7GY^6J>?WA2M99_?C=_C_49'_GK MG\)J]G@*GC#&<%TT^&!S'2?&P E6R]W>"F^5QM)Z!N((;'1L\?;!X//SVDZM MZC.UD$?,9-OUPD2VGLNT$J/)2)*$\"-18LX4$KB0//*<@DM%)-5I6>I*P M;>!YH7_@[8)2GH?'YTY"@;M8N/<@O2 )\;KE43B$D'0I*A@C7*,G3B-RT;&) MW >!SP:%IU9T!]66,7B_N68T(>M87'W%DRVH$!WX&ILC\[J8S(+C;>/VP/@\AQH1]!=3U"\]W6U+GL[I7S3Y^TD"I4%<*S3QVV*%(P+ M^J,@F0Y6!YU.%G4]H:X34(X!AY=K2,?II@.\_;%8KE5S=]$B$U%E MJ< SJT%%KR&&VI FO"DILJQLFU;2/8CL!'VC(61Q&G5U@,378;G\3G[A/7XE M)C'?".UY]G0.R'TM_Z92+ZIT)OA'8R-J<5(ENJK0-4 M_K*ZFGVI2PS+@!,GD%.L'24AQA)OQ$\=;!9!!BZ$$:ALHV'K^U#9R?ON5GAL MIK .P+@]N/EUB?]]72=MK ,<](IGIPI@B8Q.E2X05.+@+'/&>U&(P1/F*C\0 MUXDI[#!?.5R'/<%R&T.W1YHEEYT)BD(012PAK^OP; %>4*,@.2K?.&5YGKA. M8L:Q /$ 6]V=V\W+&2V$SBR"M9'""Q8*1!40O-0^\D#QKV]L"'=0 MUPGDQH+$ ,@=I9\.,+=SV)_,FJ3$!:"H#J&$#"$Q2;)+H6ZU=BFUZ5XZ>EYG M^T!O4F\[FM:Z0N"6X5JV<.>E$2"*)EXBTD&*1D.J;QH,3SHUJLVGVU6DN,;]:QA*ABL0K08=U_D!,$2QZ 16?KJ*Z@ M6N/O*5&=H&U\*#P'NB/UTBG$Q"TKUIALA2Z0F%$4L1@#4>=02Y322U^8\XU? MZ#PEJI,KKDD@=HA>.H68W%P0!TS9F0S>((G(H@!'S@!D$ FE<10R-ZJ /$]4 M)W7=22!VB%YZ@M@18?&;NR?ZCFN)DI,)S] J0&*R$P.DOJ,BC:7V7.@8; MG8Q=ZR-1.3DN.C@4-SQO:\S@M4#MM884##$D$T)4/(.QSFB6.>>IC?5] MD;1.(LG3PV;14H<'@_(;+N-BM#[4U6<26/U_O_SW]>Q;N/S!P]VS>($2LT45 M(!M9>\F#!<>" Q6<.52$(UF;@TF<5J8C@R.)XVG+?34@5VLW%Q]_U!/Z_I M__KM[>S"%1Z=9 IT$";'6#TZ9#-:IZ#0XTNU]?V2I*-UA)\,!&RRB$:)>GLME[6_H"< M:4/^%GI_<;[SODKH DGQZKXK\4Y4%TR254ZFCED2\69\0T"!P#7F$J,KI5&] M^1F".JDU3V[/QM!7![![LYA_^HC++Y6=BR2D#C)YD(6"216%JB.]-&@A8L%H MD_:-7.D#*LZ_764DAWFH9OH?MO9Z\>7+[&I]3Q3F.2WF5R0ZG*?90>,H=_W: MR*/6!A,^TJ2U!]^KA:V'W]OF0Y.Q-BD-5E#&H#Q'"(P;\)%Q[83)JK092K,7 MF4=78X=\['Y,81$*Z>T05H[G#VI MT;;37O]V[V:?UU7XZR []_#?'MFN/4O82';LYO<_AK^VH,G8A"*;!**N,E.Y MW0\9U':#+W>0=0X>SY_^.E[3%OAE!"&$I/@ZN9E*<%1+% #1B\4 M'QLW_(Y@A[.RK8=AW7W&YUMOJ M J,Q#CTY4B?)>Q=-Z8BLQTL&C:8D5*WN#0?3V*\QV@<[3^X1V^BH@R+"'4.X M^B/,\EN\JO,I;.UWJEM;"DF+*8A.TW]QEH1GB)RW*24\I:6'];#CH^E(F??O MT-[CU>RFF33B',OLH(4Y6WYD9(?V$IGC50+J%N ;V,[S_5>WP"J7:CM8!.H@F23!)D3DI)B;9IAMT#R*/GU*YND("P.+[>IKGK>BWA7GH*$1TWH.1 M?KU"NUI52EX]=SIG9:6U;0H @TF>4_KF+$;P0M8%P4HXWB9Z/:%MN]_30E[]]J"\ MIM/S> -+H##!*F3 2XJ@5'7UPA9*E+-E(0KC;)L'=0,)/!^[M@^JGM^J,YZV MSC$Z.[SJ\/QO-;=J+6L0^P!0!N%=J$OFF*/0G1<"8 H"A#!161*S M]C/)?H[Y]K#\<1GF#^* VT5[&B^SW_)F=R7EXEP^9:['>%K M.^RZ?6.>&+D@979+I(>D7-?]ZQO@(M$4)7$YR7-8$0YK/P<)?(D$D%B"#:(R MPSDZ2(%7%G,-K)A41$T\@VH3I3F*S.M1<<<@['D5U[7D!A"\>.0:+>?K]^ED M/IU]H#\CKBX[@T5I%?C$(%+7FV050V4NF8LU^&!U++S-O>JKI/4+OX:PF+:4 MT=!!MZZ416?'H.$1&2^B,+1!+*,["#]2T?@'/+_ MOIG^^#_K)Z[ LOYBB9,E0A[?UW-'QS,E-CV+?0-0%^O.DUOK3SI+30MV@@/# MU>(&P&6SHJW,IJ@4V_;]/%)9-+O-::TLSN/\ *"SNI;ZBA)9++7J+ZA=/E+.BNY#)7*.VUR^2-82,A@Z$?QBH3I#$ &#U%6[Q1S?_ACMP%F_? M3,J;>C"E\0DD;O_^+0BU4 [#JA*NSB-EQIHH@@R %/,Q-9)!Y=,*JK%.; M.]:CR!PD[$Z!QVY JIFL!@#$3XMO,%LO86-^"L^-)Z6?R9V%6%BRI;!HJX[4 M[IN;-GWMGM(RA&R:%I ZD^M#PTZ') ,PISGJ=FKJN.Q984"6['6U MN5%!R!-2^JT:;(R:DWD^ - \M3L?S!>JD81\(/(ZQ=EG'>NDY_N,B"A M4J(:I.2VZ MUSJB0O:!!? :#5<1,K3I4',LI7V/)>D<+*_"L4/)#1*97V'V8YR!%C42-/,L M""I*4PK])I590H^)H:69)0%E-7( MED_+"/2Z;93.!4K(CLE8-&VE=5F**<6IJ!+-/@G"ZR.*9 M#:ZB=0V!^:P=XS**8*JO5K0I;3^/[J$=ZXT7"@.=NH:A MV0GMG?*+2+M'G/^9XG,[^O-LBDSX^BU2:R[\XL=XCC]9\V8=ZU]OZA1419LH ML>II,B$W%)<+FBF;N0P0E=N=U_VDC*$30H9F-'2%S\M+:3BJ=W?!9 E]@3R] MF8S_&\J(.]Q?PDFF<@E,F^28=TDQC=\&49T0LD""W^ +_F&?S#^ >/E;1:R^)12KD.?W'%AUTD+ZJC,:^O= MR]O M]OO7ET-?L!WHT/TJ?X1__58B41-:KVMS(? F;.NAI1#E;*- M,74BP1WT[=M]S9VZ]1C$ P M 4FIY*USLE$_H)?(N@H$GH"&W2.],]$, &<[:U@G2B#\ &UMNSU9T6_*?][/ET, UDGS MM4!P7CJ6>$1;6A7+0@V:T;RZ@NM4N5&WV./H[!=R'0#C^:.R:RD-"X/_AIQ: M&QHT'?C=[?3/?X=R Y^7C%\O+PB1/,TL=M)R-?-?EF.%#AX\,% JHR\?@$51 MW7(T-7=<55=W8+?WYOF 5_6;^] =<%IP=ECZ"E?VC\D,XBU=/CZN<;,]-G6M MU1D30F&"6XGZ&/? 2ZEMEO>XP3>N* MI7^'Q;?IUJ+G;Q:K._1EL'+ZRUY,+B8KDV;!T06Z0U!Y51%9)2:M9%8RY$.T M7!/J^LUQZ%@Q]B^_8>G2/V9HR]ZNI+EKT7JIG35&XKD@ \W9P%6)8/ _60U M".CRM]:@+]!W$"[M\''94"K#PMIS.VZ],&F,XD5Y)DCYZY1I.Z7,I([6&14H M,[ZOB/$1B'-7B;@.9=/AT('F=Q4?'K+D@O92).=HQ#9MJRC0?7>951D*#US) MU"B_YEA*^W5P+Q8Q;BK (>A%=-'V612;VYXOT]O;=]/9GW%61E*#$1DW-7H-=P11%[%1<:):-F%9B/1#0"57Q?3_%_?IKQHV?J-=+ M5AZ_")"S::-,NZ&_9RRW@M>3.[F+R_IDA']?5DM^7<39HKMN4,\HB=^@3F?P M!?)MG,_'=;QJA[3^-O)_Y+741N(Z!9I8: P%M,55MFB!!1!.2>,;31 [A^J> MS88+8?IB M0O"RB.)2FW!II\OH-XA_*93W)_ESFR#\T1;]TSS^99&T/ ?)^! +.JQH[FDI M(O/"1Y9 9%FT=56WL44.I;#?^'^OF#U77@/0PH=D[HUTEK*0MQ&D-=0](N 6 M*^AM:)U55=7H-:N/^ HW=#LR@^_$ALG- M"1403Q[1<8W#RR1V5,6P?LF7S4L>TL6MJ!E]],*,Q/\TIREW2E,W>\>K<)F+ MT.9>Y3F*SN]%_^MS]TU)KK4F';-C .C&:1\2BYH6'7GRIHHD&HUD.8"XGG-S MN\#)TY;SW8ID^&59NWOZY/+79Q[46 4U+&A]%F E64*;S:&#TIY&QWS/&JF:1*?U\&CU:F*,YE#R,D(^U=6#Z1C9;(-1D"9$H,8_+B6F2Z0A[MPQXWTR6EMA39N:S^=I M&JAR.@85N\JI(P$,(';V6.B_RZCWDSJ=W2WE]-O/]0_7(R)<=M[HQ$*T@#ZT M$RQ*7#&@6ZL=N%)S;;.?CB>VY_%Y+<#76F0]HG(^6XP>SW%2.Q3SN5P>!0 MM!E^2N$W;X!E3P' 0%E'P0/YV5QPXV.I!UGZ)^*HS]+@KB3[(E!.8/, CL$' M[V)SCJ^3;GDJ"@J7++M"%5H6/9@<@(GBBTI6>G0@VMP:[2=H2, Y1=*[-T(= ML+WG>>1.%:Q^82:%0SW;* M *D:]3%RR8E"XUL:70"^0-90AD^WM7BZE] 0X+:B?3-"LF9>*KH:-$R6QH6B M5YI<8)QS6:4ST:DVY]@O9 RD(\KYXMU_]7("KWL^O/XQ&2^@+!DS?Q++V)0& M)Y-25(I)EP/3>/JR2*$-'I,'E95 ?7[ Z77 JP81*#I%B--V'.T9(,NDAI#V3(1LD2%CEPP$(.>1=@PCGG F1SGG:,T;^ MN;D#^'>(MXMOFQI9(VH,Q3+AH3)=5&%>N+U(WE-', M%[)PNY;7 ##X!7[ Y![H,G@Y(R/FQ3_'BV]O[^>+Z1W,?O_7.D6/Y@WBOV6" MZ2B'K 7HR)RN!CECT!,5!= ]4"4 CSFG M0\*%+[]E$"94&X1TR-Y!#)Q]I?&*^=T:U%? M8%G5N%I;48@HB\S2'IU47RMGN<@JC(DY- +FVJ MY,H>;$4=_MY^RYTN8%XU$L$ O$4B?H*_\O/#^W>?OJ#@9C]@5?CZ]ENI,]A#S$& \E<+J'/9WUEQ<;MJ@'AB MN5-L4=WTE)B.\OI?B1 ]SCLKQ@N3*JN:VJZ+&%E,:.^ T"(['FV"-F.*#R2P M<:#SL>9%(;J=1;^6"VKF+#)JRN(TDAUDX2Y!DFUJ ZEL-^09@L\'1G5/$U6 M5U"?1$K@]#+,K;]NH9T:%EP>BBD>T-^"F)@S(3-=3*':?\$J<.LHF0W"5>NH MOXWG\08E<;,.C*Q?NS,=,BDM4A:4 $&WG#$4/(:C9SYEW&;%)AO:6$$'D7<= MVND8)#T9*=^YE*Y$-9U1+[G]YRV44\O*R$,Q)9PTDHO P&9#4R D\X::/P5 M<HN@Y== QN MCM%%1\ED< 5'R[32J"/8*!-+%>U'[6@M$@ Q4&S$507DT2&HNMJRM>[D^WI] MVC','AQ"14F>LSMF%8B3^\(!;M*NL3SL%'0W8.@ 5\W)YC*K" MN%Q1['1(ZX*J.#IT/+.NKH)UV2C31-$,N#ZM<].F>U$, 5>_I,LC[GUTF;,J M1*)^3):E4C/#P]T&F4S)C8+T5U.(=I1X7RQ$.X;75U"(AH>N]'C,,@B\,.VM MQN4DP7P.@2OO4).K XZI*RM$.TJ(1Q:B'8_1AG6#6T2<%(E312#>BAJ8"(33PR M5S.8K*/1A_4H.RB,LH^"?J'1).IV-J.' 90YNFSK%6R\P!B+$]Y:U&H*]X[$ MO1-#DJR$D*(V.?MP4(?(8]#RE(S^@B?G2_8I3,YD<\]GR>=O<787\\^U.A12 MV1!L15(]GH(N(R_0CV<@9$H9O?KD^ &'R*]/[5W>YXIHV@F_!N"C?EE>OJYI MCQ+1K;1A8(1&VIUEWJC*7 ;I:_ QZ3:C/K>IZ"]4UBTVSN;P,/0 W"_&.=[^ M\QL^>1YO-S.9N3")*RA,5)JNZZGX7_C*U"5(=$3E]\23^&1%,MT0$W M!Z TGK&Q/CQD+T,,UCOD$II5Q"4A693!L HI55=D*:9-S/0UROJMS6L6-NU4 M( , V"FE\3QE3PX:BY%".CPK5*VXD4!+W$+2.'=8>]._?F>#;M'205>#8T0W M_'R[=14BRF(Q/BD;>.?9UEWRU=\QE?\7-:D(PB0XOGCM)\DI0,; M6E82#Q[=A*"@S6BL(XCL.PNO0QP]551M1'5M"NKDHH6]CVFJK)J6,;P"-565 MK+90NH1"'("5-+:0^JUXP1U4'7;C(%>BLAX[<3WWIIWL>)5RK0H)M: *W8L( MYFND=FTZRZBUB[D-)XZE=.#*ZQA$/3\)HX'0KDV#G5[;L/\Y3758VVJ'5R#' MLW%214?MY#W3(5@63/4LR9C0WJ]@5:L 7R]VU^?[6?X6T=$@=V3[=T8E^XK6 M V>RTCQ(FX %C3L#: RE#"XGTV8RUK&4#ER)'8.H RVP;H0V@"C&FYRG]Y/% M_'/\2^1(],\8B>[D6%MK4 M+Q]-:K]9($UAV59LPS]3F^VPZP4\SK ;:'7_$OO2TC@_:@PGO MZ+C%][UY>-_G7]Z'^'C[+4YN8/Y^LOT[XTD>(\^VC$"G1-*6,E8DJC00@7EP M:*:9%*KQU>C=9M$=[?@.B#_;\QC?3,9UG"/NI\?73&_'F7R]!]-5Z!RLL8%5 M4.A\!^U1ZR?+7)8AN91D=HV&[AU$7[\']*4Q^,01Z5Z&)VO('S!+TPO55-]_ M1Q82FR,^YZ%_SPGZ\;DG=5UI?0C!78VCW7K7VSC_]NYV^N?OMVM0;D 7=4Y5 MH+MK4@2FC7)[395\=JG++1C58*F,5.&1@![QKFIO$KE M@W&O0.L\"JY A1V#F^WLH@N)90 QE>W -S)MG*G?+[*3C%W\0'U:?\1;8NKC M$FW48)VG7HK&,9U!,F\3I^YF)<2@,H^-3(WCB>VYNJ852"\EOD$A])F%[>X_ M8[FPGM5BR3,*Z!GA@ED421E=36E_FW8(G3W7^UP.EYT+;0"0_ /NJ&1_]G/5 MQGIG,;BMBDW.LVRT0;N91^:C22SF(JI'RSFX-I="+Y+5\Q2%UH#K3B0#P-?C M[OG;^,>XH)F]"9YO:7&1('J=F7.Y,NUP2<$KR7(46J: =@=O-(?U=>)Z'IIP M.>76C7BNUJ?]&&?4U.8'G-$-\< G7\;/?7E!E_1XJS0R%P.L&JL0GZ!8,EZQ M7%S6 5P.IM'VOD0X[V$#;>X&/TX7,/\PC1.*LK\;HZN5QY.;+Y !+0;:6*N4 M?FU=\=$Q2[.6M/"< NM44"[H&M*!E&W27$\D^ H\Y&-P]KP>;"?& 9S&AR[N MMY];"\5GKX:!ZU+Q,*$IKH)2\>E6R'G)BI4J@[!X.K2![#E4]XS;2\#JF1R% MYC(> )Y_7<&Z#B]7#\JKPJR-G&DO"SI?W+%:$]0<\:?0*AWW*37]XN]R6'B2 MOW6F8 8 KC]FL<"&@X\+6M=ENEA2+ JI5YR:;UIJ 6-HFAA %>!4YFTBAR^2 MU7=*X+E2WW6%.Q/! /#TRV;$?;C-W).]I(SH".T,\D_ Z_3Q3!(+/V:'SNJ 2!J*9D37E"#!,V"]H8E631H MJ5QTZ4*P^I6R?O593P@[0SC# -O]W?UR!=OWVOCY+2P%]^L%]^?9]#O,%C\_ MW\9EAC:%UK\O)U][;V@JC$$KMR:F"Z>H@4@L> U):.62:A.=ZFH%_5Z_70J\ MEQ?V $"^URVB,2!33Z6&=90$%EL=A,-6X MXM0HE)2%T-1,BTI1D-?W$Q7^U-Y>MI M?)U?81[^RLO<;9[(@DM>>I9D% A6:H5]X86Q2J#UG9JG[G?ZM)S MF_^C6CRWU2HF(L7>:/9+JMXR0Q/(4P7G&S77VJ;B"JXGCT'$DR9NIS)\""=X M^<_[^8)X\6XZV]ZJ(\YS &XX,Q4BTZ%FZJ*.GPG@5(@+H-L4.#Y+TA6DV)X# MHVY$T6$1WFF5!MN[8!(Q)4>A#< EH5D0.>?, MQJ"]"!$Y>4AYP9&OO8*TV%.PU%H IVNL*2ZU1[OLZ_W='7IJTV6:\$Z.<*1Y M6-M)[9V;:">]_3+6VOF,N:3AQGU,UL;$O* "08L':Q JL>P@4ZO5Q$V; ,EE ML]5>R&4?^>"D,)*S&FC\FZ!>4(8C'V3(->D276E4HG8(>5=@ZAV#H9/*#8X2 MT0!LP(?A7@^S(]]D=/673OYZ8,LRY82+"MZB!:)2=DPG69!Q$I@KTN$9H94 MT09YAQ$XE&RRSJ#QW(R]#N4T!/BM2-^SJ(?6[K(!%=! MXG*BYHTTWBN4#60F7Y=PV#^=KQO9# =K^^S@==H29"%%QA44$2W3R@%:P[*R MY U^]%X*UW3:X_.D#6+$7T=(V ^SCL0R )SM/P(>H_$U1^5X3DQ:46EB)LTJ M \%L]=J 1%_?MPFNO$+84'+'6AVA7[')N(1V M2&1%^TKS>#S#(\,QF6U0QJ?";9LKK[/([C<@W5H-7D::5YLU\-@&Z L4@+ME MCO'>%*'N0]-'O_I"<>GS6'+)H+0/(*J1ALE(H^520L6:DF'6.6>RDU;%1IU@ M+A"4?C_),XB4L['Z^'ZRD_;V!:7Q;CK[,\[*R-5D4U:92:EI'%ZV+$G:K"Y ME-XZ;=JHWF.HO((0]3&(VE6WS00V ,.@0<9E,-IYHPNK0!R(V;! C2%]K#*! M<;ZX-L'%GE)NFP&['>[:I]T> X*3M\%WF(VGY>LBSA9G)UGL\.!-Q@_S\>H^ MOZ!))#PJC\PI;R"*C+8:YRR'9 V 2FZW]G5O0L4+K^C7DVH.M"X9/#RE^1%H MDTSO8.22!^,-A<]2H5-&LJ 4I:KI:$%;Y1H-\WN.HGY]H+X4V&D"&1ZPWF3D MV[*)[Y1,]KOO]/DJQF5B1O,E4HJ1PAV3T:@)4E-Q;W#%5)YK;F,7'DQBO^4J M?4&O(Y$-#XO(*QC?3%9#7_)JU,SM2IP/69;SD>31I%@R*RH(I@U""'=?15L[ M.ZL\E\7G2\#R(&K[K3/I"Z'="W)X8.W"@A5&\!B+9E8KSS1D8+% 9 G/C.B5 MTS%,5C(5*]CBLLR-&O8\0U#/%]X=R'K:/>,'BA_Z= :; M9EE:)R6$2CUI .T";G!OPO M9[*<*,$#P_O'L+-G5.S1N MRM8""]X[9H6.I59<98H'H.6$5P],M9R/HM;LO]Y\IDU1ZK24>"F,R\*E=ZHHUR8SZ66Z MSK>H'G;7XV"4!V[GVT@;+=ML8N*5*0NXJ5U.+&1M&#Z.NV#PNZ51B<4!U TQ MZ?TDU#RUMCH637L=N/X!_9?B'/[O__H?4$L! A0#% @ SX4F5 0!P=*( M1@ 7*$! !< ( ! &$Q,3,P,C R,65X:&EB:70Q,#0N M:'1M4$L! A0#% @ SX4F5+][KO:'G0 81X$ !< ( ! MO48 &$Q,3,P,C R,65X:&EB:70Q,#4N:'1M4$L! A0#% @ SX4F5,@. M L<[1P OJL! !< ( !>>0 &$Q,3,P,C R,65X:&EB:70Q M,#8N:'1M4$L! A0#% @ SX4F5( C&!'EG ED$$ !< M ( !Z2L! &$Q,3,P,C R,65X:&EB:70Q,#APMGB'P +)G!0 4 " 2+^ M! !W8F$M,C R,3$Q,S!?9&5F+GAM;%!+ 0(4 Q0 ( ,^%)E21)#0V_#P! M ';9# 4 " =QZ!0!W8F$M,C R,3$Q,S!?;&%B+GAM;%!+ M 0(4 Q0 ( ,^%)E1>NQ>Y!;T +JS" 4 " 0JX!@!W I8F$M,C R,3$Q,S!?<')E+GAM;%!+!08 #@ . *P# !!=0< ! end

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�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